Clustering O 0 0.00011339581396896392
of O 0 1.2612421187441214e-06
missense O 0 0.0014019941445440054
mutations O 0 6.201571522979066e-05
in O 0 2.3346639466126362e-07
the O 0 1.4937156265659723e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
gene O 0 4.590857315633912e-06
in O 0 5.0868514733792836e-08
a O 0 3.150250051930925e-07
sporadic B-Disease 0 0.0017593990778550506
T I-Disease 1 0.8264817595481873
- I-Disease 0 0.05822988599538803
cell I-Disease 0 0.006167532876133919
leukaemia I-Disease 0 0.06723017245531082
. O 0 2.019438625211478e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0015357951633632183
A B-Disease 1 0.9999985694885254
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.1204721594992861e-08
is O 0 1.8597153816912737e-09
a O 0 1.4471694953499536e-08
recessive B-Disease 0 3.482817919575609e-05
multi I-Disease 0 5.5407974286936224e-05
- I-Disease 1 0.9990686774253845
system I-Disease 0 0.011003296822309494
disorder I-Disease 0 0.05969622731208801
caused O 0 5.298071528159198e-07
by O 0 1.193624044049102e-08
mutations O 0 3.8188906614777807e-07
in O 0 2.611597382795594e-09
the O 0 4.061395220134045e-09
ATM O 0 5.262519948701083e-07
gene O 0 1.1382097397927282e-07
at O 0 4.4953857525342755e-08
11q22 O 0 1.0277441333528259e-06
- O 0 7.48890715840389e-06
q23 O 0 5.739742846344598e-06
( O 0 5.090617349878812e-08
ref O 0 7.260728580149589e-06
. O 0 3.163206940826058e-08
3 O 0 9.230777209268126e-08
) O 0 8.582217247976587e-08
. O 0 3.693193946219253e-07

The O 0 2.0584536741807824e-06
risk O 0 1.0326388064640923e-06
of O 0 4.464743241783253e-08
cancer B-Disease 0 8.476232324028388e-06
, O 0 1.776802527331256e-08
especially O 0 1.629848256357036e-08
lymphoid B-Disease 0 1.2580754855662235e-06
neoplasias I-Disease 0 1.1618506505328696e-05
, O 0 1.699415896894152e-08
is O 0 3.3259037746091735e-09
substantially O 0 2.3792131287336815e-07
elevated O 0 1.0040229199148598e-06
in O 0 7.362843490454907e-08
A B-Disease 1 0.9999964237213135
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.726188202155754e-06
and O 0 1.8025372128249728e-07
has O 0 2.1977446351684193e-07
long O 0 2.606538487270882e-07
been O 0 7.191323447841569e-08
associated O 0 4.2356809615284874e-08
with O 0 2.5702621542222914e-07
chromosomal O 1 1.0
instability O 1 0.9999996423721313
. O 0 8.786976650299039e-06

By O 0 2.1617713628074853e-06
analysing O 0 2.4665159799042158e-05
tumour B-Disease 1 0.9999961853027344
DNA O 0 3.1069537271832814e-06
from O 0 3.8698502180523064e-08
patients O 0 1.1098801167008787e-07
with O 0 1.0134387551374857e-08
sporadic B-Disease 0 5.982484799460508e-05
T I-Disease 0 0.015081350691616535
- I-Disease 0 9.164059156319126e-05
cell I-Disease 0 0.00012668762065004557
prolymphocytic I-Disease 0 0.00017485934949945658
leukaemia I-Disease 0 0.004912365693598986
( O 0 1.4902559541951632e-07
T B-Disease 0 4.530168735072948e-05
- I-Disease 0 1.8656495740287937e-05
PLL I-Disease 0 1.9735180103452876e-05
) O 0 9.775988907279043e-09
, O 0 1.6842357508650707e-09
a O 0 1.237378821627999e-08
rare O 0 1.0218573009979082e-07
clonal B-Disease 0 2.2536946744367015e-06
malignancy I-Disease 0 1.2307771612540819e-05
with O 0 8.688645358745362e-09
similarities O 0 1.4611447340939776e-07
to O 0 6.613314784686963e-09
a O 0 1.2426369266904658e-07
mature B-Disease 0 5.85239547490346e-07
T I-Disease 0 3.1491461413679644e-05
- I-Disease 0 1.2675348443735857e-05
cell I-Disease 0 7.686091521463823e-06
leukaemia I-Disease 0 2.5109111447818577e-05
seen O 0 2.1462730614985048e-07
in O 0 1.769987001409845e-08
A B-Disease 1 0.9991183876991272
- I-Disease 1 0.9995651841163635
T I-Disease 1 1.0
, O 0 1.748738753803991e-08
we O 0 2.4811568355431746e-09
demonstrate O 0 1.6492357479691577e-09
a O 0 1.2133687388171666e-09
high O 0 5.6104529910783185e-09
frequency O 0 1.4606995613064555e-08
of O 0 2.3726176578975355e-09
ATM O 0 2.466852038196521e-06
mutations O 0 6.049577905287151e-07
in O 0 9.305092163458539e-08
T B-Disease 0 0.0009409133926965296
- I-Disease 0 0.00011845835251733661
PLL I-Disease 0 0.000258159008808434
. O 0 2.2570932287635515e-06

In O 0 1.1485406048450386e-06
marked O 0 1.4129617511571269e-06
contrast O 0 1.9113139160253922e-07
to O 0 3.218642907754088e-09
the O 0 5.489777521461292e-09
ATM O 0 1.2206706969664083e-06
mutation O 0 3.066242300064914e-07
pattern O 0 8.762038987697451e-07
in O 0 1.0087085655641204e-07
A B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
, O 0 1.7150624032069572e-08
the O 0 1.5096183192397916e-09
most O 0 5.117442580804266e-10
frequent O 0 1.3575724544523382e-08
nucleotide O 0 6.147100606312961e-08
changes O 0 6.449369926997406e-09
in O 0 4.6089629890389006e-09
this O 0 2.7203453711877046e-08
leukaemia B-Disease 0 0.00016053127183113247
were O 0 1.625150503059558e-06
missense O 0 0.0003591395216062665
mutations O 0 3.226751141482964e-05
. O 0 8.753653446547105e-07

These O 0 3.6871901443191746e-07
clustered O 0 1.5996957927200128e-06
in O 0 2.4758870509344888e-08
the O 0 4.550968490946161e-09
region O 0 2.1364295221815155e-08
corresponding O 0 4.289082866648641e-09
to O 0 1.5031708100465835e-09
the O 0 4.310702017562562e-09
kinase O 0 2.982784224059287e-07
domain O 0 1.9764055281257242e-08
, O 0 9.098192421674867e-09
which O 0 1.199342936075709e-08
is O 0 1.3114940244918216e-09
highly O 0 2.2769504059994006e-09
conserved O 0 9.314731208576177e-09
in O 0 3.0661930772168944e-09
ATM O 0 2.7736720653592783e-07
- O 0 3.843113347556937e-07
related O 0 1.1478443973089725e-08
proteins O 0 8.456606082063445e-09
in O 0 5.2391015969988075e-09
mouse O 0 7.86094824434258e-06
, O 0 2.4341847648656767e-08
yeast O 0 1.4270510746428045e-06
and O 0 7.02670632790614e-08
Drosophila O 0 1.6601919696768164e-06
. O 0 4.010836676116014e-07

The O 0 9.987799103328143e-07
resulting O 0 9.129882982961135e-07
amino O 0 4.440166776475962e-07
- O 0 5.735599302170158e-07
acid O 0 8.416863295224175e-08
substitutions O 0 4.6395712161029223e-08
are O 0 1.5486666393726978e-09
predicted O 0 6.957637310733844e-08
to O 0 2.098457629884365e-09
interfere O 0 1.573034325019762e-08
with O 0 3.7044938228092406e-09
ATP O 0 2.8643964355978824e-07
binding O 0 3.130755601432611e-07
or O 0 2.08859219696933e-07
substrate O 0 2.313705635970109e-06
recognition O 0 4.24059578563174e-07
. O 0 9.498973554400436e-07

Two O 0 5.636777018480643e-07
of O 0 2.6302950928425162e-08
seventeen O 0 7.920917255432869e-07
mutated O 0 8.523416909156367e-06
T B-Disease 0 0.00015779049135744572
- I-Disease 0 1.0622818081174046e-05
PLL I-Disease 0 9.423349183634855e-06
samples O 0 1.9548153318282857e-07
had O 0 1.0368766822921316e-07
a O 0 1.7791935036370887e-08
previously O 0 2.815669688516209e-07
reported O 0 4.491967047215439e-06
A B-Disease 1 0.9999140501022339
- I-Disease 1 0.9999986886978149
T I-Disease 1 1.0
allele O 0 2.6405543394503184e-05
. O 0 1.0961501857309486e-06

In O 0 1.0040439519798383e-06
contrast O 0 6.320475449683727e-07
, O 0 2.5370340495101118e-08
no O 0 3.586010066669587e-08
mutations O 0 4.905769515062275e-07
were O 0 6.629799287338756e-08
detected O 0 4.8113601991417454e-08
in O 0 1.3087453343274547e-09
the O 0 4.6383474838762595e-09
p53 O 0 1.3175363733353151e-07
gene O 0 4.117101326528427e-08
, O 0 6.355548531900013e-09
suggesting O 0 5.3272547262395165e-08
that O 0 3.841337470333883e-09
this O 0 1.9340831158842775e-08
tumour B-Disease 1 0.9999997615814209
suppressor O 0 0.00017535423103254288
is O 0 1.198063017682216e-07
not O 0 9.825808611196862e-09
frequently O 0 6.736977553600809e-08
altered O 0 1.0620848343023681e-06
in O 0 7.446921301834664e-08
this O 0 2.286306539645011e-07
leukaemia B-Disease 0 0.004757150076329708
. O 0 1.2195896488265134e-06

Occasional O 0 0.00035477220080792904
missense O 0 0.006230777595192194
mutations O 0 7.199586980277672e-05
in O 0 1.3897350470415404e-07
ATM O 0 3.1164527172222733e-06
were O 0 4.474355250749795e-07
also O 0 3.618522370629762e-08
found O 0 1.512645297907511e-08
in O 0 1.0013705065148315e-07
tumour B-Disease 1 0.9999971389770508
DNA O 0 1.1217711062272429e-06
from O 0 7.581204997109126e-09
patients O 0 1.3391280084817936e-08
with O 0 3.0089646330111464e-09
B B-Disease 0 2.437237753838417e-07
- I-Disease 0 2.477518137311563e-06
cell I-Disease 0 1.1091305168520194e-05
non I-Disease 0 4.985048462913255e-07
- I-Disease 0 0.19137853384017944
Hodgkins I-Disease 1 0.9995318651199341
lymphomas I-Disease 0 0.010747626423835754
( O 0 4.8853760148404035e-08
B B-Disease 0 2.7670088798004144e-07
- I-Disease 0 1.1981103398284176e-06
NHL I-Disease 0 5.993924787617289e-07
) O 0 8.640537174642304e-09
and O 0 5.508636657935995e-09
a O 0 3.429341433047739e-08
B B-Disease 0 4.980278163202456e-07
- I-Disease 0 6.994946488703135e-06
NHL I-Disease 0 2.9706225177505985e-06
cell O 0 1.2423432963259984e-05
line O 0 2.9880857255193405e-05
. O 0 4.904243837700051e-07

The O 0 2.7689756620929984e-07
evidence O 0 2.1946569006559002e-08
of O 0 1.1314975623122336e-09
a O 0 1.1252438092412831e-08
significant O 0 1.1444122982595673e-08
proportion O 0 1.9187831767908392e-08
of O 0 1.5128639452299808e-09
loss O 0 7.183467687355005e-08
- O 0 8.635150834379601e-07
of O 0 3.1235809494489786e-09
- O 0 2.5191120585077442e-06
function O 0 3.7312155143354175e-08
mutations O 0 6.57707630580262e-08
and O 0 2.166168355799414e-09
a O 0 1.838376029184019e-08
complete O 0 5.161087557326027e-08
absence O 0 1.2898425438834238e-08
of O 0 7.58912932496969e-10
the O 0 3.678330307010924e-09
normal O 0 2.0451613735872343e-08
copy O 0 4.301899281244914e-08
of O 0 1.393460347109965e-09
ATM O 0 1.9673777273965243e-07
in O 0 5.66088775855178e-09
the O 0 6.35638475188216e-09
majority O 0 1.2994705755886571e-08
of O 0 1.3608493887318218e-08
mutated O 0 0.0006890248623676598
tumours B-Disease 1 0.9999997615814209
establishes O 0 8.223280474339845e-07
somatic O 0 6.761197255400475e-07
inactivation O 0 1.5405912563437596e-06
of O 0 1.6623993293052308e-09
this O 0 1.2167430396559098e-09
gene O 0 1.7879873581705397e-08
in O 0 2.5489061972194804e-09
the O 0 5.235585298635215e-09
pathogenesis O 0 8.489529790267625e-08
of O 0 4.6459533997733615e-09
sporadic B-Disease 0 9.24089690670371e-05
T I-Disease 0 0.06946264207363129
- I-Disease 0 3.511686372803524e-05
PLL I-Disease 0 1.1612878552114125e-05
and O 0 2.3259561388044858e-08
suggests O 0 1.496266399669821e-08
that O 0 1.8369521459504767e-09
ATM O 0 1.6735371843878966e-07
acts O 0 9.648011456420136e-08
as O 0 3.9093553283464644e-08
a O 0 2.8858596579084406e-06
tumour B-Disease 1 0.9999998807907104
suppressor O 0 0.005325345788151026
. O 0 3.071122591791209e-06

As O 0 7.856105526116153e-07
constitutional O 0 4.131096034143411e-07
DNA O 0 1.1961968766627251e-06
was O 0 7.963909638419864e-07
not O 0 1.5314913781594441e-09
available O 0 2.0779811205073884e-09
, O 0 1.6592472951160175e-09
a O 0 2.3183424957551324e-08
putative O 0 2.248039163532667e-05
hereditary O 0 0.011844494380056858
predisposition O 0 3.576502058422193e-05
to O 0 2.5704434847284574e-07
T B-Disease 0 0.0024591318797320127
- I-Disease 0 1.9549139324226417e-05
PLL I-Disease 0 4.046878984809155e-06
will O 0 7.918528943662295e-09
require O 0 4.352240789984307e-09
further O 0 4.184807167462168e-09
investigation O 0 3.115621183269468e-08
. O 0 2.4574445589564675e-08
. O 0 2.0163024316843803e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
protein O 0 0.00012795413204003125
kinase O 0 7.679306145291775e-05
is O 0 2.446942630740523e-07
involved O 0 2.619286121330333e-08
in O 0 4.268533526641249e-09
the O 0 5.670246050470951e-09
modulation O 0 5.8596111074393775e-08
of O 0 2.581668656631564e-09
the O 0 2.469977111729804e-08
Ca2 O 0 1.3566371308115777e-05
+ O 0 2.9396221634669928e-06
homeostasis O 0 1.2696930753008928e-05
in O 0 3.515437470014149e-07
skeletal O 0 0.0035506426356732845
muscle O 0 0.00012436628458090127
cells O 0 3.8026125821488677e-06
. O 0 7.399651735795487e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9658258557319641
DM B-Disease 1 1.0
) O 0 1.2083942237950396e-06
, O 0 1.8439878957110523e-08
the O 0 9.039726300841266e-09
most O 0 1.7721184519814415e-08
prevalent O 0 1.1085595360782463e-05
muscular B-Disease 0 0.4494796097278595
disorder I-Disease 0 0.00018012603686656803
in O 0 4.980420342803882e-08
adults O 0 1.6545792504985002e-06
, O 0 1.6143234304877296e-08
is O 0 2.4340222282148716e-08
caused O 0 1.846323556264906e-07
by O 0 7.114157707377444e-09
( O 0 2.899650475285398e-08
CTG O 0 1.2322019529165118e-06
) O 0 5.6844098317299085e-09
n O 0 9.433903613853545e-08
- O 0 4.961646595802449e-07
repeat O 0 6.269118557611364e-08
expansion O 0 7.04323444011834e-09
in O 0 1.4811086801458373e-09
a O 0 6.626483806115857e-09
gene O 0 3.0574231146829334e-08
encoding O 0 3.996753861201796e-08
a O 0 5.8819281889554986e-08
protein O 0 6.601659379157354e-07
kinase O 0 1.340192920906702e-05
( O 0 1.7329907109342457e-07
DM B-Disease 1 0.9998931884765625
protein O 0 9.663441460361355e-07
kinase O 0 5.007213076169137e-06
; O 0 8.746696522621278e-08
DMPK O 0 3.194963710484444e-06
) O 0 4.969618938588383e-09
and O 0 1.3831281675535934e-09
involves O 0 2.5763560174141276e-09
changes O 0 6.538374286435555e-09
in O 0 5.6596785036333586e-09
cytoarchitecture O 0 1.6153879869307275e-06
and O 0 6.813661457272246e-08
ion O 0 3.4680331282288535e-06
homeostasis O 0 5.8451576478546485e-05
. O 0 9.158521834251587e-07

To O 0 5.212163500800671e-07
obtain O 0 1.2734246013224038e-07
clues O 0 2.2899749296811933e-07
to O 0 7.890952780087446e-09
the O 0 6.310059585956651e-09
normal O 0 4.3412164529854635e-08
biological O 0 1.1830211477104058e-08
role O 0 6.6457994662982856e-09
of O 0 3.118627800446916e-09
DMPK O 0 1.0322667094442295e-06
in O 0 3.810687765337661e-09
cellular O 0 1.0601078770378081e-07
ion O 0 2.551515478899091e-07
homeostasis O 0 1.51936012571241e-06
, O 0 2.3358794010164274e-08
we O 0 4.699436395583234e-09
have O 0 2.4897468531293043e-09
compared O 0 4.0026262304593274e-09
the O 0 1.6612897724144204e-09
resting O 0 2.695461773782881e-07
[ O 0 3.5955576294099956e-08
Ca2 O 0 3.037081057755131e-07
+ O 0 3.114679714144586e-07
] O 0 2.6346262416154786e-07
i O 0 8.904777359930449e-08
, O 0 9.54912371398109e-10
the O 0 8.629826853123745e-10
amplitude O 0 1.5467042757677518e-08
and O 0 3.5795644226510603e-09
shape O 0 5.1287436519942275e-08
of O 0 4.16377154976999e-09
depolarization O 0 3.050905093004985e-07
- O 0 1.675451699156838e-06
induced O 0 6.84923406879534e-06
Ca2 O 0 1.5386162885988597e-06
+ O 0 4.997095857106615e-07
transients O 0 2.752701448116568e-06
, O 0 6.403844121649627e-09
and O 0 2.7788646939086448e-09
the O 0 7.500426946194239e-10
content O 0 6.104917460447723e-09
of O 0 4.782242379874901e-10
ATP O 0 7.880007046878745e-08
- O 0 9.894849881675327e-07
driven O 0 2.710629587454605e-07
ion O 0 1.9795413663814543e-07
pumps O 0 2.293395056085501e-07
in O 0 5.844183359471344e-09
cultured O 0 8.147886774168001e-07
skeletal O 0 1.0163394108531065e-05
muscle O 0 8.835866083245492e-07
cells O 0 2.541082544382789e-08
of O 0 8.950062913015699e-10
wild O 0 4.6135212983244855e-08
- O 0 1.2616463891390595e-06
type O 0 6.756074100167098e-08
and O 0 4.560233080042053e-08
DMPK O 0 2.19690332414757e-06
[ O 0 7.637899557266792e-08
- O 0 1.256495238521893e-06
/ O 0 2.207744955740054e-06
- O 0 1.9990977307315916e-05
] O 0 2.7540088467503665e-06
knockout O 0 5.740817141486332e-05
mice O 0 6.94849222782068e-05
. O 0 1.299021619161067e-06

In O 0 1.3106052847433602e-06
vitro O 0 1.0290377758792602e-05
- O 0 1.1468504453659989e-05
differentiated O 0 2.4105559077725047e-06
DMPK O 0 8.088079994195141e-06
[ O 0 3.154687533424294e-07
- O 0 1.5588597079840838e-06
/ O 0 1.8860865793612902e-06
- O 0 3.0436042379733408e-06
] O 0 3.5441550494397234e-07
myotubes O 0 3.1295314784074435e-07
exhibit O 0 3.945084969814161e-08
a O 0 1.5029479882855412e-08
higher O 0 2.6528013563620334e-08
resting O 0 2.3702786222656869e-07
[ O 0 8.192676403950827e-08
Ca2 O 0 4.7183675633277744e-07
+ O 0 4.237151927100058e-07
] O 0 1.6424597504283156e-07
i O 0 3.512393931259794e-08
than O 0 1.0804158678823228e-09
do O 0 9.108361842535828e-10
wild O 0 7.182067829347716e-09
- O 0 3.17352572665186e-07
type O 0 5.619002152457142e-08
myotubes O 0 3.2908340585890983e-07
because O 0 1.1377648823085451e-09
of O 0 2.5687102445104415e-10
an O 0 7.411828928383102e-10
altered O 0 1.822771196202666e-07
open O 0 2.7936026825159388e-08
probability O 0 4.226535121887309e-09
of O 0 1.2858968334583665e-09
voltage O 0 3.3529356642247876e-06
- O 0 1.0403012993265293e-06
dependent O 0 5.9155457421411484e-08
l O 0 2.42859726995448e-07
- O 0 1.643318370270208e-07
type O 0 4.712687839969476e-08
Ca2 O 0 7.555122465419117e-07
+ O 0 2.4024561184887716e-07
and O 0 4.211392834463368e-08
Na O 0 4.952465133101214e-06
+ O 0 2.289643816766329e-06
channels O 0 3.2346231364499545e-06
. O 0 8.314312935908674e-07

The O 0 1.330826762568904e-06
mutant O 0 7.369977083726553e-06
myotubes O 0 8.389626600546762e-06
exhibit O 0 3.2832417673489545e-07
smaller O 0 7.909852683951613e-08
and O 0 1.7308890321032777e-08
slower O 0 9.648891818869743e-07
Ca2 O 0 3.0116591460682685e-06
+ O 0 5.990723934701236e-07
responses O 0 7.39892556111954e-08
upon O 0 5.3247934950206854e-09
triggering O 0 1.3490870287569123e-07
by O 0 4.160357836013873e-09
acetylcholine O 0 2.701643097680062e-06
or O 0 5.804449187962746e-08
high O 0 2.8974287147320865e-07
external O 0 8.087055221039918e-07
K O 0 3.2759839996288065e-06
+ O 0 3.3400740448996658e-06
. O 0 3.632498248862248e-07

In O 0 4.3554075546126114e-07
addition O 0 6.708409472366839e-08
, O 0 1.6274688263706594e-08
we O 0 4.638825323866058e-09
observed O 0 7.104503207955304e-09
that O 0 3.343131327326887e-10
these O 0 1.1570473468225373e-09
Ca2 O 0 1.1445278005339787e-06
+ O 0 1.0636102842909168e-06
transients O 0 2.8832884709117934e-05
partially O 0 4.057916612509871e-06
result O 0 1.447301922752331e-08
from O 0 8.230728876235105e-10
an O 0 7.007533997516191e-10
influx O 0 6.619283787756558e-09
of O 0 1.0355298840636351e-09
extracellular O 0 4.522173924215167e-08
Ca2 O 0 9.458836984777008e-07
+ O 0 1.4975560702623625e-07
through O 0 5.3901607621753556e-09
the O 0 9.220216590222208e-09
l O 0 6.46516753022297e-07
- O 0 4.202774732675607e-07
type O 0 2.0808009537631733e-07
Ca2 O 0 2.2367469227901893e-06
+ O 0 1.1480761941129458e-06
channel O 0 4.131688911002129e-06
. O 0 7.828382422303548e-07

Neither O 0 1.6705660527804866e-05
the O 0 1.4134023729184264e-07
content O 0 2.784204014005809e-07
nor O 0 5.9211110681189894e-08
the O 0 3.786726932020201e-09
activity O 0 1.52621986160284e-08
of O 0 4.478720505574074e-09
Na O 0 1.602670408828999e-06
+ O 0 1.270026587008033e-06
/ O 0 1.0614924121910008e-06
K O 0 9.501664521849307e-07
+ O 0 8.116106187117111e-07
ATPase O 0 3.3051362606784096e-06
and O 0 1.4172127293932135e-07
sarcoplasmic O 0 3.155169906676747e-05
reticulum O 0 1.590658757777419e-05
Ca2 O 0 1.0833540727617219e-05
+ O 0 1.581894366609049e-06
- O 0 1.989338215935277e-06
ATPase O 0 2.073621089948574e-06
are O 0 1.2353154055233517e-08
affected O 0 2.089504036462131e-08
by O 0 2.278906663377711e-08
DMPK O 0 7.679386908421293e-05
absence O 0 1.855153413998778e-06
. O 0 8.31946863399935e-07

In O 0 4.805949060937564e-07
conclusion O 0 1.2502779611622827e-07
, O 0 9.506385900692749e-09
our O 0 4.650998253197258e-09
data O 0 6.591892809382216e-09
suggest O 0 1.4902850509201926e-08
that O 0 1.973726293513778e-09
DMPK O 0 1.299882910643646e-06
is O 0 1.5624899152300031e-09
involved O 0 1.310241359853137e-09
in O 0 1.4915555457406526e-09
modulating O 0 1.3468026338614436e-07
the O 0 4.424507427103208e-09
initial O 0 7.680524660713672e-09
events O 0 4.544852494348106e-09
of O 0 1.3349041871890677e-09
excitation O 0 1.9143165275181673e-07
- O 0 4.395995711092837e-05
contraction O 0 3.970385023421841e-06
coupling O 0 7.033141855572467e-07
in O 0 5.3578858683067665e-08
skeletal O 0 0.00012032782251480967
muscle O 0 6.189305167936254e-06
. O 0 6.202323987736236e-08
. O 0 2.165899388728576e-07

Constitutional O 0 4.953815368935466e-05
RB1 O 0 0.0021368481684476137
- O 0 0.00011137374531244859
gene O 0 1.2463375242077745e-05
mutations O 0 5.3662956815969665e-06
in O 0 7.530464785077129e-08
patients O 0 3.4726261333162256e-07
with O 0 6.119807238746944e-08
isolated O 0 3.9528134948341176e-05
unilateral B-Disease 0 0.00038346485234797
retinoblastoma I-Disease 0 0.0011805698741227388
. O 0 4.013195848528994e-06

In O 0 1.3822092341797543e-06
most O 0 1.4193848585364321e-07
patients O 0 1.9907906789740082e-07
with O 0 1.1507555797152236e-08
isolated O 0 4.053870270581683e-06
unilateral B-Disease 0 1.9920753402402624e-05
retinoblastoma I-Disease 0 0.00015042003360576928
, O 0 2.020924654289047e-07
tumor B-Disease 0 2.590855729067698e-06
development O 0 1.0302309227938622e-08
is O 0 6.048577194661675e-09
initiated O 0 2.5926544466869927e-08
by O 0 1.7892863857227326e-09
somatic O 0 2.375891341444003e-07
inactivation O 0 1.2832534821427544e-06
of O 0 2.154433520473731e-09
both O 0 1.2090954015775424e-08
alleles O 0 1.3172008550554892e-07
of O 0 9.468348771690671e-09
the O 0 3.9372679339066963e-07
RB1 O 0 0.0003205014218110591
gene O 0 6.331640179269016e-06
. O 0 1.5012482208476285e-06

However O 0 3.378233941475628e-06
, O 0 1.7016734688013457e-08
some O 0 1.002653959858435e-09
of O 0 6.596014845428044e-10
these O 0 7.591695272424204e-09
patients O 0 9.135181500141698e-08
can O 0 6.340065539234274e-08
transmit O 0 9.938581570168026e-06
retinoblastoma B-Disease 0 3.464518886175938e-05
predisposition O 0 4.6503260819008574e-05
to O 0 1.2301666174607817e-07
their O 0 4.7252345325432543e-07
offspring O 0 2.8996093533351086e-05
. O 0 6.119913109614572e-07

To O 0 4.316982256113988e-07
determine O 0 9.114382493180528e-08
the O 0 1.5190988023050522e-08
frequency O 0 6.515178938570898e-07
and O 0 1.555701700794998e-08
nature O 0 5.887133447401993e-09
of O 0 2.293452316948219e-09
constitutional O 0 1.4277804893936263e-07
RB1 O 0 3.5716078855330124e-05
- O 0 1.3009138456254732e-05
gene O 0 1.8160665149480337e-06
mutations O 0 6.136165779935254e-07
in O 0 1.3496874728957664e-08
patients O 0 4.165187306170992e-08
with O 0 2.9814628543789468e-09
isolated O 0 2.045327164523769e-06
unilateral B-Disease 0 8.225262718042359e-06
retinoblastoma I-Disease 0 1.724255344015546e-05
, O 0 2.461577430779016e-08
we O 0 4.0152965397055596e-09
analyzed O 0 1.9760324931894502e-08
DNA O 0 4.488934024493574e-08
from O 0 4.833700106843253e-09
peripheral O 0 1.8946461750601884e-06
blood O 0 1.7932696891875821e-06
and O 0 9.402861422813658e-08
from O 0 6.64430643837477e-08
tumor B-Disease 0 6.268915603868663e-05
tissue O 0 2.7588786906562746e-05
. O 0 1.1517653319970123e-06

The O 0 2.643412528868794e-07
analysis O 0 1.498566177815519e-07
of O 0 4.880253356986941e-08
tumors B-Disease 1 0.9999994039535522
from O 0 2.7402697000411536e-08
54 O 0 1.652392285222959e-07
( O 0 7.352413788908052e-09
71 O 0 8.114018612559448e-08
% O 0 4.060008773620893e-09
) O 0 4.720473456565344e-10
of O 0 8.444351884406842e-10
76 O 0 1.0011871864890054e-07
informative O 0 2.1238835756776098e-07
patients O 0 5.677336503140396e-07
showed O 0 4.090663423994556e-06
loss O 0 1.334597357072198e-07
of O 0 1.5293437627406092e-08
constitutional O 0 2.264572458443581e-06
heterozygosity O 0 0.0004483363009057939
( O 0 1.305004047935654e-06
LOH O 1 0.9969937801361084
) O 0 1.1000169308772456e-07
at O 0 2.766022362266085e-07
intragenic O 0 2.556548861321062e-05
loci O 0 1.3885609405406285e-05
. O 0 1.046995635078929e-06

Three O 0 2.879204430428217e-06
of O 0 9.747227380785262e-08
13 O 0 1.2618268101505237e-06
uninformative O 0 0.00011505794827826321
patients O 0 2.917728352258564e-06
had O 0 7.493283646908822e-07
constitutional O 0 8.509947519996786e-07
deletions O 0 3.635414395830594e-05
. O 0 1.4047994909560657e-06

For O 0 1.104532429963001e-06
39 O 0 2.9713874027947895e-06
randomly O 0 1.1231445569137577e-06
selected O 0 1.689508962954278e-06
tumors B-Disease 1 0.9999994039535522
, O 0 1.0801489480627424e-07
SSCP O 0 9.219354978995398e-06
, O 0 3.102545420574643e-08
hetero O 0 1.38575569508248e-06
- O 0 3.6839003314526053e-07
duplex O 0 1.956232381417067e-06
analysis O 0 1.2375464208957965e-08
, O 0 1.1269271071867593e-09
sequencing O 0 8.375717897024515e-09
, O 0 1.5115083629169135e-09
and O 0 4.7856394402856495e-09
Southern O 0 1.741183552894654e-08
blot O 0 4.420618552103406e-06
analysis O 0 2.031786472400654e-08
were O 0 8.267202922240813e-09
used O 0 5.367314148685409e-09
to O 0 1.9444769350229762e-08
identify O 0 7.998602882253181e-07
mutations O 0 6.0422648857638706e-06
. O 0 4.869189638156968e-07

Mutations O 0 0.0006712480098940432
were O 0 8.605728112343058e-07
detected O 0 3.9133175278038834e-07
in O 0 1.7153436004946343e-08
21 O 0 2.1078317047340533e-07
( O 0 1.076101607822011e-08
91 O 0 6.692179255196606e-08
% O 0 1.1590579163112125e-08
) O 0 2.6887638782113754e-09
of O 0 1.5294050470515685e-08
23 O 0 0.0020199595019221306
tumors B-Disease 1 1.0
with O 0 1.8071024896926247e-05
LOH O 1 0.9999997615814209
. O 0 3.786061142818653e-06

In O 0 1.5550733678537654e-06
6 O 0 1.3875779814043199e-06
( O 0 6.135328334266887e-08
38 O 0 2.0076372209132387e-07
% O 0 8.89058604514048e-09
) O 0 2.842246882295285e-09
of O 0 9.342577378390615e-09
16 O 0 3.147050301777199e-05
tumors B-Disease 1 1.0
without O 0 3.6483575627244136e-07
LOH O 1 0.8312302827835083
, O 0 7.962905002045773e-09
one O 0 6.276941189042873e-09
mutation O 0 1.0576096087788756e-07
was O 0 1.9473205270514882e-07
detected O 0 3.4307674923184095e-08
, O 0 1.0908894898520316e-09
and O 0 1.6882979458898717e-09
in O 0 3.934510495184895e-09
9 O 0 1.4798648351188604e-07
( O 0 4.664875596915863e-09
56 O 0 3.2791540149901266e-08
% O 0 1.6139407588156018e-09
) O 0 3.1630101315904824e-10
of O 0 8.663784689666443e-10
the O 0 1.410803406542982e-06
tumors B-Disease 1 1.0
without O 0 5.884575671188941e-07
LOH O 1 0.9311006665229797
, O 0 1.6818450632172244e-08
both O 0 1.610119859662973e-08
mutations O 0 7.549757583547034e-07
were O 0 6.327960733187865e-08
found O 0 1.192284173612279e-07
. O 0 4.4993575443186273e-07

Thus O 0 2.737619070103392e-06
, O 0 2.0458870153561293e-08
a O 0 5.294432003921656e-09
total O 0 2.512722696579317e-09
of O 0 2.3513848645961843e-09
45 O 0 7.674187685324796e-08
mutations O 0 1.710907184815369e-07
were O 0 6.415925923874966e-08
identified O 0 3.457214461377589e-07
in O 0 3.701395598909585e-07
tumors B-Disease 1 0.9999998807907104
of O 0 1.1557238366322053e-07
36 O 0 5.53725158169982e-06
patients O 0 1.9680412606248865e-06
. O 0 4.904506454295188e-07

Thirty O 0 2.947557732113637e-05
- O 0 1.9408256775932387e-05
nine O 0 1.4136652737306576e-07
of O 0 1.4942636017423183e-09
the O 0 5.562918126145178e-09
mutations O 0 1.105116638200343e-07
- O 0 1.2797615056570066e-07
including O 0 7.070908747408566e-09
34 O 0 4.2609865857912155e-08
small O 0 1.3514752872367808e-08
mutations O 0 1.5019084287359874e-07
, O 0 1.4304314399637974e-09
2 O 0 4.3917838254969865e-09
large O 0 3.331840359166449e-09
structural O 0 3.361614346886199e-07
alterations O 0 1.5586055042149383e-06
, O 0 8.129443784810064e-09
and O 0 1.1772408825549974e-08
hypermethylation O 0 2.5751814973773435e-06
in O 0 2.164467893805977e-08
3 O 0 1.5187154076556908e-06
tumors O 1 0.9999996423721313
- O 0 0.00208257045596838
were O 0 2.0287427560106153e-06
not O 0 7.730258211324781e-09
detected O 0 3.7652021944722947e-08
in O 0 1.8665917700388945e-09
the O 0 4.740542181025376e-09
corresponding O 0 1.3216654792813642e-07
peripheral O 0 1.1751849342545029e-05
blood O 0 4.793654170498485e-06
DNA O 0 4.111399448447628e-06
. O 0 7.577086762466934e-07

In O 0 1.4621513173551648e-06
6 O 0 1.7825379927671747e-06
( O 0 5.1943985113211966e-08
17 O 0 1.4529781822147925e-07
% O 0 7.305389182477029e-09
) O 0 3.631143441484852e-10
of O 0 2.5991478413978086e-10
the O 0 9.453533067471653e-09
36 O 0 2.532369478558394e-07
patients O 0 1.4297421024878076e-08
, O 0 8.497249570638132e-10
a O 0 9.981588888763326e-09
mutation O 0 1.8765385334518214e-07
was O 0 4.1713499854267866e-07
detected O 0 2.412272337437571e-08
in O 0 3.67827240888019e-10
constitutional O 0 6.575367805794485e-09
DNA O 0 7.29401747889824e-08
, O 0 1.5050011237249805e-09
and O 0 1.1309063685516207e-09
1 O 0 1.019866302520711e-09
of O 0 3.487676536462203e-10
these O 0 3.377589541386783e-09
mutations O 0 1.2103672020202794e-07
is O 0 2.8971172127967293e-09
known O 0 1.2861967491062387e-08
to O 0 5.694263283118062e-09
be O 0 1.2265673809963573e-08
associated O 0 2.7325814500045453e-08
with O 0 3.5255492747410244e-08
reduced O 0 2.9056629955448443e-06
expressivity O 0 0.00016544549725949764
. O 0 1.4882817822581274e-06

The O 0 2.786382253816555e-07
presence O 0 4.654798857472997e-08
of O 0 1.689757445078044e-09
a O 0 1.2194247389629709e-08
constitutional O 0 1.0867369582001629e-07
mutation O 0 1.5863888620515354e-06
was O 0 2.274361804666114e-06
not O 0 4.257280306063649e-09
associated O 0 4.583277313230383e-09
with O 0 6.685207387668868e-10
an O 0 3.5806841935936973e-09
early O 0 2.025623047074987e-07
age O 0 7.963304682334638e-08
at O 0 4.577723444754156e-08
treatment O 0 7.353622208938759e-07
. O 0 3.3764067097763473e-07

In O 0 2.5415924937988166e-06
1 O 0 1.545849841022573e-06
patient O 0 2.901625521189999e-06
, O 0 5.767127220224211e-08
somatic O 0 3.5836933420796413e-06
mosaicism O 0 0.00034647106076590717
was O 0 2.2182861357578076e-05
demonstrated O 0 8.627432634966681e-08
by O 0 1.2534023818844275e-09
molecular O 0 1.3989950531367867e-08
analysis O 0 4.004733877849276e-09
of O 0 1.3224661365995871e-09
DNA O 0 1.8480110952623363e-07
and O 0 2.2001767518986526e-08
RNA O 0 2.436266299810086e-07
from O 0 1.7492924442308322e-08
peripheral O 0 1.6255680748145096e-05
blood O 0 1.1544218068593182e-05
. O 0 7.825710213182901e-07

In O 0 1.1444077472333447e-06
2 O 0 1.024516677716747e-06
patients O 0 2.919605321949348e-07
without O 0 8.909020188241357e-09
a O 0 2.8660105400035718e-08
detectable O 0 6.000746907375287e-06
mutation O 0 3.4023625516965694e-07
in O 0 1.0619106483034102e-08
peripheral O 0 1.4144046872388572e-05
blood O 0 6.0399661379051395e-06
, O 0 4.2703515390485336e-08
mosaicism O 0 1.1990695384156425e-05
was O 0 1.1149738838867052e-06
suggested O 0 4.8838568744713484e-08
because O 0 2.542797750137993e-09
1 O 0 3.2305622621464636e-09
of O 0 8.648100568997563e-10
the O 0 5.812004744143451e-08
patients O 0 1.3453460496748448e-06
showed O 0 0.00033469469053670764
multifocal O 1 0.9998283386230469
tumors B-Disease 1 1.0
and O 0 4.6563798150600633e-07
the O 0 7.63977592299625e-09
other O 0 4.0514844812378215e-09
later O 0 1.0707685049737847e-07
developed O 0 1.8468676898919512e-07
bilateral B-Disease 0 6.676993962173583e-07
retinoblastoma I-Disease 0 0.0001344329648418352
. O 0 1.3236524409876438e-06

In O 0 7.632160645698605e-07
conclusion O 0 1.2198776744298812e-07
, O 0 1.1624341489380186e-08
our O 0 1.088333689835963e-08
results O 0 1.3953760813478766e-08
emphasize O 0 5.33046673467652e-08
that O 0 1.7087433690221587e-09
the O 0 2.480125438353298e-09
manifestation O 0 9.614944218583332e-08
and O 0 1.123076120990163e-08
transmissibility O 0 4.2410812284288113e-07
of O 0 2.0226063046635545e-09
retinoblastoma B-Disease 0 4.384956469039025e-07
depend O 0 7.961052261862278e-09
on O 0 1.5780956630351284e-07
the O 0 5.6836726436415574e-09
nature O 0 4.4447650004997286e-09
of O 0 4.069892756142224e-10
the O 0 2.43438780245242e-09
first O 0 3.897725520118911e-08
mutation O 0 2.7879282882281586e-08
, O 0 5.826628068916762e-10
its O 0 6.558830145664274e-10
time O 0 1.5531066432927787e-09
in O 0 3.543450810550297e-10
development O 0 6.757150949887603e-10
, O 0 1.1994018001004747e-09
and O 0 1.9602126588580404e-09
the O 0 4.064276137860645e-10
number O 0 1.0538009354021938e-09
and O 0 1.6567774929754364e-09
types O 0 1.235741287075598e-09
of O 0 1.3583125735294743e-09
cells O 0 2.081699257416858e-08
that O 0 2.4448154611889095e-09
are O 0 3.727955721899434e-09
affected O 0 3.518770697041873e-08
. O 0 1.77841990023353e-08
. O 0 1.417123485225602e-07

Hereditary B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9997983574867249
of I-Disease 0 1.3500135764843435e-07
the I-Disease 0 4.161471167662967e-08
fifth I-Disease 0 2.1037378701294074e-06
component I-Disease 0 1.3612977056709497e-07
of I-Disease 0 3.2821811934979905e-09
complement I-Disease 0 9.294927849623491e-08
in O 0 5.992929175135941e-08
man O 0 6.138942262623459e-05
. O 0 5.487507905854727e-07

I O 0 0.0034662552643567324
. O 0 2.9586139135062695e-05

Clinical O 0 0.0001332887914031744
, O 0 1.4368494021255174e-06
immunochemical O 0 1.3393879271461628e-05
, O 0 5.0909090276718416e-08
and O 0 3.003015081048943e-08
family O 0 2.1560957463861996e-07
studies O 0 1.7586505407507502e-07
. O 0 4.375607431938988e-07

The O 0 7.872838523326209e-07
first O 0 1.5749759540995e-07
recognized O 0 1.0032918851266004e-07
human O 0 1.1290203616454164e-07
kindred O 0 5.020970638724975e-05
with O 0 1.4151845789456274e-05
hereditary B-Disease 1 0.9999985694885254
deficiency I-Disease 0 0.019137047231197357
of I-Disease 0 4.844157075467592e-09
the I-Disease 0 1.923561399053142e-08
fifth I-Disease 0 1.140052631853905e-06
component I-Disease 0 9.298367587007306e-08
of I-Disease 0 6.166909649607533e-09
complement I-Disease 0 4.6328858616107027e-07
( O 0 1.2087902234725334e-07
C5 O 0 3.9528436900582165e-05
) O 0 2.7451767081743128e-08
is O 0 2.8378661198757982e-08
described O 0 1.7416424498151173e-06
. O 0 6.907073952788778e-07

The O 0 9.596546988177579e-07
proband O 0 6.231379302334972e-06
, O 0 1.6931714696966083e-08
a O 0 1.507515712262375e-08
20 O 0 2.994144310264346e-08
- O 0 4.800887154488009e-07
year O 0 2.1054184173863177e-08
- O 0 2.9859886581107276e-06
old O 0 3.973051661887439e-06
black O 0 5.094739663036307e-06
female O 0 1.398821041220799e-06
with O 0 5.107256129122106e-06
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9999935626983643
erythematosus I-Disease 1 0.9999997615814209
since O 0 3.1262939046428073e-06
age O 0 3.254275497965864e-07
11 O 0 1.0329465993663689e-07
, O 0 4.107219098159476e-08
lacked O 0 1.2206182873342186e-06
serum O 0 5.135237188369501e-06
hemolytic O 0 3.5634493542602286e-05
complement O 0 1.5167326239406975e-07
activity O 0 7.830414716636369e-08
, O 0 4.413718279749901e-09
even O 0 1.8455185823995635e-08
during O 0 2.4878809767869825e-07
remission O 0 3.3907513170561288e-06
. O 0 3.3456069559179014e-07

C5 O 0 0.01072392612695694
was O 0 5.941130802966654e-05
undetectable O 0 6.484058758360334e-06
in O 0 7.094282494790605e-08
her O 0 7.195590114861261e-07
serum O 0 1.3932664160165587e-06
by O 0 7.3541390754883196e-09
both O 0 2.8111346139780835e-08
immunodiffusion O 0 1.1646771781670395e-05
and O 0 2.019933617702918e-06
hemolytic O 0 0.0032496307976543903
assays O 0 3.256626951042563e-05
. O 0 1.100573626899859e-06

Other O 0 3.2185283771468676e-07
complement O 0 3.6408323467185255e-07
components O 0 1.8477626895219146e-07
were O 0 3.9046305744250276e-08
normal O 0 2.7813689129629893e-08
during O 0 4.097969608096719e-08
remission O 0 2.9645923405041685e-07
of O 0 6.911671679432629e-09
lupus O 0 0.00020848056010436267
, O 0 2.1921302106875373e-08
but O 0 9.92565940549639e-09
C1 O 0 2.6879299639404053e-06
, O 0 6.984399725240564e-09
C4 O 0 2.650955593708204e-06
, O 0 3.9088781988994015e-08
C2 O 0 2.3712536858511157e-06
, O 0 8.734871492777074e-09
and O 0 1.9892832270329563e-08
C3 O 0 7.764892870909534e-06
levels O 0 2.964386283110798e-07
fell O 0 2.083434628730174e-05
during O 0 4.322659208355617e-07
exacerbations O 0 0.00028473802376538515
. O 0 1.1226690048715682e-06

A O 0 9.951508218364324e-06
younger O 0 3.2614075280434918e-06
half O 0 3.653587157259608e-07
- O 0 3.349171038280474e-06
sister O 0 6.890954409755068e-06
, O 0 1.7764129722763755e-08
who O 0 3.659850449366786e-07
had O 0 1.8007725657298579e-06
no O 0 1.0802437344636928e-07
underlying O 0 1.6527985280845314e-05
disease O 0 7.747199560981244e-06
, O 0 4.3967311569304e-08
was O 0 1.5606936358381063e-05
also O 0 1.7453989187288244e-07
found O 0 3.3513195774048654e-08
to O 0 2.660945064292264e-08
lack O 0 3.986438343872578e-07
immunochemically O 0 7.34294080757536e-05
detectable O 0 4.1128652810584754e-05
C5 O 0 0.0001072427403414622
. O 0 1.2006873930658912e-06

By O 0 5.733877969760215e-06
hemolytic O 0 0.0015305191045626998
assay O 0 1.021592652250547e-05
, O 0 1.8099891008205304e-07
she O 0 1.7653047734711436e-07
exhibited O 0 6.959547960150303e-08
1 O 0 7.842563043425343e-09
- O 0 3.420346956772846e-07
2 O 0 7.715252792195315e-08
% O 0 2.090045247982175e-09
of O 0 1.5938110553559426e-10
the O 0 2.4362785122633568e-09
normal O 0 6.468503954693006e-08
serum O 0 4.839657208322024e-07
C5 O 0 2.654117679412593e-06
level O 0 1.2666402149363876e-08
and O 0 5.1835877812322906e-09
normal O 0 1.3855579794608275e-08
concentrations O 0 3.117523661444466e-08
of O 0 7.608376151324592e-10
other O 0 1.6724299722881142e-09
complement O 0 9.57618055963394e-08
components O 0 4.263433766027447e-07
. O 0 4.970574423168728e-07

C5 O 0 0.00208548572845757
levels O 0 1.1304625786578981e-06
of O 0 8.164531273280318e-09
other O 0 2.557135614367212e-09
family O 0 2.4370697460085466e-08
members O 0 3.3412523858800114e-09
were O 0 1.0692925656030638e-08
either O 0 3.4134557402865084e-09
normal O 0 1.1003921329688637e-08
or O 0 3.4998197673274944e-09
approximately O 0 2.8775886118381777e-09
half O 0 1.4455610930497187e-08
- O 0 4.7509726641692396e-07
normal O 0 4.6689905275343335e-08
, O 0 5.32673372077852e-09
consistent O 0 6.754965653499312e-08
with O 0 6.490328985364613e-08
autosomal O 0 6.775229121558368e-05
codominant O 0 1.4505413673759904e-05
inheritance O 0 6.408135959645733e-07
of O 0 7.329017837065521e-09
the O 0 1.0313519993587761e-07
gene O 0 1.9046019588131458e-05
determining O 0 0.00038004975067451596
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.970968009525677e-06

Normal O 0 0.0004945466644130647
hemolytic O 0 0.35201311111450195
titers O 0 0.0031321279238909483
were O 0 3.8521729948115535e-06
restored O 0 1.2510179203673033e-06
to O 0 7.057600015514254e-08
both O 0 4.539656686119997e-07
homozygous O 1 0.512660562992096
C5 B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
deficient I-Disease 1 1.0
( O 0 5.6239618970721494e-06
C5D B-Disease 1 0.9999997615814209
) O 0 8.96325929033992e-08
sera O 0 6.751320142939221e-07
by O 0 1.2724971076849556e-09
addition O 0 1.8549294322767196e-09
of O 0 1.5481084192359162e-09
highly O 0 5.835586947000593e-08
purified O 0 8.186191848835733e-07
human O 0 2.793350404317607e-07
C5 O 0 0.0001078790592146106
. O 0 8.00282180080103e-07

In O 0 2.287901679665083e-06
specific O 0 5.923030812482466e-07
C5 O 0 7.309142529265955e-05
titrations O 0 3.643042509793304e-05
, O 0 1.7376477501329646e-07
however O 0 7.816906233415466e-09
, O 0 3.826463590428375e-09
it O 0 9.185637139808023e-09
was O 0 1.2969543377039372e-06
noted O 0 3.0866733169432337e-08
that O 0 1.4841996520686962e-09
when O 0 2.4509694274144067e-09
limited O 0 1.3094394457624503e-09
amounts O 0 7.638154553291088e-10
of O 0 1.8761792119903475e-09
C5 O 0 4.966464985045604e-06
were O 0 3.687119232154146e-08
assayed O 0 1.0059802235673487e-07
in O 0 1.833899365699665e-09
the O 0 7.155374071032838e-10
presence O 0 2.8688968978229923e-09
of O 0 1.0454367371792728e-09
low O 0 9.277747636815548e-08
dilutions O 0 2.694646809686674e-06
of O 0 1.0997228017117777e-08
either O 0 5.147078923073423e-07
C5D B-Disease 1 1.0
serum O 0 2.92877348329057e-06
, O 0 3.1876492556648373e-09
curving O 0 1.2465443433029577e-07
rather O 0 3.3039322389072368e-09
than O 0 1.4853919205748412e-09
linear O 0 9.713724047344385e-09
dose O 0 7.89566882986037e-08
- O 0 1.3809862764446734e-07
response O 0 1.3629819939353638e-08
plots O 0 1.866710590547882e-07
were O 0 3.454337331731949e-07
consistently O 0 9.898681128106546e-07
obtained O 0 9.228151576223809e-09
, O 0 3.4039244756201015e-09
suggesting O 0 2.351377226261775e-08
some O 0 4.054290680954864e-09
inhibitory O 0 5.532530167329242e-07
effect O 0 4.064901020228717e-07
. O 0 4.933515924676612e-07

Further O 0 1.480916807850008e-06
studies O 0 1.5020701482626464e-07
suggested O 0 9.745312468112388e-08
that O 0 8.564911446740098e-09
low O 0 4.004125457868213e-07
dilutions O 0 3.363872747286223e-05
of O 0 1.178233048904076e-07
C5D B-Disease 1 0.9999997615814209
serum O 0 1.43632883009559e-06
contain O 0 6.144460495960402e-09
a O 0 8.152237995773248e-09
factor O 0 2.4423652433824827e-08
( O 0 4.194556257886006e-09
or O 0 4.310808598972926e-09
factors O 0 3.349336807900727e-09
) O 0 1.7798985618711072e-09
interfering O 0 7.423773595860439e-09
at O 0 5.547797332638993e-09
some O 0 5.584400164515557e-10
step O 0 7.1807804147283605e-09
in O 0 1.3085231787002272e-09
the O 0 1.301576535439608e-08
hemolytic O 0 1.5833576981094666e-05
assay O 0 4.1114756754723203e-07
of O 0 1.0000702488355273e-08
C5 O 0 3.396740430616774e-05
, O 0 1.175479447113048e-08
rather O 0 3.1471547590200544e-09
than O 0 1.7654006034817371e-09
a O 0 2.5883359455747268e-08
true O 0 2.1833842822616134e-07
C5 O 0 1.5760213500470854e-05
inhibitor O 0 1.5264898820532835e-06
or O 0 1.6530322000107844e-07
inactivator O 0 2.681041405594442e-05
. O 0 6.028153620718513e-07

Of O 0 4.341026169640827e-07
clinical O 0 1.5473437997570727e-06
interest O 0 2.058884263078653e-07
are O 0 1.854053088834462e-08
( O 0 1.1340735461828899e-08
a O 0 1.4151619431856943e-08
) O 0 4.9073856089876244e-09
the O 0 3.4197575882188858e-09
documentation O 0 4.5283364613624144e-08
of O 0 4.121218566410789e-08
membranous O 0 0.3802650272846222
glomerulonephritis B-Disease 1 1.0
, O 0 3.972009653807618e-05
vasculitis B-Disease 1 0.9999998807907104
, O 0 3.553835085767787e-06
and O 0 0.0007210310432128608
arthritis B-Disease 1 1.0
in O 0 6.07922885365042e-08
an O 0 1.6804888147703423e-08
individual O 0 4.634626904476136e-08
lacking O 0 5.260883995106269e-07
C5 O 0 5.067123856861144e-05
( O 0 1.601684296304029e-08
and O 0 2.4779975849043012e-09
its O 0 1.7113200856400113e-09
biologic O 0 1.89823126106603e-07
functions O 0 3.1507465525493217e-09
) O 0 1.946554029075287e-09
, O 0 1.2245937597299417e-09
and O 0 1.1221168882968868e-08
( O 0 6.06396310942614e-09
b O 0 1.2217387990176576e-08
) O 0 1.0324788801696627e-09
a O 0 4.4241361685237734e-09
remarkable O 0 5.835998706515966e-08
propensity O 0 2.6698985493567307e-06
to O 0 5.385743975239166e-07
bacterial B-Disease 1 0.9999991655349731
infections I-Disease 1 0.9999995231628418
in O 0 1.1477196970588466e-08
the O 0 1.6401957125822264e-08
proband O 0 3.661791424747207e-06
, O 0 6.523451556716964e-09
even O 0 3.243590063206625e-09
during O 0 2.3381603320160593e-09
periods O 0 5.394048763207593e-09
of O 0 8.242023175064617e-10
low O 0 1.3908793050632084e-07
- O 0 7.607033012391184e-07
dose O 0 1.1830577051341606e-07
or O 0 3.872292264617272e-09
alternate O 0 4.447209889235637e-08
- O 0 6.562204362126067e-06
day O 0 7.870796707720729e-07
corticosteroid O 0 3.554720024112612e-05
therapy O 0 1.7965416191145778e-05
. O 0 1.0881011576202582e-06

Other O 0 2.624252317673381e-07
observations O 0 5.999786480970215e-07
indicate O 0 1.529828637103492e-07
that O 0 6.363687798938145e-09
the O 0 2.299770152092151e-08
C5D B-Disease 1 0.9999994039535522
state O 0 5.946743542040167e-09
is O 0 2.194195491966866e-09
compatible O 0 1.5394935104495744e-08
with O 0 3.368614720500318e-09
normal O 0 8.453255873064336e-08
coagulation O 0 2.168524275703021e-07
function O 0 1.0744445333443764e-08
and O 0 1.1540238986640361e-08
the O 0 3.0248810123367775e-09
capacity O 0 7.624592512911477e-09
to O 0 1.8972452497934e-09
mount O 0 4.320161508530873e-07
a O 0 6.081658625589625e-07
neutrophilic O 0 0.0013559923972934484
leukocytosis O 0 0.0013340634759515524
during O 0 4.795336735696765e-06
pyogenic B-Disease 0 0.008785335347056389
infection I-Disease 0 0.0006415920797735453
. O 0 2.924398074810597e-07
. O 0 1.114584733841184e-06

Susceptibility O 0 0.07648441195487976
to O 0 7.071165600791574e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.0004998067743144929
twins O 0 0.0004594238998834044
: O 0 2.1997822230446218e-08
the O 0 2.733544723909631e-09
role O 0 7.3461334793023525e-09
of O 0 1.491325174463043e-09
genes O 0 8.719877797602749e-08
, O 0 1.8036372395613398e-08
HLA O 0 3.130046707155998e-06
, O 0 6.832268972800648e-09
and O 0 1.0808945738460807e-08
the O 0 1.9348210145153644e-08
environment O 0 6.632239433201903e-07
. O 0 4.417481704876991e-07

OBJECTIVE O 0 6.5445487962279e-06
To O 0 5.2162508978881306e-08
determine O 0 2.2713907199545247e-08
the O 0 3.701527306887442e-09
relative O 0 5.980916739645181e-08
effects O 0 1.1940412036892667e-07
of O 0 1.4875694009930385e-09
genetic O 0 2.3897484879853437e-07
and O 0 1.5543669462658727e-08
environmental O 0 2.3258140302573338e-08
factors O 0 7.079977937252124e-09
in O 0 2.346551752907544e-08
susceptibility O 0 0.0001648221368668601
to O 0 0.00023856012558098882
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.00015080794401001185
AS B-Disease 1 0.988993227481842
) O 0 3.7560718624263245e-07
. O 0 4.3343746369828295e-07

METHODS O 0 9.304555533162784e-06
Twins O 0 0.00010317282431060448
with O 0 4.985628834219824e-07
AS B-Disease 1 0.9973626732826233
were O 0 6.624306365665689e-07
identified O 0 4.89368545686375e-08
from O 0 1.691537354631123e-09
the O 0 3.416126270749942e-09
Royal O 0 2.5217892130058317e-07
National O 0 3.5145784949008885e-08
Hospital O 0 2.2043809622118715e-06
for O 0 1.5081261039995297e-07
Rheumatic B-Disease 1 0.9882491827011108
Diseases I-Disease 0 6.50661313557066e-05
database O 0 3.518963012538734e-06
. O 0 1.7415444517610013e-06

Clinical O 0 8.198801515391096e-05
and O 0 7.250552584991965e-07
radiographic O 0 1.6190175301744603e-05
examinations O 0 9.062064805220871e-07
were O 0 3.483631871858961e-07
performed O 0 7.271028579225458e-08
to O 0 2.8911333327386046e-09
establish O 0 5.9347584624447336e-08
diagnoses O 0 3.1089934054762125e-05
, O 0 3.55766260895507e-08
and O 0 1.3901103557145689e-06
disease O 0 1.2937304745719302e-05
severity O 0 8.839971087581944e-06
was O 0 2.093039711326128e-06
assessed O 0 2.671711207824501e-08
using O 0 7.432869875145798e-09
a O 0 5.165617977809234e-08
combination O 0 9.186270943928321e-08
of O 0 7.74809105763552e-09
validated O 0 5.190075853533926e-07
scoring O 0 2.595546959582862e-07
systems O 0 1.6774292816990055e-06
. O 0 5.583393090091704e-07

HLA O 0 0.0022727621253579855
typing O 0 3.268686850788072e-05
for O 0 3.081591444242804e-07
HLA O 0 2.9745981009909883e-05
- O 0 3.4779563975462224e-06
B27 O 0 2.2744354737369576e-06
, O 0 3.8901351473441537e-08
HLA O 0 1.5124210221983958e-06
- O 0 5.174433681531809e-07
B60 O 0 5.353932692742092e-07
, O 0 6.530199048171426e-09
and O 0 1.798326465518585e-08
HLA O 0 9.110564860748127e-06
- O 0 7.214384095277637e-05
DR1 O 0 0.19516237080097198
was O 0 3.3248920772166457e-06
performed O 0 5.1623281649426644e-08
by O 0 1.3246979069236886e-09
polymerase O 0 1.8215375519048393e-07
chain O 0 4.304328626858478e-07
reaction O 0 1.0070396072592303e-08
with O 0 8.284467556407549e-10
sequence O 0 2.2842247204835076e-08
- O 0 1.0101757652591914e-07
specific O 0 6.025478338500534e-09
primers O 0 6.612925744775566e-07
, O 0 8.348938429492136e-09
and O 0 2.194954262790816e-08
zygosity O 0 2.8791384920623386e-06
was O 0 1.5808431896857655e-07
assessed O 0 8.64543636680537e-08
using O 0 1.3191242942411918e-07
microsatellite O 0 3.1426414352608845e-05
markers O 0 5.505828085006215e-05
. O 0 1.5088481859493186e-06

Genetic O 0 5.785217581433244e-05
and O 0 2.443670723550895e-07
environmental O 0 5.295646587910596e-08
variance O 0 3.0974192100075015e-08
components O 0 4.6774047746112046e-08
were O 0 7.695265225038384e-08
assessed O 0 1.2875418953228746e-08
with O 0 8.731635969816409e-10
the O 0 3.036268347855753e-09
program O 0 7.510566391033535e-09
Mx O 0 1.06546558242826e-07
, O 0 5.647512457684911e-10
using O 0 5.404148240018003e-10
data O 0 1.8565788906244052e-09
from O 0 4.922917073990618e-10
this O 0 2.886888783582009e-10
and O 0 3.524377456542993e-09
previous O 0 1.7570034316349847e-08
studies O 0 3.531779535492774e-09
of O 0 2.6535085240197986e-09
twins O 0 7.235650173242902e-06
with O 0 3.427746548823052e-07
AS B-Disease 1 0.9999731779098511
. O 0 1.3144945114618167e-06

RESULTS O 0 1.403558417223394e-05
Six O 0 3.1772111697137007e-07
of O 0 2.985219893503199e-08
8 O 0 1.514419977866055e-06
monozygotic O 0 0.00018715728947427124
( O 0 4.3627159129755455e-07
MZ O 1 0.8566701412200928
) O 0 9.961660651924831e-08
twin O 0 6.83129474055022e-05
pairs O 0 1.064746447809739e-05
were O 0 2.5179899239446968e-05
disease O 0 4.399509634822607e-06
concordant O 0 2.2591086690226803e-06
, O 0 2.2912498565119677e-08
compared O 0 1.567063101504118e-08
with O 0 1.4352495858460657e-09
4 O 0 2.9737574180899173e-08
of O 0 1.8302895865573987e-09
15 O 0 6.563779209045606e-08
B27 O 0 8.049368034335203e-07
- O 0 7.035482212813804e-06
positive O 0 2.84745567569189e-07
dizygotic O 0 2.9364111924223835e-06
( O 0 2.7349646103402847e-08
DZ O 0 1.4359438864630647e-05
) O 0 1.7691229814431608e-08
twin O 0 2.7823032269225223e-06
pairs O 0 4.183795567769266e-07
( O 0 1.6924870394063873e-08
27 O 0 2.1066118449653004e-07
% O 0 5.142277714753618e-09
) O 0 1.1331215965526553e-09
and O 0 3.294468031711517e-09
4 O 0 1.2608383670453804e-08
of O 0 2.609894300675819e-09
32 O 0 8.127910291477747e-07
DZ O 0 0.00047186206211335957
twin O 0 4.146583887632005e-05
pairs O 0 5.607042794508743e-07
overall O 0 1.198565087179304e-06
( O 0 1.891392820141391e-08
12 O 0 1.613978639625202e-08
. O 0 9.14047593170153e-09
5 O 0 8.400360229643411e-08
% O 0 2.4640293361244403e-08
) O 0 3.603171094823665e-08
. O 0 2.187880312476409e-07

Nonsignificant O 0 0.00018465035827830434
increases O 0 2.768349759207922e-06
in O 0 1.6205087050025213e-08
similarity O 0 3.411680538079054e-08
with O 0 3.5405542941902013e-09
regard O 0 1.0965035990295746e-08
to O 0 9.770023901012337e-09
age O 0 9.934944245060251e-08
at O 0 8.124889916416578e-08
disease O 0 8.848362540447852e-07
onset O 0 7.582103762615588e-07
and O 0 2.7929580426189204e-08
all O 0 6.97765845103504e-10
of O 0 1.0911016534720375e-09
the O 0 9.478452511757496e-08
disease O 0 9.014880561153404e-06
severity O 0 5.0710596042335965e-06
scores O 0 3.387301603652304e-07
assessed O 0 2.0941027401022438e-07
were O 0 1.2887315392617893e-07
noted O 0 1.1146789091753817e-07
in O 0 8.168070309011455e-08
disease O 0 1.7711132386466488e-05
- O 0 0.00012555139255709946
concordant O 0 0.004639845807105303
MZ O 1 0.9960139989852905
twins O 0 6.115977885201573e-05
compared O 0 7.551542466899264e-07
with O 0 2.48004710101668e-07
concordant O 0 0.005848363507539034
DZ O 1 0.9805259108543396
twins O 0 0.0009210078860633075
. O 0 3.145625669276342e-06

HLA O 0 0.0023352757561951876
- O 0 0.00014774924784433097
B27 O 0 6.268644028750714e-06
and O 0 7.89642129461754e-08
B60 O 0 1.4939556649551378e-06
were O 0 4.547066012605683e-08
associated O 0 4.116557761335571e-09
with O 0 2.584792380133649e-09
the O 0 1.0790369486812779e-07
disease O 0 1.1940177273572772e-06
in O 0 7.164800752690326e-09
probands O 0 3.349666030771914e-06
, O 0 3.3481613037622537e-09
and O 0 1.836363616725123e-09
the O 0 2.361367101855194e-09
rate O 0 2.016392812720369e-07
of O 0 5.992309759506043e-09
disease O 0 9.254837891603529e-07
concordance O 0 8.617447520009591e-07
was O 0 4.464360188194405e-07
significantly O 0 1.947058620999087e-07
increased O 0 5.4371977142864125e-08
among O 0 1.676781025139462e-08
DZ O 0 0.00017315008153673261
twin O 0 1.5399833500850946e-05
pairs O 0 1.2487146250350634e-07
in O 0 6.282954156944243e-09
which O 0 7.457606976402076e-09
the O 0 2.950315991512298e-09
co O 0 1.1300724054308375e-06
- O 0 4.6318476961459965e-05
twin O 0 0.0003583245852496475
was O 0 3.850736902677454e-06
positive O 0 1.1492596208029227e-08
for O 0 1.703289731480595e-09
both O 0 1.105586378002954e-08
B27 O 0 4.8876959226618055e-06
and O 0 5.068919790574e-07
DR1 O 0 0.0010772725800052285
. O 0 6.443851248150168e-07

Additive O 0 3.149494659737684e-05
genetic O 0 1.160851570602972e-05
effects O 0 3.170190893797553e-06
were O 0 1.4992650676504127e-07
estimated O 0 1.1064998695076156e-08
to O 0 2.8102378202277123e-09
contribute O 0 9.092085306861009e-09
97 O 0 4.967896671814742e-08
% O 0 2.511879149125207e-09
of O 0 3.225794908967572e-10
the O 0 5.5677049637381515e-09
population O 0 1.2286864858879198e-08
variance O 0 1.5657968788218568e-07
. O 0 3.403596053885849e-07

CONCLUSION O 0 1.892565342132002e-05
Susceptibility O 0 0.00010586175631033257
to O 0 5.923855610490136e-07
AS B-Disease 1 0.9663004875183105
is O 0 1.7759859360921837e-08
largely O 0 1.534749749509956e-08
genetically O 0 5.801461000487507e-08
determined O 0 2.3479246635815798e-07
, O 0 5.773331590575026e-09
and O 0 3.2547080586198263e-09
the O 0 2.200830184762026e-09
environmental O 0 1.202292931878901e-08
trigger O 0 2.9657263667104417e-07
for O 0 2.5120614477458503e-09
the O 0 1.7630502213705768e-07
disease O 0 4.484048986341804e-06
is O 0 3.073842336220878e-08
probably O 0 2.17183355744055e-07
ubiquitous O 0 3.0197863907233113e-06
. O 0 1.058152975019766e-06

HLA O 0 0.0010854096617549658
- O 0 3.2691601518308744e-05
B27 O 0 3.3199651170434663e-06
accounts O 0 2.4302275747345448e-08
for O 0 1.1450580483796102e-09
a O 0 8.28104429473342e-09
minority O 0 2.9583526739429544e-08
of O 0 3.908769974358961e-10
the O 0 6.14961948031123e-09
overall O 0 1.913244886964094e-06
genetic O 0 2.2675224045087816e-06
susceptibility O 0 6.428300366678741e-06
to O 0 3.756250919195736e-07
AS B-Disease 1 0.9998853206634521
. O 0 2.6680070277507184e-06

Cell O 0 0.00018154995632357895
cycle O 0 2.045984729193151e-05
- O 0 6.079314971429994e-06
dependent O 0 1.769528665818143e-07
colocalization O 0 1.2496228691816214e-06
of O 0 1.1058731708146752e-08
BARD1 O 0 3.548406675690785e-05
and O 0 1.7137681140866334e-07
BRCA1 O 0 3.117831965937512e-06
proteins O 0 2.7346985120857425e-08
in O 0 8.214922964100424e-09
discrete O 0 2.884943910430593e-07
nuclear O 0 5.163165610611031e-07
domains O 0 1.0074488727696007e-06
. O 0 3.8487360143335536e-07

Germ O 0 0.0018770296592265368
- O 0 0.006922399625182152
line O 0 8.044100104598328e-05
mutations O 0 7.907120789241162e-07
of O 0 2.8295843446102253e-09
the O 0 1.7855644074415977e-08
BRCA1 O 0 1.1053723028453533e-05
gene O 0 4.6793678620815626e-07
predispose O 0 8.68828180955461e-07
women O 0 4.206335546541595e-08
to O 0 8.540832929782027e-09
early O 0 2.4384652874687163e-07
- O 0 0.00047849997645244
onset O 0 0.0053324708715081215
breast B-Disease 1 0.999575674533844
and I-Disease 1 0.979875922203064
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
by O 0 1.508208669065425e-08
compromising O 0 1.064277853402018e-06
the O 0 2.2787242315303047e-08
genes O 0 3.226297167202574e-07
presumptive O 0 6.957033292565029e-06
function O 0 3.4667881010364e-08
as O 0 2.4510828922075234e-08
a O 0 7.550181635451736e-07
tumor B-Disease 0 0.00016340267029590905
suppressor O 0 0.000360178790288046
. O 0 2.9827497201040387e-06

Although O 0 1.1840572824439732e-06
the O 0 2.7816023262516865e-08
biochemical O 0 3.7671566133212764e-07
properties O 0 1.1039979597171623e-07
of O 0 8.535182338675895e-09
BRCA1 O 0 7.546369033661904e-06
polypeptides O 0 8.121944006234116e-07
are O 0 1.733052812369351e-08
not O 0 8.667226936154293e-09
understood O 0 7.309138183586583e-09
, O 0 1.4352168342668392e-09
their O 0 2.312260383163789e-09
expression O 0 4.459457869643302e-08
pattern O 0 6.36580864465941e-07
and O 0 1.614828448737171e-08
subcellular O 0 1.3861707657270017e-06
localization O 0 1.915790477369228e-07
suggest O 0 1.8370721832638992e-08
a O 0 6.348376047071724e-09
role O 0 1.809536520624988e-08
in O 0 1.982578723414008e-08
cell O 0 5.314524969435297e-06
- O 0 4.9195241444977e-05
cycle O 0 5.3757203204440884e-06
regulation O 0 8.567780014345772e-07
. O 0 3.246885000862676e-07

When O 0 6.399929588951636e-06
resting O 0 6.453386049543042e-06
cells O 0 5.769481390416331e-07
are O 0 4.2377719111641454e-09
induced O 0 3.1422626989296987e-07
to O 0 2.4702866419090697e-09
proliferate O 0 1.2006846361600765e-07
, O 0 1.2996854703573035e-09
the O 0 1.1020193646515963e-09
steady O 0 1.4328958286569105e-07
- O 0 1.3137071164237568e-07
state O 0 1.249845338335831e-09
levels O 0 9.697576075495817e-10
of O 0 3.0414776253095965e-10
BRCA1 O 0 7.647929578524781e-08
increase O 0 2.232978246752282e-09
in O 0 8.80225115018618e-10
late O 0 3.7851478396078164e-08
G1 O 0 6.236660397007654e-07
and O 0 5.403181901897369e-09
reach O 0 3.942021820080299e-09
a O 0 8.802020445841663e-09
maximum O 0 1.8127284562297064e-08
during O 0 3.5701837930446345e-08
S O 0 3.842047135549365e-06
phase O 0 5.7733450375963e-07
. O 0 3.09950252130875e-07

Moreover O 0 7.4841518653556705e-06
, O 0 4.3712198305456695e-08
in O 0 1.6294256610649427e-08
S O 0 5.466611582960468e-06
phase O 0 1.7845010802375327e-07
cells O 0 8.577912780083352e-08
, O 0 1.1196091165288635e-08
BRCA1 O 0 1.466737785449368e-06
polypeptides O 0 2.570600372564513e-07
are O 0 5.0289954423021754e-09
hyperphosphorylated O 0 5.404874059422582e-07
and O 0 1.9559559305548646e-08
accumulate O 0 1.5943301434617752e-07
into O 0 3.0710527454402836e-08
discrete O 0 5.926788162469165e-07
subnuclear O 0 1.1378583621990401e-05
foci O 0 1.4250601452658884e-05
termed O 0 4.5385240809991956e-06
" O 0 1.9503738712955965e-06
BRCA1 O 0 5.615630288957618e-05
nuclear O 0 5.494915512826992e-06
dots O 0 0.00044121022801846266
. O 0 1.3556752946897177e-06

" O 0 0.00015460436407011002
BRCA1 O 0 0.0007371997926384211
associates O 0 2.399928416707553e-05
in O 0 6.293919341260334e-08
vivo O 0 9.87669181995443e-07
with O 0 2.0436445424820704e-08
a O 0 3.972180593336816e-07
structurally O 0 5.690335456165485e-05
related O 0 2.2650533537671436e-07
protein O 0 1.6353839100702317e-06
termed O 0 1.0509979802009184e-05
BARD1 O 0 0.0004713603702839464
. O 0 2.077748149531544e-06

Here O 0 1.1417976566008292e-05
we O 0 1.217742493508922e-07
show O 0 8.714440724588712e-08
that O 0 1.145488370823955e-09
the O 0 2.7831239535203167e-09
steady O 0 5.481064135892666e-07
- O 0 3.467050362360169e-07
state O 0 3.374891255347734e-09
levels O 0 3.2568254759723914e-09
of O 0 9.585363613950904e-10
BARD1 O 0 1.494505681876035e-06
, O 0 1.5042663781272836e-09
unlike O 0 2.558091738436019e-09
those O 0 7.036477511768169e-10
of O 0 1.8054605588346817e-09
BRCA1 O 0 2.6731697744253324e-06
, O 0 1.4259294189855609e-08
remain O 0 3.027786021903012e-08
relatively O 0 6.823309028902713e-09
constant O 0 4.876791948049686e-08
during O 0 3.0678094731229066e-08
cell O 0 4.034778612549417e-06
cycle O 0 8.39476524561178e-06
progression O 0 1.3336218216863927e-05
. O 0 5.400340228334244e-07

However O 0 1.0475855560798664e-05
, O 0 3.083984552176844e-07
immunostaining O 0 8.888493539416231e-06
revealed O 0 1.568270363350166e-06
that O 0 3.196180387021741e-08
BARD1 O 0 7.767870556563139e-06
resides O 0 1.8369186705058382e-07
within O 0 1.8979882554504002e-08
BRCA1 O 0 1.8657902955965255e-06
nuclear O 0 1.4955979565911548e-07
dots O 0 1.7624830434215255e-05
during O 0 1.2270639615508117e-07
S O 0 1.0924453590632766e-06
phase O 0 7.59522933435619e-09
of O 0 4.345420412388279e-10
the O 0 2.0477755047210167e-09
cell O 0 5.456957410387986e-07
cycle O 0 5.220680350248585e-07
, O 0 4.04657285457688e-09
but O 0 1.2958784045835614e-09
not O 0 1.3285287314701577e-09
during O 0 2.852092562122266e-09
the O 0 1.0228747626683798e-08
G1 O 0 1.1075301699747797e-05
phase O 0 1.4919111208655522e-06
. O 0 5.223290031608485e-07

Nevertheless O 0 5.4748910770285875e-05
, O 0 4.0813827695274085e-07
BARD1 O 0 8.2838159869425e-06
polypeptides O 0 1.7016317315210472e-06
are O 0 8.474691171045379e-09
found O 0 6.425255438813338e-09
exclusively O 0 3.024846595423014e-09
in O 0 9.5679741907162e-10
the O 0 1.6366229482756012e-09
nuclear O 0 8.668136430856066e-09
fractions O 0 1.0380041715052357e-08
of O 0 6.577120514883461e-10
both O 0 3.768318102004287e-09
G1 O 0 1.4926796438885503e-06
- O 0 1.386808094139269e-06
and O 0 7.212766206521337e-08
S O 0 6.025519724062178e-06
- O 0 2.512808805477107e-06
phase O 0 6.729194979016029e-07
cells O 0 1.3539439578380552e-06
. O 0 3.018384973074717e-07

Therefore O 0 2.748307679212303e-06
, O 0 8.618633273727028e-08
progression O 0 4.776372293235909e-07
to O 0 1.9313551646860105e-08
S O 0 1.0060806744149886e-05
phase O 0 8.90491307359298e-08
is O 0 4.597031644237859e-09
accompanied O 0 2.15406874559676e-08
by O 0 9.41266842247046e-10
the O 0 1.400753735225635e-09
aggregation O 0 1.5678763176651955e-08
of O 0 2.2818285039249986e-09
nuclear O 0 7.776890953437032e-08
BARD1 O 0 1.0978639011227642e-06
polypeptides O 0 1.356053758172493e-07
into O 0 3.255522784684217e-08
BRCA1 O 0 8.819307367957663e-06
nuclear O 0 9.194446306537429e-07
dots O 0 0.00011435495980549604
. O 0 9.76367232397024e-07

This O 0 6.467529374276637e-07
cell O 0 5.333224180503748e-06
cycle O 0 1.8993409867107403e-06
- O 0 1.3142375792085659e-06
dependent O 0 1.0668401984048614e-07
colocalization O 0 6.384278776749852e-07
of O 0 7.727900097620477e-09
BARD1 O 0 9.734379091241863e-06
and O 0 1.046387225756007e-07
BRCA1 O 0 4.4289186007517856e-06
indicates O 0 7.095256648881332e-08
a O 0 7.74823849525319e-09
role O 0 2.8935067675206483e-08
for O 0 6.18154771814261e-09
BARD1 O 0 4.1659295675344765e-06
in O 0 5.960509241731415e-08
BRCA1 O 0 5.698991662939079e-05
- O 0 0.00022207053552847356
mediated O 0 0.0009022330050356686
tumor B-Disease 0 0.0004965203697793186
suppression O 0 1.708655690890737e-05
. O 0 1.4861884665151592e-06

Ethnic O 0 2.437472176097799e-05
differences O 0 5.929071448917966e-06
in O 0 1.5418714838233427e-07
the O 0 1.2673368132709584e-07
HFE O 0 0.0010546933626756072
codon O 0 2.4156179279088974e-05
282 O 0 5.619152943836525e-06
( O 0 4.718183106433571e-07
Cys O 0 0.0013620767276734114
/ O 0 3.0426928788074292e-05
Tyr O 0 0.0001026648678816855
) O 0 8.348072242370108e-07
polymorphism O 0 1.83515548997093e-05
. O 0 1.1648666031760513e-06

Recent O 0 3.183639819326345e-06
studies O 0 5.2435029829212e-07
have O 0 1.9423460173584317e-07
shown O 0 1.020921672534314e-06
that O 0 2.0696872525149956e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 7.462671783287078e-05
HH B-Disease 0 0.04554436355829239
) O 0 3.11065697644608e-08
is O 0 6.0905422927248765e-09
likely O 0 3.00414342291333e-08
to O 0 8.567966780503866e-09
be O 0 2.728160275466962e-08
caused O 0 5.057557572740734e-08
by O 0 1.0664852334585362e-09
homozygosity O 0 2.0583638615789823e-07
for O 0 7.837400728405441e-10
a O 0 5.376928058353769e-08
Cys282Tyr O 0 1.1058004020014778e-05
mutation O 0 2.631678341913357e-07
in O 0 5.353981258338081e-09
the O 0 1.808867011732218e-08
HFE O 0 1.8619775801198557e-05
gene O 0 5.950195145487669e-07
located O 0 6.026331789144024e-07
4 O 0 1.0871189033423434e-06
. O 0 1.0209040510744671e-06

5 O 0 5.0933864258695394e-05
Mb O 0 0.0003095220890827477
telomeric O 0 0.0003201227227691561
to O 0 7.673593813706248e-07
HLA O 0 0.00017713032138999552
- O 0 5.423756374511868e-05
A O 0 3.8059213238739176e-06
. O 0 1.4143046200842946e-06

Population O 0 1.0947231885438669e-06
studies O 0 3.799034686835512e-08
of O 0 2.9620099706306746e-09
this O 0 3.263541215048349e-09
polymorphism O 0 9.614290092940792e-07
are O 0 1.9921526650534815e-09
facilitated O 0 1.9095644177014037e-08
by O 0 1.931848014891102e-09
the O 0 2.8363549287035994e-09
fact O 0 3.574038398568291e-09
that O 0 1.5262250352421347e-09
the O 0 9.073011675297948e-09
Cys282Tyr O 0 6.8690669650095515e-06
mutation O 0 2.2996742643499601e-07
creates O 0 8.46836130108386e-08
a O 0 5.561616234217581e-08
Rsal O 0 4.455192083696602e-06
restriction O 0 3.3039029290193866e-07
site O 0 1.5310796470657806e-06
. O 0 6.210681817719887e-07

We O 0 8.044479727686848e-06
have O 0 6.059016754988988e-08
studied O 0 5.029947658385936e-08
the O 0 1.9556239294615807e-08
codon O 0 1.720360614854144e-06
282 O 0 8.572888532398792e-07
( O 0 1.6516170830982446e-07
Cys O 0 0.00046381758875213563
/ O 0 1.8242759324493818e-05
Tyr O 0 2.327445508853998e-05
) O 0 4.99927388375454e-08
polymorphism O 0 2.9873791618229006e-07
in O 0 5.6295657024918455e-09
different O 0 9.47051592703474e-09
ethnic O 0 1.6674911762493139e-07
groups O 0 1.7823394671268034e-07
. O 0 3.5401549780544883e-07

In O 0 7.047039503049746e-07
agreement O 0 1.159558067342914e-07
with O 0 7.679441083041638e-09
previous O 0 3.649032009889197e-08
observations O 0 9.145362156459669e-08
the O 0 1.724351506027233e-08
Tyr O 0 1.0488291991350707e-05
allele O 0 8.576176355745702e-07
appeared O 0 2.190514123867615e-06
to O 0 3.9878580437857636e-09
be O 0 3.1703868419441505e-09
rare O 0 6.491540194275558e-09
or O 0 1.4455141972291585e-08
absent O 0 6.920499373563871e-08
in O 0 1.183906039869953e-08
Asiatic O 0 9.579191555530997e-07
( O 0 6.149408093847342e-09
Indian O 0 5.44461453699796e-09
, O 0 2.7466000585008032e-09
Chinese O 0 1.587377007616908e-09
) O 0 6.144964981302792e-09
populations O 0 6.047217482318956e-08
. O 0 1.5936552699713502e-07

The O 0 8.104179300971737e-07
highest O 0 1.0329914630347048e-06
allele O 0 1.4578989748770255e-06
frequency O 0 4.344178137216659e-07
( O 0 1.3457698955221531e-08
7 O 0 2.9803384649085274e-08
. O 0 3.7103349281863984e-09
5 O 0 5.669135205721432e-08
% O 0 9.425932034901052e-09
) O 0 3.1722982019033452e-09
was O 0 3.7221386151031766e-07
found O 0 3.0835902720127706e-08
in O 0 4.639889539248543e-08
Swedes O 0 6.731166649842635e-05
. O 0 1.078956302080769e-06

Saamis O 0 0.0003515803546179086
( O 0 1.4457190218308824e-06
2 O 0 4.739369501294277e-07
% O 0 4.768548578226728e-08
) O 0 3.6644649537009855e-09
and O 0 6.6466614434546045e-09
Mordvinians O 0 9.093092216971854e-07
( O 0 2.3141177862839868e-09
1 O 0 2.4723889602285e-09
. O 0 1.840101071515221e-09
8 O 0 2.6381078654935664e-08
% O 0 3.1426621305286062e-09
) O 0 1.5881068682332966e-09
had O 0 1.8463798312495783e-07
significantly O 0 2.763857480658771e-07
lower O 0 1.0633926450509534e-07
frequencies O 0 2.5143442883290845e-08
of O 0 1.7561113674346984e-09
the O 0 5.783165590855788e-08
Tyr O 0 5.5411350331269205e-05
allele O 0 5.7754546105570626e-06
. O 0 7.565815280941024e-07

Comparisons O 0 6.370494247676106e-06
with O 0 2.1613661260744266e-07
allele O 0 3.404716608201852e-06
frequencies O 0 5.1077404350508e-07
based O 0 3.106115897821837e-08
on O 0 6.722037682038717e-08
prevalence O 0 1.6208415445362334e-06
estimates O 0 1.7904928029111034e-07
of O 0 1.2652904501919693e-08
HH B-Disease 0 0.47517716884613037
showed O 0 1.0393203410785645e-05
some O 0 1.492634127409076e-09
disagreements O 0 1.6968108695891715e-07
with O 0 3.2116151960082107e-09
the O 0 1.3292644318596558e-08
RFLP O 0 1.933299245138187e-06
data O 0 5.2187186128094254e-08
, O 0 3.807070214634223e-09
particularly O 0 8.537282880638486e-09
in O 0 2.8561006004679257e-08
Finns O 0 1.527361018816009e-05
. O 0 3.2407876915385714e-07

The O 0 2.4524445052520605e-06
newly O 0 3.282732677689637e-06
described O 0 1.2766314512191457e-06
HFE O 0 3.422635927563533e-05
marker O 0 1.299393261433579e-06
provides O 0 1.3786723762621023e-08
a O 0 5.5351456751395745e-09
new O 0 4.039393264321234e-09
approach O 0 1.2845835506425374e-08
to O 0 1.1638223718080098e-09
the O 0 1.2034303553676295e-09
screening O 0 9.733233774511518e-09
of O 0 3.4261360415399622e-09
HH B-Disease 0 4.982189057045616e-05
as O 0 2.6382487305909308e-08
well O 0 6.544001784902775e-09
as O 0 2.2108226360728622e-09
studies O 0 9.278730561668169e-10
of O 0 2.439987933922083e-10
the O 0 2.2699688795313477e-09
relationship O 0 4.8682327502547196e-08
between O 0 1.5152210153246415e-08
the O 0 6.083624981556568e-08
HFE O 0 0.0004992163740098476
Tyr O 0 4.3403888412285596e-05
allele O 0 2.873493258448434e-06
and O 0 5.618980836175069e-08
different O 0 2.802858034556266e-07
disorders O 0 0.0007510794675908983
including O 0 3.7023737604613416e-06
cancer B-Disease 0 0.0056942543014883995

Autosomal B-Disease 1 0.9999669790267944
dominant I-Disease 1 0.8816601037979126
neurohypophyseal I-Disease 1 0.9996383190155029
diabetes I-Disease 1 0.9999967813491821
insipidus I-Disease 1 0.9634770154953003
associated O 0 2.7811490781459725e-06
with O 0 5.9009639841178796e-08
a O 0 4.1335866285407974e-07
missense O 0 0.00010655224468791857
mutation O 0 1.3899168607167667e-06
encoding O 0 4.841476197725569e-07
Gly23 O 0 3.1029867386678234e-05
- O 0 8.700858597876504e-05
- O 0 0.00011769161937991157
> O 0 2.4929424853326054e-06
Val O 0 4.726721454062499e-05
in O 0 4.1469246525593917e-07
neurophysin O 0 3.851982546621002e-05
II O 0 5.8594443544279784e-05
. O 0 1.964921011676779e-06

Autosomal B-Disease 1 0.9999725818634033
dominant I-Disease 1 0.9281668066978455
neurohypophyseal I-Disease 1 0.9998177886009216
diabetes I-Disease 1 0.9999991655349731
insipidus I-Disease 1 0.9997808337211609
( O 0 1.3893673894926906e-05
ADNDI B-Disease 0 0.0005932867061346769
) O 0 1.296730260946788e-07
is O 0 4.266582109835326e-08
an O 0 1.110169705498265e-06
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.0001006686725304462
by O 0 1.884840941102084e-07
progressive O 0 0.0009428059565834701
degeneration O 0 0.003307236358523369
of O 0 4.282094234753231e-09
the O 0 2.793608011586457e-08
magnocellular O 0 5.594977665168699e-06
neurons O 0 1.7397834994881123e-07
of O 0 1.3765222295347712e-09
the O 0 1.2024809592503516e-08
hypothalamus O 0 8.172260663741326e-07
leading O 0 9.775098419595452e-08
to O 0 1.146634343029973e-08
decreased O 0 3.6865785091322323e-07
ability O 0 7.57799512030033e-09
to O 0 2.1834076768811883e-09
produce O 0 5.581826112432964e-09
the O 0 1.3749170690857682e-08
hormone O 0 4.81625420434284e-07
arginine O 0 1.2829549405068974e-06
vasopressin O 0 2.9089790132275084e-06
( O 0 9.152656588184982e-08
AVP O 0 5.479294941324042e-06
) O 0 2.8274664032323926e-07
. O 0 3.067177942739363e-07

Affected O 0 2.5652088879724033e-05
individuals O 0 2.149603801626654e-07
are O 0 8.795358219515492e-09
not O 0 1.512962732874712e-08
symptomatic O 0 3.0077553674345836e-06
at O 0 2.281003332882392e-07
birth O 0 3.1087527077033883e-06
, O 0 2.9479322094516647e-08
but O 0 1.5878594439300286e-08
usually O 0 1.2711883812244196e-07
develop O 0 4.2329392613282835e-07
diabetes B-Disease 0 5.6451612181263044e-05
insipidus I-Disease 0 4.787902798852883e-05
at O 0 1.5447709245108854e-07
1 O 0 1.4788349744776497e-07
- O 0 3.62632199539803e-05
6 O 0 2.4860478333721403e-06
yr O 0 7.933622691780329e-05
of O 0 5.243862943871136e-08
age O 0 5.85776149364392e-07
. O 0 4.687943828685093e-07

The O 0 1.2111423757232842e-06
genetic O 0 3.693592589115724e-06
locus O 0 3.4613883599377004e-06
of O 0 4.32414353213062e-08
the O 0 6.765274065401172e-07
disease O 0 9.50348112382926e-06
is O 0 4.68875516190792e-09
the O 0 5.170326389247748e-09
AVP O 0 1.2035467989335302e-05
- O 0 0.0006029502837918699
neurophysin O 0 5.56976483494509e-05
II O 0 1.0523299351916648e-05
( O 0 2.0826366409210095e-08
NPII O 0 4.50547190666839e-07
) O 0 2.5042539153474763e-09
gene O 0 1.633589263860813e-08
, O 0 2.7009869896232885e-09
and O 0 1.520562697976402e-08
mutations O 0 1.8319956041068508e-07
that O 0 4.306806467013757e-09
cause O 0 4.668028807941482e-08
ADNDI B-Disease 0 1.1323268154228572e-05
have O 0 2.7882774134013744e-07
been O 0 1.0897986157942796e-07
found O 0 6.1210077006990105e-09
in O 0 1.893933454510943e-09
both O 0 3.244283064418596e-09
the O 0 1.103062974294744e-08
signal O 0 6.109434593781771e-07
peptide O 0 7.1614811858466965e-09
of O 0 3.588223052020112e-10
the O 0 4.527582753155457e-09
prepro O 0 1.4200174973666435e-06
- O 0 1.5607266732331482e-06
AVP O 0 4.100865680811694e-06
- O 0 3.832685706584016e-06
NPII O 0 2.3959632926562335e-06
precursor O 0 1.107705998038e-07
and O 0 1.713561559313348e-08
within O 0 2.557049150198054e-08
NPII O 0 1.326966503256699e-05
itself O 0 1.1725034028131631e-06
. O 0 3.495279372600635e-07

An O 0 1.0289151077813585e-06
affected O 0 1.3122750033289776e-06
girl O 0 4.704928505816497e-05
who O 0 9.54221945903555e-07
presented O 0 3.443111395995402e-08
at O 0 1.2990071240892576e-08
9 O 0 4.604624592730033e-08
months O 0 1.0388003346406549e-08
of O 0 9.262691724742922e-10
age O 0 1.9861289501932333e-08
and O 0 5.1057065242332555e-09
her O 0 1.1244890174566535e-07
similarly O 0 2.4733270720389555e-07
affected O 0 1.981580588505949e-08
younger O 0 1.218283784965024e-07
brother O 0 3.413419165099185e-07
and O 0 1.9026009567824076e-07
father O 0 4.561694595395238e-07
were O 0 2.5707025841370523e-08
all O 0 4.0486627939095854e-10
found O 0 3.2692979434756353e-09
to O 0 1.9288728392297116e-09
have O 0 3.3401628130036443e-09
a O 0 1.3944075227811936e-08
novel O 0 9.762267154656001e-07
missense O 0 2.984173443110194e-05
mutation O 0 5.409731897998427e-07
( O 0 1.145049832729228e-08
G1758 O 0 2.1220614598860266e-07
- O 0 4.275953415344702e-06
- O 0 3.579109034035355e-05
> O 0 1.078958348443848e-06
T O 0 2.891231360990787e-06
) O 0 3.288390892919324e-09
encoding O 0 1.4207928167309092e-08
the O 0 5.081884246749269e-09
amino O 0 3.8726785334119995e-08
acid O 0 2.9473699925119945e-08
substitution O 0 4.2620026619033524e-08
Gly23 O 0 1.2758744105667574e-06
- O 0 2.9825332603650168e-06
- O 0 1.346138924418483e-05
> O 0 2.12796771847934e-06
Val O 0 2.0183995729894377e-05
within O 0 4.521139089774806e-07
NPII O 0 4.537440690910444e-05
. O 0 1.1351445436957874e-06

The O 0 6.830799520685105e-06
mutation O 0 5.802959276479669e-05
was O 0 4.567663836496649e-06
confirmed O 0 3.044235086235858e-07
by O 0 2.469458948439751e-08
restriction O 0 6.502546625597461e-07
endonuclease O 0 2.537384716561064e-05
analysis O 0 1.0001361943068332e-06
. O 0 8.284292221105716e-07

A O 0 1.3901400961913168e-05
T1 O 0 0.0003909013175871223
- O 0 1.1357271432643756e-05
weighted O 0 1.526769437987241e-06
magnetic O 0 4.721595132650691e-07
resonance O 0 5.943984433542937e-07
imaging O 0 2.669180503289681e-06
of O 0 1.6244914746721406e-08
the O 0 3.2017578632803634e-07
fathers O 0 3.8098092772997916e-05
pituitary O 0 3.7263667763909325e-05
gland O 0 9.838121513894293e-06
demonstrates O 0 2.561125711508794e-07
an O 0 5.3525543108889906e-08
attenuated O 0 0.00010641820699675009
posterior O 0 0.00023853604216128588
pituitary O 0 0.000299140257993713
bright O 0 4.7783971240278333e-05
spot O 0 7.513241143897176e-05
. O 0 2.109662773364107e-06

This O 0 2.0514689822448418e-06
mutation O 0 5.2884202887071297e-05
may O 0 3.832967365724471e-07
be O 0 1.9030221842797346e-09
valuable O 0 2.6435365008126155e-09
for O 0 7.522633627132791e-10
developing O 0 5.852939910511168e-09
models O 0 3.832988682006544e-08
of O 0 1.2621618417085756e-08
dominantly B-Disease 0 0.0013290016213431954
inherited I-Disease 0 0.17810581624507904
neurodegeneration I-Disease 1 1.0
, O 0 7.38815160161721e-08
as O 0 2.7352293763271973e-09
the O 0 1.422321371791213e-09
early O 0 1.4966774486424583e-08
age O 0 6.248880524140077e-09
of O 0 3.638776502334906e-10
onset O 0 2.535532814817998e-07
of O 0 1.4386269953092778e-08
symptoms O 0 1.0163247452510404e-06
suggests O 0 1.018914197459253e-08
that O 0 1.2119993897385939e-09
this O 0 3.411893434446256e-09
mutation O 0 5.416401904767554e-07
may O 0 1.0155753926710531e-07
be O 0 4.054939939379665e-09
particularly O 0 6.995972245960047e-09
deleterious O 0 2.2997772930466454e-07
to O 0 7.018559511351441e-09
the O 0 7.972696636215915e-08
magnocellular O 0 1.762473038979806e-05
neuron O 0 6.17705791228218e-06
. O 0 6.853258582850685e-08
. O 0 6.146996156530804e-07

Frequent O 0 0.00015849391638766974
inactivation O 0 0.00016340984439011663
of O 0 1.0862971748792916e-06
PTEN O 0 0.0009501264430582523
/ O 0 5.975141903036274e-05
MMAC1 O 0 0.00014396948972716928
in O 0 2.3749018964736024e-06
primary O 0 0.00865412037819624
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.858121883444255e-06

Sporadic B-Disease 1 0.9999840259552002
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 7.580483725178055e-07
the O 0 1.6336827002305654e-08
most O 0 7.4099522073822754e-09
common O 0 5.102652167465749e-08
male B-Disease 0 3.940756869269535e-06
cancer I-Disease 0 6.591116061827051e-07
in O 0 4.0832679459867904e-09
the O 0 6.435631583201484e-09
Western O 0 9.082555862960362e-08
world O 0 4.9635303867034963e-08
, O 0 4.901969052895083e-09
yet O 0 1.8079002739312955e-09
many O 0 5.2350308116233535e-11
of O 0 5.5692186973210767e-11
the O 0 6.681867281699283e-10
major O 0 3.0353419777640056e-09
genetic O 0 1.330185206427359e-08
events O 0 3.206914067632738e-09
involved O 0 2.481478800220316e-09
in O 0 1.2355126921548276e-09
the O 0 5.635678146376222e-09
progression O 0 2.626034927288856e-07
of O 0 1.4667654868461e-09
this O 0 6.0746017105373085e-09
often O 0 8.497806334162306e-07
fatal O 0 0.00010352830577176064
cancer B-Disease 0 2.70302716671722e-05
remain O 0 2.9498008302653034e-07
to O 0 4.1377035131517914e-08
be O 0 1.2683680949976406e-07
elucidated O 0 5.382890230976045e-05
. O 0 1.2973996490472928e-06

Numerous O 0 1.2281390809221193e-05
cytogenetic O 0 0.00030546975904144347
and O 0 8.646828177916177e-07
allelotype O 0 7.93028902990045e-06
studies O 0 5.155646931598312e-08
have O 0 8.510979654374751e-08
reported O 0 6.104804128881369e-07
frequent O 0 4.4781845076613536e-07
loss O 0 6.624552497669356e-07
of O 0 2.1160547092335946e-08
heterozygosity O 0 9.105940262088552e-05
on O 0 9.58341024670517e-06
chromosomal O 0 0.11234814673662186
arm O 0 0.0006711543537676334
10q O 0 8.626495400676504e-06
in O 0 1.1036596561098122e-06
sporadic B-Disease 1 0.9990873336791992
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 6.020947694196366e-06

Deletion O 0 7.62894342187792e-05
mapping O 0 4.108475422981428e-06
studies O 0 2.1517121240322012e-07
have O 0 1.1816729994507114e-07
unambiguously O 0 2.582301021902822e-06
identified O 0 1.2315611286339845e-07
a O 0 1.869157983946934e-08
region O 0 3.57078953072687e-08
of O 0 4.494508765162664e-09
chromosome O 0 4.319611434766557e-06
10q23 O 0 3.517187678880873e-07
to O 0 6.038110456074719e-09
be O 0 5.454582563402255e-09
the O 0 6.057859547325961e-09
minimal O 0 1.2056736409249424e-07
area O 0 1.5122667207378981e-07
of O 0 2.4368651097006477e-08
loss O 0 5.155055532668484e-06
. O 0 1.87612295121653e-06

A O 0 1.1114600056316704e-05
new O 0 1.2581714372572605e-06
tumor B-Disease 0 2.8314963856246322e-05
suppressor O 0 4.892977813142352e-05
gene O 0 2.3309582957153907e-06
, O 0 1.3888393368688412e-07
PTEN O 0 7.031727727735415e-05
/ O 0 7.702981747570448e-06
MMAC1 O 0 2.9580100090242922e-05
, O 0 2.6428018884416815e-08
was O 0 2.7049921413890843e-07
isolated O 0 2.863263262042892e-07
recently O 0 4.3841788510690094e-07
at O 0 7.811988389505586e-09
this O 0 5.345407450008111e-10
region O 0 5.852225815061729e-09
of O 0 2.2962622914235453e-09
chromosome O 0 6.155446044431301e-06
10q23 O 0 4.910407938041317e-07
and O 0 3.025228778597011e-08
found O 0 7.858704798024974e-09
to O 0 2.7250905976217155e-09
be O 0 2.7706614780242944e-09
inactivated O 0 4.532250841293717e-08
by O 0 1.2185499276284872e-09
mutation O 0 2.989744274373152e-08
in O 0 1.4376093204759854e-08
three O 0 0.00013507362746167928
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
cell O 0 8.857591456035152e-05
lines O 0 8.031499601202086e-05
. O 0 9.36116350658267e-07

We O 0 9.911331289913505e-06
screened O 0 4.363771586213261e-05
80 O 0 8.463978701911401e-06
prostate B-Disease 1 0.5698555707931519
tumors I-Disease 1 0.9999998807907104
by O 0 2.1571892716565344e-08
microsatellite O 0 2.5017711777763907e-06
analysis O 0 2.930296183478731e-08
and O 0 1.3172205548528382e-08
found O 0 2.739527538153652e-08
chromosome O 0 6.708052751491778e-06
10q23 O 0 1.277324372495059e-06
to O 0 2.319987935095469e-08
be O 0 8.704270193504726e-09
deleted O 0 3.6713163353851996e-07
in O 0 4.2545060807697155e-08
23 O 0 2.287170275394601e-07
cases O 0 7.216233655071846e-08
. O 0 2.0783892296094564e-07

We O 0 5.63139519726974e-06
then O 0 2.110044050596116e-07
proceeded O 0 6.387963225051863e-08
with O 0 8.192762024350486e-10
sequence O 0 1.3552233113500733e-08
analysis O 0 3.3198255255939557e-09
of O 0 4.84911000242505e-10
the O 0 5.0264064022087496e-09
entire O 0 1.7097295312851202e-07
PTEN O 0 1.793426417862065e-05
/ O 0 1.2105754194635665e-06
MMAC1 O 0 1.8556435179561959e-06
coding O 0 1.109987579184235e-06
region O 0 2.686356594949757e-07
and O 0 5.909704015039097e-08
tested O 0 3.130429604425444e-08
for O 0 1.026814966387235e-09
homozygous O 0 2.1602697586331487e-07
deletion O 0 5.4934250925953165e-08
with O 0 1.9689021524271766e-09
new O 0 1.2176259112095522e-08
intragenic O 0 9.397462008564617e-07
markers O 0 3.689381742333353e-07
in O 0 4.8490935711242855e-09
these O 0 3.6588638785417515e-09
23 O 0 3.329948583541409e-08
cases O 0 2.0083210650057026e-09
with O 0 1.3756515038210182e-08
10q23 O 0 1.1743559298338369e-05
loss O 0 4.837345954911143e-07
of O 0 6.782386918757766e-08
heterozygosity O 0 0.00016233437054324895
. O 0 2.36535652220482e-06

The O 0 2.461209476223303e-07
identification O 0 5.990597884419913e-08
of O 0 2.193262238492366e-09
the O 0 5.254142454447219e-09
second O 0 2.0221641250373068e-07
mutational O 0 4.4279895519139245e-06
event O 0 7.100834409357049e-08
in O 0 8.798965112077894e-09
10 O 0 2.7154310799915038e-08
( O 0 7.473840213378935e-09
43 O 0 1.8361933484811743e-07
% O 0 2.871432869255841e-08
) O 0 9.528754674192896e-08
tumors B-Disease 1 0.9999985694885254
establishes O 0 1.281758159166202e-05
PTEN O 0 0.00029549779719673097
/ O 0 6.046357611921849e-06
MMAC1 O 0 7.358718903560657e-06
as O 0 1.2448806430143122e-08
a O 0 1.4341722476274299e-08
main O 0 1.030838703286463e-07
inactivation O 0 4.704236857833166e-07
target O 0 3.0068378009673324e-08
of O 0 4.439486556151451e-09
10q O 0 9.316259479419386e-07
loss O 0 2.4598040226919693e-07
in O 0 2.2539646238328714e-07
sporadic B-Disease 1 0.9998987913131714
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.783338572953653e-07
. O 0 3.129447918581718e-07

Risk O 0 0.00015182628703769296
reversals O 0 3.746809670701623e-05
in O 0 3.2233481306320755e-07
predictive O 0 5.439610959001584e-06
testing O 0 1.4700187875860138e-06
for O 0 3.0858489026286406e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999995231628418
. O 0 3.1047115953697357e-06

The O 0 5.075415856481413e-07
first O 0 6.87876919869268e-08
predictive O 0 4.6899694439161976e-07
testing O 0 1.0258293059450807e-07
for O 0 1.0532492922266101e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999936819076538
( O 0 1.0434515473889405e-07
HD B-Disease 0 7.666428427910432e-05
) O 0 6.310771993867093e-08
was O 0 5.036822017245868e-07
based O 0 4.9381729816389e-09
on O 0 8.309443799703331e-09
analysis O 0 2.9367517306866375e-09
of O 0 7.401290136321848e-10
linked O 0 9.639366282954143e-08
polymorphic O 0 2.7192385232410743e-07
DNA O 0 8.968286380195423e-08
markers O 0 3.0173691811796743e-07
to O 0 3.39544303784578e-09
estimate O 0 3.219952304789331e-08
the O 0 1.390948356494448e-09
likelihood O 0 1.4376560386608617e-08
of O 0 1.1466140259486224e-09
inheriting O 0 1.0502682812330022e-07
the O 0 1.7895125381528487e-08
mutation O 0 1.7477826474987523e-07
for O 0 1.854707321058413e-08
HD B-Disease 0 4.9821272114058957e-05
. O 0 9.72273255683831e-07

Limits O 0 2.9648092549905414e-06
to O 0 3.217134647570674e-08
accuracy O 0 1.743853346169999e-07
included O 0 7.112014088761498e-09
recombination O 0 3.908497703264402e-08
between O 0 8.394061445926582e-09
the O 0 5.8147628934079876e-09
DNA O 0 1.448763669031905e-07
markers O 0 1.484681206420646e-06
and O 0 2.3319929098875036e-08
the O 0 1.2333142507259254e-08
mutation O 0 3.881686154727504e-07
, O 0 7.162792581283384e-09
pedigree O 0 3.0961703600951296e-07
structure O 0 1.5651572482511256e-08
, O 0 1.505948699076498e-09
and O 0 1.6349537279580773e-09
whether O 0 8.681086960393714e-10
DNA O 0 1.9172684773138826e-08
samples O 0 8.92541685004744e-09
were O 0 4.5987240682165975e-09
available O 0 1.2381218272849992e-09
from O 0 3.36598771077945e-09
family O 0 4.556329358251787e-08
members O 0 1.9350572699750046e-08
. O 0 1.797037896267284e-07

With O 0 3.638236023562058e-07
direct O 0 1.2306806240758306e-07
tests O 0 1.3144798138853275e-08
for O 0 6.545033959248769e-10
the O 0 2.7058442153560236e-09
HD B-Disease 0 1.0666591151675675e-05
mutation O 0 1.6150708859186125e-07
, O 0 3.934863102017516e-09
we O 0 2.3178061692163965e-09
have O 0 1.5883977466657484e-09
assessed O 0 4.497656025392871e-09
the O 0 1.0856296972505675e-09
accuracy O 0 2.869249442483124e-07
of O 0 2.7388993295573982e-09
results O 0 2.2177671255008136e-08
obtained O 0 1.3918771690768494e-09
by O 0 4.5189099684428413e-10
linkage O 0 7.057841600044412e-08
approaches O 0 2.534045151492137e-08
when O 0 9.353150254298725e-09
requested O 0 5.473811626188763e-09
to O 0 3.7145408970928884e-09
do O 0 5.352449594653308e-09
so O 0 1.1592053983378037e-09
by O 0 5.052404050687187e-10
the O 0 8.72895888903713e-09
test O 0 1.3061330150776485e-07
individuals O 0 2.9687871716532754e-08
. O 0 1.1932772281397774e-07

For O 0 1.5711879086666158e-07
six O 0 3.7177038336722035e-08
such O 0 1.1532994559360077e-09
individuals O 0 3.984025997993967e-09
, O 0 2.5429431893542187e-09
there O 0 3.4533038650863546e-09
was O 0 9.28553660628495e-08
significant O 0 4.858026869669629e-09
disparity O 0 8.56293951301268e-08
between O 0 1.6969995186855158e-08
the O 0 2.289939260435858e-08
tests O 0 2.7816668080049567e-07
. O 0 2.3873133159213467e-07

Three O 0 2.948426754301181e-06
went O 0 3.9950930386112304e-07
from O 0 5.940236302848234e-09
a O 0 9.905536835219664e-09
decreased O 0 4.671743170092668e-07
risk O 0 7.035635185559386e-09
to O 0 3.434234008281578e-10
an O 0 8.478308055615003e-10
increased O 0 1.1926447029964038e-07
risk O 0 3.901772060999065e-08
, O 0 1.7347386860322445e-09
while O 0 2.0418160495694337e-09
in O 0 9.331850847615897e-10
another O 0 4.3978025665580844e-09
three O 0 1.4988485119715733e-08
the O 0 1.0697620922428541e-07
risk O 0 5.184668907531886e-07
was O 0 3.889263098244555e-06
decreased O 0 3.2740849746915046e-06
. O 0 3.634771417182492e-07

Knowledge O 0 7.802399863976461e-07
of O 0 9.740291240234455e-09
the O 0 8.368133741498696e-09
potential O 0 1.0397518401816797e-08
reasons O 0 1.5584034063209629e-09
for O 0 1.2413275962686043e-10
these O 0 1.3263101728000493e-10
changes O 0 1.884722600209443e-09
in O 0 4.766345540474504e-09
results O 0 3.8773791288804205e-08
and O 0 6.42258379812688e-09
impact O 0 3.2663747262517973e-09
of O 0 6.320982071095216e-10
these O 0 2.096609108548364e-09
risk O 0 1.2497458179439036e-08
reversals O 0 1.490858636543635e-07
on O 0 6.604745550475855e-08
both O 0 1.490595025188668e-08
patients O 0 1.937014282304972e-08
and O 0 3.0681708285129616e-09
the O 0 2.737698068244754e-09
counseling O 0 1.7346270198004277e-08
team O 0 1.3225922579351845e-09
can O 0 8.849352362005902e-10
assist O 0 1.0699019448168201e-09
in O 0 5.021219551260003e-10
the O 0 4.0860087535676826e-10
development O 0 2.1697731111824936e-10
of O 0 1.5446773027338878e-10
strategies O 0 3.4102538570834895e-09
for O 0 1.3674046617229152e-10
the O 0 2.0136106115842267e-09
prevention O 0 4.6537248721278957e-08
and O 0 2.738399196289265e-08
, O 0 3.202897724818854e-09
where O 0 3.433286099863153e-09
necessary O 0 1.8814039215442335e-09
, O 0 1.4925402025411927e-09
management O 0 2.2073087801999236e-09
of O 0 3.1471533712412736e-10
a O 0 2.6807308373122396e-08
risk O 0 7.6256142733655e-08
reversal O 0 6.216536263536909e-08
in O 0 1.3285996747214313e-09
any O 0 2.350725614164162e-09
predictive O 0 1.7191439383168472e-07
testing O 0 4.56525448555567e-08
program O 0 5.2873907918638e-08
. O 0 3.018485017491912e-08
. O 0 1.6512768752363627e-07

A O 0 6.716789812344359e-06
novel O 0 4.201955562166404e-06
common O 0 1.183589802167262e-06
missense O 0 0.0001450052805012092
mutation O 0 3.855616796499817e-06
G301C O 0 1.260220074073004e-06
in O 0 1.4613071641633724e-08
the O 0 1.1797673948876763e-08
N O 0 1.9379365312488517e-06
- O 0 2.4368989670620067e-06
acetylgalactosamine O 0 6.279731223912677e-06
- O 0 5.096776021673577e-06
6 O 0 8.424811426266388e-07
- O 0 4.725798135041259e-06
sulfate O 0 8.07935339253163e-06
sulfatase O 0 1.5133086890273262e-05
gene O 0 1.0214299663857673e-06
in O 0 1.809062410984552e-07
mucopolysaccharidosis B-Disease 0 8.795029862085357e-05
IVA I-Disease 0 0.006723628845065832
. O 0 9.760267857927829e-06

Mucopolysaccharidosis B-Disease 0 0.05680648982524872
IVA I-Disease 1 0.9997250437736511
( O 0 0.0019765845499932766
MPS B-Disease 1 0.999998927116394
IVA I-Disease 1 1.0
) O 0 8.889087439456489e-07
is O 0 5.988313489524444e-08
an O 0 2.0489338226070686e-07
autosomal B-Disease 1 0.9979043006896973
recessive I-Disease 1 0.9999406337738037
lysosomal I-Disease 1 0.9997212290763855
storage I-Disease 1 0.9998806715011597
disorder I-Disease 1 0.9999593496322632
caused O 0 1.2458717719709966e-05
by O 0 5.431610716755131e-08
a O 0 2.6035026166937314e-05
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999994039535522
in O 0 2.6428983801451977e-07
N O 0 6.208293143572519e-06
- O 0 1.1690761311911047e-05
acetylgalactosamine O 0 1.534055445517879e-05
- O 0 7.67996516515268e-06
6 O 0 1.6323328964062966e-06
- O 0 6.340714026009664e-05
sulfate O 0 2.876600956369657e-05
sulfatase O 0 4.150389941059984e-05
( O 0 2.236645997300002e-07
GALNS O 0 2.0904022676404566e-05
) O 0 2.5537087822158355e-07
. O 0 4.4965693746235047e-07

In O 0 9.243107115253224e-07
previous O 0 4.840478595724562e-07
studies O 0 4.073593018460997e-08
, O 0 7.577879657105768e-09
we O 0 3.1995459615075106e-09
have O 0 2.5166508876850457e-09
found O 0 2.190958525716269e-09
two O 0 5.718774787055736e-09
common O 0 2.491429818007873e-08
mutations O 0 1.483496276932783e-07
in O 0 1.3876420013048119e-08
Caucasians O 0 1.2643346281038248e-06
and O 0 1.7078734515507676e-07
Japanese O 0 6.961725773635408e-08
, O 0 1.4475172172012662e-08
respectively O 0 1.3254722830424726e-07
. O 0 1.5933208885599015e-07

To O 0 1.2686853096965933e-06
characterize O 0 4.44064289695234e-06
the O 0 9.27252870042139e-08
mutational O 0 4.482006988837384e-05
spectrum O 0 9.415824706593412e-07
in O 0 2.899964046676473e-09
various O 0 6.985794720471006e-10
ethnic O 0 8.032496445764536e-09
groups O 0 4.944761045067025e-09
, O 0 5.43878142522658e-09
mutations O 0 3.679763338482189e-08
in O 0 1.1419390988365308e-09
the O 0 5.6084417110469076e-09
GALNS O 0 1.841378661993076e-06
gene O 0 7.382545419432063e-08
in O 0 5.979103434583521e-08
Colombian O 0 2.3628928829566576e-05
MPS B-Disease 1 0.9995032548904419
IVA I-Disease 1 0.9999998807907104
patients O 0 9.18140540306922e-06
were O 0 1.4037077278317156e-07
investigated O 0 1.1221579399034454e-07
, O 0 3.979803597786713e-09
and O 0 5.50968692891729e-09
genetic O 0 9.601309614026832e-08
backgrounds O 0 1.3309735891198216e-07
were O 0 1.4679809368089991e-08
extensively O 0 2.8028733112250848e-08
analyzed O 0 2.595420234285939e-08
to O 0 2.595295089946603e-09
identify O 0 2.683232125377799e-08
racial O 0 6.172654565261837e-08
origin O 0 5.657520230073487e-09
, O 0 1.5938482755828431e-09
based O 0 5.1458100003287655e-09
on O 0 4.304221690176746e-08
mitochondrial O 0 4.4362556650412444e-07
DNA O 0 1.2058937954861904e-06
( O 0 3.633655154544613e-08
mtDNA O 0 5.264683409222926e-07
) O 0 9.197070482969139e-08
lineages O 0 1.6776340316937421e-06
. O 0 4.7118652446442866e-07

Three O 0 4.2255605876562186e-06
novel O 0 1.1075809197791386e-05
missense O 0 0.0012303475523367524
mutations O 0 8.211790554923937e-05
never O 0 7.22673303243937e-06
identified O 0 2.4847201984812273e-07
previously O 0 3.7032734212516516e-08
in O 0 3.1530431598980613e-09
other O 0 2.5046646978665876e-09
populations O 0 1.7167741006574033e-08
and O 0 2.605682780654206e-08
found O 0 1.0878107303824436e-08
in O 0 5.406748826430885e-09
16 O 0 2.4864831971171952e-08
out O 0 1.0651074688894369e-08
of O 0 3.8482967923414435e-09
19 O 0 7.762617997286725e-07
Colombian O 0 4.795327640749747e-06
MPS B-Disease 1 0.9596770405769348
IVA I-Disease 1 0.9999455213546753
unrelated O 0 2.0401353140186984e-06
alleles O 0 4.373079605102248e-07
account O 0 8.345343616156242e-08
for O 0 2.8990088551950066e-08
84 O 0 1.9499311747495085e-06
. O 0 6.743347285009804e-07

2 O 0 1.4430219380301423e-05
% O 0 1.537091236514243e-07
of O 0 1.6507464284387652e-09
the O 0 1.4761008415575816e-08
alleles O 0 1.095132944328725e-07
in O 0 8.933319861625932e-09
this O 0 1.1530756793831642e-08
study O 0 7.691522796449135e-08
. O 0 2.42890763502146e-07

The O 0 2.2633741991739953e-06
G301C O 0 1.902175063150935e-05
and O 0 3.983174110544496e-07
S162F O 0 8.06234311312437e-06
mutations O 0 1.8401691477265558e-06
account O 0 1.2896597922917863e-07
for O 0 3.6052195895308614e-08
68 O 0 3.492554242257029e-06
. O 0 6.332052748803108e-07

4 O 0 3.1542371289106086e-05
% O 0 6.934510565770324e-07
and O 0 8.578812327186824e-08
10 O 0 2.8654892503254814e-07
. O 0 4.93343122798251e-07

5 O 0 9.318123375123832e-06
% O 0 1.0495033109236829e-07
of O 0 5.185001761276453e-09
mutations O 0 9.063741686077265e-07
, O 0 2.9645775612152647e-08
respectively O 0 8.081583047214735e-08
, O 0 6.5458616305136275e-09
whereas O 0 5.305956563006475e-09
the O 0 3.261556136280319e-09
remaining O 0 2.146545341474848e-07
F69V O 0 1.1574004929570947e-05
is O 0 9.978068149507635e-09
limited O 0 3.4974709794965975e-09
to O 0 1.4605789910859812e-09
a O 0 2.9747672769531164e-08
single O 0 9.770175211087917e-07
allele O 0 5.167449216969544e-06
. O 0 5.321461458152044e-07

The O 0 1.5538947764071054e-06
skewed O 0 8.284352588816546e-06
prevalence O 0 7.887066203693394e-06
of O 0 1.1278587841445642e-08
G301C O 0 4.794376309291692e-07
in O 0 5.901433564048375e-09
only O 0 1.1545061795459333e-08
Colombian O 0 3.4336682119828765e-07
patients O 0 2.7665226554063338e-08
and O 0 2.4028756762106696e-09
haplotype O 0 1.6236047883921856e-07
analysis O 0 4.935273523187789e-09
by O 0 9.827322289268636e-10
restriction O 0 3.56022162861791e-08
fragment O 0 9.691063951322576e-07
length O 0 8.802651336736744e-07
polymorphisms O 0 1.8267179484610097e-06
in O 0 2.9425828440565738e-09
the O 0 2.925491848770889e-09
GALNS O 0 8.198645673473948e-07
gene O 0 4.5779589896710604e-08
suggest O 0 2.227483619776649e-08
that O 0 2.7411886094341753e-09
G301C O 0 1.833330713907344e-07
originated O 0 1.7554292242039082e-08
from O 0 1.1145078193663949e-09
a O 0 1.148168493614321e-08
common O 0 6.028584209616383e-08
ancestor O 0 1.1989321819783072e-06
. O 0 8.256158707808936e-07

Investigation O 0 3.55828433384886e-06
of O 0 3.970002637743164e-08
the O 0 1.0455908139306302e-08
genetic O 0 2.549175519561686e-07
background O 0 1.2751502254104707e-07
by O 0 2.1203767630595394e-09
means O 0 2.2569399682481617e-09
of O 0 7.013791769594491e-10
mtDNA O 0 6.129222640538501e-08
lineages O 0 7.92064724919328e-08
indicate O 0 3.206774934483292e-08
that O 0 2.2320074677395496e-09
all O 0 2.920362840441726e-09
our O 0 3.111897584062717e-08
patients O 0 2.845546553942313e-08
are O 0 2.24552665351041e-09
probably O 0 1.6698999516506774e-08
of O 0 1.8214856289944237e-09
native O 0 1.0659574911642267e-07
American O 0 1.4687730072182603e-06
descent O 0 0.00010274349187966436

Low O 0 4.80189046356827e-05
frequency O 0 5.512177722266642e-06
of O 0 3.4781078284140676e-07
BRCA1 O 0 0.0002303843357367441
germline O 0 6.87173887854442e-05
mutations O 0 4.20644209953025e-06
in O 0 6.6431148582069e-08
45 O 0 1.1878551049449015e-06
German O 0 0.19502964615821838
breast B-Disease 1 0.9999996423721313
/ I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 4.161244305578293e-06
. O 0 6.938460614946962e-07

In O 0 7.838302735763136e-07
this O 0 1.9885547430931183e-08
study O 0 1.2226387902103397e-08
we O 0 7.421465664236848e-09
investigated O 0 9.672554313056025e-08
45 O 0 2.2878289485106507e-07
German O 0 0.0002958908153232187
breast B-Disease 1 0.9999898672103882
/ I-Disease 1 0.9999957084655762
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999969005584717
families O 0 1.3081674410386768e-07
for O 0 1.7411737829320373e-08
germline O 0 9.945598321792204e-06
mutations O 0 6.613278742406692e-07
in O 0 7.60260743248864e-09
the O 0 8.123820549599259e-08
BRCA1 O 0 6.875592225696892e-05
gene O 0 6.3000716181704774e-06
. O 0 2.461686335664126e-06

We O 0 2.737091790550039e-06
identified O 0 8.494144481119292e-07
four O 0 7.757883224712714e-08
germline O 0 6.039712843630696e-06
mutations O 0 9.136206244875211e-07
in O 0 1.607042321438712e-08
three O 0 4.463025561562972e-06
breast B-Disease 1 0.9997432827949524
cancer I-Disease 0 0.00016158400103449821
families O 0 6.313528899681842e-08
and O 0 9.270066492206297e-09
in O 0 3.709133622464833e-08
one O 0 1.3161103197489865e-05
breast B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 5.742243729400798e-07
. O 0 3.1488720519945446e-09
among O 0 1.0335013955753425e-09
these O 0 6.669542140791407e-10
were O 0 2.2347348860307648e-08
one O 0 3.639085832674027e-08
frameshift O 0 6.004776150803082e-05
mutation O 0 3.520808888879401e-07
, O 0 4.984656243323116e-09
one O 0 2.5666068381724472e-08
nonsense O 0 4.891118805971928e-06
mutation O 0 4.095001315818081e-07
, O 0 3.0007689666433635e-09
one O 0 4.1420129548441764e-09
novel O 0 8.430696851746688e-08
splice O 0 3.0669481930090114e-05
site O 0 4.827833436138462e-06
mutation O 0 5.591801937043783e-07
, O 0 9.722824323432633e-09
and O 0 2.163848833447446e-08
one O 0 1.4980616924731294e-07
missense O 0 0.0003328872553538531
mutation O 0 1.9177832655259408e-05
. O 0 8.015509251890762e-07

The O 0 6.375794328050688e-06
missense O 0 0.0018707987619563937
mutation O 0 0.0001346192293567583
was O 0 9.215187674271874e-06
also O 0 1.9855366417687037e-07
found O 0 6.340791003367485e-08
in O 0 6.436051336322635e-08
2 O 0 1.1692271755237016e-06
. O 0 1.167063828688697e-06

8 O 0 3.627912883530371e-05
% O 0 3.359463960350695e-07
of O 0 2.0071342365923783e-09
the O 0 3.680576288189741e-09
general O 0 3.6243088530341083e-09
population O 0 2.1196810973123092e-09
, O 0 1.6876637864982058e-09
suggesting O 0 2.8135159979569835e-08
that O 0 1.7504198090989576e-09
it O 0 5.23151255649168e-09
is O 0 2.037168655988353e-08
not O 0 1.1923866338747757e-07
disease O 0 4.602219632943161e-06
associated O 0 4.1669210304462467e-07
. O 0 7.499946832467685e-07

The O 0 1.4401747421288746e-06
average O 0 3.0661126402264927e-06
age O 0 1.0807939787582654e-07
of O 0 1.4438499285063244e-08
disease O 0 4.201727278996259e-06
onset O 0 5.82114034841652e-06
in O 0 4.305888623434839e-08
those O 0 3.304866780240445e-08
families O 0 8.63757492197692e-08
harbouring O 0 1.620488183107227e-05
causative O 0 9.66443167271791e-06
mutations O 0 1.4673346413474064e-05
was O 0 1.9558199255698128e-06
between O 0 2.507697161036049e-07
32 O 0 3.0804269499640213e-06
. O 0 9.55426685322891e-07

3 O 0 4.067789268447086e-05
and O 0 1.8963653474202147e-06
37 O 0 7.39023334972444e-06
. O 0 1.5260300187946996e-06

4 O 0 3.9899015973787755e-05
years O 0 4.852667530030885e-07
, O 0 9.053978899942194e-09
whereas O 0 9.035002968005301e-09
the O 0 4.31461755212581e-09
family O 0 7.007045610407658e-08
harbouring O 0 1.040708184518735e-06
the O 0 2.4699676970385553e-08
missense O 0 1.6370460798498243e-05
mutation O 0 9.728734085001634e-07
had O 0 7.8744756137894e-07
an O 0 9.187371752261697e-09
average O 0 4.726180975467287e-07
age O 0 2.197471715703614e-08
of O 0 2.2182651271407394e-09
onset O 0 1.3267754184198566e-06
of O 0 2.3653710101712022e-08
51 O 0 2.6342872843088116e-06
. O 0 5.225995209912071e-07

2 O 0 6.795027729822323e-05
years O 0 7.398060461127898e-06
. O 0 3.345793402331765e-06

These O 0 4.826405870517192e-07
findings O 0 1.8215617103578552e-07
show O 0 6.981364890634723e-07
that O 0 2.6557479770872305e-08
BRCA1 O 0 1.1223393812542781e-05
is O 0 5.2424429242137194e-08
implicated O 0 1.4301136275207682e-07
in O 0 3.172044182875311e-09
a O 0 9.076508433736308e-09
small O 0 8.595137934719332e-09
fraction O 0 3.918470170560795e-08
of O 0 8.928008554676126e-08
breast B-Disease 1 0.9999990463256836
/ I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 1.3746370086664683e-07
suggesting O 0 3.0764994107812527e-08
the O 0 2.4909010409857046e-09
involvement O 0 1.2436940366455929e-08
of O 0 1.9599732947739312e-09
another O 0 8.438306764446679e-08
susceptibility O 0 4.23942728957627e-05
gene O 0 4.913030352327041e-06
( O 0 6.118489181972109e-07
s O 0 6.686078268103302e-05
) O 0 1.893661760732357e-06

Paternal O 0 0.2073964923620224
transmission O 0 0.35616183280944824
of O 0 0.00017838639905676246
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00015064810577314347

We O 0 2.6339282612752868e-06
report O 0 8.697569597870825e-08
a O 0 3.4215535293924404e-08
rare O 0 9.472615403183227e-08
case O 0 2.2609894756442372e-07
of O 0 1.2465008012441103e-06
paternally O 1 0.9999434947967529
transmitted O 1 0.9999998807907104
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.15724457800388336
DM B-Disease 1 1.0
) O 0 6.311257038760232e-06
. O 0 2.476634335835115e-06

The O 0 1.2050005580022116e-06
proband O 0 7.267344244610285e-06
is O 0 3.9509892246769596e-08
a O 0 3.478618282315438e-08
23 O 0 2.158840572974441e-07
year O 0 3.8485339359795034e-08
old O 0 6.0846112319268286e-05
, O 0 9.381896234117448e-06
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.007861495018005371
who O 0 0.006362192798405886
suffers O 1 0.9779874086380005
severe O 1 0.8507848978042603
muscular B-Disease 1 0.9999662637710571
weakness I-Disease 1 0.6165004372596741
. O 0 3.6009669202030636e-06

He O 0 7.264690339070512e-06
presented O 0 4.850330697081517e-07
with O 0 4.686299064360355e-07
respiratory O 0 0.004055932629853487
and O 0 9.37250831611891e-07
feeding O 0 2.0591898646671325e-05
difficulties O 0 2.1393445877038175e-06
at O 0 2.6148990173169295e-07
birth O 0 9.151910489890724e-06
. O 0 9.328982173428813e-07

His O 0 3.384943920536898e-05
two O 0 9.696651432022918e-06
sibs O 0 0.34955114126205444
suffer O 0 0.00013181981921661645
from O 0 4.1606941181271395e-07
childhood O 0 0.0001806408108677715
onset O 1 0.911050021648407
DM B-Disease 1 1.0
. O 0 3.283107071183622e-05

Their O 0 4.0548138713347726e-06
late O 0 3.589614152588183e-06
father O 0 1.9101128145848634e-06
had O 0 1.6676629854828207e-07
the O 0 2.9809681389991738e-09
adult O 0 2.9540842660935596e-08
type O 0 3.333774145630741e-08
of O 0 3.3536981192128223e-08
DM B-Disease 1 1.0
, O 0 4.423159438715629e-08
with O 0 1.098605384441953e-08
onset O 0 2.4220939849328715e-06
around O 0 1.5228360439323296e-07
30 O 0 1.1466183735819868e-07
years O 0 9.23528631346926e-08
. O 0 1.9504169301853835e-07

Only O 0 5.189199896449281e-07
six O 0 4.023155852905802e-08
other O 0 2.7600226548685214e-09
cases O 0 4.529293384791799e-09
of O 0 3.2022564599998304e-09
paternal O 0 0.00011010320304194465
transmission O 0 0.0037257138174027205
of O 0 3.0664107271149987e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 1.991144563362468e-05
been O 0 2.1136320356163196e-06
reported O 0 1.8557143448560964e-06
recently O 0 2.7909666187042603e-06
. O 0 3.676474022995535e-07

We O 0 1.5889188489381922e-06
review O 0 4.7560860139128636e-08
the O 0 5.363056665430577e-09
sex O 0 4.572714118467047e-08
related O 0 2.3468562204698173e-08
effects O 0 4.2544414213807613e-07
on O 0 1.073285147867864e-06
transmission O 0 0.0014296936569735408
of O 0 1.1073971108999103e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 1.8662722141016275e-05

Decreased O 0 0.0002462822012603283
fertility O 0 7.679013833694626e-06
of O 0 5.0295255960008944e-08
males O 0 1.4446548846080987e-07
with O 0 1.6217423848274848e-08
adult O 0 5.667297500622226e-06
onset O 0 0.014147363603115082
DM B-Disease 1 1.0
and O 0 1.6830343838591943e-06
contraction O 0 1.274328838007932e-06
of O 0 1.6731063201547158e-09
the O 0 4.7135393366204426e-09
repeat O 0 1.5079564263942302e-07
upon O 0 5.153274695857135e-09
male O 0 1.3973446755244368e-07
transmission O 0 1.9749893453990808e-07
contribute O 0 2.4802009335189723e-09
to O 0 9.4484631230074e-10
the O 0 3.8344709629711815e-09
almost O 0 2.717316860412211e-08
absent O 0 4.751008475523122e-08
occurrence O 0 6.806816088555934e-08
of O 0 8.019361175115591e-09
paternal O 0 6.0107344324933365e-05
transmission O 0 0.0006782521959394217
of O 0 8.505293408234138e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 1.3357448551687412e-05

Also O 0 8.445086677966174e-06
the O 0 5.45531406714872e-08
fathers O 0 1.656418646689417e-07
of O 0 2.90650392642533e-09
the O 0 2.5325425312416883e-08
reported O 0 7.511022431572201e-06
congenitally O 0 0.00013500408385880291
affected O 0 3.730842195182049e-07
children O 0 4.635086838788993e-07
showed O 0 1.9333713225933025e-06
, O 0 2.702563728362861e-09
on O 0 1.0402185068869585e-07
average O 0 2.776580743102386e-07
, O 0 8.96028140573435e-09
shorter O 0 6.705159876219113e-07
CTG O 0 1.873408905339602e-06
repeat O 0 4.6247811269495287e-07
lengths O 0 2.4477563783875667e-05
and O 0 2.1637166724985946e-08
hence O 0 4.206407666629275e-08
less O 0 3.997828912361001e-08
severe O 0 5.533117928280262e-06
clinical O 0 2.7309513370710192e-06
symptoms O 0 3.930457751266658e-06
than O 0 3.345021148959404e-09
the O 0 6.5632890233757735e-09
mothers O 0 2.9646943744410237e-07
of O 0 3.434504236565772e-09
children O 0 1.2788906360583496e-06
with O 0 1.878958755696658e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 1.9893641365342773e-05

We O 0 1.7980680695472984e-06
conclude O 0 5.966253411315847e-07
that O 0 2.4038945056759076e-08
paternal O 0 1.8362496120971628e-05
transmission O 0 0.00016194106137845665
of O 0 5.07502682012273e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 8.947985747909115e-07
rare O 0 4.1488224411523333e-08
and O 0 3.5390641528465494e-08
preferentially O 0 1.1388329568262634e-07
occurs O 0 7.298411652811865e-09
with O 0 3.803600545637664e-09
onset O 0 1.4858399026707048e-06
of O 0 3.5409684073783865e-08
DM B-Disease 1 1.0
past O 0 1.0376862519478891e-05
30 O 0 1.0630276392475935e-07
years O 0 5.037529948737074e-09
in O 0 1.8470565077421952e-09
the O 0 1.2917332981032814e-08
father O 0 1.280776359635638e-06
. O 0 4.236706985238925e-08
. O 0 1.8495380516014848e-07

The O 0 8.874256309354678e-06
RB1 O 0 0.0005124473827891052
gene O 0 1.0823533557413612e-05
mutation O 0 2.7265896278549917e-06
in O 0 1.4107878421043551e-08
a O 0 1.2743284116822906e-07
child O 0 1.671962127147708e-05
with O 0 4.881203039985849e-06
ectopic B-Disease 1 0.9999997615814209
intracranial I-Disease 1 0.9999955892562866
retinoblastoma I-Disease 1 0.8006506562232971
. O 0 1.2333269296505023e-05

The O 0 7.086348887241911e-06
RB1 O 0 0.0008306371746584773
gene O 0 1.7198313798871823e-05
mutation O 0 7.645654477528296e-06
was O 0 6.265896672630333e-07
investigated O 0 1.0169651432079263e-07
in O 0 5.3130051469452155e-09
a O 0 5.942199976516349e-08
child O 0 3.229404683224857e-06
with O 0 3.7284624454514415e-07
ectopic B-Disease 1 0.9999886751174927
intracranial I-Disease 1 0.6555589437484741
retinoblastoma I-Disease 0 1.401568079018034e-05
using O 0 7.670148960414735e-08
DNA O 0 2.75439788310905e-07
obtained O 0 1.081705125471899e-08
from O 0 1.409356298331943e-09
both O 0 1.2757925826889505e-09
the O 0 1.55229020748493e-08
pineal B-Disease 0 6.047704300726764e-05
and I-Disease 0 4.068657744937809e-06
retinal I-Disease 1 0.9329876899719238
tumours I-Disease 1 1.0
of O 0 8.28945445618956e-08
the O 0 3.6285788951317954e-07
patient O 0 2.0896070054732263e-05
. O 0 1.3076102050035843e-06

A O 0 3.019458381459117e-05
nonsense O 0 5.4929329053265974e-05
mutation O 0 3.402256197659881e-06
in O 0 2.3328114551190993e-08
exon O 0 3.3280837214988424e-06
17 O 0 9.15951716251584e-07
( O 0 2.2120977050121837e-08
codon O 0 3.4376131452518166e-07
556 O 0 9.302785031195526e-08
) O 0 2.198401238828751e-09
of O 0 5.75850422901425e-10
the O 0 2.3882009259068582e-08
RB1 O 0 2.223896808573045e-05
gene O 0 2.186706069551292e-07
was O 0 1.1916674793610582e-06
found O 0 1.3892574202145624e-08
to O 0 2.330991177856845e-09
be O 0 4.7235739764062146e-09
present O 0 4.299714806421662e-09
homozygously O 0 6.293126944001415e-07
in O 0 5.116156387430237e-09
both O 0 3.550732374790755e-09
the O 0 2.2539726529657855e-08
retinal B-Disease 0 3.1780356948729604e-05
and I-Disease 0 7.961639312270563e-07
the I-Disease 0 3.0440569389611483e-06
pineal I-Disease 0 0.44654300808906555
tumours I-Disease 1 1.0
. O 0 3.607838152674958e-06

The O 0 3.229227729661943e-07
same O 0 1.5014329335372167e-07
mutation O 0 8.190393145923736e-07
was O 0 9.545890122808487e-08
present O 0 3.905180179231138e-09
heterozygously O 0 2.2471631666576286e-07
in O 0 1.8153432090883825e-09
the O 0 1.9442683019121887e-09
DNA O 0 2.4646688245866244e-08
from O 0 6.174627475985517e-10
the O 0 4.816772536386793e-10
constitutional O 0 3.940736625906993e-09
cells O 0 4.177804768801252e-09
of O 0 3.250208713279079e-10
the O 0 5.4922493220033175e-09
patient O 0 1.56064174916537e-07
, O 0 5.410504044789377e-09
proving O 0 1.8950544244944467e-08
it O 0 2.1692694307517968e-09
to O 0 1.8415371449975737e-09
be O 0 4.306149214983179e-09
of O 0 8.44053982262949e-09
germline O 0 3.2563384593231604e-06
origin O 0 1.9245675275669782e-07
. O 0 3.4595791476021986e-07

The O 0 5.888584269087005e-07
initial O 0 3.2659406201673846e-07
mutation O 0 5.547894375013129e-07
was O 0 3.636789642769145e-07
shown O 0 2.775025897960859e-08
to O 0 2.7982300920825764e-09
have O 0 5.7472188785823164e-08
occurred O 0 1.8479776997537556e-07
in O 0 9.290740621281657e-09
the O 0 8.803451834182852e-08
paternally O 0 4.566742791212164e-05
derived O 0 1.980462002393324e-06
RB1 O 0 0.0001595447101863101
allele O 0 1.172561042039888e-05
. O 0 1.4375154933077283e-06

The O 0 1.283549750041857e-06
mutation O 0 3.2307109449902782e-06
is O 0 1.0602773770074236e-08
in O 0 1.5299032041227179e-09
an O 0 1.743518995844795e-09
area O 0 6.486430947916233e-08
of O 0 1.222605350292838e-09
the O 0 5.033707228818685e-09
gene O 0 2.0647744847224203e-08
that O 0 1.4367176337515275e-09
encodes O 0 8.623496583481938e-09
the O 0 1.3223425687769463e-09
protein O 0 1.501349267130081e-08
- O 0 1.3992703884468938e-07
binding O 0 2.0415445334265314e-08
region O 0 2.782812202895002e-08
known O 0 1.042949637763968e-08
as O 0 1.5602058534014418e-09
the O 0 3.3957798795114513e-09
pocket O 0 0.0029152592178434134
region O 0 1.6409332204148086e-07
and O 0 7.976574778467693e-08
has O 0 1.614955351669778e-07
been O 0 3.3778100316794735e-08
detected O 0 2.92738544516169e-08
in O 0 6.37194352837156e-10
other O 0 6.547555830849205e-10
cases O 0 2.2693975587628756e-09
of O 0 5.566728411565691e-09
retinoblastoma B-Disease 0 8.91233685251791e-06
. O 0 1.6138284308908624e-07
. O 0 7.738360068287875e-07

Low O 0 3.533043491188437e-05
levels O 0 4.0078847973745724e-07
of O 0 7.42776773421383e-09
beta O 0 5.981464568094452e-08
hexosaminidase O 0 3.3455910397606203e-07
A O 0 5.164879013364043e-08
in O 0 1.629730128627216e-08
healthy O 0 1.7887315095777012e-07
individuals O 0 5.308244510615623e-09
with O 0 5.39836371160618e-08
apparent O 0 0.04843563586473465
deficiency O 0 0.0007968981517478824
of O 0 5.4903006585504954e-09
this O 0 2.0661532929011628e-08
enzyme O 0 1.944122914210311e-06
. O 0 5.762871069237008e-07

Appreciable O 0 0.00015300887753255665
beta O 0 5.572728696279228e-06
hexosaminidase O 0 1.171001076727407e-05
A O 0 6.306644877440704e-07
( O 0 4.287122479240679e-08
hex O 0 1.055523398463265e-06
A O 0 9.76948797415389e-08
) O 0 3.984664598277732e-09
activity O 0 1.3620049088558517e-08
has O 0 1.1714082148728266e-08
been O 0 9.569640191386952e-09
detected O 0 4.092275673883705e-08
in O 0 4.2846188819112285e-09
cultured O 0 2.4968637717392994e-06
skin O 0 0.0004615146026480943
fibroblasts O 0 2.045982682830072e-06
and O 0 7.86895043347613e-07
melanoma B-Disease 0 0.004671802744269371
tissue O 0 1.3422499023363343e-06
from O 0 8.136331608454839e-09
healthy O 0 7.713442329304598e-08
individuals O 0 1.583932207616101e-09
previously O 0 4.237119455297034e-08
reported O 0 9.497279620518384e-07
as O 0 2.4880827709239384e-07
having O 0 6.4683586060709786e-06
deficiency B-Disease 0 8.00065572548192e-06
of I-Disease 0 6.602661195564963e-10
hex I-Disease 0 1.291633225264377e-06
A I-Disease 0 4.822109289648324e-08
activity O 0 4.1105575832034447e-08
indistinguishable O 0 2.585148628497791e-08
from O 0 7.234970955671827e-10
that O 0 4.6449055712827203e-10
of O 0 3.003139292800938e-09
patients O 0 3.884300951995101e-07
with O 0 2.1896617909078486e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.04188253730535507
( O 0 3.753081898594246e-07
TSD B-Disease 0 6.582841160707176e-05
) O 0 3.822581788881507e-07
. O 0 4.610671453519899e-07

Identification O 0 1.8177152014686726e-05
and O 0 7.046663199616887e-07
quantitation O 0 1.788773442967795e-05
of O 0 3.936231252055222e-08
hex O 0 2.3292217520065606e-05
A O 0 5.014066459807509e-07
, O 0 2.943431987034728e-08
amounting O 0 7.220322828516146e-08
to O 0 1.474046928962025e-08
3 O 0 5.119185857438424e-07
. O 0 6.630418170061603e-07

5 O 0 4.244322553859092e-05
% O 0 2.175889676436782e-06
- O 0 1.7448130165576003e-05
6 O 0 3.5891043808078393e-06
. O 0 5.997492849019181e-07

9 O 0 3.6958885175408795e-05
% O 0 1.8354650421770202e-07
of O 0 3.2425260254598243e-09
total O 0 1.0629319646682234e-08
beta O 0 2.2019190026867363e-08
hexosaminidase O 0 2.3538099469533336e-07
activity O 0 5.4624145207071706e-08
, O 0 3.822327787617041e-09
has O 0 2.449493763378996e-08
been O 0 1.0363088165377121e-08
obtained O 0 4.298050360063144e-09
by O 0 5.424598548131598e-09
cellulose O 0 3.311762156954501e-06
acetate O 0 3.0212438559829025e-06
gel O 0 1.1938905117858667e-05
electrophoresis O 0 4.590782737068366e-06
, O 0 4.040782286551803e-08
DEAE O 0 3.135669658149709e-06
- O 0 8.681573717694846e-07
cellulose O 0 8.08845925348578e-07
ion O 0 2.8629025905502203e-07
- O 0 4.5919338731437165e-07
exchange O 0 7.47193382721889e-08
chromatography O 0 2.897586455219425e-07
, O 0 2.1691544560553666e-08
radial O 0 1.030380190059077e-06
immunodiffusion O 0 2.2827734937891364e-06
, O 0 2.163815615574549e-08
and O 0 5.028336147461232e-08
radioimmunoassay O 0 2.027049231401179e-05
. O 0 6.601684390261653e-07

Previous O 0 9.478500032855663e-06
family O 0 7.388291578536155e-07
studies O 0 2.5979263185149648e-08
suggested O 0 2.9517975619341996e-08
that O 0 1.140611272099079e-09
these O 0 1.0732109645417154e-09
individuals O 0 1.0851783915910573e-09
may O 0 1.3523648867419524e-08
be O 0 1.87004145502101e-09
compound O 0 5.992552587485989e-08
heterozygotes O 0 1.5426687127728655e-07
for O 0 6.387324003043204e-10
the O 0 4.015955124003767e-09
common O 0 2.7811779546027537e-08
mutant O 0 1.406375758961076e-06
TSD B-Disease 0 5.502471594809322e-06
gene O 0 2.415378332898399e-07
and O 0 2.3111063285341515e-08
a O 0 9.873888018319121e-08
rare O 0 3.099354728419712e-07
( O 0 7.770411514229636e-08
allelic O 0 1.5630681673428626e-06
) O 0 7.071761842780688e-08
mutant O 0 3.4085469451383688e-06
gene O 0 5.720736226066947e-06
. O 0 1.4827553513896419e-06

Thus O 0 4.767603059008252e-06
, O 0 6.467097790618936e-08
the O 0 8.120114358689534e-09
postulated O 0 2.1130202298991207e-07
rate O 0 1.0814930107017062e-07
mutant O 0 2.096876556834104e-07
gene O 0 8.554205521704716e-08
appears O 0 9.745424023321902e-08
to O 0 1.0756845414405802e-09
code O 0 2.416102207192239e-09
for O 0 5.020903692809497e-10
the O 0 5.1058135497328294e-09
expression O 0 1.6646273692799696e-08
of O 0 1.7359036430519836e-09
low O 0 1.2411435079684452e-07
amounts O 0 5.069337394303375e-09
of O 0 2.522138498051163e-09
hex O 0 1.2145465916546527e-05
A O 0 9.79753167484887e-07
. O 0 8.396465887017257e-07

Heterozygotes O 0 0.0001531301677459851
for O 0 1.110007090687759e-07
the O 0 2.9618533403663605e-08
rare O 0 6.581681333273082e-08
mutant O 0 3.206850578862941e-06
may O 0 3.3076543104471057e-07
be O 0 2.9054507688641706e-09
indistinguishable O 0 5.994873220060981e-08
from O 0 4.690865917922338e-09
heterozygotes O 0 1.389501846915664e-07
for O 0 2.4721908964409067e-09
the O 0 1.8496557174785266e-08
common O 0 4.3323993281774165e-07
TSD B-Disease 0 8.80643492564559e-05
mutant O 0 3.152481440338306e-05
. O 0 2.0403786038514227e-06

However O 0 1.508068407929386e-06
, O 0 2.880214999834152e-08
direct O 0 2.1649674053492163e-08
visualization O 0 7.659635912204976e-07
and O 0 1.0647992354506641e-07
quantitation O 0 1.2754017916449811e-05
of O 0 1.564184337610186e-08
hex O 0 2.151488297386095e-05
A O 0 4.793187713403313e-08
by O 0 1.2810937866092331e-09
the O 0 1.4132136572087006e-09
methods O 0 3.075941990005049e-08
described O 0 5.156916245141474e-07
may O 0 7.455377470932945e-08
prevent O 0 1.5398898156604446e-08
false O 0 4.8696161769612445e-08
- O 0 4.204645392746897e-06
positive O 0 1.2823282702356664e-07
prenatal O 0 3.261015763200703e-06
diagnosis O 0 2.762400072242599e-06
of O 0 1.0106648851149203e-08
TSD B-Disease 0 2.0744533685501665e-05
in O 0 8.34564559681894e-08
fetuses O 0 1.0078438208438456e-05
having O 0 4.279997867229213e-08
the O 0 9.356825536599445e-09
incomplete O 0 1.5667230002236465e-07
hex B-Disease 0 0.00037851196248084307
A I-Disease 0 1.1723719580913894e-05
deficiency I-Disease 0 1.4136872778180987e-05
of O 0 7.040101834832058e-10
the O 0 9.252296706563357e-09
type O 0 1.53374372757753e-07
described O 0 3.770344676468085e-07
in O 0 1.9005854667852873e-08
the O 0 3.348629462607278e-08
four O 0 1.0877339491344173e-06
healthy O 0 3.891626420227112e-06
individuals O 0 3.82980289259649e-07

The O 0 6.681683771603275e-06
tumor B-Disease 0 0.0001335318956989795
suppressor O 0 9.325275459559634e-05
gene O 0 9.251288247469347e-06
Smad4 O 0 7.995026680873707e-05
/ O 0 1.5266823538695462e-05
Dpc4 O 0 6.745721748302458e-06
is O 0 1.472894695098148e-08
required O 0 2.6455238000266945e-09
for O 0 1.0764911184679704e-09
gastrulation O 0 6.068686957405589e-07
and O 0 1.597005336861912e-07
later O 0 1.9573393217342527e-07
for O 0 3.3230820317697862e-09
anterior O 0 4.301292335640028e-07
development O 0 5.7932751929001824e-09
of O 0 2.009739041852754e-09
the O 0 3.1554993284999e-08
mouse O 0 4.793148036696948e-05
embryo O 0 1.7938575183507055e-05
. O 0 7.712058618380979e-07

Mutations O 0 0.000577029655687511
in O 0 5.721308298234362e-07
the O 0 2.817415634126519e-07
SMAD4 O 0 0.00021209575061220676
/ O 0 6.464175385190174e-05
DPC4 O 0 0.00014413254393730313
tumor B-Disease 0 2.3088488887879066e-05
suppressor O 0 1.535320006951224e-05
gene O 0 4.601113232638454e-07
, O 0 9.105066922643346e-09
a O 0 7.958897541016086e-09
key O 0 1.0233181058083574e-07
signal O 0 7.574500386908767e-07
transducer O 0 5.548789090425998e-07
in O 0 5.396507685162533e-09
most O 0 2.569299217825005e-09
TGFbeta O 0 9.269325005334395e-07
- O 0 1.7014370996548678e-06
related O 0 2.3379028490921883e-08
pathways O 0 1.285547313045754e-07
, O 0 3.1580866810543284e-09
are O 0 5.640880540447313e-10
involved O 0 2.000003274105211e-09
in O 0 4.179685486604967e-09
50 O 0 3.626004740908684e-08
% O 0 1.4597972608498822e-08
of O 0 4.869987790812047e-08
pancreatic B-Disease 1 0.9816063046455383
cancers I-Disease 1 0.7026841044425964
. O 0 2.6645059278962435e-06

Homozygous O 0 0.0028634474147111177
Smad4 O 0 0.00047953479224815965
mutant O 0 0.0002553818339947611
mice O 0 0.006553648039698601
die O 0 9.586188389221206e-05
before O 0 8.19611472024917e-08
day O 0 1.522388686225895e-07
7 O 0 4.2571122094159364e-07
. O 0 2.9755116770502354e-07

5 O 0 2.3071190298651345e-05
of O 0 7.375007839982572e-07
embryogenesis O 0 7.076973270159215e-05
. O 0 4.13406951338402e-06

Mutant O 0 5.0158116209786385e-05
embryos O 0 6.056214260752313e-06
have O 0 1.6903391042433213e-07
reduced O 0 8.55658797149772e-08
size O 0 5.3561794999268386e-08
, O 0 2.950564770287656e-08
fail O 0 5.3678082423402884e-08
to O 0 4.177422407991571e-09
gastrulate O 0 1.887187636384624e-06
or O 0 1.4568487749500036e-08
express O 0 1.0709990228008337e-08
a O 0 5.711166206623375e-09
mesodermal O 0 5.108787490826217e-07
marker O 0 3.6939447909389855e-06
, O 0 3.035482265545397e-08
and O 0 7.602262286354744e-08
show O 0 6.730082077410771e-06
abnormal O 0 7.286769232450752e-06
visceral O 0 1.2153484021837357e-05
endoderm O 0 2.5105327949859202e-05
development O 0 3.796072576278675e-07
. O 0 7.203574909908639e-07

Growth B-Disease 1 0.9999983310699463
retardation I-Disease 1 0.9999997615814209
of O 0 1.0582674292436423e-07
the O 0 8.038507814944751e-08
Smad4 O 0 0.00011129687482025474
- O 0 0.00010739501885836944
deficient O 0 6.391470378730446e-06
embryos O 0 1.7429488252673764e-07
results O 0 4.05243660850374e-08
from O 0 3.90280474604765e-09
reduced O 0 3.5393274089301485e-08
cell O 0 1.995984320046773e-07
proliferation O 0 7.207238184037124e-08
rather O 0 7.381105504578045e-09
than O 0 6.2711129622528006e-09
increased O 0 8.566352960315271e-08
apoptosis O 0 3.762004553209408e-06
. O 0 4.2851112880271103e-07

Aggregation O 0 3.6715122405439615e-05
of O 0 2.6536625341577746e-07
mutant O 0 7.088573511282448e-06
Smad4 O 0 3.769664908759296e-05
ES O 0 2.3165935090219136e-06
cells O 0 1.741526602927479e-07
with O 0 1.2594731479964594e-08
wild O 0 5.885182190468186e-07
- O 0 7.520093640778214e-05
type O 0 1.8347385548622697e-06
tetraploid O 0 2.1463116354425438e-05
morulae O 0 2.410389788565226e-05
rescues O 0 1.4022071809449699e-05
the O 0 3.374796904154209e-07
gastrulation B-Disease 0 4.599030580720864e-05
defect I-Disease 0 5.691127444151789e-05
. O 0 7.94168727225042e-07

These O 0 6.381807224897784e-07
results O 0 2.0416854340510326e-07
indicate O 0 8.784983407394975e-08
that O 0 3.3969200785577414e-09
Smad4 O 0 2.5780441319511738e-06
is O 0 1.5198001079852475e-08
initially O 0 4.45968773021832e-08
required O 0 1.9893191260944576e-10
for O 0 1.0240723546939279e-10
the O 0 3.490578104337061e-10
differentiation O 0 3.153295624613861e-09
of O 0 4.817562460068814e-10
the O 0 3.2362854618384063e-09
visceral O 0 2.9529249445658934e-07
endoderm O 0 9.238983125214872e-07
and O 0 6.120085771499362e-09
that O 0 7.621070441388156e-10
the O 0 8.838881626616057e-09
gastrulation B-Disease 0 9.46730210671376e-07
defect I-Disease 0 4.8976448852045e-07
in O 0 4.3137782235191935e-09
the O 0 1.9181756627517643e-08
epiblast O 0 9.313947884947993e-06
is O 0 1.2799024950993498e-08
secondary O 0 1.6549275727584245e-08
and O 0 3.0415328922117624e-08
non O 0 9.436980974442122e-08
- O 0 3.477597056189552e-05
cell O 0 1.2309485100558959e-05
autonomous O 0 1.8483156054571737e-06
. O 0 1.0335570550523698e-06

Rescued O 0 0.00047737150453031063
embryos O 0 6.143885548226535e-05
show O 0 0.00012336799409240484
severe O 0 0.00017294581630267203
anterior O 0 0.00015917244309093803
truncations O 0 9.161979687632993e-05
, O 0 4.884286113338021e-07
indicating O 0 6.232243094927981e-07
a O 0 6.400146901341941e-08
second O 0 1.1490376294887028e-07
important O 0 2.4522084363098884e-09
role O 0 1.528533033479107e-08
for O 0 7.776042920681903e-09
Smad4 O 0 4.212648946122499e-06
in O 0 5.952193404823447e-08
anterior O 0 2.374671385041438e-05
patterning O 0 0.00017143123841378838
during O 0 7.697142905271903e-07
embryogenesis O 0 1.7436936104786582e-05
. O 0 1.9442750271991827e-06

Prevalence O 0 0.0006218397757038474
of O 0 8.369188435608521e-07
p16 O 0 2.744650191743858e-05
and O 0 4.74543895734314e-07
CDK4 O 0 8.442493708571419e-05
germline O 0 4.0968625398818403e-05
mutations O 0 2.8393551474437118e-06
in O 0 5.344974240983902e-08
48 O 0 4.309867563279113e-06
melanoma B-Disease 0 0.32918277382850647
- O 0 0.1424628347158432
prone O 0 0.0008865335839800537
families O 0 4.1479967194391065e-07
in O 0 1.0521429061327581e-07
France O 0 1.6791909729363397e-05
. O 0 6.583043727914628e-07

The O 0 4.837349933950463e-06
French O 0 0.00011769913544412702
Familial B-Disease 0 0.03971618413925171
Melanoma I-Disease 1 0.9968771934509277
Study O 0 1.1426453738749842e-06
Group O 0 2.4877699615899473e-06
. O 0 6.172861048980849e-07

Germline O 0 0.01769772730767727
mutations O 0 0.00018042116425931454
in O 0 8.322516720227213e-08
the O 0 2.1773619351961315e-08
p16 O 0 4.939184350405412e-07
and O 0 2.976015700539847e-08
CDK4 O 0 3.929550985048991e-06
genes O 0 1.2034061569465848e-07
have O 0 6.149551978751333e-08
been O 0 2.256700497582642e-07
reported O 0 4.04243181151287e-08
in O 0 4.3198358778973045e-10
a O 0 1.9016652696990377e-09
subset O 0 1.4178421103849814e-08
of O 0 1.473220567760336e-08
melanoma B-Disease 0 0.0006053006509318948
pedigrees O 0 2.013229277508799e-06
, O 0 8.572691001518251e-09
but O 0 2.4211213034419643e-09
their O 0 5.095374788766094e-09
prevalence O 0 3.244042318328866e-06
is O 0 1.961111095738488e-08
not O 0 7.244999711275568e-09
well O 0 2.4876880999613604e-08
known O 0 3.783119950639957e-07
. O 0 2.398573428763484e-07

We O 0 1.907797013700474e-06
searched O 0 5.751626872552151e-07
for O 0 7.63891616628598e-09
such O 0 1.1058373772243613e-08
germline O 0 6.6332095229881816e-06
mutations O 0 7.577824021609558e-07
in O 0 2.1262582805547936e-08
48 O 0 5.404616558735142e-07
French O 0 2.7979784135823138e-05
melanoma B-Disease 0 0.07405206561088562
- O 0 0.03075368143618107
prone O 0 7.519175414927304e-05
families O 0 3.821783067792239e-08
selected O 0 3.859771613434759e-09
according O 0 9.300027414838041e-10
to O 0 6.185046919071624e-10
two O 0 3.50399442794469e-09
major O 0 2.7967788085447864e-09
criteria O 0 3.983783081196179e-09
families O 0 3.490420175111808e-09
with O 0 1.4444606621921707e-09
at O 0 8.05443534090955e-09
least O 0 2.264701537413316e-09
three O 0 2.1758121970805178e-09
affected O 0 6.901396343295119e-09
members O 0 1.3866571224596669e-09
( O 0 2.2491100093446903e-09
n O 0 1.0698234120809502e-07
= O 0 1.9492564717893401e-07
20 O 0 7.897352105601385e-09
) O 0 7.096589982324986e-10
or O 0 1.3171244095389056e-09
families O 0 1.304506058730226e-09
with O 0 5.252796531074466e-10
two O 0 2.0374095299757755e-08
affected O 0 9.617856733257213e-09
members O 0 2.5672810544108415e-09
, O 0 5.444622530603738e-10
one O 0 5.378912315556761e-10
of O 0 1.6019421900104192e-10
them O 0 1.6657955015375592e-09
affected O 0 5.10516118268356e-09
before O 0 1.7447665534575663e-09
the O 0 1.1323870729995633e-09
age O 0 1.622329492967367e-09
of O 0 2.0597495931085064e-10
50 O 0 3.500540746159686e-09
( O 0 1.6285797155290993e-09
n O 0 8.792040517846544e-08
= O 0 4.4082398176215065e-07
28 O 0 1.104640361404563e-07
) O 0 1.8732615458816326e-09
, O 0 8.830501885270792e-10
and O 0 1.897049850541066e-09
one O 0 3.498564993265063e-09
additional O 0 1.1974640834466754e-08
minor O 0 1.3651965957706125e-07
criterion O 0 8.085419835879293e-07
. O 0 4.603066088293417e-07

Sixteen O 0 3.357667810632847e-05
different O 0 1.1937079307244858e-06
p16 O 0 2.226566539320629e-05
germline O 0 8.767355029704049e-05
mutations O 0 1.1261228792136535e-05
were O 0 1.2500132129389385e-07
found O 0 1.2483187816769714e-08
in O 0 1.4088787025912097e-08
21 O 0 2.1219825896423572e-07
families O 0 7.050708017430907e-09
, O 0 3.2168139263433204e-09
while O 0 3.972886908343298e-09
one O 0 1.460164877897796e-08
germline O 0 1.4875071201458923e-06
mutation O 0 1.6835677740800747e-07
, O 0 5.916874545874862e-09
Arg24His O 0 1.2339199884081609e-06
, O 0 1.6884758480273376e-08
was O 0 5.4262045523501e-07
detected O 0 1.1866758597989246e-07
in O 0 6.127397256250333e-09
the O 0 5.3149744161373746e-08
CDK4 O 0 3.472490425338037e-05
gene O 0 4.135441940888995e-06
. O 0 7.971781883497897e-07

The O 0 6.64247465920198e-07
frequency O 0 1.2901620038974215e-06
of O 0 2.2073265881772386e-08
p16 O 0 2.2130316210677847e-06
gene O 0 4.749785773583426e-07
mutation O 0 3.0990148047749244e-07
in O 0 6.632908000625548e-09
our O 0 6.866404778094193e-09
sample O 0 1.410080407993064e-08
( O 0 4.4378105634734766e-09
44 O 0 2.6980430334333505e-08
% O 0 5.70004399236268e-09
) O 0 8.079109603542634e-10
is O 0 6.166953059327795e-10
among O 0 6.151669174059293e-10
the O 0 1.4263094039179691e-09
highest O 0 3.4346566479825924e-08
rates O 0 6.760263460137139e-08
yet O 0 7.30378690860789e-09
reported O 0 2.7510159483767893e-08
and O 0 1.5338241787787865e-09
the O 0 4.9251269729211344e-09
CDK4 O 0 5.370590770326089e-06
mutation O 0 4.939664322023418e-08
is O 0 7.64503460537469e-10
the O 0 1.1761494000950279e-09
second O 0 2.1344014555779722e-07
mutation O 0 3.237312569126516e-07
detected O 0 3.7357441584617845e-08
in O 0 2.2586881254227364e-09
this O 0 6.249262440860548e-09
gene O 0 4.306234018258692e-07
worldwide O 0 7.814515470272454e-07
. O 0 1.1493360716485768e-06

In O 0 1.0153202083529322e-06
summary O 0 6.469034588008071e-07
, O 0 3.644608170816355e-08
our O 0 2.095474727070723e-08
results O 0 2.3931347570282924e-08
show O 0 9.570063497221781e-08
frequent O 0 4.220020599632335e-08
involvement O 0 2.3658856207475765e-08
of O 0 1.4201689824133723e-09
the O 0 9.292246971881468e-09
p16 O 0 5.261937872091949e-07
gene O 0 2.6883145665124175e-07
in O 0 5.198442565301775e-08
familial B-Disease 0 0.0005804745014756918
melanoma I-Disease 1 0.9909960627555847
and O 0 1.1104269788120291e-06
confirm O 0 9.266481981740071e-08
the O 0 2.9124418432502353e-09
role O 0 9.503503761720822e-09
of O 0 1.4820695781736504e-09
the O 0 7.725011741399612e-09
CDK4 O 0 2.0286788640078157e-06
gene O 0 4.715744950090084e-08
as O 0 1.4896542666065216e-08
a O 0 3.03580122817948e-07
melanoma B-Disease 0 0.0015404674923047423
- O 0 1.8975497368955985e-05
predisposing O 0 1.3322361155587714e-05
gene O 0 3.7701070141338278e-06
. O 0 2.2435933999531699e-07
. O 0 9.260735964744526e-07

Progression O 0 0.0006122978520579636
of O 0 2.0346581095509464e-06
somatic O 0 6.109990499680862e-05
CTG O 0 0.00014264277706388384
repeat O 0 1.0290534191881306e-05
length O 0 2.8513763936643954e-06
heterogeneity O 0 2.481358023942448e-06
in O 0 6.696724597077264e-08
the O 0 1.5314023471546534e-07
blood O 0 1.0249379556626081e-05
cells O 0 1.9679473552969284e-06
of O 0 9.839911854214733e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0006934484699741006
. O 0 2.593189265098772e-06

The O 0 7.851260193092457e-07
genetic O 0 3.2104155707202153e-06
basis O 0 8.403018227909342e-07
of O 0 7.360719337157207e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.01890752650797367
DM B-Disease 1 1.0
) O 0 3.2428189911115624e-07
is O 0 5.828464821888701e-09
the O 0 1.53960422188959e-09
expansion O 0 8.258944639294441e-09
of O 0 1.2683487593534437e-09
an O 0 1.3806854326503526e-08
unstable O 0 2.024390960286837e-05
CTG O 0 1.2203809092170559e-05
repeat O 0 3.9119890971051063e-07
in O 0 1.2231891943770279e-08
the O 0 1.9979452758889238e-08
34 O 0 1.3117691821662447e-07
UTR O 0 7.986834020812239e-07
of O 0 8.636631854130883e-09
the O 0 1.779587961436846e-07
DM B-Disease 1 0.9999983310699463
protein O 0 8.145315746332926e-07
kinase O 0 2.4167732135538245e-06
gene O 0 3.6716667750624765e-07
on O 0 3.786401236993697e-07
chromosome O 0 0.00020512616902124137
19 O 0 4.438449195731664e-06
. O 0 9.406401204614667e-07

One O 0 1.0867893251997884e-06
of O 0 7.321039774410565e-09
the O 0 6.133454188983478e-09
principal O 0 1.8045732019800198e-08
features O 0 1.705078389591108e-08
of O 0 3.335782539082288e-09
the O 0 5.198025974095799e-07
DM B-Disease 1 1.0
mutation O 0 1.653818912927818e-06
is O 0 3.364793776938768e-09
an O 0 1.0082018553347893e-09
extraordinarily O 0 1.2958747674929327e-07
high O 0 7.635409104977953e-08
level O 0 3.6467968644871007e-09
of O 0 1.3851451097224299e-09
somatic O 0 5.134631351211283e-07
mosaicism O 0 1.0934253623418044e-05
, O 0 1.2067822297012754e-08
due O 0 6.2081921825551944e-09
to O 0 2.7072690755858275e-09
an O 0 1.9385471006216903e-09
extremely O 0 7.1827145120551e-08
high O 0 6.274381547655139e-08
degree O 0 5.97487126441365e-09
of O 0 9.399536704535194e-10
somatic O 0 2.9889608299527026e-07
instability O 0 6.953444540158671e-07
both O 0 8.334141377019932e-09
within O 0 3.6727498819999482e-09
and O 0 6.851477607483503e-09
between O 0 2.136910381977941e-08
different O 0 5.690921867085308e-08
tissues O 0 4.634805009118281e-06
. O 0 5.095095616525214e-07

This O 0 1.0446607348058023e-06
instability O 0 4.167829047219129e-06
appears O 0 9.223822985404695e-07
to O 0 8.48167669431632e-09
be O 0 4.685206000942799e-09
biased O 0 3.7340203817848305e-08
towards O 0 5.305106576258822e-09
further O 0 1.6243204559174274e-09
expansion O 0 2.0810075884725165e-09
and O 0 2.2670441079952752e-09
continuous O 0 1.3632289963538824e-08
throughout O 0 4.404551834369386e-09
the O 0 2.338383264799404e-09
life O 0 2.37091679622381e-09
of O 0 9.87078613290393e-11
an O 0 5.041064232713666e-10
individual O 0 3.394948766555217e-10
, O 0 4.248711660270743e-10
features O 0 2.43021833767898e-08
that O 0 1.5511357531750036e-08
could O 0 1.3085043804039742e-07
be O 0 5.992561558088028e-09
associated O 0 3.663892078620279e-09
with O 0 3.180840923988626e-09
the O 0 2.9724930072916322e-08
progressive O 0 1.6554727153561544e-06
nature O 0 1.8707272175788603e-08
of O 0 5.605489850069034e-09
the O 0 3.679132589695655e-07
disease O 0 3.506265420583077e-05
. O 0 3.942272712720296e-07

Although O 0 2.2287981664703693e-06
increasing O 0 4.208141319850256e-07
measured O 0 3.826334591394698e-07
allele O 0 2.808332340009656e-07
size O 0 8.77371419960582e-08
between O 0 2.0264654665425041e-07
patients O 0 2.6442040734764305e-07
clearly O 0 4.0021703284764953e-08
correlates O 0 3.112521085313347e-08
with O 0 1.2137667537714947e-09
an O 0 3.0338196399526396e-09
increased O 0 1.1741499861273041e-07
severity O 0 1.7991486629398423e-06
of O 0 3.45395783085678e-08
symptoms O 0 7.691354767302983e-06
and O 0 6.295945986778406e-09
an O 0 1.0041927289705654e-09
earlier O 0 1.893672987307582e-07
age O 0 2.175983482288757e-08
of O 0 6.724134582469787e-10
onset O 0 2.435690475977026e-07
, O 0 1.3450456304298086e-09
this O 0 2.514121133501135e-10
correlation O 0 2.7932189894386283e-08
is O 0 2.4713564528155985e-09
not O 0 6.395735607789277e-10
precise O 0 6.03475029947731e-08
and O 0 3.68012855744837e-08
measured O 0 4.411801910464419e-07
allele O 0 6.579673339501824e-08
length O 0 2.862605015252484e-07
cannot O 0 1.0446419729248646e-08
be O 0 4.2773329322898235e-10
used O 0 1.6068515407141604e-09
as O 0 1.0171311570772446e-09
an O 0 2.2245316699809337e-09
accurate O 0 4.6268897335721704e-07
predictor O 0 2.589640416772454e-06
of O 0 3.6070888498329623e-09
age O 0 3.8284291292711714e-08
of O 0 2.7066509034057162e-08
onset O 0 3.099337118328549e-05
. O 0 6.683829951725784e-07

In O 0 4.695935444942734e-07
order O 0 1.936489724130297e-08
to O 0 3.9127550088835505e-09
further O 0 4.997393610040035e-09
characterize O 0 1.4644298573784909e-07
the O 0 1.0798848926185656e-08
dynamics O 0 8.419510777457617e-07
of O 0 1.678849201880439e-07
DM B-Disease 1 1.0
CTG O 0 5.109995981911197e-05
repeat O 0 6.218374437594321e-07
somatic O 0 7.175046334850776e-07
instability O 0 4.958941417498863e-07
, O 0 9.833851066787247e-09
we O 0 2.6992872381725874e-09
have O 0 2.5654895985383064e-09
studied O 0 6.526239104687193e-09
repeat O 0 5.510204914571659e-08
length O 0 1.584704278911886e-07
changes O 0 5.437412298192612e-09
over O 0 5.427434057736491e-09
time O 0 2.065743665013997e-08
in O 0 7.220846498512401e-08
111 O 0 5.104955198476091e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 2.069847596430918e-06
with O 0 1.145215922093712e-08
varying O 0 1.330169112634394e-07
clinical O 0 6.921699764461664e-07
severity O 0 6.482846856670221e-06
and O 0 5.712596262696934e-08
CTG O 0 1.5556296375507372e-06
repeat O 0 8.86444624370597e-08
size O 0 1.3811832566545945e-08
over O 0 2.135850785123239e-08
time O 0 1.574622388034186e-08
intervals O 0 3.7197324331827986e-08
of O 0 1.0136992356635233e-09
1 O 0 2.6312735101896578e-08
- O 0 5.077040896139806e-06
7 O 0 3.709367888404813e-07
years O 0 1.8059716921925428e-07
. O 0 2.344485636740501e-07

We O 0 3.815515810856596e-06
have O 0 3.0395032268870636e-08
found O 0 4.510344542296707e-09
a O 0 3.3218143791202692e-09
direct O 0 1.1411080080847569e-08
progression O 0 3.2018161277846957e-07
of O 0 8.81691997189904e-10
the O 0 2.1751442869089033e-09
size O 0 1.8397967593841713e-08
heterogeneity O 0 6.623113080195253e-08
over O 0 9.082725682674209e-09
time O 0 4.423883037674159e-09
related O 0 1.175023855992663e-09
to O 0 1.5975524236822025e-09
initial O 0 1.6380415246430857e-08
CTG O 0 5.961276769994583e-07
repeat O 0 4.940135767128595e-08
size O 0 1.8972135862327377e-08
and O 0 1.3391432851506124e-08
the O 0 2.7325541829270605e-09
time O 0 1.4918379420691963e-08
interval O 0 7.58605409600932e-08
and O 0 2.1876273237353416e-08
always O 0 2.4016856059461134e-08
biased O 0 5.335593300515029e-08
towards O 0 1.0185799759199199e-08
further O 0 1.2012110417458643e-08
expansion O 0 2.3065797449817182e-07
. O 0 3.3261053999922296e-07

Attempts O 0 1.3577839126810431e-05
to O 0 1.1853208548018301e-07
mathematically O 0 4.088086882347852e-07
model O 0 6.657689510802811e-08
the O 0 1.392217807705265e-08
dynamics O 0 8.361864729522495e-07
have O 0 3.569367379441246e-07
proved O 0 4.610336929999903e-07
only O 0 1.558026774262089e-08
partially O 0 3.712474949679745e-07
successful O 0 2.1296758134781157e-08
suggesting O 0 3.5904310635714864e-08
that O 0 4.770963624167734e-10
individual O 0 4.150773336153435e-10
specific O 0 8.862172107271249e-10
genetic O 0 5.5429559608910495e-08
and O 0 5.069920305800224e-08
/ O 0 1.2082721241313266e-06
or O 0 2.507299790011075e-08
environmental O 0 3.173510165765947e-08
factors O 0 1.332249421892584e-08
also O 0 2.730648773763278e-08
play O 0 8.322545319572328e-09
a O 0 9.316898363920245e-09
role O 0 4.3752066858360195e-08
in O 0 3.3421528655708244e-08
somatic O 0 2.0908530586893903e-06
mosaicism O 0 3.614582965383306e-05
. O 0 2.950627902009728e-07
. O 0 6.003626822348451e-07

Aspartylglucosaminuria B-Disease 1 0.9999619722366333
among O 0 2.683839738892857e-05
Palestinian O 0 0.00019693908689077944
Arabs O 0 0.00014345519593916833
. O 0 4.288216587156057e-06

Aspartylglucosaminuria B-Disease 1 0.9999998807907104
( O 0 0.002086712745949626
AGU B-Disease 1 0.9999992847442627
) O 0 5.124021527080913e-07
is O 0 1.635013724410328e-08
a O 0 4.561294275617911e-08
rare O 0 5.797290327791416e-07
disorder B-Disease 0 1.361565045954194e-05
of I-Disease 0 1.061179677463997e-08
glycoprotein I-Disease 0 1.249994329555193e-05
metabolism I-Disease 0 0.00023412935843225569
caused O 0 1.6492513168486767e-06
by O 0 2.4357499128768723e-08
the O 0 7.473764185306209e-07
deficiency B-Disease 0 3.321438271086663e-05
of I-Disease 0 1.8806900481393996e-09
the I-Disease 0 8.120257888322158e-08
lysosomal I-Disease 0 0.00013290549395605922
enzyme I-Disease 0 2.622368583615753e-06
aspartylglucosaminidase I-Disease 0 0.00011753695434890687
( O 0 3.2055035603661963e-07
AGA O 0 5.617090664600255e-06
) O 0 1.698136884442647e-07
. O 0 2.7385360112930357e-07

AGU B-Disease 1 0.9999994039535522
is O 0 1.4346080206451006e-05
inherited O 0 4.664036168833263e-05
as O 0 1.4193064146184042e-07
an O 0 1.3007493748773413e-07
autosomal O 1 0.9113171696662903
recessive O 1 0.9882014393806458
trait O 0 0.0007862482452765107
and O 0 6.685442599518865e-07
occurs O 0 2.83710832604811e-08
with O 0 1.7366786897454745e-09
a O 0 4.508454765073111e-08
high O 0 4.1246164528274676e-07
frequency O 0 1.2213752142997691e-06
in O 0 2.2108658015440597e-08
Finland O 0 9.128018973569851e-06
because O 0 6.474154989888348e-09
of O 0 1.387302606126184e-09
a O 0 5.30640491547274e-08
founder O 0 1.7326879060419742e-06
effect O 0 5.082711140858009e-07
. O 0 2.604053861432476e-07

While O 0 4.966304004483391e-06
very O 0 1.6201416030980909e-07
few O 0 6.315589473615546e-08
patients O 0 1.300289227401663e-07
with O 0 8.761774239474107e-08
AGU B-Disease 1 1.0
have O 0 1.53103576394642e-06
been O 0 2.943297943147627e-07
reported O 0 1.2464516885302146e-07
from O 0 2.3483728295303763e-09
non O 0 1.3627611039623844e-08
- O 0 9.020410516313859e-07
Finnish O 0 1.2150828752055531e-06
origin O 0 1.3871128246023545e-08
, O 0 1.7517431061264688e-08
we O 0 1.3785492569695634e-07
diagnosed O 0 1.5576528312521987e-05
the O 0 5.065666996983964e-08
disorder O 0 1.6512925867573358e-05
in O 0 9.26810450607718e-09
8 O 0 4.785632654602523e-07
patients O 0 5.081168907850042e-08
originating O 0 1.1743993333368508e-08
from O 0 2.8563389431468522e-09
3 O 0 1.3719986924343175e-08
unrelated O 0 5.514315759569399e-08
families O 0 1.7119933914955254e-08
, O 0 2.171380408810819e-09
all O 0 4.835264966196462e-10
Palestinian O 0 1.6293281532853143e-06
Arabs O 0 6.86316013798205e-07
from O 0 3.1644540321451586e-09
the O 0 4.162524991357941e-09
region O 0 5.2734414168753574e-08
of O 0 6.381774664276918e-09
Jerusalem O 0 3.836204268736765e-05
. O 0 1.820106490413309e-06

The O 0 2.2697811346006347e-06
clinical O 0 1.550880551803857e-05
diagnosis O 0 0.00021955737611278892
of O 0 4.1211995949197444e-07
AGU B-Disease 1 1.0
is O 0 6.582661171705695e-07
often O 0 7.086303099868019e-08
difficult O 0 2.4795969721935762e-08
, O 0 1.958508466515241e-09
in O 0 3.821545857540798e-10
particular O 0 1.030444618521642e-09
early O 0 5.876632513945879e-09
in O 0 9.932301647808117e-10
the O 0 3.530822967334757e-09
course O 0 6.33172732023013e-08
of O 0 2.186750114319125e-09
the O 0 2.3576966157179413e-07
disease O 0 3.156847469654167e-06
, O 0 3.6342424625246394e-09
and O 0 1.6937133917593883e-09
most O 0 2.3501239843071176e-10
of O 0 1.7165660559648188e-10
the O 0 1.4732318476262662e-08
patients O 0 5.975716987904889e-08
are O 0 1.634243673720448e-08
diagnosed O 0 9.09953723748913e-06
after O 0 2.813849064864371e-08
the O 0 1.2615070765775727e-08
age O 0 2.370999219181158e-08
of O 0 2.4283359767451884e-09
5 O 0 1.2945049832069344e-07
years O 0 1.137995937483538e-07
. O 0 2.2597501470045245e-07

However O 0 3.5251939607405802e-06
, O 0 6.430823873415648e-08
since O 0 3.827867089967185e-08
these O 0 6.789594220180106e-09
patients O 0 3.710648144306106e-08
excrete O 0 3.480542787315244e-08
early O 0 5.001942415816529e-09
large O 0 7.920156197549488e-10
amounts O 0 8.970725273726998e-10
of O 0 6.758052450983598e-10
aspartylglucosamine O 0 3.9895496684039244e-07
in O 0 4.042892687294852e-09
urine O 0 4.1040003395664826e-08
, O 0 8.663008088660717e-10
biochemical O 0 1.9885813884457093e-08
screening O 0 1.566811924647027e-08
is O 0 6.634868654487036e-09
easy O 0 4.364513372934198e-08
by O 0 1.2654980174886532e-08
urine O 0 6.027549943610211e-07
chromatography O 0 1.5533111081822426e-06
. O 0 1.519027108543014e-07
. O 0 3.0918150173420145e-07

Detection O 0 2.1936662960797548e-05
of O 0 2.849324403086939e-07
heterozygous O 0 2.386849700997118e-06
carriers O 0 1.215635307971752e-07
of O 0 1.4408677806443393e-08
the O 0 1.5095495655259583e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 9.953348580893362e-07
ATM O 0 1.6800580624476424e-06
) O 0 2.8599163925946414e-08
gene O 0 1.0936445704601283e-07
by O 0 1.7528996920646023e-08
G2 O 0 1.2504855476436205e-05
phase O 0 7.227183687064098e-07
chromosomal O 0 8.272229752037674e-05
radiosensitivity O 0 2.8582002414623275e-05
of O 0 1.5951894738464034e-07
peripheral O 0 0.0003469876537565142
blood O 0 0.00024370058963540941
lymphocytes O 0 7.824850763427094e-05
. O 0 1.4365123206516728e-06

In O 0 0.0010431241244077682
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 5.131418947712518e-05
A B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.3883733629427297e-07
patients O 0 5.2033133357554107e-08
, O 0 4.236115014322195e-09
mutations O 0 5.2223434465759055e-08
in O 0 1.085103895626105e-09
a O 0 1.3181755242896998e-08
single O 0 6.182469292070891e-08
gene O 0 4.584774870863839e-08
, O 0 4.2187950910488325e-09
ATM O 0 2.1962613061532466e-07
, O 0 4.906571593465969e-09
result O 0 7.178643901539772e-09
in O 0 4.885357185457906e-08
an O 0 0.0005698565510101616
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 4.993542006559437e-07
embraces O 0 2.682421893496212e-07
a O 0 2.4753347815931193e-08
variety O 0 6.194707857787307e-09
of O 0 2.423657718964023e-09
clinical O 0 7.924727185582014e-08
features O 0 1.105242631638248e-06
and O 0 1.8924233700090554e-06
manifests O 0 6.862139230179309e-07
extreme O 0 9.681511983217206e-07
radiosensitivity O 0 3.456585545791313e-06
and O 0 1.1224143392496444e-08
a O 0 1.335279176117865e-08
strong O 0 4.2240230868628714e-08
pre O 0 1.5178699186435551e-06
- O 0 4.891717981081456e-05
disposition O 0 1.114127917389851e-05
to O 0 4.1446631371400144e-07
malignancy B-Disease 0 0.0003052196989301592
. O 0 1.4722634205099894e-06

Heterozygotes O 0 0.00012226082617416978
for O 0 7.00788831409227e-08
the O 0 1.3713186142183531e-08
ATM O 0 6.086747248446045e-07
gene O 0 1.9638066817151412e-07
have O 0 2.558029699173403e-08
no O 0 8.028298914553034e-09
clinical O 0 3.498346501373817e-08
expression O 0 1.8489608066829533e-08
of O 0 5.240660794214591e-09
A B-Disease 1 0.9999954700469971
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
but O 0 2.2710750613441633e-07
may O 0 1.4867354991565662e-07
be O 0 2.717565728005411e-08
cancer B-Disease 0 7.023182320153865e-07
prone O 0 4.879020707448944e-07
with O 0 3.6401948122488648e-09
a O 0 6.17332602814713e-08
moderate O 0 5.672461611538893e-06
increase O 0 2.803760956737733e-08
in O 0 7.833981463534201e-09
in O 0 3.760077760261993e-08
vitro O 0 2.132332338078413e-05
radiosensitivity O 0 5.398430585046299e-05
. O 0 5.296121798892273e-07

We O 0 4.871653436566703e-05
performed O 0 1.6384279888370656e-06
a O 0 1.5706126532677445e-07
blind O 0 4.580030235956656e-06
chromosomal O 0 1.2443138984963298e-05
analysis O 0 8.351888425295328e-08
on O 0 2.9621648423017177e-07
G2 O 0 2.5231529434677213e-05
- O 0 6.550599664478796e-06
phase O 0 2.852054024060635e-07
lymphocytes O 0 2.0086943663955026e-07
from O 0 5.234906286233354e-09
7 O 0 4.396907371528869e-08
unrelated O 0 4.229860337545688e-07
A B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 7.653327429579804e-07
, O 0 3.987256746995627e-09
13 O 0 1.0489666024682265e-08
obligate O 0 4.8174022992952814e-08
A B-Disease 1 0.9976200461387634
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
heterozygotes O 0 4.886381702817744e-06
( O 0 8.544189356030074e-09
parents O 0 4.572275891234767e-09
of O 0 7.812937519169338e-10
the O 0 1.7563667853437437e-08
patients O 0 7.047417227568076e-08
) O 0 2.7000184310566056e-09
, O 0 2.6776276751405703e-09
and O 0 1.1440500102821716e-08
14 O 0 1.944261818209725e-08
normal O 0 5.462599705907678e-09
controls O 0 2.9676550994395257e-08
following O 0 2.550554656366444e-09
X O 0 6.018543103891716e-07
- O 0 3.5565741995924327e-07
irradiation O 0 3.1607580552872605e-08
with O 0 2.2238486607761843e-09
1 O 0 9.653806642972995e-09
Gy O 0 1.9887347662006505e-06
in O 0 1.802766158576219e-09
order O 0 1.3554268818438686e-09
to O 0 8.7851603769451e-10
evaluate O 0 5.102055666839078e-09
this O 0 1.3033023549269274e-09
cytogenetic O 0 2.389384121670446e-07
method O 0 5.938786351578074e-09
as O 0 9.44604838792884e-10
a O 0 2.093508255640586e-09
tool O 0 3.4176139251940185e-08
for O 0 1.900189561254706e-09
detection O 0 6.305117494775914e-08
of O 0 6.282834252857583e-09
ATM O 0 3.58379270437581e-06
carriers O 0 8.242179205808497e-07
. O 0 3.451765451245592e-07

Both O 0 6.270365247473819e-06
A B-Disease 1 0.9985449314117432
- I-Disease 1 0.9999895095825195
T I-Disease 1 0.9999998807907104
homozygotes O 0 3.918872243957594e-05
and O 0 8.571452525529821e-08
heterozygotes O 0 1.195437334899907e-06
showed O 0 2.755519972197362e-07
significantly O 0 6.69475781478468e-08
increased O 0 1.8282948488490547e-08
levels O 0 5.587748486135524e-09
of O 0 3.3944196342616806e-09
radiation O 0 4.532840193860466e-06
- O 0 5.391053855419159e-05
induced O 0 8.801146759651601e-05
chromatid O 0 0.00034230126766487956
damage O 0 1.8429000192554668e-06
relative O 0 7.41227381695353e-08
to O 0 4.865825964373016e-09
that O 0 2.8420139575047187e-09
of O 0 4.587633384289802e-09
normal O 0 2.310181344000739e-07
controls O 0 5.722170953958994e-06
. O 0 9.064156643034949e-07

These O 0 6.034256330167409e-07
results O 0 3.31622658222841e-07
show O 0 1.4532803049860377e-07
that O 0 3.782244739625185e-09
the O 0 6.631617477381724e-09
G2 O 0 3.1314054922404466e-06
- O 0 1.4366438563229167e-06
phase O 0 1.9388113514651195e-07
chromosomal O 0 2.8855927212134702e-06
radiosensitivity O 0 8.279813528133673e-07
assay O 0 2.947247423890076e-07
can O 0 1.1641581920684985e-08
be O 0 9.06140329437477e-10
used O 0 1.823839301806629e-09
for O 0 4.449843826748179e-10
the O 0 1.8321513195473926e-09
detection O 0 3.156420547156813e-08
of O 0 1.7501735172231747e-08
A B-Disease 1 0.9999984502792358
- I-Disease 1 0.9999994039535522
T I-Disease 1 0.9999998807907104
heterozygotes O 0 4.419808465172537e-05
. O 0 8.252592920143798e-07

In O 0 1.4671337567051523e-06
combination O 0 4.339138968134648e-07
with O 0 1.678182570685749e-08
molecular O 0 1.8958360215037828e-07
genetic O 0 3.1721006621410197e-07
analyses O 0 1.469885404503657e-07
, O 0 1.0072758627188705e-08
this O 0 1.6540052660829474e-09
test O 0 2.364847873081999e-08
may O 0 6.930366680535371e-08
be O 0 2.7083521536575006e-10
of O 0 1.8435429571805884e-10
value O 0 6.917814099338671e-10
in O 0 9.731726535733287e-10
studies O 0 9.264901068561926e-10
of O 0 3.7797331930988776e-10
familial B-Disease 0 4.202229604288732e-07
and I-Disease 0 1.4049453511688625e-07
sporadic I-Disease 0 8.901469118427485e-05
cancers I-Disease 0 0.00015736317436676472
aimed O 0 2.8745847657773993e-07
at O 0 9.980755066862912e-08
determination O 0 3.2217336354278814e-08
of O 0 2.656535269540683e-10
the O 0 1.3287567712794157e-09
potential O 0 3.040417695387987e-09
involvement O 0 5.579143813605469e-09
of O 0 1.1880495476290776e-09
ATM O 0 1.7592153653822606e-06
mutations O 0 7.431908102262241e-07
in O 0 2.981111890676402e-08
tumor B-Disease 0 2.4951854356913827e-05
risk O 0 1.3560305944793072e-07
or O 0 1.631225998721675e-08
development O 0 1.9891428948426437e-08
. O 0 3.5183813196226765e-08
. O 0 2.883794252284133e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 0.9999998807907104
: O 0 1.5705782061559148e-06
identification O 0 2.7766046173383074e-07
and O 0 2.3876909338582664e-08
detection O 0 6.731069390752964e-08
of O 0 4.177437951113916e-09
founder O 0 8.275203526864061e-07
- O 0 1.3930517525295727e-05
effect O 0 1.7474692981522821e-07
mutations O 0 1.413072112654845e-07
in O 0 2.075826177616591e-09
the O 0 3.8889389486485015e-09
ATM O 0 2.4075180249383266e-07
gene O 0 9.211553475552137e-08
in O 0 1.2520672498794738e-08
ethnic O 0 7.433297355419199e-07
populations O 0 1.6434295275757904e-06
. O 0 9.572653425493627e-07

To O 0 2.701486323530844e-07
facilitate O 0 1.0663763561069572e-07
the O 0 1.0270427175385066e-08
evaluation O 0 2.0201241568429396e-08
of O 0 2.577196456243769e-09
ATM O 0 1.246431907020451e-06
heterozygotes O 0 8.241762543548248e-07
for O 0 4.2720191828493626e-09
susceptibility O 0 5.11639427713817e-07
to O 0 7.817114955344096e-09
other O 0 1.1239782438110524e-08
diseases O 0 6.021632543706801e-07
, O 0 7.767825827009744e-10
such O 0 5.384331869251469e-10
as O 0 1.9421571550992667e-07
breast B-Disease 0 0.245270773768425
cancer I-Disease 0 8.698755664227065e-06
, O 0 8.062673195752268e-09
we O 0 3.771302381494479e-09
have O 0 2.819251720964644e-09
attempted O 0 5.991272189476149e-08
to O 0 1.3900810502676109e-09
define O 0 1.7462555845781935e-08
the O 0 2.599297665994982e-09
most O 0 1.8302512838630491e-09
common O 0 9.35366806231741e-09
mutations O 0 7.428833015410419e-08
and O 0 3.893904754193045e-09
their O 0 3.991982744366851e-09
frequencies O 0 1.1688905487972079e-06
in O 0 2.0854247395618586e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 6.420715180865955e-06
A B-Disease 1 0.9999984502792358
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.957550731570336e-08
homozygotes O 0 4.771109729517775e-07
from O 0 6.8580412460050866e-09
10 O 0 1.746378863742848e-08
ethnic O 0 1.0411791606657061e-07
populations O 0 5.879673494746385e-07
. O 0 4.970996201336675e-07

Both O 0 1.9187630186934257e-06
genomic O 0 9.337783922092058e-06
mutations O 0 1.1447873475844972e-05
and O 0 4.199369385560203e-08
their O 0 1.739308252979299e-08
effects O 0 4.3732256926887203e-07
on O 0 1.8054980444048851e-07
cDNA O 0 1.938688683367218e-06
were O 0 8.586536637267272e-07
characterized O 0 3.64677498509991e-06
. O 0 1.0018726470661932e-06

Protein O 0 1.9713063011295162e-05
- O 0 1.7832684534369037e-05
truncation O 0 5.248894012765959e-06
testing O 0 1.0668482985920491e-07
of O 0 2.830210288351509e-09
the O 0 3.1739564310129253e-09
entire O 0 4.327138114490481e-08
ATM O 0 3.966022177337436e-07
cDNA O 0 5.323151412994775e-07
detected O 0 2.2231633067804069e-07
92 O 0 7.782722377669415e-08
( O 0 1.2283795314260715e-08
66 O 0 1.6258887569620128e-07
% O 0 8.810872031972394e-09
) O 0 6.229852189676421e-09
truncating O 0 1.2358501635389985e-06
mutations O 0 4.706444940438814e-07
in O 0 1.2521627290595916e-08
140 O 0 1.5973893141563167e-07
mutant O 0 5.762251475971425e-06
alleles O 0 1.0251852472720202e-05
screened O 0 1.3347388630791102e-05
. O 0 1.3693487517230096e-06

The O 0 9.65874278335832e-07
haplotyping O 0 8.469307431369089e-06
of O 0 2.342956229028914e-08
patients O 0 4.778244999670278e-08
with O 0 6.515145312135928e-09
identical O 0 7.271913091244642e-06
mutations O 0 4.844893737754319e-06
indicates O 0 1.4840480844213744e-07
that O 0 1.6133814284557957e-08
almost O 0 1.4321411612172597e-08
all O 0 1.2960212070201038e-10
of O 0 1.509260494358955e-10
these O 0 4.54427828699977e-10
represent O 0 2.0397259437032744e-09
common O 0 3.0641313486512445e-08
ancestry O 0 2.794575948428246e-07
and O 0 4.084493099298925e-08
that O 0 7.717058991829617e-09
very O 0 1.3722499581092507e-08
few O 0 4.7631854016572106e-08
spontaneously O 0 2.6012367015937343e-07
recurring O 0 4.585357601172291e-06
ATM O 0 6.897545972606167e-05
mutations O 0 2.1505897166207433e-05
exist O 0 6.873207780699886e-07
. O 0 5.465676053972857e-07

Assays O 0 6.184101948747411e-05
requiring O 0 7.408139026665594e-07
minimal O 0 1.9410610718750831e-07
amounts O 0 8.858120459365182e-09
of O 0 1.6253833834412035e-09
genomic O 0 1.2276866812044318e-07
DNA O 0 2.3222774814257718e-07
were O 0 2.301911550262048e-08
designed O 0 3.2707777819496187e-08
to O 0 1.5309891132631037e-09
allow O 0 1.690318218727782e-09
rapid O 0 1.0718552267974246e-08
screening O 0 1.2246482050670693e-08
for O 0 1.8534158652272481e-09
common O 0 3.336713305657213e-08
ethnic O 0 1.0866867796721635e-06
mutations O 0 3.0022474675206468e-05
. O 0 7.579580483252357e-07

These O 0 1.4242380075302208e-06
rapid O 0 2.6577399694360793e-06
assays O 0 3.517751792969648e-06
detected O 0 1.8007347080128966e-06
mutations O 0 5.028124974160164e-07
in O 0 5.330443642037608e-09
76 O 0 1.203582939979242e-07
% O 0 3.20490833871645e-09
of O 0 9.745972917585277e-10
Costa O 0 2.703731070141657e-07
Rican O 0 1.1242085520279943e-06
patients O 0 1.2550732719773805e-07
( O 0 1.575814256860042e-09
3 O 0 3.4530995840498235e-09
) O 0 6.105775884890363e-10
, O 0 5.047664508595062e-10
50 O 0 2.9484426011805454e-09
% O 0 3.9913716776140973e-10
of O 0 5.078586995388434e-10
Norwegian O 0 0.0001627959863981232
patients O 0 9.615806106921809e-08
( O 0 1.560113482845793e-09
1 O 0 2.8245425998107976e-09
) O 0 1.0302854125399108e-09
, O 0 1.3930298026210153e-09
25 O 0 5.477059694669606e-09
% O 0 7.108104660424885e-10
of O 0 5.214673692854888e-10
Polish O 0 6.195990863488987e-06
patients O 0 5.6476473275779426e-08
( O 0 1.2693556206144763e-09
4 O 0 5.863264540550972e-09
) O 0 1.0676168837875366e-09
, O 0 9.234573661309753e-10
and O 0 4.48418235876602e-09
14 O 0 1.0978241427039848e-08
% O 0 6.11749151335772e-10
of O 0 4.283341736854851e-10
Italian O 0 5.098730071040336e-06
patients O 0 1.4668199810330407e-07
( O 0 2.26155072446943e-09
1 O 0 5.973913808077214e-09
) O 0 1.583557729389895e-09
, O 0 1.0330500899158324e-09
as O 0 1.661422888155073e-09
well O 0 2.2382657949293616e-09
as O 0 2.0003922962530396e-09
in O 0 2.9944682289340108e-09
patients O 0 1.083307399341038e-08
of O 0 2.245719388227485e-09
Amish O 0 9.685209079179913e-06
/ O 0 1.4488039141724585e-06
Mennonite O 0 1.86795864465239e-06
and O 0 2.628660809023131e-07
Irish O 0 7.804602546457318e-07
English O 0 1.3384862995735602e-07
backgrounds O 0 8.363340384676121e-07
. O 0 4.851195853916579e-07

Additional O 0 4.8756483010947704e-06
mutations O 0 2.8756710889865644e-05
were O 0 1.8588728778468067e-07
observed O 0 8.030477971487926e-08
in O 0 6.2317062621275454e-09
Japanese O 0 3.5606767312401644e-08
, O 0 2.960281797470543e-09
Utah O 0 2.5237422818236155e-08
Mormon O 0 1.4271869019921724e-07
, O 0 4.219125049331751e-09
and O 0 5.6741411569305455e-09
African O 0 2.060789050517542e-08
American O 0 2.04120055968815e-07
patients O 0 1.0019758747148444e-06
. O 0 4.2666633248700236e-07

These O 0 3.2005033290261053e-07
assays O 0 6.992952421569498e-07
should O 0 7.60974483426935e-09
facilitate O 0 3.4459413100762504e-09
screening O 0 1.8681030056200143e-08
for O 0 1.0671612926671514e-08
A B-Disease 1 0.9999480247497559
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
heterozygotes O 0 1.257319809155888e-06
in O 0 5.3295794444352396e-09
the O 0 7.839452642599554e-09
populations O 0 3.0928731575841084e-08
studied O 0 4.870470959872364e-08
. O 0 3.319371444376884e-08
. O 0 2.156634621997e-07

The O 0 3.1297033274313435e-05
von B-Disease 1 0.7609999179840088
Hippel I-Disease 1 0.9796261191368103
- I-Disease 1 0.8807188868522644
Lindau I-Disease 0 0.17219671607017517
tumor I-Disease 0 7.413849380100146e-05
suppressor O 0 2.2783824533689767e-05
gene O 0 9.560080798109993e-07
is O 0 2.0764527874916894e-08
required O 0 4.163644540255973e-09
for O 0 4.1532142169842245e-09
cell O 0 1.3018058098168694e-06
cycle O 0 1.5580675380988396e-06
exit O 0 5.153725055606628e-07
upon O 0 6.116178496995417e-08
serum O 0 3.1890792797639733e-06
withdrawal O 0 2.870565140256076e-06
. O 0 4.205132029255765e-07

The O 0 1.1180831052115536e-06
inactivation O 0 1.3431612387648784e-05
of O 0 7.050871886349341e-08
the O 0 2.9830687253706856e-07
von B-Disease 1 0.9858594536781311
Hippel I-Disease 1 0.9995567202568054
- I-Disease 1 0.997793436050415
Lindau I-Disease 1 0.9672236442565918
( I-Disease 0 1.0903989959842875e-06
VHL I-Disease 0 0.00012970180250704288
) I-Disease 0 3.6562676086759893e-07
tumor I-Disease 0 1.8444034139974974e-05
suppressor O 0 9.139606117969379e-05
gene O 0 7.149935299821664e-06
predisposes O 0 2.5037712475750595e-05
affected O 0 4.3585157527559204e-07
individuals O 0 8.343175039726702e-09
to O 0 4.474033143964107e-09
the O 0 2.939528087608778e-07
human O 0 5.551602225750685e-05
VHL B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9999887943267822
and O 0 1.2764192547365383e-07
is O 0 1.4903646317065977e-08
associated O 0 6.887880488193332e-08
with O 0 2.0406653788995754e-07
sporadic B-Disease 1 0.9982646107673645
renal I-Disease 1 0.9999992847442627
cell I-Disease 1 0.9999978542327881
carcinomas I-Disease 1 1.0
( O 0 3.382817158126272e-05
RCC B-Disease 0 0.3781636953353882
) O 0 4.3488498135957343e-07
and O 0 1.9358142253622646e-06
brain B-Disease 0 0.00029230827931314707
hemangioblastomas I-Disease 0 0.0002293367579113692
. O 0 1.7658614979154663e-06

VHL O 0 0.007693571504205465
- O 0 0.0007596742361783981
negative O 0 1.0619951353874058e-05
786 O 0 1.8432727301842533e-05
- O 0 4.7775862185517326e-05
0 O 0 1.3652216921400395e-06
RCC B-Disease 0 2.818877146637533e-05
cells O 0 4.341158899023867e-07
are O 0 4.339508752337906e-09
tumorigenic O 0 5.641240932163782e-07
in O 0 1.7827535003789308e-08
nude O 0 0.011978219263255596
mice O 0 0.00016782338207121938
which O 0 1.0678418504994625e-07
is O 0 1.4603124043333082e-08
suppressed O 0 4.10845686360517e-08
by O 0 1.543385308444556e-09
the O 0 6.023272103305999e-09
reintroduction O 0 2.029178176599089e-06
of O 0 6.157708298815123e-08
VHL B-Disease 0 0.00013016680895816535
. O 0 1.73484420429304e-06

Remarkably O 0 0.00022815553529653698
, O 0 1.7029178422944824e-07
this O 0 6.0438489768444015e-09
occurs O 0 7.132689994193697e-09
without O 0 1.6644488010086889e-09
affecting O 0 3.8601251084458e-09
the O 0 1.7211403413597282e-09
growth O 0 2.2563209967074727e-08
rate O 0 6.415510256374546e-08
and O 0 7.12332282049033e-09
cell O 0 2.2729776105734345e-07
cycle O 0 1.2589741515967035e-07
profile O 0 3.262391246039442e-08
of O 0 1.0586621579378175e-09
these O 0 3.535351567052203e-09
cells O 0 2.7197332386208473e-08
in O 0 1.2646341751576529e-08
culture O 0 2.2713567204846186e-07
. O 0 3.276897757586994e-07

The O 0 1.3080617691230145e-06
786 O 0 8.58690054883482e-06
- O 0 4.981559413863579e-06
0 O 0 1.790202617257819e-07
cell O 0 1.1623430964391446e-06
line O 0 5.155438884685282e-06
, O 0 3.12671621927052e-09
like O 0 2.8688968978229923e-09
many O 0 3.361740441576444e-09
cancer B-Disease 0 3.4051024044856604e-07
cells O 0 3.178477570031646e-08
, O 0 3.137894388771656e-09
fails O 0 3.3300501911526226e-08
to O 0 1.134124905100009e-09
exit O 0 6.25003977461347e-08
the O 0 9.831882863409191e-09
cell O 0 8.630326533420885e-07
cycle O 0 6.110197432462883e-07
upon O 0 3.861025277274166e-08
serum O 0 1.2011695389446686e-06
withdrawal O 0 2.5150889086944517e-06
. O 0 4.771624162458465e-07

Here O 0 6.136281172075542e-06
, O 0 6.67715980284811e-08
it O 0 6.692687293252675e-09
is O 0 4.5723371755457265e-09
shown O 0 8.42516367782764e-09
that O 0 4.925152508050701e-10
reintroduction O 0 6.383152140188031e-08
of O 0 6.157010457030765e-10
the O 0 5.377889245039569e-09
wild O 0 2.5408627379874815e-07
- O 0 1.2068547221133485e-05
type O 0 4.085428884081921e-07
VHL B-Disease 0 9.099094313569367e-06
gene O 0 3.6165013739264396e-07
restores O 0 2.4527230380044784e-06
the O 0 1.4045080654057074e-08
ability O 0 2.0449117954512985e-08
of O 0 1.6134675817625066e-08
VHL O 0 8.74807228683494e-05
- O 0 0.004931782837957144
negative O 0 2.2387070202967152e-05
RCC B-Disease 0 0.001683901879005134
cancer I-Disease 0 3.1007880352262873e-06
cells O 0 6.812596353711342e-08
to O 0 2.8362738824228018e-09
exit O 0 5.521851775824871e-08
the O 0 6.858694945321986e-09
cell O 0 4.4042519675713265e-07
cycle O 0 1.9304422949062428e-07
and O 0 7.44106865013805e-09
enter O 0 6.853311163013132e-08
G0 O 0 1.337301182502415e-05
/ O 0 1.7803496348278713e-06
quiescence O 0 5.6039389164652675e-06
in O 0 1.958668889301407e-07
low O 0 1.8822658603312448e-05
serum O 0 2.8573662348208018e-05
. O 0 7.107080364221474e-07

Both O 0 9.331436558568384e-06
VHL O 0 0.000412634399253875
- O 0 0.00012355740182101727
positive O 0 5.879000468667073e-07
and O 0 1.239743880887545e-07
VHL O 0 6.955108983675018e-05
- O 0 0.0002764663950074464
negative O 0 2.3210959625430405e-06
RCC B-Disease 0 3.516418291837908e-05
cells O 0 1.8595608253235696e-07
exit O 0 9.293083991224194e-08
the O 0 1.3143695021256008e-08
cell O 0 1.4258118881116388e-06
cycle O 0 3.3892240480781766e-07
by O 0 8.300509612979567e-09
contact O 0 3.825477392638277e-07
inhibition O 0 2.819339442794444e-06
. O 0 4.623176153017994e-07

The O 0 6.527613095386187e-06
cyclin O 0 0.00016952838632278144
- O 0 1.2641787179745734e-05
dependent O 0 2.0687816686404403e-06
kinase O 0 5.7129836932290345e-06
inhibitor O 0 1.9964156763307983e-06
, O 0 2.277846355980273e-08
p27 O 0 1.0647976296240813e-06
, O 0 9.557929558923206e-09
accumulates O 0 6.80117082652032e-08
upon O 0 3.871982290348797e-09
serum O 0 1.4940027881493734e-07
withdrawal O 0 2.460470227561018e-07
, O 0 4.242139084453811e-09
only O 0 4.88049045621608e-10
in O 0 3.12902953547578e-10
the O 0 1.1571112956687557e-09
presence O 0 3.5551848132087116e-09
of O 0 2.0679817858137994e-09
VHL B-Disease 0 4.256801730662119e-06
, O 0 1.0903074887380626e-08
as O 0 3.24690763164881e-09
a O 0 1.2757154443931995e-08
result O 0 7.944806590387543e-09
of O 0 5.202890340783028e-10
the O 0 2.6290447596721833e-09
stabilization O 0 2.824991263139509e-08
of O 0 2.308175650611588e-09
the O 0 2.886792671574767e-08
protein O 0 9.689354101283243e-07
. O 0 2.7547366698854603e-07

We O 0 1.5771764765304397e-06
propose O 0 4.000231967893342e-07
that O 0 7.711173921620684e-09
the O 0 5.162345217968323e-09
loss O 0 5.9456581880112935e-08
of O 0 3.343783472331552e-09
wild O 0 8.585717523601488e-07
- O 0 0.0001434144505765289
type O 0 7.774086157041893e-07
VHL B-Disease 0 1.221241291204933e-05
gene O 0 2.9206884732957406e-07
results O 0 2.492404149734284e-08
in O 0 2.1746424661017727e-09
a O 0 8.973107590293239e-09
specific O 0 1.1160399715492986e-08
cellular O 0 3.206670044164639e-06
defect O 0 2.3317277282330906e-06
in O 0 2.2519270004295322e-08
serum O 0 8.28883571557526e-07
- O 0 1.1445343943705666e-06
dependent O 0 4.102935946548314e-08
growth O 0 1.334915022965788e-08
control O 0 2.9276534974087554e-08
, O 0 4.185652713317722e-09
which O 0 1.220173917459988e-08
may O 0 5.918864331988516e-08
initiate O 0 5.447515150081017e-07
tumor B-Disease 0 1.091567628463963e-05
formation O 0 1.7192140830957214e-06
. O 0 6.189266059664078e-07

This O 0 1.4097234952714643e-06
is O 0 1.2915614888697746e-07
corrected O 0 1.2529437753983075e-06
by O 0 3.067971654502344e-09
the O 0 2.6082969117879884e-09
reintroduction O 0 1.5355864491084503e-07
of O 0 2.0389205879212113e-09
wild O 0 2.8753029823747056e-07
- O 0 0.00035915098851546645
type O 0 2.6256868750351714e-06
VHL B-Disease 0 5.0763515901053324e-05
, O 0 8.077545743390147e-08
implicating O 0 1.7256845694646472e-06
VHL B-Disease 0 1.043634802044835e-05
as O 0 1.8426131731530404e-08
the O 0 6.323228163296335e-09
first O 0 6.444158628937657e-08
tumor B-Disease 0 8.602207799413009e-07
suppressor O 0 1.5739128684799653e-06
involved O 0 9.324009120348364e-09
in O 0 2.434633827874677e-09
the O 0 1.954858497299483e-09
regulation O 0 8.495778303085899e-09
of O 0 8.62546645219453e-10
cell O 0 1.52317582546857e-07
cycle O 0 2.0483281559791067e-07
exit O 0 1.3338136284346547e-07
, O 0 1.8933672407683844e-08
which O 0 1.1853272141593152e-08
is O 0 2.172068080952272e-09
consistent O 0 1.462916277006343e-08
with O 0 1.3974021939588965e-09
its O 0 8.02324695570178e-09
gatekeeper O 0 1.202218072648975e-06
function O 0 1.2983136343791557e-08
in O 0 7.0874088820005454e-09
the O 0 1.6314352535573562e-07
kidney O 0 1.2812828572350554e-05
. O 0 9.005568557540755e-08
. O 0 3.1979189429875987e-07

Piebaldism B-Disease 1 0.9999998807907104
with O 0 0.2567530870437622
deafness B-Disease 1 1.0
: O 0 6.742222353750549e-07
molecular O 0 5.13052441419859e-07
evidence O 0 8.12814562323183e-08
for O 0 9.510666032497284e-09
an O 0 1.087852723458127e-07
expanded O 0 0.0006079150480218232
syndrome O 1 0.9999761581420898
. O 0 2.218166173406644e-06

In O 0 9.554612461215584e-07
a O 0 4.6524201025022194e-07
South O 0 3.872863771903212e-07
African O 0 1.5849340684326307e-07
girl O 0 3.7461231841007248e-06
of O 0 2.1493695712138106e-08
Xhosa O 0 8.125791646307334e-05
stock O 0 4.937620587952551e-07
with O 0 3.45659394440645e-08
severe O 0 1.9865432477672584e-05
piebaldism B-Disease 0 0.00026457817875780165
and O 0 1.1300893675070256e-05
profound O 0 0.000674316834192723
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 1.1295214790152386e-05
identified O 0 4.4992546577304893e-07
a O 0 2.0909713072114755e-08
novel O 0 1.8362896980761434e-07
missense O 0 1.5214467339319526e-06
substitution O 0 2.9041061111456656e-08
at O 0 2.1737601940685636e-08
a O 0 1.2369091528796616e-08
highly O 0 1.8602555940105958e-08
conserved O 0 5.94489790728403e-08
residue O 0 1.084916476656872e-07
in O 0 2.680969890533902e-09
the O 0 4.429590916288362e-09
intracellular O 0 9.942791479033986e-08
kinase O 0 3.513446529268549e-07
domain O 0 2.2522792519907853e-08
of O 0 2.940002241658135e-09
the O 0 1.2775075219906284e-08
KIT O 0 5.212031737755751e-06
proto O 0 5.3655221563531086e-05
- O 0 2.374322502873838e-05
oncogene O 0 1.2014322237519082e-05
, O 0 1.0455075027948624e-07
R796G O 0 4.005449227406643e-06
. O 0 4.412652288010577e-07

Though O 0 1.566810897202231e-05
auditory B-Disease 0 6.355340156005695e-05
anomalies I-Disease 0 0.0004466002865228802
have O 0 5.712644792765786e-07
been O 0 8.228946768440437e-08
observed O 0 9.819198254490402e-08
in O 0 6.8964092214685024e-09
mice O 0 1.4630579698859947e-06
with O 0 1.152996542685969e-08
dominant O 0 2.083166691591032e-06
white O 0 5.278641765471548e-06
spotting O 0 3.347698657307774e-05
( O 0 7.41002637028032e-08
W O 0 0.000893372402060777
) O 0 5.928928459297822e-09
due O 0 5.764242860806235e-09
to O 0 1.1186378046090795e-08
KIT O 0 6.537835724884644e-05
mutations O 0 3.497065699775703e-05
, O 0 4.827584689337527e-06
deafness B-Disease 1 1.0
is O 0 1.3724181258112367e-07
not O 0 1.0809976913606079e-08
typical O 0 8.610680168885665e-08
in O 0 4.35074092308696e-08
human O 0 5.025834184380074e-07
piebaldism B-Disease 0 7.374384586000815e-05
. O 0 1.6997147440633853e-06

Thus O 0 2.418811618554173e-06
, O 0 3.2226125767920166e-08
the O 0 8.29997137685723e-09
occurrence O 0 2.711092292884132e-07
of O 0 3.635506402588362e-07
sensorineural B-Disease 1 0.9999998807907104
deafness I-Disease 1 1.0
in O 0 6.8097647272225e-06
this O 0 8.118414740465596e-08
patient O 0 8.977945640253893e-07
extends O 0 1.3051767666638625e-07
considerably O 0 1.590066318613026e-07
the O 0 2.5578088536093446e-09
phenotypic O 0 1.2747052835493378e-07
range O 0 3.647716795285305e-08
of O 0 3.3115030717567606e-09
piebaldism B-Disease 0 2.8517297323560342e-06
due O 0 1.278480166178042e-08
to O 0 4.964692656983516e-09
KIT O 0 2.421955286990851e-06
gene O 0 3.152055967348133e-07
mutation O 0 1.45493331160651e-07
in O 0 4.181870405517429e-09
humans O 0 8.649160498919173e-09
and O 0 1.15244249698776e-08
tightens O 0 8.755357703194022e-05
the O 0 1.5237040074111974e-08
clinical O 0 5.553421900117428e-08
similarity O 0 5.2082480550552646e-08
between O 0 4.226948391305996e-08
piebaldism B-Disease 0 4.9429490900365636e-06
and O 0 1.1306954483814025e-08
the O 0 9.47741440882055e-10
various O 0 2.7417321746270318e-09
forms O 0 7.930639611686274e-08
of O 0 1.6800869389044237e-06
Waardenburg B-Disease 1 0.9999995231628418
syndrome I-Disease 1 0.9999769926071167
. O 0 1.4661151226391667e-07
. O 0 6.062369948267587e-07

Cycloheximide O 0 0.0002981627476401627
facilitates O 0 1.058127327269176e-05
the O 0 1.9598927281094802e-07
identification O 0 1.3515504804217926e-07
of O 0 1.2251925696205035e-08
aberrant O 0 2.7601774945651414e-06
transcripts O 0 2.033661075984128e-06
resulting O 0 1.894769638965954e-07
from O 0 4.472992198856218e-09
a O 0 1.1862907101090059e-08
novel O 0 1.1217128559337652e-07
splice O 0 4.382605402497575e-05
- O 0 5.3526840929407626e-05
site O 0 1.0115367103935569e-06
mutation O 0 2.166194832398105e-07
in O 0 8.242342808273406e-09
COL17A1 O 0 3.919400569429854e-06
in O 0 1.5688156551618704e-08
a O 0 1.8485488340047596e-07
patient O 0 4.3708296288968995e-06
with O 0 3.3618164252402494e-07
generalized O 0 0.0003759016690310091
atrophic B-Disease 1 0.9996739625930786
benign I-Disease 1 0.9995986819267273
epidermolysis I-Disease 1 0.9995821118354797
bullosa I-Disease 1 0.9809455871582031
. O 0 6.946061330381781e-05

Patients O 0 0.001381979789584875
with O 0 6.210709216247778e-06
generalized O 0 0.0004133037000428885
atrophic B-Disease 1 0.9967610239982605
benign I-Disease 1 0.9937790036201477
epidermolysis I-Disease 1 0.9971297383308411
bullosa I-Disease 1 0.894709050655365
often O 0 8.243062620749697e-05
show O 0 1.8612958228914067e-05
decreased O 0 2.0605748431989923e-06
expression O 0 1.0698600760861154e-07
of O 0 1.0883316470255977e-08
type O 0 8.418209631599893e-07
XVII O 0 4.285722388885915e-05
collagen O 0 3.5173591186321573e-06
, O 0 2.6128192942564965e-08
a O 0 4.973604106339735e-08
transmembrane O 0 5.520245167645044e-07
hemidesmosomal O 0 9.855822327153874e-07
protein O 0 1.4897358369125868e-07
encoded O 0 2.1058465904388868e-07
by O 0 8.796234141073e-08
COL17A1 O 0 9.278990182792768e-05
. O 0 1.2265052191651193e-06

This O 0 8.933047865866683e-07
report O 0 1.2668122906234203e-07
documents O 0 1.3203496074254417e-08
a O 0 2.4905556728072042e-08
novel O 0 1.854306646009718e-07
splice O 0 3.14411663566716e-05
- O 0 2.072333882097155e-05
site O 0 3.934524102078285e-07
mutation O 0 8.962882702689967e-08
in O 0 4.211495152617317e-09
COL17A1 O 0 2.470131221343763e-06
in O 0 6.0098113152662336e-09
a O 0 6.714503086868717e-08
patient O 0 8.624649581179256e-07
with O 0 1.3733136938753887e-07
generalized O 0 6.065376874175854e-05
atrophic B-Disease 1 0.9680321216583252
benign I-Disease 1 0.9346760511398315
epidermolysis I-Disease 1 0.7822926044464111
bullosa I-Disease 0 0.010801183991134167
, O 0 2.2097663077147445e-07
and O 0 9.270296530417e-09
applies O 0 7.610267971358553e-09
a O 0 7.629597398306487e-09
new O 0 4.425511956895889e-09
methodology O 0 1.9391213967878684e-08
to O 0 3.1574844960857718e-09
define O 0 3.698536943375075e-08
and O 0 3.9462893397512744e-08
characterize O 0 1.1645361297496493e-07
the O 0 1.100192825731483e-08
resulting O 0 1.381497298780232e-07
mRNA O 0 2.4874040605027403e-07
splice O 0 2.3082326151779853e-05
variants O 0 5.087626504973741e-06
. O 0 1.2017516155538033e-06

Mutational O 0 0.001010590116493404
analysis O 0 3.7507634260691702e-06
of O 0 1.2117104120079603e-07
COL17A1 O 0 5.374811735237017e-05
identified O 0 8.898289252101677e-07
a O 0 1.5639210459994501e-07
maternally O 0 8.446221727353986e-06
inherited O 0 4.07655807066476e-06
G O 0 1.2134837561461609e-05
- O 0 1.2137707017245702e-06
to O 0 3.189737185493868e-08
- O 0 1.5405914382427e-05
T O 0 5.176465947442921e-06
transversion O 0 1.684185946260186e-07
at O 0 4.0439878112863425e-09
the O 0 4.544263632055845e-09
- O 0 9.812025609789998e-07
1 O 0 3.4931257886228195e-08
position O 0 3.707238249717193e-08
of O 0 1.0148798246234492e-08
exon O 0 4.553867711365456e-06
32 O 0 3.522649876686046e-06
. O 0 7.093869385244034e-07

This O 0 7.808012014720589e-07
acceptor O 0 1.7586449985174113e-06
splice O 0 4.6186156396288425e-05
- O 0 3.1766121537657455e-05
site O 0 7.226039997476619e-07
mutation O 0 3.7438979916259996e-07
led O 0 1.4568404260728585e-08
to O 0 2.6286888221704885e-09
the O 0 4.136604836446622e-09
formation O 0 1.310556996259038e-08
of O 0 1.6903891619790556e-09
aberrant O 0 3.6620605214920943e-07
transcripts O 0 1.6794255941476877e-07
present O 0 1.1186997994627745e-08
at O 0 4.094329142390052e-08
extremely O 0 1.1185060344587328e-07
low O 0 1.9157973838446196e-06
levels O 0 2.638702483181987e-07
. O 0 2.6120477514268714e-07

Based O 0 3.86319516110234e-06
on O 0 3.694018460009829e-07
our O 0 3.601308762313238e-08
recent O 0 1.755255141233647e-08
finding O 0 2.1325698540408666e-08
that O 0 1.2278313477054326e-08
cycloheximide O 0 4.005025402875617e-06
stabilized O 0 6.791889973101206e-06
mutant O 0 9.453642633161508e-07
COL17A1 O 0 1.5480642332477146e-06
transcripts O 0 2.669353591500112e-07
in O 0 1.416928352426794e-08
keratinocytes O 0 1.377869921270758e-06
homozygous O 0 6.251386253097735e-07
for O 0 3.4483806921059568e-09
a O 0 9.549896873295438e-08
frameshift O 0 0.0006714233313687146
mutation O 0 8.57741042636917e-07
, O 0 2.8001734264648803e-09
the O 0 2.35595942754685e-09
effects O 0 4.520595808799044e-08
of O 0 8.185764843737786e-10
the O 0 4.293388311538138e-09
splice O 0 4.341597741586156e-05
- O 0 3.022915370820556e-05
site O 0 7.917956281744409e-07
mutation O 0 6.311193345709398e-08
on O 0 5.568321359561423e-09
splicing O 0 1.1961621737555106e-07
of O 0 6.57479093391089e-09
COL17A1 O 0 2.974250719489646e-06
transcripts O 0 3.3991841519309673e-07
were O 0 2.3927514192223498e-08
determined O 0 1.465407262202234e-08
using O 0 9.245099796828526e-09
reverse O 0 2.69816979425741e-07
transcriptase O 0 1.008758431453316e-06
polymerase O 0 9.312208817391365e-07
chain O 0 8.9253677515444e-07
reaction O 0 1.4912803436573085e-08
of O 0 6.359073823070105e-10
total O 0 4.412868293002248e-09
RNA O 0 9.894720420788872e-08
from O 0 6.254031958974338e-09
keratinocytes O 0 4.521371863575041e-07
incubated O 0 5.936217917223985e-07
for O 0 9.86959047821756e-09
2 O 0 1.6689659787516575e-07
. O 0 3.494479301480169e-07

5 O 0 1.6508487533428706e-05
h O 0 1.3419116839941125e-05
in O 0 1.4231253508967256e-08
the O 0 7.596490547712165e-09
presence O 0 2.8373031923933922e-08
or O 0 1.7202681945605036e-08
absence O 0 2.318302527726246e-08
of O 0 6.285518772131127e-09
10 O 0 5.6942877080246035e-08
microg O 0 3.390531446711975e-06
cycloheximide O 0 6.333089459076291e-06
per O 0 5.137349603501207e-07
ml O 0 1.1188211828994099e-05
. O 0 7.778098165545089e-07

Using O 0 1.0539913546381285e-06
this O 0 3.995945974111237e-08
approach O 0 1.3302997103892267e-07
, O 0 3.8914320654726e-09
an O 0 3.937986381430392e-09
abnormally O 0 1.775171881490678e-06
spliced O 0 0.003263558493927121
transcript O 0 0.002588994801044464
was O 0 0.00011510446347529069
identified O 0 1.2153977024809137e-07
that O 0 1.0956062723721516e-09
contains O 0 1.60963686823834e-09
an O 0 1.1817666845104213e-09
extra O 0 4.0243303800480135e-08
264 O 0 6.414922637532072e-08
bases O 0 3.537430970368405e-08
upstream O 0 5.6018908622945673e-08
from O 0 5.347429166135953e-09
exon O 0 2.758598895979958e-07
32 O 0 1.3269547594063624e-07
, O 0 2.051070868702709e-09
resulting O 0 6.406862151919768e-09
in O 0 3.2114741976840833e-09
a O 0 1.1782229591972282e-07
premature O 0 2.3441441499016946e-06
termination O 0 5.942789016444294e-07
codon O 0 1.1862498467962723e-06
27 O 0 6.756640686944593e-07
bp O 0 1.6900519312912365e-06
downstream O 0 2.5832568439909664e-07
from O 0 5.794248192358964e-09
the O 0 2.788593178593146e-08
cryptic O 0 4.2236465560563374e-06
splice O 0 0.0001237034739460796
site O 0 1.5286113921320066e-05
. O 0 1.26399106648023e-06

Three O 0 8.642953162052436e-07
other O 0 2.2067666805014596e-08
splice O 0 6.258203484321712e-06
variants O 0 1.2711462886727531e-06
, O 0 1.685740791401713e-08
including O 0 3.598636055812676e-09
one O 0 1.1774564434574586e-08
derived O 0 3.202482501407644e-09
from O 0 8.621748870396573e-10
the O 0 7.078057029374918e-10
skipping O 0 1.851508635297705e-08
of O 0 1.4992279639969297e-09
exon O 0 5.013836812395311e-07
32 O 0 5.128929387865355e-07
, O 0 2.2540886490673984e-08
were O 0 1.0028231400838195e-07
also O 0 1.8207853713647637e-07
identified O 0 1.2429551361492486e-06
. O 0 3.2396380333921115e-07

These O 0 4.506383106672729e-07
results O 0 2.286286928665504e-07
indicate O 0 5.145115622440244e-08
the O 0 3.636058787392926e-09
usefulness O 0 3.726009722981871e-08
of O 0 2.4257529318560955e-09
cycloheximide O 0 1.756104211381171e-06
treatment O 0 3.8965808357716014e-08
in O 0 2.3315069874740857e-09
evaluating O 0 1.1526139154227621e-08
the O 0 5.214338294479148e-09
abnormal O 0 1.209775177812844e-07
processing O 0 5.0092268111257e-09
of O 0 4.5378861779354907e-10
mRNA O 0 9.887848761991336e-09
due O 0 2.7736699603764237e-09
to O 0 1.4084078348020057e-09
splice O 0 5.630052783089923e-06
- O 0 4.231125330989016e-06
site O 0 7.851829195715254e-07
mutations O 0 3.780169777201081e-07
, O 0 8.639202242477495e-09
because O 0 6.38330810431853e-09
( O 0 1.560932716415664e-08
i O 0 3.195766140606793e-08
) O 0 4.233659200991724e-09
aberrant O 0 1.857793563431187e-07
splicing O 0 3.4988445918315847e-07
often O 0 9.321843208454084e-08
generates O 0 4.557650612468933e-08
a O 0 2.2967453716660202e-08
premature O 0 3.6161284810987127e-07
termination O 0 1.9145063845371624e-07
codon O 0 4.7553876925121585e-07
, O 0 9.369362174993512e-09
( O 0 7.213121211435691e-09
ii O 0 1.1597548876807195e-07
) O 0 2.680448307756933e-09
transcripts O 0 3.394861991523612e-08
with O 0 9.726812244537086e-09
premature O 0 4.814352791981946e-07
termination O 0 1.5300767586268194e-07
codons O 0 1.788509820244144e-07
can O 0 5.209983555687359e-09
occur O 0 4.974682887848303e-09
at O 0 6.886354153579077e-09
low O 0 2.995701322561217e-07
or O 0 6.490118664714828e-08
undetectable O 0 5.558603106692317e-07
levels O 0 1.2700779095098369e-08
due O 0 3.5972225198577235e-09
to O 0 2.12443307390231e-09
nonsense O 0 1.5488127758089831e-07
- O 0 7.506358912223732e-08
mediated O 0 1.7122357576226932e-07
mRNA O 0 5.8758509169365425e-08
decay O 0 2.37707133976528e-08
, O 0 1.724163145588875e-09
and O 0 3.0838060993687577e-09
( O 0 3.0714026877376455e-09
iii O 0 1.4643265444647113e-07
) O 0 2.6327229285527665e-09
the O 0 1.1973217972638395e-09
levels O 0 1.3804239973325139e-09
of O 0 2.0002463574364526e-10
these O 0 2.4900209671940843e-10
transcripts O 0 2.252073194597415e-08
can O 0 3.0630951108889803e-09
be O 0 1.0386235205217531e-09
increased O 0 5.7111226858808095e-09
by O 0 9.360145547532284e-09
cycloheximide O 0 1.0542745258135255e-05
. O 0 3.242855939333822e-07

A O 0 1.2782121302734595e-05
deletion O 0 0.00010957606718875468
mutation O 0 6.296588253462687e-06
in O 0 5.000590164172536e-08
COL17A1 O 0 1.5505995179410093e-05
in O 0 3.214227461967312e-08
five O 0 1.0987064058554097e-07
Austrian O 0 1.064644857251551e-05
families O 0 6.512016170745483e-08
with O 0 1.0065983246931864e-07
generalized O 0 7.62223862693645e-05
atrophic B-Disease 1 0.9940061569213867
benign I-Disease 1 0.9916785955429077
epidermolysis I-Disease 1 0.9599276185035706
bullosa I-Disease 0 0.013586020097136497
represents O 0 3.3025655739038484e-06
propagation O 0 8.371711146537564e-07
of O 0 1.5409593601134475e-08
an O 0 4.528431674089006e-08
ancestral O 0 1.5647203326807357e-05
allele O 0 4.511896622716449e-05
. O 0 1.2060502285748953e-06

Patients O 0 0.0011761360801756382
with O 0 5.005646471545333e-06
generalized O 0 0.0005945215816609561
atrophic B-Disease 1 0.9990259408950806
benign I-Disease 1 0.9990686774253845
epidermolysis I-Disease 1 0.9990743398666382
bullosa I-Disease 1 0.7544902563095093
, O 0 1.0844794360309606e-06
a O 0 1.7601807655864832e-07
usually O 0 5.337140152050779e-08
nonlethal O 0 7.075545340740064e-07
form O 0 1.76084057557091e-07
of O 0 1.8251317612794082e-07
junctional B-Disease 1 0.8408234715461731
epidermolysis I-Disease 1 0.7849416732788086
bullosa I-Disease 0 0.012412738986313343
, O 0 2.393591955751617e-07
have O 0 2.8277677088794917e-08
generalized O 0 6.229390692169545e-07
blistering B-Disease 0 0.001038760645315051
, O 0 2.011623109865468e-06
nail B-Disease 1 0.9999969005584717
dystrophy I-Disease 1 0.9998828172683716
, O 0 1.4590117416446446e-06
patchy B-Disease 0 0.14043675363063812
alopecia I-Disease 1 0.9999685287475586
, O 0 9.252314612240298e-07
and O 0 3.7171550957282307e-06
dental B-Disease 0 0.14950281381607056
abnormalities I-Disease 1 0.9999057054519653
. O 0 4.163998710282613e-06

Skin B-Disease 1 0.9999189376831055
fragility I-Disease 0 0.006492537911981344
in O 0 1.0235289238380574e-07
most O 0 1.5950016418742052e-08
cases O 0 8.215393698662865e-09
is O 0 4.725322355625394e-09
due O 0 8.425886655061277e-09
to O 0 1.0736824762602737e-08
mutations O 0 1.205765727263497e-07
in O 0 1.9107329052303612e-09
the O 0 3.017113670011895e-09
gene O 0 1.6394112378748105e-07
encoding O 0 4.7288682480939315e-07
type O 0 6.639214916503988e-06
XVII O 0 0.000538477033842355
collagen O 0 0.00012589534162543714
( O 0 3.669765646918677e-07
COL17A1 O 0 3.16024998028297e-05
) O 0 3.4644986612875073e-07
. O 0 6.732956876476237e-07

Recently O 0 0.00010177597869187593
, O 0 2.838026489371259e-07
we O 0 3.0567292697014636e-08
reported O 0 9.321025373765224e-08
five O 0 1.6930650659219282e-08
Austrian O 0 4.595920927386032e-06
families O 0 5.1370456333188486e-08
with O 0 4.2903291586071646e-08
generalized O 0 2.61647546722088e-05
atrophic B-Disease 1 0.8852497339248657
benign I-Disease 1 0.6121092438697815
epidermolysis I-Disease 1 0.6741739511489868
bullosa I-Disease 0 0.17947529256343842
who O 0 1.959153996722307e-05
share O 0 2.2277772870893386e-07
the O 0 3.229627409950808e-08
same O 0 1.6665008217842114e-07
COL17A1 O 0 0.0003322296543046832
mutation O 0 1.3098283488943707e-05
. O 0 5.718155193790153e-07

Affected O 0 3.117118831141852e-05
individuals O 0 7.289024495094054e-08
in O 0 5.53441736883542e-09
three O 0 2.5153756411100403e-08
families O 0 1.7454331313615512e-08
are O 0 1.4337147025145214e-09
homozygous O 0 8.886384961215299e-08
for O 0 1.9920045613019965e-09
4003delTC O 0 4.404663798140973e-07
, O 0 5.0873731893830154e-09
whereas O 0 3.801055026286804e-09
those O 0 6.892053039386781e-10
in O 0 1.1143079792219623e-09
two O 0 2.2813161137946736e-08
others O 0 1.3658282682627032e-07
are O 0 1.1100489416548953e-08
compound O 0 1.4873779718982405e-06
heterozygotes O 0 1.4233258298190776e-05
. O 0 4.878592108070734e-07

To O 0 4.3400413574090635e-07
determine O 0 9.784723431494058e-08
if O 0 1.3944873700211247e-08
the O 0 2.7870761254433774e-09
occurrence O 0 3.603734555213123e-08
of O 0 1.6491540355545453e-09
4003delTC O 0 4.852491883866605e-07
in O 0 2.7000803815013796e-09
these O 0 2.076424143737654e-09
unrelated O 0 3.127743752884271e-08
families O 0 2.17596287654942e-08
signifies O 0 3.892681021966382e-08
propagation O 0 1.7605996660563505e-08
of O 0 4.2509409881041904e-10
an O 0 1.7288525056002868e-09
ancestral O 0 3.300958439922397e-07
allele O 0 6.562489716088749e-07
or O 0 1.1330357985173123e-08
a O 0 4.002032483185758e-08
mutational O 0 1.0131594535778277e-05
hot O 0 1.7173466403619386e-05
spot O 0 1.1197691492270678e-05
, O 0 2.0351142993035864e-08
haplotypes O 0 6.978129931667354e-07
were O 0 1.1860139892405641e-07
determined O 0 2.7524539092382838e-08
for O 0 6.2969669478718515e-09
polymorphisms O 0 1.83151332748821e-05
both O 0 2.253731778978363e-08
within O 0 2.6733983915505632e-08
and O 0 1.9119757155294792e-07
flanking O 0 0.00030711552244611084
COL17A1 O 0 0.0005719188484363258
. O 0 1.3500140312316944e-06

Five O 0 7.698692570556886e-06
intragenic O 0 8.822540257824585e-05
polymorphisms O 0 0.00029930484015494585
were O 0 1.1535748853930272e-06
chosen O 0 3.670629666885361e-08
based O 0 1.3928313613575938e-08
on O 0 1.0726920862680345e-07
their O 0 2.0337196815489733e-07
informativeness O 0 5.237259392742999e-05
. O 0 4.218910305553436e-07

One O 0 8.672106446283578e-07
of O 0 1.8592233530512203e-08
these O 0 2.6932189811645912e-09
, O 0 2.6317541479414785e-09
not O 0 1.8956356484522985e-09
previously O 0 5.014056725372029e-08
reported O 0 4.6625561367363844e-07
, O 0 5.140855741103678e-09
was O 0 9.397805911248724e-08
2988 O 0 5.528533364440591e-08
A O 0 2.152101608032808e-08
or O 0 1.9507586657141474e-08
C O 0 8.678413365714732e-08
that O 0 7.770344923052619e-10
introduces O 0 2.3312948016496193e-08
a O 0 3.2414624318022334e-09
new O 0 3.866034603561275e-09
restriction O 0 1.1576152481040936e-08
site O 0 2.6824185539453538e-08
for O 0 6.317417700074657e-09
Eco0109 O 0 2.1828066110174404e-06
I O 0 1.7936151834874181e-06
. O 0 2.3881787569735025e-07

All O 0 2.5280837689933833e-07
the O 0 5.598932162342862e-08
4003delTC O 0 2.009914396694512e-06
alleles O 0 5.870282961950579e-07
showed O 0 6.349008572215098e-07
the O 0 3.533342729511446e-09
same O 0 1.2425227069456923e-08
haplotype O 0 5.989421651975135e-07
for O 0 2.416166600127667e-09
these O 0 1.952246364567145e-09
five O 0 3.4007463511898095e-08
polymorphic O 0 3.7685540519305505e-06
markers O 0 5.015720671508461e-05
. O 0 1.0807564194692532e-06

Fourteen O 0 5.730753036914393e-05
microsatellite O 0 0.00023069359303917736
polymorphisms O 0 0.0015789835015311837
were O 0 1.3668176279679756e-06
selected O 0 1.7114384576188968e-08
based O 0 1.252105441551521e-08
on O 0 1.6175432904219633e-07
their O 0 4.045162071975028e-08
high O 0 6.818295901211968e-07
heterozygosity O 0 3.248791699661524e-06
and O 0 3.4803836257424337e-08
their O 0 5.561305194135002e-09
location O 0 5.970191807591618e-08
within O 0 1.8843712368266097e-08
10q23 O 0 1.1875515610881848e-06
- O 0 3.912827651220141e-06
q25 O 0 6.154343282105401e-06
near O 0 3.7059205624245806e-06
COL17A1 O 0 4.6394779928959906e-05
. O 0 1.0669210723790457e-06

Three O 0 4.471417469176231e-06
families O 0 9.82433789431525e-07
shared O 0 5.654566166413133e-07
microsatellite O 0 5.5148560932138935e-05
polymorphisms O 0 0.00015324322157539427
covering O 0 6.803376209063572e-07
at O 0 8.33206286188215e-08
most O 0 7.399768797711204e-09
19 O 0 1.3681970756351802e-07
cM O 0 5.635208140120085e-07
, O 0 7.321709905028229e-09
whereas O 0 5.739438257990059e-09
the O 0 4.936854924864065e-09
others O 0 1.7415256792219225e-08
shared O 0 5.138973691032334e-09
smaller O 0 7.9940418729052e-09
regions O 0 1.2665315907156582e-08
consistent O 0 1.4478873211487553e-08
with O 0 5.056397078817554e-09
cross O 0 2.9141465347493067e-06
- O 0 3.5852899600286037e-06
over O 0 2.310119029402813e-08
events O 0 1.269414351412479e-08
during O 0 8.519503325032929e-09
passage O 0 4.5518797620047735e-09
of O 0 6.116289696933563e-10
this O 0 1.909741698113976e-09
mutation O 0 5.5420048994392346e-08
through O 0 4.722330970707844e-09
several O 0 2.0934214362000603e-08
generations O 0 4.0489376829100365e-07
. O 0 1.9260141925769858e-07

These O 0 9.716280828797608e-07
results O 0 2.6206510028714547e-07
indicate O 0 1.0147601869903156e-07
that O 0 9.548036139506166e-09
4003delTC O 0 1.470224901822803e-06
occurs O 0 2.1984023490517757e-08
on O 0 1.2940341242995146e-08
a O 0 4.9888058128999546e-08
single O 0 2.2331313687118381e-07
ancestral O 0 1.0767862477223389e-06
allele O 0 2.0759734979947098e-06
. O 0 6.78760301298098e-08
. O 0 2.983045988003141e-07

The O 0 3.7704521673731506e-06
haptoglobin O 0 8.078477549133822e-05
- O 0 1.4346900570672005e-05
gene O 0 3.2763559829618316e-06
deletion O 0 5.154593054612633e-06
responsible O 0 3.175932761223521e-07
for O 0 4.039757328655469e-08
anhaptoglobinemia B-Disease 0 0.00010793709952849895
. O 0 1.0132725947187282e-06

We O 0 6.065543402655749e-06
have O 0 5.154486615310816e-08
found O 0 7.728430340137038e-09
an O 0 2.9826687786282946e-09
allelic O 0 1.3343419595912565e-06
deletion O 0 1.1393505019441363e-06
of O 0 1.5693332855448716e-08
the O 0 3.135024684297605e-08
haptoglobin O 0 1.1969515071541537e-05
( O 0 2.6051163004581213e-08
Hp O 0 1.1690115542251078e-07
) O 0 2.3521429248773984e-09
gene O 0 1.8855686789720494e-08
from O 0 2.2805319854768413e-09
an O 0 2.6753814719171487e-09
individual O 0 7.935645029988336e-09
with O 0 4.8775270045098296e-08
anhaptoglobinemia B-Disease 0 8.673148840898648e-05
. O 0 1.0925006108664093e-06

The O 0 1.2289546020838316e-06
Hp O 0 4.761604941450059e-06
gene O 0 6.290139253906091e-07
cluster O 0 1.9932356565277587e-07
consists O 0 1.4745333842824948e-08
of O 0 1.6567774929754364e-09
coding O 0 5.568610390582762e-07
regions O 0 3.185250463388911e-08
of O 0 1.3069243465224645e-09
the O 0 7.459129314213442e-09
alpha O 0 2.983819413771016e-08
chain O 0 3.9371929005938e-07
and O 0 6.6981526991582996e-09
beta O 0 8.755939084892361e-09
chain O 0 3.02446139244239e-08
of O 0 5.779796641292023e-10
the O 0 5.0060173784061135e-09
haptoglobin O 0 7.60984846692736e-07
gene O 0 8.236452231358271e-08
( O 0 8.159673825502978e-09
Hp O 0 8.602981438343704e-08
) O 0 1.7918136974159893e-09
and O 0 1.6451890960667015e-09
of O 0 3.4177538577040423e-10
the O 0 2.7872568697517863e-09
alpha O 0 9.528859479246421e-09
chain O 0 1.68734828775996e-07
and O 0 4.136146980471267e-09
beta O 0 5.567662775263216e-09
chain O 0 3.958531991088421e-08
of O 0 4.131272268725894e-10
the O 0 1.8417092295663906e-09
haptoglobin O 0 1.0284735481036478e-06
- O 0 5.079556331111235e-07
related O 0 2.8000842533515424e-08
gene O 0 2.7254642986918043e-07
( O 0 2.2522277376424427e-08
Hpr O 0 1.8275542288392899e-06
) O 0 6.430355359299256e-09
, O 0 1.7042905975372946e-09
in O 0 2.1675734540593794e-09
tandem O 0 1.0535884484852431e-06
from O 0 1.3247036356744957e-08
the O 0 2.7355959275610076e-08
5 O 0 2.9822723490724456e-07
side O 0 5.007910203858046e-06
. O 0 5.122008701619052e-07

Southern O 0 4.749241270474158e-05
blot O 0 8.687502122484148e-05
and O 0 1.471690609378129e-07
PCR O 0 1.8585869838716462e-06
analyses O 0 1.1412956268941343e-07
have O 0 1.5165280586870722e-08
indicated O 0 3.187723862652092e-08
that O 0 3.8347469644151033e-10
the O 0 1.0946328288241602e-09
individual O 0 1.1265531840720655e-09
with O 0 4.962893651594413e-09
anhaptoglobinemia B-Disease 0 6.785518962715287e-06
was O 0 1.5181911976469564e-06
homozygous O 0 1.0592529520181415e-07
for O 0 5.343888664910423e-10
the O 0 1.4210252974322657e-09
gene O 0 2.5555573657243258e-08
deletion O 0 8.858970090841467e-08
and O 0 6.220697290615362e-09
that O 0 4.3810144401135176e-10
the O 0 9.478787754702012e-10
gene O 0 3.922545843693115e-08
deletion O 0 2.9087857456033817e-07
was O 0 8.249688789874199e-07
included O 0 7.247929811882159e-09
at O 0 1.725183906842176e-08
least O 0 2.2068078475712127e-09
from O 0 6.440687427833325e-10
the O 0 2.6905695449386258e-09
promoter O 0 3.3649340025476704e-07
region O 0 1.320792986092556e-08
of O 0 1.3119493269542204e-09
Hp O 0 7.955440395335245e-08
to O 0 3.6816785176085887e-09
Hpr O 0 7.349016186708468e-07
alpha O 0 1.667146953820975e-08
but O 0 2.9906781495725454e-09
not O 0 1.8278789593040301e-09
to O 0 1.134716143269543e-08
Hpr O 0 5.174935722607188e-06
beta O 0 2.096396798378919e-07
( O 0 2.9859034356150005e-08
Hpdel O 0 1.964553803190938e-06
) O 0 8.499818449081431e-08
. O 0 2.3640998847440642e-07

In O 0 4.888134981229086e-07
addition O 0 7.870708884638589e-08
, O 0 8.598335377030253e-09
we O 0 1.6577035300002763e-09
found O 0 2.403893528679646e-09
seven O 0 4.442756385003577e-09
individuals O 0 2.398743981224527e-10
with O 0 5.366492250580279e-10
hypohaptoglobinemia B-Disease 0 4.6313439838741033e-07
in O 0 3.1337255013141885e-09
three O 0 1.5313665002736343e-08
families O 0 1.3201658433104058e-08
, O 0 9.935920974868395e-10
and O 0 1.473973165744269e-09
the O 0 2.801225917892225e-09
genotypes O 0 5.422707971547425e-08
of O 0 5.694738569594904e-10
six O 0 9.62527124670487e-09
of O 0 4.4704992485655737e-10
the O 0 6.2605720607677995e-09
seven O 0 4.672045861298102e-08
individuals O 0 1.5818973908565681e-09
were O 0 5.700609317926819e-09
found O 0 3.527935277247707e-09
to O 0 4.773059281149017e-09
be O 0 3.8246557920729174e-08
Hp2 O 0 1.6440895706182346e-05
/ O 0 7.35692992748227e-06
Hpdel O 0 2.106361171172466e-05
. O 0 7.751935413580213e-07

The O 0 1.3351349252843647e-06
phenotypes O 0 1.7599233615328558e-05
and O 0 1.2084755951491388e-07
genotypes O 0 2.3069194412528304e-06
in O 0 1.2482330724594703e-08
one O 0 7.742062990701015e-09
of O 0 7.307893734598281e-10
these O 0 6.80562883825786e-10
three O 0 2.412106780980139e-08
families O 0 1.202184449766719e-07
showed O 0 1.0582115237411927e-06
the O 0 3.474544874038088e-09
father O 0 9.255283117681756e-08
to O 0 1.706053298633492e-09
be O 0 7.94055043940034e-09
hypohaptoglobinemic B-Disease 0 6.360832571772335e-07
( O 0 9.794840494237178e-09
Hp2 O 0 2.465920090344298e-07
) O 0 2.7696838156288095e-09
and O 0 4.638064599049585e-09
Hp2 O 0 1.1012530194420833e-06
/ O 0 4.051587438880233e-07
Hpdel O 0 4.956095267516503e-07
, O 0 3.5134506415346323e-09
the O 0 2.234529228317683e-09
mother O 0 7.517635225440245e-08
to O 0 1.2712551011873074e-09
be O 0 1.6983651152102652e-09
Hp2 O 0 1.0740207301296323e-07
- O 0 7.744208119220275e-08
1 O 0 6.801557539404257e-09
and O 0 5.90251403309594e-09
Hp1 O 0 7.33555111764872e-07
/ O 0 2.2405251343116106e-07
Hp2 O 0 3.2235539038083516e-07
, O 0 2.2385646669675907e-09
one O 0 7.198576179590077e-10
of O 0 1.1316091119706329e-10
the O 0 1.2017811190645489e-09
two O 0 7.929350509527922e-09
children O 0 2.6481504988851157e-08
to O 0 2.0585448901044856e-09
be O 0 6.562888010819279e-09
hypohaptoglobinemic B-Disease 0 1.0080563015435473e-06
( O 0 1.0795512039862842e-08
Hp2 O 0 2.8337399271549657e-07
) O 0 2.5639730338866684e-09
and O 0 4.2081147455519385e-09
Hp2 O 0 1.24159134884394e-06
/ O 0 3.746862660136685e-07
Hpdel O 0 6.999017045927758e-07
, O 0 5.286107551683017e-09
and O 0 2.089136419414217e-09
the O 0 7.188313277950442e-10
other O 0 5.900935295954923e-10
child O 0 3.2826463325363875e-08
to O 0 1.9159624997655555e-09
be O 0 4.205571002557917e-09
Hp1 O 0 3.0532658001902746e-07
and O 0 9.6613765876441e-09
Hp1 O 0 2.020866077145911e-06
/ O 0 4.130426418669231e-07
Hpdel O 0 7.32831438199355e-07
, O 0 1.3333120385539132e-08
showing O 0 3.355956934569804e-08
an O 0 1.684589134853809e-09
anomalous O 0 2.3203048726827546e-07
inheritance O 0 3.612085777149332e-07
of O 0 1.520832348944623e-08
Hp O 0 5.720752142224228e-06
phenotypes O 0 1.1627156482063583e-06
in O 0 1.5251055529574842e-08
the O 0 2.3831091766624013e-08
child O 0 1.4427550922846422e-06
with O 0 1.1472572225557087e-07
Hp1 O 0 0.0001426382950739935
. O 0 6.243415100470884e-07

The O 0 2.1021096472395584e-06
Hp2 O 0 4.702766455011442e-05
/ O 0 1.3983693861518987e-05
Hpdel O 0 7.736080078757368e-06
individuals O 0 2.552994615712123e-08
had O 0 9.847087767411722e-08
an O 0 3.1112605825001083e-09
extremely O 0 9.170900483468358e-08
low O 0 4.327559395278513e-07
level O 0 7.786728595249315e-09
of O 0 1.6531284119380985e-09
Hp O 0 2.2813645728092524e-07
( O 0 6.764452553653655e-09
mean O 0 2.27465104529756e-08
+ O 0 1.7824244480380003e-07
/ O 0 5.951137040938193e-07
- O 0 1.7621335928197368e-06
SD O 0 1.4150603419693653e-05
= O 0 8.303559866362775e-07
0 O 0 5.2370459968642535e-08
. O 0 7.184945527427544e-09
049 O 0 1.2136722489231033e-06
+ O 0 2.1446628295507253e-07
/ O 0 2.9522743716370314e-07
- O 0 3.561234507287736e-07
0 O 0 3.529384073885922e-08
. O 0 8.53895976149488e-09
043 O 0 1.623384719096066e-06
mg O 0 7.495756335629267e-07
/ O 0 4.0092533026836463e-07
ml O 0 4.549646916984784e-07
; O 0 1.2836919971448424e-08
n O 0 1.0075837053591385e-07
= O 0 1.285022790398216e-07
6 O 0 2.4291294309364275e-08
) O 0 1.0613755430100014e-09
, O 0 1.6334389396632787e-09
compared O 0 4.51537163215221e-09
with O 0 6.70360711385598e-10
the O 0 2.8721161005051954e-09
level O 0 8.077619462198982e-09
( O 0 9.777793019694059e-10
1 O 0 1.5652699136836645e-09
. O 0 9.71108859992853e-10
64 O 0 1.523817338977551e-08
+ O 0 3.4686074457113136e-08
/ O 0 4.7536101277501075e-08
- O 0 4.382180662787505e-08
1 O 0 8.562086151187032e-09
. O 0 2.9796778377999544e-09
07 O 0 8.498457049199715e-08
mg O 0 2.3049152275689266e-07
/ O 0 1.4505553735943977e-07
ml O 0 9.337645678897388e-08
) O 0 5.877637820894677e-10
obtained O 0 1.3243719454436587e-09
from O 0 2.0529768995913855e-09
52 O 0 7.260136669628992e-08
healthy O 0 5.6772396561655114e-08
volunteers O 0 3.9792663386606364e-08
having O 0 5.5178723812332464e-08
phenotype O 0 2.4112478058668785e-06
Hp2 O 0 8.064596954682202e-07
, O 0 3.5765341799276484e-09
whereas O 0 6.6859886516112965e-09
the O 0 2.2831170287673785e-09
serum O 0 2.7948183856096875e-07
Hp O 0 1.0655610793719461e-07
level O 0 3.674347492932384e-09
of O 0 4.33479169226203e-10
an O 0 7.538404900309104e-10
individual O 0 2.84575651932073e-09
with O 0 1.646715652725561e-08
Hp1 O 0 2.8844571716035716e-05
/ O 0 5.434912509372225e-06
Hpdel O 0 8.338822226505727e-06
was O 0 2.2479805465991376e-06
0 O 0 6.089139219511708e-07
. O 0 4.6764279204580816e-07

50 O 0 1.2250380677869543e-05
mg O 0 1.3155544365872629e-05
/ O 0 4.479672043089522e-06
ml O 0 2.442380491629592e-06
, O 0 1.6134737990114445e-08
which O 0 8.184612987349738e-09
was O 0 8.509437776638151e-08
approximately O 0 1.1842757885460742e-09
half O 0 2.4617545779648253e-09
the O 0 4.956137167333452e-10
level O 0 2.0968009550870192e-09
of O 0 7.784912714470238e-10
Hp O 0 1.0214149170906239e-07
in O 0 2.457162029401161e-09
control O 0 2.45553820832356e-07
sera O 0 5.932143380960042e-07
from O 0 1.2442177288463085e-09
the O 0 5.562344806975261e-09
Hp1 O 0 6.396403023245512e-06
phenotype O 0 1.1064977343266946e-06
( O 0 1.960844597803657e-09
1 O 0 2.5468747111290213e-09
. O 0 2.0446455639699934e-09
26 O 0 1.8525613043607336e-08
+ O 0 3.945002546856813e-08
/ O 0 9.095158759464539e-08
- O 0 6.5590242570579e-08
0 O 0 1.2253888570512572e-08
. O 0 1.0882418299829055e-09
33 O 0 4.47260184444076e-08
mg O 0 1.3293359302224417e-07
/ O 0 1.494735215601395e-07
ml O 0 2.6338528869018774e-07
; O 0 1.1149420942047072e-08
n O 0 9.359720820611983e-08
= O 0 2.1321881149560795e-07
9 O 0 3.679005544654501e-08
) O 0 2.0097850050859734e-09
, O 0 1.2525873671620502e-09
showing O 0 3.1989067394988524e-08
a O 0 1.4521215341289917e-08
gene O 0 2.8759393444488524e-07
- O 0 1.1662521501420997e-05
dosage O 0 6.331935765047092e-06
effect O 0 9.129073532676557e-07
. O 0 4.4033404833498935e-07

The O 0 7.965945201249269e-07
other O 0 9.784629639852938e-08
allele O 0 3.1699339615443023e-06
( O 0 4.33169660141175e-08
Hp2 O 0 1.1457881328169606e-06
) O 0 2.0802612965553635e-09
of O 0 8.061346590260143e-10
individuals O 0 7.193058926269202e-10
with O 0 2.5094371025602413e-09
Hp2 O 0 6.327975825115573e-06
/ O 0 2.1127978016011184e-06
Hpdel O 0 3.0944217996875523e-06
was O 0 3.2085438306239666e-07
found O 0 4.26539203957077e-09
to O 0 2.0958375035462495e-09
have O 0 8.722285116391504e-09
, O 0 8.723512467945227e-10
in O 0 6.847529765430238e-10
all O 0 2.008194943670105e-09
exons O 0 5.529798272618791e-07
, O 0 1.6562980320600218e-08
no O 0 1.4880638943282065e-08
mutation O 0 5.0562267261966554e-08
, O 0 2.20922924398792e-09
by O 0 2.8728941448008527e-09
DNA O 0 2.545480413118639e-07
sequencing O 0 9.629551414036541e-07
. O 0 3.7244538475533773e-07

On O 0 1.8024117025561281e-06
the O 0 1.7359774062697397e-08
basis O 0 1.1801454924409427e-08
of O 0 1.2130539905896853e-09
the O 0 3.6722875851324943e-09
present O 0 3.159400296937065e-09
study O 0 1.3164813683630427e-09
, O 0 5.406766701021581e-10
the O 0 3.954347405077385e-10
mechanism O 0 1.0882175160986662e-08
of O 0 1.553823736344384e-09
anhaptoglobinemia B-Disease 0 2.1251651105558267e-06
and O 0 1.049741182868047e-08
the O 0 1.0595186950013158e-09
mechanism O 0 5.0980384358467745e-09
of O 0 1.0236999026247418e-09
anomalous O 0 2.5264546366088325e-07
inheritance O 0 5.090671493235277e-07
of O 0 2.675744958935411e-08
Hp O 0 1.237445576407481e-05
phenotypes O 0 6.006346666254103e-06
were O 0 4.096555983323924e-07
well O 0 2.5940798309420643e-07
explained O 0 4.224609710945515e-06
. O 0 6.608884177694563e-07

However O 0 4.77721550851129e-06
, O 0 4.082756177581359e-08
the O 0 9.08594799398088e-09
mechanism O 0 1.2902415846838267e-07
of O 0 4.746796733456904e-08
hypohaptoglobinemia B-Disease 0 9.936417336575687e-05
remains O 0 1.039678136294242e-05
unknown O 0 1.1260960491199512e-05

ATM O 0 0.0014962784480303526
mutations O 0 0.0007372792460955679
and O 0 2.309320962012862e-06
phenotypes O 0 0.00015146855730563402
in O 0 1.7845581169240177e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.2331575817370322e-05
in O 0 3.42873960335055e-08
the O 0 5.120201151953552e-08
British O 0 7.602183359267656e-06
Isles O 0 2.251353180326987e-06
: O 0 2.5107969037208022e-09
expression O 0 2.2724078174718443e-09
of O 0 2.915536145842168e-10
mutant O 0 8.35757774098056e-08
ATM O 0 1.8953443259306368e-07
and O 0 7.966156623240295e-09
the O 0 3.3646141428533838e-09
risk O 0 3.5765221895189825e-08
of O 0 1.9385112182135344e-08
leukemia B-Disease 0 0.10909753292798996
, O 0 7.018694759608479e-06
lymphoma B-Disease 1 1.0
, O 0 7.763395615256741e-07
and O 0 9.840337042987812e-06
breast B-Disease 1 0.9928727149963379
cancer I-Disease 0 0.000952074711676687
. O 0 1.1095831951024593e-06

We O 0 8.394453288929071e-06
report O 0 1.1493083462710274e-07
the O 0 9.748134743858827e-09
spectrum O 0 1.991141971302568e-07
of O 0 4.217073357182244e-09
59 O 0 3.3125223808383453e-07
ATM O 0 3.5613193176686764e-06
mutations O 0 2.9784091566398274e-06
observed O 0 4.923260803479934e-07
in O 0 1.636533738746948e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 2.3346679881797172e-05
A B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.1580915071363052e-07
patients O 0 4.2038649894493574e-08
in O 0 3.9988257150014306e-09
the O 0 3.766552580941607e-08
British O 0 3.979945631726878e-06
Isles O 0 1.7191852748510428e-05
. O 0 8.831198670122831e-07

Of O 0 1.5259237216014299e-06
51 O 0 5.204809895076323e-06
ATM O 0 1.2288830475881696e-05
mutations O 0 2.4696671516721835e-06
identified O 0 1.3027903378315386e-07
in O 0 8.359805292457168e-09
families O 0 2.8844258537219503e-08
native O 0 4.61290294850869e-09
to O 0 2.8824993503206997e-09
the O 0 7.698447213044801e-09
British O 0 7.526931540269288e-07
Isles O 0 3.8740830632377765e-07
, O 0 4.272964648777133e-09
11 O 0 7.687749992157933e-09
were O 0 1.2722454201252731e-08
founder O 0 2.3275632088370912e-07
mutations O 0 1.2798408022263175e-07
, O 0 1.985919650948631e-09
and O 0 6.114438733106908e-09
2 O 0 5.830054661259965e-09
of O 0 2.428552636768444e-10
these O 0 7.475747243468334e-10
11 O 0 7.962936088290462e-09
conferred O 0 6.529551122014254e-09
a O 0 1.3758588934820182e-08
milder O 0 1.625296863494441e-05
clinical O 0 1.044087071022659e-06
phenotype O 0 3.3962335237447405e-06
with O 0 1.122465764780145e-08
respect O 0 1.4190541186565042e-08
to O 0 3.3119718523266783e-08
both O 0 1.4596267874367186e-06
cerebellar B-Disease 1 0.8966418504714966
degeneration I-Disease 1 0.9171275496482849
and O 0 2.687743005935772e-07
cellular O 0 4.157071089139208e-06
features O 0 1.6962258087005466e-05
. O 0 4.4170910769025795e-06

We O 0 1.4168698726280127e-05
report O 0 1.2063189558375598e-07
, O 0 2.7135707014736e-09
in O 0 1.3564379619523947e-09
two O 0 1.3045196567418316e-07
A B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
families O 0 5.70166704960684e-08
, O 0 8.270968909762644e-10
an O 0 7.404424295920364e-10
ATM O 0 4.381988389923208e-07
mutation O 0 1.603740713562729e-07
( O 0 6.299465393766468e-09
7271T O 0 8.973282916713288e-08
- O 0 3.107176951289148e-07
- O 0 2.702318170122453e-06
> O 0 2.4875558324310987e-07
G O 0 1.3373918363868142e-06
) O 0 4.557491717349649e-09
that O 0 3.6400351621779237e-09
may O 0 1.052950011626308e-07
be O 0 2.5272572923284997e-09
associated O 0 1.4438986672971055e-09
with O 0 3.478342613938423e-10
an O 0 2.761860518063486e-09
increased O 0 8.348145286163344e-08
risk O 0 1.1044549808048032e-07
of O 0 2.1820765638835837e-08
breast B-Disease 1 0.6463853716850281
cancer I-Disease 0 9.578393473930191e-06
in O 0 1.2375934943520406e-08
both O 0 9.220588736980062e-08
homozygotes O 0 2.7261812647338957e-05
and O 0 1.9303539033899142e-07
heterozygotes O 0 3.1004094580566743e-06
( O 0 1.4630920475156017e-08
relative O 0 6.730838464363842e-08
risk O 0 3.3155494350012304e-08
12 O 0 8.817731433907738e-09
. O 0 1.3194124681703556e-09
7 O 0 1.8486998598632454e-08
; O 0 1.8699923387544004e-08
P O 0 4.644034561351873e-06
= O 0 2.6578007350508415e-07
. O 0 9.161106540034325e-09
0025 O 0 5.034852961216529e-07
) O 0 4.34595293086204e-09
, O 0 1.4661502012458527e-09
although O 0 1.801875870732772e-09
there O 0 8.474880242026472e-10
is O 0 6.054067247518446e-10
a O 0 7.272412894110403e-09
less O 0 2.9283572899885257e-08
severe O 0 6.767759259673767e-06
A B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 3.268424916313961e-05
in O 0 7.975978100205339e-09
terms O 0 6.024811760596549e-09
of O 0 1.046164821438822e-09
the O 0 5.797055724343636e-09
degree O 0 6.264253471499615e-08
of O 0 2.923263480170135e-07
cerebellar B-Disease 1 0.9775384068489075
degeneration I-Disease 1 0.999263346195221
. O 0 4.99370753459516e-06

This O 0 2.3411257643601857e-06
mutation O 0 1.1058162272092886e-05
( O 0 1.0990333976224065e-07
7271T O 0 1.8958500049848226e-06
- O 0 6.598338131880155e-06
- O 0 1.7814329112297855e-05
> O 0 8.831198670122831e-07
G O 0 4.469558916753158e-06
) O 0 5.2491642144048e-09
also O 0 3.301387163645586e-09
allows O 0 1.7135147745150903e-09
expression O 0 2.6865287772182e-09
of O 0 2.001845494925547e-10
full O 0 3.2764080337699397e-09
- O 0 1.3170929946682008e-07
length O 0 3.254957903209288e-08
ATM O 0 2.838705270846731e-08
protein O 0 6.929927742760356e-09
at O 0 2.1643058456533026e-09
a O 0 3.985926255722916e-09
level O 0 6.215620906857566e-09
comparable O 0 5.846914508111922e-09
with O 0 1.663750581748502e-09
that O 0 7.74726327534836e-09
in O 0 3.584642271903249e-08
unaffected O 0 4.415086550579872e-06
individuals O 0 7.527851408895003e-08
. O 0 1.7953044562091236e-07

In O 0 4.570246971979941e-07
addition O 0 7.904528587232562e-08
, O 0 1.7848151401267387e-08
we O 0 4.767227501645266e-09
have O 0 2.3938273585599745e-09
studied O 0 1.1403943567245278e-08
18 O 0 1.3091870698644925e-07
A B-Disease 1 0.9997251629829407
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
patients O 0 1.5500836525461636e-07
, O 0 8.662694450656261e-10
in O 0 1.2493257539603064e-09
15 O 0 1.2496147228091559e-08
families O 0 5.616073828207391e-09
, O 0 5.22949727965738e-09
who O 0 1.6853299200647598e-07
developed O 0 8.881384928827174e-06
leukemia B-Disease 0 0.13119563460350037
, O 0 5.52038954992895e-06
lymphoma B-Disease 1 1.0
, O 0 1.1451660952843667e-07
preleukemic O 0 1.2137545127188787e-05
T O 0 2.7255700842943043e-05
- O 0 1.323923925156123e-06
cell O 0 1.5235433465932147e-06
proliferation O 0 4.1898766767189954e-07
, O 0 6.077304703921982e-08
or O 0 1.3376647984841838e-05
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 3.106726467194676e-07
mostly O 0 4.106866313691171e-08
in O 0 1.0636502167926665e-07
childhood O 0 1.6412917830166407e-05
. O 0 1.7286574802710675e-06

A O 0 3.876598384522367e-06
wide O 0 1.5500792187594925e-06
variety O 0 1.1117020903839148e-07
of O 0 1.1360307361485411e-08
ATM O 0 7.886253115430009e-06
mutation O 0 1.0274080750605208e-06
types O 0 1.9585618460382648e-08
, O 0 3.577216300953978e-09
including O 0 1.4792404634533796e-08
missense O 0 6.531268445542082e-05
mutations O 0 1.5051919035613537e-06
and O 0 1.5245092299664975e-08
in O 0 1.9082790458924137e-08
- O 0 1.27902803797042e-05
frame O 0 0.00010852950799744576
deletions O 0 2.2825493033451494e-06
, O 0 3.74026463134669e-08
were O 0 8.082908919959664e-08
seen O 0 1.3711635915569786e-07
in O 0 8.493365122319574e-09
these O 0 5.021684401640414e-08
patients O 0 6.498293600998295e-07
. O 0 2.0740549189213198e-07

We O 0 7.676217137486674e-06
also O 0 1.3727741077218525e-07
show O 0 1.4178642970819055e-07
that O 0 3.889421229530399e-09
25 O 0 8.433121756468154e-09
% O 0 5.70062830274054e-10
of O 0 1.8229201481645418e-10
all O 0 6.682355113696303e-09
A B-Disease 1 0.9999935626983643
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 1.6409505576575611e-07
carried O 0 1.846201591604313e-08
in O 0 2.3120574343948874e-09
- O 0 3.6931660929440113e-07
frame O 0 7.587668733322062e-06
deletions O 0 1.736625222292787e-06
or O 0 1.2868966337009624e-07
missense O 0 6.819760073994985e-06
mutations O 0 3.273327706665441e-07
, O 0 2.483012684351138e-09
many O 0 2.547417554676912e-10
of O 0 1.3887693217640162e-09
which O 0 5.565244123317825e-07
were O 0 6.503588565465179e-07
also O 0 4.5640879875463725e-07
associated O 0 1.1196091165288635e-08
with O 0 5.63319613178237e-09
expression O 0 2.566166124040592e-08
of O 0 3.6790459567725975e-09
mutant O 0 2.382583261351101e-06
ATM O 0 6.725745151925366e-06
protein O 0 2.681892510736361e-06
. O 0 3.6176672324472747e-07

The O 0 2.717667257456924e-06
DMPK O 0 4.1200804844265804e-05
gene O 0 3.960763933719136e-06
of O 0 1.514869154561893e-07
severely O 1 0.9511099457740784
affected O 0 0.0011776596074923873
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.00029437083867378533
is O 0 1.1667972898976586e-07
hypermethylated O 0 1.1043302038160618e-05
proximal O 0 8.091660674836021e-06
to O 0 1.1235908203843792e-07
the O 0 6.58438139566897e-08
largely O 0 3.737540623660607e-07
expanded O 0 8.793664960649039e-07
CTG O 0 7.70660990383476e-05
repeat O 0 1.189636441267794e-05
. O 0 1.4872092606310616e-06

Using O 0 1.5445338021891075e-06
methylation O 0 6.620234671572689e-06
- O 0 5.991197667754022e-06
sensitive O 0 2.8837337140430463e-07
restriction O 0 5.629343036162027e-08
enzymes O 0 4.5409386473238555e-08
, O 0 3.985029195519019e-09
we O 0 1.54085577630525e-09
characterized O 0 6.590711087994805e-09
the O 0 1.1143760358933719e-09
methylation O 0 1.1915954445385069e-07
pattern O 0 1.7008059103318374e-06
on O 0 3.04772385106844e-07
the O 0 3.2309831254906385e-08
5 O 0 4.9525887391155266e-08
side O 0 5.0272621621161306e-08
of O 0 8.418332697601727e-10
the O 0 8.362835757225184e-09
CTG O 0 1.3005189885006985e-06
repeat O 0 4.905301054236588e-08
in O 0 1.3809585697188709e-09
the O 0 2.1085115875507654e-09
DMPK O 0 2.610902072319732e-07
gene O 0 1.044534325700397e-08
of O 0 8.335218626420726e-10
normal O 0 2.1764234858778764e-08
individuals O 0 7.746638330807798e-10
and O 0 1.6384782419720523e-09
of O 0 2.758528072632771e-09
patients O 0 1.0646286341398081e-07
affected O 0 5.62891351307826e-08
with O 0 3.100929916399764e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.8615232022511918e-07
showing O 0 1.6184213791348157e-07
expansions O 0 1.0911838188576439e-07
of O 0 3.42966655075827e-09
the O 0 4.390379260144073e-08
repetitive O 0 2.173131906602066e-05
sequence O 0 2.377920736762462e-06
. O 0 7.859755442041205e-07

The O 0 7.156376113925944e-07
gene O 0 2.2264230210566893e-06
segment O 0 1.4467880191659788e-06
analyzed O 0 2.272769563660404e-07
corresponds O 0 1.9660535599541618e-07
to O 0 6.262924845401585e-09
the O 0 1.3075783122928897e-08
genomic O 0 7.199859055617708e-07
SacI O 0 9.293930816056672e-06
- O 0 2.6307825464755297e-06
HindIII O 0 3.482984993752325e-06
fragment O 0 4.810199811799976e-07
carrying O 0 7.600551299447034e-08
exons O 0 2.908363285314408e-06
11 O 0 3.0883731483299925e-07
- O 0 7.6095384429208934e-06
15 O 0 6.437500132960849e-07
. O 0 3.9057636058714706e-07

There O 0 1.0037002766694059e-06
is O 0 6.764093285482886e-08
constitutive O 0 2.559694678438973e-07
methylation O 0 9.610229199097375e-07
in O 0 3.191909669908455e-08
intron O 0 2.5239085516659543e-05
12 O 0 3.8870354046594e-07
at O 0 7.330583251530243e-09
restriction O 0 5.720291351707374e-09
sites O 0 4.3166421548335165e-09
of O 0 1.8751344921241753e-09
SacII O 0 9.722102731757332e-07
and O 0 1.0315424070483914e-08
HhaI O 0 4.2118830378967687e-07
, O 0 2.039157953603876e-09
localized O 0 5.045956186222611e-08
1 O 0 5.103661937511106e-09
, O 0 1.5310416268121685e-09
159 O 0 2.375788632491549e-08
- O 0 2.9848018812117516e-07
1 O 0 1.2742344068783495e-08
, O 0 3.9215191094399415e-09
232 O 0 2.322418701794504e-08
bp O 0 1.4832090755589888e-07
upstream O 0 1.3566716638990783e-08
of O 0 4.138796527719535e-10
the O 0 1.9428707531687905e-09
CTG O 0 7.406252962027793e-07
repeat O 0 8.369158166487978e-08
, O 0 3.1543365697217496e-09
whereas O 0 1.7853658551558738e-09
most O 0 8.31438640158666e-10
, O 0 1.5525972729690807e-09
if O 0 5.564379512712492e-10
not O 0 4.721616986280708e-10
all O 0 1.7116848216591762e-10
, O 0 3.278656790506318e-10
of O 0 6.352172954304791e-11
the O 0 6.984875455806616e-10
other O 0 2.7661242740784076e-10
sites O 0 2.063356374648606e-09
of O 0 5.718466256077193e-10
SacII O 0 2.0783237175692193e-07
, O 0 2.113310859641615e-09
HhaI O 0 7.765670062553909e-08
, O 0 1.2706490304381646e-09
and O 0 1.7530593643400039e-09
HpaII O 0 1.050536795332846e-07
in O 0 8.906739235037264e-10
this O 0 5.814194126152472e-10
region O 0 9.621380137048163e-09
are O 0 1.400184856947817e-09
unmethylated O 0 2.3033045692955056e-07
, O 0 1.998691434579314e-09
in O 0 1.6044535700032725e-09
normal O 0 2.613158400777138e-08
individuals O 0 6.368675031787063e-10
and O 0 1.8958199454743863e-09
most O 0 5.439785288885446e-10
of O 0 1.5923047325117068e-09
the O 0 1.1022390111747882e-07
patients O 0 9.375744411954656e-07
. O 0 3.466379041583423e-07

In O 0 4.877061883235001e-07
a O 0 5.350594634023764e-08
number O 0 8.394190231797438e-09
of O 0 4.275785503438101e-09
young O 0 1.4183959251568012e-07
and O 0 4.063118126396148e-07
severely O 0 0.0017886949935927987
affected O 0 1.8065091467178718e-07
patients O 0 5.426556981547037e-08
, O 0 5.267316804946631e-09
however O 0 5.030098559899443e-09
, O 0 1.4049948982020055e-09
complete O 0 1.7127371743086428e-09
methylation O 0 4.107704754119368e-08
of O 0 9.837805015067147e-10
these O 0 4.693593846916144e-10
restriction O 0 5.9143019370822e-09
sites O 0 2.1776070724399688e-08
was O 0 8.112438081298023e-07
found O 0 5.6417657212648464e-09
in O 0 2.6916577855473633e-09
the O 0 2.3848233610124225e-08
mutated O 0 8.461815014015883e-06
allele O 0 9.385994417243637e-06
. O 0 7.423216743518424e-07

In O 0 8.37378706819436e-07
most O 0 1.492549372983376e-08
of O 0 3.0895053182433685e-09
these O 0 9.101662534760635e-09
patients O 0 2.3456614428596367e-08
, O 0 1.2515462000095567e-09
the O 0 2.530585518911721e-09
onset O 0 8.551201062800828e-07
of O 0 9.060872052657487e-09
the O 0 3.5109385407849913e-06
disease O 0 0.24940750002861023
was O 0 0.10944356769323349
congenital O 1 0.9999983310699463
. O 0 5.283980954118306e-06

Preliminary O 0 1.2840814633818809e-05
in O 0 3.461621815858962e-07
vivo O 0 1.4883732546877582e-05
footprinting O 0 2.5413612092961557e-05
data O 0 8.739124979229018e-08
gave O 0 1.978230912413892e-08
evidence O 0 2.3701660634145583e-09
for O 0 4.983550794257496e-10
protein O 0 1.1757687268243444e-08
- O 0 6.500128790776216e-08
DNA O 0 4.10549567675389e-08
contact O 0 8.615210767004555e-09
in O 0 3.4912190916003283e-09
normal O 0 2.0592997529433887e-08
genes O 0 1.5227017868824078e-08
at O 0 3.910054502398452e-09
an O 0 2.9449409577608776e-09
Sp1 O 0 8.037784482439747e-07
consensus O 0 2.178874147773513e-08
binding O 0 1.449857656155018e-08
site O 0 3.802434633826124e-08
upstream O 0 2.0656687027553744e-08
of O 0 4.755228988351234e-10
the O 0 3.300128170735661e-09
CTG O 0 1.5656775076422491e-06
repeat O 0 8.95450966709177e-08
and O 0 3.603251474970648e-09
for O 0 3.964799877298475e-10
a O 0 3.3877707306118054e-09
significant O 0 1.6935679525431624e-09
reduction O 0 3.182783148147905e-09
of O 0 2.236489465845537e-10
this O 0 5.681122794420901e-10
interaction O 0 3.3061891002716948e-09
in O 0 3.0960116692568818e-09
cells O 0 1.3743166604740509e-08
with O 0 1.7863400758599823e-09
a O 0 5.047150253290056e-08
hypermethylated O 0 9.47068565437803e-06
DMPK O 0 5.9780477386084385e-06
gene O 0 6.726153856106976e-07
. O 0 8.268783346920827e-08
. O 0 3.8796733292656427e-07

The O 0 1.1042670848837588e-05
hemochromatosis B-Disease 1 0.9999922513961792
gene O 0 3.832806214632001e-06
product O 0 2.3374443003376655e-07
complexes O 0 6.534549612524643e-08
with O 0 7.676629110164868e-09
the O 0 1.2997110054868699e-08
transferrin O 0 9.200568911182927e-07
receptor O 0 2.6281870191269263e-07
and O 0 2.4753582295033993e-08
lowers O 0 2.551798161221086e-06
its O 0 4.36363656319827e-09
affinity O 0 2.1443741005100492e-08
for O 0 2.0500501296538687e-09
ligand O 0 1.1887726003578791e-07
binding O 0 5.962623959021585e-07
. O 0 4.4524551867652917e-07

We O 0 7.163626833062153e-06
recently O 0 2.299574134667637e-06
reported O 0 2.326196266722036e-07
the O 0 4.733603287121468e-09
positional O 0 4.265914981260721e-07
cloning O 0 7.095771081822022e-08
of O 0 2.364080042838168e-09
a O 0 3.2330419230675034e-08
candidate O 0 8.282261774184008e-07
gene O 0 4.608601102518151e-06
for O 0 1.8107564756064676e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.0651571974158287
HFE O 0 0.16844284534454346
. O 0 4.074458956893068e-06

The O 0 3.661812399968767e-07
gene O 0 7.650627367183915e-07
product O 0 1.3027555212374864e-07
, O 0 6.985025891026453e-09
a O 0 7.57621787528251e-09
member O 0 4.168149825289902e-09
of O 0 4.436572498267566e-10
the O 0 3.324273523119814e-09
major O 0 8.69507754686083e-09
histocompatibility O 0 8.19156653619757e-08
complex O 0 9.391082578247278e-09
class O 0 1.1243148634321187e-08
I O 0 1.5612700110523292e-07
- O 0 1.2537525151401496e-07
like O 0 1.3941097165570682e-08
family O 0 2.583329994365613e-08
, O 0 3.998688491435587e-09
was O 0 1.6588215601132106e-07
found O 0 3.4486502542563358e-09
to O 0 2.1737922573095148e-09
have O 0 3.862040021118673e-09
a O 0 1.0173101472332746e-08
mutation O 0 1.1904550234476119e-07
, O 0 4.488289739867923e-09
Cys O 0 1.965273440873716e-06
- O 0 8.833059723656334e-07
282 O 0 3.610157364164479e-07
- O 0 5.755496658821357e-06
- O 0 1.6985148249659687e-05
> O 0 8.343591275661311e-07
Tyr O 0 5.966895514575299e-06
( O 0 3.740535703400383e-08
C282Y O 0 1.4083217081406474e-07
) O 0 2.9475597518313634e-09
, O 0 9.00241825529946e-10
in O 0 2.3942750004835034e-09
85 O 0 2.90351884757456e-08
% O 0 5.2709148157248364e-09
of O 0 6.392421703083073e-09
patient O 0 2.815067773553892e-06
chromosomes O 0 3.060467497562058e-05
. O 0 1.416762870576349e-06

This O 0 9.84933876679861e-07
mutation O 0 3.272730282333214e-06
eliminates O 0 6.917912287462968e-07
the O 0 2.384436825764169e-08
ability O 0 5.430792171523535e-08
of O 0 4.548182719332772e-09
HFE O 0 2.1795180146000348e-05
to O 0 1.2542280103389203e-08
associate O 0 1.953152484190923e-08
with O 0 1.0283247142695018e-08
beta2 O 0 1.3847113223164342e-05
- O 0 8.882187830749899e-05
microglobulin O 0 2.2417110812966712e-05
( O 0 5.570852579239727e-08
beta2m O 0 1.1967628097409033e-06
) O 0 1.0083062385035646e-08
and O 0 7.164746573806724e-09
prevents O 0 4.9947086466772816e-08
cell O 0 8.42340568851796e-07
- O 0 9.265275366487913e-06
surface O 0 7.513143373216735e-06
expression O 0 2.2274807633948512e-06
. O 0 3.478701842141163e-07

A O 0 5.175335445528617e-06
second O 0 1.288900307372387e-06
mutation O 0 1.1266718047409086e-06
that O 0 7.667629198238046e-09
has O 0 1.2545319449941417e-08
no O 0 2.8481459413143284e-09
effect O 0 9.986216298329964e-09
on O 0 5.958656856819289e-08
beta2m O 0 3.0587993933295365e-06
association O 0 1.0641043601822275e-08
, O 0 4.162326483481138e-09
H63D O 0 1.1604513474594569e-06
, O 0 1.0523773852355589e-08
was O 0 1.2059737741765275e-07
found O 0 4.732122693695828e-09
in O 0 2.1119730408969417e-09
eight O 0 1.1733962246296414e-08
out O 0 9.131258416061883e-09
of O 0 1.3095792228412506e-09
nine O 0 3.561648611594137e-07
patients O 0 8.22347132611867e-08
heterozygous O 0 7.168905113985602e-08
for O 0 2.09556971775271e-09
the O 0 3.605205733947514e-08
C282Y O 0 3.289624146418646e-06
mutant O 0 6.319634849205613e-06
. O 0 8.827122996990511e-07

In O 0 1.4565314359060721e-06
this O 0 5.6605880871529735e-08
report O 0 6.202336066962744e-08
, O 0 6.1987499577753624e-09
we O 0 3.6710690043406657e-09
demonstrate O 0 6.164345922599068e-09
in O 0 3.42977113376719e-09
cultured O 0 5.793752961835708e-07
293 O 0 2.4296232936649176e-07
cells O 0 1.744011228765885e-07
overexpressing O 0 1.4276554338721326e-06
wild O 0 7.594508133479394e-08
- O 0 1.206049091706518e-06
type O 0 9.528917388479385e-08
or O 0 1.3609323445962218e-08
mutant O 0 5.420949378276418e-07
HFE O 0 2.9049315344309434e-06
proteins O 0 9.767116893044658e-09
that O 0 1.650475645043059e-09
both O 0 7.615373887048804e-10
the O 0 2.5012083515463246e-09
wild O 0 1.1677101241502896e-07
- O 0 9.01054863788886e-06
type O 0 2.9337309115362586e-07
and O 0 6.878794778231168e-08
H63D O 0 1.6410147509304807e-05
HFE O 0 1.2525910278782248e-05
proteins O 0 5.631104471603976e-08
form O 0 1.131407501020476e-08
stable O 0 1.3812154975312296e-07
complexes O 0 2.6941092912124986e-08
with O 0 5.681440207183641e-09
the O 0 5.97681122371796e-08
transferrin O 0 9.41665712161921e-06
receptor O 0 3.096491127507761e-06
( O 0 3.993028485638206e-07
TfR O 0 9.282228711526841e-05
) O 0 2.2241387398480583e-07
. O 0 2.902235110013862e-07

The O 0 1.6875507071745233e-06
C282Y O 0 1.712217999738641e-05
mutation O 0 4.67268864667858e-06
nearly O 0 1.831062803603345e-07
completely O 0 4.005656819572323e-07
prevents O 0 7.171065874445048e-08
the O 0 8.426448872000947e-09
association O 0 5.3345523554071406e-09
of O 0 1.0330816202497317e-09
the O 0 1.4573574347309659e-08
mutant O 0 5.056929694546852e-06
HFE O 0 1.831516965467017e-05
protein O 0 2.2565455992662464e-07
with O 0 2.7414928993607646e-08
the O 0 2.0673131473358808e-07
TfR O 0 0.0005406411364674568
. O 0 1.1370286756573478e-06

Studies O 0 2.908674105128739e-06
on O 0 4.4870250803796807e-07
cell O 0 1.7783099792723078e-06
- O 0 1.1359621794326813e-06
associated O 0 5.2970612784974946e-08
transferrin O 0 2.884465288843785e-07
at O 0 1.6766788846211966e-08
37 O 0 4.822394217285364e-08
degrees O 0 9.488998387041647e-08
C O 0 1.5297615618692362e-07
suggest O 0 1.381480885243036e-08
that O 0 8.80181427742599e-10
the O 0 4.129808939268287e-09
overexpressed O 0 9.60524516813166e-07
wild O 0 1.1084626549973109e-07
- O 0 4.396481472213054e-06
type O 0 3.6812454595747113e-07
HFE O 0 8.247129699157085e-06
protein O 0 1.9630221004263149e-07
decreases O 0 8.638530601956518e-08
the O 0 1.9476271706508896e-09
affinity O 0 7.440728033714095e-09
of O 0 2.0106016851428876e-09
the O 0 4.117934082614738e-08
TfR O 0 4.446196180651896e-05
for O 0 5.357211918521898e-08
transferrin O 0 1.5405810700030997e-05
. O 0 9.722750746732345e-07

The O 0 2.156347818527138e-06
overexpressed O 0 6.227160338312387e-05
H63D O 0 3.309518797323108e-05
protein O 0 9.340804467683483e-07
does O 0 7.260856449420316e-08
not O 0 3.6523515323239053e-09
have O 0 2.4157058575724477e-09
this O 0 4.605630321563581e-10
effect O 0 8.666433792825501e-09
, O 0 1.1596388294066173e-09
providing O 0 8.526699901700852e-10
the O 0 8.014250374444032e-10
first O 0 3.4629801248797776e-09
direct O 0 2.86952617223335e-09
evidence O 0 1.9054484656777504e-09
for O 0 4.763198724333506e-10
a O 0 1.142647843010991e-08
functional O 0 3.1532973565617795e-08
consequence O 0 2.1338474098797633e-08
of O 0 2.7555622228447874e-09
the O 0 4.01434121499733e-08
H63D O 0 0.00012981849431525916
mutation O 0 4.7501935114269145e-06
. O 0 4.074922799190972e-07

Addition O 0 1.8800508314598119e-06
of O 0 6.82797249851319e-08
soluble O 0 7.385924618574791e-07
wild O 0 7.4474883149378e-07
- O 0 5.517754834727384e-05
type O 0 3.0059029541007476e-06
HFE O 0 0.00022508301481138915
/ O 0 1.1364723832230084e-05
beta2m O 0 4.8895144573180005e-06
heterodimers O 0 2.4044095425779233e-06
to O 0 2.9179034299886553e-08
cultured O 0 7.066839771141531e-07
cells O 0 1.9188769329048228e-07
also O 0 2.3198730048079597e-08
decreased O 0 1.1018816081787008e-07
the O 0 1.4945599202675908e-09
apparent O 0 4.441953649347852e-08
affinity O 0 1.5450000390160312e-08
of O 0 9.708976955735693e-10
the O 0 8.116120220336143e-09
TfR O 0 2.367064780628425e-06
for O 0 4.692895516633655e-10
its O 0 6.473842573129218e-10
ligand O 0 6.4988245895847285e-09
under O 0 3.327585096357666e-09
steady O 0 2.3244288627211063e-07
- O 0 2.5969012540372205e-07
state O 0 1.7014551989547044e-09
conditions O 0 4.207065273931221e-08
, O 0 1.0671261652106523e-09
both O 0 8.291834441287449e-10
in O 0 4.695207778127042e-09
293 O 0 1.0175938314205268e-07
cells O 0 3.170122653273211e-08
and O 0 1.2310088060019098e-08
in O 0 6.872788560485787e-08
HeLa O 0 0.00024464275338687
cells O 0 5.1688093662960455e-06
. O 0 4.950501875100599e-07

Furthermore O 0 6.569129254785366e-06
, O 0 8.911828786040132e-08
at O 0 1.3577976964995742e-08
4 O 0 3.7611179948271456e-08
degrees O 0 1.0045160934168962e-06
C O 0 5.6757462516543455e-06
, O 0 6.310697742151206e-09
the O 0 4.7443959871884545e-09
added O 0 2.1432703078971826e-07
soluble O 0 6.271869068541491e-08
complex O 0 1.4462202102549782e-08
of O 0 1.8321836492418697e-08
HFE O 0 0.0004448149702511728
/ O 0 8.614303624199238e-06
beta2m O 0 2.639649210323114e-06
inhibited O 0 1.8509230415020284e-07
binding O 0 3.783408075719308e-08
of O 0 3.322650821147022e-09
transferrin O 0 4.480841653276002e-07
to O 0 2.6291564481084606e-08
HeLa O 0 1.20140239232569e-05
cell O 0 1.9636172510217875e-06
TfR O 0 4.279045242583379e-06
in O 0 6.057258694625034e-09
a O 0 7.652350575426681e-08
concentration O 0 3.8061427858337993e-06
- O 0 4.6096429286990315e-06
dependent O 0 4.935172341902216e-07
manner O 0 1.8483226540411124e-06
. O 0 5.318462967807136e-07

Scatchard O 0 0.00015855726087465882
plots O 0 4.887994691671338e-06
of O 0 5.214161902244996e-08
these O 0 4.222393545916248e-09
data O 0 2.2593356518996188e-08
indicate O 0 1.4644795598428573e-08
that O 0 1.198000254554188e-09
the O 0 7.050950046050275e-09
added O 0 1.7065187307707674e-07
heterodimer O 0 5.585022790910443e-07
substantially O 0 3.633780636391748e-07
reduced O 0 1.55348089947438e-08
the O 0 1.6963643822975882e-09
affinity O 0 2.5899163702547412e-08
of O 0 6.1440506016197105e-09
TfR O 0 1.569797495903913e-05
for O 0 2.755847461344274e-08
transferrin O 0 1.2917901585751679e-05
. O 0 5.744927307205216e-07

These O 0 7.120981990738073e-07
results O 0 1.222704355541282e-07
establish O 0 3.5147795784951086e-08
a O 0 1.153526696384688e-08
molecular O 0 6.14315069924487e-08
link O 0 5.810784955428971e-07
between O 0 2.1364583346894506e-07
HFE O 0 0.0010025291703641415
and O 0 6.690137155374032e-08
a O 0 9.834039360612223e-09
key O 0 4.6848597889947996e-08
protein O 0 3.0774149450962796e-08
involved O 0 3.744617060874589e-09
in O 0 5.266252323110621e-09
iron O 0 1.0526791811571456e-05
transport O 0 1.5073604586746114e-08
, O 0 2.418891975608517e-09
the O 0 3.4806408866216998e-09
TfR O 0 6.456698429246899e-06
, O 0 9.21594356384503e-09
and O 0 5.816548576120795e-09
raise O 0 8.40739300400628e-09
the O 0 5.568509542364097e-10
possibility O 0 2.9961135794565052e-09
that O 0 2.632436713057018e-09
alterations O 0 1.3178267010971467e-07
in O 0 1.559518403304594e-09
this O 0 1.0823009155558339e-09
regulatory O 0 2.8061846180094108e-08
mechanism O 0 1.7934630136551277e-07
may O 0 2.778903933631227e-07
play O 0 5.288356419441698e-09
a O 0 4.8754595916022936e-09
role O 0 1.0549518592029017e-08
in O 0 1.2063219756441868e-08
the O 0 5.44965637061523e-08
pathogenesis O 0 1.130740565713495e-05
of O 0 9.579572179063689e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 7.711433681834023e-06
. O 0 1.6911272950892453e-06

Genomic O 0 4.508843630901538e-05
organization O 0 8.072107107182092e-07
of O 0 2.0047821180924075e-08
the O 0 6.981977662690042e-08
UBE3A O 0 7.2388349508401e-05
/ O 0 3.48648109138594e-06
E6 O 0 1.0201118129771203e-05
- O 0 2.0669338482548483e-05
AP O 0 4.88270688947523e-06
gene O 0 4.1843941289698705e-07
and O 0 5.562496596667188e-08
related O 0 3.4216029121125757e-07
pseudogenes O 0 1.2086537935829256e-05
. O 0 1.7011336694849888e-06

The O 0 4.758990144182462e-06
UBE3A O 0 0.0002524251176510006
gene O 0 4.537191216513747e-06
encodes O 0 1.7053682768164435e-06
the O 0 9.787728316723587e-08
E6 O 0 5.793924628960667e-06
- O 0 7.99319695943268e-06
AP O 0 1.5657238918720395e-06
ubiquitin O 0 5.027425231673988e-07
- O 0 2.4755360072958865e-07
protein O 0 3.5303536094488663e-08
ligase O 0 3.823649308287713e-08
and O 0 1.058810195075921e-08
has O 0 2.345397476233302e-08
recently O 0 1.0784794568508005e-07
been O 0 9.629682296008468e-08
shown O 0 7.515954969505856e-09
to O 0 1.1560613577543677e-09
be O 0 1.3574377177860697e-08
mutated O 0 3.9266124076675624e-05
in O 0 0.029965514317154884
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.8248605556436814e-05
who O 0 5.525801611838688e-07
lack O 0 7.340156571444822e-08
15q11 O 0 1.7917841432790738e-06
- O 0 2.80054405266128e-06
q13 O 0 3.624024884629762e-06
deletions O 0 3.382334398338571e-06
or O 0 4.790929892806162e-07
chromosome O 0 0.00017871994350571185
15 O 0 1.6058021401477163e-06
paternal O 0 6.601600034628063e-05
uniparental B-Disease 0 0.005106221418827772
disomy I-Disease 0 0.0008410920272581279
. O 0 3.986198407801567e-06

Previous O 0 1.351252922177082e-05
UBE3A O 0 0.00011187795462319627
cDNA O 0 9.709023288451135e-06
analysis O 0 4.410943859056715e-07
has O 0 1.0617814183433438e-07
shown O 0 2.697291812125968e-08
a O 0 1.3126959963472018e-08
coding O 0 2.5786907826841343e-06
region O 0 1.7008012775932002e-07
of O 0 8.886957836296006e-09
approximately O 0 1.184337818926906e-07
2 O 0 5.680922186002135e-07
. O 0 5.93692618622299e-07

6 O 0 3.3214000723091885e-05
kb O 0 5.058650640421547e-05
and O 0 1.272743475055904e-07
a O 0 1.3701269097055047e-07
3 O 0 7.924785450086347e-07
- O 0 4.534819527179934e-05
untranslated O 0 0.00011873066978296265
region O 0 2.579785359557718e-06
( O 0 2.6001224284755153e-08
UTR O 0 1.1272672963968944e-06
) O 0 3.8573868543778644e-09
of O 0 1.5923715679377892e-09
< O 0 2.1079702605675266e-07
50 O 0 3.182110930310955e-08
bp O 0 3.6352187748889264e-07
, O 0 2.347132488367265e-09
whereas O 0 3.4733522724650356e-09
Northern O 0 8.945493235046342e-09
analysis O 0 8.75218209017703e-09
has O 0 1.1451940729045873e-08
indicated O 0 8.849728061477435e-09
mRNA O 0 9.974089998365798e-09
sizes O 0 1.6928098034441064e-08
of O 0 1.9527790495743602e-09
5 O 0 4.86645959085763e-08
- O 0 3.5108648717141477e-06
8 O 0 5.185301574783807e-07
kb O 0 2.3721635443507694e-05
. O 0 1.0763540103653213e-06

We O 0 3.6682054087577853e-06
have O 0 2.879385441190152e-08
analyzed O 0 2.9126876910368082e-08
additional O 0 6.564240262463272e-09
cDNA O 0 1.5686487131461035e-07
clones O 0 9.00068926057429e-07
and O 0 6.117168105390647e-09
provide O 0 1.3397583042973338e-09
evidence O 0 1.1812167910463245e-09
for O 0 3.4677305471575437e-10
an O 0 1.785566805523331e-09
additional O 0 3.085431643512493e-08
0 O 0 2.8788562644876947e-07
. O 0 3.9584799083058897e-07

5 O 0 1.4286606528912671e-05
kb O 0 2.4573337213951163e-05
of O 0 1.2041637376114522e-07
5 O 0 5.905062039346376e-07
- O 0 6.014422979205847e-06
UTR O 0 3.085211574216373e-05
and O 0 1.8484729480405804e-07
> O 0 2.6546140929895046e-07
2 O 0 5.204742592468392e-08
kb O 0 1.2224461443111068e-06
of O 0 1.506814228946496e-08
3 O 0 7.317189556488302e-07
- O 0 5.023365520173684e-05
UTR O 0 0.00019948036060668528
. O 0 1.4611114238505252e-06

We O 0 5.765818514191778e-06
have O 0 4.619879234724067e-08
established O 0 1.1452945258838554e-08
the O 0 2.643238961042016e-09
genomic O 0 5.433755490003023e-08
organization O 0 8.231485715270992e-09
of O 0 2.1574888542374993e-09
UBE3A O 0 5.020304797653807e-06
and O 0 7.324894912841273e-09
the O 0 1.3941302556830237e-09
sequence O 0 3.6538587266932154e-08
of O 0 4.994515467870997e-09
intron O 0 4.859032924287021e-05
- O 0 3.8254569517448545e-05
exon O 0 7.223536158562638e-06
borders O 0 6.7561131800175644e-06
. O 0 1.2896452972199768e-06

We O 0 3.054059197893366e-05
have O 0 9.967019565237933e-08
also O 0 4.682456733462459e-08
mapped O 0 8.132942070915306e-07
two O 0 1.5666625330368333e-08
highly O 0 1.3205360360757368e-08
homologous O 0 1.0274546013988584e-07
processed O 0 8.945155371975488e-08
pseudogenes O 0 5.00109592849185e-07
, O 0 2.6896987748159518e-08
UBE3AP1 O 0 3.3303886084468104e-06
and O 0 2.7636009036768883e-08
UBE3AP2 O 0 1.1621679050222156e-06
, O 0 3.3580105363029134e-09
to O 0 8.754882929729035e-10
chromosomes O 0 7.069644425428123e-08
2 O 0 5.692159632531002e-08
and O 0 3.4201637078012936e-08
21 O 0 1.3412808641533047e-07
, O 0 4.2714001224908316e-09
respectively O 0 4.125001140664608e-08
, O 0 3.4825200501131803e-09
and O 0 1.5822241294927153e-08
determined O 0 5.8395176694148176e-08
their O 0 1.1770409535927229e-08
genomic O 0 7.514695425925311e-07
organization O 0 1.566416756304534e-07
. O 0 2.5543835135977133e-07

These O 0 1.3478013443091186e-06
results O 0 2.9581084959318105e-07
will O 0 1.441621044762087e-08
form O 0 1.4782414181624404e-09
the O 0 7.543539681797995e-10
basis O 0 2.4351864968963355e-09
for O 0 9.179204618625647e-10
studies O 0 3.750578514427616e-09
of O 0 2.358396367085902e-09
mutation O 0 2.6074954462274036e-07
and O 0 2.283858613338907e-08
imprinting O 0 1.4241718417906668e-05
of O 0 3.6174668593957904e-07
UBE3A O 0 0.000803341856226325
. O 0 3.4899705951829674e-06

Mutation O 0 0.0009666995028965175
spectrum O 0 2.817780477926135e-05
and O 0 5.078147182757675e-07
genotype O 0 0.00011285558139206842
- O 0 0.002101726131513715
phenotype O 0 0.0001829985558288172
analyses O 0 7.275710345311381e-07
in O 0 1.6085826359812927e-07
Cowden B-Disease 0 0.3251650929450989
disease I-Disease 0 6.22059014858678e-05
and O 0 4.6351442506420426e-07
Bannayan B-Disease 0 0.2570553719997406
- I-Disease 1 0.9999810457229614
Zonana I-Disease 1 0.9999961853027344
syndrome I-Disease 1 0.9999682903289795
, O 0 1.27983469155879e-07
two O 0 1.2711656154351658e-06
hamartoma B-Disease 1 0.9787616729736328
syndromes I-Disease 1 0.8577253818511963
with O 0 3.906407528120326e-06
germline O 0 0.006022054702043533
PTEN O 0 0.014004969969391823
mutation O 0 0.0003724164271261543
. O 0 4.7127959987847134e-06

The O 0 4.4227257603779435e-05
tumour B-Disease 1 0.9999957084655762
suppressor O 0 0.0050053377635777
gene O 0 4.0671922761248425e-05
PTEN O 0 0.0008425451233051717
, O 0 1.221944359031113e-07
which O 0 2.0858008653590332e-08
maps O 0 2.6175237621828273e-07
to O 0 1.505631388454276e-07
10q23 O 0 2.656583092175424e-05
. O 0 8.17416207610222e-07

3 O 0 1.5798672393430024e-05
and O 0 2.487826407104876e-07
encodes O 0 7.825425996088597e-07
a O 0 1.4235874346013588e-07
403 O 0 9.616812803869834e-07
amino O 0 5.466531547426712e-07
acid O 0 4.7449049134229426e-07
dual O 0 5.007195227335615e-07
specificity O 0 1.218245870404644e-06
phosphatase O 0 0.0003529168607201427
( O 0 1.840520269524859e-07
protein O 0 4.056590228174173e-07
tyrosine O 0 2.9885811727581313e-06
phosphatase O 0 5.1267088565509766e-05
; O 0 1.2425374507074594e-07
PTPase O 0 1.725370225358347e-06
) O 0 7.875600616102929e-09
, O 0 3.976388995852176e-09
was O 0 7.020690873105195e-07
shown O 0 2.956558908806528e-08
recently O 0 8.18226055798732e-08
to O 0 2.3177355590320303e-09
play O 0 1.2059607534808947e-08
a O 0 1.9491146474592824e-08
broad O 0 8.953178110004956e-08
role O 0 8.040669996489669e-08
in O 0 5.4417000683315564e-08
human O 0 5.530346243176609e-07
malignancy B-Disease 0 0.00020143949950579554
. O 0 6.097164373386477e-07

Somatic O 0 0.0012761858524754643
PTEN O 0 0.0021759981755167246
deletions O 0 8.200569573091343e-05
and O 0 1.131336148318951e-06
mutations O 0 6.948618192836875e-06
were O 0 6.699279708755057e-08
observed O 0 1.0023584451346323e-07
in O 0 2.1302485109231384e-08
sporadic B-Disease 0 0.003018283750861883
breast I-Disease 1 0.83255535364151
, I-Disease 0 1.4942791040084558e-06
brain I-Disease 0 0.00010434777504997328
, I-Disease 0 2.3091725154245069e-07
prostate I-Disease 0 0.002704368904232979
and I-Disease 0 6.501345524156932e-06
kidney I-Disease 0 0.0022594903130084276
cancer I-Disease 0 4.03313351853285e-05
cell O 0 1.602053816895932e-05
lines O 0 8.047092705965042e-05
and O 0 3.420770511297633e-08
in O 0 1.2994631148899316e-08
several O 0 6.276321329323764e-08
primary O 0 1.698022424534429e-05
tumours B-Disease 1 0.9999997615814209
such O 0 4.7117975299215686e-08
as O 0 1.3172002581995912e-05
endometrial B-Disease 1 0.9993472695350647
carcinomas I-Disease 1 1.0
, O 0 0.18284130096435547
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9336925148963928
thyroid B-Disease 1 0.9999997615814209
tumours I-Disease 1 1.0
. O 0 7.147535598051036e-06

In O 0 6.906968792463886e-07
addition O 0 8.507036142191282e-08
, O 0 3.5221280114683395e-08
PTEN O 0 5.4817970521980897e-05
was O 0 2.5210922558471793e-06
identified O 0 6.939599472843838e-08
as O 0 4.563581068595113e-09
the O 0 4.020070498711448e-09
susceptibility O 0 5.810607603962126e-07
gene O 0 1.1205795402702279e-07
for O 0 2.893859907260321e-08
two O 0 1.44289251693408e-05
hamartoma B-Disease 1 0.9999847412109375
syndromes I-Disease 1 0.9999929666519165
Cowden B-Disease 1 0.9980762004852295
disease I-Disease 0 0.10928383469581604
( O 0 1.9448967236712633e-07
CD B-Disease 0 9.02572810446145e-06
; O 0 3.9462861423089635e-07
MIM O 0 5.541489736060612e-05
158350 O 0 1.958197799467598e-06
) O 0 1.887248757270754e-08
and O 0 5.8574435968239413e-08
Bannayan B-Disease 0 5.7369321439182386e-05
- I-Disease 0 0.00423069205135107
Zonana I-Disease 0 0.0005879990058019757
( I-Disease 0 2.154550031718827e-07
BZS I-Disease 0 5.326743576006265e-06
) I-Disease 0 2.4396882736255066e-08
or I-Disease 0 2.9057405370735978e-08
Ruvalcaba I-Disease 0 2.0380746718728915e-05
- I-Disease 0 5.637522190227173e-05
Riley I-Disease 0 8.977849938673899e-05
- I-Disease 1 0.9948110580444336
Smith I-Disease 1 0.9560026526451111
syndrome I-Disease 1 0.9998952150344849
( O 0 7.228507001855178e-07
MIM O 0 0.00012273507309146225
153480 O 0 1.2208197404106613e-05
) O 0 5.267641540740442e-07
. O 0 7.252994009832037e-07

Constitutive O 0 3.036112684640102e-05
DNA O 0 7.374596407316858e-06
from O 0 1.492807797376372e-07
37 O 0 2.728897641190997e-07
CD B-Disease 0 7.365455303443014e-07
families O 0 9.785134125195327e-08
and O 0 2.3398746051839225e-08
seven O 0 8.257246975063026e-08
BZS B-Disease 0 7.428474873449886e-06
families O 0 1.0413300799427816e-07
was O 0 4.0645676335770986e-07
screened O 0 1.30030684886151e-06
for O 0 1.2348823474894743e-07
germline O 0 0.00010205909347860143
PTEN O 0 0.0005934232613071799
mutations O 0 7.105232361936942e-05
. O 0 2.5002111669891747e-06

PTEN O 0 0.02973628230392933
mutations O 0 0.001558711752295494
were O 0 3.528957677190192e-06
identified O 0 9.603819250969536e-08
in O 0 4.746577353387238e-09
30 O 0 9.512715948289951e-09
of O 0 1.0243071946192117e-09
37 O 0 2.2760838191970834e-07
( O 0 9.071004392069426e-09
81 O 0 7.377548172371462e-08
% O 0 6.269666119607109e-09
) O 0 1.5243455386837468e-09
CD B-Disease 0 2.370457252709457e-07
families O 0 1.438594043889907e-08
, O 0 1.039065389285554e-09
including O 0 1.9304851051060723e-09
missense O 0 3.875481979775941e-06
and O 0 8.545236340751217e-08
nonsense O 0 2.3009802134765778e-06
point O 0 5.21889774063311e-07
mutations O 0 6.100904670347518e-07
, O 0 4.856164803612728e-09
deletions O 0 2.4425824562968046e-07
, O 0 7.123349909932131e-09
insertions O 0 4.119203538266447e-07
, O 0 6.592031365215689e-09
a O 0 2.1569837471702158e-08
deletion O 0 4.880007054453017e-06
/ O 0 2.501215249139932e-06
insertion O 0 1.2756516980516608e-06
and O 0 2.432799988127954e-07
splice O 0 0.00025480837211944163
site O 0 1.7577262042323127e-05
mutations O 0 4.0168433770304546e-05
. O 0 1.2736204553220887e-06

These O 0 1.1424297099438263e-06
mutations O 0 6.669320555374725e-06
were O 0 5.276268666420947e-08
scattered O 0 3.694637840112591e-08
over O 0 2.2563298784916697e-08
the O 0 9.047177229604131e-09
entire O 0 1.7247232975137194e-08
length O 0 1.173307069279872e-07
of O 0 3.542385051957808e-09
PTEN O 0 8.01886653789552e-06
, O 0 3.3563072321385334e-09
with O 0 1.2650798186797374e-09
the O 0 3.99367339198875e-09
exception O 0 6.188401791007436e-09
of O 0 1.1431507962456067e-09
the O 0 5.177609896378499e-09
first O 0 6.340815161820501e-08
, O 0 2.5771241141114842e-08
fourth O 0 2.1919163373240735e-06
and O 0 1.6593057239333575e-07
last O 0 2.4955633648460207e-07
exons O 0 4.776574860443361e-05
. O 0 1.5377464706034516e-06

A O 0 9.121753464569338e-06
hot O 0 1.5111612810869701e-05
spot O 0 2.281946308357874e-06
for O 0 4.1272123496582935e-08
PTEN O 0 6.813533400418237e-05
mutation O 0 9.833074727794155e-07
in O 0 2.0364266717365354e-08
CD B-Disease 0 1.025540132104652e-05
was O 0 1.4640712606706074e-06
identified O 0 3.02824219033937e-08
in O 0 1.957963124965545e-09
exon O 0 2.830272194387362e-07
5 O 0 6.221684856200227e-08
that O 0 5.161741589709834e-10
contains O 0 1.0360988733637555e-09
the O 0 2.859271486244097e-09
PTPase O 0 5.638863171952835e-07
core O 0 9.460914185410729e-08
motif O 0 1.2181212127870822e-07
, O 0 9.282376534081038e-10
with O 0 4.2844774950090425e-10
13 O 0 2.8573088339811648e-09
of O 0 4.1118236593362667e-10
30 O 0 1.1301824365261837e-08
( O 0 2.202027005182572e-09
43 O 0 4.713730206162836e-08
% O 0 3.4050673392016506e-09
) O 0 1.2451435438265435e-09
CD B-Disease 0 2.104958184645511e-06
mutations O 0 7.0781032945888e-07
identified O 0 5.09080209099011e-08
in O 0 4.990554192119134e-09
this O 0 3.34582033190145e-08
exon O 0 2.4148670490831137e-05
. O 0 2.0511286038527032e-06

Seven O 0 3.1549270715913735e-06
of O 0 2.443711899502432e-08
30 O 0 6.297101151631068e-08
( O 0 8.072644774870241e-09
23 O 0 4.8009280106953156e-08
% O 0 3.527908187805906e-09
) O 0 1.0268287331527404e-09
were O 0 6.449394351903948e-09
within O 0 4.5564119144358983e-10
the O 0 1.0349711088153413e-09
core O 0 9.72240172814054e-08
motif O 0 1.323196414659833e-07
, O 0 1.3111238761354116e-09
the O 0 9.589533611631396e-10
majority O 0 3.998551267869743e-09
( O 0 1.3703661538855272e-09
five O 0 1.1234739805132676e-09
of O 0 9.153695579300347e-10
seven O 0 2.5762345146063126e-08
) O 0 6.802124974392143e-10
of O 0 2.618608940796463e-10
which O 0 8.914527782621917e-09
were O 0 6.525345241925606e-08
missense O 0 8.190696462406777e-06
mutations O 0 2.56257692399231e-07
, O 0 2.707516877364924e-09
possibly O 0 1.9139434925818932e-08
pointing O 0 3.3871850746436394e-07
to O 0 2.2117421227818568e-09
the O 0 5.430768279524045e-09
functional O 0 1.2392280979156567e-08
significance O 0 1.177079234082612e-08
of O 0 3.2091167501135942e-09
this O 0 1.3246176600034687e-08
region O 0 7.19661954917683e-07
. O 0 6.963816190364014e-07

Germline O 0 0.05610034242272377
PTEN O 0 0.046210434287786484
mutations O 0 0.0021516461856663227
were O 0 4.225064913043752e-06
identified O 0 1.7518108563763235e-07
in O 0 8.425211639462304e-09
four O 0 1.0941177741585761e-08
of O 0 4.0057801520276826e-09
seven O 0 2.514738355330337e-07
( O 0 2.6453838231077498e-08
57 O 0 1.6589291362834047e-07
% O 0 1.3061375980782941e-08
) O 0 9.394915956306704e-09
BZS B-Disease 0 2.6950478968501557e-06
families O 0 7.240112864792536e-08
studied O 0 1.9422756736275915e-07
. O 0 3.3402608323740424e-07

Interestingly O 0 0.00011810532305389643
, O 0 5.068799282526015e-07
none O 0 4.2062552552124544e-08
of O 0 1.4317007579478513e-09
these O 0 1.0562545504910759e-08
mutations O 0 2.009381432799273e-06
was O 0 2.9635539249284193e-06
observed O 0 1.482729743429445e-07
in O 0 6.864558699248846e-09
the O 0 4.622082272476291e-08
PTPase O 0 1.831206100177951e-05
core O 0 2.1133175778231816e-06
motif O 0 1.2331341167737264e-05
. O 0 6.92539742885856e-07

It O 0 3.2076029583549825e-06
is O 0 9.987419957724342e-08
also O 0 4.941370335131978e-08
worthy O 0 2.187193359759476e-08
of O 0 2.3242607838369622e-09
note O 0 6.119772422152892e-08
that O 0 1.944869154613116e-09
a O 0 1.0420707852176747e-08
single O 0 1.9263890749243728e-07
nonsense O 0 1.6111355307657504e-06
point O 0 1.7171711874652829e-07
mutation O 0 1.4157050998164777e-07
, O 0 2.7833786386821657e-09
R233X O 0 1.1890208639897537e-07
, O 0 9.612172391371132e-09
was O 0 1.6910550471038732e-07
observed O 0 6.863197121731446e-09
in O 0 9.26198562289926e-10
the O 0 3.3309124347624675e-09
germline O 0 2.1229439539638406e-07
DNA O 0 2.5021067884267723e-08
from O 0 1.2838284879634898e-09
two O 0 2.4596893410944176e-09
unrelated O 0 8.506176385481012e-08
CD B-Disease 0 1.109850018110592e-05
families O 0 6.916540939982951e-08
and O 0 1.496648849297344e-08
one O 0 5.905253530613663e-08
BZS B-Disease 0 1.719481952022761e-05
family O 0 1.295735387429886e-06
. O 0 5.23885944403446e-07

Genotype O 0 0.0888637900352478
- O 0 0.02039289101958275
phenotype O 0 0.00019423369667492807
studies O 0 3.0087053914940043e-07
were O 0 3.0738752343495435e-07
not O 0 1.2090354495342126e-08
performed O 0 2.555933065195859e-07
on O 0 7.295756887515381e-08
this O 0 2.0197534755794777e-09
small O 0 1.2304524510398096e-08
group O 0 4.3496044099811115e-08
of O 0 9.552134194734663e-09
BZS B-Disease 0 1.704950955172535e-05
families O 0 3.6726680718857097e-07
. O 0 3.8303363680824987e-07

However O 0 5.082796178612625e-06
, O 0 2.060781838508774e-07
genotype O 0 1.2567177691380493e-05
- O 0 6.048217255738564e-05
phenotype O 0 7.548838311777217e-06
analysis O 0 4.293390887255555e-08
inthe O 0 2.4790542738628574e-06
group O 0 7.769285303993456e-08
of O 0 2.3510935420745227e-09
CD B-Disease 0 3.2144776014320087e-06
families O 0 2.9688722591458827e-08
revealed O 0 3.786627900126405e-08
two O 0 1.3864349668324394e-09
possible O 0 3.940916926126192e-09
associations O 0 2.4475403925805495e-09
worthy O 0 5.086936649689733e-09
of O 0 8.767616632709974e-10
follow O 0 1.1674156752405906e-08
- O 0 3.296398290331126e-06
up O 0 1.733780976564958e-07
in O 0 1.122273118880912e-08
independent O 0 1.0404328065760637e-07
analyses O 0 7.283965146598348e-07
. O 0 3.17589041287647e-07

The O 0 1.6838597503010533e-06
first O 0 6.41105714294099e-07
was O 0 7.448042538271693e-07
an O 0 9.042967263894752e-09
association O 0 1.9560268071927567e-08
noted O 0 1.7541539776289028e-08
in O 0 3.3743505767347415e-09
the O 0 6.232323990218447e-09
group O 0 2.0684403523318906e-08
of O 0 7.437346849492599e-10
CD B-Disease 0 1.452535116186482e-06
families O 0 8.739775125832239e-08
with O 0 3.8872320828886586e-07
breast B-Disease 1 0.9994462132453918
disease I-Disease 0 0.00027847610181197524
. O 0 7.315556445064431e-07

A O 0 4.815551619685721e-06
correlation O 0 3.703648644659552e-06
was O 0 1.6734539940443938e-06
observed O 0 2.2046169334544174e-08
between O 0 2.5663118297103438e-09
the O 0 1.8656201028477426e-09
presence O 0 5.2600807265434923e-08
/ O 0 9.427694749319926e-07
absence O 0 8.948974894451567e-09
of O 0 1.5845185163954056e-09
a O 0 1.3988395153319289e-07
PTEN O 0 0.00021144640049897134
mutation O 0 1.2297917919568135e-06
and O 0 1.1037196046004283e-08
the O 0 8.506237492156288e-09
type O 0 8.836946108203847e-08
of O 0 1.916295921944311e-08
breast O 0 0.000771123799495399
involvement O 0 2.5388260382896988e-06
( O 0 1.7632166304792918e-07
unaffected O 0 9.808641152631026e-06
versus O 0 4.6295073843793944e-05
benign O 0 0.007511438336223364
versus O 0 0.0035146246664226055
malignant O 1 0.8510822653770447
) O 0 7.7902427619847e-07
. O 0 7.38423409529787e-07

Specifically O 0 1.7975158925764845e-06
and O 0 4.155221233759221e-08
more O 0 2.7882991471273044e-09
directly O 0 6.1760796477017266e-09
, O 0 1.2591890863333788e-09
an O 0 3.1111422327256832e-09
association O 0 1.7045124423020752e-08
was O 0 5.924488277742057e-07
also O 0 7.415540181909819e-08
observed O 0 1.607299893180425e-08
between O 0 1.955954953558603e-09
the O 0 1.0235455816243189e-09
presence O 0 4.911121731510093e-09
of O 0 8.63213223123438e-10
a O 0 1.3655338193530042e-07
PTEN O 0 0.0005987538024783134
mutation O 0 2.3239765141624957e-05
and O 0 1.9643775885924697e-05
malignant B-Disease 1 0.999987006187439
breast I-Disease 1 0.9999934434890747
disease I-Disease 0 0.09292826056480408
. O 0 2.991826249854057e-06

Secondly O 0 0.00018575279682409018
, O 0 4.3851531472682836e-07
there O 0 4.258403052403992e-08
appeared O 0 1.5448607655343949e-06
to O 0 3.451045227365057e-09
be O 0 2.6253870188952533e-09
an O 0 1.4642749235349584e-09
interdependent O 0 1.7194141719301115e-06
association O 0 2.177378455314738e-08
between O 0 3.400013426357873e-08
mutations O 0 1.8726770179000596e-07
upstream O 0 5.032135419469341e-08
and O 0 4.429075328715726e-09
within O 0 1.369974134135532e-09
the O 0 2.8388067452311816e-09
PTPase O 0 5.365964739212359e-07
core O 0 1.0184365351051383e-07
motif O 0 2.0873933692655555e-07
, O 0 4.075565218641941e-09
the O 0 1.3516963104365232e-09
core O 0 4.108495943455637e-08
motif O 0 4.506503259449346e-08
containing O 0 2.368810259056886e-09
the O 0 1.543438377105133e-09
majority O 0 4.1114494031546656e-09
of O 0 2.139176613624727e-09
missense O 0 2.7075831894762814e-05
mutations O 0 8.221978760047932e-07
, O 0 3.96340338326695e-09
and O 0 5.784519530038779e-09
the O 0 2.0195531913458353e-09
involvement O 0 5.5529638665063885e-09
of O 0 5.064579866598251e-10
all O 0 1.1606522409834952e-09
major O 0 1.6820727921640355e-08
organ O 0 1.6850998463269207e-06
systems O 0 4.4851682901025924e-07
( O 0 1.236206337296153e-08
central O 0 2.4982917068427923e-08
nervous O 0 3.514053048547794e-07
system O 0 4.9267736557112585e-08
, O 0 3.191514252876004e-08
thyroid O 0 1.940725815074984e-05
, O 0 7.367071930275415e-08
breast O 0 0.0031601518858224154
, O 0 1.9023882487090304e-06
skin O 1 0.9861541390419006
and O 0 0.0005804318934679031
gastrointestinal O 1 0.9950137734413147
tract O 0 0.17503859102725983
) O 0 8.407346854255593e-07
. O 0 9.72011889643909e-07

However O 0 2.3329644136538263e-06
, O 0 1.9986694965723473e-08
these O 0 5.107301248585827e-10
observations O 0 1.1456222637207247e-08
would O 0 9.98593119305724e-09
need O 0 1.6494560162172434e-09
to O 0 1.7799121065920076e-09
be O 0 5.944339243058039e-09
confirmed O 0 1.6249160239567573e-08
by O 0 1.8877581442477975e-10
studying O 0 4.3282150086199067e-10
a O 0 1.1928040777320348e-09
larger O 0 2.8314091071734993e-09
number O 0 1.2918657255056587e-09
of O 0 1.174568997619474e-09
CD B-Disease 0 8.712620910955593e-06
families O 0 2.3270173699074803e-07
. O 0 1.7303551658187644e-07

Molecular O 0 0.0006646036636084318
defects O 1 0.8470366597175598
leading O 0 3.4956727290591516e-07
to O 0 1.0950886419891503e-08
human O 0 4.998606328854294e-08
complement B-Disease 0 7.456481853296282e-06
component I-Disease 0 0.35463812947273254
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
in O 0 1.6664222002304996e-08
an O 0 9.163378500431918e-09
African O 0 4.254376406720439e-08
- O 0 3.636911287685507e-06
American O 0 2.9422935199363565e-07
family O 0 5.296303697832627e-07
. O 0 1.7971235877212166e-07

Complement B-Disease 0 0.001864604651927948
component I-Disease 1 0.9349762797355652
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.7101957610066165e-06
C6D B-Disease 0 0.00016358507855329663
) O 0 2.3839191953811678e-07
was O 0 1.978625004994683e-05
diagnosed O 0 1.7187130652018823e-05
in O 0 3.896846845208302e-09
a O 0 6.023550014333523e-08
16 O 0 2.0696170111023093e-07
- O 0 3.547638243617257e-06
year O 0 3.603322085155014e-08
- O 0 5.652798336086562e-07
old O 0 4.3163237251064857e-07
African O 0 8.228582260016992e-09
- O 0 2.0364893771329662e-07
American O 0 6.266249386044365e-08
male O 0 7.636281793566013e-07
with O 0 2.8365566322463565e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999994039535522
. O 0 3.5924326766689774e-06

The O 0 4.914398687105859e-06
patients O 0 6.272758128034184e-06
father O 0 9.023895017890027e-07
and O 0 9.447642668192202e-08
two O 0 1.7862123513623374e-07
brothers O 0 0.00012159602192696184
also O 0 2.2141264821584627e-07
had O 0 1.226639710694144e-06
C6D B-Disease 0 5.676065939042019e-06
, O 0 5.478313358509013e-09
but O 0 4.055697999660879e-09
gave O 0 3.5979446977307816e-08
no O 0 4.8903698868230094e-09
history O 0 4.997927405270275e-09
of O 0 3.4039391749729475e-08
meningitis B-Disease 1 0.9999538660049438
or O 0 1.504790105855136e-07
other O 0 7.748138131091764e-08
neisserial B-Disease 0 0.004403458442538977
infection I-Disease 0 0.0001655599189689383
. O 0 8.742940735828597e-07

By O 0 3.651709334917541e-07
using O 0 2.2015899503458058e-07
exon O 0 2.0554209640977206e-06
- O 0 1.1085520554843242e-06
specific O 0 7.527204815005462e-08
polymerase O 0 1.7178473399326322e-06
chain O 0 3.2589327929599676e-06
reaction O 0 2.3364280821169814e-07
( O 0 1.9803790607397787e-08
PCR O 0 3.51846921375909e-07
) O 0 6.81256739909486e-09
/ O 0 9.192282135472851e-08
single O 0 3.408916171565579e-08
- O 0 2.809033958328655e-06
strand O 0 2.2257629552768776e-06
conformation O 0 1.8718287719821092e-07
polymorphism O 0 9.272298484575003e-08
as O 0 7.063653550964943e-10
a O 0 3.5134506415346323e-09
screening O 0 1.3108595098287878e-08
step O 0 1.2273069671664416e-08
and O 0 1.2439423935362015e-09
nucleotide O 0 1.0579461751092367e-08
sequencing O 0 3.3722145076353627e-09
of O 0 2.497765050346601e-10
target O 0 1.7041029920505935e-08
exons O 0 2.6999305191566236e-07
, O 0 2.724354075667179e-08
we O 0 5.4849422781444446e-09
determined O 0 2.6029245425718273e-09
that O 0 9.535291445317284e-10
the O 0 3.5943283904771306e-09
proband O 0 3.037923534066067e-06
was O 0 2.1953439954813803e-07
a O 0 9.172873127738512e-09
compound O 0 1.7423205633804173e-07
heterozygote O 0 4.34530079473916e-07
for O 0 9.674395506920064e-09
two O 0 1.8670418455712934e-07
C6 O 0 0.0005553200608119369
gene O 0 1.1380016985640395e-05
mutations O 0 2.1468849809025414e-05
. O 0 1.736267449814477e-06

The O 0 1.2674662457357044e-06
first O 0 3.008240696544817e-07
, O 0 1.7874043578558485e-08
1195delC O 0 1.4163047978854593e-07
located O 0 6.487789860898374e-09
in O 0 1.95463112362404e-09
exon O 0 3.6646667922468623e-07
7 O 0 5.339899757927924e-07
, O 0 8.781344540409464e-09
is O 0 1.2045716646369442e-09
a O 0 9.13606612584772e-09
novel O 0 2.543488335504662e-07
mutation O 0 1.5457023039289197e-07
, O 0 2.8501456750262832e-09
while O 0 3.2251690207374395e-09
the O 0 2.137920285250061e-09
second O 0 1.4949647209050454e-07
, O 0 4.826284261127967e-09
1936delG O 0 6.218718340278429e-08
in O 0 1.3934284837091582e-09
exon O 0 1.1786533349322781e-07
12 O 0 9.821127378017991e-08
, O 0 6.593050105863085e-09
has O 0 3.734526288212692e-08
been O 0 3.547058824437954e-08
described O 0 4.7738542008346485e-08
before O 0 4.086603055952764e-09
to O 0 5.788084234126245e-09
cause O 0 6.627902138234276e-08
C6D B-Disease 0 9.189422485178511e-07
in O 0 1.4020341554399351e-09
an O 0 1.5332216607433224e-09
unrelated O 0 4.4712198388197066e-08
African O 0 3.053093422522579e-08
- O 0 3.6042683859704994e-06
American O 0 1.3791870401291817e-07
individual O 0 9.141316326122251e-08
. O 0 2.933574023700203e-07

Both O 0 1.245553357875906e-05
mutations O 0 7.229058974189684e-05
result O 0 3.3093266438299906e-07
in O 0 1.7589725587185967e-07
premature O 0 2.0924604541505687e-05
termination O 0 9.442970622330904e-06
codons O 0 1.1405558325350285e-05
and O 0 1.0375488272984512e-06
C6 O 0 0.001214834046550095
null O 0 0.00012886217155028135
alleles O 0 2.784655589493923e-05
. O 0 4.006151812063763e-06

Allele O 0 0.00015421389252878726
- O 0 7.440130502800457e-06
specific O 0 1.7211500846769923e-07
PCR O 0 2.1452551663969643e-06
indicated O 0 1.8249907896006334e-07
that O 0 7.428897497163689e-10
the O 0 2.4308290935692867e-09
probands O 0 3.2277762329613324e-06
two O 0 2.8775633609257056e-07
brothers O 0 6.545208452735096e-05
also O 0 1.1030508062503941e-07
inherited O 0 2.182389238214455e-07
the O 0 5.04826402902836e-09
1195delC O 0 6.291686531767482e-07
mutation O 0 5.8095000809998965e-08
from O 0 1.3454868330597947e-09
their O 0 5.164334293539241e-09
heterozygous O 0 3.8561685755666986e-07
mother O 0 2.764120949905191e-07
and O 0 9.578021931133662e-09
the O 0 6.244460948323649e-09
1936delG O 0 7.558033985333168e-07
mutation O 0 1.595023633171877e-07
from O 0 2.875991889084162e-09
their O 0 2.7112287526165346e-08
homozygous O 0 9.002680599223822e-06
father O 0 5.757597705269291e-07
. O 0 4.957616894785133e-08
. O 0 1.8750250774246524e-07

PAX6 O 0 0.053240519016981125
mutations O 0 0.004646417684853077
reviewed O 0 0.00013377440336626023
. O 0 1.1430505765019916e-05

Mutations O 0 0.001992786768823862
in O 0 4.892789320365409e-07
PAX6 O 0 3.4754186344798654e-05
are O 0 2.0800957400979314e-08
responsible O 0 1.468176957786227e-08
for O 0 3.1408702305668612e-09
human O 0 9.028390479670634e-08
aniridia B-Disease 1 1.0
and O 0 3.1532665616396116e-06
have O 0 1.4345721410791157e-07
also O 0 8.815448637733425e-08
been O 0 1.040728037082772e-08
found O 0 6.852850287231149e-09
in O 0 7.683865987928584e-09
patients O 0 6.902610749648375e-08
with O 0 2.4825433797559526e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999995231628418
, O 0 4.791893957190041e-07
with O 0 0.00010978502541547641
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999972581863403
, O 0 3.2954821449493465e-07
with O 0 1.3226492683315882e-06
autosomal B-Disease 1 0.7235503196716309
dominant I-Disease 0 0.008148236200213432
keratitis I-Disease 1 0.8850120306015015
, O 0 3.1909058861856465e-07
and O 0 2.4721080649214855e-07
with O 0 8.951868721851497e-07
isolated B-Disease 1 0.8772403001785278
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 8.652843462186866e-06

No O 0 2.4888520329113817e-06
locus O 0 2.754261004156433e-06
other O 0 2.5817488591428628e-08
than O 0 1.5740488024107435e-08
chromosome O 0 4.56406314697233e-06
11p13 O 0 1.6191822851396864e-06
has O 0 1.6717777384656074e-07
been O 0 6.134673213864517e-08
implicated O 0 1.926117221273671e-07
in O 0 6.444158628937657e-08
aniridia B-Disease 1 0.9999994039535522
, O 0 7.346417163489605e-08
and O 0 8.395954864681698e-08
PAX6 O 0 4.687667569669429e-06
is O 0 4.758426896955825e-08
clearly O 0 4.341150372511038e-08
the O 0 2.2552875122983096e-09
major O 0 5.906782618581019e-09
, O 0 5.171451267216298e-09
if O 0 3.074597243468702e-09
not O 0 1.6666661384334702e-09
only O 0 1.4870418230117366e-09
, O 0 5.436012084913955e-09
gene O 0 1.7343515423817735e-07
responsible O 0 7.978383678164391e-07
. O 0 4.316307240515016e-07

Twenty O 0 2.134704845957458e-05
- O 0 1.6848311133799143e-05
eight O 0 4.0553680946686654e-07
percent O 0 8.115441829659176e-08
of O 0 2.092326534253175e-09
identified O 0 2.1167618058370863e-07
PAX6 O 0 7.170229309849674e-06
mutations O 0 5.078132403468771e-07
are O 0 4.8329900081967025e-09
C O 0 9.516826935396239e-07
- O 0 2.19971188926138e-05
T O 0 7.457363608409651e-06
changes O 0 6.727653101279429e-09
at O 0 5.345787368327137e-09
CpG O 0 3.513945898703241e-07
dinucleotides O 0 3.2002071748138405e-07
, O 0 3.300984374732252e-09
20 O 0 4.177509449476702e-09
% O 0 1.0275202910747794e-09
are O 0 2.9695090830728077e-10
splicing O 0 1.2611178590304917e-07
errors O 0 1.7009940620482666e-06
, O 0 5.471505026832801e-09
and O 0 6.752824521782941e-09
more O 0 5.882371256760166e-10
than O 0 9.500508157955778e-10
30 O 0 6.840692456933084e-09
% O 0 1.5734655800514474e-09
are O 0 6.216590020535762e-10
deletion O 0 1.8662888123799348e-07
or O 0 2.0100237918541097e-08
insertion O 0 7.397626404781477e-07
events O 0 3.6524897950585e-07
. O 0 6.207211526998435e-07

There O 0 1.0482995094207581e-06
is O 0 2.8007999475221368e-08
a O 0 5.321324181295495e-08
noticeably O 0 2.2857358999317512e-05
elevated O 0 1.1170023753948044e-05
level O 0 3.036350904039864e-08
of O 0 1.412060579575325e-09
mutation O 0 5.275343184507619e-08
in O 0 2.2001296340334875e-09
the O 0 7.039393956631557e-09
paired O 0 2.2762054641134455e-07
domain O 0 2.8578989841321345e-08
compared O 0 4.3417383466248793e-08
with O 0 2.9990065986140735e-09
the O 0 1.0248236925747278e-08
rest O 0 2.0155905389174222e-08
of O 0 1.1880086914217713e-09
the O 0 2.2146814160350914e-08
gene O 0 1.2432348057700437e-06
. O 0 5.089812020742102e-07

Increased O 0 3.2141564588528126e-05
mutation O 0 9.089606464840472e-06
in O 0 5.1287436519942275e-08
the O 0 2.1175001307938146e-08
homeodomain O 0 2.871561719075544e-06
is O 0 3.2396346938412535e-08
accounted O 0 2.3273672766777054e-08
for O 0 5.560019666894789e-10
by O 0 2.687287281588624e-09
the O 0 4.137790199365554e-08
hypermutable O 0 1.3292563380673528e-05
CpG O 0 4.77275261800969e-06
dinucleotide O 0 3.0797395993431564e-06
in O 0 5.187052209976173e-08
codon O 0 3.807584107562434e-06
240 O 0 6.134498562460067e-07
. O 0 5.477573381540424e-07

Very O 0 2.20534207073797e-06
nearly O 0 3.026395063443488e-07
all O 0 1.2397103787975539e-08
mutations O 0 6.273717758631392e-07
appear O 0 1.5805356667897286e-07
to O 0 3.5467408565637015e-08
cause O 0 6.330537303256278e-07
loss O 0 1.4235737921808322e-07
of O 0 1.0481621126601226e-09
function O 0 1.7347054903638082e-09
of O 0 4.418020116414567e-10
the O 0 5.21640730610784e-09
mutant O 0 1.0321809895685874e-06
allele O 0 1.3353331951293512e-07
, O 0 1.6865149277123237e-09
and O 0 8.698556874797703e-10
more O 0 2.6981278322679714e-10
than O 0 5.212127951459422e-10
80 O 0 2.4590889324827003e-09
% O 0 8.568158404997916e-10
of O 0 5.531987090634516e-10
exonic O 0 9.875627711153356e-07
substitutions O 0 2.19824357827747e-07
result O 0 4.3030151886114254e-08
in O 0 4.586454238619808e-08
nonsense O 0 1.202580733661307e-05
codons O 0 1.2259391041880008e-05
. O 0 1.071305291588942e-06

In O 0 3.4279818805771356e-07
a O 0 5.222821641837072e-08
gene O 0 5.957667781331111e-08
with O 0 3.6968634820055968e-09
such O 0 3.4660725400925685e-09
extraordinarily O 0 3.8500613186442934e-07
high O 0 1.0307581277402278e-07
sequence O 0 3.573153861680112e-08
conservation O 0 4.293838617996926e-09
throughout O 0 1.5516320450714716e-09
evolution O 0 3.3271536636902965e-09
, O 0 2.0865318361984464e-09
there O 0 1.8090178244278832e-09
are O 0 2.3231172541215983e-09
presumed O 0 1.952983211594983e-06
undiscovered O 0 5.310512278811075e-06
missense O 0 3.414674574742094e-05
mutations O 0 7.90191904798121e-07
, O 0 1.9814285767694173e-09
these O 0 5.866617192040735e-10
are O 0 8.637138226852414e-10
hypothesized O 0 1.0613380396762295e-07
to O 0 7.26664461936366e-09
exist O 0 5.192523300223684e-09
in O 0 1.5051389024023365e-09
as O 0 3.4401182347210124e-08
- O 0 8.859441550157499e-06
yet O 0 1.0983585951862551e-07
unidentified O 0 1.6174691381820594e-06
phenotypes O 0 2.833482540154364e-06
. O 0 6.057791779312538e-08
. O 0 2.52370938369495e-07

Genetic O 0 0.0003685030387714505
heterogeneity O 0 0.0002310343406861648
and O 0 9.973501846616273e-07
penetrance O 0 9.898946700559463e-06
analysis O 0 5.9002207564162745e-08
of O 0 4.2583359061154624e-09
the O 0 4.183579704886142e-08
BRCA1 O 0 6.51940717943944e-05
and O 0 1.1598516493904754e-06
BRCA2 O 0 4.3586060201050714e-05
genes O 0 1.054586618920439e-06
in O 0 1.3088753121337504e-06
breast B-Disease 1 0.9988133907318115
cancer I-Disease 0 0.002264059381559491
families O 0 1.4043091596249724e-06
. O 0 1.2164324516561464e-06

The O 0 0.001122978050261736
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Linkage O 0 0.0017451238818466663
Consortium O 0 3.8017158658476546e-05
. O 0 2.387897211519885e-06

The O 0 8.924635039875284e-07
contribution O 0 3.244693687065592e-07
of O 0 3.5072122983592635e-08
BRCA1 O 0 2.891628901124932e-05
and O 0 9.93906382973364e-07
BRCA2 O 0 0.0005169816431589425
to O 0 2.0100515030208044e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.00018588814418762922
assessed O 0 2.2422051415560418e-07
by O 0 4.305443113139518e-09
linkage O 0 4.819893092644634e-06
and O 0 1.3882461757930287e-07
mutation O 0 4.720199342500564e-08
analysis O 0 1.6075136777260468e-09
in O 0 1.5367555006307043e-09
237 O 0 3.1817105394793543e-08
families O 0 7.582809935513524e-09
, O 0 8.340816926022399e-10
each O 0 3.6073208309339577e-10
with O 0 6.715970002346694e-10
at O 0 8.079376279113148e-09
least O 0 8.272151852395382e-10
four O 0 2.323835124329321e-09
cases O 0 2.881515470676277e-09
of O 0 2.8721178324531138e-08
breast B-Disease 1 0.8787878155708313
cancer I-Disease 0 1.5318961231969297e-05
, O 0 3.1410380962881845e-09
collected O 0 3.912501433944726e-09
by O 0 1.2455646292153233e-08
the O 0 1.2114555829612073e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999997615814209
Linkage O 0 0.00013778936408925802
Consortium O 0 7.4697127274703234e-06
. O 0 9.171781130135059e-07

Families O 0 3.8359994505299255e-05
were O 0 4.743638442050724e-07
included O 0 1.4947630688766367e-08
without O 0 4.37175096124065e-09
regard O 0 2.6746262982157987e-09
to O 0 8.474751456155616e-10
the O 0 2.3752710909263897e-09
occurrence O 0 1.4463614661508473e-07
of O 0 8.033418907871237e-08
ovarian B-Disease 0 0.02284867875277996
or I-Disease 0 4.2492226270951505e-07
other I-Disease 0 4.2760242990880215e-07
cancers I-Disease 0 0.027348952367901802
. O 0 1.4254379721023724e-06

Overall O 0 0.0033542662858963013
, O 0 1.2537429938674904e-05
disease O 0 2.3561602574773133e-05
was O 0 9.161080924968701e-07
linked O 0 5.747064619754383e-07
to O 0 1.1366895869002747e-08
BRCA1 O 0 1.6077344753284706e-06
in O 0 4.872084957696643e-09
an O 0 2.246773433967064e-09
estimated O 0 1.9125970140976278e-08
52 O 0 1.0685936757681702e-07
% O 0 1.1882897998916064e-09
of O 0 2.5939228542881665e-10
families O 0 4.844471490628166e-09
, O 0 9.007072865330201e-10
to O 0 1.1371465991061314e-09
BRCA2 O 0 2.7917710099245596e-07
in O 0 2.714539037995678e-09
32 O 0 3.7078464742990036e-08
% O 0 7.935821444426949e-10
of O 0 2.3751337008270923e-10
families O 0 6.963356113942609e-09
, O 0 2.1381201253944937e-09
and O 0 3.313063379195569e-09
to O 0 7.879548680200799e-10
neither O 0 3.1440712255914605e-09
gene O 0 3.936874826138137e-09
in O 0 3.3435409996229737e-09
16 O 0 3.596325726107352e-08
% O 0 3.794977221360796e-09
( O 0 1.2525444015309972e-09
95 O 0 8.586649613562258e-09
% O 0 9.95622428945353e-09
confidence O 0 5.70558356116635e-08
interval O 0 1.5273256792625034e-07
[ O 0 2.5065585163019932e-08
CI O 0 8.502030368617852e-07
] O 0 6.491617199344546e-08
6 O 0 1.4218610289162825e-08
% O 0 3.2131408644886505e-09
- O 0 6.092683406677679e-07
28 O 0 5.964290608062583e-07
% O 0 4.796258057382374e-09
) O 0 1.2233004609285558e-09
, O 0 2.2955923828504865e-09
suggesting O 0 7.218353914595355e-08
other O 0 2.949732191837029e-08
predisposition O 0 5.271452391752973e-05
genes O 0 3.0884871193848085e-06
. O 0 9.704372132546268e-07

The O 0 9.197822237183573e-07
majority O 0 4.2832567714867764e-07
( O 0 3.7689169118948485e-08
81 O 0 1.2856307307629322e-07
% O 0 3.951627913778566e-09
) O 0 6.969119725752648e-10
of O 0 1.3051556502219341e-09
the O 0 7.767342253828247e-07
breast B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 2.0326436356299382e-07
were O 0 2.7231124022364384e-08
due O 0 3.485643329526056e-09
to O 0 1.1988214865255031e-08
BRCA1 O 0 1.6561043594265357e-06
, O 0 4.38049019280129e-09
with O 0 2.5378554813215715e-09
most O 0 8.676058982359791e-09
others O 0 6.786851969309282e-08
( O 0 4.751731452756758e-09
14 O 0 2.992180370142705e-08
% O 0 4.057918889799339e-09
) O 0 2.9108477850314785e-09
due O 0 1.1377090380904065e-08
to O 0 1.1469006011566307e-07
BRCA2 O 0 0.00016315325046889484
. O 0 1.030315274874738e-06

Conversely O 0 5.82947104703635e-05
, O 0 8.340665402783998e-08
the O 0 3.5651193108776624e-09
majority O 0 5.844405848165479e-09
of O 0 8.698606279722298e-10
families O 0 1.1049117176753498e-08
with O 0 1.236659130654516e-08
male B-Disease 0 2.443114453853923e-06
and I-Disease 0 5.31793034497241e-07
female I-Disease 0 1.9682029233081266e-05
breast I-Disease 1 0.5794612169265747
cancer I-Disease 0 8.949890616349876e-05
were O 0 3.4601697507241624e-07
due O 0 3.101208179145942e-08
to O 0 1.406173169016256e-07
BRCA2 O 0 0.0001994828344322741
( O 0 1.1602571703406284e-07
76 O 0 5.865940124749613e-07
% O 0 4.000094477873972e-08
) O 0 6.280608033648605e-08
. O 0 2.2310217673293664e-07

The O 0 6.700857966279727e-07
largest O 0 2.1601996991194028e-07
proportion O 0 6.232765770164406e-08
( O 0 1.3404517495985147e-08
67 O 0 3.0671193940179364e-07
% O 0 5.339051867281341e-09
) O 0 7.451005923364562e-10
of O 0 4.98667940274089e-10
families O 0 1.1270201660806833e-08
due O 0 4.9238590982270125e-09
to O 0 1.6086669774040274e-09
other O 0 1.375204838893751e-09
genes O 0 4.756131133376584e-08
was O 0 7.103116104190121e-07
found O 0 1.399758353670677e-08
in O 0 5.056281615622993e-09
families O 0 3.577079965566554e-09
with O 0 8.857981015353289e-10
four O 0 1.4460767694401966e-08
or O 0 1.566441554246012e-08
five O 0 5.092362975744891e-09
cases O 0 3.111676250000528e-09
of O 0 7.671768997852269e-09
female O 0 6.211165600689128e-05
breast B-Disease 1 0.8872473835945129
cancer I-Disease 0 6.583871436305344e-05
only O 0 1.252676895546756e-07
. O 0 3.7325185076042544e-07

These O 0 6.015685585225583e-07
estimates O 0 5.565870537793671e-07
were O 0 6.461574741933873e-08
not O 0 3.2143849804100455e-09
substantially O 0 9.970708703122e-08
affected O 0 9.638387865607001e-09
either O 0 2.71420774744513e-09
by O 0 1.5581745893555876e-09
changing O 0 2.3201605969802586e-08
the O 0 7.069412166771372e-09
assumed O 0 9.221134433801126e-08
penetrance O 0 2.130165768221559e-07
model O 0 1.890880696464592e-08
for O 0 3.506461565550012e-09
BRCA1 O 0 9.281054076382134e-07
or O 0 1.1231638730180293e-08
by O 0 1.0107492620647918e-09
including O 0 2.075790428435198e-09
or O 0 7.717960670561297e-08
excluding O 0 1.360189799015643e-06
BRCA1 O 0 0.0001563325640745461
mutation O 0 2.6264508505846607e-06
data O 0 5.591055582954141e-07
. O 0 5.989490432511957e-07

Among O 0 2.1221394490567036e-06
those O 0 6.478146730160006e-08
families O 0 5.496045218933432e-08
with O 0 7.551652458914759e-08
disease O 0 2.1026828562753508e-06
due O 0 1.03950794638763e-08
to O 0 1.4279488702584331e-08
BRCA1 O 0 5.20700905326521e-06
that O 0 1.5872075209699688e-07
were O 0 1.712941070763918e-06
tested O 0 1.367338740010382e-07
by O 0 6.514259132117672e-10
one O 0 6.780117578486511e-10
of O 0 1.4839866835369975e-10
the O 0 5.876920616820769e-10
standard O 0 5.2711159881368985e-09
screening O 0 3.3134996968442465e-09
methods O 0 3.856680752534203e-09
, O 0 2.757233996675268e-09
mutations O 0 5.926387558474744e-08
were O 0 9.425823677133849e-09
detected O 0 1.8225396303250818e-08
in O 0 8.581323984735434e-10
the O 0 2.206685500993899e-09
coding O 0 1.5698189770319004e-07
sequence O 0 2.8297476362126872e-08
or O 0 5.042259054732767e-09
splice O 0 4.5802039494446944e-07
sites O 0 1.3900738338179508e-08
in O 0 1.1723911841343693e-09
an O 0 1.8997257100750176e-09
estimated O 0 3.351587807287615e-08
63 O 0 9.741260953433084e-08
% O 0 3.5607972126427967e-09
( O 0 2.1620736312399913e-09
95 O 0 1.2543380556451211e-08
% O 0 6.253781492659982e-09
CI O 0 1.640250843593094e-06
51 O 0 4.2335489069955656e-07
% O 0 1.8701349802086042e-08
- O 0 2.8218785246281186e-06
77 O 0 3.07765617435507e-07
% O 0 2.4057658976062157e-08
) O 0 3.1363523333993726e-08
. O 0 2.1082337298139464e-07

The O 0 1.3314170246303547e-06
estimated O 0 5.562792466662358e-07
sensitivity O 0 1.3327013448360958e-06
was O 0 3.909467807261535e-07
identical O 0 6.379208628004562e-08
for O 0 1.5646490769682941e-09
direct O 0 5.472715614018853e-09
sequencing O 0 4.2964131807821104e-08
and O 0 1.6142802650165322e-08
other O 0 3.4892484457316186e-09
techniques O 0 8.375064908250351e-07
. O 0 4.256405929936591e-07

The O 0 3.482104830254684e-06
penetrance O 0 6.282392860157415e-05
of O 0 3.4846485164052865e-07
BRCA2 O 0 0.00022068819089327008
was O 0 1.1503690302561154e-06
estimated O 0 2.2522277376424427e-08
by O 0 1.502362456662354e-09
maximizing O 0 4.6339639681036715e-08
the O 0 9.54852730217226e-09
LOD O 0 1.7198739442392252e-05
score O 0 1.776986380264134e-07
in O 0 2.3693175421612978e-08
BRCA2 O 0 3.729416857822798e-05
- O 0 6.660439248662442e-05
mutation O 0 7.685201239837625e-07
families O 0 9.328368300032253e-09
, O 0 1.918072367601553e-09
over O 0 4.982878554216086e-09
all O 0 4.476935266950477e-09
possible O 0 8.18795840018538e-08
penetrance O 0 5.43900887350901e-06
functions O 0 4.5034914819552796e-07
. O 0 8.596253451287339e-07

The O 0 4.410859730796801e-07
estimated O 0 1.5404972941723827e-07
cumulative O 0 1.8521009792493714e-07
risk O 0 1.2168138141532836e-07
of O 0 1.8953580038783002e-08
breast B-Disease 0 0.08971434831619263
cancer I-Disease 0 2.7277361368760467e-05
reached O 0 6.03684100042301e-07
28 O 0 1.72138172160885e-07
% O 0 3.165329331977773e-09
( O 0 1.187768550181545e-09
95 O 0 9.025684200025808e-09
% O 0 3.7418752540929745e-09
CI O 0 4.912332656203944e-07
9 O 0 5.456354301713873e-08
% O 0 3.043109542133493e-09
- O 0 1.632745778579192e-07
44 O 0 3.265697046117566e-08
% O 0 6.86332490840158e-10
) O 0 1.699893975581901e-10
by O 0 3.015461214062043e-10
age O 0 2.9387687838777765e-09
50 O 0 1.5728535140979716e-09
years O 0 1.8958490333176314e-09
and O 0 4.283188914655511e-09
84 O 0 2.010269106733631e-08
% O 0 1.8499335396882088e-09
( O 0 1.0523688587227298e-09
95 O 0 7.340489549534368e-09
% O 0 4.474212111915676e-09
CI O 0 4.440047973730543e-07
43 O 0 1.157306570576111e-07
% O 0 4.853164981000191e-09
- O 0 9.510578280469417e-08
95 O 0 3.743133447642322e-08
% O 0 3.3848643887779417e-09
) O 0 8.243878912850278e-10
by O 0 1.0933516314537428e-09
age O 0 2.3410084537545117e-08
70 O 0 2.7744649244709763e-08
years O 0 5.6896084288382553e-08
. O 0 1.5963263422236196e-07

The O 0 3.094289422733709e-05
corresponding O 0 0.004043577704578638
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.00012146901281084865
were O 0 5.978801027595182e-07
0 O 0 1.4510245591736748e-06
. O 0 6.308690103651315e-07

4 O 0 1.2489052096498199e-05
% O 0 4.622082485639112e-07
( O 0 4.213047688494953e-08
95 O 0 6.200833979619347e-08
% O 0 2.443865732004724e-08
CI O 0 1.3139969041731092e-06
0 O 0 4.327889158162179e-08
% O 0 6.661078355563177e-09
- O 0 1.0214480283821104e-07
1 O 0 2.2757619788649208e-08
% O 0 2.149216804525622e-09
) O 0 3.725622033101672e-10
by O 0 4.0686973235004587e-10
age O 0 4.12085476853008e-09
50 O 0 3.67102681586573e-09
years O 0 1.657763704088211e-09
and O 0 5.249774837068344e-09
27 O 0 3.6073931397595516e-08
% O 0 1.878230904139855e-09
( O 0 7.212484498531069e-10
95 O 0 5.0697530618037945e-09
% O 0 2.777110763574342e-09
CI O 0 2.5201856601597683e-07
0 O 0 1.3474266147284197e-08
% O 0 2.5493680499977245e-09
- O 0 1.1939044952669065e-07
47 O 0 2.2957912904075783e-07
% O 0 2.274233468213538e-09
) O 0 6.226237303508242e-10
by O 0 6.416960296462548e-10
age O 0 2.1038045971977226e-08
70 O 0 2.3024913531344282e-08
years O 0 4.4240707097742415e-08
. O 0 1.5136792796965892e-07

The O 0 2.5696936063468456e-06
lifetime O 0 4.609950792655582e-06
risk O 0 9.085932219932147e-07
of O 0 1.239265259300737e-07
breast B-Disease 1 0.974797248840332
cancer I-Disease 0 0.000171221952768974
appears O 0 3.191682083070191e-07
similar O 0 5.698685523469749e-09
to O 0 4.295903188733519e-09
the O 0 7.307661142874622e-09
risk O 0 3.003026449732715e-08
in O 0 2.860024217454793e-09
BRCA1 O 0 8.442377179562754e-07
carriers O 0 4.586655677485396e-08
, O 0 7.524489475940754e-09
but O 0 5.4013891137572045e-09
there O 0 2.5288002802881238e-09
was O 0 8.649972471630463e-08
some O 0 2.980921343098686e-10
suggestion O 0 6.224032400581336e-09
of O 0 5.681068393492694e-10
a O 0 3.8143330272077947e-08
lower O 0 1.227222469424305e-06
risk O 0 6.106864702815074e-08
in O 0 5.116898460499897e-09
BRCA2 O 0 3.0144058200676227e-06
carriers O 0 3.865402220526448e-08
< O 0 5.735195429679152e-08
50 O 0 1.1600023164248796e-08
years O 0 3.2769831292966956e-09
of O 0 3.2375944147844393e-09
age O 0 1.5570515188301215e-07
. O 0 1.6036626959703426e-07

Eye B-Disease 1 0.9989125728607178
movement I-Disease 0 0.0010536611080169678
abnormalities I-Disease 0 0.4858449399471283
correlate O 0 6.81765959598124e-06
with O 0 7.289343670890958e-07
genotype O 0 0.003193344920873642
in O 0 5.130405497766333e-06
autosomal O 1 0.9963893890380859
dominant O 1 0.8812099695205688
cerebellar B-Disease 1 0.9999141693115234
ataxia I-Disease 1 0.9999992847442627
type I-Disease 0 0.05319313704967499
I I-Disease 0 0.0055698007345199585
. O 0 3.2457135148433736e-06

We O 0 5.5966534091567155e-06
compared O 0 1.2115154959246865e-06
horizontal O 0 0.00013576110359281301
eye O 0 0.0034240963868796825
movements O 0 9.836808203544933e-06
( O 0 7.235998822352485e-08
visually O 0 3.942032265058515e-07
guided O 0 3.3628552387199306e-07
saccades O 0 2.309016235813033e-05
, O 0 2.9322080763449776e-08
antisaccades O 0 1.252360789294471e-06
, O 0 1.2296688112201082e-08
and O 0 8.316246358219814e-09
smooth O 0 2.4619512828394363e-07
pursuit O 0 4.099373711596854e-07
) O 0 4.076552428955438e-09
in O 0 8.008138041581958e-10
control O 0 5.8220347654014404e-08
subjects O 0 2.512287800016111e-08
( O 0 7.040387384193991e-09
n O 0 1.860678366938373e-07
= O 0 3.063634892441769e-07
14 O 0 4.055173974393256e-08
) O 0 3.827274053236351e-09
and O 0 1.7283060316231058e-08
patients O 0 1.1367198737843864e-08
with O 0 8.023457453987248e-10
three O 0 6.228307203315353e-09
forms O 0 1.220229783882587e-08
of O 0 3.159582817602313e-08
autosomal O 0 0.011379708535969257
dominant O 0 0.00012309230805840343
cerebellar B-Disease 0 0.0006560200708918273
ataxias I-Disease 0 0.0001432506978744641
type I-Disease 0 4.7426706260012e-06
I I-Disease 0 1.4171887414704543e-05
spinocerebellar B-Disease 0 0.0006251244922168553
ataxias I-Disease 0 1.2496617273427546e-05
1 I-Disease 0 1.089046435254204e-07
and I-Disease 0 3.4907944979067906e-08
2 I-Disease 0 9.714839421803845e-08
( O 0 1.1814607958626766e-08
SCA1 B-Disease 0 1.0560852388152853e-06
, O 0 9.550912949407575e-09
n O 0 2.1043788933639007e-07
= O 0 3.549394307356124e-07
11 O 0 1.7049027078996914e-08
; O 0 6.44595088417077e-09
SCA2 B-Disease 0 7.439836053890758e-07
, O 0 5.2726445431972024e-09
n O 0 1.6661988411215134e-07
= O 0 2.9577159921245766e-07
10 O 0 1.2082747247177394e-08
) O 0 5.043740536336827e-09
and O 0 3.456818120639582e-08
SCA3 B-Disease 1 0.9999963045120239
/ O 0 1.0966669833578635e-05
Machado B-Disease 0 2.7799321742350003e-06
- I-Disease 0 6.462658348027617e-05
Joseph I-Disease 0 0.0002122191508533433
disease I-Disease 0 2.5158822609228082e-05
( O 0 1.452789888389816e-07
MJD B-Disease 1 0.9999765157699585
) O 0 4.8987189416038746e-08
( O 0 2.0636013786656804e-08
n O 0 1.065210994966037e-06
= O 0 2.1942985313216923e-06
16 O 0 2.6640864803084696e-07
) O 0 7.712912974966457e-08
. O 0 2.969280785691808e-07

In O 0 3.914653007086599e-06
SCA1 B-Disease 0 3.236237171222456e-05
, O 0 1.2657038439556345e-07
saccade O 0 7.278268640220631e-06
amplitude O 0 1.0499513791728532e-06
was O 0 7.024173100944608e-07
significantly O 0 4.705367757651402e-07
increased O 0 8.999627709727065e-08
, O 0 4.58085658294749e-09
resulting O 0 4.694475919109209e-08
in O 0 6.32113241749721e-08
hypermetria B-Disease 0 7.210291369119659e-05
. O 0 1.001399823508109e-06

The O 0 3.7232182421576e-06
smooth O 0 1.4016871318744961e-05
pursuit O 0 2.0732037228299305e-05
gain O 0 5.212864198256284e-05
was O 0 1.1845760127471294e-05
decreased O 0 1.338139372819569e-05
. O 0 5.969349672341195e-07

In O 0 6.018306976329768e-06
SCA2 B-Disease 0 7.736225234111771e-05
, O 0 3.346267476445064e-07
saccade O 0 2.1224235752015375e-05
velocity O 0 4.745746991829947e-06
was O 0 1.997684194066096e-06
markedly O 0 4.2387684516143054e-05
decreased O 0 1.995574166357983e-05
. O 0 9.099459816752642e-07

The O 0 1.8518567230785266e-06
percentage O 0 1.0455806886966457e-06
of O 0 8.996483558121326e-09
errors O 0 3.7533075669671234e-07
in O 0 1.6879511122169788e-08
antisaccades O 0 1.9907989553757943e-05
was O 0 2.1158546132937772e-06
greatly O 0 2.420651590284706e-08
increased O 0 1.2969523233152813e-08
and O 0 1.560182738558069e-08
was O 0 1.2563546647470503e-07
significantly O 0 5.321486540310616e-08
correlated O 0 4.81036899202536e-08
with O 0 1.6870014718506354e-08
age O 0 3.4356500577814586e-07
at O 0 8.176283472494106e-07
disease O 0 2.9219801945146173e-05
onset O 0 4.526774137048051e-05
. O 0 9.588825378159527e-07

In O 0 7.685846412641695e-07
addition O 0 5.214997145230882e-08
, O 0 4.403392761531677e-09
a O 0 6.743968938849321e-09
correlation O 0 1.0140713868622697e-07
between O 0 3.1229092201101594e-08
smooth O 0 1.8785792690323433e-06
pursuit O 0 3.4835561564250384e-06
gain O 0 3.425658860578551e-06
and O 0 1.6839409866520327e-08
the O 0 1.4982418639064576e-09
number O 0 1.6223696830408585e-09
of O 0 6.827657106356355e-09
trinucleotide O 0 2.9847142286598682e-05
repeats O 0 1.7231357560376637e-05
was O 0 1.7434704204788432e-06
found O 0 2.173145077222216e-07
. O 0 3.3430717394367093e-07

In O 0 1.1905306564585771e-05
SCA3 B-Disease 1 0.9998575448989868
, O 0 5.926025323788053e-07
gaze B-Disease 0 2.6536356017459184e-05
- I-Disease 0 5.065524601377547e-05
evoked I-Disease 0 5.361153671401553e-05
nystagmus I-Disease 0 0.0007621598779223859
was O 0 7.980263944773469e-06
often O 0 2.6868683278280514e-08
present O 0 5.435722094659923e-09
as O 0 9.783245324967993e-09
was O 0 3.305762561467418e-07
saccade O 0 1.0613982794893673e-06
hypometria O 0 2.439070613036165e-06
and O 0 5.1907438347598145e-08
smooth O 0 1.0451809657752165e-06
pursuit O 0 1.7849431515060132e-06
gain O 0 4.188333150523249e-06
was O 0 2.8078927698516054e-06
markedly O 0 3.338605893077329e-05
decreased O 0 7.881230885686819e-06
. O 0 3.614890999870113e-07

Three O 0 2.3606039576407056e-06
major O 0 3.241109141072229e-07
criteria O 0 1.232108530757614e-07
, O 0 2.306579105493256e-08
saccade O 0 2.4359555936825927e-06
amplitude O 0 1.7117460515692073e-07
, O 0 8.654209793235168e-09
saccade O 0 5.149494768375007e-07
velocity O 0 1.650234793260097e-07
, O 0 4.0289980240970635e-09
and O 0 2.1193133914465534e-09
presence O 0 3.667282921782089e-09
of O 0 2.0682815460304482e-09
gaze B-Disease 0 4.561648438539123e-06
- I-Disease 0 8.798800990916789e-06
evoked I-Disease 0 3.0477633572445484e-06
nystagmus I-Disease 0 9.522533218842e-06
, O 0 2.543015797940029e-09
permitted O 0 1.8190796646777585e-09
the O 0 1.5500939420931559e-09
correct O 0 3.5741287263135746e-08
assignment O 0 9.08912056729605e-09
of O 0 8.421319197537969e-10
90 O 0 4.405408926544396e-09
% O 0 3.6345595977316236e-10
of O 0 9.265991446349986e-11
the O 0 2.641721952301168e-09
SCA1 B-Disease 0 1.6705869256838923e-06
, O 0 1.6458042706446463e-09
90 O 0 1.548787653682382e-09
% O 0 4.249846585757666e-10
of O 0 8.260322287290123e-11
the O 0 1.9376784621272236e-09
SCA2 B-Disease 0 1.978766704269219e-06
, O 0 3.4926110892286033e-09
and O 0 3.98718835725731e-09
93 O 0 1.1203738381482253e-08
% O 0 9.631988540093062e-10
of O 0 1.2160927820303868e-10
the O 0 5.423739679599748e-09
patients O 0 2.0828588631616185e-08
with O 0 1.716630038117728e-08
SCA3 B-Disease 1 0.9999997615814209
to O 0 9.045503901461416e-09
their O 0 6.593150914113721e-09
genetically O 0 1.7151040765384096e-07
confirmed O 0 3.506751511395123e-07
patient O 0 1.736829347009916e-07
group O 0 1.0297342356579975e-07
and O 0 2.0049618854045548e-08
, O 0 6.455326051479915e-09
therefore O 0 4.146431198392975e-09
, O 0 3.5706246848121737e-09
may O 0 1.298680096795124e-08
help O 0 5.38200373156883e-09
orient O 0 7.365343321907858e-07
diagnoses O 0 3.825031853921246e-06
of O 0 4.444112189361249e-09
SCA1 B-Disease 0 5.1438441914797295e-06
, O 0 4.463404312815555e-09
SCA2 B-Disease 0 6.479827447947173e-07
, O 0 2.7224253962288003e-09
and O 0 1.923007353354933e-08
SCA3 B-Disease 1 0.9999490976333618
at O 0 2.1053780940860634e-08
early O 0 1.6910671973846547e-08
clinical O 0 4.8633786775553745e-08
stages O 0 4.4239524044087375e-08
of O 0 3.7247287476560587e-09
the O 0 2.2691676804242888e-07
diseases O 0 2.5174615075229667e-05
. O 0 6.631620408370509e-08
. O 0 4.6825198296573944e-07

Genetic O 0 4.7696019464638084e-05
basis O 0 5.571627070821705e-07
and O 0 9.082175012053995e-08
molecular O 0 1.4884124084346695e-06
mechanism O 0 7.988038305484224e-06
for O 0 8.490236723446287e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 0 0.00016276122187264264

Ventricular B-Disease 1 0.9966997504234314
fibrillation I-Disease 1 0.9982749223709106
causes O 0 4.1498005884932354e-05
more O 0 3.9732444889750695e-08
than O 0 6.329068380495073e-09
300 O 0 6.1685332397587445e-09
, O 0 1.5696888233662776e-09
000 O 0 1.3842952562015398e-08
sudden O 0 9.910548470770664e-08
deaths O 0 4.2839755565182713e-07
each O 0 1.0462850141834679e-08
year O 0 1.2788776260208579e-08
in O 0 7.433947235568894e-09
the O 0 6.450331824225941e-08
USA O 0 1.1025814274034929e-05
alone O 0 5.881299784959992e-07
. O 0 1.2058129073011514e-07

In O 0 4.1838913489300467e-07
approximately O 0 5.8301470318156134e-08
5 O 0 3.634195522295158e-08
- O 0 6.641708409915736e-07
12 O 0 6.966281773657101e-08
% O 0 1.2780136948720155e-09
of O 0 1.3977506652107508e-10
these O 0 4.2926817656052663e-10
cases O 0 1.036960739497772e-09
, O 0 1.145285088988146e-09
there O 0 1.021883577756455e-09
are O 0 1.1300481661535855e-09
no O 0 9.329097494514826e-09
demonstrable O 0 3.1388499337481335e-05
cardiac O 0 1.9668443201226182e-05
or O 0 7.123610856751839e-08
non O 0 2.2092795859407488e-07
- O 0 0.021230926737189293
cardiac O 0 0.0009553759591653943
causes O 0 2.333862596515246e-07
to O 0 2.7620188358667974e-09
account O 0 3.752854027538888e-09
for O 0 9.00173158235873e-10
the O 0 1.0456985499729399e-08
episode O 0 9.221922482538503e-06
, O 0 6.104431093945095e-08
which O 0 2.5451182494862223e-08
is O 0 3.585693741925411e-09
therefore O 0 5.94125637576326e-09
classified O 0 1.9935797013204137e-07
as O 0 9.06729565031128e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.00013210672477725893
IVF B-Disease 1 1.0
) O 0 1.8327100406168029e-06
. O 0 1.0919912938334164e-06

A O 0 6.378457328537479e-06
distinct O 0 2.284757556481054e-06
group O 0 4.2656546384023386e-07
of O 0 4.351039706307347e-08
IVF B-Disease 1 1.0
patients O 0 1.4602237570215948e-05
has O 0 2.2479453321011533e-07
been O 0 2.359616857461333e-08
found O 0 8.465804945956279e-09
to O 0 1.2585696929079404e-09
present O 0 1.997624288208044e-09
with O 0 4.790214891414735e-09
a O 0 2.053546523939076e-07
characteristic O 0 4.386442924442235e-06
electrocardiographic O 0 4.4136253563920036e-05
pattern O 0 5.9007539675803855e-05
. O 0 1.1099409675807692e-06

Because O 0 6.402448207154521e-07
of O 0 7.178630578863476e-09
the O 0 2.54633092389156e-09
small O 0 1.2606068411358251e-09
size O 0 4.633625483307924e-09
of O 0 1.3868501902436492e-09
most O 0 2.051618652743059e-09
pedigrees O 0 2.5305610051873373e-07
and O 0 8.105785376244512e-09
the O 0 1.82562109873885e-09
high O 0 4.7468510899761895e-08
incidence O 0 1.3996723282616585e-06
of O 0 4.613536663811146e-09
sudden B-Disease 0 1.7600542605578084e-06
death I-Disease 0 3.6449496292334516e-06
, O 0 6.743493319305571e-09
however O 0 1.4515448842900014e-09
, O 0 4.5808631887744866e-10
molecular O 0 8.49313774864413e-09
genetic O 0 1.9012453833511245e-08
studies O 0 1.8865100592790895e-09
of O 0 2.614248595378399e-09
IVF B-Disease 1 1.0
have O 0 8.813033787191671e-07
not O 0 1.711947739124753e-08
yet O 0 1.2018825046311576e-08
been O 0 7.283590974793697e-08
done O 0 1.8232042009458382e-07
. O 0 1.6149877524185285e-07

Because O 0 9.642497752793133e-05
IVF B-Disease 1 0.9999990463256836
causes O 0 0.001008037943392992
cardiac O 1 0.5472301244735718
rhythm O 0 0.2985922396183014
disturbance O 0 3.946328070014715e-05
, O 0 3.487334154783639e-08
we O 0 7.56753770758678e-09
investigated O 0 6.748243208676286e-08
whether O 0 1.206427846511815e-08
malfunction O 0 1.5358133396148332e-06
of O 0 2.159287859626602e-09
ion O 0 3.722358883351262e-07
channels O 0 8.664931101520779e-07
could O 0 4.6053099822529475e-07
cause O 0 1.0044943365983272e-07
the O 0 6.162419907695948e-08
disorder O 0 6.166440016386332e-06
by O 0 1.0286614893217916e-09
studying O 0 1.0657618787490719e-08
mutations O 0 1.1785038367406742e-07
in O 0 5.521132440122756e-09
the O 0 5.5844484592171284e-08
cardiac O 0 2.871568540285807e-05
sodium O 0 2.148240128008183e-06
channel O 0 6.997228410909884e-06
gene O 0 3.7717611576226773e-06
SCN5A O 0 6.377146928571165e-05
. O 0 1.6450070461360156e-06

We O 0 4.49129038315732e-06
have O 0 7.670660551184483e-08
now O 0 6.698203769417432e-09
identified O 0 3.0132621731127074e-08
a O 0 5.3563638857667684e-08
missense O 0 7.264067244250327e-05
mutation O 0 6.011470077282866e-07
, O 0 4.436760736581391e-09
a O 0 1.32045547829307e-08
splice O 0 0.00010324546019546688
- O 0 3.218582787667401e-05
donor O 0 2.361436486353341e-07
mutation O 0 1.75463824803046e-07
, O 0 2.2201191995918634e-09
and O 0 3.515998159286937e-09
a O 0 7.437524374154236e-08
frameshift O 0 0.000162243697559461
mutation O 0 2.9863423378628795e-07
in O 0 3.84335985259554e-09
the O 0 6.767730376111558e-09
coding O 0 1.3122036079948884e-06
region O 0 1.1069456462564631e-07
of O 0 5.344940934293163e-09
SCN5A O 0 1.2687151865975466e-05
in O 0 2.8221045056397998e-08
three O 0 9.520213097857777e-07
IVF B-Disease 1 1.0
families O 0 1.8650786159923882e-06
. O 0 4.5143576699047117e-07

We O 0 9.004878847918008e-06
show O 0 2.6546419462647464e-07
that O 0 3.31286775789863e-09
sodium O 0 2.949012056774336e-08
channels O 0 1.9498397563211256e-08
with O 0 2.4615853799758725e-09
the O 0 2.1065792665808658e-08
missense O 0 1.5453557352884673e-05
mutation O 0 3.885189983066084e-07
recover O 0 8.660802564008918e-08
from O 0 3.0525504346456955e-09
inactivation O 0 1.1040274472406963e-07
more O 0 5.160492033695618e-10
rapidly O 0 4.134632636265678e-09
than O 0 6.916362482733973e-10
normal O 0 4.647211948594077e-09
and O 0 4.351892624043785e-09
that O 0 1.6397506685805752e-09
the O 0 1.946566108301795e-08
frameshift O 0 0.0001093157843570225
mutation O 0 3.716024536970508e-07
causes O 0 2.664810061503431e-08
the O 0 3.0243272330920945e-09
sodium O 0 8.118941252632794e-08
channel O 0 3.09163510792132e-07
to O 0 4.214605109353897e-09
be O 0 9.953224022751783e-09
non O 0 3.655092228882495e-08
- O 0 2.2377391815098235e-06
functional O 0 1.0877619160964969e-06
. O 0 4.708851122359192e-07

Our O 0 4.90251341034309e-06
results O 0 5.300356065163214e-07
indicate O 0 1.4640417589362187e-07
that O 0 7.28740889854862e-09
mutations O 0 1.6745381969940354e-07
in O 0 5.397712499188856e-09
cardiac O 0 1.7277511688007507e-06
ion O 0 6.734510975547892e-07
- O 0 5.7932061281462666e-06
channel O 0 2.3442626115866005e-06
genes O 0 3.3209165195557944e-08
contribute O 0 2.1230961433360562e-09
to O 0 9.373504195053783e-10
the O 0 2.184690650608445e-09
risk O 0 1.5325207769478766e-08
of O 0 2.9294562331472207e-09
developing O 0 3.2417767670267494e-07
IVF B-Disease 1 0.9999997615814209
. O 0 1.2253623538072134e-07
. O 0 2.57558184557638e-07

Molecular O 0 2.569282332842704e-05
heterogeneity O 0 2.142466837540269e-05
in O 0 4.0029837578003935e-07
mucopolysaccharidosis B-Disease 0 3.568455213098787e-05
IVA I-Disease 0 0.0006303879781626165
in O 0 2.265584839733492e-07
Australia O 0 5.986326101492523e-08
and O 0 1.6402552205363463e-08
Northern O 0 1.9582037680265785e-07
Ireland O 0 9.218496188623249e-08
: O 0 2.8998592416229485e-09
nine O 0 1.8127215284380327e-08
novel O 0 9.212396889779484e-08
mutations O 0 1.1056880566684413e-07
including O 0 2.0647894505287923e-09
T312S O 0 2.3129435078317329e-07
, O 0 1.1033822744366262e-09
a O 0 4.712514378724109e-09
common O 0 1.8616043817587524e-08
allele O 0 2.1471615241352993e-07
that O 0 1.0059837407538907e-08
confers O 0 5.19702496148966e-07
a O 0 2.7800460884463973e-06
mild O 0 0.015083220787346363
phenotype O 0 0.0011019754456356168
. O 0 2.5987349090428324e-06

Mucopolysaccharidosis B-Disease 0 0.05257129296660423
IVA I-Disease 1 0.9992786049842834
( O 0 0.007829360663890839
MPS B-Disease 1 0.9999979734420776
IVA I-Disease 1 0.9999998807907104
) O 0 9.08967592749832e-07
is O 0 7.77420652298133e-08
an O 0 4.1285912288913096e-07
autosomal B-Disease 1 0.9998810291290283
recessive I-Disease 1 0.9999929666519165
lysosomal I-Disease 1 0.999349057674408
storage I-Disease 1 0.9999237060546875
disorder I-Disease 1 0.9999896287918091
caused O 0 9.340723408968188e-06
by O 0 2.1062417587813798e-08
a O 0 1.2019169844279531e-05
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999947547912598
in O 0 1.778797127371945e-07
N O 0 5.2788032007811125e-06
- O 0 6.489749921456678e-06
acetylgalactosamine O 0 9.609738299332093e-06
- O 0 1.83190823008772e-05
6 O 0 1.6649821645842167e-06
- O 0 4.008478936157189e-05
sulfate O 0 1.8279679352417588e-05
sulfatase O 0 5.4453470511361957e-05
( O 0 3.4459634434824693e-07
GALNS O 0 1.4808582818659488e-05
) O 0 2.475462679285556e-07
. O 0 3.197232842921949e-07

Previous O 0 3.5012317312066443e-06
studies O 0 5.072076803003256e-08
of O 0 6.555732401380965e-09
patients O 0 2.7866843055335266e-08
from O 0 1.616195732800918e-09
a O 0 1.3171200130557281e-08
British O 0 2.9638434284606774e-07
- O 0 9.777895684237592e-06
Irish O 0 2.681897512957221e-07
population O 0 3.930257896911371e-09
showed O 0 2.2264515564529574e-08
that O 0 2.0532656130889393e-10
the O 0 1.9358905589683673e-09
I113F O 0 5.313028168529854e-07
mutation O 0 5.6506099355146944e-08
is O 0 4.567897726737158e-10
the O 0 9.782830101556783e-10
most O 0 1.5761509875034108e-09
common O 0 8.44693381907291e-09
single O 0 4.765202845646854e-07
mutation O 0 1.79848314019182e-06
among O 0 5.290064564178465e-07
MPS B-Disease 1 0.9999130964279175
IVA I-Disease 1 1.0
patients O 0 6.818694237153977e-05
and O 0 1.2920185099574155e-07
produces O 0 3.5405571452429285e-07
a O 0 4.035961183035397e-07
severe O 0 0.00025116262258961797
clinical O 0 4.80210583191365e-05
phenotype O 0 0.0012866086326539516
. O 0 4.117755906918319e-06

We O 0 6.9743105086672585e-06
studied O 0 9.737310620039352e-07
mutations O 0 1.3868450423615286e-06
in O 0 5.9871236857134136e-09
the O 0 1.5658560670317456e-08
GALNS O 0 4.710980192612624e-06
gene O 0 1.2370819035822933e-07
from O 0 1.2835256413268326e-08
23 O 0 1.4203843079485523e-07
additional O 0 2.3233187107507547e-07
MPS B-Disease 1 0.9998313188552856
IVA I-Disease 1 1.0
patients O 0 2.1981855752528645e-05
( O 0 1.179128439332544e-08
15 O 0 1.814239958264352e-08
from O 0 2.212556582392722e-09
Australia O 0 2.7992337336968376e-09
, O 0 7.537886981268116e-10
8 O 0 3.8973002602915585e-09
from O 0 7.488991093929087e-10
Northern O 0 2.8173072763593154e-08
Ireland O 0 5.6235265333270945e-08
) O 0 1.613888467311142e-09
, O 0 2.0423526758683863e-10
with O 0 3.677851634353857e-10
various O 0 6.3356631052613466e-09
clinical O 0 8.450980999441526e-07
phenotypes O 0 1.573483314132318e-05
( O 0 5.249827239595106e-08
severe O 0 2.785079914247035e-06
, O 0 1.0620240686876059e-08
16 O 0 2.696936896029456e-08
cases O 0 2.545563537736939e-09
; O 0 3.8125418377887854e-09
intermediate O 0 3.1833780056444994e-09
, O 0 1.2304330887502601e-09
4 O 0 1.2948513372634807e-08
cases O 0 1.5247795914774542e-08
; O 0 5.304684336238097e-08
mild O 0 5.3735930123366416e-06
, O 0 1.4192165664894674e-08
3 O 0 6.690877540904694e-08
cases O 0 4.860596547473506e-08
) O 0 6.610896008396594e-08
. O 0 2.2644334762844665e-07

We O 0 1.4954638345443527e-06
found O 0 3.589712349594265e-08
two O 0 9.776063514266298e-09
common O 0 4.1037576892222205e-08
mutations O 0 1.5344123482918803e-07
that O 0 4.243611684273674e-09
together O 0 2.1108949255221887e-08
accounted O 0 3.4044067120930777e-08
for O 0 1.3572403201322913e-09
32 O 0 6.935735541446775e-08
% O 0 9.63538693277144e-10
of O 0 1.363160001544017e-10
the O 0 4.116141649745941e-09
44 O 0 9.016448387910714e-08
unrelated O 0 4.875294834505439e-08
alleles O 0 5.8742930519883885e-08
in O 0 2.1712903475190615e-08
these O 0 1.169524495026053e-07
patients O 0 1.0321288073100732e-06
. O 0 3.3213825645361794e-07

One O 0 2.8127492441853974e-06
is O 0 6.062543178586566e-08
the O 0 2.1688856932655654e-08
T312S O 0 3.156687853334006e-06
mutation O 0 5.142103987054725e-07
, O 0 4.320892976750201e-09
a O 0 9.65192814561533e-09
novel O 0 2.4385747110500233e-07
mutation O 0 3.027393802312872e-07
found O 0 1.0271289596630595e-08
exclusively O 0 3.005731130656386e-08
in O 0 5.467803987357911e-08
milder O 0 0.00041165846050716937
patients O 0 8.120139682432637e-06
. O 0 7.176469694059051e-07

The O 0 6.470478410847136e-07
other O 0 2.5856861540773934e-08
is O 0 1.140838179480852e-08
the O 0 1.1821549961155142e-08
previously O 0 2.1526031446228444e-07
described O 0 2.3814060057247843e-07
I113F O 0 7.616237098773126e-07
that O 0 8.777308657670346e-09
produces O 0 1.0068940525798098e-07
a O 0 4.509245741246559e-07
severe O 0 0.0006838847766630352
phenotype O 0 0.0005168584757484496
. O 0 1.026058725983603e-06

The O 0 1.7510536736153881e-06
I113F O 0 6.376007149810903e-06
and O 0 7.789346057052171e-08
T312S O 0 1.8774850332192727e-06
mutations O 0 6.176412057357084e-07
accounted O 0 8.036361975882755e-08
for O 0 2.840079282862007e-09
8 O 0 8.557599784353442e-08
( O 0 7.285129832723669e-09
18 O 0 4.276203569020254e-08
% O 0 3.621993593938555e-09
) O 0 9.87687487352673e-10
and O 0 7.830202264358377e-09
6 O 0 9.721419047536983e-08
( O 0 5.997924379386177e-09
14 O 0 1.4721532437533824e-08
% O 0 1.3930829823038948e-09
) O 0 4.853940027693682e-10
of O 0 6.323369605709672e-10
44 O 0 5.937396352351243e-08
unrelated O 0 5.614523956865014e-08
alleles O 0 2.6516966045164736e-07
, O 0 8.075820545627721e-08
respectively O 0 6.113123731665837e-07
. O 0 6.140281243460777e-07

The O 0 9.368040423396451e-07
relatively O 0 2.269524941311829e-07
high O 0 1.4907804768427013e-07
residual O 0 9.254812312065042e-07
GALNS O 0 6.813298114138888e-06
activity O 0 2.1541350747611432e-07
seen O 0 1.714839044097971e-07
when O 0 8.415670826877886e-09
the O 0 6.245151062955756e-09
T312S O 0 3.8348466091520095e-07
mutant O 0 2.4276619114971254e-07
cDNA O 0 2.8764713988493895e-07
is O 0 2.1859422716374866e-08
overexpressed O 0 1.3544346302296617e-06
in O 0 1.716384367966839e-08
mutant O 0 1.2589612197189126e-06
cells O 0 5.2591175858651695e-08
provides O 0 2.4216155747325274e-09
an O 0 7.863978912503455e-10
explanation O 0 6.14286710387546e-09
for O 0 1.0442310349745298e-09
the O 0 6.388426498915578e-08
mild O 0 0.0009913953253999352
phenotype O 0 8.34235324873589e-05
in O 0 3.788780844615758e-08
patients O 0 1.0667017846799354e-07
with O 0 1.0234836089750843e-08
this O 0 6.972290123030689e-08
mutation O 0 6.596193088626023e-06
. O 0 8.127615842568048e-07

The O 0 3.261209826632694e-07
distribution O 0 8.351234725978429e-08
and O 0 1.9207494261763713e-08
relative O 0 4.4408018595731846e-08
frequencies O 0 2.1188901300206453e-08
of O 0 7.859630168915999e-10
the O 0 3.895851197199818e-09
I113F O 0 3.896901148436882e-07
and O 0 2.4306077150981764e-08
T312S O 0 3.3285013500972127e-07
mutations O 0 8.14888423406046e-08
in O 0 2.5653523749724627e-09
Australia O 0 3.8569898386242585e-09
corresponded O 0 1.4875985776541256e-08
to O 0 8.482578528479223e-10
those O 0 8.663520456586582e-10
observed O 0 5.186683527114155e-09
in O 0 8.963695341535072e-10
Northern O 0 3.552719007871019e-08
Ireland O 0 1.0932525640328095e-07
and O 0 6.169556865387449e-09
are O 0 2.115193020735262e-10
unique O 0 3.5615832505442313e-10
to O 0 6.570550215023729e-10
these O 0 1.9870209644334835e-10
two O 0 9.4175889309156e-10
populations O 0 4.835608802267188e-09
, O 0 2.0945785106363246e-09
suggesting O 0 8.517227811921657e-09
that O 0 6.637802529851911e-10
both O 0 2.9879527740916956e-09
mutations O 0 1.304795915757495e-07
were O 0 6.595744395099246e-08
probably O 0 1.433745566714606e-08
introduced O 0 7.035420690471028e-09
to O 0 2.8263371643078017e-09
Australia O 0 2.5839741457645005e-09
by O 0 1.0963880914260926e-09
Irish O 0 1.928785664517818e-08
migrants O 0 1.0918767223699888e-08
during O 0 4.792106267359486e-09
the O 0 3.6923326618421015e-09
19th O 0 4.905141963718052e-07
century O 0 5.593727223640599e-07
. O 0 3.2732057775319845e-07

Haplotype O 0 0.00022780643485020846
analysis O 0 1.9673711904033553e-06
using O 0 2.853890634924028e-07
6 O 0 2.6421221832606534e-07
RFLPs O 0 5.21413198839582e-07
provides O 0 1.4953533522543694e-08
additional O 0 2.3853681252461456e-09
data O 0 1.0674687800360516e-08
that O 0 6.287242393376857e-10
the O 0 3.02820613029553e-09
I113F O 0 9.8673524462356e-07
mutation O 0 1.0669602801272049e-07
originated O 0 1.5331931280115896e-08
from O 0 1.3053323977274545e-09
a O 0 1.4739092613069715e-08
common O 0 1.0906657621490012e-07
ancestor O 0 1.2190153029223438e-06
. O 0 6.641404297624831e-07

The O 0 2.2530792875841144e-07
other O 0 1.9051586974683232e-08
9 O 0 1.2151542705396423e-07
novel O 0 1.3863144943115913e-07
mutations O 0 2.8816828034905484e-07
identified O 0 1.7444079958295333e-08
in O 0 1.7767779469934908e-09
these O 0 4.868722314199658e-09
23 O 0 2.985442506542313e-07
patients O 0 1.9692674158022783e-08
were O 0 2.0491127017407962e-08
each O 0 1.4910804813084155e-09
limited O 0 2.5952553439623216e-09
to O 0 2.2189929893556837e-09
a O 0 3.703358331108575e-08
single O 0 9.810004257815308e-07
family O 0 7.823053351785347e-07
. O 0 4.1653632365523663e-07

These O 0 2.9420269243018993e-07
data O 0 8.070031043416748e-08
provide O 0 6.607426605853561e-09
further O 0 4.898678795939304e-09
evidence O 0 3.725624253547721e-09
for O 0 1.4145162818834933e-09
extensive O 0 1.4038684525985445e-07
allelic O 0 5.138004780746996e-06
heterogeneity O 0 1.3004001630179118e-05
in O 0 1.7963951677302248e-06
MPS B-Disease 1 0.9975685477256775
IVA I-Disease 1 0.9999690055847168
in O 0 4.993337370251538e-07
British O 0 5.319408046489116e-06
- O 0 0.0006826748722232878
Irish O 0 2.611290710774483e-06
patients O 0 5.132648439598597e-08
and O 0 1.0670203609564055e-09
provide O 0 4.195530312056661e-10
evidence O 0 6.136867680694991e-10
for O 0 2.9884184016282234e-10
their O 0 3.831181150104612e-09
transmission O 0 7.8931674352134e-07
to O 0 4.473042825026141e-09
Australia O 0 5.787333279272389e-09
by O 0 1.2035037411095573e-09
British O 0 1.1597880700264795e-07
- O 0 6.259235306060873e-06
Irish O 0 3.1104707431950374e-07
migrants O 0 8.054699662807252e-08
. O 0 1.7543714037060454e-08
. O 0 9.178144466659433e-08

Identification O 0 1.165863977803383e-05
of O 0 2.819705855472421e-07
constitutional O 0 2.5451242890994763e-06
WT1 O 0 0.001019282964989543
mutations O 0 3.514999843901023e-05
, O 0 3.062886477778193e-08
in O 0 2.3953997896342116e-08
patients O 0 1.6548445103126141e-07
with O 0 1.082380407524397e-07
isolated O 0 0.0205678828060627
diffuse B-Disease 1 0.9991315007209778
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 1.361769079721853e-07
and O 0 1.0393969240851675e-08
analysis O 0 1.4409776483148562e-08
of O 0 1.9718608967878026e-08
genotype O 0 0.0015682829543948174
/ O 0 0.00027244380908086896
phenotype O 0 1.795353091438301e-05
correlations O 0 8.56942222071666e-07
by O 0 2.068652360520673e-09
use O 0 1.5975584188865355e-09
of O 0 2.064293180836785e-09
a O 0 6.707487898438558e-08
computerized O 0 1.5951673049130477e-05
mutation O 0 3.992749498138437e-06
database O 0 9.642213854021975e-07
. O 0 8.298817988361407e-07

Constitutional O 0 3.91512548958417e-05
mutations O 0 1.2900690308015328e-05
of O 0 3.7439548350448604e-08
the O 0 3.987266694593927e-08
WT1 O 0 7.908735824457835e-06
gene O 0 2.1455649346080463e-07
, O 0 7.364146625832291e-09
encoding O 0 3.679637217146592e-08
a O 0 3.1578298376189196e-07
zinc O 0 0.00036040772101841867
- O 0 5.253125345916487e-05
finger O 0 2.5634628400439397e-05
transcription O 0 3.1091479968381464e-07
factor O 0 2.9741658025272955e-08
involved O 0 1.1480896233706517e-08
in O 0 3.8929705681312043e-08
renal O 0 0.00015715100744273514
and O 0 2.1860262222617166e-07
gonadal O 0 6.567357104358962e-06
development O 0 1.363967605527705e-08
, O 0 2.7433746385696622e-09
are O 0 8.454634214949408e-10
found O 0 3.5465901326858784e-09
in O 0 2.6697895005867167e-09
most O 0 8.307985410738183e-09
patients O 0 3.5433263434470064e-08
with O 0 6.441540989499117e-08
Denys B-Disease 1 0.9999716281890869
- I-Disease 1 1.0
Drash I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
( O 0 1.3871043620383716e-06
DDS B-Disease 1 1.0
) O 0 1.2047014763538755e-07
, O 0 5.58692008212347e-08
or O 0 2.4052674234553706e-06
diffuse B-Disease 1 0.9974627494812012
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.4401404769159853e-05
DMS B-Disease 0 0.0008368618437089026
) O 0 4.4871963922332725e-08
associated O 0 5.0432717557669093e-08
with O 0 6.534910568234409e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 1.2872694242105354e-05
/ O 0 6.622192449867725e-05
or O 0 5.421246896730736e-06
Wilms B-Disease 0 0.1681545376777649
tumor I-Disease 0 0.005044124089181423
( O 0 2.1931355149718e-06
WT B-Disease 1 0.9996237754821777
) O 0 7.510110435759998e-07
. O 0 1.120177103075548e-06

Most O 0 1.4398959137906786e-05
mutations O 0 0.00023174141824711114
in O 0 1.2978031236343668e-06
DDS B-Disease 1 1.0
patients O 0 0.000598955899477005
lie O 0 2.7749049422709504e-06
in O 0 2.288079237189322e-08
exon O 0 1.7262112805838115e-06
8 O 0 3.928794853891304e-07
or O 0 1.560840523495699e-08
exon O 0 4.973528575646924e-07
9 O 0 1.6119609824727377e-07
, O 0 5.389657165011386e-09
encoding O 0 8.152242259029663e-08
zinc O 0 4.272269507055171e-05
finger O 0 0.0001251132634934038
2 O 0 3.9270153706638666e-07
or O 0 1.1950629641432897e-07
zinc O 0 1.9463233911665156e-05
finger O 0 4.414517752593383e-05
3 O 0 8.795966266461619e-08
, O 0 7.538810464779999e-09
respectively O 0 1.2415394934350843e-08
, O 0 1.0346039580610977e-09
with O 0 1.1597959259646018e-09
a O 0 1.3354885197713884e-07
hot O 0 0.00010336535342503339
spot O 0 0.0020020429510623217
( O 0 7.03129146018e-08
R394W O 0 5.233601427789836e-07
) O 0 6.901106797130296e-09
in O 0 9.177282933592323e-09
exon O 0 2.600522520879167e-06
9 O 0 2.294010755576892e-06
. O 0 9.148866979558079e-07

We O 0 2.058732434306876e-06
analyzed O 0 2.300705261859548e-07
a O 0 1.088478995825426e-08
series O 0 2.1052416698807974e-08
of O 0 3.5180238722176682e-09
24 O 0 8.774699153946131e-07
patients O 0 3.306209350739664e-08
, O 0 2.4833632927823146e-09
10 O 0 4.3636614321940215e-09
with O 0 1.3156813416514979e-08
isolated B-Disease 0 7.915154856164008e-05
DMS I-Disease 0 0.011769908480346203
( O 0 7.975206273158619e-08
IDMS B-Disease 0 5.43757732884842e-06
) O 0 8.281659802378272e-09
, O 0 3.5907652407018986e-09
10 O 0 8.621194425018075e-09
with O 0 3.657805081047627e-08
DDS B-Disease 1 1.0
, O 0 1.7610101110676624e-07
and O 0 2.2510768360461952e-08
4 O 0 6.93269299745225e-08
with O 0 1.4807005754846614e-07
urogenital B-Disease 0 0.18269221484661102
abnormalities I-Disease 1 0.9990935325622559
and O 0 3.923477379430551e-06
/ O 0 0.00024488664348609746
or O 0 1.6049514670157805e-05
WT B-Disease 1 0.9999979734420776
. O 0 3.8085975120338844e-06

We O 0 6.5353119680366945e-06
report O 0 1.0101090310854488e-06
WT1 O 0 7.227239984786138e-05
heterozygous O 0 9.102479452849366e-06
mutations O 0 1.546736029922613e-06
in O 0 2.1696676455462693e-08
16 O 0 5.417042530098115e-07
patients O 0 1.3065640303011605e-07
, O 0 5.576271000506949e-09
4 O 0 3.4369371348930144e-08
of O 0 5.765672383972742e-09
whom O 0 9.120084314417909e-07
presented O 0 1.8852706773486716e-07
with O 0 5.109961875859881e-07
IDMS B-Disease 0 0.0024252093862742186
. O 0 1.339527329946577e-06

One O 0 6.634581950493157e-06
male O 0 5.806370154459728e-06
and O 0 1.0688035700923137e-07
two O 0 2.7397220492275665e-07
female O 0 3.612859654822387e-05
IDMS B-Disease 0 0.00284253666177392
patients O 0 4.611322765413206e-06
with O 0 7.274954327840533e-07
WT1 O 0 0.01522026490420103
mutations O 0 0.0003443105088081211
underwent O 0 0.00015332202019635588
normal O 0 1.481982872064691e-05
puberty O 0 0.00023603251611348242
. O 0 3.982231191912433e-06

Two O 0 7.444232778652804e-06
mutations O 0 7.102807285264134e-05
associated O 0 1.8541049939813092e-07
with O 0 4.268551734298853e-08
IDMS B-Disease 0 8.972201612778008e-05
are O 0 6.6591221425937874e-09
different O 0 5.4329238885486575e-09
from O 0 5.8055311669136245e-09
those O 0 1.1017719181438679e-08
described O 0 2.277296061947709e-06
in O 0 1.9294536741654156e-06
DDS B-Disease 1 1.0
patients O 0 0.00021960904996376485
. O 0 1.5234707007039106e-06

No O 0 1.5653069567633793e-05
WT1 O 0 0.0008131449576467276
mutations O 0 0.00011364023521309718
were O 0 5.327773351382348e-07
detected O 0 2.0751332385771093e-07
in O 0 2.9928464151396383e-09
the O 0 4.224439464906027e-09
six O 0 6.087582704594752e-08
other O 0 2.83190733085803e-08
IDMS B-Disease 0 0.00031808321364223957
patients O 0 3.33747465219858e-07
, O 0 9.191209571213221e-09
suggesting O 0 8.542368590269689e-08
genetic O 0 1.734670860287224e-07
heterogeneity O 0 4.627480905128323e-07
of O 0 2.3787723790746895e-08
this O 0 6.192318551256903e-07
disease O 0 7.669441401958466e-05
. O 0 4.9928752332562e-07

We O 0 7.328891570068663e-06
analyzed O 0 5.99981967752683e-06
genotype O 0 0.00015616138989571482
/ O 0 0.00010075031605083495
phenotype O 0 2.0401534129632637e-05
correlations O 0 2.367615707044024e-06
, O 0 4.6751747362350216e-08
on O 0 8.405633167285487e-08
the O 0 8.649127636317644e-09
basis O 0 4.0343115514929195e-09
of O 0 7.303030957750423e-10
the O 0 9.800707800877717e-09
constitution O 0 1.3192571479692106e-08
of O 0 7.756055797614181e-10
a O 0 4.740264714087061e-08
WT1 O 0 6.453509286075132e-06
mutation O 0 4.315055690540248e-08
database O 0 5.312437600935027e-09
of O 0 1.1710546976573255e-09
84 O 0 5.54281847087168e-08
germ O 0 1.8179292737841024e-06
- O 0 1.3704650882573333e-05
line O 0 8.060041000135243e-05
mutations O 0 1.582058786198104e-07
, O 0 6.953027598122219e-10
to O 0 3.4431144046997986e-10
compare O 0 2.2062394133826047e-09
the O 0 3.866268416530261e-10
distribution O 0 2.7378235234465365e-09
and O 0 2.028451406843601e-09
type O 0 4.260724661975246e-09
of O 0 2.4097144279977556e-09
mutations O 0 1.8762487741241785e-07
, O 0 1.8276942181927325e-09
according O 0 6.713805067448675e-10
to O 0 8.079325541920923e-10
the O 0 9.187616889505534e-09
different O 0 1.650702330380227e-07
symptoms O 0 1.713456367724575e-05
. O 0 3.530027754550247e-07

This O 0 6.494663580269844e-07
demonstrated O 0 1.6728220089134993e-06
( O 0 3.818394844756767e-08
1 O 0 3.202667286927863e-08
) O 0 6.935362062421291e-09
the O 0 5.531335833808271e-09
association O 0 1.0221863355752703e-08
between O 0 1.2301989649188272e-08
mutations O 0 2.2287420620159537e-07
in O 0 3.983950058739083e-09
exons O 0 1.878115426734439e-06
8 O 0 4.6064783987276314e-07
and O 0 1.2482810518577026e-07
9 O 0 5.238534868112765e-07
and O 0 3.452367707268422e-07
DMS B-Disease 0 8.025352144613862e-05
; O 0 1.1339481353900283e-08
( O 0 1.5792384067125909e-09
2 O 0 6.974335331477732e-09
) O 0 2.1021429041923057e-09
among O 0 2.870659487896887e-09
patients O 0 6.380216799328764e-09
with O 0 7.83060549736092e-09
DMS B-Disease 0 3.200731589458883e-05
, O 0 2.0544734802285802e-09
a O 0 2.9072080298675473e-09
higher O 0 4.4396561982296134e-09
frequency O 0 1.0169066477772049e-08
of O 0 7.390667522422234e-10
exon O 0 5.94797711528372e-07
8 O 0 2.879902467611828e-07
mutations O 0 1.27970295693558e-07
among O 0 3.6028255934184017e-09
46 O 0 8.175021548595396e-08
, O 0 1.5070902747993387e-08
XY O 0 4.145524144405499e-05
patients O 0 6.50454410333623e-08
with O 0 7.244792321614568e-09
female O 0 2.009408490266651e-06
phenotype O 0 2.7000664886145387e-06
than O 0 5.134848546362036e-09
among O 0 5.805265601566134e-09
46 O 0 1.4121722813342785e-07
, O 0 1.4916444968093856e-08
XY O 0 1.4808863852522336e-05
patients O 0 3.174067231270783e-08
with O 0 1.7167928190175985e-09
sexual O 0 5.8341068864820045e-08
ambiguity O 0 2.571311483734462e-07
or O 0 1.5398832431401388e-07
male O 0 6.537256922456436e-06
phenotype O 0 1.3918580407334957e-05
; O 0 3.6863529118136285e-08
and O 0 2.5113966017897837e-08
( O 0 6.161277710248214e-09
3 O 0 1.2782241043396425e-08
) O 0 2.8979902921832945e-09
statistically O 0 3.51778410845327e-08
significant O 0 3.13666781437405e-09
evidence O 0 3.2851936726530084e-09
that O 0 8.643850080147786e-09
mutations O 0 1.0097134151010323e-07
in O 0 3.0495825864562676e-09
exons O 0 1.7567841723575839e-06
8 O 0 2.9759090125480725e-07
and O 0 7.34709004746037e-08
9 O 0 1.0966775931819939e-07
preferentially O 0 7.740501217767815e-08
affect O 0 1.3580386593048388e-08
amino O 0 2.0006986289899942e-08
acids O 0 3.8574605731866995e-09
with O 0 3.388324620878791e-10
different O 0 1.2476230049074388e-09
functions O 0 1.2303678964542542e-08
. O 0 2.007985244745214e-08
. O 0 1.4824115623923717e-07

The O 0 8.190727385226637e-06
185delAG O 0 0.00013096047041472048
BRCA1 O 0 0.00020945907454006374
mutation O 0 7.0379992394009605e-06
originated O 0 2.002842904857971e-07
before O 0 5.8866613805719226e-09
the O 0 9.220370578155723e-10
dispersion O 0 4.211119630781468e-08
of O 0 1.0294800567578477e-09
Jews O 0 2.6552969600857068e-08
in O 0 2.4049939817416544e-09
the O 0 5.5715081437313074e-09
diaspora O 0 5.0105285254176124e-08
and O 0 4.9399567103591835e-08
is O 0 9.832781699969928e-09
not O 0 2.631663775787274e-09
limited O 0 1.105198421669229e-08
to O 0 3.524096925389131e-08
Ashkenazim O 0 3.179539635311812e-05
. O 0 5.000904934604478e-07

The O 0 8.972638170234859e-07
185delAG O 0 3.2712028769310564e-05
mutation O 0 3.137458406854421e-06
in O 0 4.2335244643254555e-08
BRCA1 O 0 6.194572961248923e-06
is O 0 3.939776505035297e-08
detected O 0 2.2762618812066648e-07
in O 0 1.4584335517042746e-08
Ashkenazi O 0 2.9860054837627104e-06
Jews O 0 2.8181242228697556e-08
both O 0 4.212442838991137e-09
in O 0 3.6923061941251945e-08
familial B-Disease 0 0.005172650795429945
breast I-Disease 1 0.9999803304672241
and I-Disease 1 0.9997435212135315
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 7.276050268956169e-07
in O 0 1.0078005097113873e-08
the O 0 1.4673426917966026e-08
general O 0 3.104919343854817e-08
population O 0 1.1074905614805175e-07
. O 0 2.574511199782137e-07

All O 0 4.278706455806969e-06
tested O 0 3.239902525820071e-06
Ashkenazi O 0 7.863647624617442e-06
mutation O 0 5.631135309158708e-07
carriers O 0 4.373896800302646e-08
share O 0 1.6894423637836553e-08
the O 0 2.293076173387476e-09
same O 0 1.137064664646914e-08
allelic O 0 9.8559257821762e-07
pattern O 0 9.326196050096769e-06
at O 0 7.610415764247591e-08
the O 0 1.0350883883347706e-07
BRCA1 O 0 7.334606198128313e-05
locus O 0 4.363792686490342e-05
. O 0 2.2028825696907006e-06

Our O 0 3.1566487450618297e-06
previous O 0 2.7946745717599697e-07
study O 0 3.212266008745246e-08
showed O 0 2.156058656055393e-07
that O 0 2.437616997141845e-09
this O 0 3.6133203096255784e-09
Ashkenazi O 0 6.850945737824077e-06
mutation O 0 6.665604814770631e-07
also O 0 4.359853633673083e-08
occurs O 0 4.816756771219843e-09
in O 0 1.6837732319530119e-09
Iraqi O 0 8.405649509768409e-08
Jews O 0 1.583830488982585e-08
with O 0 9.729851369044695e-10
a O 0 2.2802154830969812e-08
similar O 0 1.2962529183369043e-07
allelic O 0 3.305771679151803e-05
pattern O 0 0.00011469634773675352
. O 0 1.512794597147149e-06

We O 0 5.560916633839952e-06
extended O 0 3.1639311259823444e-07
our O 0 9.863493133366319e-09
analysis O 0 7.765726728337086e-09
to O 0 1.0717096099455148e-09
other O 0 1.4724164110191396e-09
non O 0 1.1959347290257938e-08
- O 0 3.734889730822033e-07
Ashkenazi O 0 4.458782143501594e-07
subsets O 0 5.87894497527941e-08
354 O 0 7.525081002768275e-08
of O 0 1.5729075819592708e-09
Moroccan O 0 7.25848110505467e-07
origin O 0 1.3296954648467363e-08
, O 0 4.982489087979047e-09
200 O 0 1.389623260905637e-08
Yemenites O 0 5.418613113761239e-07
and O 0 1.6566897187431096e-08
150 O 0 2.695923839723946e-08
Iranian O 0 2.1671039007742365e-07
Jews O 0 3.610938961173815e-07
. O 0 3.131191306238179e-07

Heteroduplex O 0 0.00032408343395218253
analysis O 0 1.450234663025185e-06
complemented O 0 1.1200050948900753e-06
by O 0 1.020528461737058e-08
direct O 0 1.687207529244006e-08
DNA O 0 1.6485454068515537e-07
sequencing O 0 8.782554772324147e-08
of O 0 7.25509474719388e-09
abnormally O 0 1.1758515938709024e-06
migrating O 0 7.13804126917239e-08
bands O 0 3.4827317563213e-07
were O 0 4.770568295953126e-08
employed O 0 5.815752501803217e-07
. O 0 3.1428859870175074e-07

Four O 0 8.110573617159389e-07
of O 0 1.8340051255449907e-08
Moroccan O 0 1.8308652443010942e-06
origin O 0 2.8256055273345737e-08
( O 0 4.016666999007157e-09
1 O 0 2.482292815741971e-09
. O 0 7.496908649429201e-10
1 O 0 5.187979379428498e-09
% O 0 3.926151848077097e-09
) O 0 8.548521335249859e-10
and O 0 1.7325637813314643e-08
none O 0 6.886511805248574e-09
of O 0 2.890955252965455e-10
the O 0 8.460704137291941e-09
Yemenites O 0 1.5732466636109166e-06
or O 0 1.9340388845989764e-08
Iranians O 0 1.1143005451685895e-07
was O 0 1.0581906906281802e-07
a O 0 7.691050463165539e-09
carrier O 0 4.086675176040444e-08
of O 0 1.65612978886287e-09
the O 0 4.703626999003063e-08
185delAG O 0 2.0355106244096532e-05
mutation O 0 4.660511876863893e-06
. O 0 4.526627037648723e-07

BRCA1 O 0 0.0008763427613303065
allelic O 0 0.00013279034465085715
patterns O 0 0.00010985958215314895
were O 0 1.0643357200024184e-06
determined O 0 5.3005475564305016e-08
for O 0 1.1959021550822513e-09
four O 0 8.994973654807836e-09
of O 0 1.7189815126883445e-09
these O 0 4.116267326992329e-09
individuals O 0 8.318828403908185e-10
and O 0 1.0783982595796715e-09
for O 0 5.114202950018409e-10
12 O 0 4.370550144017216e-09
additional O 0 3.4691942651932095e-09
non O 0 3.1961317148443413e-08
- O 0 2.3144891656556865e-06
Ashkenazi O 0 4.188485036138445e-06
185delAG O 0 8.770967383497918e-07
mutation O 0 4.050366726460197e-07
carriers O 0 9.928768207601024e-08
who O 0 3.0238334147725254e-07
had O 0 8.811576117295772e-05
breast B-Disease 1 0.9999933242797852
/ I-Disease 1 0.9999951124191284
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 4.051528321724618e-06

Six O 0 1.0660287443897687e-05
non O 0 1.902861754388141e-06
- O 0 0.00010695862874854356
Ashkenazi O 0 8.262950723292306e-05
individuals O 0 1.2526787607214374e-08
shared O 0 1.1156355839148091e-08
the O 0 9.164234704428509e-09
common O 0 5.863468643951819e-08
Ashkenazi O 0 4.969430847268086e-06
haplotype O 0 4.777083177032182e-06
, O 0 1.4395931557942276e-08
four O 0 2.3430320794659565e-08
had O 0 2.934833389645064e-07
a O 0 1.2597374698941621e-08
closely O 0 7.380996436268106e-08
related O 0 1.4946490267675472e-08
pattern O 0 7.158422704378609e-06
, O 0 2.0944838752257056e-08
and O 0 8.319021915781377e-09
the O 0 7.3418475743380895e-09
rest O 0 3.439009432781859e-08
( O 0 6.429668353291618e-09
n O 0 3.32677501546641e-07
= O 0 8.461884135613218e-07
6 O 0 1.0532030358945121e-07
) O 0 6.185286505200338e-09
displayed O 0 5.7934109065627126e-08
a O 0 5.9247600603384853e-08
distinct O 0 1.0241377594866208e-06
BRCA1 O 0 7.877385360188782e-05
allelic O 0 0.00011835346231237054
pattern O 0 0.00047275613178499043
. O 0 5.081720701127779e-06

We O 0 3.4012700780294836e-06
conclude O 0 4.3059219478891464e-07
that O 0 1.359474399720284e-08
the O 0 1.9632445003026078e-08
185delAG O 0 2.391684756730683e-05
BRCA1 O 0 0.00017341924831271172
mutation O 0 2.660443215063424e-06
occurs O 0 1.5956558740981563e-08
in O 0 6.230502225257339e-10
some O 0 1.5242059836495514e-09
non O 0 1.7133524821133506e-08
- O 0 2.1483958789758617e-06
Ashkenazi O 0 1.8003501054408844e-06
populations O 0 1.7151441156215697e-08
at O 0 8.835072229373964e-09
rates O 0 2.411039723426711e-08
comparable O 0 6.946429653709174e-09
with O 0 1.3702590173636509e-09
that O 0 4.586058199862464e-09
of O 0 2.493464634767406e-08
Ashkenazim O 0 6.582665810128674e-05
. O 0 6.799665470680338e-07

The O 0 1.1213796824449673e-06
majority O 0 2.453263050483656e-07
of O 0 6.078368475215257e-09
Jewish O 0 2.730977541887114e-07
185delAG O 0 1.787772930583742e-06
mutation O 0 4.2110153231078584e-07
carriers O 0 1.735348575948592e-08
have O 0 1.994369336344448e-09
a O 0 4.519170815342477e-09
common O 0 1.599300070154186e-08
allelic O 0 1.5398186405946035e-06
pattern O 0 2.1835601728525944e-05
, O 0 1.2460231957334145e-08
supporting O 0 1.2374141711291031e-08
the O 0 5.3745670136606805e-09
founder O 0 5.394658231239191e-08
effect O 0 8.64052118743075e-09
notion O 0 5.178795170479589e-09
, O 0 1.8056189876602957e-09
but O 0 1.5934167318931713e-09
dating O 0 1.1565558288850752e-08
the O 0 2.6691326926453485e-09
mutations O 0 3.7000329911052177e-08
origin O 0 1.1639955665998514e-09
to O 0 7.699956228179872e-10
an O 0 1.510493841117011e-09
earlier O 0 2.2951427425255133e-08
date O 0 5.110580758582728e-08
than O 0 3.861023500917327e-09
currently O 0 1.6445437012180264e-08
estimated O 0 5.6806843673484764e-08
. O 0 1.349120424265493e-07

However O 0 2.4485068479407346e-06
, O 0 3.489330069328389e-08
the O 0 4.405854348021876e-09
different O 0 7.09346759109053e-09
allelic O 0 1.2602957895069267e-06
pattern O 0 6.763126748410286e-06
at O 0 1.0363172009419941e-07
the O 0 2.5765539035660368e-08
BRCA1 O 0 6.930313702468993e-06
locus O 0 9.267812970392697e-07
even O 0 2.7115079959116883e-08
in O 0 2.646654229110368e-09
some O 0 1.4935624959022675e-09
Jewish O 0 5.125712121412107e-08
mutation O 0 7.071842134109829e-08
carriers O 0 8.422126995810686e-09
, O 0 2.150229549968685e-09
might O 0 7.59588125731625e-09
suggest O 0 4.0042755777847105e-09
that O 0 1.847591968306972e-09
the O 0 9.115075805254946e-09
mutation O 0 4.672179727549519e-07
arose O 0 5.0987317479211924e-08
independently O 0 6.67512196628195e-08
. O 0 3.3402091759171526e-08
. O 0 1.7473976754445175e-07

Crystal O 0 0.00012591083941515535
structure O 0 1.4454144547926262e-06
of O 0 3.1839991976312376e-08
the O 0 3.43223746313015e-07
hemochromatosis B-Disease 1 1.0
protein O 0 9.906530067382846e-06
HFE O 0 0.0002566435723565519
and O 0 1.5227314520416257e-07
characterization O 0 1.376077278791854e-07
of O 0 4.255802821262478e-09
its O 0 1.2318237985198266e-08
interaction O 0 5.6117830382618195e-08
with O 0 5.111643375244057e-08
transferrin O 0 1.3567950190918054e-05
receptor O 0 6.442760422942229e-06
. O 0 7.57341695134528e-07

HFE O 0 0.0028612115420401096
is O 0 7.356266564784164e-07
an O 0 3.597087072648719e-08
MHC O 0 2.667483158802497e-06
- O 0 1.945363692357205e-06
related O 0 2.754428685136645e-08
protein O 0 3.1354311147424596e-08
that O 0 1.6478177711221065e-09
is O 0 1.3418477440296783e-09
mutated O 0 7.549692782049533e-08
in O 0 1.1873049210464615e-08
the O 0 2.685355298126524e-07
iron B-Disease 1 0.9943853616714478
- I-Disease 1 0.9999943971633911
overload I-Disease 1 0.9999834299087524
disease I-Disease 1 0.9986372590065002
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 8.335117308888584e-05

HFE O 0 0.0028746472671628
binds O 0 7.324988109758124e-05
to O 0 1.3104090612614527e-06
transferrin O 0 2.1312080207280815e-05
receptor O 0 6.582248715858441e-06
( O 0 2.408838497558463e-07
TfR O 0 3.374958032509312e-05
) O 0 1.0052549015426848e-08
and O 0 7.835685877921605e-09
reduces O 0 3.472128540238373e-08
its O 0 1.8303455417978398e-09
affinity O 0 1.1352509154960444e-08
for O 0 2.318610858864645e-09
iron O 0 1.2759456694766413e-05
- O 0 2.0802326616831124e-06
loaded O 0 2.9062206863272877e-07
transferrin O 0 7.026169441815e-07
, O 0 1.4776500911750645e-08
implicating O 0 2.466840214765398e-06
HFE O 0 9.563635103404522e-05
in O 0 2.946317181340419e-07
iron O 0 0.0017565563321113586
metabolism O 0 3.9224505599122494e-05
. O 0 9.559488489685464e-07

The O 0 1.1078228453698102e-05
2 O 0 2.453645720379427e-05
. O 0 3.650689677670016e-06

6 O 0 1.8640668713487685e-05
A O 0 1.0399768370916718e-06
crystal O 0 1.0969388313242234e-05
structure O 0 2.1723722909428034e-07
of O 0 1.3427162492973821e-08
HFE O 0 0.00023567225434817374
reveals O 0 6.51160064535361e-07
the O 0 3.2159550578114704e-09
locations O 0 4.1751139434609286e-08
of O 0 6.88777532786844e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 1.9306504327687435e-05
and O 0 4.599007041861114e-08
a O 0 1.0933734984064358e-07
patch O 0 0.007948928512632847
of O 0 3.4883452570966256e-08
histidines O 0 4.812764927919488e-06
that O 0 1.8949894098341247e-08
could O 0 3.1891350005253116e-08
be O 0 2.8353974723671627e-09
involved O 0 5.3156203883020225e-09
in O 0 1.9049807065130153e-08
pH O 0 9.647469596529845e-06
- O 0 3.291384700787603e-06
dependent O 0 2.625236277253862e-07
interactions O 0 3.675899051813758e-07
. O 0 2.3799302084626106e-07

We O 0 8.844187505019363e-06
also O 0 1.8609303253924736e-07
demonstrate O 0 8.599241141382663e-08
that O 0 1.889467604598849e-08
soluble O 0 8.173024070856627e-07
TfR O 0 6.030473377904855e-05
and O 0 6.623655934845374e-08
HFE O 0 1.3071778084849939e-05
bind O 0 2.962582925647439e-07
tightly O 0 2.0228599169058725e-06
at O 0 2.2563252599638872e-08
the O 0 2.0349191220958573e-09
basic O 0 8.901411163719786e-09
pH O 0 1.1468929272950845e-07
of O 0 4.159134425751887e-10
the O 0 2.3999993103984707e-09
cell O 0 1.919339922551444e-07
surface O 0 4.922124503536907e-07
, O 0 1.62573758899498e-08
but O 0 3.905895162858997e-09
not O 0 1.8533734547077074e-09
at O 0 4.85506257419388e-09
the O 0 1.0165052799493424e-08
acidic O 0 1.869544803412282e-06
pH O 0 1.3959637499283417e-06
of O 0 1.4263537906344936e-08
intracellular O 0 3.2529585496376967e-06
vesicles O 0 1.3147704521543346e-05
. O 0 9.198813586408505e-07

TfR O 1 0.8361982703208923
HFE O 0 0.01513668429106474
stoichiometry O 0 0.00023658901045564562
( O 0 4.095768872502958e-06
2 O 0 6.438507398343063e-07
1 O 0 1.668878581995159e-07
) O 0 2.85101702246493e-08
differs O 0 1.0045422271787174e-07
from O 0 5.896632515600686e-08
TfR O 0 3.686863055918366e-05
transferrin O 0 2.137235924237757e-06
stoichiometry O 0 7.026237085483444e-07
( O 0 1.9873604983899895e-08
2 O 0 1.915981684419421e-08
2 O 0 4.308271073227843e-08
) O 0 3.1221274454651393e-09
, O 0 1.5941644671002564e-09
implying O 0 9.113371390867542e-09
a O 0 1.8347531272056017e-09
different O 0 4.853495383372319e-10
mode O 0 6.850667588764736e-09
of O 0 5.044488715633122e-10
binding O 0 6.5843535068665915e-09
for O 0 1.6108899769662344e-09
HFE O 0 4.577388608595356e-06
and O 0 2.53047591769473e-08
transferrin O 0 1.830916147582684e-07
to O 0 8.630967052170035e-09
TfR O 0 5.774078090325929e-06
, O 0 4.396687014462941e-09
consistent O 0 1.579787678451794e-08
with O 0 2.3239461466317834e-09
our O 0 1.3773161278152202e-08
demonstration O 0 3.491267364097439e-08
that O 0 2.6966218147350673e-09
HFE O 0 2.8045849376212573e-06
, O 0 1.2970017948532586e-08
transferrin O 0 2.5159232563964906e-07
, O 0 7.036011329120129e-09
and O 0 2.6430537758415085e-08
TfR O 0 1.7703971025184728e-05
form O 0 3.626454159189052e-08
a O 0 1.1940126398712891e-07
ternary O 0 1.7718450635584304e-06
complex O 0 3.045897983611212e-06
. O 0 1.9058929865423124e-06

Identification O 0 1.956280812009936e-06
of O 0 4.348583715341192e-08
three O 0 4.679885279301743e-08
novel O 0 8.190994549295283e-07
mutations O 0 1.5597520359733608e-06
and O 0 2.5607537423866233e-08
a O 0 1.9647728777272278e-08
high O 0 5.6606531018132955e-08
frequency O 0 5.527816071548841e-08
of O 0 9.433697156779886e-10
the O 0 1.6603657115865644e-08
Arg778Leu O 0 4.197097496216884e-06
mutation O 0 1.3858202407845965e-07
in O 0 9.656346833253338e-09
Korean O 0 3.593555959469086e-07
patients O 0 2.66096833456686e-07
with O 0 1.3774322837889486e-07
Wilson B-Disease 0 0.0004887484828941524
disease I-Disease 0 7.000342884566635e-05
. O 0 7.673256732232403e-07

Four O 0 1.1750796147680376e-05
mutations O 0 4.0984647057484835e-05
- O 0 2.2558348064194433e-05
- O 0 9.048524589161389e-06
R778L O 0 1.4525157894240692e-06
, O 0 1.0013911477813053e-08
A874V O 0 1.220119685285681e-07
, O 0 2.162065415589609e-09
L1083F O 0 8.851825583633399e-08
, O 0 1.6323798979200888e-09
and O 0 2.0095511921169873e-09
2304delC O 0 1.265030249442134e-07
- O 0 5.267686447041342e-07
- O 0 6.53936240269104e-07
in O 0 3.596563935559516e-09
the O 0 6.064298840868787e-09
copper O 0 2.919967130310397e-07
- O 0 1.153288380351114e-07
transporting O 0 1.5675682973892435e-08
enzyme O 0 1.0613922185598312e-08
, O 0 2.3870976306739067e-09
P O 0 2.409100261502317e-07
- O 0 1.2894003020846867e-07
type O 0 7.415681579914235e-08
ATPase O 0 5.970966299173597e-07
( O 0 1.246439218505202e-08
ATP7B O 0 6.16500756223104e-07
) O 0 3.2571920716151226e-09
, O 0 1.6590605556032756e-09
were O 0 1.651585002093725e-08
identified O 0 3.766617240330561e-08
in O 0 1.03270778595288e-08
Korean O 0 3.1699232749815565e-07
Patients O 0 1.4562186834155e-07
with O 0 8.060217027150429e-08
Wilson B-Disease 0 0.00021029534400440753
disease I-Disease 0 4.231369894114323e-05
. O 0 4.953590746481495e-07

Arg778Leu O 0 0.0002706901868805289
, O 0 2.1206675171470124e-07
the O 0 1.0798930638600268e-08
most O 0 2.8597677559361045e-09
frequently O 0 1.0452362175783492e-07
reported O 0 1.6911050693124707e-07
mutation O 0 1.2009270022872442e-08
of O 0 3.563274952878004e-10
this O 0 1.1484700968011907e-09
enzyme O 0 1.66500520037971e-08
, O 0 9.871548911632999e-09
was O 0 9.052667451214802e-07
found O 0 9.958103674989616e-09
in O 0 2.4393473907480256e-09
six O 0 4.8775152805546895e-09
of O 0 1.0559840779578167e-09
eight O 0 5.200296726570741e-08
unrelated O 0 1.8777845411932503e-07
patients O 0 5.320613638559735e-08
studied O 0 8.200051304640965e-09
, O 0 6.564111476592416e-10
an O 0 9.229396136234413e-10
allele O 0 8.715903021538907e-08
frequency O 0 1.0047990173234211e-07
of O 0 1.2919082692519623e-08
37 O 0 1.0799558367580175e-06
. O 0 1.641869431523446e-07

5 O 0 1.5008021364337765e-05
% O 0 2.704233850181481e-07
, O 0 1.1039764657994056e-08
which O 0 7.709953564472016e-09
is O 0 2.696261880430484e-09
considerably O 0 6.670082797199939e-08
higher O 0 2.2488279682875145e-08
than O 0 2.161826273550105e-09
those O 0 2.696599887830331e-10
in O 0 7.500698950835272e-10
other O 0 1.4519131452672696e-09
Asian O 0 4.154222921215478e-08
populations O 0 2.7099730459667626e-07
. O 0 2.1331095467758132e-07

The O 0 8.544956813238969e-07
novel O 0 7.478170687136299e-07
single O 0 2.481561125478038e-07
nucleotide O 0 5.78136166495824e-07
deletion O 0 7.69257042065874e-07
, O 0 2.090077977356941e-08
2304delC O 0 7.870706895118929e-07
, O 0 1.9243209692376695e-08
was O 0 4.0420474078928237e-07
found O 0 1.9718381594202583e-08
in O 0 1.4111835255903316e-08
one O 0 1.584459425885143e-07
patient O 0 3.6233132050256245e-06
. O 0 7.204426992757362e-07

Since O 0 3.978215318056755e-06
a O 0 5.587153850683535e-07
mutation O 0 5.6650283113413025e-06
at O 0 2.590611245523178e-07
cDNA O 0 8.522978532710113e-06
nucleotide O 0 1.4433714568440337e-05
2302 O 0 3.840992576442659e-05
( O 0 6.499955418348691e-08
2302insC O 0 7.050716703815851e-07
) O 0 2.431020362791969e-08
had O 0 8.970303042588057e-07
been O 0 1.0771164937750655e-07
previously O 0 2.519873305573128e-07
described O 0 8.505655273438606e-07
, O 0 5.554531501417159e-09
this O 0 3.8397679480439706e-10
region O 0 2.7005231384436e-09
of O 0 4.163753786201596e-10
the O 0 4.704961309442979e-09
ATP7B O 0 8.414361218456179e-06
gene O 0 3.628869933436363e-07
may O 0 1.0014124995905149e-07
be O 0 5.213065090714508e-09
susceptible O 0 1.2071232902144402e-07
to O 0 1.957642936645243e-08
gene O 0 4.591531705955276e-06
rearrangements O 0 0.0043638008646667
causing O 0 9.156251326203346e-05
Wilson B-Disease 0 0.0012138901511207223
disease I-Disease 0 0.0001990990131162107
. O 0 1.2503297739385744e-06

Disruption O 0 4.970766167389229e-05
of O 0 6.70649029643755e-08
splicing O 0 1.7772724731912604e-06
regulated O 0 2.0879747353319544e-07
by O 0 6.797900020671932e-09
a O 0 4.303704415065113e-08
CUG O 0 1.5249071111611556e-05
- O 0 1.6149505199791747e-06
binding O 0 5.66008054647682e-07
protein O 0 1.4272538919612998e-06
in O 0 1.5183534287643852e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 7.489078598155174e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9668226838111877
DM B-Disease 1 1.0
) O 0 3.220295184291899e-06
is O 0 1.1096007312971778e-07
caused O 0 8.669049833542886e-08
by O 0 2.19190310346562e-09
a O 0 2.8937053642152932e-08
CTG O 0 2.2743963654647814e-06
expansion O 0 3.515684809940467e-08
in O 0 1.123277471037909e-08
the O 0 2.4794834629915385e-08
3 O 0 1.9507405113472487e-07
untranslated O 0 3.4955601222463883e-06
region O 0 1.0452701815211185e-07
of O 0 1.2145594752155375e-08
the O 0 9.842672170634614e-07
DM B-Disease 1 1.0
gene O 0 4.920200080960058e-05
. O 0 1.6261985820165137e-06

One O 0 1.4114790474195615e-06
model O 0 1.0736372360042878e-06
of O 0 1.686000388190223e-07
DM B-Disease 1 0.9999997615814209
pathogenesis O 0 1.5136522051761858e-05
suggests O 0 3.899469902535202e-07
that O 0 1.0940155448224687e-08
RNAs O 0 2.2957081569074944e-07
from O 0 2.0886901097583177e-09
the O 0 1.0104080905293245e-09
expanded O 0 9.178928728204028e-09
allele O 0 4.201187664421013e-08
create O 0 3.6024410121626715e-09
a O 0 7.890335496085754e-09
gain O 0 6.124712115251896e-08
- O 0 1.4755609356598143e-07
of O 0 2.599530812830153e-09
- O 0 1.4458969417319167e-06
function O 0 1.9016370700342122e-08
mutation O 0 2.0159594882329657e-08
by O 0 3.4325903230936206e-10
the O 0 2.6298974109550954e-09
inappropriate O 0 2.5000266745678346e-08
binding O 0 8.087316594185268e-09
of O 0 6.174674105352551e-10
proteins O 0 5.918127765625059e-09
to O 0 6.1834932729709635e-09
the O 0 5.4731984278078016e-08
CUG O 0 4.738781353808008e-05
repeats O 0 9.064295227290131e-06
. O 0 5.254506163510086e-07

Data O 0 3.6194380754750455e-06
presented O 0 8.367241548512538e-07
here O 0 9.249141896816582e-08
indicate O 0 6.470515501177942e-08
that O 0 2.603197657435885e-09
the O 0 8.440523835417935e-09
conserved O 0 7.704708337996635e-08
heterogeneous O 0 2.3636512480607053e-07
nuclear O 0 1.7604459401354688e-07
ribonucleoprotein O 0 7.85641304901219e-07
, O 0 7.72963915096625e-09
CUG O 0 5.676102432516927e-07
- O 0 3.0736435974176857e-07
binding O 0 1.0007423867364196e-07
protein O 0 1.4656875180207862e-07
( O 0 1.541909000479791e-08
CUG O 0 1.9708320451172767e-06
- O 0 2.254475657537114e-05
BP O 0 1.8623150026542135e-05
) O 0 3.793978464727843e-09
, O 0 3.2132509986126934e-09
may O 0 1.095845014731367e-08
mediate O 0 3.5579921586759156e-07
the O 0 2.815051303173277e-08
trans O 0 1.6630967820674414e-06
- O 0 5.620816955342889e-05
dominant O 0 3.77826722797181e-07
effect O 0 1.464568999409721e-08
of O 0 2.209043836742808e-09
the O 0 3.916549928817403e-08
RNA O 0 2.92093250209291e-06
. O 0 3.7283987808223173e-07

CUG O 0 0.004416323266923428
- O 0 0.4455878734588623
BP O 0 0.0024394800420850515
was O 0 9.301007821704843e-07
found O 0 1.060445242728747e-08
to O 0 1.7689667508591356e-09
bind O 0 2.033980983640049e-08
to O 0 2.974362756091864e-09
the O 0 7.970563764558847e-09
human O 0 1.5755453830479382e-07
cardiac O 0 8.33759768283926e-05
troponin O 0 0.0001102270616684109
T O 0 2.9875533073209226e-05
( O 0 2.002443189041969e-08
cTNT O 0 1.8870404971949029e-07
) O 0 6.156473109086846e-09
pre O 0 1.3566851464474894e-07
- O 0 1.7231109268323053e-06
messenger O 0 6.652446700172732e-07
RNA O 0 1.675792304922652e-07
and O 0 3.785391111676972e-09
regulate O 0 2.2898518636793597e-08
its O 0 7.623240705356693e-09
alternative O 0 1.0234606406811508e-07
splicing O 0 3.6007847938890336e-06
. O 0 5.551536332859541e-07

Splicing O 0 0.00012613362923730165
of O 0 7.716251957390341e-07
cTNT O 0 2.927871173596941e-05
was O 0 5.265359050099505e-06
disrupted O 0 1.7149734048871323e-05
in O 0 7.397683248200337e-07
DM B-Disease 1 1.0
striated O 0 0.0012330354657024145
muscle O 0 3.25254222843796e-05
and O 0 4.4640110274940525e-08
in O 0 1.591883425078322e-08
normal O 0 1.5889507665178826e-07
cells O 0 1.1495987450871326e-07
expressing O 0 1.646461278426159e-08
transcripts O 0 9.963979152871616e-08
that O 0 1.4262149683474945e-08
contain O 0 2.4833650513755856e-07
CUG O 0 8.284086652565747e-05
repeats O 0 1.6163054169737734e-05
. O 0 7.79288086505403e-07

Altered O 0 0.00014294616994448006
expression O 0 2.8173615191917634e-06
of O 0 4.6883286586307804e-08
genes O 0 5.31807756942726e-07
regulated O 0 1.6305051531162462e-07
posttranscriptionally O 0 2.0363720523164375e-06
by O 0 1.527422632818798e-08
CUG O 0 3.224727333872579e-05
- O 0 0.0004617319209501147
BP O 0 4.872317367698997e-05
therefore O 0 2.8552509689916405e-08
may O 0 1.9316130916990915e-08
contribute O 0 1.4230140621407372e-08
to O 0 1.1486267226246127e-07
DM B-Disease 1 0.9999998807907104
pathogenesis O 0 4.7333618567790836e-05
. O 0 2.556762126459944e-07
. O 0 7.883612624937086e-07

Identification O 0 2.510116701159859e-06
of O 0 5.697416582961523e-08
a O 0 1.0698560259925216e-07
novel O 0 1.035168907037587e-06
nonsense O 0 2.431050961604342e-05
mutation O 0 6.095542630646378e-07
and O 0 8.453348243619985e-09
a O 0 1.1644223363305173e-08
missense O 0 6.54480231787602e-07
substitution O 0 1.1470652871992115e-08
in O 0 4.8087702708699e-09
the O 0 6.945873209929232e-09
vasopressin O 0 8.341467037098482e-07
- O 0 5.982679340377217e-06
neurophysin O 0 3.924233169527724e-06
II O 0 6.387743951563607e-07
gene O 0 7.105101929028024e-08
in O 0 7.157356929354819e-09
two O 0 3.555227223728252e-08
Spanish O 0 6.173656288410712e-07
kindreds O 0 6.759000370948343e-06
with O 0 4.554739518880524e-07
familial B-Disease 0 0.10628271102905273
neurohypophyseal I-Disease 1 0.9958571791648865
diabetes I-Disease 1 0.9998576641082764
insipidus I-Disease 1 0.5434409379959106
. O 0 1.0894534170802217e-05

Familial B-Disease 1 0.9997311234474182
neurohypophyseal I-Disease 1 0.9999567270278931
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9999966621398926
( O 0 0.0012731681345030665
FNDI B-Disease 1 1.0
) O 0 1.6045194684011221e-07
is O 0 1.216314426955023e-08
an O 0 7.895277320812966e-08
autosomal B-Disease 1 0.9958206415176392
dominant I-Disease 1 0.9969767332077026
disease I-Disease 1 0.9906105399131775
caused O 0 8.052634075284004e-05
by O 0 1.5915243238850962e-06
deficiency O 0 0.006667380686849356
in O 0 1.6861298135495417e-08
the O 0 1.8017088621036237e-07
antidiuretic O 0 6.339250830933452e-05
hormone O 0 3.625331601142534e-06
arginine O 0 3.6114663544140058e-06
vasopressin O 0 5.477361810335424e-06
( O 0 3.9647055416480725e-08
AVP O 0 9.490090633335058e-07
) O 0 3.640354462319806e-09
encoded O 0 4.438199585621305e-09
by O 0 1.1864733640010172e-09
the O 0 8.279448238113218e-09
AVP O 0 1.0146291970158927e-05
- O 0 0.00015939524746499956
neurophysin O 0 2.4746468625380658e-05
II O 0 2.232584847661201e-06
( O 0 2.0583023285780655e-08
AVP O 0 1.4290189938037656e-06
- O 0 9.386925739818253e-06
NPII O 0 6.382059837051202e-06
) O 0 1.902783708374045e-08
gene O 0 2.005452017783682e-07
on O 0 6.936151635272836e-07
chromosome O 0 0.00012321396206971258
20p13 O 0 3.320950418128632e-05
. O 0 1.3277208381623495e-06

In O 0 3.183811259077629e-07
this O 0 9.367521869307893e-09
study O 0 1.1225342433363039e-08
, O 0 5.290949456338012e-09
we O 0 2.5770734435326403e-09
analyzed O 0 1.1400550725682024e-08
two O 0 8.425532271871816e-09
families O 0 1.0901162639243012e-08
with O 0 1.1972677071980797e-08
FNDI B-Disease 1 0.9965903759002686
using O 0 1.2055030751412232e-08
direct O 0 1.4983598362050543e-08
automated O 0 1.1253784037990044e-07
fluorescent O 0 3.2436417995995726e-07
, O 0 5.9068732127798285e-09
solid O 0 3.3112016240011144e-08
phase O 0 3.848496987757244e-08
, O 0 4.7439070449684095e-09
single O 0 4.692828881047717e-08
- O 0 1.3076427194391727e-06
stranded O 0 1.3883281724247354e-07
DNA O 0 2.196864024028855e-08
sequencing O 0 1.519492975887715e-08
of O 0 1.6449757112013685e-09
PCR O 0 1.0870473943214165e-06
- O 0 1.157186716227443e-06
amplified O 0 2.2400665784516605e-06
AVP O 0 1.0114486940437928e-05
- O 0 1.8184327927883714e-05
NPII O 0 2.800282345560845e-05
DNA O 0 5.640430572384503e-06
. O 0 5.415110990725225e-07

In O 0 6.008426680637058e-07
one O 0 3.2211502798418223e-08
of O 0 1.8278509816838096e-09
the O 0 7.343472496756931e-09
families O 0 2.3282552774617216e-08
, O 0 6.068128222125324e-09
affected O 0 1.0050210441647778e-08
individuals O 0 1.1453376025372108e-09
presented O 0 5.911584111117918e-09
a O 0 2.23124239084882e-08
novel O 0 5.388281465457112e-07
nonsense O 0 1.7295150200880016e-06
mutation O 0 6.959295717479108e-08
in O 0 1.7881399694275046e-09
exon O 0 1.6073896347279515e-07
3 O 0 1.994663101356764e-08
of O 0 8.542327400995475e-10
the O 0 4.487176852308039e-09
gene O 0 2.4116834751453098e-08
, O 0 1.6447874173763921e-09
consisting O 0 1.3134091592093e-09
in O 0 1.726947584934635e-09
a O 0 4.31315498872209e-08
G O 0 7.893318979768082e-06
to O 0 1.660615822629552e-08
T O 0 1.7023866121235187e-06
transition O 0 2.1601250566050112e-08
at O 0 1.0916309634012578e-08
nucleotide O 0 1.058743919202243e-07
2101 O 0 2.547506028349744e-07
, O 0 2.5274116133289226e-09
which O 0 1.098309443392509e-09
produces O 0 1.8765442533208443e-09
a O 0 4.437421097236438e-09
stop O 0 9.8100819911906e-08
signal O 0 1.2963765527729265e-07
in O 0 8.00408006540465e-09
codon O 0 1.6153973092514207e-06
82 O 0 2.9121108013896446e-07
( O 0 3.4576228102878304e-08
Glu O 0 1.929041900439188e-05
) O 0 1.965844731444122e-08
of O 0 2.09275867746328e-08
NPII O 0 0.0001066319236997515
. O 0 1.0658227438398171e-06

The O 0 4.6147015382302925e-06
premature O 0 2.1124807972228155e-05
termination O 0 2.3864945433160756e-06
eliminates O 0 6.289922680480231e-07
part O 0 2.6913410167139773e-08
of O 0 2.591110659366791e-09
the O 0 1.829581997014884e-08
C O 0 1.333003865511273e-06
- O 0 8.904605124371301e-07
terminal O 0 8.103578608142925e-08
domain O 0 4.725754898515788e-09
of O 0 9.621228258538395e-10
NPII O 0 1.5826336721147527e-06
, O 0 6.117993334164851e-10
including O 0 1.8512526234193416e-10
a O 0 1.8400450052524775e-09
cysteine O 0 8.183614674805995e-09
residue O 0 1.4254833757831875e-08
in O 0 1.0852859722021435e-09
position O 0 3.958486516353332e-08
85 O 0 9.915686938199997e-09
, O 0 2.3698043527531354e-09
which O 0 4.956290489133153e-09
could O 0 1.0255550186855089e-08
be O 0 1.3338505855386984e-09
involved O 0 1.4304779583085292e-09
in O 0 2.020454692441831e-09
the O 0 1.7488821058009307e-08
correct O 0 9.92982677416876e-07
folding O 0 4.53775243158816e-07
of O 0 8.918099148047531e-09
the O 0 9.205388806776682e-08
prohormone O 0 0.0002603422908578068
. O 0 1.1147888017148944e-06

In O 0 1.206848764923052e-06
the O 0 4.17361718518805e-08
second O 0 1.6650297141040937e-07
family O 0 6.572562227802337e-08
, O 0 2.5159117011952503e-09
a O 0 3.6863088137550903e-09
G279A O 0 3.8727968387775036e-08
substitution O 0 6.191282153622524e-09
at O 0 7.621336450824856e-09
position O 0 2.2971615720734917e-08
- O 0 2.1405087125003774e-07
1 O 0 2.8753170955297946e-09
of O 0 3.335157428008273e-10
the O 0 3.1039466552584827e-09
signal O 0 1.0518876933929278e-06
peptide O 0 2.2232644170117055e-08
was O 0 3.912495927238524e-08
observed O 0 6.570277655271184e-09
in O 0 1.172261510085093e-09
all O 0 4.004260478751576e-09
affected O 0 4.13241139085585e-08
individuals O 0 1.779492109221792e-08
. O 0 1.1248559417254e-07

This O 0 4.6500122152792756e-06
missense O 0 0.000748451508115977
mutation O 0 2.3851885998738e-05
, O 0 1.3558559430748574e-07
which O 0 6.977065680757732e-08
replaces O 0 2.986962499562651e-06
Ala O 0 3.151440978399478e-05
with O 0 1.1691063406260582e-07
Thr O 0 7.096713670762256e-05
, O 0 1.624937695510198e-08
is O 0 2.6824633625466276e-09
frequent O 0 6.54321752335818e-08
among O 0 1.5602385872170998e-07
FNDI B-Disease 1 1.0
patients O 0 1.5109923197087483e-06
and O 0 3.871053877446684e-08
is O 0 7.740734275785144e-09
thought O 0 6.2960539004564e-09
to O 0 1.344640288003518e-09
reduce O 0 9.364020669977435e-09
the O 0 2.0117219001747344e-09
efficiency O 0 1.5547820808592405e-08
of O 0 8.756552705158072e-10
cleavage O 0 1.7592220729056862e-06
by O 0 1.6954595949414397e-08
signal O 0 1.5734896123831277e-06
peptidases O 0 3.1431247862201417e-06
. O 0 4.899008487768697e-08
. O 0 4.176679624379176e-07

Genetic O 0 9.26892607822083e-05
heterogeneity O 0 7.624651334481314e-05
of O 0 6.233889848772378e-07
Saethre B-Disease 0 0.20049931108951569
- I-Disease 1 0.9999591112136841
Chotzen I-Disease 1 0.9999306201934814
syndrome I-Disease 1 0.9999812841415405
, O 0 3.14415053992434e-08
due O 0 1.6976825278902652e-08
to O 0 1.942608562899295e-08
TWIST O 0 0.00015578615420963615
and O 0 2.7443816179584246e-06
FGFR O 0 0.0008920726832002401
mutations O 0 2.0740695617860183e-05
. O 0 4.978321612725267e-07

Thirty O 0 5.394549953052774e-05
- O 0 2.645565109560266e-05
two O 0 1.9583943355883093e-07
unrelated O 0 7.551016665274801e-07
patients O 0 1.2469580212837172e-07
with O 0 2.1733692623371326e-09
features O 0 1.1339960792611237e-07
of O 0 5.733379637717917e-08
Saethre B-Disease 0 0.05939267575740814
- I-Disease 1 0.998640239238739
Chotzen I-Disease 1 0.999625563621521
syndrome I-Disease 1 0.9989833235740662
, O 0 7.0167658350328566e-09
a O 0 4.2255862808815436e-08
common O 0 1.5253738183673704e-06
autosomal B-Disease 0 0.02906825765967369
dominant I-Disease 0 0.0017597331898286939
condition I-Disease 0 2.4395878426730633e-05
of O 0 2.150780886722714e-07
craniosynostosis B-Disease 1 0.6172093152999878
and O 0 5.0157879741163924e-05
limb B-Disease 0 0.46984463930130005
anomalies I-Disease 0 0.00022514462762046605
, O 0 5.129976443640771e-08
were O 0 5.609664555095151e-08
screened O 0 1.8444104910031456e-07
for O 0 4.67963312544839e-09
mutations O 0 2.838551722561533e-07
in O 0 6.576496236476714e-09
TWIST O 0 1.7261720131500624e-05
, O 0 4.9106933630582716e-08
FGFR2 O 0 5.727969437430147e-06
, O 0 2.2470359795079276e-08
and O 0 5.219276388856997e-08
FGFR3 O 0 3.677389395306818e-05
. O 0 3.974488436142565e-07

Nine O 0 2.4483586457790807e-05
novel O 0 1.951300191649352e-06
and O 0 9.961318170326194e-08
three O 0 7.595479445399178e-08
recurrent O 0 0.0001165491048595868
TWIST O 0 0.03262070566415787
mutations O 0 3.140179251204245e-05
were O 0 1.4941082326913602e-07
found O 0 1.4257716784982222e-08
in O 0 2.6379721518310362e-08
12 O 0 3.654493241356249e-07
families O 0 1.5676467057801347e-07
. O 0 2.1172058950469363e-07

Seven O 0 9.211637916450854e-06
families O 0 3.6088974297854293e-07
were O 0 2.4390693909026595e-08
found O 0 6.97925939263655e-09
to O 0 2.235424512164741e-09
have O 0 8.028467668452777e-09
the O 0 5.6928510794307385e-09
FGFR3 O 0 2.265179318783339e-06
P250R O 0 2.416122413251287e-07
mutation O 0 4.132648001586858e-08
, O 0 1.6647853096074527e-09
and O 0 3.830699313311925e-09
one O 0 1.537456917333202e-08
individual O 0 3.833147577125828e-09
was O 0 5.650566663462087e-07
found O 0 6.009386765981617e-09
to O 0 4.03525834968832e-09
have O 0 7.414037828112896e-09
an O 0 3.2365572444348345e-09
FGFR2 O 0 3.478274720691843e-06
VV269 O 0 6.970321351218445e-07
- O 0 1.2426374951246544e-06
270 O 0 6.944961228327884e-07
deletion O 0 8.953031283454038e-06
. O 0 1.0896712865360314e-06

To O 0 4.210629924727982e-07
date O 0 2.4375026441703085e-07
, O 0 1.0837144515107866e-08
our O 0 4.670965392250537e-09
detection O 0 3.0880809021027744e-08
rate O 0 2.8769315818522045e-08
for O 0 9.799731026660652e-10
TWIST O 0 2.9375930807873374e-06
or O 0 4.79927990681972e-08
FGFR O 0 4.9409786697651725e-06
mutations O 0 1.660071831111054e-07
is O 0 3.4061196085843903e-09
68 O 0 9.094308239809834e-08
% O 0 2.7992761442163783e-09
in O 0 1.876787836252447e-09
our O 0 7.437524374154236e-08
Saethre B-Disease 0 0.0016423966735601425
- I-Disease 1 0.9963011741638184
Chotzen I-Disease 1 0.996778666973114
syndrome I-Disease 1 0.998292863368988
patients O 0 2.0182146442948579e-07
, O 0 1.1039549274727278e-09
including O 0 1.1653616960316526e-09
our O 0 1.2074223398883532e-08
five O 0 6.349444703346308e-08
patients O 0 6.760043902431789e-08
elsewhere O 0 3.4684155991726584e-08
reported O 0 8.88389450892646e-08
with O 0 2.6045649192951714e-08
TWIST O 0 0.004864930175244808
mutations O 0 6.22092848061584e-05
. O 0 6.974217967581353e-07

More O 0 4.725721396425797e-07
than O 0 4.890027582860057e-08
35 O 0 4.192990132878549e-08
different O 0 3.4261620207587384e-09
TWIST O 0 1.841874109231867e-05
mutations O 0 1.4012857718626037e-06
are O 0 2.497890116970325e-09
now O 0 1.4056336539169934e-08
known O 0 1.981278252571883e-08
in O 0 6.091320781109744e-09
the O 0 1.845993757854103e-08
literature O 0 9.498342024016893e-08
. O 0 1.9558521557883068e-07

The O 0 3.3733428494997497e-07
most O 0 1.9876296164511587e-08
common O 0 1.41503235795426e-08
phenotypic O 0 2.3995252718123083e-07
features O 0 7.370444450316427e-07
, O 0 2.549952959896018e-08
present O 0 2.3468638143953058e-09
in O 0 9.258858679750404e-10
more O 0 6.097082838607548e-10
than O 0 9.999171490804315e-10
a O 0 7.585978067936594e-09
third O 0 2.3593160847212857e-07
of O 0 3.47479023332653e-09
our O 0 5.329226482331251e-08
patients O 0 1.1689976986417605e-08
with O 0 2.3192567866203717e-09
TWIST O 0 7.516995538026094e-05
mutations O 0 1.6578820805079886e-06
, O 0 3.541601234502423e-09
are O 0 3.325935304943073e-09
coronal B-Disease 0 5.381290520745097e-06
synostosis I-Disease 0 2.8948595627298346e-06
, O 0 1.0698107288931169e-08
brachycephaly B-Disease 0 1.4017482499184553e-06
, O 0 3.307717122424947e-08
low B-Disease 0 2.5787923732423224e-05
frontal I-Disease 1 0.9998200535774231
hairline I-Disease 1 0.9999995231628418
, O 0 1.4362575484483386e-06
facial B-Disease 0 0.02575894258916378
asymmetry I-Disease 0 0.00020145832968410105
, O 0 5.310404276315239e-07
ptosis B-Disease 0 0.0005128802731633186
, O 0 1.9688735619638464e-07
hypertelorism B-Disease 0 3.322946577100083e-05
, O 0 1.1077693784500298e-07
broad B-Disease 0 4.29261444878648e-06
great I-Disease 0 8.745078048377763e-06
toes I-Disease 0 0.32976019382476807
, O 0 5.530801061581769e-08
and O 0 1.3867375514564628e-07
clinodactyly B-Disease 0 2.2480347979580984e-05
. O 0 8.408886174038344e-07

Significant O 0 2.802376457111677e-06
intra O 0 2.3152808353188448e-05
- O 0 6.565512740053236e-05
and O 0 2.5813949378061807e-07
interfamilial O 0 5.359365331969457e-06
phenotypic O 0 3.782131670959643e-06
variability O 0 1.408866410201881e-05
is O 0 7.812642977000905e-09
present O 0 3.1235929398576445e-09
for O 0 2.0608588169324094e-09
either O 0 4.4153541267633045e-08
TWIST O 0 0.0005825983826071024
mutations O 0 2.6568211978883483e-05
or O 0 4.945660521116224e-07
FGFR O 0 0.0006656927871517837
mutations O 0 4.2772997403517365e-05
. O 0 1.0259510645482806e-06

The O 0 4.49886840669933e-07
overlap O 0 3.5423707345216826e-07
in O 0 1.9445881349611227e-08
clinical O 0 7.015859182502027e-08
features O 0 2.870073103622417e-07
and O 0 1.027781948437223e-07
the O 0 6.638299687722338e-09
presence O 0 1.3399097831268136e-08
, O 0 2.5320774366122123e-09
in O 0 6.262778629029242e-10
the O 0 1.572499574997721e-09
same O 0 3.1346343298821466e-09
genes O 0 8.323498335016666e-09
, O 0 7.414755476276014e-10
of O 0 4.3163356222564175e-10
mutations O 0 9.665044764517461e-09
for O 0 1.7751036751612048e-10
more O 0 3.6369585121320824e-10
than O 0 7.924507716694507e-10
one O 0 6.329841095720212e-09
craniosynostotic B-Disease 0 2.79753021459328e-06
condition I-Disease 0 5.6886538146727617e-08
- O 0 4.0852178528894e-08
such O 0 8.992996902712491e-10
as O 0 7.050277694986562e-09
Saethre B-Disease 0 4.396899271341681e-07
- I-Disease 0 8.843469458952313e-07
Chotzen I-Disease 0 6.513196808555222e-07
, I-Disease 0 7.1695311909536485e-09
Crouzon I-Disease 0 2.7449681283542304e-07
, I-Disease 0 5.271055592004359e-09
and I-Disease 0 6.948844344378813e-08
Pfeiffer I-Disease 0 0.009362888522446156
syndromes I-Disease 0 0.000632737239357084
- O 0 6.620322892558761e-06
support O 0 2.130098231134525e-08
the O 0 2.8727791256955015e-09
hypothesis O 0 2.5454871988017658e-08
that O 0 2.4678472598793633e-09
TWIST O 0 1.962263695531874e-06
and O 0 4.7439275618899046e-08
FGFRs O 0 9.727833685246878e-07
are O 0 6.060768553695084e-10
components O 0 1.6080227149828374e-09
of O 0 2.0514256959813792e-10
the O 0 6.233271676592267e-10
same O 0 1.3284374711375335e-09
molecular O 0 1.1495095542102263e-08
pathway O 0 1.0745429435132792e-08
involved O 0 1.3883031391159761e-09
in O 0 1.1317219383855104e-09
the O 0 5.414664716596462e-09
modulation O 0 2.5952897431125166e-07
of O 0 4.225038097160905e-08
craniofacial O 0 0.39169201254844666
and O 0 1.2311317732383031e-05
limb O 0 0.00018508289940655231
development O 0 1.3119425545937702e-08
in O 0 1.1080394379803238e-08
humans O 0 2.9327116735089476e-08
. O 0 2.3535667637020197e-08
. O 0 2.2740856309155788e-07

Mutation O 0 0.00021918819402344525
analysis O 0 3.0181627153069712e-06
of O 0 6.727899517500191e-07
UBE3A O 0 0.466401606798172
in O 0 0.0392053946852684
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0019771999213844538
. O 0 6.767165359633509e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.5124144554138184
AS B-Disease 1 0.9999743700027466
) O 0 3.1942673217599804e-07
is O 0 3.189414599091833e-08
caused O 0 8.886046742873077e-08
by O 0 8.51493719977725e-09
chromosome O 0 1.3134145774529316e-05
15q11 O 0 1.6389437860198086e-06
- O 0 3.463138455117587e-06
q13 O 0 8.906932862373651e-07
deletions O 0 4.5793655090164975e-07
of O 0 4.417356702646202e-09
maternal O 0 1.4535467016685288e-06
origin O 0 2.6200254410468915e-08
, O 0 8.873898948991155e-09
by O 0 1.775864078013001e-08
paternal O 0 3.2928557629929855e-05
uniparental B-Disease 0 0.0014798752963542938
disomy I-Disease 0 0.0008368434500880539
( O 0 6.922584248059138e-07
UPD B-Disease 1 0.9999895095825195
) O 0 1.3845171231707809e-08
15 O 0 2.0294006475296555e-08
, O 0 2.7173363559285235e-09
by O 0 7.564463722076198e-09
imprinting O 0 0.012779956683516502
defects O 1 0.9666026830673218
, O 0 2.4098532946936757e-08
and O 0 1.0335019062779338e-08
by O 0 4.3490211432128945e-09
mutations O 0 3.19264415793441e-07
in O 0 7.939399360168409e-09
the O 0 2.1225957880233182e-07
UBE3A O 0 0.00011809608986368403
gene O 0 6.0095894696132746e-06
. O 0 1.0174944691243581e-06

UBE3A O 0 0.0021156754810363054
encodes O 0 4.219905167701654e-05
a O 0 1.967939851965639e-06
ubiquitin O 0 7.345880931097781e-06
- O 0 4.449222615221515e-06
protein O 0 3.3577182989574794e-07
ligase O 0 6.435382715608284e-07
and O 0 8.284270336389454e-08
shows O 0 2.157993549189996e-06
brain O 0 2.013514495047275e-05
- O 0 6.04738443144015e-06
specific O 0 1.4932635394870886e-07
imprinting O 0 7.778026338201016e-05
. O 0 3.190886445736396e-06

Here O 0 6.115693395258859e-06
we O 0 2.2776494290610572e-07
describe O 0 3.44041723110422e-07
UBE3A O 0 2.8167110940557905e-05
coding O 0 1.3830484931531828e-05
- O 0 0.00013880663027521223
region O 0 4.7527851165796164e-06
mutations O 0 3.2005355024011806e-06
detected O 0 1.249394756541733e-07
by O 0 2.566909129697592e-09
SSCP O 0 1.0422178320368403e-06
analysis O 0 1.4366116296571363e-08
in O 0 9.549018464838355e-09
13 O 0 3.820967151568766e-07
AS B-Disease 1 0.983870267868042
individuals O 0 1.3957673239417545e-08
or O 0 3.03433047577073e-08
families O 0 1.584826776479531e-07
. O 0 2.7546789738153166e-07

Two O 0 5.047158538218355e-06
identical O 0 8.557061846659053e-06
de O 0 1.615769178897608e-05
novo O 0 7.31597310732468e-06
5 O 0 3.970268096509244e-07
- O 0 4.709897893917514e-06
bp O 0 1.3035252095505712e-06
duplications O 0 4.5945361648591643e-07
in O 0 1.8327114048588555e-08
exon O 0 2.4322205263160868e-06
16 O 0 1.259435634892725e-06
were O 0 2.7087352805210685e-07
found O 0 2.9078094598844473e-07
. O 0 5.462279091261735e-07

Among O 0 1.040382699102338e-06
the O 0 1.549905626063719e-08
other O 0 1.6653347589823397e-09
11 O 0 1.404749117028814e-08
unique O 0 8.464287049037011e-09
mutations O 0 3.81898900059241e-07
, O 0 6.6596430592369416e-09
8 O 0 2.596945414268248e-08
were O 0 6.417759657040278e-09
small O 0 8.438946430544547e-09
deletions O 0 3.630143510235939e-07
or O 0 3.086850242084438e-08
insertions O 0 1.0312137419532519e-06
predicted O 0 1.2596266287800972e-06
to O 0 7.742801955146206e-09
cause O 0 5.0612438684538574e-08
frameshifts O 0 9.167557664113701e-07
, O 0 6.1236584691926055e-09
1 O 0 7.93370702467655e-09
was O 0 1.8011728286637663e-07
a O 0 1.0396606242579765e-08
mutation O 0 2.6383444762245745e-08
to O 0 7.125628975757081e-10
a O 0 6.940787944387239e-09
stop O 0 4.066994563345361e-08
codon O 0 9.688710633781739e-08
, O 0 2.7505318023202108e-09
1 O 0 3.9980174726395035e-09
was O 0 2.7636327004643135e-08
a O 0 3.122611502703876e-08
missense O 0 2.8831721010647016e-06
mutation O 0 8.90858302682318e-08
, O 0 3.3083971118230693e-09
and O 0 1.6586689355335693e-08
1 O 0 3.711299001452062e-08
was O 0 2.4154023776645772e-06
predicted O 0 1.066957679540792e-06
to O 0 7.192157092106299e-09
cause O 0 1.8218479169718194e-08
insertion O 0 4.142891540936944e-08
of O 0 1.8814685365242667e-09
an O 0 2.1518880899407122e-08
isoleucine O 0 0.00024051556829363108
in O 0 1.170086338930787e-08
the O 0 9.074656581731233e-09
hect O 0 3.9033059806570236e-07
domain O 0 8.077111424142913e-09
of O 0 7.930027190461431e-10
the O 0 4.792069852044278e-09
UBE3A O 0 2.5582430680515245e-06
protein O 0 3.957241290208913e-08
, O 0 2.3408555094306394e-09
which O 0 6.079780012768765e-10
functions O 0 9.075551976600593e-10
in O 0 2.232616314046254e-09
E2 O 0 2.2980891856150265e-07
binding O 0 2.362161133362406e-08
and O 0 1.1310147485232847e-08
ubiquitin O 0 2.5574328788025014e-07
transfer O 0 3.3834209034466767e-07
. O 0 4.7576105544067104e-07

Eight O 0 3.948901849071262e-06
of O 0 1.5739017200644412e-08
the O 0 9.691738078743128e-09
cases O 0 1.7913702521354935e-08
were O 0 1.4529518921335693e-07
familial O 0 3.0525864076480502e-06
, O 0 9.90317872151536e-08
and O 0 5.7973352340923157e-08
five O 0 4.865299274570134e-08
were O 0 4.600472607307893e-07
sporadic O 0 5.71900382055901e-05
. O 0 1.389042381561012e-06

In O 0 8.080980364866264e-07
two O 0 1.3963575895559188e-07
familial O 0 1.396855259372387e-05
cases O 0 2.0299935954426473e-07
and O 0 4.687926136170972e-08
one O 0 2.318939351653171e-08
sporadic O 0 5.2279920055298135e-06
case O 0 1.2070462673818838e-07
, O 0 1.6200667474208785e-08
mosaicism O 0 2.2809042548033176e-06
for O 0 1.22071863728479e-08
UBE3A O 0 6.74800539854914e-05
mutations O 0 3.332978394610109e-06
was O 0 3.3991972259173053e-07
detected O 0 6.058300527911342e-08
in O 0 2.8076607705429524e-09
the O 0 2.4257078123923748e-08
mother O 0 4.316300874052104e-06
of O 0 2.7251321199628364e-09
three O 0 1.037740844367363e-06
AS B-Disease 1 0.9999998807907104
sons O 0 0.00016400613822042942
, O 0 3.4539824333990055e-09
in O 0 5.852781037596344e-10
the O 0 1.3550372379711462e-08
maternal O 0 8.457390094918082e-07
grandfather O 0 5.262429567665095e-07
of O 0 7.706817406472055e-10
two O 0 3.8870794583090174e-08
AS B-Disease 1 0.9990794658660889
first O 0 2.791675228763779e-07
cousins O 0 6.303918326011626e-06
, O 0 8.0750774955618e-09
and O 0 6.107130801069616e-09
in O 0 3.0470708178853556e-09
the O 0 3.3755881645447516e-08
mother O 0 2.001520897465525e-06
of O 0 2.081269379061723e-09
an O 0 3.528387892970386e-08
AS B-Disease 1 0.9999812841415405
daughter O 0 0.011480187065899372
. O 0 1.261677653019433e-06

The O 0 3.217006110389775e-07
frequencies O 0 1.9807083617706667e-07
with O 0 8.39566371979572e-09
which O 0 1.825684847744924e-08
we O 0 1.045040498581784e-08
detected O 0 7.274081070818283e-08
mutations O 0 5.0723091504778495e-08
were O 0 1.0100519531874852e-08
5 O 0 1.5322987323429516e-08
( O 0 3.380915547523955e-09
14 O 0 1.6085573761870364e-08
% O 0 1.3026636436208605e-09
) O 0 1.7735740653890275e-10
of O 0 2.6857283064174453e-10
35 O 0 7.366394161323342e-09
in O 0 1.651826786464028e-09
sporadic O 0 6.441958930736291e-07
cases O 0 7.078897468204559e-09
and O 0 2.6497824379134727e-08
8 O 0 4.8891791948335594e-08
( O 0 3.17854853548738e-09
80 O 0 6.720727530051818e-09
% O 0 1.805453675451929e-09
) O 0 3.1000457756391597e-10
of O 0 4.2841916125802015e-10
10 O 0 6.56614362881669e-09
in O 0 9.45614786473925e-09
familial O 0 6.4910809669527225e-06
cases O 0 1.2120594305997656e-07
. O 0 5.471382280575199e-08
. O 0 3.105920711732324e-07

The O 0 1.7051754184649326e-05
hemochromatosis B-Disease 1 0.9999938011169434
845 O 0 0.00024247200053650886
G O 0 0.00022270854969974607
- O 0 3.215808828826994e-05
- O 0 6.101188319007633e-06
> O 0 1.1507297159596419e-07
A O 0 1.6450833584258362e-08
and O 0 2.9417634994644004e-09
187 O 0 3.0039029041972753e-08
C O 0 1.2241348201769142e-07
- O 0 8.876261858858925e-07
- O 0 7.204082066891715e-06
> O 0 7.415468985527696e-07
G O 0 5.987873464619042e-06
mutations O 0 6.713971174576727e-07
: O 0 1.0871408662183057e-08
prevalence O 0 3.7429947497003013e-07
in O 0 1.650293945942849e-08
non O 0 1.858729206105636e-07
- O 0 4.2840558307943866e-05
Caucasian O 0 3.459955769358203e-05
populations O 0 1.3937847143097315e-06
. O 0 3.046305607767863e-07

Hemochromatosis B-Disease 1 0.986854076385498
, O 0 2.0306209989939816e-05
the O 0 1.0607267540763132e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 2.9708442639275745e-07
iron I-Disease 0 0.3667653799057007
metabolism I-Disease 0 9.829026566876564e-06
, O 0 1.2314385067213607e-08
leads O 0 8.399030093642068e-08
, O 0 1.1170622649103734e-08
if O 0 2.038113144919862e-08
untreated O 0 5.623923016173649e-07
, O 0 2.9006888002669484e-09
to O 0 1.4000520742740719e-08
progressive O 0 1.118952513934346e-05
iron B-Disease 1 0.5119860768318176
overload I-Disease 0 8.762224024394527e-05
and O 0 7.931938057481602e-07
premature B-Disease 0 1.1216075108677614e-05
death I-Disease 0 8.624381734989583e-06
. O 0 7.776281449878297e-07

The O 0 2.259092070744373e-05
hemochromatosis B-Disease 1 0.999998927116394
gene O 0 2.8313588700257242e-05
, O 0 2.3097936718841083e-07
HFE O 0 7.372612162726e-05
, O 0 7.85665505986799e-08
recently O 0 1.2883300541943754e-06
has O 0 3.9342728541669203e-07
been O 0 7.464782925126201e-08
identified O 0 9.159799674307578e-08
, O 0 1.614941513849999e-09
and O 0 1.7128646279118698e-09
characterization O 0 1.4716674989756484e-08
of O 0 4.121560037706473e-10
this O 0 6.66806665439168e-10
gene O 0 3.785934765687671e-08
has O 0 4.289535411317047e-07
shown O 0 2.2159785117992215e-08
that O 0 6.064260760219042e-10
it O 0 4.799229347263179e-10
contains O 0 6.329969881591069e-10
two O 0 1.2162099771728663e-08
mutations O 0 2.1185793741551606e-07
that O 0 1.916770298038273e-09
result O 0 5.627149857190261e-09
in O 0 5.7946016873700046e-09
amino O 0 4.4712198388197066e-08
acid O 0 2.099523399579084e-08
substitutions O 0 3.185888175494256e-08
- O 0 1.1481854045314321e-07
cDNA O 0 4.105077380245348e-07
nucleotides O 0 1.781985901061489e-07
845 O 0 3.8534221857844386e-07
G O 0 1.0407478612250998e-06
- O 0 6.9829627591389e-07
- O 0 2.2948595415073214e-06
> O 0 4.4085712858077386e-08
A O 0 2.1782426529171062e-08
( O 0 6.753031023265521e-09
C282Y O 0 8.461789491320815e-08
) O 0 1.835929408500192e-09
and O 0 1.94593785529662e-09
187 O 0 4.082039950503713e-08
C O 0 1.856415678958001e-07
- O 0 4.262212314642966e-06
- O 0 5.20507492183242e-05
> O 0 2.371407617829391e-06
G O 0 1.3185323041398078e-05
( O 0 9.970214165377911e-08
H63D O 0 5.0915828069264535e-06
) O 0 1.5733621694380417e-07
. O 0 3.8731630525035143e-07

Although O 0 0.0004529960569925606
hemochromatosis B-Disease 1 1.0
is O 0 5.633789328385319e-07
common O 0 6.679465514025651e-08
in O 0 2.451143643611431e-08
Caucasians O 0 2.1258097149257082e-06
, O 0 1.3945884447252865e-08
affecting O 0 2.7018023374125733e-08
> O 0 6.403931962495335e-08
= O 0 9.858325000777768e-08
1 O 0 9.162504532866933e-09
/ O 0 2.339748021995547e-07
300 O 0 4.0537799783635364e-09
individuals O 0 2.416506439395505e-10
of O 0 1.827937384790701e-10
northern O 0 7.626134390648076e-09
European O 0 5.5491522488182454e-09
origin O 0 3.257614622498295e-09
, O 0 3.304058360242834e-09
it O 0 5.387745805052191e-09
has O 0 8.750484425945615e-08
not O 0 3.88580279064854e-09
been O 0 9.823128976904627e-09
recognized O 0 2.2166157798153563e-09
in O 0 2.055892345254051e-09
other O 0 7.189441930677276e-09
populations O 0 3.2949668593573733e-07
. O 0 1.997580056922743e-07

The O 0 9.583934570400743e-07
present O 0 7.476296559616458e-08
study O 0 1.5035185541023566e-08
used O 0 1.0255041260620601e-08
PCR O 0 3.842732212433475e-07
and O 0 1.1092997631578783e-08
restriction O 0 1.9595519873405465e-08
- O 0 1.9198159861844033e-07
enzyme O 0 2.1788991944049485e-08
digestion O 0 3.479321364352472e-08
to O 0 1.3157083200709963e-09
analyze O 0 5.378443024284252e-09
the O 0 1.5921467477753026e-09
frequency O 0 1.5391586671853474e-08
of O 0 6.357630533138092e-10
the O 0 5.2910196224331685e-09
845 O 0 2.2507555286210845e-07
G O 0 1.3614759382107877e-06
- O 0 8.308771839438123e-07
- O 0 5.986018436487939e-07
> O 0 2.6083878168492447e-08
A O 0 7.395860368575313e-09
and O 0 1.2941198113125552e-09
187 O 0 1.0776914471932741e-08
C O 0 6.688299691859356e-08
- O 0 3.00267743114091e-07
- O 0 2.13786597669241e-06
> O 0 2.9756873232145153e-07
G O 0 1.6477264352943166e-06
mutations O 0 9.348587326485358e-08
in O 0 3.7933993723981985e-09
HLA O 0 7.927067713353608e-07
- O 0 1.3179649727135256e-07
typed O 0 1.0019054030863117e-07
samples O 0 1.2581910624476222e-08
from O 0 1.8092662923407943e-09
non O 0 7.227374698715039e-09
- O 0 1.185654923574475e-06
Caucasian O 0 1.6555673028051388e-06
populations O 0 2.497253070998795e-08
, O 0 1.8982841964998443e-09
comprising O 0 2.283983890905006e-09
Australian O 0 8.757458758168468e-09
Aboriginal O 0 3.336878862114645e-08
, O 0 3.673562565253974e-09
Chinese O 0 2.1865917965158133e-09
, O 0 3.0455367117099286e-09
and O 0 1.736808741270579e-08
Pacific O 0 2.0394669775214425e-07
Islanders O 0 3.489275286483462e-06
. O 0 4.419398749178072e-07

Results O 0 5.560477438848466e-05
showed O 0 3.778378641072777e-06
that O 0 4.38481206899155e-09
the O 0 7.580178262855952e-09
845 O 0 4.0773173282104835e-07
G O 0 3.4270376545464387e-06
- O 0 1.549139369672048e-06
- O 0 2.2967315089772455e-06
> O 0 1.0043966369721602e-07
A O 0 8.350327362904864e-08
mutation O 0 2.476539577855874e-07
was O 0 9.088170571658338e-08
present O 0 1.9534236450624576e-09
in O 0 1.3691225930756445e-09
these O 0 1.6283684400875131e-09
populations O 0 1.1564786461804033e-08
( O 0 2.1320156751158947e-09
allele O 0 2.3561225859225488e-08
frequency O 0 1.8946931135133127e-08
0 O 0 6.402598895505207e-09
. O 0 1.0297431796146839e-09
32 O 0 2.6100202887846535e-08
% O 0 1.9019916752682775e-09
) O 0 3.8235359323124385e-10
, O 0 1.7199524027233792e-09
and O 0 1.3436205925643208e-08
, O 0 5.5676308008401065e-09
furthermore O 0 4.816260723572441e-09
, O 0 2.209608496173132e-09
it O 0 1.0104412417888398e-08
was O 0 1.325107405136805e-06
always O 0 5.580413287020747e-08
seen O 0 1.2243422276014826e-08
in O 0 7.063895579584312e-10
conjunction O 0 7.487424014129829e-09
with O 0 7.585891026451463e-09
HLA O 0 1.8865970560000278e-05
haplotypes O 0 1.6853779243319877e-06
common O 0 2.8674158158992213e-08
in O 0 1.5139269393671384e-08
Caucasians O 0 6.948472446310916e-07
, O 0 8.605209877998732e-09
suggesting O 0 2.2416722700313585e-08
that O 0 2.5428608108057915e-09
845 O 0 1.2806039251245238e-07
G O 0 1.5470458265554043e-06
- O 0 1.3000378658034606e-06
- O 0 3.174756329826778e-06
> O 0 6.835477961431025e-08
A O 0 9.379271403986422e-08
may O 0 1.414458239423766e-07
have O 0 5.422570836799423e-09
been O 0 4.9739998786435535e-09
introduced O 0 3.077354593372661e-09
into O 0 1.920107406405691e-09
these O 0 1.2229598445046008e-09
populations O 0 1.0680328621504032e-08
by O 0 9.20859921649253e-09
Caucasian O 0 4.305997663323069e-06
admixture O 0 1.4301603187050205e-05
. O 0 1.8855056396205327e-06

187 O 0 3.7173515011090785e-05
C O 0 1.1126159733976237e-05
- O 0 7.008434749877779e-06
- O 0 9.989084901462775e-06
> O 0 9.221853360941168e-07
G O 0 7.588334483443759e-06
was O 0 2.694654597235058e-07
present O 0 2.8260029871773895e-09
at O 0 3.6960741134350883e-09
an O 0 4.324108182629516e-09
allele O 0 1.894773191679633e-07
frequency O 0 1.1043181302738958e-07
of O 0 1.3853862945722994e-08
2 O 0 1.0954771596516366e-06
. O 0 5.750222271672101e-07

68 O 0 0.00040186147089116275
% O 0 4.401010755827883e-07
in O 0 7.343555985528383e-09
the O 0 5.043480744149065e-09
two O 0 1.351140177519028e-08
populations O 0 7.001607826850886e-08
analyzed O 0 1.2534727034108073e-07
( O 0 4.465762870609069e-09
Australian O 0 2.2390441500874658e-08
Aboriginal O 0 4.553167443077655e-08
and O 0 2.795820286394246e-08
Chinese O 0 1.9028417952426935e-08
) O 0 5.723994078721262e-08
. O 0 2.231849691725074e-07

In O 0 1.1553385093066026e-06
the O 0 1.2623355871710373e-07
Australian O 0 1.4089759758917353e-07
Aboriginal O 0 9.400780953683352e-08
samples O 0 1.2244660396731888e-08
, O 0 2.062183757089997e-09
187 O 0 1.3049572089585126e-08
C O 0 5.060848451421407e-08
- O 0 2.3324074049924093e-07
- O 0 1.740461925692216e-06
> O 0 2.2726568715825124e-07
G O 0 2.842102276190417e-06
was O 0 1.4776607315525325e-07
found O 0 4.089854233058077e-09
to O 0 1.309954034134364e-09
be O 0 4.121837537951478e-09
associated O 0 5.248222745279918e-09
with O 0 6.233132676669584e-09
HLA O 0 1.8357173757976852e-05
haplotypes O 0 1.0705107342801057e-06
common O 0 1.69862186538694e-08
in O 0 2.126801668111966e-08
Caucasians O 0 8.614587727606704e-07
, O 0 2.36871215975043e-08
suggesting O 0 1.1860886672820925e-07
that O 0 5.4373812119479226e-09
it O 0 9.330948458341481e-09
was O 0 1.772386326592823e-07
introduced O 0 1.511843450430206e-08
by O 0 3.816273963508365e-09
recent O 0 5.586003837265707e-08
admixture O 0 4.9996165216725785e-06
. O 0 1.0641184644555324e-06

In O 0 7.504082191189809e-07
the O 0 2.7534147406527154e-08
Chinese O 0 9.513096976832003e-09
samples O 0 8.542576424019899e-09
analyzed O 0 1.043047159754451e-08
, O 0 1.2237882929255761e-09
187 O 0 1.3574377177860697e-08
C O 0 3.102551460187897e-08
- O 0 1.4801979375533847e-07
- O 0 1.933590738190105e-06
> O 0 2.5417571691832563e-07
G O 0 4.498998350754846e-06
was O 0 4.849516699323431e-07
present O 0 3.93941368415085e-09
in O 0 5.150660786767958e-09
association O 0 1.9094650305362393e-09
with O 0 5.447270967628981e-10
a O 0 6.856890166773155e-09
wide O 0 3.512313284659285e-08
variety O 0 2.9073079499397636e-09
of O 0 3.178148411109305e-09
HLA O 0 2.8678316539298976e-06
haplotypes O 0 6.964161798350688e-07
, O 0 5.796358948373381e-09
showing O 0 5.8348415876707804e-08
this O 0 1.2641800939405812e-09
mutation O 0 1.4371405399060677e-08
to O 0 6.519367823365485e-10
be O 0 5.142807513180969e-09
widespread O 0 1.6479473785580012e-08
and O 0 6.622544646006645e-08
likely O 0 4.4138467103493895e-08
to O 0 2.7759563536733367e-09
predate O 0 2.3573929297526774e-07
the O 0 2.341105531655785e-09
more O 0 9.161730818441072e-10
genetically O 0 1.634835911090704e-08
restricted O 0 1.6359340548888213e-08
845 O 0 4.4764337303604407e-07
G O 0 4.220658865961013e-06
- O 0 6.948114787519444e-06
- O 0 1.4688635019410867e-05
> O 0 5.02937211876997e-07
A O 0 5.603909585261135e-07
mutation O 0 7.3088872341031674e-06
. O 0 9.723178209242178e-07

Genotype O 0 0.26425421237945557
- O 0 0.030029190704226494
phenotype O 0 0.0026511976029723883
correlations O 0 0.0007374717388302088
in O 0 4.7287059715017676e-05
attenuated B-Disease 1 0.9997900128364563
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999982118606567
coli I-Disease 1 0.9999997615814209
. O 0 5.125398456584662e-05

Germ O 0 0.0024100053124129772
- O 0 0.004295863676816225
line O 0 5.238133599050343e-05
mutations O 0 1.0282519724569283e-06
of O 0 8.353732816601678e-09
the O 0 7.010186919842454e-08
tumor B-Disease 0 1.948355020431336e-05
suppressor O 0 9.36768192332238e-05
APC O 0 4.594115580403013e-06
are O 0 6.758522630434527e-08
implicated O 0 5.009763299312908e-06
in O 0 2.615068751765648e-06
attenuated B-Disease 1 0.9999321699142456
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 1.0
( O 0 0.0002640539896674454
AAPC B-Disease 1 0.9999997615814209
) O 0 3.1877519290901546e-07
, O 0 1.7719765210699734e-08
a O 0 9.505446740831758e-08
variant O 0 0.00019560716464184225
of O 0 6.619869964197278e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0001267946936422959
FAP B-Disease 0 0.0003610168641898781
) O 0 2.7214564397581853e-06
. O 0 2.9927052764833206e-06

AAPC B-Disease 1 0.9999983310699463
is O 0 3.4338752357143676e-06
recognized O 0 1.5373461792478338e-07
by O 0 7.909321197985264e-09
the O 0 7.606697494111359e-09
occurrence O 0 8.408695606476613e-08
of O 0 6.729629298263262e-09
< O 0 8.451238500128966e-07
100 O 0 5.5432522572118614e-08
colonic B-Disease 0 2.91152423415042e-06
adenomas I-Disease 0 1.4639046639786102e-05
and O 0 2.357588080315054e-08
a O 0 3.145470017784646e-08
later O 0 1.2665926760746515e-06
onset O 0 8.254233398474753e-05
of O 0 0.0001780567254172638
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.9014660185566754e-07
age O 0 1.4624021105191787e-07
> O 0 2.334073911924861e-07
40 O 0 1.3830120337843255e-07
years O 0 7.015484726480281e-08
) O 0 6.840812716291111e-08
. O 0 2.6566021915641613e-07

The O 0 7.806902431184426e-07
aim O 0 5.478984235196549e-07
of O 0 6.221658299665478e-09
this O 0 1.8712722482661093e-09
study O 0 7.068374330287952e-09
was O 0 5.2947783046874974e-08
to O 0 9.053858107677115e-09
assess O 0 8.807379003883398e-07
genotype O 0 3.513471529004164e-05
- O 0 0.0005075802328065038
phenotype O 0 3.644077878561802e-05
correlations O 0 7.902816832938697e-06
in O 0 2.855953653124743e-06
AAPC B-Disease 1 0.9999997615814209
families O 0 5.66101562071708e-06
. O 0 1.6418097175119328e-06

By O 0 3.91920366382692e-07
protein O 0 1.1304130111966515e-06
- O 0 1.6741370245654252e-06
truncation O 0 3.127952140857815e-06
test O 0 1.1521604648123684e-07
( O 0 1.7764298476663498e-08
PTT O 0 1.928392521222122e-07
) O 0 2.2922759246313262e-09
assay O 0 2.6256083529574425e-08
, O 0 1.5374679307456063e-09
the O 0 8.476659374423434e-10
entire O 0 8.047478239348038e-09
coding O 0 2.437242301311926e-07
region O 0 3.1614273865443465e-08
of O 0 1.4595653574644984e-09
the O 0 7.2534342976382504e-09
APC B-Disease 0 1.90797933896647e-07
gene O 0 5.301387062672802e-08
was O 0 8.174154686457769e-07
screened O 0 1.293389431111791e-07
in O 0 7.858375283831265e-09
affected O 0 2.8618263314683645e-08
individuals O 0 2.961975997806121e-09
from O 0 8.429616116245597e-09
11 O 0 8.19447109279281e-07
AAPC B-Disease 1 0.9999866485595703
kindreds O 0 3.281241515651345e-05
, O 0 2.858662107030341e-08
and O 0 6.891188952806715e-09
their O 0 7.195779527791046e-09
phenotypic O 0 1.095289121622045e-06
differences O 0 1.4464155810856028e-06
were O 0 7.619368602718168e-07
examined O 0 4.9990917432296555e-06
. O 0 1.0017198519562953e-06

Five O 0 5.779543243988883e-06
novel O 0 3.4971503737324383e-06
germ O 0 4.780986637342721e-05
- O 0 0.00013194166240282357
line O 0 8.49847710924223e-05
APC B-Disease 0 6.657030553469667e-06
mutations O 0 1.5805009070390952e-06
were O 0 6.455993428744478e-08
identified O 0 1.6194650243051e-07
in O 0 4.546458853837976e-08
seven O 0 7.584475270050461e-07
kindreds O 0 0.00023540858819615096
. O 0 2.1497505713341525e-06

Mutations O 0 0.00214498583227396
were O 0 6.522110425066785e-07
located O 0 4.1962465502365376e-08
in O 0 5.294310767567367e-09
three O 0 6.826719634034362e-09
different O 0 2.4245734309147338e-09
regions O 0 7.127535894824177e-09
of O 0 1.061936427682042e-09
the O 0 1.3679173349601115e-08
APC B-Disease 0 3.792938798596879e-07
gene O 0 4.6796355235301235e-08
( O 0 2.019298950273196e-09
1 O 0 2.563953493961435e-09
) O 0 8.952213970125911e-10
at O 0 1.8169921123245558e-09
the O 0 1.8372744436945254e-09
5 O 0 6.458294343758553e-09
end O 0 1.5061964120377525e-08
spanning O 0 5.225372490258451e-08
exons O 0 2.495634703336691e-07
4 O 0 4.092704841696104e-08
and O 0 1.4320537644607612e-08
5 O 0 2.2985773284744937e-08
, O 0 2.483296901445442e-09
( O 0 1.3411517452155408e-09
2 O 0 1.8318193628630297e-09
) O 0 4.568568856555544e-10
within O 0 5.386777135463205e-10
exon O 0 3.525044789398635e-08
9 O 0 8.789425010036211e-08
, O 0 4.830206901118572e-09
and O 0 2.4475790283418064e-08
( O 0 2.9439077842141614e-09
3 O 0 7.141089497508801e-09
) O 0 8.488242886350861e-10
at O 0 2.482917871304835e-09
the O 0 4.053315905139243e-09
3 O 0 5.704897887426341e-08
distal O 0 2.052553099929355e-06
end O 0 2.0412181811479968e-07
of O 0 2.75348166489664e-09
the O 0 2.680812549726852e-08
gene O 0 1.0659721283445833e-06
. O 0 4.917741875942738e-07

Variability O 0 0.00037795951357111335
in O 0 1.4655016400411114e-07
the O 0 1.222170098458264e-08
number O 0 8.503808146542724e-08
of O 0 3.2038976769399596e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.0035152225755155087
most O 0 1.3117048780486584e-08
apparent O 0 9.736598372001026e-08
in O 0 4.513037943354448e-09
individuals O 0 1.4124376113144876e-09
with O 0 4.5054351360818146e-09
mutations O 0 5.621788545795425e-07
in O 0 8.780004279174136e-09
region O 0 9.591919791773762e-08
1 O 0 3.542312398963077e-08
, O 0 6.489361048522824e-09
and O 0 9.07175206066313e-08
upper O 0 1.4155030839901883e-05
- O 0 0.19330057501792908
gastrointestinal O 0 0.00021140022727195174
manifestations O 0 6.032483952367329e-07
were O 0 2.2089929530011432e-07
more O 0 1.5385365870201895e-08
severe O 0 6.0199031395313796e-06
in O 0 2.2845471292498587e-08
them O 0 6.750496339691381e-08
. O 0 5.542035523831146e-07

In O 0 5.911034577366081e-07
individuals O 0 3.235219736552608e-08
with O 0 1.0730642152623204e-08
mutations O 0 4.465033214273717e-07
in O 0 7.326879103430883e-09
either O 0 1.794215265249477e-08
region O 0 7.586618266941514e-08
2 O 0 1.9984891252988746e-07
or O 0 2.7162080584730575e-08
region O 0 3.123761160850336e-08
3 O 0 3.277765969755819e-08
, O 0 2.4261090914023953e-09
the O 0 1.5419316934384142e-09
average O 0 1.3499242612624585e-08
number O 0 3.7164524235855367e-10
of O 0 1.1714612613289432e-09
adenomas B-Disease 0 8.173008723133535e-07
tended O 0 3.161385393468663e-07
to O 0 3.897530298502261e-09
be O 0 3.024183126143498e-09
lower O 0 1.0078081480457968e-08
than O 0 6.594958468220113e-10
those O 0 2.1717190545889054e-10
in O 0 5.051614127005166e-10
individuals O 0 2.0356791252673645e-10
with O 0 8.428678865968209e-10
mutations O 0 6.66341932742398e-08
in O 0 3.316054097979304e-09
region O 0 4.4903124774009484e-08
1 O 0 1.4080002941341263e-08
, O 0 3.368235468315106e-09
although O 0 8.718194166590365e-09
age O 0 2.0756411700517674e-08
at O 0 3.261918735120162e-08
diagnosis O 0 6.54437417324516e-06
was O 0 1.2550892733997898e-06
similar O 0 2.014787696680287e-07
. O 0 6.077015086702886e-07

In O 0 7.661340532649774e-06
all O 0 1.0710050446505193e-06
AAPC B-Disease 1 0.9999611377716064
kindreds O 0 8.255193097284064e-05
, O 0 3.995930697442418e-08
a O 0 3.206976728620248e-08
predominance O 0 3.002797029694193e-06
of O 0 1.0742932232687963e-07
right O 0 0.002940321806818247
- O 1 0.9999583959579468
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 7.823731721146032e-05
rectal B-Disease 1 0.9914933443069458
polyp I-Disease 0 0.0020928194280713797
sparing O 0 1.548025647934992e-05
was O 0 7.2475977503927425e-06
observed O 0 4.786783392773941e-06
. O 0 4.622206120075134e-07

No O 0 9.932363172993064e-05
desmoid B-Disease 0 0.14802832901477814
tumors I-Disease 1 1.0
were O 0 5.490672265295871e-06
found O 0 6.755944781389189e-08
in O 0 3.113375868224466e-08
these O 0 6.812517483467673e-08
kindreds O 0 8.639742009108886e-05
. O 0 1.520157297818514e-06

Our O 0 2.8798770017601782e-06
data O 0 1.7833731646987871e-07
suggest O 0 5.8535455593755614e-08
that O 0 4.908705886208509e-09
, O 0 9.027716352250081e-09
in O 0 7.745566676931048e-08
AAPC B-Disease 1 0.9999998807907104
families O 0 3.97011660879798e-07
, O 0 1.8439096916011977e-09
the O 0 6.559631726688053e-10
location O 0 1.8763875786476092e-08
of O 0 1.8810810686886725e-09
the O 0 7.497001064393771e-08
APC B-Disease 0 1.4286225450632628e-05
mutation O 0 4.592276127368677e-06
may O 0 2.383278143724965e-07
partially O 0 6.239129675122967e-07
predict O 0 1.6664944268995896e-07
specific O 0 2.569119317286095e-08
phenotypic O 0 3.7599779716401827e-06
expression O 0 3.1174695322988555e-06
. O 0 8.12302062058734e-07

This O 0 4.853148993788636e-07
should O 0 6.525792883849135e-08
help O 0 1.098104718266768e-08
in O 0 1.5008558840179376e-09
the O 0 1.7592695078505471e-09
design O 0 4.3130974347604933e-08
of O 0 2.6663136143412203e-09
tailored O 0 2.529714492993662e-06
clinical O 0 2.1198769672992057e-07
- O 0 1.3198772649047896e-05
management O 0 2.053612391250681e-08
protocols O 0 1.242506098009244e-08
in O 0 2.4101969309242577e-09
this O 0 1.4679578663745474e-09
subset O 0 5.50794574394331e-08
of O 0 2.7901730703661087e-08
FAP B-Disease 0 1.3110819054418243e-05
patients O 0 8.204621053664596e-07
. O 0 6.690570586442846e-08
. O 0 5.028873601986561e-07

Wilms B-Disease 0 0.02462955377995968
' I-Disease 0 0.00025427344371564686
tumor I-Disease 0 5.273131682770327e-05
1 O 0 3.7090916293891496e-07
and O 0 7.616717567771047e-08
Dax O 0 0.289183109998703
- O 0 7.593314876430668e-06
1 O 0 4.4131567733529664e-08
modulate O 0 2.3002159821317036e-07
the O 0 1.3450667246672765e-08
orphan O 0 1.033865714816784e-06
nuclear O 0 9.388310218128026e-08
receptor O 0 2.519198289974156e-07
SF O 0 1.052673178492114e-05
- O 0 4.807333766621014e-07
1 O 0 7.293026627053223e-09
in O 0 2.0634192132718e-09
sex O 0 5.485624754442142e-08
- O 0 3.463550513060909e-07
specific O 0 3.660394298776737e-08
gene O 0 6.219050305844576e-07
expression O 0 8.825372219689598e-07
. O 0 2.5609938347770367e-07

Products O 0 6.82564177623135e-06
of O 0 3.187949459970696e-07
steroidogenic O 0 2.6720133973867632e-05
factor O 0 4.6345252258106484e-07
1 O 0 2.0333803263383743e-07
( O 0 5.28418482304005e-08
SF O 0 0.00024799659149721265
- O 0 1.249205342901405e-05
1 O 0 6.917028372299683e-08
) O 0 9.97186511142445e-09
and O 0 4.938515019148326e-08
Wilms B-Disease 0 6.388394831446931e-05
tumor I-Disease 0 4.961295871908078e-06
1 O 0 5.0157879627477087e-08
( O 0 3.491580358172541e-08
WT1 O 0 3.697105967148673e-06
) O 0 8.625635317116576e-09
genes O 0 3.036582540971722e-08
are O 0 6.286499099061871e-10
essential O 0 1.7210615155249798e-09
for O 0 2.2697179691277825e-09
mammalian O 0 1.6859729612406227e-07
gonadogenesis O 0 1.1720250086000306e-06
prior O 0 1.2388145620434443e-08
to O 0 4.8143871111960834e-09
sexual O 0 1.289058531028786e-07
differentiation O 0 1.5331866052292753e-06
. O 0 4.852454935644346e-07

In O 0 2.141436880265246e-06
males O 0 1.4297482948677498e-06
, O 0 6.672258479056836e-08
SF O 0 0.0003701027890201658
- O 0 9.86371287581278e-06
1 O 0 4.269822184710392e-08
participates O 0 9.377013832079228e-09
in O 0 2.1448434139870187e-09
sexual O 0 8.501841008978772e-09
development O 0 9.535563449958318e-10
by O 0 9.158498404104876e-10
regulating O 0 2.9925967481858606e-08
expression O 0 1.446016106854131e-08
of O 0 2.477373861609067e-09
the O 0 4.608543591189118e-08
polypeptide O 0 1.583838093210943e-05
hormone O 0 2.5566066597093595e-06
Mullerian O 0 4.66341371065937e-05
inhibiting O 0 7.498740615119459e-06
substance O 0 2.6252837415086105e-06
( O 0 6.774203029635828e-07
MIS O 0 0.001212214701808989
) O 0 5.53039910755615e-07
. O 0 1.0391529485787032e-06

Here O 0 9.927791325026192e-06
, O 0 2.4296119249811454e-07
we O 0 2.8915977168253448e-08
show O 0 1.1662566379300188e-07
that O 0 2.532682685796317e-08
WT1 O 0 2.6726429496193305e-05
- O 0 2.26412812480703e-05
KTS O 0 4.3576375901466236e-05
isoforms O 0 3.8918724953873607e-07
associate O 0 7.263779622235234e-08
and O 0 2.880028127094647e-08
synergize O 0 2.3321256321651163e-06
with O 0 8.032913711986112e-08
SF O 0 0.029792597517371178
- O 0 1.5426643585669808e-05
1 O 0 8.970544485009668e-08
to O 0 3.126526948449282e-08
promote O 0 6.722793841618113e-07
MIS O 0 0.004284196998924017
expression O 0 5.701477221009554e-06
. O 0 9.07332434962882e-07

In O 0 1.7103408254115493e-06
contrast O 0 2.334869577680365e-06
, O 0 1.6427981108790846e-07
WT1 O 0 0.0001316780981142074
missense O 0 0.0003765536821447313
mutations O 0 1.6259526091744192e-05
, O 0 2.4216028293722047e-08
associated O 0 7.116128131201549e-08
with O 0 5.979752870644006e-08
male B-Disease 0 3.452848977758549e-05
pseudohermaphroditism I-Disease 1 0.9999996423721313
in O 0 3.18673824040161e-06
Denys B-Disease 1 0.9997289776802063
- I-Disease 1 0.9999957084655762
Drash I-Disease 1 0.9998677968978882
syndrome I-Disease 1 0.9998974800109863
, O 0 4.62021390035261e-08
fail O 0 1.1418563161669226e-07
to O 0 1.120318326996994e-08
synergize O 0 8.013621481950395e-06
with O 0 3.515591799896356e-07
SF O 1 0.8935964703559875
- O 0 0.0005662987241521478
1 O 0 1.3816754744766513e-06
. O 0 1.1413580978114624e-06

Additionally O 0 4.3459244807309005e-06
, O 0 4.579260703962973e-08
the O 0 8.086544767138548e-09
X O 0 3.727272996911779e-05
- O 0 0.0005781498621217906
linked O 0 1.0429245776322205e-05
, O 0 1.2320258591103084e-08
candidate O 0 6.903189841978019e-08
dosage O 0 2.1302673758327728e-07
- O 0 3.046604888368165e-07
sensitive O 0 1.1586725889856098e-07
sex O 0 8.492008163329956e-08
- O 0 5.03490582559607e-07
reversal O 0 3.2978712738440663e-07
gene O 0 8.921131211536704e-08
, O 0 1.370021873725591e-08
Dax O 0 0.000320343766361475
- O 0 1.263866920453438e-06
1 O 0 1.921295478268803e-08
, O 0 4.8606123570493764e-09
antagonizes O 0 6.355514301503717e-07
synergy O 0 2.47313124646098e-07
between O 0 5.3844505742972615e-08
SF O 0 0.0012468789936974645
- O 0 1.5958657968440093e-05
1 O 0 9.267524347933431e-08
and O 0 2.086580863647214e-08
WT1 O 0 2.3374716420221375e-06
, O 0 7.61726681730579e-09
most O 0 1.3912719865061263e-09
likely O 0 2.6614053183493525e-09
through O 0 2.7303700966818667e-10
a O 0 1.4340292286973977e-09
direct O 0 3.573254359068301e-09
interaction O 0 1.1388422649361019e-08
with O 0 3.2004141559127675e-08
SF O 0 0.3730456829071045
- O 0 8.771436114329845e-05
1 O 0 5.868603807357431e-07
. O 0 3.783690090131131e-07

We O 0 3.7380507365014637e-06
propose O 0 1.5797113519511186e-06
that O 0 4.2894289009609565e-08
WT1 O 0 1.0402504813100677e-05
and O 0 4.055955855619686e-07
Dax O 0 0.48657387495040894
- O 0 3.3053049264708534e-05
1 O 0 5.1215195639997546e-08
functionally O 0 9.585811255874432e-08
oppose O 0 2.4150022426283613e-08
each O 0 1.4368053413704729e-09
other O 0 1.522756032379391e-09
in O 0 7.555883918541895e-09
testis O 0 5.237181426309689e-07
development O 0 4.914541662515148e-09
by O 0 7.810691649012824e-09
modulating O 0 2.2403144157578936e-06
SF O 0 0.001184887601993978
- O 0 1.774396514520049e-05
1 O 0 2.443642870275653e-07
- O 0 8.392516065214295e-06
mediated O 0 9.869659152172972e-06
transactivation O 0 1.914850145112723e-05
. O 0 1.9740063805784303e-07
. O 0 4.4927028852725925e-07

A O 0 1.2070918273821007e-05
mouse O 0 2.168622631870676e-05
model O 0 2.9397174330370035e-06
for O 0 1.2854213764512679e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999992847442627
imprinting O 0 0.001004796358756721
- O 0 0.03204135596752167
centre O 0 5.980739661026746e-05
mutations O 0 6.517591828014702e-05
. O 0 2.2317547063721577e-06

Imprinting O 0 0.00026268427609466016
in O 0 7.522497185163957e-07
the O 0 1.2352310818641854e-07
15q11 O 0 4.60100864074775e-06
- O 0 1.1935591828660108e-05
q13 O 0 1.166558604381862e-06
region O 0 5.79207402040538e-08
involves O 0 2.0784460375011804e-08
an O 0 3.0528766181703304e-09
imprinting O 0 4.32911338066333e-06
centre O 0 2.3553484425065108e-06
( O 0 1.7849037803330248e-08
IC O 0 1.8159160219965997e-07
) O 0 1.8965324866115907e-09
, O 0 7.015825698175604e-10
mapping O 0 2.4474390514228617e-08
in O 0 2.2897284068790213e-09
part O 0 1.0835781161233626e-08
to O 0 5.384930723550951e-09
the O 0 1.2839564966782291e-08
promoter O 0 3.0483156479022e-06
and O 0 2.679805533034596e-08
first O 0 2.951189514988073e-08
exon O 0 8.986519901554857e-07
of O 0 1.2093933321466466e-07
SNRPN O 0 0.00021000199194531888
. O 0 8.587617799094005e-07

Deletion O 0 0.0001183858621516265
of O 0 4.89229478262132e-07
this O 0 1.0617206669394363e-07
IC O 0 6.334013505693292e-06
abolishes O 0 8.126119610096794e-06
local O 0 2.096858651157163e-07
paternally O 0 2.682531658138032e-06
derived O 0 1.1910216812793806e-07
gene O 0 2.156552199039652e-07
expression O 0 8.375130988724777e-08
and O 0 3.1857119608957873e-08
results O 0 3.0514755167132535e-07
in O 0 1.0042344001703896e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.317554026376456e-05
PWS B-Disease 1 0.9999994039535522
) O 0 3.054723947570892e-06
. O 0 1.6901261687962688e-06

We O 0 5.940165010542842e-06
have O 0 3.87347611763289e-08
created O 0 2.6029210786759904e-08
two O 0 1.0384279214292746e-08
deletion O 0 5.10482141180546e-06
mutations O 0 1.5687279528719955e-06
in O 0 2.0481163431895766e-08
mice O 0 1.377288754156325e-05
to O 0 1.332402348452888e-07
understand O 0 1.2467266969906632e-06
PWS B-Disease 1 1.0
and O 0 1.0783168846728586e-07
the O 0 4.708740952708013e-09
mechanism O 0 2.2814379718738564e-08
of O 0 3.521273050921536e-09
this O 0 2.4462162073746185e-08
IC O 0 7.194689715106506e-06
. O 0 3.8818603798063123e-07

Mice O 0 0.008559172973036766
harbouring O 0 7.251277565956116e-05
an O 0 2.375966090539805e-07
intragenic O 0 1.3411849067779258e-05
deletion O 0 5.838052402395988e-06
in O 0 1.285826840558002e-07
Snrpn O 0 1.64435914484784e-05
are O 0 3.6237576495068424e-08
phenotypically O 0 1.7954565691979951e-06
normal O 0 1.246734484539047e-07
, O 0 3.8080720798916445e-09
suggesting O 0 2.1903288072167015e-08
that O 0 2.860155001727094e-09
mutations O 0 7.40236956175977e-08
of O 0 2.2514707875842532e-09
SNRPN O 0 2.3030612283037044e-05
are O 0 7.269139956633808e-09
not O 0 2.4688735500433268e-09
sufficient O 0 8.870514101033677e-09
to O 0 3.6501596412108483e-08
induce O 0 2.4074284738162532e-05
PWS B-Disease 1 0.9999983310699463
. O 0 2.614188588268007e-06

Mice O 0 0.0010152991162613034
with O 0 1.1099731977992633e-07
a O 0 5.6074927812233e-08
larger O 0 5.635498823153284e-08
deletion O 0 6.378296575348941e-07
involving O 0 2.8722601186359498e-08
both O 0 2.4284068089741595e-08
Snrpn O 0 6.798110462113982e-06
and O 0 6.188852097466224e-08
the O 0 5.310657158474896e-08
putative O 0 0.0002083416620735079
PWS O 1 0.9999997615814209
- O 0 0.0421915240585804
IC O 0 1.7558699255459942e-05
lack O 0 1.0354537494094984e-07
expression O 0 4.8519549267211914e-08
of O 0 2.8697559883994472e-09
the O 0 1.3597907688733812e-08
imprinted O 0 2.255585241073277e-05
genes O 0 1.3439149597616051e-06
Zfp127 O 0 8.947456990426872e-06
( O 0 3.090644185022029e-08
mouse O 0 9.111529379879357e-07
homologue O 0 2.5814958917180775e-06
of O 0 1.3944129406695538e-08
ZNF127 O 0 2.5538271074765362e-05
) O 0 2.27603109692609e-08
, O 0 1.5861159496921573e-08
Ndn O 0 5.602875262411544e-06
and O 0 1.2101843971379367e-08
Ipw O 0 7.16608099082805e-07
, O 0 3.6490458654725444e-08
and O 0 2.4634280393343033e-08
manifest O 0 4.903701622538392e-08
several O 0 8.77643824281904e-09
phenotypes O 0 2.7900300665351097e-06
common O 0 1.6249632039944117e-07
to O 0 2.9077309591230005e-06
PWS B-Disease 1 1.0
infants O 0 0.057464033365249634
. O 0 1.1254089713474968e-06

These O 0 1.3325853842616198e-07
data O 0 5.983746831361714e-08
demonstrate O 0 2.897499662424252e-08
that O 0 1.287617346079628e-09
both O 0 2.0237020947888595e-09
the O 0 4.200881420501901e-09
position O 0 1.1315502490560903e-07
of O 0 8.818601404669835e-10
the O 0 7.774766608292794e-09
IC O 0 3.364706344655133e-07
and O 0 8.189547706649591e-09
its O 0 6.630653248684837e-10
role O 0 2.2001296340334875e-09
in O 0 7.186503614420303e-10
the O 0 8.882106716789906e-10
coordinate O 0 2.6456866919488675e-08
expression O 0 1.2034308660702209e-08
of O 0 7.311324323744373e-10
genes O 0 9.244235599226158e-09
is O 0 1.3518973718262828e-09
conserved O 0 7.878606211875194e-09
between O 0 7.020326986406644e-09
mouse O 0 9.653065717429854e-06
and O 0 5.027779792499132e-08
human O 0 7.493152764936895e-09
, O 0 3.1783062848234067e-09
and O 0 6.745075165071057e-09
indicate O 0 1.4032067952030047e-08
that O 0 4.669484798824897e-10
the O 0 1.7398946727809061e-09
mouse O 0 1.8900244640462915e-06
is O 0 1.4374248458182137e-09
a O 0 1.2501981672130569e-09
suitable O 0 4.211454740499221e-09
model O 0 1.8607984486607165e-08
system O 0 9.585003013512505e-09
in O 0 2.0957575674884765e-09
which O 0 6.279335718062384e-09
to O 0 4.834628808403352e-10
investigate O 0 3.106149781828549e-09
the O 0 8.876619439490696e-10
molecular O 0 9.406858403337992e-09
mechanisms O 0 3.98016775093879e-09
of O 0 6.153065834624272e-10
imprinting O 0 1.7374005665260484e-06
in O 0 3.634826484244513e-08
this O 0 4.657869645541268e-09
region O 0 8.010785812473387e-09
of O 0 1.1876916117259384e-09
the O 0 1.8814478863760087e-08
genome O 0 2.115014297032758e-07
. O 0 3.5338839410314904e-08
. O 0 1.980544084290159e-07

Mutations O 0 0.00010665796435205266
of O 0 3.9578225141667644e-08
the O 0 4.098258798990173e-08
ATM O 0 1.9960730242019054e-06
gene O 0 1.1074056374127395e-06
detected O 0 8.265864721579419e-07
in O 0 9.68937570178241e-08
Japanese O 0 2.9930713935755193e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 2.2168629584484734e-05
: O 0 6.7083298915804335e-09
possible O 0 5.141964187771464e-09
preponderance O 0 2.370877894009027e-07
of O 0 4.201618164501042e-09
the O 0 1.2268809079785115e-08
two O 0 8.329632095183115e-08
founder O 0 7.475021902791923e-06
mutations O 0 2.0971697267668787e-06
4612del165 O 0 8.021075927899801e-07
and O 0 7.386348244153851e-08
7883del5 O 0 8.049144526012242e-06
. O 0 8.15596479242231e-07

The O 0 1.4077419336899766e-06
ATM O 0 1.5622988939867355e-05
( O 0 1.0216814416708075e-06
A O 1 0.9907221794128418
- O 1 0.999969482421875
T O 1 0.9999998807907104
, O 0 2.601565896043212e-08
mutated O 0 3.7367709637692315e-07
) O 0 9.525225941331428e-09
gene O 0 6.359309878689601e-08
on O 0 2.0981006798592716e-07
human O 0 3.5904659512198123e-07
chromosome O 0 0.0001758159778546542
11q22 O 0 3.276363713666797e-05
. O 0 1.0419971658848226e-06

3 O 0 4.547473508864641e-05
has O 0 6.658171969320392e-07
recently O 0 1.1408335467422148e-06
been O 0 4.698166122807379e-08
identified O 0 3.058502429098553e-08
as O 0 1.897835222308686e-09
the O 0 2.1878263645191964e-09
gene O 0 2.8321343492621054e-08
responsible O 0 7.04267044682183e-09
for O 0 1.2373474467253232e-09
the O 0 4.6000423026271164e-08
human O 0 1.2593607607414015e-05
recessive B-Disease 1 0.9999904632568359
disease I-Disease 1 0.9998869895935059
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0005744871450588107
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.939918767377094e-07
. O 0 4.997453402211249e-07

In O 0 6.887452741466404e-07
order O 0 2.0986226090258242e-08
to O 0 2.566551637883663e-09
define O 0 2.1305208264266184e-08
the O 0 3.5439797763103797e-09
types O 0 1.2767085166842662e-08
of O 0 1.1220375739640076e-08
disease O 0 4.397735210659448e-06
- O 0 3.4243555546709104e-06
causing O 0 1.6985433148875018e-07
ATM O 0 5.069988446848583e-07
mutations O 0 1.5949171938700601e-07
in O 0 4.870719383376354e-09
Japanese O 0 1.084537899487259e-07
A B-Disease 1 0.9999861717224121
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 3.8144827385622193e-07
as O 0 4.0847871751736875e-09
well O 0 1.6525072421558207e-09
as O 0 1.2256453629788666e-09
to O 0 9.913659893001636e-10
look O 0 8.36797386938315e-09
for O 0 5.468976937983427e-10
possible O 0 5.49792966708651e-09
mutational O 0 1.398322069690039e-06
hotspots O 0 9.70353880802577e-07
, O 0 1.3505321305729012e-08
reverse O 0 3.581645842132275e-07
- O 0 2.0957400010956917e-06
transcribed O 0 5.756576229032362e-07
RNA O 0 7.146256564283249e-08
derived O 0 5.687750270766401e-09
from O 0 1.6819051706917776e-09
ten O 0 6.712182365475883e-09
patients O 0 1.0066901090510783e-08
belonging O 0 6.731400770121354e-09
to O 0 2.070894788985811e-09
eight O 0 7.359653775296238e-09
unrelated O 0 4.837511724531396e-08
Japanese O 0 2.1992289589434222e-07
A B-Disease 1 0.9990585446357727
- I-Disease 1 0.9998997449874878
T I-Disease 1 1.0
families O 0 1.3055526437710796e-07
was O 0 8.766321002440236e-08
analyzed O 0 2.7979218941709405e-08
for O 0 2.879620097928637e-09
mutations O 0 1.0370310121743387e-07
by O 0 1.0514979997822138e-09
the O 0 4.617506821347206e-09
restriction O 0 1.2289365258766338e-07
endonuclease O 0 2.3062398213369306e-06
fingerprinting O 0 9.676371064415434e-07
method O 0 6.920722626091447e-07
. O 0 4.855130555370124e-07

As O 0 2.7281141683488386e-06
has O 0 3.147283109683485e-07
been O 0 7.76524089474151e-08
reported O 0 1.8230564080568001e-07
by O 0 1.3749951177643993e-09
others O 0 1.8776191268443654e-08
, O 0 4.779782791786147e-09
mutations O 0 5.726538176986651e-08
that O 0 1.954776562840266e-09
lead O 0 3.212002752661647e-08
to O 0 7.772216648049834e-09
exon O 0 6.143374093880993e-07
skipping O 0 1.2896404086859548e-06
or O 0 2.3388848546801455e-07
premature O 0 3.3107789931818843e-07
protein O 0 7.982205829648592e-08
truncation O 0 2.8308490982453804e-06
were O 0 2.220981514255982e-06
also O 0 1.7302890853443387e-07
predominant O 0 4.485750366711727e-07
in O 0 1.5982509538048362e-08
our O 0 8.280857599629599e-08
mutants O 0 6.3464449340244755e-06
. O 0 4.2173974179604556e-07

Six O 0 2.6549710128165316e-06
different O 0 2.403853898158559e-07
mutations O 0 2.237210082967067e-06
were O 0 7.316338468399408e-08
identified O 0 1.1734940130736504e-07
on O 0 3.2213074518949725e-07
12 O 0 4.8160426757704045e-08
of O 0 1.2098121393577799e-09
the O 0 1.4952222571196216e-08
16 O 0 2.4469704840157647e-07
alleles O 0 8.003745506357518e-07
examined O 0 1.7984624491873547e-06
. O 0 4.7634446787014895e-07

Four O 0 2.5620397536840755e-06
were O 0 1.7730879164901125e-07
deletions O 0 9.634032949179527e-07
involving O 0 5.713010153840514e-08
a O 0 5.354882546271256e-07
loss O 0 8.05531897185574e-07
of O 0 1.923622816590864e-09
a O 0 6.966507015704337e-08
single O 0 3.922868074823782e-07
exon O 0 1.6031794984883163e-06
exon O 0 2.1826567717653234e-06
7 O 0 5.113305974191462e-07
, O 0 1.4179881269171801e-08
exon O 0 8.272410241261241e-07
16 O 0 1.7690175013740372e-07
, O 0 1.1928638521396806e-08
exon O 0 8.965624260781624e-07
33 O 0 1.0844836424439563e-06
or O 0 8.105417492743072e-08
exon O 0 5.867143499926897e-06
35 O 0 2.325531568203587e-06
. O 0 8.870262035998167e-07

The O 0 1.7192173800140154e-06
others O 0 6.299732149273041e-07
were O 0 4.708608614123477e-08
minute O 0 1.208134534635974e-07
deletions O 0 3.944867614791292e-07
, O 0 9.920927190876228e-09
4649delA O 0 1.823569419912019e-07
in O 0 9.340705986460307e-09
exon O 0 1.4141454585114843e-06
33 O 0 8.580528287893685e-07
and O 0 2.2466846161250942e-08
7883del5 O 0 3.521722362620494e-07
in O 0 2.4543762577877715e-08
exon O 0 4.821607944904827e-06
55 O 0 1.7432525964977685e-06
. O 0 6.915483936609235e-07

The O 0 3.029877234439482e-06
mutations O 0 5.029486601415556e-06
4612del165 O 0 3.181509327987442e-06
and O 0 6.12702564239953e-08
7883del5 O 0 1.9606475234468235e-06
were O 0 7.557026293625313e-08
found O 0 2.950653499311784e-09
in O 0 9.942479062274856e-10
more O 0 3.850210983369351e-10
than O 0 3.595505837505897e-10
two O 0 1.3269864096443484e-09
unrelated O 0 2.7611720909703763e-08
families O 0 8.985850286080677e-09
; O 0 4.44840386748524e-09
44 O 0 1.71768466117328e-08
% O 0 2.6589548340894e-09
( O 0 9.745749762757328e-10
7 O 0 8.083738123332296e-09
of O 0 8.713601507004398e-10
16 O 0 4.376558848662171e-08
) O 0 5.709507866491492e-10
of O 0 2.1860277477081524e-10
the O 0 5.644047451625056e-09
mutant O 0 1.5424847106260131e-06
alleles O 0 1.378754461711651e-07
had O 0 8.963033906184137e-07
one O 0 3.585850949505698e-09
of O 0 8.136840090600117e-10
the O 0 8.898473957685837e-09
two O 0 2.383014390261451e-07
mutations O 0 1.1205137525394093e-05
. O 0 4.345590980392444e-07

The O 0 9.6021494755405e-07
4612del165 O 0 1.0327627023798414e-05
mutations O 0 1.3700450836040545e-06
in O 0 3.36666849953815e-09
three O 0 5.318459894709804e-09
different O 0 3.908257273366189e-09
families O 0 1.238127680380785e-07
were O 0 1.049743616476917e-07
all O 0 9.019019975298193e-10
ascribed O 0 4.35470930426618e-08
to O 0 9.494964814393825e-10
the O 0 1.8551276070866152e-09
same O 0 1.3457031933228336e-08
T O 0 2.012818413277273e-06
- O 0 4.3884998035537137e-07
- O 0 2.8064050638931803e-07
> O 0 9.95246551838136e-09
A O 0 4.8402406527259245e-09
substitution O 0 1.2050088926685021e-08
at O 0 4.427698652165191e-09
the O 0 2.7275970371221092e-09
splice O 0 1.8294235815119464e-06
donor O 0 1.3351370853342814e-07
site O 0 9.302519288212352e-08
in O 0 2.124385467539014e-08
intron O 0 5.500533734448254e-05
33 O 0 4.049025392305339e-06
. O 0 4.394400718865654e-07

Microsatellite O 0 0.001292213681153953
genotyping O 0 0.00010007650416810066
around O 0 9.42674148518563e-07
the O 0 2.325517023393786e-08
ATM O 0 1.4113121551417862e-06
locus O 0 2.3407440039591165e-06
also O 0 3.7295757238098304e-07
indicated O 0 8.868589418398187e-08
that O 0 2.0704880032695883e-09
a O 0 8.202992063388592e-09
common O 0 6.981205302736271e-08
haplotype O 0 2.796660555759445e-05
was O 0 8.657499165565241e-06
shared O 0 1.615444489289075e-08
by O 0 1.606358157602017e-09
the O 0 5.028486960156897e-09
mutant O 0 5.188437626202358e-07
alleles O 0 8.462660616714857e-08
in O 0 2.7806635216620634e-08
both O 0 3.057706692288775e-07
mutations O 0 1.608236379979644e-05
. O 0 6.345920837702579e-07

This O 0 7.285215701813286e-07
suggests O 0 5.353177243705431e-07
that O 0 5.035762473681871e-09
these O 0 1.4518162227972198e-09
two O 0 2.8112417282954993e-08
founder O 0 2.7498637791723013e-05
mutations O 0 1.0262544492434245e-05
may O 0 2.3733255716251733e-07
be O 0 7.147765934689687e-09
predominant O 0 1.0636989600243396e-07
among O 0 8.365611314786747e-09
Japanese O 0 6.579710998266819e-08
ATM O 0 1.5215860003081616e-06
mutant O 0 6.707515694870381e-06
alleles O 0 7.497510978282662e-06
. O 0 1.298184429288085e-06

W474C O 0 0.0003277404757682234
amino O 0 1.847100065788254e-05
acid O 0 2.8446675059967674e-06
substitution O 0 3.8467399576802563e-07
affects O 0 2.377539232156778e-07
early O 0 1.807949523424668e-08
processing O 0 5.173118378110075e-09
of O 0 4.094824757050475e-10
the O 0 1.113700354160585e-09
alpha O 0 7.769904719623355e-09
- O 0 8.461043421448267e-09
subunit O 0 6.408023445203526e-09
of O 0 6.104600158707285e-10
beta O 0 9.441983195301873e-09
- O 0 2.3746137856051064e-07
hexosaminidase O 0 2.5102909262386675e-07
A O 0 3.667466685897125e-08
and O 0 1.9935145090244077e-08
is O 0 4.691179444904492e-09
associated O 0 2.5505025647021284e-08
with O 0 1.2832592233280593e-07
subacute O 0 0.10416034609079361
G B-Disease 0 0.013277185149490833
( I-Disease 0 1.1721338921688584e-07
M2 I-Disease 0 3.554367503966205e-05
) I-Disease 0 2.7855318762703973e-07
gangliosidosis I-Disease 0 2.1914165699854493e-05
. O 0 1.2682473879976897e-06

Mutations O 0 0.0004520783550105989
in O 0 2.4393210651396657e-07
the O 0 1.1083020012847555e-07
HEXA O 0 4.843004353460856e-05
gene O 0 4.912135977974685e-07
, O 0 6.810410457802618e-09
encoding O 0 2.7583453743318387e-08
the O 0 2.5247135493344786e-09
alpha O 0 1.2283114969591225e-08
- O 0 1.3412162935821925e-08
subunit O 0 9.50910639119229e-09
of O 0 1.2103869018176283e-09
beta O 0 1.495943813267786e-08
- O 0 5.08460175296932e-07
hexosaminidase O 0 1.1626646028162213e-06
A O 0 1.501452828733818e-07
( O 0 5.8108713396620715e-09
Hex O 0 5.105553668727225e-07
A O 0 5.5123809516999245e-08
) O 0 3.3955724898504513e-09
, O 0 1.2251264447371568e-09
that O 0 1.6026949767322662e-09
abolish O 0 5.539574132740199e-08
Hex O 0 6.914086156939447e-07
A O 0 1.8224005415845568e-08
enzyme O 0 1.8098873511007696e-07
activity O 0 6.272898076531419e-07
cause O 0 2.9150245609343983e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 0 0.0041520302183926105
( O 0 4.4236823981691487e-08
TSD B-Disease 0 4.9228469833906274e-06
) O 0 1.2797707782397083e-08
, O 0 3.69529873367469e-09
the O 0 2.552624600582476e-08
fatal O 0 5.133185550221242e-05
infantile B-Disease 0 0.00022619054652750492
form I-Disease 0 5.218679177687591e-08
of I-Disease 0 2.520716257947697e-08
G I-Disease 0 0.0010342035675421357
( I-Disease 0 4.743556658581838e-08
M2 I-Disease 0 6.920934993104311e-06
) I-Disease 0 2.8079087499577327e-08
gangliosidosis I-Disease 0 1.035905597746023e-06
, I-Disease 0 1.810285610304163e-08
Type I-Disease 0 6.178237299536704e-08
1 I-Disease 0 2.155160387928845e-07
. O 0 2.547506028349744e-07

Less O 0 5.978851913823746e-05
severe O 0 0.0010363212786614895
, O 0 7.701445383645478e-07
subacute O 0 0.002661683363839984
( O 0 5.944285135228711e-07
juvenile O 0 8.741943020140752e-05
- O 0 0.20778478682041168
onset O 0 0.006902635097503662
) O 0 9.964568192799561e-08
and O 0 6.150760327727767e-07
chronic O 0 0.0029534450732171535
( O 0 4.524054730836724e-08
adult O 0 5.38555411822017e-07
- O 0 0.0006525461794808507
onset O 0 2.6298535885871388e-05
) O 0 3.527242053991131e-09
variants O 0 1.6463232554997376e-08
are O 0 2.403732990430285e-09
characterized O 0 2.997424175532615e-08
by O 0 6.508459327037031e-10
a O 0 7.627240172780603e-09
broad O 0 2.9025895287304593e-07
spectrum O 0 7.163942683519053e-08
of O 0 7.692411152504519e-10
clinical O 0 4.5959993144606415e-08
manifestations O 0 2.0856265336988145e-07
and O 0 5.2120540772193635e-08
are O 0 2.0722619176183343e-09
associated O 0 7.580829297637592e-09
with O 0 5.41816680410534e-09
residual O 0 1.965603360076784e-06
levels O 0 2.2354086581799493e-08
of O 0 2.3476429689139877e-09
Hex O 0 6.600175765925087e-06
A O 0 1.2062648124810949e-07
enzyme O 0 1.9737333900593512e-07
activity O 0 3.3029641599569004e-07
. O 0 1.7895760606734257e-07

We O 0 4.414775048644515e-06
identified O 0 5.904171871407016e-07
a O 0 1.1696873514210893e-07
1422 O 0 6.84226779412711e-06
G O 0 9.46372438193066e-06
- O 0 7.952760824991856e-06
- O 0 2.2401167370844632e-05
> O 0 8.586135322730115e-07
C O 0 6.426667482628545e-07
( O 0 1.4148920257639475e-08
amino O 0 2.6081988124815325e-08
acid O 0 6.441602806717128e-08
W474C O 0 8.477928048478134e-08
) O 0 9.356893038159342e-10
substitution O 0 1.420461526180361e-09
in O 0 1.1359390095222466e-09
the O 0 2.7642161892771355e-09
first O 0 1.3974695178831098e-08
position O 0 2.774210905442942e-08
of O 0 1.0850480514079663e-09
exon O 0 1.5549250065305387e-07
13 O 0 3.280349147871675e-08
of O 0 2.2395640897343583e-09
HEXA O 0 8.389106369577348e-06
of O 0 2.019926892415924e-09
a O 0 1.0429854313542819e-08
non O 0 3.1328188043744376e-08
- O 0 1.984659320442006e-06
Jewish O 0 3.3144624467240646e-07
proband O 0 6.690731879643863e-06
who O 0 4.6949770649007405e-07
manifested O 0 4.287993249363353e-07
a O 0 1.02864284201587e-07
subacute O 0 8.711319242138416e-05
variant O 0 5.578886430157581e-06
of O 0 1.4522883873269166e-07
G B-Disease 0 0.0034404343459755182
( I-Disease 0 2.1031149799455306e-07
M2 I-Disease 0 3.744984496734105e-05
) I-Disease 0 3.0111883120298444e-07
gangliosidosis I-Disease 0 3.147624011035077e-05
. O 0 1.6060503185144626e-06

On O 0 5.3460726121556945e-06
the O 0 1.0680597739565201e-07
second O 0 1.771839947650733e-06
maternally O 0 1.946672455233056e-05
inherited O 0 1.0422424566058908e-05
allele O 0 1.156964913207048e-06
, O 0 1.3675650833988584e-08
we O 0 6.477057112874718e-09
identified O 0 2.1044467501951658e-08
the O 0 7.866818307888934e-09
common O 0 8.615869546702015e-07
infantile O 1 0.9837538599967957
disease O 0 0.00021954123803880066
- O 0 3.1812378438189626e-05
causing O 0 1.5453678088306333e-06
4 O 0 2.7895197263205773e-07
- O 0 2.89511117443908e-05
bp O 0 5.793383479613112e-06
insertion O 0 7.497272349610284e-07
, O 0 5.24882608488042e-08
+ O 0 9.004793355416041e-07
TATC O 0 5.084507847641362e-06
1278 O 0 6.6731508923112415e-06
, O 0 1.6032338123750378e-08
in O 0 1.2046067254800619e-08
exon O 0 3.4784868603310315e-06
11 O 0 1.8648598825166118e-06
. O 0 8.466324175060436e-07

Pulse O 0 0.0009224587702192366
- O 0 3.470470983302221e-05
chase O 0 2.0418851818249095e-06
analysis O 0 4.920959995047269e-08
using O 0 3.025880701557071e-08
proband O 0 3.901425770891365e-06
fibroblasts O 0 5.526381983145257e-07
revealed O 0 5.19090747275186e-07
that O 0 2.2614601302706205e-09
the O 0 2.435237789200073e-09
W474C O 0 1.5228549443691008e-07
- O 0 2.9524340305897567e-08
containing O 0 7.167971993737865e-09
alpha O 0 1.0353624624315216e-08
- O 0 1.1102734731593955e-08
subunit O 0 1.3929588149608207e-08
precursor O 0 2.8698178056174584e-08
was O 0 8.205875445810307e-08
normally O 0 6.876142766287785e-09
synthesized O 0 1.68956475476989e-08
, O 0 1.5411143472476851e-09
but O 0 1.0714233944497664e-09
not O 0 4.664250652375301e-10
phosphorylated O 0 6.3942513506276555e-09
or O 0 2.295579282218796e-09
secreted O 0 1.3226786776954214e-08
, O 0 1.8740906604364227e-09
and O 0 1.7044465838722545e-09
the O 0 3.7081697712437744e-09
mature O 0 2.0910670528451192e-08
lysosomal O 0 2.1755650436716678e-07
alpha O 0 3.3659954823406224e-08
- O 0 5.6611714427390325e-08
subunit O 0 1.1632707952458077e-07
was O 0 6.8876425984854e-07
not O 0 4.244220974669588e-08
detected O 0 9.727843917062273e-07
. O 0 2.069751303679368e-07

When O 0 1.8613294514580048e-06
the O 0 5.407504843901734e-08
W474C O 0 1.0705801969379536e-06
- O 0 2.752063608113531e-07
containing O 0 2.40983499821823e-08
alpha O 0 4.432829570077956e-08
- O 0 2.8924363348892257e-08
subunit O 0 4.6237932593840014e-08
was O 0 1.4862916941638105e-07
transiently O 0 2.5453178409406974e-07
co O 0 2.8888342740174267e-07
- O 0 8.633355719211977e-07
expressed O 0 5.4177946573474856e-09
with O 0 6.365578064659871e-10
the O 0 1.885513523092186e-09
beta O 0 7.533262902370552e-09
- O 0 1.4882229670831748e-08
subunit O 0 1.3563301592967036e-08
to O 0 2.7108084665883325e-09
produce O 0 4.272785236736354e-09
Hex O 0 7.027362585176888e-07
A O 0 8.852652655377824e-08
( O 0 1.1778989339461532e-08
alphabeta O 0 1.7382014050326688e-07
) O 0 2.6891127102857126e-09
in O 0 4.83275952589679e-09
COS O 0 2.7403346393839456e-05
- O 0 2.328585424038465e-06
7 O 0 6.71418263209489e-08
cells O 0 1.192240528524735e-08
, O 0 4.919331608732591e-10
the O 0 6.653837480996572e-10
mature O 0 3.875469722913749e-09
alpha O 0 4.023384292395349e-09
- O 0 7.635041932019249e-09
subunit O 0 7.533420998129259e-09
was O 0 5.919462253700658e-08
present O 0 1.7137861130223087e-09
, O 0 1.0410967643537106e-09
but O 0 7.341661723003767e-10
its O 0 1.1154350776365618e-09
level O 0 8.299433140734891e-09
was O 0 1.5834702082884178e-07
much O 0 3.2964040386218585e-09
lower O 0 2.9263976131232994e-08
than O 0 8.989343713849962e-10
that O 0 4.308957080034759e-10
from O 0 3.3455935244397494e-10
normal O 0 1.789119186135224e-09
alpha O 0 4.027392197514246e-09
- O 0 9.029937686477751e-09
subunit O 0 1.023223994423006e-08
transfections O 0 1.1282271827894874e-07
, O 0 1.6225089050081465e-09
although O 0 5.784990819712732e-10
higher O 0 1.4182308660792842e-09
than O 0 2.5261187586167466e-10
in O 0 1.1153030721189339e-09
those O 0 3.240151924543966e-09
cells O 0 1.6381633827222686e-08
transfected O 0 1.2856000353167474e-07
with O 0 1.1507461650239748e-09
an O 0 3.023288952519465e-09
alpha O 0 5.402051073133407e-08
- O 0 1.493754808734593e-07
subunit O 0 1.7367663929235277e-07
associated O 0 9.860620053814273e-08
with O 0 1.7894737425194762e-07
infantile O 0 0.07776451110839844
TSD B-Disease 0 0.0009170189150609076
. O 0 3.6761584851774387e-06

Furthermore O 0 1.0354363439546432e-05
, O 0 5.2333618327793374e-08
the O 0 5.740587560865151e-09
precursor O 0 1.78894588032108e-08
level O 0 2.99156832639369e-09
of O 0 6.086764980928194e-10
the O 0 1.4877538090374287e-09
W474C O 0 6.929877116590433e-08
alpha O 0 1.2003224192369544e-08
- O 0 1.379863956429972e-08
subunit O 0 1.741622135398302e-08
was O 0 3.5561292577313e-08
found O 0 2.279957778128505e-09
to O 0 1.457528986392731e-09
accumulate O 0 3.181995822387762e-08
in O 0 1.1311479530817792e-09
comparison O 0 4.837158673609565e-09
to O 0 8.435466214429255e-10
the O 0 2.513652619384743e-09
normal O 0 2.138794208406125e-08
alpha O 0 2.519798236733095e-08
- O 0 5.889180343388034e-08
subunit O 0 1.1684553413715548e-07
precursor O 0 2.52925104859969e-07
levels O 0 1.4995553954122443e-07
. O 0 1.6045760276028886e-07

We O 0 4.7796124817978125e-06
conclude O 0 4.492822824886389e-07
that O 0 3.829997652360362e-09
the O 0 9.580634063866e-09
1422 O 0 9.49108596159931e-07
G O 0 2.9181317131588003e-06
- O 0 1.9194769720343174e-06
- O 0 5.3352541726781055e-06
> O 0 4.0776518517304794e-07
C O 0 4.264361166406161e-07
mutation O 0 6.156675169677328e-08
is O 0 1.7893204695695886e-09
the O 0 3.4107485724632625e-09
cause O 0 6.761075610484113e-08
of O 0 8.534286166650418e-09
Hex B-Disease 0 0.0700296089053154
A I-Disease 0 0.003617619862779975
enzyme I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999996423721313
in O 0 2.958922529217034e-08
the O 0 1.3544202204229805e-07
proband O 0 8.432653703493997e-05
. O 0 6.85678116951749e-07

The O 0 1.3470792055159109e-06
resulting O 0 1.0359649422753137e-06
W474C O 0 1.2825952353523462e-06
substitution O 0 1.7581255917775707e-07
clearly O 0 8.177267574183134e-08
interferes O 0 6.662784102218211e-08
with O 0 2.403893528679646e-09
alpha O 0 1.1962906221185676e-08
- O 0 1.571618923890128e-08
subunit O 0 1.1639183838951794e-08
processing O 0 6.864480095458703e-09
, O 0 1.966128815311663e-09
but O 0 8.479925095450369e-10
because O 0 1.599716470401802e-10
the O 0 2.8569585586168955e-10
base O 0 3.395203451717066e-09
substitution O 0 1.1601814620121331e-08
falls O 0 1.9011278027392109e-06
at O 0 3.3130320709062744e-09
the O 0 1.7459717005507969e-09
first O 0 5.828631799431605e-09
position O 0 1.8410219126963057e-08
of O 0 1.4435215245356403e-09
exon O 0 4.1799191308200534e-07
13 O 0 6.333708313377429e-08
, O 0 2.6479873849183377e-09
aberrant O 0 1.2360936807453982e-07
splicing O 0 6.052364369679708e-07
may O 0 2.1008057160543103e-07
also O 0 8.369283044373788e-09
contribute O 0 2.779930063923075e-09
to O 0 5.2745754430816305e-09
Hex B-Disease 0 9.387273894390091e-05
A I-Disease 0 1.2856131434091367e-05
deficiency I-Disease 0 2.1419828044599853e-05
in O 0 7.733444107316245e-09
this O 0 1.0756131985090178e-08
proband O 0 4.856422037846642e-06
. O 0 7.099155396872447e-08
. O 0 2.738972000315698e-07

Two O 0 9.937623872247059e-06
frequent O 0 6.966279761400074e-05
missense O 0 0.031008386984467506
mutations O 0 0.00853846687823534
in O 0 0.00018345682474318892
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.9459444704116322e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 7.508900307584554e-05
an O 0 0.0003700033121276647
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.8109021186828613
by O 0 1.1216940265512676e-06
early O 0 0.0002137597039109096
childhood O 1 0.9998102784156799
deafness B-Disease 1 1.0
and O 1 0.9509384036064148
goiter B-Disease 1 1.0
. O 0 1.9164925106451847e-05

A O 0 5.395113021222642e-06
century O 0 1.2569219052238623e-06
after O 0 1.0144660222977109e-07
its O 0 6.169297961378106e-09
recognition O 0 1.4204270648576767e-08
as O 0 6.902584459567151e-08
a O 0 6.4751357058412395e-06
syndrome O 1 0.8779033422470093
by O 0 1.4432221639992804e-08
Vaughan O 0 1.3141285535311908e-06
Pendred O 0 1.1477544603621936e-06
, O 0 1.2652662917389534e-08
the O 0 2.836853951748708e-08
disease O 0 6.0664692682621535e-06
gene O 0 6.028009806868795e-07
( O 0 1.1220167550618498e-07
PDS O 0 7.2741609074000735e-06
) O 0 1.5366595107479952e-08
was O 0 4.636758035303501e-07
mapped O 0 2.0685172330559e-06
to O 0 8.127152995029974e-08
chromosome O 0 5.304188744048588e-05
7q22 O 0 8.366854672203772e-06
- O 0 3.869175270665437e-05
q31 O 0 3.1305153243010864e-05
. O 0 1.150610501099436e-06

1 O 0 1.6927902834140696e-05
and O 0 4.660191450511775e-07
, O 0 3.744218801671195e-08
recently O 0 5.833138629895984e-07
, O 0 6.007988773149009e-09
found O 0 3.6493570387818863e-09
to O 0 1.9241694904081896e-09
encode O 0 9.554561586355703e-08
a O 0 1.6537764224722196e-07
putative O 0 1.8004730009124614e-05
sulfate O 0 1.7529820979689248e-05
transporter O 0 7.186568109318614e-05
. O 0 1.0257681424263865e-06

We O 0 7.611389264639001e-06
performed O 0 1.270171992473479e-06
mutation O 0 4.311633290399186e-07
analysis O 0 1.293242046784826e-08
of O 0 1.3336419746323713e-09
the O 0 1.813378425197243e-08
PDS B-Disease 0 4.452898338058731e-06
gene O 0 1.1231728791472051e-07
in O 0 1.7050261647000298e-08
patients O 0 3.007463078574801e-08
from O 0 4.28363833293588e-09
14 O 0 3.880316157278685e-08
Pendred B-Disease 0 8.183787372217921e-07
families O 0 1.518131398370315e-08
originating O 0 9.543010826007503e-09
from O 0 2.966946022198158e-09
seven O 0 8.101520343473112e-09
countries O 0 1.1302205837893098e-09
and O 0 7.179246530597538e-09
identified O 0 2.0350080376374535e-07
all O 0 2.4887036431664455e-08
mutations O 0 3.2456946428283118e-06
. O 0 2.96499393925842e-07

The O 0 1.2720654467557324e-06
mutations O 0 2.672247092050384e-06
include O 0 1.4074311494027825e-08
three O 0 4.030652434039439e-08
single O 0 1.3502274498478073e-07
base O 0 2.1904253344473545e-07
deletions O 0 7.389052711914701e-07
, O 0 1.2879495692175169e-08
one O 0 6.087092607742761e-09
splice O 0 1.067505763785448e-05
site O 0 1.3280956636663177e-06
mutation O 0 5.344393798623059e-07
and O 0 6.522918738482986e-08
10 O 0 3.174224900703848e-07
missense O 0 9.944466000888497e-05
mutations O 0 4.787482976098545e-05
. O 0 9.19498120310891e-07

One O 0 1.690599492576439e-05
missense O 0 0.0014038566732779145
mutation O 0 5.745111411670223e-05
( O 0 3.774158017222362e-07
L236P O 0 2.1058797301520826e-06
) O 0 2.9677286406126768e-08
was O 0 2.339252773708722e-07
found O 0 8.062181144907754e-09
in O 0 3.1078801754347296e-09
a O 0 3.760823830134541e-08
homozygous O 0 6.25275220045296e-07
state O 0 1.0568828034962507e-09
in O 0 2.2470305616195674e-09
two O 0 1.5107309181416895e-08
consanguineous O 0 4.295751750760246e-06
families O 0 7.206138263882167e-08
and O 0 7.295906101489891e-09
in O 0 1.0306568931639504e-09
a O 0 2.4613846960619412e-08
heterozygous O 0 6.359067583616707e-08
state O 0 9.214445872984811e-10
in O 0 2.009961308502284e-09
five O 0 5.681136450164104e-09
additional O 0 1.1991325266080821e-08
non O 0 7.39089998091913e-08
- O 0 2.7655589292407967e-05
consanguineous O 0 5.312399298418313e-05
families O 0 7.25266204426589e-07
. O 0 3.3018807243934134e-07

Another O 0 2.1968193323118612e-05
missense O 0 0.0020435114856809378
mutation O 0 4.3440417357487604e-05
( O 0 2.3725108633243508e-07
T416P O 0 2.1907940208620857e-06
) O 0 2.627632511575939e-08
was O 0 1.33254346224021e-07
found O 0 5.593208118881421e-09
in O 0 1.2096760260149608e-09
a O 0 2.8161041498719896e-08
homozygous O 0 4.313192221161444e-07
state O 0 1.3534867671083362e-09
in O 0 3.437820472740327e-09
one O 0 2.1628585145094803e-08
family O 0 3.082995903014307e-08
and O 0 1.1822722356669146e-08
in O 0 1.7894433712584146e-09
a O 0 1.7072455449351764e-08
heterozygous O 0 9.108161691528949e-08
state O 0 2.9647682087130534e-09
in O 0 7.06769975877819e-09
four O 0 1.0853966614376986e-07
families O 0 2.385099264756718e-07
. O 0 3.617860215854307e-07

Pendred B-Disease 0 0.0015730521408841014
patients O 0 3.2261239539366215e-05
in O 0 4.2311754100410326e-08
three O 0 2.5715461760000835e-08
non O 0 7.351631836627348e-08
- O 0 4.777971753355814e-06
consanguineous O 0 7.581490990560269e-06
families O 0 7.368139876007263e-08
were O 0 4.999064273647491e-08
shown O 0 1.9032482256875483e-08
to O 0 2.4154525046782283e-09
be O 0 4.7265120706185826e-09
compound O 0 1.5871410141699016e-07
heterozygotes O 0 5.460809688884183e-07
for O 0 9.75985514628519e-09
L236P O 0 1.9547385363694048e-06
and O 0 1.4191358843618218e-07
T416P O 0 7.941657713672612e-06
. O 0 6.2460588878821e-07

In O 0 1.2847767720813863e-06
total O 0 2.0754933416355925e-07
, O 0 1.5346413917427526e-08
one O 0 6.358348958457327e-09
or O 0 4.181472057496194e-09
both O 0 9.528328126506835e-10
of O 0 8.2298179382434e-10
these O 0 3.1562321645139946e-09
mutations O 0 1.7751452219272323e-07
were O 0 5.463550323270283e-08
found O 0 1.299606910976081e-08
in O 0 7.919496169961349e-09
nine O 0 2.692070033560867e-08
of O 0 8.805861040350749e-10
the O 0 1.8121198763765278e-08
14 O 0 2.257951194906127e-07
families O 0 5.001840008844738e-08
analyzed O 0 5.05289108332363e-07
. O 0 2.661506641743472e-07

The O 0 1.5924868534966663e-07
identification O 0 3.9012956420947376e-08
of O 0 2.9285736058426437e-09
two O 0 3.495511791129502e-08
frequent O 0 8.30981480248738e-06
PDS B-Disease 0 0.0002804245159495622
mutations O 0 1.1332149369991384e-06
will O 0 2.831560319549453e-09
facilitate O 0 7.79189868183039e-09
the O 0 9.813896362231844e-09
molecular O 0 3.584633532227599e-06
diagnosis O 0 0.0021168275270611048
of O 0 4.256470128893852e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.1876911230501719e-05

Insertional O 0 0.0018827288877218962
mutation O 0 6.189849955262616e-05
by O 0 1.2328925436122518e-07
transposable O 0 1.4848968930891715e-05
element O 0 6.889916335239832e-07
, O 0 5.7979875123237434e-08
L1 O 0 7.45268471291638e-06
, O 0 2.0132313593990148e-08
in O 0 1.0341861589324708e-08
the O 0 1.2623151235402474e-07
DMD B-Disease 1 0.9999992847442627
gene O 0 1.1008728506567422e-06
results O 0 1.2925940495733812e-07
in O 0 1.0747543655043046e-07
X B-Disease 1 0.994306743144989
- I-Disease 1 0.9999973773956299
linked I-Disease 1 0.999924898147583
dilated I-Disease 1 0.9997084736824036
cardiomyopathy I-Disease 1 1.0
. O 0 9.591107300366275e-06

X B-Disease 1 0.988067626953125
- I-Disease 1 0.9999619722366333
linked I-Disease 1 0.997189462184906
dilated I-Disease 1 0.9999822378158569
cardiomyopathy I-Disease 1 1.0
( O 0 1.1105192243121564e-05
XLDCM B-Disease 0 0.00015544236521236598
) O 0 2.3084497868808285e-08
is O 0 4.052419733113766e-09
a O 0 3.074674737035821e-08
clinical O 0 8.753519864512782e-07
phenotype O 0 3.954339717893163e-06
of O 0 8.3248794524593e-09
dystrophinopathy B-Disease 0 5.595392576651648e-05
which O 0 1.683861512447038e-07
is O 0 1.658675330418191e-08
characterized O 0 2.20468891143355e-07
by O 0 1.0149224571875948e-08
preferential O 0 1.5120388070499757e-06
myocardial B-Disease 0 0.0012520361924543977
involvement I-Disease 0 3.740767908766429e-07
without O 0 1.3010206245667177e-08
any O 0 6.432317789517583e-09
overt O 0 6.608121907447639e-07
clinical O 0 1.7832961702879402e-06
signs O 0 1.5453808373422362e-05
of O 0 1.6177406223505386e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 5.524873631657101e-05

To O 0 4.0394652955910715e-07
date O 0 2.0674156075983774e-07
, O 0 4.0436947124078415e-09
several O 0 6.37477937104336e-09
mutations O 0 5.488701049216616e-07
in O 0 2.1936232386110532e-08
the O 0 4.470019575819606e-06
Duchenne B-Disease 1 0.9999994039535522
muscular I-Disease 1 0.9974974989891052
dystrophy I-Disease 1 0.821056604385376
gene O 0 5.0145245040766895e-06
, O 0 4.3568491037149215e-07
DMD O 1 0.9999998807907104
, O 0 1.5259163888003968e-07
have O 0 5.224445231988284e-08
been O 0 6.986054756907834e-08
identified O 0 6.765912985429168e-08
in O 0 9.19266529564311e-09
patients O 0 2.4718056934602828e-08
with O 0 1.4510057155803224e-08
XLDCM B-Disease 0 4.401033584144898e-05
, O 0 8.048782973446578e-09
but O 0 1.4220283839350145e-09
a O 0 2.3262742843144224e-09
pathogenic O 0 1.703387830787051e-08
correlation O 0 1.4971485384762673e-08
of O 0 9.10304776002846e-10
these O 0 6.746079250774528e-09
cardiospecific O 0 1.82290532393381e-05
mutations O 0 1.5260953887263895e-06
in O 0 4.9383363176502826e-08
DMD O 1 0.9999973773956299
with O 0 5.2308266162981454e-08
the O 0 1.847406849719846e-07
XLDCM B-Disease 0 0.012817967683076859
phenotype O 0 0.00011393817840144038
has O 0 1.2420426855896949e-06
remained O 0 1.3389169453148497e-06
to O 0 1.281788630791425e-08
be O 0 4.55775506225109e-08
elucidated O 0 1.623347998247482e-05
. O 0 7.850541123843868e-07

We O 0 1.2241376680321991e-05
report O 0 2.7505603839017567e-07
here O 0 8.511463533977803e-09
the O 0 1.4528162006754997e-09
identification O 0 8.951740682050513e-09
of O 0 1.5243544204679438e-09
a O 0 2.9669534384879626e-08
unique O 0 6.011085673662819e-08
de O 0 1.0980397746607196e-06
novo O 0 1.9632088879006915e-06
L1 O 0 1.8493101379135624e-06
insertion O 0 3.7264115348989435e-07
in O 0 1.4983683627178834e-08
the O 0 1.7864705270653758e-08
muscle O 0 2.4714856294849596e-07
exon O 0 3.875213678838918e-07
1 O 0 1.1556367951470747e-07
in O 0 1.7345583103178797e-07
DMD O 1 0.9999996423721313
in O 0 9.66549151826257e-08
three O 0 4.19183095345943e-07
XLDCM B-Disease 0 0.0010863867355510592
patients O 0 1.64310520744948e-07
from O 0 2.7248827638715056e-09
two O 0 1.4010885784898619e-08
unrelated O 0 3.0911988346815633e-07
Japanese O 0 4.0294730752066243e-07
families O 0 1.914407903313986e-07
. O 0 1.8413348357171344e-07

The O 0 4.845536523134797e-07
insertion O 0 2.1131240828253794e-06
was O 0 3.682744704747165e-07
a O 0 3.5208518767149144e-08
5 O 0 6.62753620872536e-08
- O 0 3.394286238744826e-07
truncated O 0 1.5363276872903953e-07
form O 0 1.436784202724084e-08
of O 0 4.1643595238838316e-09
human O 0 2.5855678487118894e-08
L1 O 0 3.0668932140542893e-06
inversely O 0 5.379337721933553e-07
integrated O 0 6.786049056017873e-08
in O 0 7.104895782816811e-09
the O 0 6.90965462624149e-09
5 O 0 7.276356228658187e-08
- O 0 4.632392119674478e-06
untranslated O 0 3.997450676251901e-06
region O 0 7.06209704048888e-08
in O 0 4.451738977451214e-09
the O 0 7.599402884750361e-09
muscle O 0 1.4067954623442347e-07
exon O 0 1.9945571239077253e-07
1 O 0 3.5728611180729786e-08
, O 0 7.234781218556918e-09
which O 0 6.277264041898434e-09
affected O 0 2.321735248500545e-09
the O 0 6.512383410317568e-10
transcription O 0 6.418618880843496e-08
or O 0 1.450192321783561e-08
the O 0 3.2314746434281005e-09
stability O 0 1.7071446478666985e-08
of O 0 5.366758704106189e-10
the O 0 9.852024973611151e-09
muscle O 0 1.0272566441926756e-07
form O 0 9.417912005815765e-10
of O 0 6.136399721690111e-10
dystrophin O 0 1.8544869817560539e-07
transcripts O 0 1.3473730575697118e-07
but O 0 1.3959484235215314e-08
not O 0 8.503021065031646e-10
that O 0 2.469908721991487e-10
of O 0 3.4340769117235936e-10
the O 0 2.353939443366926e-08
brain O 0 1.5999460174498381e-06
or O 0 1.8027222381533647e-08
Purkinje O 0 5.269950634101406e-06
cell O 0 9.729077419251553e-07
form O 0 1.5800106112351386e-08
, O 0 2.1606565425713598e-08
probably O 0 1.7294543397383677e-07
due O 0 6.837379107338393e-09
to O 0 2.7633044741293133e-09
its O 0 3.044863028378586e-09
unique O 0 5.302587702260553e-09
site O 0 4.5008594184992035e-08
of O 0 3.94228516498174e-09
integration O 0 4.311555414915347e-07
. O 0 3.701741775330447e-07

We O 0 3.697349256981397e-06
speculate O 0 2.739481601565785e-07
that O 0 1.794009052424883e-09
this O 0 5.34347011083014e-10
insertion O 0 3.3592868931009434e-08
of O 0 1.0918949078231321e-09
an O 0 3.798047654157699e-09
L1 O 0 6.037000275682658e-06
sequence O 0 1.8314243277472997e-07
in O 0 2.7689466719493794e-07
DMD O 1 1.0
is O 0 4.347820947714354e-08
responsible O 0 4.460978697551354e-09
for O 0 3.5429845168799545e-10
some O 0 2.8774280180776657e-10
of O 0 2.2519849873781084e-10
the O 0 1.7228285464909732e-09
population O 0 8.819139862836778e-10
of O 0 7.13123116113934e-10
Japanese O 0 9.757290087009096e-08
patients O 0 2.1765979241195055e-08
with O 0 7.4258128535120704e-09
XLDCM B-Disease 0 2.2144369722809643e-05
. O 0 6.226219539939848e-08
. O 0 2.5020023031174787e-07

Severe O 0 0.08281044661998749
early O 0 4.180268297204748e-05
- O 0 0.12409356236457825
onset O 1 0.6995982527732849
obesity B-Disease 1 1.0
, O 0 8.328546391567215e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.541088022349868e-05
red O 0 0.0002246085787191987
hair O 1 0.9993763566017151
pigmentation O 1 0.9304761290550232
caused O 0 9.771434633876197e-06
by O 0 8.445681487501133e-08
POMC O 0 0.0013839113526046276
mutations O 0 9.878332093649078e-06
in O 0 4.504758521761687e-08
humans O 0 4.716221724265779e-07
. O 0 6.300044788076775e-07

Sequential O 0 3.7883251934545115e-05
cleavage O 0 7.767123315716162e-05
of O 0 3.365584788639353e-08
the O 0 9.9470751635522e-09
precursor O 0 8.492494174561216e-08
protein O 0 1.0180714582475048e-07
pre O 0 5.995776746203774e-07
- O 0 9.99211442831438e-06
pro O 0 4.110991540073883e-06
- O 0 3.8689242501277477e-05
opiomelanocortin O 0 1.0641799235600047e-05
( O 0 8.723104372165835e-08
POMC O 0 5.82127358939033e-06
) O 0 1.9399537976028114e-08
generates O 0 1.0262461103138776e-07
the O 0 2.1654175341723203e-08
melanocortin O 0 1.7728876628098078e-05
peptides O 0 2.091650685542845e-06
adrenocorticotrophin O 0 9.370620318804868e-06
( O 0 7.168398497015005e-08
ACTH O 0 2.247215434181271e-06
) O 0 1.1241711561638112e-08
, O 0 1.0396368210763285e-08
melanocyte O 0 3.769384420593269e-06
- O 0 6.246981229196535e-06
stimulating O 0 1.3547887647291645e-06
hormones O 0 7.038549938442884e-07
( O 0 2.442640045785538e-08
MSH O 0 1.658891051192768e-06
) O 0 4.872940273514814e-09
alpha O 0 7.405896784717925e-09
, O 0 9.080919349813144e-10
beta O 0 3.5031255674056183e-09
and O 0 1.3718933766782015e-09
gamma O 0 1.5986108437004987e-08
as O 0 1.4352222743596599e-09
well O 0 1.0343237377696823e-09
as O 0 1.1903267260748862e-09
the O 0 2.6817676967993975e-09
opioid O 0 9.919549626147273e-08
- O 0 3.7223480831016786e-07
receptor O 0 3.218083577394282e-07
ligand O 0 4.1769942527025705e-07
beta O 0 9.73483224697702e-07
- O 0 1.1479951353976503e-05
endorphin O 0 9.699156362330541e-05
. O 0 9.410574079993239e-07

While O 0 1.258706674889254e-06
a O 0 1.1525352050512083e-07
few O 0 2.501233353768839e-08
cases O 0 8.71915784017574e-09
of O 0 1.2138438698627851e-08
isolated O 0 0.011870150454342365
ACTH B-Disease 1 0.9967595934867859
deficiency I-Disease 0 0.002232549712061882
have O 0 9.100694597918846e-08
been O 0 3.1017648893794103e-07
reported O 0 2.12938880395086e-06
( O 0 6.797863960628092e-08
OMIM O 0 3.205784014426172e-05
201400 O 0 8.760701462051657e-07
) O 0 1.0966688890334808e-08
, O 0 3.827018257851478e-09
an O 0 1.7855235512342915e-08
inherited O 0 0.00015404813166242093
POMC O 0 0.015357364900410175
defect O 0 0.00010984010441461578
has O 0 1.183356175715744e-06
not O 0 2.5139655690509244e-08
been O 0 1.408855041518109e-07
described O 0 3.9763952486282506e-07
so O 0 7.994166395519642e-08
far O 0 1.6410959347012977e-07
. O 0 2.4821741817504517e-07

Recent O 0 4.260838522895938e-06
studies O 0 1.4628525946136506e-07
in O 0 2.1911017000775246e-08
animal O 0 6.466690649631346e-08
models O 0 9.339141371356163e-08
elucidated O 0 4.3776904590231425e-07
a O 0 1.1719625270245615e-08
central O 0 2.6786288742641773e-09
role O 0 4.448293289271987e-09
of O 0 1.2408405414277013e-09
alpha O 0 3.527822656224089e-08
- O 0 8.66346056227485e-07
MSH O 0 1.6203254062929773e-06
in O 0 1.4992451724538114e-09
the O 0 1.052750331353991e-09
regulation O 0 7.067565199747605e-09
of O 0 4.401157216449292e-10
food O 0 9.170249448686718e-09
intake O 0 1.3097373852133387e-08
by O 0 4.536553355194428e-10
activation O 0 6.9282752868105035e-09
of O 0 8.182174937587661e-10
the O 0 1.3388469888298005e-08
brain O 0 9.91347519629926e-07
melanocortin O 0 2.0603467874025228e-06
- O 0 9.052805580722634e-07
4 O 0 9.261163569362907e-08
- O 0 5.148945092514623e-07
receptor O 0 2.1635500502270588e-07
( O 0 1.2231401669282604e-08
MC4 O 0 1.990681766983471e-06
- O 0 7.838242481739144e-07
R O 0 1.6085625702544348e-06
; O 0 7.75893127524796e-09
refs O 0 1.5057231905757362e-07
3 O 0 2.655408515295221e-08
- O 0 8.470539114568965e-07
5 O 0 4.0380314203503076e-08
) O 0 1.5244357998156488e-09
and O 0 1.8730577089343114e-09
the O 0 9.125751265770532e-10
linkage O 0 1.2193508780455886e-07
of O 0 2.101970597578884e-09
human O 0 6.395082863264179e-08
obesity B-Disease 1 0.9992196559906006
to O 0 1.9422751407205396e-08
chromosome O 0 2.7072035209130263e-06
2 O 0 1.5431799837983817e-08
in O 0 1.3145067256914444e-09
close O 0 2.3077321387177108e-08
proximity O 0 1.738671429052374e-08
to O 0 7.931559409257716e-09
the O 0 1.8233114573718012e-08
POMC O 0 8.10702385933837e-06
locus O 0 4.446357593224093e-07
, O 0 1.5716668855247917e-08
led O 0 1.009478012292675e-08
to O 0 5.66570235172037e-10
the O 0 1.6215127018881503e-09
proposal O 0 8.151647357124148e-09
of O 0 5.790157242557825e-10
an O 0 3.1840825531759265e-09
association O 0 8.731007916651379e-09
of O 0 4.743599735235193e-09
POMC O 0 3.642739829956554e-05
with O 0 1.4433244643896614e-07
human O 0 3.5562084121920634e-06
obesity B-Disease 1 0.9999992847442627
. O 0 2.3816473913029768e-06

The O 0 4.07708398597606e-07
dual O 0 3.7500836924664327e-07
role O 0 1.3795671804928133e-07
of O 0 1.714725605950207e-08
alpha O 0 3.4831003858926124e-07
- O 0 3.660821221274091e-06
MSH O 0 4.946697572449921e-06
in O 0 7.037527893771767e-09
regulating O 0 3.98177952831702e-08
food O 0 1.5182472168362438e-08
intake O 0 8.359809555713582e-08
and O 0 1.555603645897463e-08
influencing O 0 3.4480376598367e-07
hair O 0 0.004805278964340687
pigmentation O 0 8.049994357861578e-05
predicts O 0 1.4655940958618885e-06
that O 0 4.04526856456755e-09
the O 0 1.4408787052389016e-08
phenotype O 0 1.2827584214392118e-05
associated O 0 3.3741400784492726e-08
with O 0 6.441378985755364e-09
a O 0 5.232807893662539e-07
defect O 0 1.4453412404691335e-05
in O 0 5.710155903670966e-08
POMC O 0 1.1056094990635756e-05
function O 0 2.5341806875189832e-08
would O 0 1.8680601954201848e-08
include O 0 2.6074079784166315e-08
obesity B-Disease 1 0.9999831914901733
, O 0 2.2442261382593642e-08
alteration O 0 4.1439952269684e-07
in O 0 2.2782771225138276e-07
pigmentation O 1 0.6889404058456421
and O 0 0.000842431967612356
ACTH B-Disease 1 0.9951289892196655
deficiency I-Disease 0 0.025843465700745583
. O 0 1.0270974826198653e-06

The O 0 6.735384658895782e-07
observation O 0 9.55135078584135e-07
of O 0 1.6688810333675974e-08
these O 0 2.100444795871681e-08
symptoms O 0 8.361146797142283e-07
in O 0 2.080031258344661e-09
two O 0 1.4466285946923563e-08
probands O 0 2.4863516046025325e-06
prompted O 0 4.3365158575170426e-08
us O 0 2.8674744800838425e-09
to O 0 7.678587210513399e-10
search O 0 9.682056045789977e-09
for O 0 2.669326093496238e-09
mutations O 0 1.811007734886516e-07
within O 0 9.640484854855913e-09
their O 0 5.62766828693384e-08
POMC O 0 0.00016297369438689202
genes O 0 4.360637376521481e-06
. O 0 6.887301537972235e-07

Patient O 0 0.0005496265948750079
1 O 0 5.912550477660261e-06
was O 0 3.883784756908426e-06
found O 0 2.3204039578672564e-08
to O 0 5.004967551514028e-09
be O 0 1.4627312694415195e-09
a O 0 4.622662252984355e-09
compound O 0 7.703768289957225e-08
heterozygote O 0 2.7719164563677623e-07
for O 0 1.6221191057042006e-09
two O 0 1.4273306980783218e-08
mutations O 0 1.7481276870512374e-07
in O 0 4.5985051322361414e-09
exon O 0 9.698275107439258e-07
3 O 0 2.8045263888998306e-07
( O 0 1.2677399574556603e-08
G7013T O 0 2.108163243974559e-07
, O 0 1.1748698014457659e-08
C7133delta O 0 8.403899300901685e-07
) O 0 2.443212077096746e-09
which O 0 2.044232116915623e-09
interfere O 0 8.191735290097313e-09
with O 0 1.2085045186793764e-09
appropriate O 0 7.95965604538651e-09
synthesis O 0 2.3741760557527414e-08
of O 0 7.917366318110908e-09
ACTH O 0 6.663420663244324e-06
and O 0 5.201685837619152e-08
alpha O 0 4.848550361202797e-07
- O 0 2.1258878405205905e-05
MSH O 0 0.0001739074068609625
. O 0 7.767905572109157e-07

Patient O 0 0.00225888192653656
2 O 0 1.3354137081478257e-05
was O 0 1.7613540421734797e-06
homozygous O 0 4.0299153170053614e-07
for O 0 2.1179920040026445e-09
a O 0 3.0673120932078746e-08
mutation O 0 1.4906554213212075e-07
in O 0 4.968576217123655e-09
exon O 0 1.5032153442007257e-06
2 O 0 8.97512904884934e-07
( O 0 6.661284146503021e-08
C3804A O 0 1.1242933624089346e-06
) O 0 3.44317037104247e-08
which O 0 1.506883933188874e-07
abolishes O 0 8.679975871928036e-05
POMC O 0 0.00039792811730876565
translation O 0 4.229628757457249e-06
. O 0 2.3563347895105835e-06

These O 0 4.560833417599497e-07
findings O 0 1.1496624097162567e-07
represent O 0 8.351995539612744e-09
the O 0 2.375071694871167e-09
first O 0 8.577320187441728e-09
examples O 0 7.74823849525319e-09
of O 0 4.12263156945869e-09
a O 0 9.056847375177313e-06
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999392032623291
within O 0 1.5696716815227774e-08
the O 0 1.1589916582011028e-08
POMC O 0 4.936927780363476e-06
gene O 0 5.758883503403922e-08
and O 0 6.829753651516057e-09
define O 0 3.248978330816499e-08
a O 0 3.6348197340885235e-08
new O 0 8.122346457639651e-07
monogenic B-Disease 0 0.21244174242019653
endocrine I-Disease 0 0.34475207328796387
disorder I-Disease 0 0.00016649728058837354
resulting O 0 7.804574408964982e-08
in O 0 2.227152151590417e-08
early O 0 8.053083888626134e-07
- O 0 0.3812151551246643
onset O 1 0.748934805393219
obesity B-Disease 1 1.0
, O 0 6.164037768030539e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.1542809261300135e-05
red O 0 0.0002386142878094688
hair O 1 0.9793381690979004
pigmentation O 0 0.0024976779241114855
. O 0 2.1916414993938815e-07
. O 0 4.904421757601085e-07

A O 0 5.583362963079708e-06
European O 0 8.443166166216542e-07
multicenter O 0 1.8156897567678243e-05
study O 0 2.2415252942664665e-07
of O 0 8.118319669847551e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.1581386516468228e-08
classification O 0 2.4280224053541133e-08
of O 0 1.9228378889124542e-09
105 O 0 5.138143706062692e-07
mutations O 0 4.528241674961464e-07
and O 0 6.637248528562623e-09
a O 0 1.2175515706758233e-08
general O 0 2.8370419347112374e-09
system O 0 3.6401253122875232e-09
for O 0 1.794868143001338e-09
genotype O 0 5.496799531101715e-07
- O 0 8.622478162578773e-07
based O 0 5.4315584918640525e-08
prediction O 0 1.1515929827510263e-06
of O 0 9.354258878602195e-08
metabolic O 0 0.014063917100429535
phenotype O 0 0.00036460638511925936
. O 0 1.4005202046973864e-06

Phenylketonuria B-Disease 1 0.9769392609596252
( O 0 5.138342748978175e-05
PKU B-Disease 0 0.0002954085066448897
) O 0 4.902107093585073e-07
and O 0 2.270911409141263e-06
mild B-Disease 1 0.9735403656959534
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.0008157673291862011
MHP B-Disease 1 1.0
) O 0 9.748509199880573e-08
are O 0 5.5967753098684625e-08
allelic B-Disease 0 0.02661704085767269
disorders I-Disease 1 0.9551469683647156
caused O 0 2.266908495585085e-06
by O 0 1.9341715784548796e-08
mutations O 0 8.142449701153964e-07
in O 0 8.4919236087444e-09
the O 0 4.740273595871258e-08
gene O 0 7.181808541645296e-06
encoding O 0 6.245698023121804e-05
phenylalanine O 0 0.1182314082980156
hydroxylase O 0 0.18514351546764374
( O 0 3.2228144846158102e-06
PAH O 0 0.0002874347264878452
) O 0 5.357957775231625e-07
. O 0 8.760634955251589e-07

Previous O 0 5.12926544615766e-06
studies O 0 1.9819553642719256e-07
have O 0 3.154698902108066e-08
suggested O 0 1.7661088591580665e-08
that O 0 9.31453025820872e-10
the O 0 2.0147361556865917e-09
highly O 0 4.631498740081952e-08
variable O 0 3.1442459658137523e-06
metabolic O 0 0.00042996645788662136
phenotypes O 0 9.094866982195526e-05
of O 0 2.5423635179322446e-06
PAH B-Disease 1 0.9994593262672424
deficiency I-Disease 0 0.040928423404693604
correlate O 0 2.803472671075724e-05
with O 0 9.96881408354966e-06
PAH O 0 0.16442464292049408
genotypes O 0 0.0007260233978740871
. O 0 3.825710791716119e-06

We O 0 4.420597178977914e-06
identified O 0 9.37354570851312e-07
both O 0 3.6871405484362185e-08
causative O 0 2.989173935930012e-06
mutations O 0 4.731836725113681e-06
in O 0 3.811118887142584e-08
686 O 0 3.0278952181106433e-05
patients O 0 1.271723363061028e-06
from O 0 1.3571323620453768e-08
seven O 0 5.167076366774381e-08
European O 0 8.681608676397445e-08
centers O 0 6.116062536420941e-07
. O 0 4.3128014226567757e-07

On O 0 2.348536554563907e-06
the O 0 1.8224630693453037e-08
basis O 0 9.279354173941101e-09
of O 0 1.0851866072414396e-09
the O 0 6.330975743651379e-09
phenotypic O 0 5.529660711545148e-07
characteristics O 0 5.2174449649555754e-08
of O 0 1.0154878715695759e-08
297 O 0 1.179949435936578e-06
functionally O 0 5.115918611409143e-06
hemizygous O 0 1.4849153558316175e-05
patients O 0 1.3277775678943726e-07
, O 0 1.6462970986452774e-09
105 O 0 6.847375555452118e-09
of O 0 7.436992133236231e-10
the O 0 3.220431565864601e-08
mutations O 0 8.366634460799105e-07
were O 0 1.0746990852794625e-07
assigned O 0 1.5712261713929365e-08
to O 0 4.056254887530031e-09
one O 0 2.911752838841153e-09
of O 0 8.111875615668396e-10
four O 0 2.371813323520655e-08
arbitrary O 0 2.685926119738724e-06
phenotype O 0 8.557965338695794e-05
categories O 0 5.33397553681425e-07
. O 0 7.263640213750477e-07

We O 0 8.598827889727545e-07
proposed O 0 9.890418084523844e-08
and O 0 3.236781154214441e-08
tested O 0 4.7972850580890736e-08
a O 0 2.7160977911222517e-09
simple O 0 4.653057050774123e-09
model O 0 1.0717570830820478e-08
for O 0 8.648001759148372e-10
correlation O 0 9.38950961426599e-08
between O 0 5.857767959582816e-08
genotype O 0 1.8767296978694503e-06
and O 0 3.9442952015633637e-08
phenotypic O 0 4.315658316045301e-06
outcome O 0 1.4524686093864148e-06
. O 0 1.1406507383071585e-06

The O 0 1.1647842939055408e-06
observed O 0 3.801031652983511e-06
phenotype O 0 7.2324492066400126e-06
matched O 0 9.596025165592437e-07
the O 0 1.9361943159879047e-08
predicted O 0 5.865319508302491e-06
phenotype O 0 1.5502536143685575e-06
in O 0 8.22847212589295e-09
79 O 0 1.980744315233096e-07
% O 0 1.8958163927607075e-09
of O 0 2.312422198169628e-10
the O 0 4.491980565290987e-09
cases O 0 7.283240233135757e-09
, O 0 5.142277714753618e-09
and O 0 8.50940118368726e-09
in O 0 1.3236017837314762e-09
only O 0 2.380050823092006e-09
5 O 0 2.815785604681764e-09
of O 0 9.814133949959114e-10
184 O 0 5.255247259583484e-08
patients O 0 2.123194420278196e-08
was O 0 5.0085795066934224e-08
the O 0 3.2199569677260342e-09
observed O 0 1.263773867776763e-07
phenotype O 0 1.1124021170871856e-07
more O 0 4.648920415295521e-10
than O 0 1.0184765253384853e-09
one O 0 3.5365252948338366e-09
category O 0 4.16393248769964e-08
away O 0 1.065559089852286e-07
from O 0 3.0296620767700233e-09
that O 0 6.425524556874507e-09
expected O 0 9.688137936336716e-08
. O 0 2.2038314284600347e-07

Among O 0 9.533632692182437e-07
the O 0 1.9407938367521638e-08
seven O 0 1.6919480927413133e-08
contributing O 0 2.2957644674193034e-08
centers O 0 1.160750429107793e-08
, O 0 1.803299287672644e-09
the O 0 7.84677878229445e-10
proportion O 0 5.774906775002364e-09
of O 0 9.256156952019978e-10
patients O 0 1.007519934148604e-08
for O 0 6.692990606183002e-10
whom O 0 2.7883379161153243e-08
the O 0 5.6262483560942655e-09
observed O 0 2.748011525000038e-07
phenotype O 0 1.2300556591071654e-06
did O 0 3.4105028134945314e-08
not O 0 2.1852615272877074e-09
match O 0 1.7872475055469295e-08
the O 0 1.6549147829891808e-08
predicted O 0 5.624970526696416e-06
phenotype O 0 1.4555483858202933e-06
was O 0 1.9060969691508944e-07
4 O 0 1.7619770531496215e-08
% O 0 3.4531326686959574e-09
- O 0 1.8869955908940028e-07
23 O 0 1.8281104985362617e-07
% O 0 5.765079080788382e-09
( O 0 6.306053013105384e-09
P O 0 6.73943247875286e-07
< O 0 8.041267562930443e-08
. O 0 2.0946027134982614e-09
0001 O 0 1.1164789981421563e-07
) O 0 1.0484360046802976e-09
, O 0 4.780272844229216e-10
suggesting O 0 5.6576174856104444e-09
that O 0 5.678880143911158e-10
differences O 0 2.863178805156963e-09
in O 0 2.88394974568007e-10
methods O 0 1.5005868769790709e-09
used O 0 1.7690847675666532e-09
for O 0 9.456541105734573e-10
mutation O 0 8.632782311224219e-08
detection O 0 1.4180346852299408e-07
or O 0 3.1221446761264815e-07
phenotype O 0 1.9972416339442134e-05
classification O 0 4.218009053147398e-07
may O 0 2.5915551304933615e-07
account O 0 6.5313572328307146e-09
for O 0 1.2265808368994158e-09
a O 0 1.284421902170152e-08
considerable O 0 2.1513546499818403e-08
proportion O 0 2.794354081459005e-08
of O 0 1.5960516464019747e-08
genotype O 0 0.00012796474038623273
- O 0 0.04633840546011925
phenotype O 0 0.000208731580642052
inconsistencies O 0 8.823785174172372e-05
. O 0 2.4764572117419448e-06

Our O 0 2.4210917217715178e-06
data O 0 2.606747102618101e-07
indicate O 0 1.3621846051137254e-07
that O 0 5.414757531241321e-09
the O 0 2.5925308122509705e-08
PAH O 0 6.878340354887769e-05
- O 0 6.885211041662842e-05
mutation O 0 3.069816557399463e-06
genotype O 0 6.752299555046193e-07
is O 0 3.2418767670350235e-09
the O 0 1.2814114214165784e-09
main O 0 5.006058145795578e-08
determinant O 0 2.390810891483852e-07
of O 0 1.9568439313388808e-08
metabolic O 0 0.08488740772008896
phenotype O 0 5.004278136766516e-05
in O 0 4.356844485187139e-08
most O 0 2.2427846602113277e-07
patients O 0 2.3865538878453663e-06
with O 0 1.721587250358425e-05
PAH B-Disease 1 0.9998282194137573
deficiency I-Disease 0 0.16112150251865387
. O 0 1.2722401834253105e-06

In O 0 5.605310207101866e-07
the O 0 2.4195161429929612e-08
present O 0 8.444645871463763e-09
study O 0 2.1717492248995995e-09
, O 0 1.1513739961444003e-09
the O 0 1.2096899038027686e-09
classification O 0 2.2200101312819243e-08
of O 0 5.092421595520591e-09
105 O 0 3.347919346197159e-06
PAH O 0 0.00010759037832031026
mutations O 0 1.2517111827037297e-06
may O 0 1.0852658327564768e-08
allow O 0 1.6469913211025755e-09
the O 0 2.9126416833946678e-09
prediction O 0 1.760429171326905e-07
of O 0 6.707507882453001e-10
the O 0 6.127175211645408e-09
biochemical O 0 1.3043520539213205e-06
phenotype O 0 9.70353880802577e-07
in O 0 2.758833161919938e-09
> O 0 4.112369111908265e-08
10 O 0 5.429940053147675e-09
, O 0 2.414683342166768e-09
000 O 0 9.496599062686073e-09
genotypes O 0 1.4498112932415097e-07
, O 0 1.259569248901471e-08
which O 0 1.233226498698059e-07
may O 0 7.823920356031522e-08
be O 0 4.6237971784712784e-10
useful O 0 7.99449451083234e-10
for O 0 3.5750183369209765e-10
the O 0 3.0991607058439286e-09
management O 0 1.6501806143764952e-08
of O 0 7.1605246176886794e-09
hyperphenylalaninemia B-Disease 1 0.9999903440475464
in O 0 7.404925099763204e-07
newborns O 0 5.110678102937527e-05
. O 0 3.580768179745064e-07

Somatic O 0 0.0002936552045866847
instability O 0 4.12100380344782e-05
of O 0 1.0423296714634489e-07
the O 0 7.933272172522265e-08
CTG O 0 1.720776162983384e-05
repeat O 0 8.985183512777439e-07
in O 0 2.137562482573685e-08
mice O 0 9.090907155950845e-07
transgenic O 0 2.1040578701558843e-07
for O 0 1.867069876482219e-08
the O 0 2.435175019854796e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 7.88502802606672e-06
is O 0 4.0353214103561186e-08
age O 0 1.503997459906259e-08
dependent O 0 9.034761383475143e-09
but O 0 3.891877486950079e-09
not O 0 1.0381343562571033e-09
correlated O 0 1.6934103896915076e-08
to O 0 1.596531906677967e-09
the O 0 5.36532862582817e-09
relative O 0 9.823638436046167e-08
intertissue O 0 1.24939640500088e-06
transcription O 0 5.787181862615398e-07
levels O 0 9.442400283887764e-08
and O 0 4.9288413350723204e-08
proliferative O 0 0.00024627678794786334
capacities O 0 4.31772514275508e-06
. O 0 8.197222882699862e-07

A O 0 2.9286558856256306e-05
( O 0 2.357966877752915e-06
CTG O 0 2.336164834559895e-05
) O 0 4.971925449126502e-08
nexpansion O 0 4.772988972945313e-07
in O 0 5.6629398947904974e-09
the O 0 1.6330314878132413e-08
3 O 0 3.457247146343434e-07
- O 0 6.704197585349903e-05
untranslated O 0 9.983810741687194e-05
region O 0 3.0952628549130168e-06
( O 0 4.70126799712034e-08
UTR O 0 2.119564442182309e-06
) O 0 4.993829794130988e-09
of O 0 1.4359068378766437e-09
the O 0 7.567209081571491e-08
DM O 1 0.9999998807907104
protein O 0 2.219952421000926e-06
kinase O 0 7.729420758550987e-06
gene O 0 8.62836827764113e-07
( O 0 5.432708860553248e-08
DMPK O 0 5.642770247504814e-06
) O 0 6.757385762057311e-09
is O 0 5.641034306336223e-09
responsible O 0 3.902799150523606e-08
for O 0 1.8147838432014396e-07
causing O 0 0.027891097590327263
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0003787866444326937
DM B-Disease 1 1.0
) O 0 3.8751272768422496e-06
. O 0 2.7664918889058754e-06

Major O 0 1.0577226930763572e-05
instability O 0 1.444649478798965e-05
, O 0 4.1790499949456716e-08
with O 0 4.54943194228008e-09
very O 0 2.5816784265941806e-09
large O 0 1.4779480972393344e-09
expansions O 0 6.398291674258871e-08
between O 0 2.9574104942753365e-08
generations O 0 3.93668919684842e-08
and O 0 1.4609810250476585e-08
high O 0 3.1300352532070974e-08
levels O 0 7.258195378057053e-09
of O 0 2.013917921317443e-09
somatic O 0 7.080520276758762e-07
mosaicism O 0 9.22962135518901e-06
, O 0 1.0652456694515422e-08
is O 0 7.166331528196679e-09
observed O 0 1.295019700364719e-07
in O 0 6.057676671389345e-08
patients O 0 1.4135845276541659e-06
. O 0 5.341651672097214e-07

There O 0 8.103808113446576e-07
is O 0 1.7492657988782412e-08
a O 0 2.229506712581042e-08
good O 0 3.0710118892329774e-08
correlation O 0 4.645450601969969e-08
between O 0 2.7614300179834572e-08
repeat O 0 4.566460916066717e-07
size O 0 1.321317597557936e-07
( O 0 7.827947179350758e-09
at O 0 2.161455237015275e-09
least O 0 1.510335412291397e-09
in O 0 4.2946330935933474e-09
leucocytes O 0 1.0858839232241735e-06
) O 0 2.636225238106249e-09
, O 0 2.4579072110952893e-09
clinical O 0 7.017572301037944e-08
severity O 0 3.453629688010551e-06
and O 0 1.1281873213420113e-07
age O 0 6.830655507883421e-08
of O 0 2.08377279875549e-08
onset O 0 4.379513848107308e-05
. O 0 9.051622100741952e-07

The O 0 1.26924533105921e-05
trinucleotide O 0 0.0007636676891706884
repeat O 0 4.241129499860108e-05
instability O 0 8.323315341840498e-06
mechanisms O 0 1.070560870175541e-06
involved O 0 2.1675958805644768e-07
in O 0 3.412878584185819e-07
DM B-Disease 1 1.0
and O 0 8.414806984546885e-07
other O 0 2.429069034803888e-08
human O 0 2.9229863685031887e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 0.9999990463256836
are O 0 9.406790013599675e-08
unknown O 0 1.0476727538843988e-06
. O 0 8.458205229544546e-07

We O 0 4.679797257267637e-06
studied O 0 5.579231014962716e-07
somatic O 0 2.0631389361369656e-06
instability O 0 4.376191782284877e-07
by O 0 4.645182460905062e-09
measuring O 0 3.394638952158857e-07
the O 0 2.4317067470747133e-08
CTG O 0 6.0437751017161645e-06
repeat O 0 4.940841904499393e-07
length O 0 2.876057010325894e-07
at O 0 5.477477138526865e-09
several O 0 2.2464521354237377e-09
ages O 0 2.1325496035728975e-08
in O 0 8.957816710619682e-10
various O 0 1.2810765781523514e-09
tissues O 0 2.255615427770863e-08
of O 0 1.6428749471941728e-09
transgenic O 0 1.1031713711417979e-06
mice O 0 9.000131626635266e-07
carrying O 0 1.2706012242347242e-08
a O 0 2.2382158348932535e-08
( O 0 2.3123673642544418e-08
CTG O 0 1.5128898667171597e-06
) O 0 4.410891207839995e-09
55expansion O 0 1.1396065247026854e-07
surrounded O 0 6.809270303165249e-08
by O 0 1.4935140901783939e-09
45 O 0 2.1785458770295918e-08
kb O 0 1.7026498255745537e-07
of O 0 1.584760322970169e-09
the O 0 3.5280582011409933e-08
human O 0 8.263389759122219e-07
DM B-Disease 1 1.0
region O 0 3.2806812555463694e-07
, O 0 3.211149790516288e-09
using O 0 7.404187929438422e-09
small O 0 6.068315627771881e-08
- O 0 4.977418484486407e-06
pool O 0 2.0273289464967092e-06
PCR O 0 1.635841363167856e-05
. O 0 8.538733027307899e-07

These O 0 6.535571515087213e-07
mice O 0 9.450232028029859e-06
have O 0 6.407280039866237e-08
been O 0 4.106843221052259e-08
shown O 0 1.514579750505618e-08
to O 0 3.258558978203041e-09
reproduce O 0 1.905815167901892e-07
the O 0 5.1997388617053275e-09
intergenerational O 0 4.799047133019485e-07
and O 0 3.904362699813646e-08
somatic O 0 1.4703410045058263e-07
instability O 0 8.797324824172392e-08
of O 0 8.490639302749514e-10
the O 0 7.565863491265645e-09
55 O 0 9.889173924193528e-08
CTG O 0 6.713106586175854e-07
repeat O 0 1.5614396886576287e-07
suggesting O 0 2.5406368564517834e-08
that O 0 8.092496117662051e-10
surrounding O 0 3.87019571945757e-09
sequences O 0 4.10978913123472e-08
and O 0 9.654911536927102e-09
the O 0 3.859550901097464e-09
chromatin O 0 1.7823121822857502e-07
environment O 0 4.611656123643115e-08
are O 0 1.2560013029627726e-09
involved O 0 4.556744315209471e-09
in O 0 1.2196806231656865e-08
instability O 0 4.484946657612454e-06
mechanisms O 0 1.9461895135464147e-06
. O 0 7.17401974270615e-07

As O 0 2.82400810647232e-06
observed O 0 4.564627715808456e-07
in O 0 2.4831026124161326e-09
some O 0 6.031385391125355e-10
of O 0 4.5715237151355836e-10
the O 0 9.1610017349808e-09
tissues O 0 4.4682192879008653e-07
of O 0 3.2956638307268804e-08
DM B-Disease 1 1.0
patients O 0 8.92366472271533e-07
, O 0 1.9162731401678457e-09
there O 0 9.122932409511009e-10
is O 0 6.719877432281862e-10
a O 0 5.125963653540566e-09
tendency O 0 7.853719097283829e-08
for O 0 1.9043875365554186e-09
repeat O 0 2.4139851007021207e-07
length O 0 2.170609860741024e-07
and O 0 8.119805272599478e-09
somatic O 0 8.995113631726781e-08
mosaicism O 0 7.964304700180946e-07
to O 0 4.1558294583410316e-09
increase O 0 1.0873045575010565e-08
with O 0 6.135279395635962e-09
the O 0 1.9440468790321574e-08
age O 0 2.514325103675219e-08
of O 0 7.767426146720879e-10
the O 0 2.8132530971447522e-08
mouse O 0 4.694065501098521e-05
. O 0 5.835052547809028e-07

Furthermore O 0 1.8556842405814677e-05
, O 0 2.8118483896832913e-07
we O 0 5.33643778055648e-08
observed O 0 2.864147141679041e-08
no O 0 3.1105191755642636e-09
correlation O 0 3.177180474267516e-08
between O 0 3.862776321028605e-09
the O 0 6.6876975068907996e-09
somatic O 0 8.901107548808795e-07
mutation O 0 5.981419235467911e-07
rate O 0 9.24635116916761e-07
and O 0 1.5202878955733468e-07
tissue O 0 5.56887198399636e-06
proliferation O 0 1.7272915329158423e-06
capacity O 0 2.3377162960969144e-07
. O 0 3.013331593137991e-07

The O 0 1.3633481330543873e-06
somatic O 0 8.504166544298641e-06
mutation O 0 4.759189778269501e-06
rates O 0 2.3599010035013634e-07
in O 0 3.296026784838091e-09
different O 0 3.156900518774819e-09
tissues O 0 3.602374363254057e-07
were O 0 1.4717677743192326e-07
also O 0 2.180379077287853e-08
not O 0 1.6354526621853438e-09
correlated O 0 7.255786194093616e-09
to O 0 7.393219370044335e-10
the O 0 1.7164915044887152e-09
relative O 0 4.12971665753048e-08
inter O 0 4.187819513390423e-07
- O 0 1.249552133231191e-05
tissue O 0 3.707104383465776e-07
difference O 0 8.815074892254415e-09
in O 0 9.160419645048989e-10
transcriptional O 0 6.522508044781716e-08
levels O 0 6.660926032964198e-09
of O 0 1.9193886757751244e-10
the O 0 1.1102009311869665e-09
three O 0 1.2287755701834158e-08
genes O 0 1.0251622484247491e-07
( O 0 6.853843714793584e-09
DMAHP O 0 7.803173502907157e-07
, O 0 8.297122100486831e-09
DMPK O 0 8.916808269532339e-07
and O 0 3.7876681346915575e-08
59 O 0 5.5724147074442953e-08
) O 0 1.4262496739192443e-09
surrounding O 0 8.239434023948888e-09
the O 0 1.999283405496044e-08
repeat O 0 2.272679239467834e-06
. O 0 6.39332640162138e-08
. O 0 4.111287523755891e-07

A O 0 1.2045458788634278e-05
novel O 0 8.163900929503143e-06
missense O 0 0.00038484399556182325
mutation O 0 1.3767319614998996e-05
in O 0 5.578688799801057e-08
patients O 0 1.6486649201397086e-07
from O 0 6.492617554698654e-09
a O 0 1.7534205198899144e-07
retinoblastoma B-Disease 0 0.00010633838246576488
pedigree O 0 9.893211245071143e-05
showing O 0 1.4457162251346745e-05
only O 0 7.06946892137239e-08
mild O 0 3.6646806620410644e-06
expression O 0 5.574242933903406e-08
of O 0 5.8281979242735815e-09
the O 0 3.1477514994548983e-07
tumor B-Disease 0 0.0005911074695177376
phenotype O 0 0.00013656477676704526
. O 0 1.6825064221848152e-06

We O 0 6.014417067490285e-06
have O 0 4.5330811104804525e-08
used O 0 1.512506919709722e-08
single O 0 8.08246198857887e-08
strand O 0 5.103784587845439e-06
conformation O 0 8.191986466954404e-07
polymorphism O 0 2.025796987936701e-07
analysis O 0 4.57084592397905e-09
to O 0 7.735594387270339e-10
study O 0 1.8180181804439144e-09
the O 0 3.777716806041553e-09
27 O 0 3.381471458396845e-08
exons O 0 4.005744003166001e-08
of O 0 1.2070647814610425e-09
the O 0 8.935534978604665e-09
RB1 O 0 5.614492692984641e-06
gene O 0 3.135030368639491e-08
in O 0 3.6134237824114734e-09
individuals O 0 9.519844912375675e-10
from O 0 6.371603245014512e-10
a O 0 2.1992578425056308e-08
family O 0 5.24410324942437e-07
showing O 0 5.845417490490945e-06
mild O 0 3.693395001391764e-06
expression O 0 3.529788017431201e-08
of O 0 2.9519819921830504e-09
the O 0 1.341087738637725e-07
retinoblastoma B-Disease 0 0.000613127020187676
phenotype O 0 0.0004079964419361204
. O 0 1.470768893341301e-06

In O 0 1.1846829011119553e-06
this O 0 5.291315119393403e-08
family O 0 2.5187321739394974e-07
affected O 0 5.073635023222778e-08
individuals O 0 7.428759385419426e-09
developed O 0 1.4711993401306245e-07
unilateral B-Disease 0 0.003785892389714718
tumors I-Disease 1 1.0
and O 0 3.469885768936365e-06
, O 0 8.516335192609858e-09
as O 0 2.5826534244544064e-09
a O 0 8.622032865446272e-09
result O 0 6.3084231172183536e-09
of O 0 9.6458674381239e-10
linkage O 0 5.240003702056129e-07
analysis O 0 2.267006316003517e-08
, O 0 1.2299409490879043e-08
unaffected O 0 5.484478720063635e-07
mutation O 0 1.6881610065411223e-07
carriers O 0 3.953763183517367e-08
were O 0 3.4272751747721486e-08
also O 0 4.3324732246219355e-08
identified O 0 5.914293765840739e-08
within O 0 4.9413015901222934e-09
the O 0 5.366825206465364e-08
pedigree O 0 2.1453990484587848e-05
. O 0 7.070857463986613e-07

A O 0 6.522746389237e-06
single O 0 1.1529951962074847e-06
band O 0 1.546618022985058e-06
shift O 0 1.726941007973437e-07
using O 0 2.4495125927614936e-08
SSCP O 0 5.117738965054741e-06
was O 0 1.4758465738395898e-07
identified O 0 1.8396740131265688e-08
in O 0 2.98083180361175e-09
exon O 0 8.662121899760677e-07
21 O 0 7.414535616590001e-07
which O 0 1.0474791700687547e-08
resulted O 0 1.4841184281522146e-08
in O 0 4.9652419953361004e-09
a O 0 1.2502898982802435e-07
missense O 0 1.4409069081011694e-05
mutation O 0 1.6599388175109198e-07
converting O 0 4.466557612659017e-08
a O 0 5.0964271025577546e-08
cys O 0 2.645108543219976e-05
- O 0 1.4563270269718487e-05
- O 0 9.292645700043067e-06
> O 0 7.027362585176888e-07
arg O 0 4.927507006868836e-07
at O 0 1.9566350317745673e-08
nucleotide O 0 2.52951650736577e-07
position O 0 2.0780977649792476e-07
28 O 0 8.57884501215267e-08
in O 0 9.167835379741973e-09
the O 0 3.9943000018638486e-08
exon O 0 1.6057842003647238e-05
. O 0 1.5441037248820066e-06

The O 0 2.3829513793316437e-06
mutation O 0 1.2472292837628629e-05
destroyed O 0 8.615327260486083e-07
an O 0 2.5025171268566737e-08
NdeI O 0 7.598197043989785e-06
restriction O 0 3.730820594682882e-07
enzyme O 0 8.087471883300168e-07
site O 0 2.310354147994076e-06
. O 0 7.666856731702865e-07

Analysis O 0 1.8780580148813897e-06
of O 0 7.154807235565386e-08
all O 0 7.872567486799653e-09
family O 0 9.063865746838928e-08
members O 0 1.0491647550736616e-08
demonstrated O 0 4.749124116187886e-08
that O 0 1.2015106687357502e-09
the O 0 8.127615025443902e-09
missense O 0 1.1664989870041609e-05
mutation O 0 6.50124434287136e-07
co O 0 3.3094974583036674e-07
- O 0 1.1831248230009805e-06
segregated O 0 2.4086591565719573e-07
with O 0 4.465884373416884e-08
patients O 0 2.7187095952285745e-07
with O 0 4.677431491018069e-07
tumors B-Disease 1 1.0
or O 0 4.532377715804614e-06
who O 0 4.347906269686064e-06
, O 0 6.016646736384246e-09
as O 0 2.394279441375602e-09
a O 0 7.886875152962602e-09
result O 0 3.490579825182749e-09
of O 0 1.0045030363059482e-09
linkage O 0 6.300837753769883e-07
analysis O 0 3.732496622887993e-08
had O 0 3.3797066407714738e-06
been O 0 7.67604717566428e-08
predicted O 0 1.7615543868032546e-07
to O 0 1.7000699736868796e-09
carry O 0 1.9029215536647826e-08
the O 0 3.972358086912209e-08
predisposing O 0 3.6359342630021274e-05
mutation O 0 1.7220861991518177e-05
. O 0 9.027406804307248e-07

These O 0 2.978481177251524e-07
observations O 0 7.43533917102468e-07
point O 0 3.5058153002864856e-07
to O 0 6.2655303167957754e-09
another O 0 1.7565980670042336e-08
region O 0 3.560309735917144e-08
of O 0 1.7431566190495573e-09
the O 0 3.358524836016841e-08
RB1 O 0 1.3262149877846241e-05
gene O 0 9.843763848493836e-08
where O 0 3.3394130127817334e-08
mutations O 0 6.603888635936528e-08
only O 0 1.3461286529903305e-09
modify O 0 2.0420664270659472e-08
the O 0 3.1726732352410636e-09
function O 0 1.3484208194469716e-09
of O 0 2.1838397756823724e-10
the O 0 1.2465527499117002e-09
gene O 0 3.610490750816098e-08
and O 0 1.832292007009073e-08
raise O 0 8.591007016889307e-09
important O 0 1.1025470536552007e-09
questions O 0 2.375506680252215e-09
for O 0 9.482007401473425e-10
genetic O 0 8.322135869320846e-08
counseling O 0 3.1059261829113893e-08
in O 0 4.800321473652502e-09
families O 0 7.554485925709287e-09
with O 0 3.959768957173537e-09
these O 0 7.453511585708839e-09
distinctive O 0 1.8725818335951772e-06
phenotypes O 0 5.221823357715039e-06
. O 0 5.8637816380269214e-08
. O 0 5.061972956355021e-07

Maternal B-Disease 0 0.007125833071768284
disomy I-Disease 0 0.008899809792637825
and O 0 0.0006223651580512524
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
consistent O 0 2.174217797801248e-06
with O 0 3.5871526193886893e-08
gamete O 0 3.154177875330788e-06
complementation O 0 1.572430119267665e-05
in O 0 1.504666080620609e-08
a O 0 4.109561757559277e-08
case O 0 4.2510020392683145e-08
of O 0 4.692324750976695e-09
familial O 0 7.071814252412878e-06
translocation O 0 5.2673414757009596e-05
( O 0 8.793399075557318e-08
3 O 0 7.852894867710347e-08
; O 0 5.396654501055309e-08
15 O 0 4.051648616609782e-08
) O 0 8.860892464213066e-09
( O 0 7.046379035813288e-09
p25 O 0 3.3227229323529173e-07
; O 0 1.7939004948175352e-08
q11 O 0 2.545410211496346e-07
. O 0 5.413415049559944e-09
2 O 0 8.237536519573041e-08
) O 0 9.384191912431561e-08
. O 0 2.8292546971897536e-07

Maternal B-Disease 0 0.08682391047477722
uniparental I-Disease 1 0.7742249965667725
disomy I-Disease 0 0.22766421735286713
( I-Disease 0 4.11330875067506e-05
UPD I-Disease 1 0.9999873638153076
) I-Disease 0 2.6637385985850415e-07
for I-Disease 0 1.8254969091913154e-08
chromosome I-Disease 0 3.34883552568499e-05
15 I-Disease 0 2.462991517404589e-07
is O 0 3.772698153881038e-09
responsible O 0 2.6557667176518862e-09
for O 0 3.987490615475764e-10
an O 0 1.342774447188333e-09
estimated O 0 1.2235672031124523e-08
30 O 0 5.760462329362781e-09
% O 0 6.437543276227586e-10
of O 0 3.3944633215376996e-10
cases O 0 1.204138122545828e-08
of O 0 9.296555845139665e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.4550220839737449e-05
PWS B-Disease 1 0.9999979734420776
) O 0 1.3326048247108702e-06
. O 0 1.3619408036902314e-06

We O 0 7.166278010117821e-06
report O 0 9.359113306572908e-08
on O 0 1.4347249610580093e-08
an O 0 2.709009683243835e-09
unusual O 0 2.0532873179490707e-08
case O 0 2.3493015532949357e-08
of O 0 5.233967925732941e-09
maternal B-Disease 0 1.5419700503116474e-06
disomy I-Disease 0 5.256498297967482e-06
15 I-Disease 0 5.982604989185347e-08
in O 0 3.3961441658902913e-08
PWS B-Disease 1 0.9999994039535522
that O 0 5.1010271562290654e-08
is O 0 6.2589844418425855e-09
most O 0 9.623026819838287e-10
consistent O 0 7.017783687501833e-09
with O 0 1.193179555158963e-09
adjacent O 0 4.177710977160132e-08
- O 0 2.114345761583536e-06
1 O 0 3.130202586021369e-08
segregation O 0 2.8351934133752366e-08
of O 0 1.1866273519345327e-09
a O 0 2.5090505673119878e-08
paternal O 0 5.4027800615585875e-06
t O 0 7.39669212634908e-06
( O 0 4.450652735243921e-09
3 O 0 1.0988862264582622e-08
; O 0 1.0248197845896811e-08
15 O 0 1.6838768601701304e-08
) O 0 2.1120296622711976e-09
( O 0 2.75149703021782e-09
p25 O 0 1.2682168915034708e-07
; O 0 8.930593153877453e-09
q11 O 0 6.268592045444166e-08
. O 0 1.6546837233732958e-09
2 O 0 5.295765159729626e-09
) O 0 6.755784820455801e-10
with O 0 7.517814148982893e-10
simultaneous O 0 1.0251368820490825e-07
maternal O 0 3.1636100175091997e-06
meiotic O 0 6.363305601553293e-06
nondisjunction O 0 4.238871497364016e-06
for O 0 2.7247802236729513e-08
chromosome O 0 3.243036917410791e-05
15 O 0 6.974231041567691e-07
. O 0 4.6638817252642184e-07

The O 0 3.107531711066258e-06
patient O 0 7.606788585690083e-06
( O 0 2.1647306880367978e-07
J O 0 1.4954874131944962e-05
. O 0 2.165136869791695e-08
B O 0 1.2511057434494433e-07
. O 0 2.0478769791054674e-09
) O 0 8.388519878721468e-10
, O 0 4.990837187968111e-10
a O 0 5.736209729434449e-09
17 O 0 3.9210124924693446e-08
- O 0 4.070005843459512e-07
year O 0 1.3782568863973665e-08
- O 0 8.533132245247543e-07
old O 0 3.588669642340392e-06
white O 0 7.145682729969849e-07
male O 0 1.3731748538248212e-07
with O 0 4.6468151992939966e-08
PWS B-Disease 1 0.9999996423721313
, O 0 7.722569250745437e-08
was O 0 3.822731002856017e-07
found O 0 6.806488705990432e-09
to O 0 2.0705710479518302e-09
have O 0 8.250961691658176e-09
47 O 0 2.2576772451543548e-08
chromosomes O 0 6.388280127112012e-08
with O 0 4.69189531671077e-09
a O 0 9.860976746267625e-08
supernumerary O 0 7.292300870176405e-05
, O 0 9.7072820892663e-08
paternal O 0 1.0779045624076389e-05
der O 0 0.00038247762131504714
( O 0 9.08841002456029e-09
15 O 0 6.565843424510831e-09
) O 0 7.335237417471774e-10
consisting O 0 6.113268780083558e-10
of O 0 1.4733434472447016e-09
the O 0 8.43820942009188e-08
short O 0 1.3577464414993301e-05
arm O 0 5.8046971389558166e-05
and O 0 1.6329972041262408e-08
the O 0 1.02589545747378e-08
proximal O 0 4.499513124756049e-06
long O 0 5.09981964569306e-06
arm O 0 9.543297892378177e-06
of O 0 4.692521926585869e-09
chromosome O 0 3.2455493510497035e-06
15 O 0 6.990759260361301e-08
, O 0 1.2655028136521196e-08
and O 0 1.1439817626524018e-07
distal O 0 0.0007238400867208838
chromosome O 0 0.07843067497015
arm O 0 0.0013158582150936127
3p O 0 0.0004632087657228112
. O 0 3.4387321647955105e-06

The O 0 3.1712038435216527e-06
t O 0 2.5886283765430562e-05
( O 0 3.748263210923142e-08
3 O 0 1.8346980823480408e-08
; O 0 1.2378910341226401e-08
15 O 0 2.7359035925655917e-08
) O 0 3.3326663650967703e-09
was O 0 1.605736343890385e-07
present O 0 2.4168855805584144e-09
in O 0 8.756185776448433e-10
the O 0 1.3475311977373394e-09
balanced O 0 9.254131683178457e-09
state O 0 8.716510291328916e-10
in O 0 3.7426750587599145e-09
the O 0 4.0499177345054704e-08
patients O 0 1.7945596653134999e-07
father O 0 1.9492509295560012e-07
and O 0 1.5738265801701345e-08
a O 0 1.9327322320350504e-07
sister O 0 4.1238654375774786e-05
. O 0 8.264028110716026e-07

Fluorescent O 0 0.00010930786083918065
in O 0 3.0666865313833114e-07
situ O 0 1.1062254543503514e-06
hybridization O 0 3.6304552963883907e-07
analysis O 0 6.478270364596028e-08
demonstrated O 0 9.529735933710981e-08
that O 0 5.312650319666545e-09
the O 0 8.1952549635389e-08
PWS B-Disease 1 0.9999995231628418
critical O 0 4.4877270966026117e-07
region O 0 1.5021976196294418e-07
resided O 0 2.1570951957983198e-07
on O 0 3.376901958063172e-08
the O 0 2.6461495217233733e-09
derivative O 0 1.0358962043710562e-07
chromosome O 0 2.1855312297702767e-06
3 O 0 1.0218377610726748e-07
and O 0 4.2258442078946246e-08
that O 0 1.0003279093950823e-08
there O 0 5.912339506863873e-09
was O 0 4.546649847725348e-07
no O 0 5.324062080092062e-09
deletion O 0 9.743787643401447e-08
of O 0 5.819255743944041e-09
the O 0 4.4709389612762607e-07
PWS B-Disease 1 0.9999997615814209
region O 0 2.477262341926689e-07
on O 0 2.1497841373729898e-07
the O 0 2.1276091999311575e-08
normal O 0 3.529788017431201e-08
pair O 0 6.481509018385623e-08
of O 0 3.4180553942775305e-09
15s O 0 1.624840990643861e-07
present O 0 1.779512537325445e-08
in O 0 1.0834379793323023e-07
J O 0 0.000310220435494557
. O 0 1.0409125934529584e-06

B O 0 0.0012028635246679187
. O 0 3.881244265357964e-05

Methylation O 0 2.707131534407381e-05
analysis O 0 1.1502681900310563e-06
at O 0 1.0611456957576593e-07
exon O 0 1.8298527493243455e-06
alpha O 0 1.3898278439228307e-07
of O 0 2.3669313176100104e-09
the O 0 5.48972511893453e-09
small O 0 1.4903534406585095e-08
nuclear O 0 1.224317003334363e-07
ribonucleoprotein O 0 1.4983588698669337e-06
- O 0 9.003530863083142e-07
associated O 0 1.642110447619416e-07
polypeptide O 0 8.813377689875779e-07
N O 0 6.562765406670223e-07
( O 0 8.829647235586435e-09
SNRPN O 0 1.977050914092615e-07
) O 0 2.1548935968951355e-09
gene O 0 2.247807628918963e-08
showed O 0 7.894027476140764e-08
a O 0 1.796077953031272e-08
pattern O 0 1.068404071702389e-05
characteristic O 0 9.17467914973713e-08
of O 0 1.0506200354143402e-09
only O 0 4.911739903690204e-09
the O 0 9.075279194803443e-09
maternal O 0 1.6401257880716003e-06
chromosome O 0 7.183685283962404e-06
15 O 0 5.53226726651701e-08
in O 0 5.4134797977667404e-08
J O 0 0.0002582983288448304
. O 0 7.388474614344887e-07

B O 0 0.0016688861651346087
. O 0 3.5818953620037064e-05

Maternal B-Disease 0 0.00394666800275445
disomy I-Disease 0 0.002208748133853078
was O 0 1.1667582839436363e-05
confirmed O 0 2.4409780507994583e-07
by O 0 4.911009376940001e-09
polymerase O 0 5.872589667887951e-07
chain O 0 6.422011438189656e-07
reaction O 0 2.4286613609092456e-08
analysis O 0 5.3140389866257465e-09
of O 0 1.6893287879682362e-09
microsatellite O 0 4.1496286939946e-06
repeats O 0 1.102006194741989e-06
at O 0 1.617195621861356e-08
the O 0 7.1719927774438474e-09
gamma O 0 2.7077257414021005e-07
- O 0 9.555678843753412e-07
aminobutyric O 0 2.4446080715279095e-06
acid O 0 3.5304688594806066e-07
receptor O 0 3.530785193106567e-07
beta3 O 0 1.0281755749019794e-06
subunit O 0 6.956999527574226e-07
( O 0 1.5190239821549767e-07
GABRB3 O 0 8.333409823535476e-06
) O 0 1.4816539817275043e-07
locus O 0 7.391847702820087e-06
. O 0 1.259477699022682e-06

A O 0 2.842893445631489e-05
niece O 0 0.00039089424535632133
( O 0 3.9525426132058783e-07
B O 0 3.729896036475111e-07
. O 0 7.631576259825579e-09
B O 0 5.2492868718445607e-08
. O 0 6.835784716052729e-10
) O 0 6.027314203294054e-10
with O 0 7.787244182821951e-10
45 O 0 1.3131141507471966e-08
chromosomes O 0 7.583984995562787e-08
and O 0 5.849078554831522e-09
the O 0 1.7725131362666957e-09
derivative O 0 2.7326910512215363e-08
3 O 0 3.512172597197605e-08
but O 0 9.754178798004887e-09
without O 0 2.7168594041171445e-09
the O 0 4.199118830428006e-09
der O 0 6.370257324306294e-06
( O 0 3.0004023710006322e-09
15 O 0 3.5931699837732367e-09
) O 0 1.4146106508405865e-09
demonstrated O 0 7.4194419497075614e-09
a O 0 2.9645040200421136e-08
phenotype O 0 2.340161472602631e-06
consistent O 0 2.3645410962558344e-08
with O 0 3.0204532208699675e-09
that O 0 1.5681274945222867e-08
reported O 0 1.6275285474876e-07
for O 0 3.0757409952286707e-09
haploinsufficiency O 0 7.124398280211608e-07
of O 0 8.632548009757102e-09
distal O 0 3.572411515051499e-05
3 O 0 2.2988681394053856e-06
p O 0 2.5265479052904993e-05
. O 0 9.126418945015757e-07

Uniparental B-Disease 1 0.9999964237213135
disomy I-Disease 1 0.9999842643737793
associated O 0 1.8501428712625057e-05
with O 0 2.773738287942251e-07
unbalanced O 0 4.66780002170708e-05
segregation O 0 3.839248620352009e-06
of O 0 1.8494404230295913e-08
non O 0 4.3789384562842315e-08
- O 0 2.2747651655663503e-06
Robertsonian O 0 3.860329798044404e-06
translocations O 0 4.051029918628046e-06
has O 0 4.2374588815619063e-07
been O 0 4.8241791006375934e-08
reported O 0 7.446183047932209e-08
previously O 0 6.365547733366839e-08
but O 0 2.131236165325845e-08
has O 0 7.442789495826219e-08
not O 0 4.00957933521795e-09
, O 0 9.6035912555692e-10
to O 0 3.8136088731377527e-10
our O 0 1.8282485525489278e-09
knowledge O 0 1.2683535333124496e-09
, O 0 1.7152412823406848e-09
been O 0 8.995008293766205e-09
observed O 0 9.970610115317413e-09
in O 0 8.999087586225585e-10
a O 0 1.5941713726874696e-08
case O 0 7.77056001766141e-08
of O 0 2.1007656414440135e-07
PWS B-Disease 1 0.9999994039535522
. O 0 2.779380565698375e-06

Furthermore O 0 1.4072898920858279e-05
, O 0 1.5822806176402082e-07
our O 0 3.6690966709329587e-08
findings O 0 5.8511908207492525e-08
are O 0 4.629191252547571e-09
best O 0 5.917960876899997e-08
interpreted O 0 7.879075525352164e-08
as O 0 8.089784842013614e-09
true O 0 6.989413492419772e-08
gamete O 0 2.1972596186969895e-06
complementation O 0 1.0198230484093074e-05
resulting O 0 4.784856741935073e-07
in O 0 1.5384622997771658e-07
maternal B-Disease 0 0.0016960219945758581
UPD I-Disease 1 1.0
15 I-Disease 0 1.6695594240445644e-05
and O 0 1.6691517885192297e-05
PWS B-Disease 1 0.999997615814209

Schwartz B-Disease 0 0.19328682124614716
- I-Disease 1 0.9994669556617737
Jampel I-Disease 1 0.9927041530609131
syndrome I-Disease 1 0.9997305274009705
type I-Disease 0 1.3343928912945557e-06
2 I-Disease 0 6.909544367772469e-07
and O 0 3.939934742902551e-07
Stuve B-Disease 0 0.1276751160621643
- I-Disease 1 0.9999986886978149
Wiedemann I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.998683512210846
: O 0 8.17035683553513e-09
a O 0 1.7789218986763444e-08
case O 0 2.8165873189323065e-08
for O 0 1.2056526443871007e-08
" O 0 2.4788479890958115e-07
lumping O 0 3.2845612167875515e-06
" O 0 1.5329526377172442e-06
. O 0 4.030868296922563e-07

Recent O 0 1.025583242153516e-05
studies O 0 2.877703195736103e-07
demonstrated O 0 1.2859298692546872e-07
the O 0 2.11276285355666e-09
existence O 0 4.53942083922243e-09
of O 0 5.345743847584572e-10
a O 0 1.3267112741743858e-08
genetically O 0 9.016344648671293e-08
distinct O 0 3.909392631840092e-08
, O 0 1.22389396395306e-08
usually O 0 5.057014806908455e-09
lethal O 0 7.369528542966464e-09
form O 0 1.2691424577937482e-09
of O 0 5.492979959775823e-10
the O 0 2.0630032793178543e-08
Schwartz B-Disease 0 0.01640200987458229
- I-Disease 1 0.9996647834777832
Jampel I-Disease 1 0.99983811378479
syndrome I-Disease 1 0.9997636675834656
( O 0 2.3034934315546707e-07
SJS B-Disease 0 8.133312803693116e-05
) O 0 1.3786039865237854e-08
of O 0 1.980303565574104e-08
myotonia B-Disease 0 0.15014854073524475
and O 0 5.446291197586106e-06
skeletal B-Disease 1 0.7020106911659241
dysplasia I-Disease 1 0.9988918900489807
, O 0 1.8328798034872307e-07
which O 0 9.27895058566719e-08
we O 0 5.016390502987633e-08
called O 0 1.0543502639848157e-06
SJS B-Disease 0 0.0002950105699710548
type I-Disease 0 6.783693606848828e-07
2 I-Disease 0 8.695527071722609e-07
. O 0 7.618307904522226e-07

This O 0 6.507312718895264e-06
disorder O 0 0.0009805187582969666
is O 0 5.2881169665397465e-08
reminiscent O 0 2.591194288470433e-06
of O 0 1.0962065921660269e-08
another O 0 2.468319735271507e-07
rare O 0 2.393493616636988e-07
condition O 0 9.90298758551944e-07
, O 0 7.909261690031144e-09
the O 0 4.292530775273917e-08
Stuve B-Disease 0 0.02436191216111183
- I-Disease 1 0.9999902248382568
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 0.9999995231628418
( O 0 7.534156338806497e-07
SWS B-Disease 0 0.003964515868574381
) O 0 2.138243537785911e-08
, O 0 2.515465613583956e-09
which O 0 2.5397635106116923e-09
comprises O 0 3.6226019961560496e-09
campomelia B-Disease 0 3.5685607713276113e-07
at O 0 2.6362620531017456e-08
birth O 0 4.830168336411589e-07
with O 0 1.472434689731017e-07
skeletal B-Disease 0 0.23896771669387817
dysplasia I-Disease 1 0.9989011287689209
, O 0 5.925900836700748e-07
contractures B-Disease 0 8.543662988813594e-05
, O 0 4.4268308130313017e-08
and O 0 9.949355472826937e-08
early B-Disease 0 5.89249452787044e-07
death I-Disease 0 8.157177035172936e-06
. O 0 6.143491191323847e-07

To O 0 6.72972134907468e-07
test O 0 6.306560607072242e-08
for O 0 1.6165224714370652e-09
possible O 0 2.001851306943081e-08
nosologic O 0 3.088993707933696e-06
identity O 0 1.0800500405139246e-07
between O 0 3.3106267949278845e-08
these O 0 5.08789952391453e-08
disorders O 0 2.324796878383495e-05
, O 0 4.770401851317274e-09
we O 0 2.341578930753485e-09
reviewed O 0 6.276354547196661e-09
the O 0 1.5245840145894363e-09
literature O 0 1.556053952356251e-09
and O 0 8.295568121319263e-10
obtained O 0 9.030208247828853e-10
a O 0 2.0999990635317545e-09
follow O 0 3.3364444540495697e-09
- O 0 4.517751222010702e-07
up O 0 5.3605337058115765e-08
of O 0 2.132909404650718e-10
the O 0 1.197776322570121e-09
only O 0 1.3866437997833714e-09
two O 0 9.290280544860252e-09
surviving O 0 6.932058340680669e-07
patients O 0 1.2836773422009173e-08
, O 0 3.482996391301896e-10
one O 0 8.136917251100328e-10
with O 0 1.951434791536144e-09
SJS B-Disease 0 3.239664465581882e-06
type I-Disease 0 9.584272042673092e-09
2 I-Disease 0 9.989435945101377e-09
at O 0 1.5261267805044554e-08
age O 0 4.934745945206487e-09
10 O 0 2.155247091906176e-09
years O 0 1.3483307803596745e-09
and O 0 1.3684019473103604e-09
another O 0 1.9166970233186476e-09
with O 0 2.1286036044898538e-08
SWS B-Disease 0 0.0016947361873462796
at O 0 7.469895990652731e-08
age O 0 5.366876365542339e-08
7 O 0 6.553434417355675e-08
years O 0 6.95360427016567e-08
. O 0 2.2031295543456508e-07

Patients O 0 0.0017961252015084028
reported O 0 1.479040383856045e-05
as O 0 6.864875956580363e-08
having O 0 2.508189993477572e-07
either O 0 8.979135373010649e-07
neonatal O 1 0.9999812841415405
SJS B-Disease 1 0.9977511763572693
or O 0 4.059638740727678e-06
SWS B-Disease 0 0.035555772483348846
presented O 0 9.901686581770264e-08
a O 0 2.6272315878372865e-08
combination O 0 6.667715979347122e-08
of O 0 3.985135776929383e-09
a O 0 2.654436741522659e-07
severe O 0 2.7051599317928776e-05
, O 0 8.02173616420987e-08
prenatal O 0 0.00044435029849410057
- O 1 0.985059380531311
onset O 1 0.9893865585327148
neuromuscular B-Disease 1 0.9999954700469971
disorder I-Disease 1 0.9819040894508362
( O 0 2.8098753546146327e-07
with O 0 4.815501142729772e-06
congenital B-Disease 1 1.0
joint I-Disease 0 0.0002944101288449019
contractures I-Disease 1 0.9997372031211853
, O 0 2.0509471141849644e-05
respiratory O 0 0.19774585962295532
and O 0 2.0676002350228373e-06
feeding O 0 1.5128382983675692e-05
difficulties O 0 3.2335543664885336e-07
, O 0 5.8565694516232725e-09
tendency O 0 8.008787233393377e-08
to O 0 6.355488135767473e-09
hyperthermia B-Disease 0 3.5046072298428044e-05
, O 0 8.645630877879285e-09
and O 0 4.5724850572526066e-09
frequent O 0 1.778040825684002e-07
death O 0 4.218035428493749e-06
in O 0 6.56231549100994e-08
infancy O 0 6.445452072512126e-06
) O 0 2.5582089779874195e-09
with O 0 1.6647631051469602e-09
a O 0 4.673881903727306e-08
distinct O 0 8.446565402664419e-07
campomelic B-Disease 0 0.00021925610781181604
- I-Disease 0 0.024072475731372833
metaphyseal I-Disease 0 0.002274627098813653
skeletal I-Disease 0 0.07012385129928589
dysplasia I-Disease 1 0.9971241354942322
. O 0 4.698776137956884e-06

The O 0 6.319341991911642e-07
similarity O 0 5.291568072607333e-07
of O 0 5.376412648416817e-09
the O 0 1.3442281066033956e-08
clinical O 0 1.6009762759949808e-07
and O 0 3.8194219342813085e-08
radiographic O 0 2.82416976915556e-06
findings O 0 2.1044010622972564e-07
is O 0 6.104940997175845e-09
so O 0 1.4677227211379318e-09
extensive O 0 5.5633955220457665e-09
that O 0 1.2600643195526118e-08
these O 0 4.9472927088345386e-08
disorders O 0 0.00012289387814234942
appear O 0 1.5702622135904676e-07
to O 0 1.019213513586692e-08
be O 0 1.555657114238329e-08
a O 0 8.021200414987106e-08
single O 0 1.5624392517565866e-06
entity O 0 3.4119714200642193e-06
. O 0 1.0970716175506823e-06

The O 0 5.520419108506758e-07
follow O 0 1.6779560496615886e-07
- O 0 1.8235500647278968e-06
up O 0 7.761938292105697e-08
observation O 0 8.885978530770444e-08
of O 0 8.396603967675276e-10
an O 0 2.656957542868099e-09
identical O 0 1.595394820697038e-07
and O 0 1.1185226966858863e-08
unique O 0 5.478835607419796e-09
pattern O 0 4.455599992070347e-06
of O 0 6.451722356359824e-08
progressive O 0 0.0012551669497042894
bone B-Disease 0 0.21711081266403198
dysplasia I-Disease 1 0.8134918212890625
in O 0 5.7650815676879574e-08
the O 0 6.576411237801949e-08
two O 0 1.0646991768226144e-06
patients O 0 5.392229809331184e-07
( O 0 1.9665113981659488e-09
one O 0 2.2370452157360887e-09
with O 0 1.2653146086449851e-08
SJS B-Disease 0 5.355646135285497e-05
type I-Disease 0 3.4309834973100806e-08
2 I-Disease 0 2.5402005832120267e-08
, O 0 2.301502322055171e-09
one O 0 8.162195364036506e-09
with O 0 9.134291900636526e-08
SWS B-Disease 0 0.26980331540107727
) O 0 1.4177745200072422e-08
surviving O 0 8.062907141948017e-08
beyond O 0 5.42042286610922e-08
infancy O 0 2.532415237510577e-07
adds O 0 2.662208942183497e-08
to O 0 7.28263893634562e-10
the O 0 1.0121440352506283e-09
evidence O 0 3.7030101207591315e-09
in O 0 2.3082682432118418e-09
favor O 0 1.4075222765086437e-08
of O 0 6.798237084382208e-09
identity O 0 9.089121135730238e-07
. O 0 2.8617509428841004e-07

The O 0 2.1173805180296768e-06
hypothesis O 0 5.600145414064173e-06
that O 0 1.5379107765056688e-07
SWS B-Disease 0 0.0015290812589228153
and O 0 3.259369520947075e-07
SJS B-Disease 0 0.00011213149991817772
type I-Disease 0 1.0388087900992105e-07
2 I-Disease 0 4.0975084658612104e-08
are O 0 9.31941745996312e-10
the O 0 6.7700156591854466e-09
same O 0 1.0588494205876486e-06
disorder O 0 5.414609404397197e-05
should O 0 1.0938652650338554e-08
be O 0 2.1060195809496918e-09
testable O 0 1.2270938931635555e-08
by O 0 5.008498060732336e-10
molecular O 0 2.1831672469829755e-08
methods O 0 7.365161280858956e-08
. O 0 4.173951495545225e-08
. O 0 2.74967902669232e-07

A O 0 1.3721391042054165e-05
mouse O 0 5.0638725952012464e-05
model O 0 6.130572728579864e-06
of O 0 1.1378064073142014e-06
severe O 1 0.981056272983551
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 2.8285010557738133e-05
defects O 1 0.9937981963157654
in O 0 1.14387955818529e-06
hemostasis O 0 0.015359261073172092
and O 0 7.68169411458075e-05
thrombosis B-Disease 0 0.23025543987751007
. O 0 4.145669208810432e-06

von B-Disease 1 0.9953387975692749
Willebrand I-Disease 1 0.9848567247390747
factor I-Disease 0 0.00013993651373311877
( I-Disease 0 9.557971679896582e-06
vWf I-Disease 0 0.0015840379055589437
) I-Disease 0 6.378326361300424e-05
deficiency I-Disease 1 0.9909496903419495
causes O 0 0.0006730602472089231
severe O 1 0.9999949932098389
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 1.5797580772414221e-06
humans O 0 1.6769303101682453e-06
. O 0 9.25021481634758e-07

We O 0 9.017012985168549e-07
generated O 0 1.1737704852521347e-07
a O 0 2.31140155904086e-08
mouse O 0 1.3224412214185577e-06
model O 0 6.310615674465225e-08
for O 0 3.040429241707443e-09
this O 0 1.7141106312124066e-08
disease O 0 4.664718176172755e-07
by O 0 2.4350939042960817e-09
using O 0 4.734635083991634e-08
gene O 0 6.551128421961039e-07
targeting O 0 2.5285614810854895e-06
. O 0 1.2293097597648739e-06

vWf B-Disease 0 0.0040371916256845
- I-Disease 0 0.3195958137512207
deficient I-Disease 0 0.001523509039543569
mice O 0 0.0002735046437010169
appeared O 0 7.668899343116209e-06
normal O 0 1.3075037941234768e-07
at O 0 4.2878912864807717e-08
birth O 0 6.29423141162988e-07
; O 0 1.4729396369261849e-08
they O 0 8.370943049840207e-09
were O 0 2.3094054668604258e-08
viable O 0 1.3142208388217114e-07
and O 0 1.0465668509596071e-07
fertile O 0 4.039741270389641e-06
. O 0 5.575204795604805e-07

Neither O 0 0.00026837788755074143
vWf O 0 0.0012225756654515862
nor O 0 3.5523276892490685e-05
vWf O 0 0.0005075318040326238
propolypeptide O 0 0.0003829185734502971
( O 0 3.202843572580605e-06
von B-Disease 0 0.03555701673030853
Willebrand I-Disease 0 0.3103336691856384
antigen O 0 9.371327178087085e-05
II O 0 1.675885869190097e-05
) O 0 3.00591480595358e-08
were O 0 2.8817535024927565e-08
detectable O 0 9.355329666504986e-08
in O 0 1.81448467362344e-09
plasma O 0 2.3043591568239208e-07
, O 0 8.736337875348e-09
platelets O 0 2.6148990173169295e-07
, O 0 5.246221235211124e-09
or O 0 7.78049358274302e-09
endothelial O 0 2.1653252701980819e-07
cells O 0 4.152036581217544e-08
of O 0 2.9942739399047014e-09
the O 0 3.197814635313989e-08
homozygous O 0 1.6066236639744602e-05
mutant O 0 2.6565274310996756e-05
mice O 0 6.452694651670754e-05
. O 0 5.744084319303511e-07

The O 0 2.0764248347404646e-06
mutant O 0 0.00013901274360250682
mice O 0 0.11003659665584564
exhibited O 0 0.00014852856111247092
defects O 0 0.04443333297967911
in O 0 4.391024432948143e-08
hemostasis O 0 2.8020717763865832e-06
with O 0 7.696186798966664e-09
a O 0 1.50006457033669e-07
highly O 0 6.666915055575373e-07
prolonged O 0 0.0001889719715109095
bleeding O 0 0.3263227641582489
time O 0 1.0289254248618818e-07
and O 0 9.933731348610308e-08
spontaneous O 0 6.453297487496457e-07
bleeding O 0 3.502355684759095e-05
events O 0 1.5386186547061698e-08
in O 0 1.0379289427930871e-08
approximately O 0 2.6281938403371896e-08
10 O 0 2.189856651568789e-08
% O 0 1.1447048642310165e-08
of O 0 1.8715409666469895e-08
neonates O 0 5.80626874580048e-05
. O 0 1.6287408470816445e-06

As O 0 8.46538739551761e-07
in O 0 2.702173418356324e-08
the O 0 1.8392599443473046e-08
human O 0 9.584531568407328e-08
disease O 0 6.313673566182842e-07
, O 0 1.5678635056914914e-09
the O 0 1.4292178551755796e-09
factor O 0 1.1349088779866179e-08
VIII O 0 3.0398505259654485e-06
level O 0 1.531544668864626e-08
in O 0 2.9466939999167607e-09
these O 0 2.476665095230146e-09
mice O 0 8.764930043980712e-07
was O 0 2.548981115069182e-07
reduced O 0 1.2575168462092279e-08
strongly O 0 4.407535225681158e-09
as O 0 1.0581857612379508e-09
a O 0 4.4225161310862404e-09
result O 0 3.3767200147138965e-09
of O 0 5.595840457672807e-10
the O 0 1.549952877155647e-08
lack O 0 1.1034711810964382e-08
of O 0 1.8328013551283107e-09
protection O 0 3.248278090950407e-08
provided O 0 1.4332916187242972e-08
by O 0 2.1295701202461714e-08
vWf O 0 6.413059509213781e-06
. O 0 4.798246209247736e-07

Defective O 0 0.18261803686618805
thrombosis B-Disease 0 0.15388555824756622
in O 0 1.1096519756392809e-06
mutant O 0 4.032564538647421e-05
mice O 0 0.0074109239503741264
was O 0 1.2645743481698446e-05
also O 0 3.7036099342913076e-07
evident O 0 8.428848019548241e-08
in O 0 1.0184667553758686e-09
an O 0 2.349049399441583e-09
in O 0 1.508392877269671e-08
vivo O 0 7.807223028066801e-07
model O 0 2.1247181791750336e-07
of O 0 1.8807416779509367e-07
vascular B-Disease 1 0.5315199494361877
injury I-Disease 0 0.007739906199276447
. O 0 1.635480543882295e-06

In O 0 3.462398012743506e-07
this O 0 1.1013517209335077e-08
model O 0 7.475212271401688e-08
, O 0 6.940840791003211e-09
the O 0 6.869614654902989e-09
exteriorized O 0 3.5622160794446245e-06
mesentery O 0 6.286771622399101e-06
was O 0 1.554609184495348e-06
superfused O 0 3.92210523614267e-07
with O 0 1.2528890813712223e-08
ferric O 0 1.8099389080816763e-06
chloride O 0 3.4514033586674486e-07
and O 0 3.165421702533422e-08
the O 0 4.684705512403298e-09
accumulation O 0 5.692007576385549e-08
of O 0 7.591927086991745e-09
fluorescently O 0 5.5486867495346814e-05
labeled O 0 1.0944456334982533e-05
platelets O 0 9.369699910166673e-06
was O 0 1.1575642702155164e-06
observed O 0 8.630937742282185e-08
by O 0 1.0756830093328063e-08
intravital O 0 1.1773237247325596e-06
microscopy O 0 1.418439296685392e-06
. O 0 4.0386333921560436e-07

We O 0 6.565472176589537e-06
conclude O 0 4.4771255147679767e-07
that O 0 9.722509908272059e-09
these O 0 9.430643821417561e-09
mice O 0 2.2092149265517946e-06
very O 0 3.013693117281946e-08
closely O 0 7.723467092546343e-07
mimic O 0 0.00018109491793438792
severe O 0 0.0004530086007434875
human O 0 2.8994600143050775e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 3.870555701723788e-06
will O 0 2.418139501969563e-07
be O 0 8.812619967102364e-09
very O 0 7.734236584511223e-10
useful O 0 6.549742415096205e-10
for O 0 2.1625674861969202e-10
investigating O 0 2.189229020288508e-09
the O 0 6.808770769417549e-10
role O 0 5.247472234515271e-09
of O 0 1.5764817229424466e-09
vWf O 0 1.309750246036856e-07
in O 0 9.589556704270308e-09
normal O 0 1.4794854052979645e-07
physiology O 0 1.0669419481246223e-07
and O 0 9.554852908877365e-08
in O 0 1.2291791051666223e-07
disease O 0 2.1158446088520577e-06
models O 0 2.7341701525074313e-07
. O 0 5.847441997275382e-08
. O 0 2.756655419489107e-07

Oral O 0 0.00010052422294393182
contraceptives O 0 0.00047563505358994007
and O 0 3.11192764002044e-07
the O 0 7.131427537387935e-08
risk O 0 1.5679802345403004e-06
of O 0 1.426075641575153e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.482648586825235e-06

Hereditary B-Disease 1 0.9999992847442627
Ovarian I-Disease 1 0.9999996423721313
Cancer I-Disease 1 0.9418255090713501
Clinical O 0 4.031495700473897e-05
Study O 0 9.380108849654789e-07
Group O 0 3.4111451441276586e-06
. O 0 9.399828400091792e-07

BACKGROUND O 0 4.370293390820734e-05
Women O 0 1.858794576037326e-06
with O 0 9.063709427437061e-08
mutations O 0 1.0654864581738366e-06
in O 0 5.637226241361759e-09
either O 0 1.805736893345511e-08
the O 0 3.6727168861716564e-08
BRCA1 O 0 1.0861316695809364e-05
or O 0 4.193518421402587e-08
the O 0 2.7211966013851452e-08
BRCA2 O 0 5.865230377821717e-06
gene O 0 6.884597070211385e-08
have O 0 1.017785677959182e-08
a O 0 1.9611148260878508e-08
high O 0 4.049123276672617e-07
lifetime O 0 3.9632621451346495e-07
risk O 0 1.4259912859415635e-06
of O 0 5.3202143135422375e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 3.0559708648070227e-06

Oral O 0 0.0001360158494208008
contraceptives O 0 0.001698697218671441
protect O 0 0.00012228799459990114
against O 0 0.029744841158390045
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 9.938355560734635e-08
general O 0 2.7801544177918913e-08
, O 0 2.792073772184267e-08
but O 0 5.525842006193216e-09
it O 0 3.999817366207026e-09
is O 0 1.9049979371743575e-09
not O 0 1.5667694919230257e-09
known O 0 4.643136097826073e-09
whether O 0 2.341052018905998e-09
they O 0 6.18803586149852e-09
also O 0 2.2111864339535714e-08
protect O 0 3.447994245675545e-08
against O 0 5.6181125529519704e-08
hereditary B-Disease 0 6.621965439990163e-05
forms I-Disease 0 5.96786946971406e-07
of I-Disease 0 2.2482963686343282e-05
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 2.5424410523555707e-06

METHODS O 0 4.797042947757291e-06
We O 0 1.9480931712223537e-07
enrolled O 0 8.40550526959305e-08
207 O 0 5.409402206169034e-07
women O 0 2.1307874931153492e-07
with O 0 2.4933087843237445e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.1331602795271465e-07
161 O 0 6.650797956808674e-08
of O 0 2.8961835152330195e-09
their O 0 5.4896336365573006e-08
sisters O 0 9.90962053037947e-06
as O 0 9.731285111058696e-09
controls O 0 1.0972341613069148e-07
in O 0 4.951037357869836e-09
a O 0 2.682045163737712e-08
case O 0 8.284143149239753e-08
- O 0 7.881561941758264e-06
control O 0 1.350780280517938e-06
study O 0 7.471577134765539e-08
. O 0 2.842864716967597e-07

All O 0 8.705102345629712e-07
the O 0 6.589708334558964e-08
patients O 0 1.5999735580862762e-07
carried O 0 3.336834097922292e-08
a O 0 1.991093867559357e-08
pathogenic O 0 2.544555854910868e-07
mutation O 0 1.46029634606748e-07
in O 0 4.519912444322927e-09
either O 0 5.8219015386384854e-08
BRCA1 O 0 1.1510623153299093e-05
( O 0 2.767979445650326e-08
179 O 0 5.254906909613055e-08
women O 0 5.723579121763578e-08
) O 0 1.5336436121060615e-08
or O 0 9.345003348926184e-08
BRCA2 O 0 4.0003978938329965e-05
( O 0 5.899635979744744e-08
28 O 0 4.0062872130874894e-07
women O 0 1.4921003810286493e-07
) O 0 7.7606507886685e-08
. O 0 2.406140708899329e-07

The O 0 8.775293167673226e-07
control O 0 8.379866471841524e-07
women O 0 2.5506031420263753e-07
were O 0 7.957504521982628e-08
enrolled O 0 1.1652755205204812e-08
regardless O 0 4.9615307418093835e-09
of O 0 6.321307366441431e-10
whether O 0 6.9893570930901205e-09
or O 0 3.34090337616999e-08
not O 0 9.020401314785431e-09
they O 0 1.323834641908661e-08
had O 0 4.3371116476009774e-07
either O 0 7.639517463076118e-08
mutation O 0 1.1574869631658657e-06
. O 0 2.453974161653605e-07

Lifetime O 0 5.1080420234939083e-05
histories O 0 4.534613253781572e-06
of O 0 6.816807740506192e-08
oral O 0 4.6394114860959235e-07
- O 0 3.3423173135815887e-06
contraceptive O 0 6.508504611701937e-06
use O 0 2.4667002662681625e-08
were O 0 3.1750722939705156e-08
obtained O 0 1.6644234879237274e-09
by O 0 1.271871163943672e-09
interview O 0 2.505598502011708e-07
or O 0 8.179665833552008e-09
by O 0 1.2563008411348164e-09
written O 0 7.721740580279857e-09
questionnaire O 0 1.5097024075316767e-08
and O 0 7.524618261811611e-09
were O 0 2.04168468798116e-08
compared O 0 1.0568752095707623e-08
between O 0 1.2915757352516266e-08
patients O 0 2.9814700042152253e-08
and O 0 7.741886243195495e-09
control O 0 3.9747462210470985e-07
women O 0 1.0523596927214385e-07
, O 0 3.4633631518232733e-09
after O 0 2.5225186384147946e-09
adjustment O 0 1.026212448351771e-08
for O 0 9.951510726580182e-10
year O 0 5.088256038732197e-09
of O 0 2.7264526192283256e-09
birth O 0 1.6637440012345905e-06
and O 0 8.616709834541325e-08
parity O 0 2.5116969482041895e-06
. O 0 4.620108313702076e-07

RESULTS O 0 7.478130100935232e-06
The O 0 1.752098199858665e-07
adjusted O 0 1.6933940059971064e-05
odds O 0 1.663881448621396e-05
ratio O 0 9.260539627575781e-06
for O 0 1.8467160771251656e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 4.866644687240296e-08
with O 0 2.3892841038986035e-09
any O 0 2.612080551855911e-09
past O 0 1.2055537013111461e-08
use O 0 4.236349493424996e-09
of O 0 4.5292067873958786e-09
oral O 0 4.970209488419641e-07
contraceptives O 0 0.00018648339028004557
was O 0 1.1175703548360616e-05
0 O 0 6.178933631417749e-07
. O 0 5.401494149737118e-07

5 O 0 8.316727871715557e-06
( O 0 3.2387330861638475e-07
95 O 0 3.088779294557753e-07
percent O 0 7.696423267589125e-07
confidence O 0 1.2690759376710048e-07
interval O 0 8.190676226149662e-08
, O 0 2.7286273240889614e-09
0 O 0 4.397928243804472e-09
. O 0 5.302868144596573e-10
3 O 0 6.300282517912592e-09
to O 0 3.0879498957858686e-09
0 O 0 2.5946629733653026e-08
. O 0 7.750011299378912e-09
8 O 0 1.8116833189196768e-07
) O 0 5.479998321789026e-08
. O 0 2.2804684363109118e-07

The O 0 1.1672084383462789e-06
risk O 0 1.1680838269967353e-06
decreased O 0 3.151680232349463e-07
with O 0 5.753599374713758e-09
increasing O 0 1.153938100628693e-08
duration O 0 3.791715741385815e-08
of O 0 6.285396092486906e-10
use O 0 5.731572993994405e-09
( O 0 6.332883994986105e-09
P O 0 1.3073344007352716e-07
for O 0 5.840024019931889e-10
trend O 0 2.997463965925817e-08
, O 0 6.390382112364534e-10
< O 0 8.772037318749426e-09
0 O 0 2.169310731048313e-09
. O 0 6.463626300856617e-10
001 O 0 2.52699852154592e-08
) O 0 5.507372891067064e-10
; O 0 3.320381469773537e-10
use O 0 3.5361860661886624e-10
for O 0 6.625545112548537e-10
six O 0 6.2887330898320215e-09
or O 0 3.582255381218147e-09
more O 0 1.2961849371606604e-09
years O 0 1.1772812058552518e-08
was O 0 9.544015000528816e-08
associated O 0 9.043998328017722e-10
with O 0 5.318092077821746e-10
a O 0 2.0819056700815963e-08
60 O 0 4.688489241289062e-08
percent O 0 4.672839182262578e-08
reduction O 0 6.698513033143172e-08
in O 0 4.097109851386449e-08
risk O 0 1.2076477560185594e-06
. O 0 3.213146158032032e-07

Oral O 0 3.2278840080834925e-05
- O 0 1.8165783330914564e-05
contraceptive O 0 2.7092262826045044e-05
use O 0 3.582886165531818e-07
protected O 0 1.953251558006741e-05
against O 0 0.007159500382840633
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
both O 0 1.7298889432026954e-08
for O 0 2.720193625904699e-09
carriers O 0 1.0988379983700725e-08
of O 0 1.1375825836879017e-09
the O 0 4.4225689777022126e-08
BRCA1 O 0 7.035155431367457e-05
mutation O 0 9.799867939364049e-07
( O 0 1.1635831853595846e-08
odds O 0 4.811594180864631e-07
ratio O 0 7.348378971983038e-08
, O 0 2.1891581880595368e-09
0 O 0 4.10583833598821e-09
. O 0 8.971187681616755e-10
5 O 0 3.196422682094635e-09
; O 0 2.480021299433588e-09
95 O 0 2.2773599894776453e-08
percent O 0 1.1313938585999495e-07
confidence O 0 4.813351850430081e-08
interval O 0 3.275572524330528e-08
, O 0 7.159415282842474e-10
0 O 0 1.8276418156659702e-09
. O 0 2.190146952685268e-10
3 O 0 1.7680155117716367e-09
to O 0 1.5180726675723122e-09
0 O 0 4.131881059521447e-09
. O 0 1.6264812829902553e-09
9 O 0 4.044483503662377e-08
) O 0 4.926899999091461e-10
and O 0 5.441383454929394e-10
for O 0 3.2784569503618854e-10
carriers O 0 2.2734440996430294e-09
of O 0 5.740256603381511e-10
the O 0 6.77879157251482e-08
BRCA2 O 0 9.154732106253505e-05
mutation O 0 1.0756706387837767e-06
( O 0 1.1502223173920356e-08
odds O 0 4.046027015647269e-07
ratio O 0 1.055866150068141e-07
, O 0 3.338264775720745e-09
0 O 0 2.433046430994068e-09
. O 0 3.70030450724812e-10
4 O 0 4.123716923487564e-09
; O 0 3.7114955553363416e-09
95 O 0 2.1274672690196894e-08
percent O 0 1.3592726588740334e-07
confidence O 0 3.289753891522196e-08
interval O 0 1.681745587234218e-08
, O 0 6.597978274847094e-10
0 O 0 8.841304355300394e-10
. O 0 2.3883170441330037e-10
2 O 0 1.7078634062528408e-09
to O 0 1.5357445315444807e-09
1 O 0 6.3438854169817205e-09
. O 0 2.2954171896572007e-09
1 O 0 2.2041586333898522e-08
) O 0 3.054765329579823e-08
. O 0 1.5665796126995701e-07

CONCLUSIONS O 0 1.618261194380466e-05
Oral O 0 6.355190635076724e-06
- O 0 5.58170222575427e-06
contraceptive O 0 4.682064627559157e-06
use O 0 6.062300172970936e-08
may O 0 5.916900036595507e-08
reduce O 0 1.6447632589233763e-08
the O 0 5.578483897039632e-09
risk O 0 1.7955680675640906e-07
of O 0 6.12071858085983e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
in O 0 3.9651819605524e-08
women O 0 4.4569326007604104e-08
with O 0 1.2321974551809944e-08
pathogenic O 0 3.375592143584072e-07
mutations O 0 2.470641788931971e-07
in O 0 9.993171623534636e-09
the O 0 1.7437251642604679e-07
BRCA1 O 0 0.000375655188690871
or O 0 6.270030553423567e-06
BRCA2 O 0 0.001511819427832961
gene O 0 0.00015908032946754247

A O 0 1.0245216799376067e-05
Japanese O 0 1.712978701107204e-06
family O 0 3.041898821720679e-07
with O 0 1.0966273578105756e-07
adrenoleukodystrophy B-Disease 1 0.9999997615814209
with O 0 2.9064997519867575e-08
a O 0 1.0507532266501585e-07
codon O 0 1.628627501304436e-06
291 O 0 1.9673703377520724e-07
deletion O 0 6.270972221500415e-07
: O 0 4.872326542226801e-09
a O 0 1.2951947070405367e-08
clinical O 0 1.564264096032275e-07
, O 0 9.251432508960988e-09
biochemical O 0 3.328228501686681e-07
, O 0 1.649947556359166e-08
pathological O 0 4.6491513217006286e-07
, O 0 3.1192005423008595e-08
and O 0 9.813636836497608e-08
genetic O 0 4.061137133248849e-06
report O 0 1.3633169828608516e-06
. O 0 5.293400135997217e-07

We O 0 7.289716450031847e-06
report O 0 2.2068871885494445e-07
a O 0 3.411406979125786e-08
Japanese O 0 1.2701438834028522e-07
family O 0 2.404136125733203e-07
with O 0 3.459183744780603e-06
adrenoleukodystrophy B-Disease 1 1.0
( O 0 8.291246922453865e-05
ALD B-Disease 1 1.0
) O 0 4.329449865281276e-08
with O 0 3.1711606673923143e-09
a O 0 2.2054496895407283e-08
three O 0 1.2196224474791961e-08
base O 0 1.7986650391321746e-07
pair O 0 1.4876588920742506e-06
deletion O 0 3.7603651890094625e-06
( O 0 4.6595069136401435e-08
delGAG O 0 5.342945996744675e-07
291 O 0 1.3089736228266702e-07
) O 0 6.420660891848229e-09
in O 0 1.4934665060195584e-08
the O 0 1.1077394219682901e-06
ALD B-Disease 1 0.9999998807907104
gene O 0 1.733164390316233e-05
. O 0 1.8590585568745155e-06

A O 0 1.305362616221828e-06
variety O 0 1.5172460621215578e-07
of O 0 2.6985473411400562e-08
phenotypes O 0 8.293656719615683e-06
were O 0 5.699731104868988e-07
observed O 0 1.8299402881893911e-07
within O 0 7.2919972282647905e-09
this O 0 7.214923769538473e-09
family O 0 7.743365131318569e-07
. O 0 5.497853408087394e-07

While O 0 4.007596544397529e-06
the O 0 1.0151899232369033e-07
proband O 0 9.884946848615073e-06
( O 0 1.0632182778635979e-07
patient O 0 2.2601165028390824e-07
1 O 0 5.724375995441733e-08
) O 0 8.827155006940757e-09
was O 0 3.614622130498901e-07
classified O 0 2.252940944913462e-08
as O 0 2.8957483522162875e-08
having O 0 1.9668501494152224e-08
a O 0 8.583604049761107e-09
rare O 0 8.59718696233358e-09
intermediate O 0 9.301344583434457e-09
type O 0 6.5584080388703114e-09
of O 0 3.634270218100255e-09
adult O 0 1.4531683518725913e-06
cerebral O 0 1.870641608547885e-05
and O 0 1.934790248014906e-07
cerebello O 0 4.450926644494757e-05
- O 0 0.002208579797297716
brain O 0 9.877013326331507e-06
stem O 0 1.2241932267897937e-07
forms O 0 9.972530357060805e-09
, O 0 9.415114909927524e-09
his O 0 2.3796101800144243e-07
younger O 0 1.9738718037842773e-06
brother O 0 2.6892607820627745e-06
( O 0 1.4138642256966705e-08
patient O 0 5.842614569928628e-08
2 O 0 2.3365922530160788e-08
) O 0 5.674595460192222e-09
and O 0 5.4869538246293814e-08
nephew O 0 4.635081859305501e-05
( O 0 3.167438933360245e-08
patient O 0 3.5208927329222206e-07
3 O 0 7.584114314340695e-08
) O 0 1.1739133221055909e-08
had O 0 5.079793936602073e-07
a O 0 1.3881060567655368e-06
childhood O 0 0.0027482544537633657
ALD B-Disease 1 1.0
type O 0 2.7024754672311246e-05
. O 0 2.6252489533362677e-06

Another O 0 9.979638889490161e-06
nephew O 0 0.0002539243723731488
( O 0 4.847727268497692e-07
patient O 0 7.403626227642235e-07
4 O 0 8.417858765596975e-08
) O 0 4.001763365124589e-09
of O 0 2.4851734004016635e-09
patient O 0 1.034637989505427e-06
1 O 0 6.043620714990539e-07
was O 0 3.357325113029219e-05
classified O 0 9.908204390285391e-08
as O 0 7.145111169393203e-08
having O 0 4.052638047369328e-08
an O 0 1.607204858089517e-08
adolescent O 0 3.2340649340767413e-06
form O 0 2.0114471510623844e-07
. O 0 4.1752338120204513e-07

The O 0 7.248996780617745e-07
tau O 0 6.154151606097003e-07
level O 0 4.824445909434871e-08
in O 0 8.915548299626153e-09
the O 0 7.346599062429959e-08
cerebrospinal O 0 0.00037846900522708893
fluid O 0 5.15297069796361e-05
( O 0 3.2273928241011163e-07
CSF O 0 0.00018654992163646966
) O 0 8.492085257216786e-09
in O 0 4.5226289380195794e-09
patient O 0 5.952749120297085e-07
1 O 0 2.584627054602606e-07
was O 0 5.0167924200650305e-05
as O 0 2.043648450467117e-08
high O 0 6.189407031342853e-08
as O 0 4.26391144614513e-09
that O 0 2.2586881254227364e-09
of O 0 6.998535084790092e-09
patients O 0 3.9523615669168066e-07
with O 0 2.766106490525999e-06
Alzheimers B-Disease 1 0.9999990463256836
disease I-Disease 0 0.0004005154478363693
( O 0 1.1262792298794011e-07
AD B-Disease 0 1.076249736797763e-05
) O 0 2.648658892212552e-07
. O 0 3.469841942660423e-07

His O 0 2.907999987655785e-05
brain O 0 8.813282329356298e-05
magnetic O 0 3.507755764076137e-06
resonance O 0 4.702927981270477e-06
image O 0 2.95092959277099e-05
( O 0 3.364231417890551e-07
MRI O 0 3.8103684346424416e-05
) O 0 2.2031336754935182e-07
showed O 0 7.966746488818899e-05
abnormalities B-Disease 0 0.013341188430786133
in I-Disease 0 7.931800993787874e-09
the I-Disease 0 4.145286780499191e-08
bilateral I-Disease 0 1.3965229754830943e-06
cerebellar I-Disease 0 0.0007846345542930067
hemispheres I-Disease 0 0.00012201601202832535
and O 0 3.051998419323354e-06
brain O 0 1.5065151274029631e-05
stem O 0 4.089420428954327e-07
, O 0 1.2457071818516852e-08
but O 0 3.3308618085925445e-09
not O 0 1.1784173636897322e-09
in O 0 1.5190979585355535e-09
the O 0 3.9213713165509034e-08
cerebral O 0 1.8004180674324743e-05
white O 0 1.1507717090353253e-06
matter O 0 4.115576324181802e-09
, O 0 1.148746209267415e-09
where O 0 2.9833742143381414e-09
marked O 0 1.404299077023552e-08
reductions O 0 1.8250407407549574e-08
of O 0 7.060204643138945e-10
the O 0 2.1981298559126117e-08
cerebral O 0 1.2928993783134501e-05
blood O 0 4.0317334537576244e-07
flow O 0 5.871436670190633e-08
and O 0 2.1735447219839443e-08
oxygen O 0 8.341540080891718e-08
metabolism O 0 1.2464064980122203e-07
were O 0 1.7815839470358696e-08
clearly O 0 2.7313257433547733e-08
demonstrated O 0 8.999847089796731e-09
by O 0 1.5669517905436692e-09
positron O 0 8.740456109990191e-07
emission O 0 7.607025622746733e-07
tomography O 0 1.3700338968192227e-05
( O 0 1.2871790033841535e-07
PET O 0 2.2817048375145532e-06
) O 0 1.266128606403072e-07
. O 0 2.9174202609283384e-07

In O 0 2.6689081096265e-06
patients O 0 2.175230065404321e-06
2 O 0 1.3094955875203595e-07
and O 0 2.2663449783522083e-08
3 O 0 2.2095843377201163e-08
, O 0 2.952646349640986e-09
the O 0 2.589781278317105e-09
autopsy O 0 3.8931152630539145e-06
findings O 0 1.719104574249286e-07
showed O 0 1.388422447234916e-06
massive O 0 6.492254556178523e-07
demyelination B-Disease 1 0.999975323677063
of I-Disease 0 2.0659328470173932e-08
the I-Disease 0 3.9071309743121674e-07
cerebral I-Disease 0 9.32676121010445e-05
white I-Disease 0 1.1830391031253384e-06
matter I-Disease 0 5.616073828207391e-09
with O 0 1.007600225477745e-09
sparing O 0 1.365039903333809e-08
of O 0 1.5863691471551533e-09
the O 0 1.227859502961337e-08
U O 0 1.445881662220927e-05
- O 0 0.0006240782095119357
fibers O 0 3.311364253022475e-06
, O 0 9.45461042789475e-10
compatible O 0 8.128854922517803e-09
with O 0 2.4083632865767868e-09
the O 0 1.1677141031896099e-08
findings O 0 1.2350106715075526e-07
of O 0 1.072328004170231e-07
childhood O 0 0.0004883382353000343
ALD B-Disease 1 1.0
. O 0 7.570494744868483e-06

Oleic O 1 0.7214956879615784
and O 0 9.225114808941726e-06
erucic O 0 0.000984437414444983
acids O 0 4.312943019613158e-06
( O 0 7.03016524994382e-08
Lorenzos O 0 1.8772487919704872e-06
Oil O 0 4.442911176738562e-07
) O 0 2.889595007715684e-09
were O 0 2.4767028428129834e-09
administered O 0 1.5534028507957487e-09
to O 0 2.1922124116002806e-09
patients O 0 1.1040270031514865e-08
1 O 0 4.805597697554731e-09
and O 0 1.4882910903679658e-08
4 O 0 4.220849803004967e-08
, O 0 5.543291603515854e-09
but O 0 2.0104828912792527e-09
sufficient O 0 3.49419027045883e-09
effectiveness O 0 4.4056715609031016e-08
was O 0 7.341696459661762e-07
not O 0 1.2255431336427591e-08
obtained O 0 7.784741740124446e-08
. O 0 2.0487969720761612e-07

The O 0 4.504857429310505e-07
findings O 0 1.8878093044349953e-07
in O 0 5.501643141059276e-09
this O 0 4.213672522013212e-09
family O 0 3.6781216294912156e-08
suggest O 0 2.466055804006828e-08
that O 0 4.22431067903517e-09
delGAG291 O 0 5.029477847529051e-07
is O 0 3.1366198527393863e-09
part O 0 1.1737268934552958e-09
of O 0 5.683322701344196e-10
the O 0 1.3843877155750306e-08
cause O 0 5.31996420249925e-08
of O 0 5.493715704574242e-09
Japanese O 0 2.070029040623922e-06
ALD B-Disease 1 0.9999994039535522
with O 0 7.001301582931774e-08
phenotypic O 0 9.54850565904053e-06
variations O 0 3.0191127734724432e-05
. O 0 1.5033027693789336e-06

Moreover O 0 1.564820558996871e-05
, O 0 8.076990809513518e-08
although O 0 3.928114278295425e-09
the O 0 4.3610637323610035e-10
scale O 0 2.2381559716677657e-08
of O 0 5.556139437423724e-10
the O 0 2.119151520929563e-09
study O 0 1.9197412548521697e-09
is O 0 1.9769741399500163e-09
limited O 0 2.076447902510381e-09
, O 0 2.3498560874912755e-09
there O 0 5.783666878755866e-10
is O 0 3.412191085239158e-10
a O 0 1.0403583550200324e-09
possibility O 0 2.269648691211046e-09
that O 0 2.1640622627217e-09
PET O 0 1.005193865921683e-07
can O 0 6.0494764753116215e-09
detect O 0 7.797016365884701e-08
an O 0 7.493682119275036e-09
insidious B-Disease 0 4.365490531199612e-05
lesion I-Disease 0 0.00956878624856472
which O 0 1.2350920997050707e-07
is O 0 1.0658228966065053e-08
undetectable O 0 1.8895923403761117e-07
by O 0 3.289570171816081e-09
computed O 0 1.5469527170353103e-07
tomogram O 0 2.595020077933441e-06
( O 0 2.7310550265724487e-08
CT O 0 2.662285851329216e-06
) O 0 9.224526031914593e-09
or O 0 1.01490691406525e-08
MRI O 0 2.198570570044467e-07
analysis O 0 7.332918716684844e-09
, O 0 4.1830992003610845e-09
and O 0 5.191671537119191e-09
that O 0 1.5800639685537021e-09
the O 0 2.3764266110504195e-09
higher O 0 8.324926525915544e-09
level O 0 2.394151543683165e-09
of O 0 5.306419748052349e-10
tau O 0 5.332406072255935e-09
reflects O 0 3.2877638389550157e-09
the O 0 7.395137280319375e-10
process O 0 7.744500152284672e-09
of O 0 1.9473310075568406e-08
neuronal B-Disease 0 0.0007935200119391084
degeneration I-Disease 1 0.890181839466095
in O 0 2.0073814084753394e-05
ALD B-Disease 1 1.0
. O 0 1.336308014288079e-05

Lorenzos O 0 0.0006090076640248299
Oil O 0 7.134658517315984e-05
should O 0 1.1842091396374599e-07
be O 0 2.5179902607419535e-09
given O 0 5.713625683689827e-10
in O 0 7.971776017079435e-10
the O 0 4.409241860514612e-09
early O 0 1.483683149672288e-07
stage O 0 1.3836731795890955e-06
. O 0 2.646872943046219e-08
. O 0 1.3849957269940205e-07

Nonsense O 0 0.0014010305749252439
mutation O 0 4.0494818676961586e-05
in O 0 9.154909008657341e-08
exon O 0 1.7447196114517283e-06
4 O 0 3.0347592883117613e-07
of O 0 6.205705727069244e-09
human O 0 5.127628455170452e-08
complement O 0 2.3298284190786944e-07
C9 O 0 7.403353720292216e-06
gene O 0 2.796909086555388e-07
is O 0 9.841864212489781e-09
the O 0 5.472151620722343e-09
major O 0 4.377193363325205e-08
cause O 0 1.2326091791692306e-07
of O 0 8.008478324939006e-09
Japanese O 0 1.1376610018487554e-06
complement B-Disease 0 2.7547666832106188e-05
C9 I-Disease 0 0.4807909429073334
deficiency I-Disease 0 0.0026172702200710773
. O 0 1.0731724842116819e-06

Deficiency B-Disease 1 0.9978321194648743
of I-Disease 0 2.1123695148617117e-07
the I-Disease 0 9.81747589889892e-08
ninth I-Disease 0 2.4236351237050258e-06
component I-Disease 0 4.890036819915622e-08
of I-Disease 0 2.0896624430832844e-09
human I-Disease 0 1.715137543101264e-08
complement I-Disease 0 1.0231561731188776e-07
( O 0 2.457280423584507e-08
C9 O 0 1.4781596746615833e-06
) O 0 3.0994384836446898e-09
is O 0 7.644800903428006e-10
the O 0 1.0254996851699616e-09
most O 0 2.3319339792493565e-09
common O 0 4.906470962851017e-07
complement B-Disease 1 0.9999958276748657
deficiency I-Disease 1 0.9999996423721313
in O 0 4.303433698282788e-08
Japan O 0 7.763256348880532e-08
but O 0 6.8254171203818714e-09
is O 0 2.7486752873784326e-09
rare O 0 2.420133204950048e-09
in O 0 1.487297063285098e-09
other O 0 3.983235963289644e-09
countries O 0 1.921046255404235e-08
. O 0 1.7970533860989235e-07

We O 0 3.155739477733732e-06
studied O 0 1.2240181490597024e-07
the O 0 5.802830216339316e-09
molecular O 0 5.6140098791956916e-08
basis O 0 3.8088153075932496e-08
of O 0 1.027133222919474e-07
C9 B-Disease 1 0.9937955141067505
deficiency I-Disease 0 0.00030915666138753295
in O 0 4.633139649712348e-09
four O 0 3.1886788320889536e-08
Japanese O 0 4.347249102920614e-07
C9 B-Disease 0 8.2490558270365e-05
- I-Disease 0 0.001139956759288907
deficient I-Disease 0 0.00013814771955367178
patients O 0 1.6499608364028973e-06
who O 0 2.7581513677432667e-06
had O 0 0.0014139835257083178
suffered O 0 0.36636587977409363
from O 0 1.352521576336585e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 0.9999997615814209
. O 0 5.300949851516634e-06

Direct O 0 5.739283096772851e-06
sequencing O 0 2.880258989534923e-06
of O 0 9.588627847278985e-08
amplified O 0 3.6502440252661472e-06
C9 O 0 8.408762369072065e-06
cDNA O 0 9.681374422143563e-07
and O 0 8.57802717746381e-08
DNA O 0 3.929199579033593e-07
revealed O 0 2.51748559776388e-07
a O 0 3.239511059405231e-08
nonsense O 0 5.42119778401684e-07
substitution O 0 6.104221483838046e-08
( O 0 1.5491194105266004e-08
CGA O 0 9.937282356986543e-07
- O 0 7.960212315083481e-06
- O 0 7.626160822837846e-06
> O 0 1.6357381582565722e-07
TGA O 0 5.436937158265209e-07
) O 0 4.17144230269173e-09
at O 0 2.8575812827114078e-09
codon O 0 4.231037920021663e-08
95 O 0 8.419460684194746e-09
in O 0 2.0861021798879165e-09
exon O 0 3.326984199247818e-07
4 O 0 1.5382907747607533e-07
in O 0 7.06396630079098e-09
the O 0 2.8053390721538563e-08
four O 0 7.82121844622452e-07
C9 B-Disease 0 0.0005148547934368253
- I-Disease 0 0.02822861261665821
deficient I-Disease 0 0.00010685322195058689
individuals O 0 8.858530975430767e-08
. O 0 1.6944824210440856e-07

An O 0 8.97502673069539e-07
allele O 0 5.406130185292568e-06
- O 0 1.2237840110174147e-06
specific O 0 4.221944749360773e-08
polymerase O 0 3.256237732784939e-07
chain O 0 9.532514582133444e-07
reaction O 0 2.9435611281769525e-08
system O 0 1.2059815368559157e-08
designed O 0 5.10403452835817e-08
to O 0 3.3833538193306367e-09
detect O 0 4.947169784941252e-08
exclusively O 0 5.780295353474685e-09
only O 0 1.0300909014659965e-09
one O 0 9.622054264468716e-10
of O 0 1.9109140658724044e-10
the O 0 1.4068453069171483e-09
normal O 0 9.748506002438262e-09
and O 0 6.426541965254273e-09
mutant O 0 3.5721663493859523e-07
alleles O 0 6.374331462666305e-08
indicated O 0 3.45124462342028e-08
that O 0 6.288969345291662e-10
all O 0 2.241071495046043e-10
the O 0 2.0040509252083893e-09
four O 0 7.010962832509904e-08
patients O 0 4.8153168563658255e-08
were O 0 2.36605259829048e-08
homozygous O 0 4.7891848709014084e-08
for O 0 5.007504411125296e-10
the O 0 1.5841287170914597e-09
mutation O 0 1.2301896390454203e-08
in O 0 9.273811163446055e-10
exon O 0 1.2211278033191775e-07
4 O 0 3.934767960345198e-07
and O 0 8.805634621467107e-08
that O 0 4.029036215769111e-09
the O 0 7.672442237094401e-09
parents O 0 2.508280338986424e-08
of O 0 2.9401872048140376e-09
patient O 0 2.303708726003606e-07
2 O 0 1.692800992714183e-07
were O 0 3.5499900263857853e-07
heterozygous O 0 4.732459728984395e-06
. O 0 3.8444918004643114e-07

The O 0 9.731842283144942e-07
common O 0 4.54189148513251e-07
mutation O 0 6.597234687433229e-07
at O 0 1.8833004489238192e-08
codon O 0 2.4649324359415914e-07
95 O 0 2.3643426771968734e-08
in O 0 3.6426186511562264e-09
exon O 0 3.840600015792006e-07
4 O 0 6.119026352280343e-07
might O 0 1.584429440981694e-07
be O 0 3.0296734010448745e-09
responsible O 0 5.089392018930994e-09
for O 0 8.36139602000685e-10
most O 0 1.8020005043695164e-08
Japanese O 0 2.1417001789814094e-06
C9 B-Disease 0 0.02169344201683998
deficiency I-Disease 0 7.888668187661096e-05
. O 0 4.3038031805053834e-08
. O 0 2.63444803749735e-07

BRCA1 O 0 0.0009837890975177288
required O 0 3.5141667353855155e-07
for O 0 1.5028991384724577e-08
transcription O 0 1.2293097597648739e-06
- O 0 6.722814578097314e-05
coupled O 0 1.1586495020310394e-05
repair O 0 8.077812708506826e-06
of O 0 3.624331412765969e-08
oxidative O 0 8.407944733335171e-06
DNA O 0 2.107333784806542e-05
damage O 0 4.270204226486385e-05
. O 0 1.4868461448713788e-06

The O 0 3.2446485420223325e-05
breast B-Disease 1 0.9992772936820984
and I-Disease 0 0.3020731508731842
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
susceptibility O 0 0.0003535095020197332
gene O 0 1.4788909538765438e-05
BRCA1 O 0 3.5737881262321025e-05
encodes O 0 3.869728971039876e-06
a O 0 4.815767624677392e-06
zinc O 0 0.012742086313664913
finger O 0 0.000109127773612272
protein O 0 4.174182777205715e-07
of O 0 1.787554282373094e-08
unknown O 0 4.891324465461366e-07
function O 0 5.926358994656766e-07
. O 0 9.733550996315898e-07

Association O 0 4.276736035535578e-06
of O 0 2.8394470774628644e-08
the O 0 2.629427342526469e-08
BRCA1 O 0 2.186010533478111e-06
protein O 0 5.5771891993572353e-08
with O 0 3.1089708585341214e-09
the O 0 1.3554560140960348e-08
DNA O 0 4.630059322607849e-07
repair O 0 2.653206593095092e-06
protein O 0 9.091742469991004e-08
Rad51 O 0 4.187303147773491e-06
and O 0 1.708138164246975e-08
changes O 0 2.289859413195927e-09
in O 0 4.668095354709578e-10
the O 0 7.109026700646837e-10
phosphorylation O 0 1.0513942605427928e-08
and O 0 7.836536752847678e-09
cellular O 0 6.844884836709753e-08
localization O 0 4.417940502321471e-08
of O 0 3.2275057626485193e-10
the O 0 1.2019714112909696e-09
protein O 0 1.45234597681565e-08
after O 0 8.01293964514116e-09
exposure O 0 2.357318251711149e-08
to O 0 1.3641073826065053e-09
DNA O 0 5.2786241155899916e-08
- O 0 2.8996899459343695e-07
damaging O 0 1.7445219668843492e-07
agents O 0 1.51481067689474e-08
are O 0 1.0880695233694837e-09
consistent O 0 6.061546375946136e-09
with O 0 9.980327675407352e-10
a O 0 6.477737013454998e-09
role O 0 2.0408904788382642e-08
for O 0 7.206547802951491e-09
BRCA1 O 0 2.1632397420034977e-06
in O 0 7.0736099644364e-08
DNA O 0 5.754069206886925e-06
repair O 0 6.740442768204957e-05
. O 0 1.099355813494185e-06

Here O 0 4.2122869672311936e-06
, O 0 3.720463226386528e-08
it O 0 6.918978723291502e-09
is O 0 7.263983636818239e-09
shown O 0 1.5640470252265004e-08
that O 0 7.1617951569180605e-09
mouse O 0 1.4672814359073527e-05
embryonic O 0 3.2202337933995295e-06
stem O 0 2.1597868453682167e-06
cells O 0 1.0040630513685755e-06
deficient B-Disease 0 1.7546611843499704e-06
in I-Disease 0 2.1164785479754755e-08
BRCA1 I-Disease 0 4.166453891230049e-06
are O 0 1.4039831519596646e-08
defective O 0 3.94632024836028e-07
in O 0 3.113542135224634e-08
the O 0 2.318488334651647e-08
ability O 0 2.4037294821255273e-08
to O 0 3.842363316408637e-09
carry O 0 8.751982250032597e-09
out O 0 6.811475827817048e-09
transcription O 0 2.0214720564126765e-07
- O 0 3.1697284157417016e-06
coupled O 0 4.3259007043161546e-07
repair O 0 2.3427355699823238e-07
of O 0 1.6627798027357699e-09
oxidative O 0 2.5098555056501937e-07
DNA O 0 1.4149885601000278e-06
damage O 0 2.5888896288961405e-06
, O 0 1.1638850772044407e-08
and O 0 2.4370047313482246e-08
are O 0 4.440528389437759e-09
hypersensitive O 0 1.292829779231397e-06
to O 0 9.84374466383997e-08
ionizing O 0 8.923154382500798e-06
radiation O 0 2.951800070150057e-06
and O 0 5.818360193643457e-08
hydrogen O 0 4.243492526256887e-07
peroxide O 0 2.0734052668558434e-05
. O 0 7.88985516919638e-07

These O 0 1.1006566182913957e-06
results O 0 5.407446792560222e-07
suggest O 0 1.5076845727435284e-07
that O 0 1.080585398938183e-08
BRCA1 O 0 3.754607178052538e-06
participates O 0 7.024280535006255e-08
, O 0 7.572302784808471e-09
directly O 0 1.0632624558581938e-08
or O 0 1.0177506837294459e-08
indirectly O 0 1.9723046307262848e-08
, O 0 1.387254866536125e-09
in O 0 1.565287788274361e-09
transcription O 0 3.716261858244252e-07
- O 0 2.8703774660243653e-05
coupled O 0 3.984457634942373e-06
repair O 0 1.933505927809165e-06
of O 0 8.342093238411508e-09
oxidative O 0 8.713540751159599e-07
DNA O 0 2.4674309315741993e-06
damage O 0 2.785664264592924e-06
. O 0 4.9032621518563246e-08
. O 0 2.571583479493711e-07

Truncation O 0 0.0015026223845779896
mutations O 0 0.0005315560265444219
in O 0 1.7821780318172387e-07
the O 0 3.976891349566358e-08
transactivation O 0 5.561770649364917e-06
region O 0 1.7229714899258397e-07
of O 0 1.231464352713374e-08
PAX6 O 0 1.6485233572893776e-05
result O 0 5.0223551539829714e-08
in O 0 2.520355657509299e-08
dominant O 0 4.132642516196938e-06
- O 0 0.0005340169882401824
negative O 0 5.287226940708933e-06
mutants O 0 1.2830531886720564e-05
. O 0 7.268747026500932e-07

PAX6 O 0 0.0018062784802168608
is O 0 7.990780090949556e-07
a O 0 1.0891274371260806e-07
transcription O 0 2.651188424351858e-07
factor O 0 3.29067653126458e-08
with O 0 4.032480571680708e-09
two O 0 1.1068861383023432e-08
DNA O 0 1.914333012109637e-07
- O 0 5.036946504333173e-07
binding O 0 3.637545376022899e-08
domains O 0 4.744732962080889e-08
( O 0 8.239968707357548e-09
paired O 0 2.1358411572691693e-07
box O 0 1.720257273518655e-06
and O 0 1.4403875070456706e-07
homeobox O 0 1.433561692465446e-06
) O 0 5.954518211837012e-09
and O 0 4.905251760334295e-09
a O 0 2.3046089481226772e-08
proline O 0 3.2735417789808707e-06
- O 0 4.475047262531007e-06
serine O 0 2.9430302674882114e-06
- O 0 7.467782779713161e-06
threonine O 0 1.0558964277151972e-05
( O 0 9.14808353513763e-08
PST O 0 4.476661160879303e-06
) O 0 3.9900207582377334e-08
- O 0 2.5317851850559236e-06
rich O 0 6.798511549277464e-07
transactivation O 0 2.0250319721526466e-05
domain O 0 3.835003553831484e-06
. O 0 1.4874731277814135e-06

PAX6 O 0 0.006348801776766777
regulates O 0 0.0001703080051811412
eye O 0 0.0003747409500647336
development O 0 2.339674409768122e-07
in O 0 1.8979953608777578e-08
animals O 0 1.8138004875822844e-08
ranging O 0 2.616958916235035e-08
from O 0 5.326987739806555e-09
jellyfish O 0 4.510957651859826e-08
to O 0 4.481959248181511e-09
Drosophila O 0 5.434460348396897e-08
to O 0 1.1421749768203426e-08
humans O 0 8.896662961888069e-08
. O 0 2.1334491862035065e-07

Heterozygous O 0 0.0034530474804341793
mutations O 0 6.937315629329532e-05
in O 0 6.09570420806449e-08
the O 0 1.5617457549410574e-08
human O 0 8.831200659642491e-08
PAX6 O 0 1.1353091394994408e-05
gene O 0 1.044429723151552e-06
result O 0 5.085134446858319e-08
in O 0 3.739856424544996e-09
various O 0 6.6998264713902245e-09
phenotypes O 0 3.7804293242515996e-06
, O 0 1.5827735566631418e-08
including O 0 4.3514795322607824e-08
aniridia B-Disease 1 1.0
, O 0 1.0045179806184024e-05
Peters B-Disease 1 0.9999998807907104
anomaly I-Disease 1 0.9999979734420776
, O 0 8.407988048020343e-07
autosomal B-Disease 0 0.002724006772041321
dominant I-Disease 0 0.0002557692932896316
keratitis I-Disease 0 0.4191921651363373
, O 0 1.2243186802152195e-06
and O 0 2.202844825660577e-06
familial B-Disease 0 0.3384265601634979
foveal I-Disease 1 0.9966136813163757
dysplasia I-Disease 1 0.9999924898147583
. O 0 1.993261139432434e-05

It O 0 3.906891379301669e-06
is O 0 5.296384131270315e-08
believed O 0 5.006812742180955e-08
that O 0 3.70231800772558e-09
the O 0 5.933578073324952e-09
mutated O 0 1.7994987047131872e-06
allele O 0 6.330555493150314e-07
of O 0 1.3329865211630931e-08
PAX6 O 0 1.0091152944369242e-05
produces O 0 4.38811902370162e-08
an O 0 1.884754796677157e-09
inactive O 0 9.507858322876928e-08
protein O 0 1.4586316865461413e-07
and O 0 3.046331755740539e-07
aniridia B-Disease 1 0.9999998807907104
is O 0 1.957156428034068e-07
caused O 0 4.195406404505775e-07
due O 0 2.3959984218890895e-08
to O 0 4.916288176559647e-08
genetic O 0 1.0404905879113358e-05
haploinsufficiency O 0 0.0001479411293985322
. O 0 8.815176784082723e-07

However O 0 4.123033249925356e-06
, O 0 3.0984235621644984e-08
several O 0 1.1277920819452447e-08
truncation O 0 2.8782242225133814e-06
mutations O 0 4.533644641924184e-06
have O 0 5.258887370018783e-08
been O 0 4.3430883778228235e-08
found O 0 7.130826595869166e-09
to O 0 2.779272811892497e-09
occur O 0 3.848260377026236e-09
in O 0 7.975030635876124e-10
the O 0 8.54138715311592e-09
C O 0 4.6889007876416144e-07
- O 0 1.3201654383010464e-06
terminal O 0 1.2786000525011332e-07
half O 0 1.3370224039022105e-08
of O 0 2.879477101203065e-09
PAX6 O 0 1.2426600051185233e-06
in O 0 1.1955743950409214e-08
patients O 0 4.7917616541326424e-08
with O 0 2.8712356936466676e-08
Aniridia B-Disease 1 0.9999992847442627
resulting O 0 2.2928243481601385e-07
in O 0 4.877477532971852e-09
mutant O 0 1.5641879258510016e-07
proteins O 0 8.692722985870205e-09
that O 0 9.722987970306463e-10
retain O 0 7.41399563963796e-09
the O 0 1.1212711870101089e-09
DNA O 0 1.7317873357569624e-08
- O 0 3.443236096245528e-08
binding O 0 6.2147318402594465e-09
domains O 0 1.2796633086509246e-08
but O 0 9.448648974341722e-09
have O 0 3.0875625611770374e-08
lost O 0 3.270893671469821e-07
most O 0 1.5688745858000175e-09
of O 0 1.5007243225895195e-09
the O 0 4.7720241980186984e-08
transactivation O 0 8.281335794890765e-06
domain O 0 1.83932866093528e-06
. O 0 6.175834528221458e-07

It O 0 1.0226523272649501e-06
is O 0 3.48031718999664e-08
not O 0 4.383415408426572e-09
clear O 0 1.3063965909054787e-08
whether O 0 3.2178326669907165e-09
such O 0 1.8152531700010854e-09
mutants O 0 5.801111910841428e-06
really O 0 1.3336346000869526e-06
behave O 0 3.156582906171934e-08
as O 0 4.8240571537405685e-09
loss O 0 2.211937299989586e-08
- O 0 4.7147958071036555e-07
of O 0 6.844921074389276e-09
- O 0 3.1107754239201313e-06
function O 0 1.5019908872204724e-08
mutants O 0 3.0718265975338e-07
as O 0 1.4585197050109855e-08
predicted O 0 3.3958534118028183e-07
by O 0 2.0902096053987407e-08
haploinsufficiency O 0 1.2766674444719683e-05
. O 0 5.40017026651185e-07

Contrary O 0 1.2049777978972998e-05
to O 0 4.546025422769162e-08
this O 0 4.309608669927911e-09
theory O 0 9.266689637854597e-09
, O 0 3.2722238252347324e-09
our O 0 2.6538879982496155e-09
data O 0 2.0727094707240212e-08
showed O 0 2.0454272942060925e-07
that O 0 4.5475559429242196e-10
these O 0 5.863977081688176e-10
mutants O 0 6.5798616333268e-08
are O 0 1.4269543324729739e-09
dominant O 0 6.467209345828451e-08
- O 0 5.246594696473039e-07
negative O 0 2.9972355264362704e-08
in O 0 2.7169837490959026e-09
transient O 0 2.00708029751695e-07
transfection O 0 1.4821290506006335e-06
assays O 0 2.937902365829359e-07
when O 0 1.765455337476851e-08
they O 0 3.8609497821084915e-09
are O 0 6.63622046204182e-10
coexpressed O 0 7.549721914301699e-08
with O 0 3.863947828364189e-09
wild O 0 4.2814593825823977e-07
- O 0 8.286725642392412e-05
type O 0 3.1073477657628246e-06
PAX6 O 0 0.00010596618085401133
. O 0 1.1654688023554627e-06

We O 0 2.3948757643665886e-06
found O 0 5.645267009413146e-08
that O 0 3.1080105156178206e-09
the O 0 2.6815223375109554e-09
dominant O 0 2.3552962602479965e-07
- O 0 9.962426702259108e-06
negative O 0 2.1372164837885066e-07
effects O 0 1.1608027961074185e-07
result O 0 7.140980251563178e-09
from O 0 8.976835941254535e-10
the O 0 1.023065521188471e-09
enhanced O 0 3.660917968772992e-08
DNA O 0 1.0551957529969513e-07
binding O 0 4.2097383357031504e-08
ability O 0 2.319656111637869e-08
of O 0 4.589374658081624e-09
these O 0 1.9740621581831874e-08
mutants O 0 6.000712801323971e-06
. O 0 4.4701758383780543e-07

Kinetic O 0 1.710047945380211e-05
studies O 0 2.6205935910184053e-07
of O 0 1.3603199455758386e-08
binding O 0 7.462334394858772e-08
and O 0 6.46336175691431e-08
dissociation O 0 3.6255667055229424e-06
revealed O 0 2.595920989278966e-07
that O 0 7.992330131045833e-10
various O 0 1.2268381865965239e-09
truncation O 0 3.6205076980877493e-07
mutants O 0 9.310592190558964e-07
have O 0 1.1121639609257272e-08
3 O 0 7.838645288416046e-09
- O 0 3.695653276736266e-07
5 O 0 2.6826896259990463e-08
- O 0 2.71830515430338e-07
fold O 0 1.0990648036113271e-07
higher O 0 2.266395737748894e-09
affinity O 0 1.7784598238534954e-09
to O 0 1.4041770524109154e-10
various O 0 2.69183120238381e-10
DNA O 0 9.067389505901247e-09
- O 0 1.3596351600142498e-08
binding O 0 3.5011884502722523e-09
sites O 0 6.39832631321724e-09
when O 0 2.8437707744188856e-09
compared O 0 3.161232831061511e-09
with O 0 9.197115291570412e-10
the O 0 6.695061838257743e-09
wild O 0 5.511118956746941e-07
- O 0 5.882236655452289e-05
type O 0 3.99456166633172e-06
PAX6 O 0 0.000157890870468691
. O 0 1.928592610056512e-06

These O 0 1.3138102303855703e-06
results O 0 1.0757327117971727e-07
provide O 0 5.484324994142753e-09
a O 0 9.71874580812937e-09
new O 0 1.6427598836799007e-08
insight O 0 3.9014146580029774e-08
into O 0 3.06348102441234e-09
the O 0 1.4391696723237146e-09
role O 0 8.74373995429778e-09
of O 0 6.466799096216391e-09
mutant O 0 2.253664661111543e-06
PAX6 O 0 1.3594398296845611e-05
in O 0 1.8608575658163318e-07
causing O 0 3.350924998812843e-06
aniridia B-Disease 1 0.9999942779541016
. O 0 1.9511014670570148e-07
. O 0 9.050733638105157e-07

Reversal O 0 0.0008317770552821457
of O 0 9.415705790161155e-06
severe O 1 0.6903454661369324
hypertrophic B-Disease 1 0.9999927282333374
cardiomyopathy I-Disease 1 1.0
and O 0 5.1589198847068474e-05
excellent O 0 3.8057037272665184e-06
neuropsychologic O 0 1.9289904230390675e-05
outcome O 0 2.261000418002368e-07
in O 0 3.68681014606409e-08
very B-Disease 0 1.0192993471491718e-07
- I-Disease 0 0.00015870912466198206
long I-Disease 0 7.030351298453752e-06
- I-Disease 0 1.9255332517786883e-05
chain I-Disease 0 4.255173735145945e-06
acyl I-Disease 0 8.942363365349593e-07
- I-Disease 0 1.113001076191722e-06
coenzyme I-Disease 0 1.712488597149786e-06
A I-Disease 0 3.788531785176019e-06
dehydrogenase I-Disease 0 0.002510811435058713
deficiency I-Disease 0 0.01211630366742611
. O 0 1.4501737268801662e-06

Very B-Disease 0 7.299247045011725e-06
- I-Disease 0 0.0001062009614543058
long I-Disease 0 3.4142697131755995e-06
- I-Disease 0 1.3651040717377327e-05
chain I-Disease 0 2.9832729069312336e-06
acyl I-Disease 0 4.369710779883462e-07
- I-Disease 0 2.941092702712922e-07
coenzyme I-Disease 0 8.919753469172065e-08
A I-Disease 0 7.996850825975343e-08
dehydrogenase I-Disease 0 2.0381071408337448e-06
( I-Disease 0 2.266734497879952e-07
VLCAD I-Disease 0 0.00014422960521187633
) I-Disease 0 4.1428768327023135e-07
deficiency I-Disease 0 9.504441550234333e-06
is O 0 7.968770532329472e-09
a O 0 2.500988500742096e-07
disorder O 0 5.848140426678583e-05
of O 0 8.35884872429915e-09
fatty O 0 9.718041837913916e-07
acid O 0 1.411617489566197e-07
beta O 0 1.2799904247629001e-08
oxidation O 0 1.4166743333987597e-08
that O 0 3.742824716823634e-09
reportedly O 0 1.7132028062860627e-07
has O 0 1.9200351530912485e-08
high O 0 3.7678891118275715e-08
rates O 0 9.065750106174164e-08
of O 0 6.900974902634971e-09
morbidity O 0 0.0029038230422884226
and O 0 4.970347049493284e-07
mortality O 0 7.016903691692278e-05
. O 0 4.929885335513973e-07

We O 0 1.5136720321606845e-06
describe O 0 1.8067606788463308e-07
the O 0 5.876228836854125e-09
outcome O 0 9.704057113424369e-09
of O 0 9.55068912844581e-10
a O 0 2.2868009708076897e-08
5 O 0 6.113880601787969e-08
- O 0 1.1848252370327828e-06
year O 0 2.2086531714649027e-08
- O 0 1.263201738765929e-06
old O 0 4.013532816316001e-06
girl O 0 7.88615652709268e-05
with O 0 2.9643342713825405e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
who O 0 1.600443511051708e-06
was O 0 5.211795723880641e-07
first O 0 1.862701992649818e-08
seen O 0 1.6126621460443857e-07
at O 0 7.448253569464214e-09
5 O 0 5.172654748974992e-09
months O 0 3.5217433413947674e-09
of O 0 5.494530386229712e-10
age O 0 3.4167406681717694e-08
with O 0 1.9722959621049085e-07
severe O 1 0.8182944655418396
hypertrophic B-Disease 1 0.9999850988388062
cardiomyopathy I-Disease 1 1.0
, O 0 0.001654052291996777
hepatomegaly B-Disease 1 1.0
, O 0 6.287037103902549e-05
encephalopathy B-Disease 0 0.07545147836208344
, O 0 1.774148330468961e-07
and O 0 5.169294468032604e-07
hypotonia B-Disease 0 0.012031756341457367
. O 0 2.6410616555949673e-06

Biochemical O 0 0.0006306703435257077
studies O 0 4.797821748070419e-05
indicated O 0 0.3373340368270874
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 1.6690722986822948e-05
by O 0 1.7119607065296805e-08
a O 0 3.3317758152406896e-07
stable O 0 1.1089623512816615e-05
yet O 0 4.933629043080145e-07
inactive O 0 1.2682111218964565e-06
enzyme O 0 2.4547330212953966e-06
. O 0 6.189762302710733e-07

Molecular O 0 1.4211271263775416e-05
genetic O 0 3.437037094045081e-06
analysis O 0 1.059653058632648e-07
of O 0 1.8924898981254046e-08
her O 0 2.316226982657099e-06
VLCAD O 0 0.00034881269675679505
gene O 0 1.1121470606667572e-06
revealed O 0 6.795788749514031e-07
a O 0 1.046828472794914e-07
T1372C O 0 3.988870957982726e-06
( O 0 4.6532012021316405e-08
F458L O 0 1.272516897188325e-06
) O 0 4.02370083918413e-08
missense O 0 7.55942801333731e-06
mutation O 0 9.741360145198996e-07
and O 0 3.903707579411275e-08
a O 0 3.653113367363403e-07
1668 O 0 0.0008962678257375956
ACAG O 0 0.00023731013061478734
1669 O 0 4.087901834282093e-05
splice O 0 0.0003319077368360013
site O 0 2.5855935746221803e-05
mutation O 0 3.6716559407068416e-05
. O 0 1.5713122820670833e-06

After O 0 6.476494036178337e-06
initial O 0 8.609052315478039e-07
treatment O 0 3.426497983127774e-07
with O 0 2.6122913610038268e-08
intravenous O 0 4.225709744787309e-06
glucose O 0 1.554594564368017e-05
and O 0 3.018911343133368e-08
carnitine O 0 2.863497741145693e-07
, O 0 2.707279289637654e-09
the O 0 3.6532712410775048e-09
patient O 0 1.0163640951077468e-07
has O 0 4.187603508398752e-08
thrived O 0 1.1903585317440957e-07
on O 0 2.0016987178905765e-08
a O 0 2.6431898447754065e-08
low O 0 1.1769509455916705e-06
- O 0 3.2623065635561943e-06
fat O 0 9.308879498348688e-07
diet O 0 5.9511943817369684e-08
supplemented O 0 1.6395606650121408e-08
with O 0 3.3184899272953317e-09
medium O 0 9.604185180478453e-08
- O 0 4.017070750705898e-06
chain O 0 4.438660653249826e-06
triglyceride O 0 1.1474743359940476e-06
oil O 0 1.5641909101304918e-07
and O 0 4.853756951916921e-09
carnitine O 0 3.969954036620038e-07
and O 0 7.731850715231303e-09
avoidance O 0 2.7558641590985644e-07
of O 0 5.1326775718507633e-08
fasting O 0 8.325664384756237e-05
. O 0 8.247808978012472e-07

Her O 0 0.0005444104317575693
ventricular O 0 0.010948763228952885
hypertrophy O 0 0.0007199729443527758
resolved O 0 2.2671288206765894e-06
significantly O 0 4.858854367739696e-07
over O 0 1.9680172158587084e-08
1 O 0 4.1501522218823084e-08
year O 0 4.0914095222888136e-08
, O 0 8.128513862004638e-09
and O 0 1.208634614613402e-07
cognitively O 0 1.7553038560436107e-06
, O 0 1.1920018749833616e-08
she O 0 1.4715305951540358e-07
is O 0 1.089093148998188e-09
in O 0 1.893391443630321e-09
the O 0 5.003611747156356e-09
superior O 0 7.781341793133834e-08
range O 0 4.819286303359149e-08
for O 0 8.67156035866401e-09
age O 0 1.137530389883068e-07
. O 0 1.3979177992951008e-07

Clinical O 0 6.127169035607949e-05
recognition O 0 3.0310159218061017e-06
of O 0 2.090049565595109e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 8.811061036340107e-08
important O 0 7.398484935805527e-09
because O 0 1.1146742195933257e-08
it O 0 6.873624780467935e-09
is O 0 1.5840532219257852e-09
one O 0 8.997474432170804e-10
of O 0 3.3908720276087934e-10
the O 0 4.015855648020761e-09
few O 0 9.164850212073361e-08
directly O 0 4.976949412593967e-07
treatable O 0 1.583161429152824e-05
causes O 0 1.2309246244512906e-07
of O 0 5.673147995821637e-08
cardiomyopathy B-Disease 1 1.0
in O 0 1.7403589254172402e-06
children O 0 4.3807826841657516e-06
. O 0 1.0086162660627451e-07
. O 0 7.049640657896816e-07

Cloning O 0 8.530400918971281e-06
of O 0 6.058242973949746e-08
a O 0 8.438434662139116e-08
novel O 0 1.871280801424291e-07
member O 0 8.338720824951906e-09
of O 0 1.3799028586447548e-09
the O 0 9.312527637916901e-09
low O 0 3.244840627303347e-06
- O 0 7.305138296942459e-06
density O 0 9.354532721772557e-07
lipoprotein O 0 2.8952104912605137e-05
receptor O 0 1.6762107861723052e-06
family O 0 1.1660002883218112e-06
. O 0 7.558812171737372e-07

A O 0 3.6170295061310753e-06
gene O 0 1.9477156456559896e-06
encoding O 0 5.530040425583138e-07
a O 0 2.007089676681062e-07
novel O 0 8.096130272861046e-07
transmembrane O 0 7.506329779971566e-07
protein O 0 2.320807226396937e-07
was O 0 6.211961363078444e-07
identified O 0 2.7733749519143203e-08
by O 0 1.7094734516831522e-09
DNA O 0 3.19688773231519e-08
sequence O 0 1.0431347341466335e-08
analysis O 0 4.7808588199416135e-09
within O 0 1.5668172315130846e-09
the O 0 1.0535301520064877e-08
insulin B-Disease 0 8.093282667687163e-05
- I-Disease 1 0.5671948194503784
dependent I-Disease 0 0.013063892722129822
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.1240992989769438e-06
IDDM B-Disease 0 5.352694643079303e-05
) O 0 9.982525739360426e-08
locus O 0 2.8857853067165706e-06
IDDM4 O 0 2.089840199914761e-05
on O 0 1.8585162706585834e-06
chromosome O 0 0.00032975419890135527
11q13 O 0 4.955261465511285e-05
. O 0 2.954867341031786e-06

Based O 0 1.6816130710139987e-06
on O 0 2.8808966590077034e-07
its O 0 3.269399329042244e-08
chromosomal O 0 2.7300418878439814e-05
position O 0 1.4649973536506877e-06
, O 0 1.0259267213541534e-08
this O 0 1.798514337458812e-09
gene O 0 2.7895612930706193e-08
is O 0 5.566208383100957e-09
a O 0 1.2413193140048406e-08
candidate O 0 1.0324718857646076e-07
for O 0 6.688042120117643e-09
conferring O 0 9.949856121238554e-07
susceptibility O 0 7.28614249965176e-05
to O 0 3.0689795949001564e-06
diabetes B-Disease 0 0.4060642123222351
. O 0 2.114932613039855e-06

The O 0 6.498826792267209e-07
gene O 0 9.264853133572615e-07
, O 0 3.774873746920093e-08
termed O 0 4.5275464799487963e-07
low O 0 2.4494947865605354e-06
- O 0 3.1586482691636775e-06
density O 0 7.032430744402518e-07
lipoprotein O 0 3.68804512618226e-06
receptor O 0 2.1448488496389473e-07
related O 0 3.457306263499049e-08
protein O 0 3.576420226636401e-07
5 O 0 1.1506923414117409e-07
( O 0 2.038385282787658e-08
LRP5 O 0 3.3447117857576814e-06
) O 0 3.5695284505976588e-09
, O 0 1.2605467780701929e-09
encodes O 0 1.3844378976557437e-08
a O 0 6.017289777560109e-09
protein O 0 2.252395248092398e-08
of O 0 2.762940765066446e-09
1615 O 0 1.5503630947932834e-06
amino O 0 2.217614714083993e-08
acids O 0 5.397259528194809e-09
that O 0 2.332591342302237e-10
contains O 0 5.475677689048553e-10
conserved O 0 7.343611940768824e-09
modules O 0 1.8577132721020462e-08
which O 0 7.976586502422833e-09
are O 0 3.9647846117318863e-10
characteristic O 0 7.495454035222338e-09
of O 0 4.698600952757204e-10
the O 0 1.0823883123123323e-08
low O 0 5.143328962731175e-06
- O 0 6.119887257227674e-05
density O 0 3.2825009839143604e-06
lipoprotein O 0 0.0001044756209012121
( O 0 1.155046192025111e-07
LDL O 0 8.865426025295164e-06
) O 0 5.349022913492263e-08
receptor O 0 4.864469360654766e-07
family O 0 4.91247305944853e-07
. O 0 5.340490929484076e-07

These O 0 7.01279475379124e-07
modules O 0 6.827854122093413e-07
include O 0 2.936332776926065e-08
a O 0 4.51378916466183e-08
putative O 0 3.7634722502843942e-06
signal O 0 2.378936869718018e-06
peptide O 0 4.4917602082250596e-08
for O 0 8.958362940347797e-10
protein O 0 8.389435812716783e-09
export O 0 2.6597766211722274e-09
, O 0 1.5942435149796097e-09
four O 0 5.007077419350026e-09
epidermal O 0 3.559607932857034e-07
growth O 0 1.352438943058587e-07
factor O 0 5.87425930120844e-08
( O 0 1.8159536097073214e-08
EGF O 0 6.743907192685583e-07
) O 0 9.038863879595738e-09
repeats O 0 1.7482143732650002e-07
with O 0 3.673268356152448e-09
associated O 0 2.9587930328034417e-08
spacer O 0 2.196945388277527e-06
domains O 0 1.2998229692584573e-07
, O 0 5.097883004623327e-09
three O 0 1.6627234700195004e-08
LDL O 0 2.4984642550407443e-06
- O 0 1.689475084276637e-06
receptor O 0 2.7438269967205997e-07
( O 0 1.0821116447345958e-08
LDLR O 0 8.489949436807365e-07
) O 0 5.382692069844097e-09
repeats O 0 1.0491811508472892e-07
, O 0 1.6514392076061313e-09
a O 0 6.1503118153893865e-09
single O 0 1.2063063081768632e-07
transmembrane O 0 6.763551851918237e-08
spanning O 0 4.9973007065773345e-08
domain O 0 2.1184414222830128e-08
, O 0 4.322599167494445e-09
and O 0 4.992362967470854e-09
a O 0 1.2967420914833383e-08
cytoplasmic O 0 8.796634460850328e-07
domain O 0 3.968348778471409e-07
. O 0 4.3841956198775733e-07

The O 0 3.2809879257911234e-07
encoded O 0 4.831020419260312e-07
protein O 0 4.0232566789200064e-07
has O 0 4.7301401906452156e-08
a O 0 9.147538726494986e-09
unique O 0 5.108999001635084e-09
organization O 0 4.010435983303751e-09
of O 0 1.4713916751674105e-09
EGF O 0 1.0411330322313006e-06
and O 0 7.022914871868124e-08
LDLR O 0 5.552951733989175e-06
repeats O 0 1.0889253871937399e-06
; O 0 1.705618224434602e-08
therefore O 0 6.6157874734074085e-09
, O 0 1.9036976439679165e-09
LRP5 O 0 9.658263024903135e-07
likely O 0 1.578185226946971e-08
represents O 0 1.5145181775366723e-09
a O 0 1.3358211203851056e-09
new O 0 6.195393087438106e-09
category O 0 1.5575455591942955e-08
of O 0 1.5870713632182287e-09
the O 0 3.754044186621286e-08
LDLR O 0 8.271409024018794e-05
family O 0 1.3942448049419909e-06
. O 0 3.910963073394669e-07

Both O 0 1.3880915048503084e-06
human O 0 1.7119222661676758e-07
and O 0 9.78347287627912e-08
mouse O 0 1.2685047295235563e-05
LRP5 O 0 1.6914025763981044e-05
cDNAs O 0 2.5418228233320406e-06
have O 0 4.29176942873255e-08
been O 0 1.8464515250116165e-08
isolated O 0 8.661380945795827e-08
and O 0 5.191958862837964e-09
the O 0 1.151453155046056e-09
encoded O 0 1.8294144865649287e-08
mature O 0 6.105220329288841e-09
proteins O 0 1.982403796674248e-09
are O 0 4.2674891398419845e-10
95 O 0 4.180451096402749e-09
% O 0 1.2039468311186852e-09
identical O 0 1.205254740455075e-08
, O 0 4.155353838797282e-09
indicating O 0 6.947387021227769e-08
a O 0 2.5844537177022175e-08
high O 0 9.194948091817423e-08
degree O 0 5.682903037040887e-09
of O 0 7.777046784340769e-10
evolutionary O 0 7.491897946465542e-08
conservation O 0 3.459878783473869e-08
. O 0 2.422887135367091e-08
. O 0 2.0880206363926845e-07

The O 0 3.0724643238499993e-06
APC B-Disease 0 1.4944551367079839e-05
variants O 0 3.0662001790915383e-06
I1307K O 0 3.548687345755752e-06
and O 0 3.2571563224337297e-08
E1317Q O 0 5.106566618451325e-07
are O 0 7.807012813998426e-09
associated O 0 2.4297233380821126e-07
with O 0 0.057332318276166916
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 9.16788758331677e-06
but O 0 5.684044523945886e-08
not O 0 9.671572875902257e-09
always O 0 2.4157902345223192e-08
with O 0 2.313574887224945e-09
a O 0 1.125610253893683e-07
family O 0 3.202206926289364e-07
history O 0 1.5013941379038442e-07
. O 0 6.394851084223774e-07

Classical O 0 0.06527997553348541
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999994039535522
polyposis I-Disease 1 1.0
( O 0 0.0010626105358824134
FAP B-Disease 0 0.0001894979359349236
) O 0 2.410086210602458e-07
is O 0 1.549926231803056e-08
a O 0 4.6186631408318135e-08
high O 0 1.6520707504241727e-05
- O 1 0.999666690826416
penetrance O 1 0.9943787455558777
autosomal B-Disease 1 0.9839868545532227
dominant I-Disease 0 0.07253607362508774
disease I-Disease 0 8.275236177723855e-05
that O 0 1.2621714340355084e-08
predisposes O 0 1.3694689187104814e-06
to O 0 1.0271798522865083e-08
hundreds O 0 2.385260167159231e-08
or O 0 1.6591371831964352e-08
thousands O 0 3.579879859216817e-08
of O 0 6.013315669406438e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.5408540368080139
carcinoma I-Disease 1 1.0
and O 0 1.3009084796067327e-06
that O 0 1.782379399628553e-08
results O 0 4.367744210753699e-08
from O 0 6.6435306145251616e-09
truncating O 0 1.846599843702279e-06
mutations O 0 5.361832791095367e-07
in O 0 7.579701311044573e-09
the O 0 4.425657351703194e-08
APC B-Disease 0 4.368571353552397e-06
gene O 0 4.039987743453821e-06
. O 0 1.2599017509273835e-06

A O 0 1.4227138308342546e-05
variant O 0 4.12401495850645e-05
of O 0 5.832671376992948e-07
FAP B-Disease 0 0.00016275362577289343
is O 0 5.254693860479165e-06
attenuated B-Disease 0 0.3904551863670349
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999966621398926
coli I-Disease 1 0.9999998807907104
, O 0 8.547108905077039e-07
which O 0 2.9130600154303465e-08
results O 0 1.6057615681575044e-08
from O 0 3.4344256327756284e-09
germ O 0 5.127451004227623e-06
- O 0 5.2569539548130706e-05
line O 0 9.475211845710874e-05
mutations O 0 9.635064657231851e-08
in O 0 2.001010690477756e-09
the O 0 7.026060622195018e-09
5 O 0 5.335084196644857e-08
and O 0 2.3384112424196246e-08
3 O 0 2.6365283289919716e-08
regions O 0 6.558257936717382e-09
of O 0 1.9061208167414634e-09
the O 0 6.992799939098404e-08
APC B-Disease 0 3.995693532488076e-06
gene O 0 1.7032991763699101e-06
. O 0 7.444861012118054e-07

Attenuated B-Disease 1 0.9999072551727295
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 1.0
patients O 0 0.2309630811214447
have O 0 5.098700967209879e-06
" O 0 1.2359632819425315e-06
multiple O 0 2.1611676856991835e-05
" O 1 0.8596656322479248
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 2.215934671312425e-07
typically O 0 2.8573591492886408e-08
fewer O 0 3.2614067002612046e-09
than O 0 1.129276783196076e-09
100 O 0 6.400058705224865e-09
) O 0 2.1503321345761606e-09
without O 0 1.887471068329205e-09
the O 0 1.0600933464388618e-08
florid O 0 0.0001230788038810715
phenotype O 0 7.674972039239947e-06
of O 0 1.1353634477018204e-08
classical O 0 9.515647434454877e-07
FAP B-Disease 0 4.0753606299404055e-05
. O 0 1.1013286211891682e-06

Another O 0 3.79624248125765e-06
group O 0 7.780316195749037e-07
of O 0 1.1413431089124515e-08
patients O 0 5.321506435507217e-08
with O 0 8.106697535481544e-09
multiple O 0 1.6299560456900508e-06
adenomas B-Disease 0 0.0003512687690090388
has O 0 1.5927632830425864e-06
no O 0 5.66784841282697e-08
mutations O 0 1.565322236274369e-07
in O 0 2.348462535550766e-09
the O 0 7.558276671204567e-09
APC B-Disease 0 2.0132068812017678e-07
gene O 0 4.100182238175876e-08
, O 0 4.5785419899857516e-09
and O 0 1.2158295703557087e-08
their O 0 3.4181027785962215e-08
phenotype O 0 5.216875706537394e-06
probably O 0 1.264082527541177e-07
results O 0 8.575470999971913e-09
from O 0 1.032480878571107e-09
variation O 0 9.09125716930248e-08
at O 0 2.194121151433137e-08
a O 0 2.121429609758252e-08
locus O 0 1.2221954648339306e-06
, O 0 2.5109800461109444e-08
or O 0 2.1227895885544967e-08
loci O 0 1.0374088788012159e-07
, O 0 3.832445472085055e-09
elsewhere O 0 8.50750225822594e-09
in O 0 3.776549739598067e-09
the O 0 4.100690631503312e-08
genome O 0 1.9079316189163364e-06
. O 0 5.084688723400177e-07

Recently O 0 0.00010219299292657524
, O 0 1.8250621280913037e-07
however O 0 7.555048142648957e-09
, O 0 2.382894326302676e-09
a O 0 1.6274563918727836e-08
missense O 0 6.132326689112233e-06
variant O 0 9.09592813513882e-07
of O 0 2.312517288771687e-08
APC B-Disease 0 3.2567390917392913e-06
( O 0 2.876284099784243e-08
I1307K O 0 5.400082727646804e-07
) O 0 9.160809000263725e-09
was O 0 1.790045587313216e-07
described O 0 4.872134340416778e-08
that O 0 1.8400450052524775e-09
confers O 0 1.717497788433775e-08
an O 0 3.0542277595912992e-09
increased O 0 4.820812478101288e-07
risk O 0 3.205376742698718e-06
of O 0 0.0006713104667142034
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 8.160175468674424e-08
including O 0 1.7468153146182885e-08
multiple O 0 2.64520804194035e-06
adenomas B-Disease 0 0.00023688602959737182
, O 0 1.2306242069826112e-07
in O 0 2.2614530337250471e-07
Ashkenazim O 0 0.00015286698180716485
. O 0 9.80132540462364e-07

We O 0 7.931794243631884e-06
have O 0 3.806287907082151e-08
studied O 0 7.991083350589179e-09
a O 0 3.4440095220134026e-09
set O 0 1.198179155892376e-08
of O 0 2.128484721808377e-09
164 O 0 5.040478754381184e-07
patients O 0 1.0952686579912552e-07
with O 0 6.722921597202003e-08
multiple O 1 0.9878227114677429
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.00025627337163314223
/ I-Disease 0 0.19935494661331177
or I-Disease 0 6.762165139662102e-05
carcinoma I-Disease 1 1.0
and O 0 9.390008131049399e-07
analyzed O 0 1.564347826388257e-06
codons O 0 5.147254341864027e-06
1263 O 0 1.4288187230704352e-05
- O 0 1.0766480954771396e-05
1377 O 0 1.0870311598409899e-05
( O 0 6.75774955993802e-08
exon O 0 1.6905790971577517e-06
15G O 0 4.628020633390406e-06
) O 0 9.047177229604131e-09
of O 0 1.1954324197205324e-09
the O 0 6.909562255685842e-09
APC B-Disease 0 1.8956768599309726e-07
gene O 0 4.098000871977092e-08
for O 0 9.443658299801427e-09
germ O 0 1.1520859516167548e-05
- O 0 4.338295184425078e-05
line O 0 3.255369301768951e-05
variants O 0 3.270826709922403e-06
. O 0 1.3402160448094946e-06

Three O 0 5.4346019169315696e-06
patients O 0 1.0297633252775995e-06
with O 0 9.906519160551852e-09
the O 0 2.047831237916853e-08
I1307K O 0 3.784004093176918e-06
allele O 0 1.2754035196849145e-06
were O 0 1.9830217468097544e-07
detected O 0 1.3386267028181464e-07
, O 0 1.3896648276556789e-09
each O 0 1.634024693331071e-09
of O 0 1.226186174818622e-08
Ashkenazi O 0 7.826006913091987e-05
descent O 0 3.134835424134508e-05
. O 0 7.436005944327917e-07

Four O 0 2.729024345171638e-05
patients O 0 1.7248834410565905e-05
had O 0 3.1608428230356367e-07
a O 0 6.466456170528545e-08
germ O 0 2.2142934540170245e-05
- O 0 5.906034493818879e-05
line O 0 1.19786272989586e-05
E1317Q O 0 1.4885487189530977e-06
missense O 0 2.662519364093896e-06
variant O 0 2.145106634543481e-07
of O 0 9.255262334306735e-09
APC O 0 5.783529104519403e-07
that O 0 4.824279997706071e-08
was O 0 1.2587187256940524e-06
not O 0 2.1708752573346146e-09
present O 0 7.34882044106655e-10
in O 0 1.326371568133311e-09
controls O 0 1.2664586392929778e-06
; O 0 3.047049190740836e-08
one O 0 1.657618264871985e-09
of O 0 3.0724853217201087e-10
these O 0 1.7125215689972606e-09
individuals O 0 1.5836755240528078e-09
had O 0 7.110172361990408e-08
an O 0 9.258823707725128e-10
unusually O 0 3.24574536136879e-08
large O 0 2.180278180219375e-09
number O 0 2.8953548447674393e-09
of O 0 3.346999344344681e-09
metaplastic B-Disease 0 1.1425001503084786e-05
polyps I-Disease 0 3.287272193119861e-06
of I-Disease 0 5.860893992348792e-09
the I-Disease 0 7.833073567553583e-08
colorectum I-Disease 0 2.2692294805892743e-05
. O 0 7.169259674810746e-07

There O 0 1.1761969744839007e-06
is O 0 2.3895680101304606e-08
increasing O 0 4.4097299145562374e-09
evidence O 0 3.289030825470718e-09
that O 0 1.4547903992578881e-09
there O 0 1.235170965507848e-09
exist O 0 3.4902536416581142e-09
germ O 0 1.5573426708215266e-06
- O 0 5.41586268809624e-06
line O 0 4.0741715565673076e-06
variants O 0 1.0819878326628896e-08
of O 0 5.117227752649001e-10
the O 0 2.602110305005567e-09
APC B-Disease 0 1.39127990905763e-07
gene O 0 2.6230255301129546e-08
that O 0 3.189157604666093e-09
predispose O 0 3.410509563650521e-08
to O 0 1.8313023320004618e-09
the O 0 1.7955084086196393e-09
development O 0 5.921074297532414e-09
of O 0 3.9841498988835156e-08
multiple O 1 0.9634276628494263
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9792996048927307
carcinoma I-Disease 1 1.0
, O 0 7.252260729728732e-07
but O 0 2.6221552928973324e-08
without O 0 4.0241672216723146e-09
the O 0 7.09112768504383e-09
florid O 0 8.405421249335632e-05
phenotype O 0 4.214271939417813e-06
of O 0 2.3549979744075245e-09
classical O 0 5.024328686431545e-08
FAP B-Disease 0 6.083741368456685e-07
, O 0 4.323316815657563e-09
and O 0 2.189178838207795e-09
possibly O 0 3.894208955301792e-09
with O 0 1.4367341760745944e-09
importance O 0 1.0270568395753799e-07
for O 0 0.0003971292171627283
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 1.6390515611419687e-06
in O 0 6.3066907252107285e-09
the O 0 5.611973108443635e-09
general O 0 7.671711266254988e-09
population O 0 8.620634872613664e-09
. O 0 1.2059769183281333e-08
. O 0 2.043389883965574e-07

Genomic O 0 4.895731035503559e-05
structure O 0 1.031506940307736e-06
of O 0 4.9142066416152375e-08
the O 0 2.934072256266518e-07
human O 0 0.0001296675472985953
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999911785125732
diarrhea I-Disease 1 1.0
( O 0 2.10417274502106e-05
CLD B-Disease 0 0.0038147149607539177
) O 0 3.337439409278886e-07
gene O 0 5.264590527076507e-06
. O 0 1.5311057950384566e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.999998927116394
diarrhea I-Disease 1 1.0
( O 0 0.00031670278985984623
CLD B-Disease 0 0.1543785184621811
) O 0 2.456044114751421e-07
is O 0 4.337798031883722e-08
caused O 0 1.487766496666154e-07
by O 0 1.0179196152648728e-08
mutations O 0 5.12370831984299e-07
in O 0 3.644710533379225e-09
a O 0 4.896775607221571e-08
gene O 0 8.616576110398455e-07
which O 0 1.4555995164755586e-07
encodes O 0 1.6883105899978545e-06
an O 0 4.327939109316503e-07
intestinal O 0 0.0008817804628051817
anion O 0 3.885637124767527e-05
transporter O 0 0.0005057444795966148
. O 0 3.56910572918423e-06

We O 0 8.75382283993531e-06
report O 0 1.0272546546730155e-07
here O 0 5.6130859960035195e-09
the O 0 1.2360877876815834e-09
complete O 0 4.64160399005209e-09
genomic O 0 6.370138549982585e-08
organization O 0 3.793906078186637e-09
of O 0 5.070650010985389e-10
the O 0 5.37163602487567e-09
human O 0 6.375377381573344e-08
CLD B-Disease 0 1.064841853803955e-05
gene O 0 1.2004088034700544e-07
which O 0 3.166381645769434e-08
spans O 0 2.549583939526201e-07
approximately O 0 1.8352299235857572e-08
39kb O 0 7.422062822115549e-07
, O 0 9.238858567073294e-09
and O 0 1.5066962788523597e-08
comprises O 0 5.9355052428600175e-08
21 O 0 2.7673044655784906e-07
exons O 0 1.4603294403059408e-05
. O 0 1.2680587815339095e-06

All O 0 2.151803755623405e-06
exon O 0 2.9379543775576167e-05
/ O 0 1.6266598322545178e-05
intron O 0 7.048726547509432e-05
boundaries O 0 2.3860759483795846e-06
conform O 0 3.3506745467093424e-07
to O 0 1.6113947509666104e-08
the O 0 3.539941673125213e-08
GT O 0 9.811064046516549e-06
/ O 0 5.959703412372619e-05
AG O 0 0.004296710714697838
rule O 0 2.4848557131917914e-06
. O 0 1.1500520713525475e-06

An O 0 2.9692924385926744e-07
analysis O 0 7.900670340177385e-08
of O 0 4.7496651056633254e-09
the O 0 1.555511808248866e-08
putative O 0 1.5705212490502163e-06
promoter O 0 2.408784212093451e-06
region O 0 1.1294307711295914e-07
sequence O 0 7.269157009659466e-08
shows O 0 1.0855374910079263e-07
a O 0 5.89461919275891e-08
putative O 0 2.4656642381160054e-06
TATA O 0 2.442581035211333e-06
box O 0 6.060982400413195e-07
and O 0 5.700503891148401e-08
predicts O 0 2.9295426884345943e-07
multiple O 0 3.547640758938542e-08
transcription O 0 2.943331764981849e-07
factor O 0 7.317441230725308e-08
binding O 0 1.4303932971415634e-07
sites O 0 3.532617540713545e-07
. O 0 5.825739322062873e-07

The O 0 7.314559411497612e-07
genomic O 0 1.3474902971211122e-06
structure O 0 3.231257892366557e-07
was O 0 2.3063927301336662e-07
determined O 0 1.0868153488274856e-08
using O 0 4.844877832255179e-09
DNA O 0 4.676628506672387e-08
from O 0 8.46331449366744e-10
several O 0 7.380341893181708e-10
sources O 0 4.74182415555191e-10
including O 0 1.7898520165982035e-10
multiple O 0 4.1314476284526336e-09
large O 0 1.2375156899224748e-08
- O 0 5.157386567589128e-06
insert O 0 4.627371708920691e-06
libaries O 0 2.0669062905653846e-06
and O 0 7.39418171136208e-09
genomic O 0 2.2726588611021725e-07
DNA O 0 3.8407171132348594e-07
from O 0 4.644883588866833e-08
Finnish O 0 0.00013571372255682945
CLD B-Disease 0 0.010019637644290924
patients O 0 1.7961518778975005e-06
and O 0 8.272995444258413e-08
controls O 0 5.469657480716705e-06
. O 0 1.3614122735816636e-06

Exon O 0 6.960402970435098e-05
- O 0 1.0038141226687003e-05
specific O 0 7.551162184427085e-08
primers O 0 1.2345108189038e-06
developed O 0 7.942204405253506e-08
in O 0 1.8401151713476338e-09
this O 0 5.932737634495311e-10
study O 0 1.7326454715416162e-09
will O 0 5.201223340911554e-10
facilitate O 0 6.383588324609946e-09
mutation O 0 6.131023866373653e-08
screening O 0 1.362605139831885e-08
studies O 0 4.5466994613718725e-09
of O 0 2.777863050695828e-09
patients O 0 5.406751668601828e-08
with O 0 1.4654323976515116e-08
the O 0 1.2257287380634807e-06
disease O 0 0.0001003770885290578
. O 0 9.090283015211753e-07

Genomic O 0 4.5419779780786484e-05
sequencing O 0 3.253460818086751e-06
of O 0 1.0174055375955504e-07
a O 0 4.9319447725793e-07
BAC O 0 5.984916060697287e-05
clone O 0 0.00018629875557962805
H O 1 0.9999940395355225
_ O 0 2.0159312441592192e-07
RG364P16 O 0 9.040726354214712e-07
revealed O 0 1.4980774665218632e-07
the O 0 2.3580994934491173e-09
presence O 0 4.758651694913851e-09
of O 0 6.420792231232042e-10
another O 0 6.22191942412087e-09
, O 0 2.533526721748558e-09
highly O 0 3.934878201050651e-09
homologous O 0 3.2347568179602604e-08
gene O 0 4.132608211193656e-08
3 O 0 1.719005382483374e-08
of O 0 1.1544901701299182e-09
the O 0 2.8948536012762816e-08
CLD B-Disease 0 5.273780334391631e-05
gene O 0 8.357162784022876e-08
, O 0 2.2647361763716845e-09
with O 0 9.363463338019073e-10
a O 0 5.326571184127715e-09
similar O 0 9.044865301177651e-09
genomic O 0 6.828310716855412e-08
structure O 0 5.891876853070244e-08
, O 0 3.788569458151869e-09
recently O 0 8.69209699772e-08
identified O 0 3.6031639893963074e-08
as O 0 3.203993159672791e-08
the O 0 4.417462150740903e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 2.8725791707984172e-05
( O 0 2.792465920720133e-07
PDS B-Disease 0 1.9089700799668208e-05
) O 0 4.510355466891269e-08
. O 0 3.8698946269732915e-08
. O 0 4.7437782768611214e-07

The O 0 3.135445467705722e-06
APCI1307K O 0 0.00017268511874135584
allele O 0 3.801258935709484e-05
and O 0 1.2634066024475032e-06
cancer B-Disease 0 2.2585341866943054e-05
risk O 0 9.62189758979548e-08
in O 0 3.132823112039773e-09
a O 0 2.8923810901915203e-08
community O 0 1.739752875096201e-08
- O 0 1.1699455626512645e-06
based O 0 2.620755346072201e-08
study O 0 6.491552628773434e-09
of O 0 8.08935229912322e-09
Ashkenazi O 0 1.3447659512166865e-05
Jews O 0 5.798672191303922e-07
. O 0 2.38688102172091e-07

Mutations O 0 0.002038127277046442
in O 0 5.31046509877342e-07
APC O 0 7.980811460583936e-06
are O 0 7.946780300471801e-08
classically O 0 0.00012783752754330635
associated O 0 6.152206424303586e-06
with O 0 8.066761074587703e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 4.503188029048033e-05
FAP B-Disease 0 5.0503789680078626e-05
) O 0 6.934862284424526e-08
, O 0 1.4796694536300947e-08
a O 0 2.4954920263553504e-07
highly O 0 9.20891179703176e-05
penetrant O 1 0.9998886585235596
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 9.683807729743421e-05
by O 0 1.3751693472840998e-07
multiple O 0 0.00015461099974345416
intestinal O 1 0.9512341022491455
polyps B-Disease 0 0.04896923527121544
and O 0 3.7194988067312806e-07
, O 0 1.7248680705961306e-08
without O 0 3.793225733517147e-09
surgical O 0 4.3544605432543904e-07
intervention O 0 5.0271179219407713e-08
, O 0 1.895791079675746e-09
the O 0 2.2658466214409145e-09
development O 0 4.444894585731163e-08
of O 0 2.3900751330074854e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.3859122393332655e-06
CRC B-Disease 0 8.432170579908416e-05
) O 0 2.86681512307041e-07
. O 0 6.388864903783542e-07

APC B-Disease 0 0.00029288404039107263
is O 0 1.3178307654015953e-06
a O 0 2.3440054519596742e-06
tumour O 1 0.9999983310699463
- O 0 0.00010263216245220974
suppressor O 0 6.567116361111403e-05
gene O 0 1.0590141528155073e-06
, O 0 3.051189878533478e-08
and O 0 4.3886714706786734e-08
somatic O 0 3.037886017409619e-06
loss O 0 3.4064639748976333e-06
occurs O 0 5.773279099230422e-07
in O 0 1.9109797904093284e-06
tumours B-Disease 1 1.0
. O 0 8.028200682019815e-06

The O 0 3.214207936252933e-06
germline O 0 6.316789949778467e-05
T O 0 2.7193835194339044e-05
- O 0 9.860813179329853e-07
to O 0 1.3439384716207314e-08
- O 0 6.281507012317888e-07
A O 0 8.247111082937408e-08
transversion O 0 4.451351287571015e-07
responsible O 0 1.2549770112002534e-08
for O 0 7.069556606786875e-10
the O 0 5.47971357178767e-09
APC O 0 2.9555789637925045e-07
I1307K O 0 2.520575037578965e-07
allele O 0 8.222858838280445e-08
converts O 0 1.2849315389473759e-08
the O 0 1.1351182216401412e-09
wild O 0 2.2356855922112118e-08
- O 0 3.13293270437498e-07
type O 0 1.4985168661496573e-08
sequence O 0 1.5738805814180523e-08
to O 0 2.5779143264514914e-09
a O 0 2.4931037501119135e-07
homopolymer O 0 0.015221880748867989
tract O 0 0.0016651690239086747
( O 0 7.662033141286884e-08
A8 O 0 3.528793968143873e-05
) O 0 1.8539894952596114e-08
that O 0 3.1470588357507268e-09
is O 0 7.086949249668351e-09
genetically O 0 7.798337833264668e-07
unstable O 0 0.00027285871328786016
and O 0 2.8396207198966295e-06
prone O 0 3.657251363620162e-05
to O 0 6.140503217011428e-08
somatic O 0 8.546784556529019e-06
mutation O 0 1.4055811334401369e-05
. O 0 6.939638410585758e-07

The O 0 3.490946028250619e-06
I1307K O 0 2.730601954681333e-05
allele O 0 1.4158243175188545e-05
was O 0 1.2771233741659671e-06
found O 0 6.144111353023618e-08
in O 0 4.365004357964608e-08
6 O 0 7.97876396063657e-07
. O 0 1.054814902090584e-06

1 O 0 1.1044376151403412e-05
% O 0 2.8797433060390176e-07
of O 0 1.0067937594726573e-08
unselected O 0 1.1197926141903736e-05
Ashkenazi O 0 3.726981594809331e-05
Jews O 0 3.4209764976367296e-07
and O 0 1.5891561844227908e-08
higher O 0 1.421137074686385e-08
proportions O 0 4.7630489774519447e-08
of O 0 2.232480200703435e-09
Ashkenazim O 0 1.2942311968799913e-06
with O 0 1.1226948259945857e-08
family O 0 1.9426869357630494e-07
or O 0 1.2668069260257653e-08
personal O 0 4.6019728472401766e-08
histories O 0 2.7282183623356104e-07
of O 0 2.2707626001761128e-08
CRC B-Disease 0 8.782208169577643e-05
( O 0 4.816006082819513e-08
ref O 0 2.060529550362844e-05
. O 0 1.684692918502151e-08
2 O 0 1.2955929662439303e-07
) O 0 7.503582111212381e-08
. O 0 3.116061293439998e-07

To O 0 6.239403091967688e-07
evaluate O 0 3.696467558711447e-07
the O 0 1.411312755550398e-08
role O 0 4.1005890238920983e-08
of O 0 7.663229162346852e-09
I1307K O 0 7.928700824777479e-07
in O 0 3.420313632318539e-08
cancer B-Disease 0 1.5844609606574522e-06
, O 0 8.325593547908738e-09
we O 0 1.899404189487086e-08
genotyped O 0 4.623608163001336e-07
5 O 0 4.349620752464034e-08
, O 0 1.4455639352206617e-08
081 O 0 1.9200699625798734e-06
Ashkenazi O 0 1.6519400105607929e-06
volunteers O 0 5.058695862203422e-08
in O 0 2.4101738382853455e-09
a O 0 2.599353798871107e-08
community O 0 1.0948968309776319e-07
survey O 0 8.19466720258788e-07
. O 0 2.3248301772582636e-07

Risk O 0 4.115454794373363e-05
of O 0 3.143809124139807e-07
developing O 0 8.234980668930802e-06
colorectal B-Disease 1 1.0
, I-Disease 0 3.4857564514823025e-06
breast I-Disease 0 0.02059343084692955
and I-Disease 0 4.4254971953705535e-07
other I-Disease 0 6.16217334936664e-08
cancers I-Disease 0 0.002061723731458187
were O 0 1.2698120599452523e-07
compared O 0 2.6518199192082648e-08
between O 0 1.6126184831932733e-08
genotyped O 0 2.1058858692413196e-06
I1307K O 0 4.4491446260508383e-07
carriers O 0 1.5779203721422164e-08
and O 0 1.3818992616876358e-09
non O 0 5.025821536719377e-09
- O 0 4.778636935043323e-07
carriers O 0 1.68197651362334e-08
and O 0 1.5282348719836136e-09
their O 0 1.2163068330295346e-09
first O 0 2.543662169784966e-08
- O 0 5.0200560508528724e-06
degree O 0 1.8442909777149907e-07
relatives O 0 3.8803611346338585e-07
. O 0 2.0229184372055897e-07

Sperm O 0 4.5066335587762296e-05
DNA O 0 3.998648026026785e-06
analysis O 0 2.0150029911292222e-07
in O 0 5.5751684158167336e-08
a O 0 1.6494134342792677e-06
Friedreich B-Disease 1 0.9817093014717102
ataxia I-Disease 1 0.9982349872589111
premutation O 0 0.0003990825789514929
carrier O 0 5.737181709264405e-06
suggests O 0 1.2449285691218392e-07
both O 0 8.86591333681963e-09
meiotic O 0 1.4394964864550275e-06
and O 0 2.1739094080430732e-08
mitotic O 0 2.860143695215811e-07
expansion O 0 3.3952371580880936e-08
in O 0 9.321804661510669e-09
the O 0 4.1361570168874096e-08
FRDA B-Disease 0 3.352893691044301e-05
gene O 0 3.919060418411391e-06
. O 0 9.85240149020683e-07

Friedreich B-Disease 1 0.9998916387557983
ataxia I-Disease 1 0.9999922513961792
is O 0 0.00014980710693635046
usually O 0 1.4325327356345952e-05
caused O 0 4.1125423422272434e-07
by O 0 2.486093109155263e-09
an O 0 2.689215072848583e-09
expansion O 0 2.3958659056688703e-08
of O 0 3.540345128172362e-09
a O 0 5.600309123110492e-07
GAA O 0 1.7249558368348517e-05
trinucleotide O 0 9.559548743709456e-06
repeat O 0 6.051175773791329e-07
in O 0 1.9702818931932597e-08
intron O 0 1.1570848982955795e-05
1 O 0 1.1281368017534987e-07
of O 0 1.313672726155346e-08
the O 0 8.37711127132934e-08
FRDA B-Disease 0 8.640566375106573e-05
gene O 0 4.176670245215064e-06
. O 0 1.0165244930249173e-06

Occasionally O 0 3.419190761633217e-05
, O 0 5.3722533976952036e-08
a O 0 1.909815594558495e-08
fully O 0 1.8326485218267408e-08
expanded O 0 1.8075736463174508e-08
allele O 0 1.5595438185300736e-07
has O 0 3.9200028112418295e-08
been O 0 2.4614553950641493e-08
found O 0 5.603373320894889e-09
to O 0 3.928031677702393e-09
arise O 0 2.9141919988262543e-09
from O 0 3.9459244205453103e-10
a O 0 4.78312056628738e-09
premutation O 0 1.932621529476819e-07
of O 0 2.159761480768907e-09
100 O 0 1.5552359400317073e-08
or O 0 1.919207548439772e-08
less O 0 9.153058044830686e-08
triplet O 0 0.0001943772949744016
repeats O 0 5.3732892411062494e-05
. O 0 1.5480997035410837e-06

We O 0 6.460689746745629e-06
have O 0 7.351491149165668e-08
examined O 0 1.2563330642478832e-07
the O 0 5.2214637058511926e-09
sperm O 0 6.951721331915905e-08
DNA O 0 3.386951874517763e-08
of O 0 3.1333551309131735e-09
a O 0 1.2068147725585732e-07
premutation O 0 3.650122744147666e-05
carrier O 0 3.7568593143078033e-06
. O 0 5.009172241443594e-07

This O 0 5.765751893704874e-07
mans O 0 7.108271347533446e-06
leucocyte O 0 5.869001597602619e-06
DNA O 0 1.3047005040789372e-06
showed O 0 5.882292271053302e-07
one O 0 1.275394279076636e-08
normal O 0 1.3968171685974085e-07
allele O 0 3.0896012503944803e-07
and O 0 1.423983331250156e-08
one O 0 9.974680637014899e-09
allele O 0 5.5125912723497095e-08
of O 0 2.3745643229489133e-09
approximately O 0 3.523122416027036e-08
100 O 0 5.845579664764955e-08
repeats O 0 3.942350758734392e-06
. O 0 6.878033786961169e-07

His O 0 8.088573849818204e-06
sperm O 0 9.25886160985101e-06
showed O 0 5.406884611147689e-07
an O 0 3.6166438732720962e-09
expanded O 0 2.8635954052447232e-08
allele O 0 2.2724725567968562e-07
in O 0 6.086245285530367e-09
a O 0 3.547586402419256e-08
tight O 0 8.238388545578346e-06
range O 0 2.333922566322144e-07
centering O 0 2.0322792693150404e-07
on O 0 3.849936192068526e-08
a O 0 4.936591135873414e-09
size O 0 2.1002083627763568e-08
of O 0 5.043163220364022e-09
approximately O 0 4.438489753511021e-08
320 O 0 5.496626158674189e-07
trinucleotide O 0 3.293794725323096e-05
repeats O 0 1.9791968952631578e-05
. O 0 1.3689766547031468e-06

His O 0 0.00010244570148643106
affected O 0 1.3513405065168627e-05
son O 0 5.435852290247567e-05
has O 0 1.9696868491791975e-07
repeat O 0 2.6930771923616703e-07
sizes O 0 2.832518646300741e-07
of O 0 1.5159294264321943e-08
1040 O 0 2.0160114218015224e-06
and O 0 7.822234238119563e-08
540 O 0 1.5793739294167608e-06
. O 0 2.803772360948642e-07

These O 0 1.812951921920103e-07
data O 0 5.481263087858679e-08
suggest O 0 2.0267082234681766e-08
that O 0 6.613942171718179e-10
expansion O 0 6.9882108988394975e-09
occurs O 0 1.7107650851500011e-09
in O 0 1.0297687147442502e-09
two O 0 1.0489006108116428e-08
stages O 0 3.389169194178976e-07
, O 0 2.8569544507917044e-09
the O 0 9.759701935507792e-10
first O 0 1.1591485105100219e-08
during O 0 2.018926359426132e-08
meiosis O 0 3.1791866916819345e-08
followed O 0 2.0941321565715043e-08
by O 0 7.305455684836204e-10
a O 0 6.479701664119375e-09
second O 0 7.915240729516881e-08
mitotic O 0 2.1055625438748393e-06
expansion O 0 1.2348723430477548e-06
. O 0 1.0068399660667637e-06

We O 0 2.034918543358799e-05
also O 0 4.4238305463295546e-07
show O 0 4.102983837128704e-07
that O 0 2.685483835307423e-09
in O 0 1.3695978795524866e-09
all O 0 1.632853297017789e-09
informative O 0 6.027583765444433e-08
carrier O 0 1.4915283941263624e-07
father O 0 4.589876212435229e-08
to O 0 2.329995529848361e-09
affected O 0 8.568375342576928e-09
child O 0 5.628580623806556e-08
transmissions O 0 2.730006372075877e-07
, O 0 1.906273583429652e-09
with O 0 9.299956360564465e-10
the O 0 5.009360481977865e-09
notable O 0 1.3543782984015706e-08
exception O 0 2.8460607204294774e-09
of O 0 5.680505510419209e-10
the O 0 9.758664099024372e-09
premutation O 0 2.416040388197871e-06
carrier O 0 1.2611697286502022e-07
, O 0 1.0309793019303015e-09
the O 0 7.411460889450439e-10
expansion O 0 1.6706549033074225e-08
size O 0 8.527375428002415e-08
decreases O 0 7.690040320085245e-07
. O 0 2.648514119130141e-08
. O 0 1.2879574740054522e-07

The O 0 1.3882186067348812e-06
R496H O 0 1.4908153389114887e-05
mutation O 0 3.0237083592510317e-06
of O 0 2.4193500536284773e-08
arylsulfatase O 0 4.34362073065131e-06
A O 0 1.5363159491244005e-06
does O 0 5.772221811639611e-07
not O 0 2.8700566190309473e-07
cause O 0 2.6180776330875233e-05
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999997615814209
. O 0 1.2178137694718316e-05

Deficiency B-Disease 1 0.9989187717437744
of I-Disease 0 7.91049899362406e-07
arylsulfatase I-Disease 0 0.00013000876060687006
A I-Disease 0 5.005599177820841e-06
( O 0 1.1003617146343458e-06
ARSA O 0 0.00028509742696769536
) O 0 1.900450286029809e-07
enzyme O 0 1.8145188960261294e-06
activity O 0 7.166947398218326e-06
causes O 0 9.561137267155573e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 8.511575288139284e-05
MLD B-Disease 1 0.9999995231628418
) O 0 1.6877953612493002e-06
. O 0 1.1019652674804092e-06

A O 0 5.111748578201514e-06
number O 0 1.1489137818898598e-07
of O 0 4.492025951208234e-08
ARSA O 0 0.0007333886460401118
gene O 0 6.7100995693181176e-06
mutations O 0 3.94679727833136e-06
responsible O 0 2.1365072200296709e-07
for O 0 1.7040321154127014e-07
MLD B-Disease 1 1.0
have O 0 4.233716481394367e-06
been O 0 6.910988190611533e-07
identified O 0 1.7851986058303737e-06
. O 0 3.047581458304194e-07

Recently O 0 2.9921695386292413e-05
, O 0 9.674658230096611e-08
the O 0 2.1465591970581954e-08
R496H O 0 1.3574723425335833e-06
mutation O 0 1.9889347413482028e-07
of O 0 6.5500080914659975e-09
ARSA O 0 0.00015271866868715733
was O 0 7.70605936395441e-07
proposed O 0 4.703274658623968e-09
to O 0 3.3229932139278162e-09
be O 0 5.05261832373094e-09
a O 0 4.03609874410904e-08
cause O 0 2.2512020336762362e-07
of O 0 9.465734507330126e-08
MLD B-Disease 1 0.9999998807907104
( O 0 1.8840752602500288e-07
Draghia O 0 1.0114737960975617e-05
et O 0 4.173910838289885e-06
al O 0 2.5724693841766566e-06
. O 0 3.856896313436664e-08
, O 0 2.3600444265525766e-08
1997 O 0 5.289176030487397e-08
) O 0 4.210477300148341e-08
. O 0 2.592316548089002e-07

We O 0 2.5704875952214934e-06
have O 0 5.623033061397109e-08
investigated O 0 5.735764219139128e-08
the O 0 8.270073514893284e-09
R496H O 0 9.929258339980152e-07
mutation O 0 1.2462066933949245e-07
and O 0 4.620088311924064e-09
found O 0 5.4760569412337645e-09
this O 0 1.4826576633097943e-09
mutation O 0 3.598541908900188e-08
at O 0 3.195587572335512e-09
a O 0 5.000568847890463e-09
relatively O 0 2.940776067106299e-09
high O 0 1.0428820473862288e-08
frequency O 0 3.643461354840838e-08
in O 0 1.2733907261974764e-09
an O 0 9.039134440946839e-10
African O 0 3.5056924030385517e-09
American O 0 5.0726258749023145e-09
population O 0 1.9015420349433043e-09
( O 0 1.817089145816908e-09
f O 0 6.838086363814e-08
= O 0 7.58893321517462e-08
0 O 0 9.36089517011851e-09
. O 0 1.528491555546907e-09
09 O 0 2.886550376501873e-08
, O 0 5.181146622845745e-09
n O 0 5.92783976571809e-07
= O 0 1.055161988006148e-06
61 O 0 3.015988170318451e-07
subjects O 0 8.873835355416304e-08
) O 0 6.893413484476696e-08
. O 0 2.508733132344787e-07

The O 0 2.6872430680668913e-06
ARSA O 0 0.00019727734616026282
enzyme O 0 1.0554891787251108e-06
activity O 0 2.3465770482289372e-07
in O 0 8.09299471882241e-09
subjects O 0 2.6204252989714405e-08
with O 0 6.5423160222621846e-09
and O 0 3.631486578115073e-08
without O 0 5.221882481976081e-09
the O 0 3.1694071811472213e-09
R496H O 0 4.3063363364126417e-07
mutation O 0 1.8096888254603982e-07
was O 0 2.4105457896439475e-07
determined O 0 3.0815968443675956e-08
and O 0 1.5017359800140184e-08
found O 0 1.1276673816951188e-08
to O 0 8.200145451553453e-09
be O 0 3.886145094611493e-08
normal O 0 3.2265432992062415e-07
. O 0 3.0299528930299857e-07

It O 0 2.6149489258386893e-06
is O 0 6.538002850220437e-08
therefore O 0 1.1449101222638092e-08
concluded O 0 1.1837524738211869e-08
that O 0 1.1571246183450512e-09
the O 0 3.4213363253599027e-09
R496H O 0 9.69875600276282e-07
mutation O 0 7.620525366291986e-08
of O 0 3.531402503753611e-09
ARSA O 0 7.364166231127456e-05
does O 0 3.54223814724719e-08
not O 0 4.167044931335795e-09
negatively O 0 1.262205184815457e-08
influence O 0 1.0791436189094838e-08
the O 0 2.670976106955436e-09
activity O 0 1.865610421702968e-08
of O 0 3.680140636674878e-09
ARSA O 0 0.0001380736066494137
and O 0 1.6432431948487647e-07
is O 0 6.910867433873591e-09
not O 0 3.484446731150115e-09
a O 0 7.829444115259321e-08
cause O 0 1.6178918258447084e-06
of O 0 1.5805009070390952e-06
MLD B-Disease 1 0.9999995231628418

Down O 0 0.0003299708478152752
- O 0 2.4683891751919873e-05
regulation O 0 1.5170479628068279e-06
of O 0 5.194250007889423e-08
transmembrane O 0 4.781016286869999e-06
carbonic O 0 1.1177856322319712e-05
anhydrases O 0 2.5597493731766008e-05
in O 0 1.745062377267459e-06
renal B-Disease 1 0.9984935522079468
cell I-Disease 1 0.9989159107208252
carcinoma I-Disease 1 1.0
cell O 0 0.00929215271025896
lines O 0 4.563181573757902e-05
by O 0 1.2256273329569467e-08
wild O 0 3.5269249565317295e-07
- O 0 7.481125794583932e-05
type O 0 4.479868493945105e-06
von B-Disease 1 0.7803692817687988
Hippel I-Disease 1 0.7309118509292603
- I-Disease 0 0.019412491470575333
Lindau I-Disease 0 0.0027185173239558935
transgenes O 0 0.00019313895609229803
. O 0 3.5246457628090866e-06

To O 0 1.7131812910520239e-06
discover O 0 4.343794898886699e-06
genes O 0 1.6410301668656757e-06
involved O 0 2.241788337187245e-07
in O 0 2.3705612761659722e-07
von B-Disease 1 0.9953625202178955
Hippel I-Disease 1 0.9999309778213501
- I-Disease 1 0.9998078942298889
Lindau I-Disease 1 0.99781334400177
( O 0 6.319221483863657e-07
VHL B-Disease 0 2.8588352506631054e-05
) O 0 6.90346624310223e-08
- O 0 9.065783160622232e-06
mediated O 0 3.6532743251882493e-05
carcinogenesis O 0 0.00015824084402993321
, O 0 8.11055258509441e-08
we O 0 7.152596737114436e-08
used O 0 3.039421926587238e-06
renal B-Disease 1 0.9883918166160583
cell I-Disease 1 0.9966501593589783
carcinoma I-Disease 1 1.0
cell O 0 0.010709630325436592
lines O 0 0.000234351129620336
stably O 0 2.446279177092947e-05
transfected O 0 1.3919880984758493e-05
with O 0 6.733252178037219e-08
wild O 0 2.3525130927737337e-06
- O 0 0.0006628799019381404
type O 0 9.015610885398928e-06
VHL O 0 0.0006109121604822576
- O 0 0.0011584825115278363
expressing O 0 6.376475539582316e-06
transgenes O 0 0.00016788419452495873
. O 0 3.965234554925701e-06

Large O 0 1.5196457070487668e-06
- O 0 2.0585164293152047e-06
scale O 0 3.0155911190377083e-07
RNA O 0 1.900886985595207e-07
differential O 0 8.09861901984732e-08
display O 0 3.28900746637828e-08
technology O 0 1.4155426164563778e-08
applied O 0 5.0526662853656035e-09
to O 0 1.70075753480603e-09
these O 0 1.1989924608712954e-09
cell O 0 2.953674140826479e-07
lines O 0 7.744310437374224e-07
identified O 0 3.855211971881545e-08
several O 0 3.38786110276601e-09
differentially O 0 3.588627635053854e-07
expressed O 0 7.777867239155967e-09
genes O 0 2.962000067441295e-08
, O 0 1.4172519824384722e-09
including O 0 9.859576488580046e-10
an O 0 7.763268250471356e-09
alpha O 0 4.7277046633098507e-07
carbonic O 0 3.9284941522055306e-06
anhydrase O 0 2.2945619093661662e-06
gene O 0 4.135132485316717e-07
, O 0 8.14944414173624e-08
termed O 0 4.7849393922660965e-06
CA12 O 0 0.00016046945529524237
. O 0 1.274943883800006e-06

The O 0 6.60338457691978e-07
deduced O 0 9.818315902521135e-07
protein O 0 2.9987938887643395e-07
sequence O 0 2.524460285258101e-07
was O 0 3.777968231588602e-07
classified O 0 1.0849636744580948e-08
as O 0 3.1816418388785905e-09
a O 0 1.0473872436023157e-08
one O 0 3.75091637749847e-08
- O 0 1.3541656699089799e-05
pass O 0 1.2781456462107599e-06
transmembrane O 0 3.466871874024946e-07
CA O 0 1.825173541192271e-07
possessing O 0 8.737920609291905e-09
an O 0 2.985975910974048e-09
apparently O 0 5.029597787142848e-07
intact O 0 5.627754262604867e-08
catalytic O 0 7.294281800795943e-08
domain O 0 2.7380545830624214e-08
in O 0 8.426208175649208e-09
the O 0 2.0830098534929675e-08
extracellular O 0 1.6921921996981837e-06
CA O 0 2.8520551495603286e-05
module O 0 8.70828444021754e-06
. O 0 1.3254992836664314e-06

Reintroduced O 0 5.181160304346122e-05
wild O 0 8.167497981048655e-06
- O 0 5.1905914006056264e-05
type O 0 1.961956968443701e-06
VHL B-Disease 0 5.652078107232228e-05
strongly O 0 8.291144126815198e-07
inhibited O 0 4.384462783946219e-07
the O 0 9.111633225700189e-09
overexpression O 0 2.7185123485651275e-07
of O 0 2.4415720556447695e-09
the O 0 1.8156487868736804e-08
CA12 O 0 5.706884621758945e-06
gene O 0 8.84018334090797e-08
in O 0 1.9716576815653752e-08
the O 0 1.2487026879171026e-07
parental O 0 0.009085144847631454
renal B-Disease 1 0.9999614953994751
cell I-Disease 1 0.9999510049819946
carcinoma I-Disease 1 1.0
cell O 0 0.1137813851237297
lines O 0 0.0067360252141952515
. O 0 1.9016971464225207e-06

Similar O 0 8.934888683143072e-06
results O 0 1.8817800082615577e-06
were O 0 1.140033774049698e-07
obtained O 0 1.2749856281857319e-08
with O 0 1.7675240826520167e-08
CA9 O 0 9.077313006855547e-05
, O 0 1.658131232318283e-08
encoding O 0 5.288076820875176e-08
another O 0 6.392387490450346e-07
transmembrane O 0 3.5512669001036556e-06
CA O 0 1.6657221522109467e-06
with O 0 4.198414060851974e-09
an O 0 1.5184586033001324e-08
intact O 0 7.504089012400073e-07
catalytic O 0 1.4329684745462146e-06
domain O 0 1.3205734603616293e-06
. O 0 4.5319569608182064e-07

Although O 0 1.2470858337110258e-06
both O 0 2.3049341990599714e-08
domains O 0 5.721472717823417e-08
of O 0 3.5234901663017126e-09
the O 0 1.8110418054106958e-08
VHL B-Disease 0 4.790993898495799e-06
protein O 0 6.302159505366944e-08
contribute O 0 7.116587319444534e-09
to O 0 1.8276209434731072e-09
regulation O 0 1.9546655849467243e-08
of O 0 2.1697328378422753e-09
CA12 O 0 1.2873380910605192e-05
expression O 0 3.597032005586698e-08
, O 0 6.555253562190444e-10
the O 0 1.4038484819067776e-09
elongin O 0 1.5227473681989068e-07
binding O 0 2.4080154759076322e-08
domain O 0 5.3742621020091974e-08
alone O 0 7.653853373312813e-08
could O 0 4.144677845374645e-08
effectively O 0 2.9515229016396916e-07
regulate O 0 1.1197648746019695e-06
CA9 O 0 0.0001335276901954785
expression O 0 1.8278575453223311e-06
. O 0 7.612765671183297e-07

We O 0 1.7364565792377107e-05
mapped O 0 4.724414975498803e-05
CA12 O 0 0.00016390155360568315
and O 0 1.0135913726116996e-06
CA9 O 0 0.0002524646115489304
loci O 0 7.093989097484155e-06
to O 0 1.456361786722482e-07
chromosome O 0 3.5680466680787504e-05
bands O 0 3.8032510474295123e-06
15q22 O 0 5.034453351981938e-06
and O 0 1.400175477783705e-07
17q21 O 0 1.48570152305183e-05
. O 0 5.045215516474855e-07

2 O 0 4.493853703024797e-05
respectively O 0 3.486999730739626e-06
, O 0 3.9607371604688524e-08
regions O 0 2.3889032263468835e-07
prone O 0 4.268419615982566e-06
to O 0 1.3464734216483976e-08
amplification O 0 1.0678901389837847e-06
in O 0 1.2235952695505148e-08
some O 0 1.6069810371277526e-08
human O 0 1.3439560007100226e-06
cancers B-Disease 0 0.0017393020680174232
. O 0 6.305310193965852e-07

Additional O 0 1.1636518593149958e-06
experiments O 0 6.147827775748738e-07
are O 0 8.273575602402161e-09
needed O 0 1.2362960433165426e-08
to O 0 2.064722393058105e-09
define O 0 2.2412402600480164e-08
the O 0 3.1995641691651144e-09
role O 0 1.0487885226950766e-08
of O 0 1.3344161331474425e-08
CA O 0 2.859076630556956e-06
IX O 0 4.3547443056013435e-06
and O 0 1.1105000794486841e-06
CA O 0 1.583057837706292e-06
XII O 0 4.815289571524772e-07
enzymes O 0 1.7666545559791302e-08
in O 0 1.1767889995795144e-09
the O 0 2.0087427277104553e-09
regulation O 0 1.8016841352164192e-08
of O 0 1.249266134983884e-09
pH O 0 2.5202604092555703e-07
in O 0 1.0556154839136411e-09
the O 0 2.0686445889595007e-09
extracellular O 0 4.052877500271279e-08
microenvironment O 0 1.3017971696172026e-06
and O 0 1.2652711767202618e-08
its O 0 2.9569182657951387e-09
potential O 0 5.5034270474152436e-09
impact O 0 2.4280778276875026e-08
on O 0 1.0921130524366163e-06
cancer B-Disease 0 8.441221325483639e-06
cell O 0 3.8184280128916726e-06
growth O 0 5.210463882576732e-07
. O 0 2.6728790203378594e-07

A O 0 3.5460245726426365e-06
gene O 0 3.427318915782962e-06
encoding O 0 9.328430223831674e-07
a O 0 3.296569559552154e-07
transmembrane O 0 1.7263611198359285e-06
protein O 0 2.98792059538755e-07
is O 0 1.033196461719399e-08
mutated O 0 1.001737928163493e-06
in O 0 2.943140771094477e-07
patients O 0 4.5924557525722776e-06
with O 0 6.737987860105932e-05
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9294470548629761
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999827146530151
( O 0 0.00046247593127191067
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 3.423333509999793e-06
. O 0 2.091638862111722e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0004834307183045894
WFS B-Disease 0 0.027499493211507797
; O 0 2.9687151254620403e-05
OMIM O 0 0.004091647453606129
222300 O 0 3.760326580959372e-05
) O 0 1.5251337970312306e-07
is O 0 3.814704285787229e-08
an O 0 5.51077221189189e-07
autosomal B-Disease 1 0.9999986886978149
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999374151229858
defined O 0 3.167021077388199e-06
by O 0 1.0377986825460539e-07
young O 0 6.635289082623785e-07
- O 0 4.747823913930915e-05
onset O 0 5.8034678659169e-05
non O 0 4.2176870351795515e-07
- O 0 0.00010413533891551197
immune O 0 1.5312727555283345e-05
insulin B-Disease 0 0.000224602161324583
- I-Disease 0 0.09552880376577377
dependent I-Disease 0 0.00698326388373971
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.002226414391770959
progressive O 0 0.11630422621965408
optic B-Disease 1 0.9999905824661255
atrophy I-Disease 0 0.008619319647550583
. O 0 4.049836206831969e-06

Linkage O 0 7.802489562891424e-05
to O 0 2.900464437516348e-07
markers O 0 9.583957762515638e-06
on O 0 2.678288637980586e-06
chromosome O 0 0.0006185055244714022
4p O 0 0.026345673948526382
was O 0 1.137997332989471e-05
confirmed O 0 2.0144226198226534e-07
in O 0 1.34667370588204e-08
five O 0 1.2673596927470498e-07
families O 0 3.5677643950293714e-07
. O 0 5.224126766734116e-07

On O 0 1.5686981669205124e-06
the O 0 2.0911546272373016e-08
basis O 0 1.5938370623302944e-08
of O 0 7.234808752087929e-09
meiotic O 0 5.364836397347972e-05
recombinants O 0 0.0003587090759538114
and O 0 3.4431095627951436e-06
disease O 0 1.3177528671803884e-05
- O 0 6.610210675717099e-06
associated O 0 2.1105130088017177e-07
haplotypes O 0 3.825995008810423e-06
, O 0 2.0074722328899952e-08
the O 0 2.781109031957385e-08
WFS B-Disease 0 2.3505050194216892e-05
gene O 0 2.8734854140566313e-07
was O 0 4.265646396106604e-07
localized O 0 3.023178862804343e-07
to O 0 1.3354752859129349e-08
a O 0 2.9496007414309133e-07
BAC O 0 4.1131515899905935e-05
/ O 0 4.161982360528782e-06
P1 O 0 3.752624024855322e-06
contig O 0 1.2246549658812e-06
of O 0 3.1582676474073423e-09
less O 0 8.796632755547762e-09
than O 0 7.081490061011664e-09
250 O 0 5.715549633578121e-08
kb O 0 1.6212439732044004e-05
. O 0 6.447797886721673e-07

Mutations O 0 0.0006551585393026471
in O 0 1.598004786274032e-07
a O 0 6.753020187488801e-08
novel O 0 6.322380272649752e-07
gene O 0 1.8688033378566615e-06
( O 0 7.187237116568213e-08
WFS1 O 0 2.1769005797978025e-06
) O 0 4.707851886109893e-09
encoding O 0 1.3751006555651202e-08
a O 0 2.3669597837283618e-08
putative O 0 7.305823714887083e-07
transmembrane O 0 1.458659539821383e-07
protein O 0 7.12621996967755e-08
were O 0 3.3247189890062145e-08
found O 0 7.612502628262519e-09
in O 0 1.8861285866478283e-09
all O 0 2.5215083354623857e-09
affected O 0 6.430600940632303e-09
individuals O 0 4.989580970615748e-10
in O 0 1.138828698010741e-09
six O 0 1.1014172685008816e-07
WFS B-Disease 0 1.317913756793132e-05
families O 0 2.0016221569107984e-08
, O 0 1.6549046577551962e-09
and O 0 2.6177116030368097e-09
these O 0 1.3204698445790086e-09
mutations O 0 1.5611151127359335e-07
were O 0 2.910227614449923e-08
associated O 0 1.2170825236523797e-08
with O 0 3.019084005018158e-08
the O 0 5.56493250769563e-06
disease O 0 0.005960125010460615
phenotype O 0 0.0002112946385750547
. O 0 1.2410635008563986e-06

WFS1 O 0 0.0013883692445233464
appears O 0 2.0956276785000227e-05
to O 0 1.6071435737785578e-08
function O 0 1.2764894030681262e-08
in O 0 1.0564519925537752e-08
survival O 0 2.8873441237919906e-07
of O 0 5.394305890860096e-09
islet O 0 4.21986214860226e-06
beta O 0 2.4513684593330254e-07
- O 0 1.3474437764671165e-05
cells O 0 7.399743822134042e-07
and O 0 9.423042257594716e-08
neurons O 0 4.1423317043154384e-07
. O 0 2.0690952950985775e-08
. O 0 1.0920791737589752e-07

Stable O 0 6.14917153143324e-05
interaction O 0 9.112138172895357e-07
between O 0 6.121324958030527e-08
the O 0 8.422255781681542e-09
products O 0 3.49921407405418e-08
of O 0 2.1987911491549994e-09
the O 0 4.174070866724833e-08
BRCA1 O 0 0.00010228668543277308
and O 0 3.693261305670603e-06
BRCA2 O 0 0.00038284939364530146
tumor B-Disease 0 1.126725419453578e-05
suppressor O 0 1.0705990462156478e-05
genes O 0 2.526444973227626e-07
in O 0 2.1864636323698505e-08
mitotic O 0 6.907931037858361e-06
and O 0 1.075561840480077e-06
meiotic O 0 0.00030067539773881435
cells O 0 2.0916686480632052e-05
. O 0 1.0013644669015775e-06

BRCA1 O 0 0.0778966173529625
and O 0 1.7997690520132892e-05
BRCA2 O 0 0.0001623723073862493
account O 0 2.804395649036451e-07
for O 0 4.472787473730477e-09
most O 0 2.224832762465212e-09
cases O 0 2.7188706841485555e-09
of O 0 1.5253984742003013e-09
familial O 0 3.1895781376078958e-06
, O 0 2.5243105383765396e-08
early O 0 1.751383251757943e-07
onset O 0 5.935872195550473e-06
breast B-Disease 0 0.000148377672303468
and I-Disease 0 3.8126420349726686e-06
/ I-Disease 0 0.05491345375776291
or I-Disease 0 0.06719451397657394
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
and O 0 4.723018065533324e-08
encode O 0 5.145086490188078e-08
products O 0 8.342001223127227e-08
that O 0 4.074212522908738e-09
each O 0 6.221017478935664e-09
interact O 0 1.6138923086828072e-08
with O 0 3.381007118719026e-08
hRAD51 O 0 1.4482441656582523e-05
. O 0 7.873604772612453e-07

Results O 0 5.546970896830317e-06
presented O 0 2.5540424530845485e-07
here O 0 3.6002578696070486e-08
show O 0 2.380016468350732e-07
that O 0 3.7838770339249095e-08
BRCA1 O 0 2.429653068247717e-05
and O 0 1.45099136261706e-06
BRCA2 O 0 6.374434451572597e-05
coexist O 0 4.624604628133966e-07
in O 0 3.0249849292118824e-09
a O 0 1.0442395392828985e-08
biochemical O 0 2.3700616225141857e-07
complex O 0 3.775846124653981e-08
and O 0 5.784731982316771e-08
colocalize O 0 1.3824848110743915e-06
in O 0 1.5391645291629175e-08
subnuclear O 0 1.597418190613098e-06
foci O 0 8.960350328379718e-07
in O 0 7.093873932717543e-09
somatic O 0 2.1084187551423383e-07
cells O 0 1.17678780497954e-07
and O 0 1.0125016380868601e-08
on O 0 2.9190168504555913e-08
the O 0 5.517079681993664e-09
axial O 0 8.012377605837173e-08
elements O 0 1.4743534393346636e-08
of O 0 6.466133406490826e-09
developing O 0 9.801759404126642e-08
synaptonemal O 0 7.269153684319463e-06
complexes O 0 1.9075714590144344e-06
. O 0 6.252089974623232e-07

Like O 0 3.3617430744925514e-05
BRCA1 O 0 0.0008701870683580637
and O 0 3.3172750590892974e-06
RAD51 O 0 0.0003670227888505906
, O 0 3.6014537840856065e-07
BRCA2 O 0 1.3826027497998439e-05
relocates O 0 3.0495543796860147e-06
to O 0 5.389886226225826e-08
PCNA O 0 1.643769610382151e-05
+ O 0 3.2552316042711027e-07
replication O 0 1.3318992841959698e-07
sites O 0 2.81273813129701e-08
following O 0 1.7519838024782075e-08
exposure O 0 8.095344128378201e-08
of O 0 5.9503970639696036e-09
S O 0 5.023254743719008e-06
phase O 0 2.753793921783654e-07
cells O 0 1.1677635569640188e-07
to O 0 1.7053709555625574e-08
hydroxyurea O 0 1.1763521797547583e-05
or O 0 4.3628654111671494e-07
UV O 0 4.247205288265832e-05
irradiation O 0 4.547327534965007e-06
. O 0 5.698046265933954e-07

Thus O 0 8.637081009510439e-06
, O 0 4.388809600186505e-07
BRCA1 O 0 1.4606888726120815e-05
and O 0 3.6847509932158573e-07
BRCA2 O 0 1.576721842866391e-05
participate O 0 9.871699901964348e-09
, O 0 3.1806104416887138e-09
together O 0 7.414532543492669e-09
, O 0 1.0730799582248096e-09
in O 0 7.882028918437811e-10
a O 0 2.236449070380786e-08
pathway O 0 2.139133243872493e-07
( O 0 3.056804942502822e-08
s O 0 1.7850726408141782e-06
) O 0 3.435060902390319e-09
associated O 0 2.0294150804289757e-09
with O 0 6.348227499231029e-10
the O 0 1.6412933234732918e-09
activation O 0 5.584008810899377e-09
of O 0 7.914296995537029e-10
double O 0 7.394100407509541e-07
- O 0 2.4894003217923455e-05
strand O 0 3.095449574175291e-05
break O 0 3.5401892546360614e-06
repair O 0 7.398455636575818e-06
and O 0 8.257688222101933e-08
/ O 0 7.360456493188394e-07
or O 0 6.32680183798584e-08
homologous O 0 1.5006427247499232e-06
recombination O 0 7.918351002444979e-06
. O 0 9.421187883162929e-07

Dysfunction O 0 0.003894837573170662
of O 0 1.0185958387864957e-07
this O 0 2.0276672785257688e-08
pathway O 0 3.7393164120658184e-07
may O 0 2.704749704207643e-07
be O 0 2.093164974681372e-09
a O 0 9.507056475399622e-09
general O 0 7.368165189092224e-09
phenomenon O 0 4.7559229443550066e-08
in O 0 2.552958955348572e-09
the O 0 4.881675508272565e-09
majority O 0 2.052620518000481e-09
of O 0 6.365821203502264e-10
cases O 0 5.897383026365333e-09
of O 0 1.6221878951228064e-08
hereditary B-Disease 1 0.5204252004623413
breast I-Disease 0 0.2394544929265976
and I-Disease 0 3.917358844773844e-05
/ I-Disease 0 0.19755202531814575
or I-Disease 0 0.3715236186981201
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.6414400028661476e-07
. O 0 7.289580139513419e-07

A O 0 1.14378335638321e-05
novel O 0 5.873828285984928e-06
Arg362Ser O 0 2.9785836886730976e-05
mutation O 0 1.1532624739629682e-06
in O 0 1.2734787446788687e-08
the O 0 2.263295151294642e-08
sterol O 0 4.051122687087627e-06
27 O 0 7.112084290383791e-07
- O 0 5.972337930870708e-06
hydroxylase O 0 2.379653960815631e-05
gene O 0 1.1206195722479606e-06
( O 0 5.529249946789605e-08
CYP27 O 0 4.220594746584538e-06
) O 0 6.391787987780617e-09
: O 0 1.0143683670804649e-09
its O 0 1.6537528013671476e-09
effects O 0 3.329446940369962e-08
on O 0 6.165688404280445e-08
pre O 0 3.9824107034291956e-07
- O 0 5.138751362210314e-07
mRNA O 0 1.3692113043362042e-07
splicing O 0 4.595035818510951e-07
and O 0 3.8756340359213937e-08
enzyme O 0 3.584704586501175e-07
activity O 0 5.14742282575753e-07
. O 0 3.329434434817813e-07

A O 0 8.231242645706516e-06
novel O 0 3.1226943519868655e-06
C O 0 1.658234737078601e-06
to O 0 8.599073453297024e-09
A O 0 8.109330451588903e-08
mutation O 0 2.024510621367881e-07
in O 0 3.4443969898489968e-09
the O 0 1.498079704731481e-08
sterol O 0 1.9704168607859174e-06
27 O 0 5.691583737643668e-07
- O 0 5.698177574231522e-06
hydroxylase O 0 1.6970496290014125e-05
gene O 0 5.206490527598362e-07
( O 0 2.340847693460546e-08
CYP27 O 0 7.805660970916506e-06
) O 0 8.564552622658539e-09
was O 0 7.095743370655327e-08
identified O 0 1.4471196685406085e-08
by O 0 1.4827395977690117e-09
sequencing O 0 6.459737988961933e-08
amplified O 0 5.73680324578163e-07
CYP27 O 0 1.1468911225165357e-06
gene O 0 6.739779934150647e-08
products O 0 2.1303462105493054e-08
from O 0 3.438351603435308e-09
a O 0 8.52574899568026e-08
patient O 0 4.0869044823921286e-06
with O 0 1.973040070879506e-06
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 0.9999997615814209
( O 0 2.721440978348255e-06
CTX B-Disease 0 0.00032206441392190754
) O 0 5.210334848015918e-07
. O 0 6.030850272509269e-07

The O 0 3.1185038551484467e-06
mutation O 0 9.74573049461469e-06
changed O 0 4.318423520999204e-07
the O 0 4.094375682939244e-08
adrenodoxin O 0 3.9879014366306365e-06
cofactor O 0 7.820218570486759e-07
binding O 0 1.6519291534677905e-07
residue O 0 5.146628154761856e-07
362Arg O 0 7.198390790108533e-07
to O 0 2.551738731426667e-08
362Ser O 0 2.3713757855148287e-06
( O 0 3.574190188260218e-08
CGT O 0 1.0372698397986824e-06
362Arg O 0 3.0941660611460975e-07
to O 0 1.3905512297185396e-08
AGT O 0 2.9122379601176362e-06
362Ser O 0 7.372771619884588e-07
) O 0 5.093042876325171e-09
, O 0 2.78730483138645e-09
and O 0 1.078983036251202e-08
was O 0 7.459771609319432e-07
responsible O 0 1.0231404701244173e-07
for O 0 5.091103361110072e-08
deficiency O 0 5.792388492409373e-06
in O 0 2.016320221898127e-09
the O 0 5.807790692813342e-09
sterol O 0 7.720469739069813e-07
27 O 0 1.6903535993151309e-07
- O 0 3.864680309106916e-07
hydroxylase O 0 8.610661552665988e-07
activity O 0 2.601441906335822e-08
, O 0 1.7374539584835702e-09
as O 0 2.5549369286892443e-09
confirmed O 0 1.3585464309073814e-08
by O 0 1.0392675608983382e-09
expression O 0 6.477143710270639e-09
of O 0 1.2419675288199983e-09
mutant O 0 1.6933111623984587e-07
cDNA O 0 2.0823432578254142e-07
into O 0 1.553847397417485e-07
COS O 0 0.00014010528684593737
- O 0 1.4995802303019445e-05
1 O 0 4.597411304985144e-07
cells O 0 6.5528718096175e-07
. O 0 2.2343584760164958e-07

Quantitative O 0 1.5533702026004903e-05
analysis O 0 1.7689224023342831e-06
showed O 0 2.8814210963901132e-06
that O 0 2.0157202573756194e-09
the O 0 3.971098561095232e-09
expression O 0 1.864920307070861e-08
of O 0 2.3738351284663395e-09
CYP27 O 0 2.5620593078201637e-06
gene O 0 9.568676517801578e-08
mRNA O 0 4.2627100071968016e-08
in O 0 4.516250040609293e-09
the O 0 1.7174585309476242e-08
patient O 0 4.5252889435687393e-07
represented O 0 1.1263071542089165e-07
52 O 0 1.4532694194713258e-06
. O 0 4.6894018623788725e-07

5 O 0 2.0576941096805967e-05
% O 0 1.3687882471913326e-07
of O 0 7.234946863832192e-09
the O 0 3.28890692458117e-08
normal O 0 3.4844558172153484e-07
level O 0 3.6392805213836255e-07
. O 0 4.1006796891451813e-07

As O 0 7.332180302910274e-07
the O 0 8.341014989809992e-08
mutation O 0 8.509160238645563e-07
occurred O 0 1.4795404013057123e-07
at O 0 7.758856668260705e-09
the O 0 3.3642868491057243e-09
penultimate O 0 6.709790909553703e-07
nucleotide O 0 9.280915236331566e-08
of O 0 1.7206052138618588e-09
exon O 0 3.3251919262511365e-07
6 O 0 2.7704996341526567e-07
( O 0 9.949466139858032e-09
- O 0 5.215842975303531e-07
2 O 0 1.7000481022932945e-08
position O 0 1.7197891111209174e-08
of O 0 2.2976949232145216e-09
exon O 0 2.958224172289192e-07
6 O 0 7.407962243632937e-08
- O 0 5.226478947406576e-07
intron O 0 6.974157713557361e-06
6 O 0 9.396533329208978e-08
splice O 0 1.4315273801912554e-06
site O 0 1.0046226606164055e-07
) O 0 1.097723023590902e-09
of O 0 9.352962154762778e-11
the O 0 1.1458226589766696e-09
gene O 0 2.1861966459368887e-08
, O 0 3.3823086553752546e-09
we O 0 2.289029854551927e-09
hypothesized O 0 1.3270807563969811e-08
that O 0 1.1291174661920422e-09
the O 0 1.0066324662716397e-08
mutation O 0 1.1507268027344253e-06
may O 0 1.6156469939687668e-07
partially O 0 3.9391758832607593e-07
affect O 0 7.511283151018233e-09
the O 0 4.279408383212058e-09
normal O 0 2.672078203147521e-08
splicing O 0 1.3245195873423654e-07
efficiency O 0 2.1485663026510338e-08
in O 0 2.8115727523925216e-09
exon O 0 3.772491936615552e-07
6 O 0 2.2459867921043042e-07
and O 0 4.0245911492320374e-08
cause O 0 2.0423312818707018e-08
alternative O 0 1.014281814093465e-08
splicing O 0 1.444109329895582e-07
elsewhere O 0 5.999276453394486e-08
, O 0 2.7490631993032366e-09
which O 0 3.147911487033639e-09
resulted O 0 1.1743432892785677e-08
in O 0 7.14565384640764e-09
decreased O 0 3.7476846159734123e-07
transcript O 0 5.929705935159291e-07
in O 0 2.755637318330173e-08
the O 0 1.1687451006991978e-07
patient O 0 1.0198968993790913e-05
. O 0 6.654400976913166e-07

Transfection O 0 0.000551288016140461
of O 0 7.937825898807205e-07
constructed O 0 1.7339161786367185e-06
minigenes O 0 8.515950867149513e-06
, O 0 3.306266194158525e-08
with O 0 7.736423945914339e-09
or O 0 5.360431387657627e-08
without O 0 3.2305806918486724e-09
the O 0 2.914275487597706e-09
mutation O 0 4.2251834031503677e-08
, O 0 6.79719613927432e-10
into O 0 6.398082064151822e-09
COS O 0 1.7979882613872178e-05
- O 0 6.174980740070168e-07
1 O 0 1.662869308916015e-08
cells O 0 1.56646535742766e-08
confirmed O 0 6.992797008109619e-09
that O 0 4.757469418414928e-10
the O 0 1.6558581172887443e-09
mutant O 0 7.308179306164675e-07
minigene O 0 4.31080479756929e-06
was O 0 2.3742832411244308e-07
responsible O 0 5.4193556309201085e-09
for O 0 4.068619607888735e-10
a O 0 3.767642642316105e-09
mRNA O 0 3.797680037109785e-08
species O 0 2.0348802642899955e-09
alternatively O 0 2.658068964933591e-08
spliced O 0 1.4917325643182267e-05
at O 0 8.444634147508623e-08
an O 0 1.2785117853297834e-08
activated O 0 1.2374068774079205e-06
cryptic O 0 7.823829264452797e-07
5 O 0 4.875713344176802e-08
splice O 0 2.6482241537451046e-06
site O 0 5.907889999434701e-07
88 O 0 1.722325748687581e-07
bp O 0 7.012112632764911e-07
upstream O 0 7.439425075972395e-08
from O 0 3.7644682926440964e-09
the O 0 5.394182434059758e-09
3 O 0 2.854793557105495e-08
end O 0 2.8568525323180438e-08
of O 0 5.9917386607821754e-09
exon O 0 2.276054146932438e-06
6 O 0 1.5431086239914293e-06
. O 0 9.655435633248999e-07

Our O 0 1.799381948330847e-06
data O 0 1.9150945718138246e-07
suggest O 0 6.344420455661748e-08
that O 0 1.3454304337301437e-09
the O 0 1.886571121545444e-09
C O 0 4.5828429051653075e-08
to O 0 6.823825948742979e-10
A O 0 2.536545196107909e-08
mutation O 0 1.0322317223199207e-07
at O 0 5.952860426816642e-09
the O 0 3.71498010132143e-09
penultimate O 0 4.3016530071326997e-07
nucleotide O 0 4.741069048463942e-08
of O 0 1.3561665124228739e-09
exon O 0 1.943035243812119e-07
6 O 0 3.216729638211291e-08
of O 0 6.582039913105575e-10
the O 0 6.165874921748582e-09
CYP27 O 0 2.04636899070465e-06
gene O 0 4.4123066089696295e-08
not O 0 3.968418482713787e-09
only O 0 7.403750501566719e-09
causes O 0 6.209473468743454e-08
the O 0 1.1641797925676656e-07
deficiency B-Disease 0 4.904487013845937e-06
in I-Disease 0 2.3127852966098317e-09
the I-Disease 0 1.2235392254922317e-08
sterol I-Disease 0 9.557428484185948e-07
27 I-Disease 0 1.536693901016406e-07
- I-Disease 0 3.0506492976201116e-07
hydroxylase I-Disease 0 7.704251743234636e-07
activity I-Disease 0 3.7496644011980607e-08
, O 0 2.8422253439686074e-09
but O 0 3.5586107394181e-09
also O 0 3.903900847035402e-08
partially O 0 2.26900993993695e-07
leads O 0 2.5447008056289633e-08
to O 0 1.8263943690755013e-09
alternative O 0 1.723989662139047e-08
pre O 0 1.5408616604872805e-07
- O 0 2.93392645289714e-07
mRNA O 0 4.5042003904427474e-08
splicing O 0 7.601681772939628e-08
of O 0 3.244895685483584e-09
the O 0 2.1879861478169005e-08
gene O 0 1.364745344289986e-06
. O 0 6.90648107593006e-07

To O 0 8.054988711592159e-07
our O 0 7.330824303153349e-08
knowledge O 0 1.836557217416157e-08
, O 0 5.625293564293088e-09
this O 0 9.86870141161944e-10
is O 0 1.663661763906532e-09
the O 0 2.112102048812403e-09
first O 0 3.081802546489598e-08
report O 0 9.459251160137683e-09
regarding O 0 3.824902172766542e-09
effects O 0 3.56598484074766e-08
on O 0 8.123186034936225e-08
pre O 0 1.912243874357955e-07
- O 0 6.666063256943744e-08
mRNA O 0 1.6118804069265025e-08
splicing O 0 2.6578153011769245e-08
of O 0 7.171400695504815e-10
a O 0 4.275785503438101e-09
mutation O 0 2.1436214581171953e-08
at O 0 2.911941798799944e-09
the O 0 2.6868978153515855e-09
- O 0 3.6823587379331e-06
2 O 0 1.024749849420914e-07
position O 0 9.174188875249456e-08
of O 0 1.764861923270189e-09
a O 0 4.0266261436272544e-08
5 O 0 9.503126108256765e-08
splice O 0 2.0326784579083323e-05
site O 0 4.622189408109989e-06
. O 0 6.983049161135568e-07

ATM O 0 0.0034156765323132277
germline O 0 0.0036357692442834377
mutations O 0 0.0002235505817225203
in O 0 1.4849530316496384e-06
classical O 0 0.0002447339938953519
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.005485412199050188
in O 0 9.717247451135336e-08
the O 0 8.222639280575095e-08
Dutch O 0 1.9797840650426224e-05
population O 0 1.4318167984583852e-07
. O 0 3.2221953460975783e-07

Germline O 0 0.041846297681331635
mutations O 0 0.0002464658464305103
in O 0 9.603928674550843e-08
the O 0 1.1033239211144519e-08
ATM O 0 9.382828807247279e-07
gene O 0 1.9911514925752272e-07
are O 0 3.794514036314922e-09
responsible O 0 3.7976075617507377e-08
for O 0 4.801807307330819e-08
the O 0 0.006644561421126127
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.020572282373905182
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.0535533192523872e-06
. O 0 7.372961476903583e-07

In O 0 6.821176725679834e-07
our O 0 7.873081386833292e-08
study O 0 1.2642024316278366e-08
, O 0 4.193212443937e-09
we O 0 2.87232415630001e-09
have O 0 1.923413650573025e-09
determined O 0 4.2308583303452e-09
the O 0 2.6526176810648394e-09
ATM O 0 4.95146537105029e-07
mutation O 0 1.1819829381920499e-07
spectrum O 0 2.764797812915276e-08
in O 0 1.9692927288872397e-09
19 O 0 3.2956698703401344e-08
classical O 0 9.758890939792764e-08
A B-Disease 1 0.9999985694885254
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.0569294179040298e-07
, O 0 5.402066571846831e-10
including O 0 2.430809442621751e-10
some O 0 2.2765889173825826e-10
immigrant O 0 2.6456666191165823e-08
populations O 0 1.132059335162694e-08
, O 0 2.1113608639211634e-09
as O 0 1.7646432093343378e-09
well O 0 3.93171228907363e-09
as O 0 7.735686757825988e-09
12 O 0 1.3412496890907732e-08
of O 0 1.3829856149172315e-09
Dutch O 0 3.4211819865959114e-07
ethnic O 0 1.330946872712957e-07
origin O 0 3.288851075922139e-07
. O 0 4.552515804334689e-07

Both O 0 7.139531703614921e-07
the O 0 3.3172764091204954e-08
protein O 0 3.801583261520136e-07
truncation O 0 2.3636901005374966e-06
test O 0 3.6778203593712533e-07
( O 0 4.670041064969155e-08
PTT O 0 2.3625401013305236e-07
) O 0 1.7478142266824648e-09
and O 0 7.906119647849152e-10
the O 0 1.5120302787607898e-09
restriction O 0 2.6372376282779442e-08
endonuclease O 0 3.618098673996428e-07
fingerprinting O 0 3.540945385793748e-07
( O 0 1.5717628087941193e-08
REF O 0 1.986445113288937e-06
) O 0 2.2403332522458186e-09
method O 0 5.74642644579626e-09
were O 0 6.276366537605327e-09
used O 0 8.553907804298433e-09
and O 0 1.8254585398835843e-08
compared O 0 7.976312943469566e-09
for O 0 1.9637068360278676e-10
their O 0 8.350717339844493e-10
detection O 0 1.2525163128884742e-08
efficiency O 0 6.634033766772518e-09
, O 0 5.912245693018292e-10
identifying O 0 7.74699682182245e-09
76 O 0 2.1804872574193723e-08
% O 0 2.4399846587641605e-09
and O 0 2.6503066408167797e-09
60 O 0 1.5422825683231167e-08
% O 0 1.073294897402377e-09
of O 0 6.071459446310712e-10
the O 0 2.585622027595491e-08
mutations O 0 2.679295221241773e-06
, O 0 3.616279897755703e-08
respectively O 0 3.432686241922056e-07
. O 0 3.862922994812834e-07

Most O 0 7.1149656832858454e-06
patients O 0 7.349945008172654e-06
were O 0 1.4248287527607317e-07
found O 0 2.194811798972296e-08
to O 0 1.2042758790187236e-08
be O 0 4.9059842410770216e-08
compound O 0 2.6412858460389543e-06
heterozygote O 0 6.172201392473653e-05
. O 0 1.8817117961589247e-06

Seventeen O 0 0.0001626707671675831
mutations O 0 5.540268830372952e-05
were O 0 3.3893726936184976e-07
distinct O 0 5.841076955448443e-08
, O 0 5.661665358758228e-09
of O 0 2.473398375002489e-09
which O 0 1.1211588457626931e-07
10 O 0 5.0284416630574924e-08
were O 0 2.0903397057736584e-07
not O 0 2.7131219937359674e-08
reported O 0 1.0616676036079298e-06
previously O 0 8.597860983172723e-07
. O 0 5.439790129457833e-07

Mutations O 0 0.0009707317803986371
are O 0 1.4970449058182567e-07
small O 0 7.331872353688595e-08
deletions O 0 3.6679464301414555e-06
or O 0 4.833997877540241e-07
point O 0 7.498726517951582e-06
mutations O 0 1.8855394955608062e-05
frequently O 0 7.353068554039055e-07
affecting O 0 4.105285142941284e-07
splice O 0 6.72782989568077e-05
sites O 0 7.030082997516729e-06
. O 0 2.3821719423722243e-06

Moreover O 0 3.2668482162989676e-05
, O 0 2.9989968197696726e-07
a O 0 4.5047843855172687e-07
16 O 0 1.8695270682655973e-06
. O 0 8.801987974038639e-07

7 O 0 4.24590143666137e-05
- O 0 9.38598532229662e-06
kb O 0 4.8842716751096305e-06
genomic O 0 3.5478512927511474e-07
deletion O 0 2.4579114210609987e-07
of O 0 3.030575124185475e-09
the O 0 5.369853894876542e-09
3 O 0 5.73207863396874e-08
end O 0 2.8426494935729352e-08
of O 0 3.0516464355478945e-10
the O 0 1.5444159284783154e-09
gene O 0 1.501521040836451e-08
, O 0 2.949471777924373e-09
most O 0 1.034191621229752e-09
likely O 0 6.304658128897245e-09
a O 0 1.626803802778909e-09
result O 0 1.710354080586285e-09
of O 0 3.298534501094963e-10
recombination O 0 1.7666479834588245e-08
between O 0 1.6529527968600632e-08
two O 0 2.1121056192896503e-07
LINE O 0 0.03278174251317978
elements O 0 3.7065845504002937e-07
, O 0 1.0078316137196452e-07
was O 0 1.846115537773585e-06
identified O 0 1.0133227306141634e-06
. O 0 3.59093860424764e-07

The O 0 1.243214683199767e-06
most O 0 5.2264489625031274e-08
frequently O 0 1.9101987902558903e-07
found O 0 5.483982334908433e-08
mutation O 0 1.8573312843273015e-07
, O 0 3.762845590671304e-09
identified O 0 1.7464786949972222e-08
in O 0 1.7483977599042078e-09
three O 0 1.2487284095641371e-08
unrelated O 0 7.73778552343174e-08
Turkish O 0 4.782986593454552e-07
A B-Disease 1 0.9998989105224609
- I-Disease 1 0.9999873638153076
T I-Disease 1 1.0
individuals O 0 3.468759501856766e-08
, O 0 5.852035744879913e-09
was O 0 1.793791426507596e-07
previously O 0 4.1300474151739763e-08
described O 0 4.193870140056788e-08
to O 0 3.0007571982793024e-09
be O 0 2.806290311241355e-09
a O 0 2.8148367192670776e-08
Turkish O 0 3.860506581077061e-07
A B-Disease 1 0.9998219609260559
- I-Disease 1 0.9999840259552002
T I-Disease 1 0.9999998807907104
founder O 0 1.7192245650221594e-05
mutation O 0 3.592011353248381e-06
. O 0 3.5050797464464267e-07

The O 0 4.7165318051156646e-07
presence O 0 1.5564458522021596e-07
of O 0 5.394429347660434e-09
a O 0 7.231363241544386e-08
founder O 0 2.8192910122015746e-06
mutation O 0 3.545114850567188e-07
among O 0 2.9813036483972155e-09
relatively O 0 3.1810474254712062e-09
small O 0 1.6764476473696277e-09
ethnic O 0 6.77352929301378e-09
population O 0 1.5227414884577684e-09
groups O 0 8.978085497268751e-10
in O 0 8.336569767841695e-10
Western O 0 5.07154229723028e-09
Europe O 0 7.046139671729179e-08
could O 0 1.516123049327689e-08
indicate O 0 5.090790011763602e-09
a O 0 5.611052067422406e-09
high O 0 1.1555971468624193e-07
carrier O 0 8.674309981415718e-08
frequency O 0 2.630671325221101e-08
in O 0 2.3811588256705818e-09
such O 0 5.259686908232197e-09
communities O 0 1.27755185985734e-07
. O 0 3.146352867133828e-07

In O 0 1.5853845525271026e-06
patients O 0 7.058258688630303e-07
of O 0 4.439926648558412e-09
Dutch O 0 4.861352635998628e-07
ethnic O 0 3.2337080568822785e-08
origin O 0 2.6149631793259687e-08
, O 0 1.2928252246524607e-08
however O 0 6.887404424560373e-09
, O 0 2.0093249286645687e-09
no O 0 1.803189153548601e-09
significant O 0 4.578315060399518e-09
founder O 0 2.812325874401722e-07
effect O 0 6.997202461889174e-08
could O 0 6.879805880544154e-08
be O 0 1.176948938308442e-08
identified O 0 4.973817908648925e-07
. O 0 2.0781612874998245e-07

The O 0 1.4848200180495041e-06
observed O 0 1.1214940514037153e-06
genetic O 0 2.489535120275832e-07
heterogeneity O 0 4.967631639374304e-07
including O 0 1.7617820091686553e-08
the O 0 1.205264066328482e-08
relative O 0 1.2437146779120667e-07
high O 0 1.1377235864529212e-07
percentage O 0 8.432128595359245e-08
of O 0 1.2482086475529286e-09
splice O 0 2.0047698853886686e-05
- O 0 2.2350424842443317e-05
site O 0 1.6503402093803743e-06
mutations O 0 7.850878205317713e-07
had O 0 8.074570700955519e-07
no O 0 1.6193501650718645e-08
reflection O 0 7.956820979870827e-08
on O 0 2.1332050437194994e-07
the O 0 1.8539034840614477e-07
phenotype O 0 7.189337338786572e-05
. O 0 7.111473792065226e-07

All O 0 3.27734005622915e-06
patients O 0 6.313147423497867e-06
manifested O 0 1.9951025933551136e-06
classical O 0 9.49629281876696e-07
A B-Disease 1 0.9999165534973145
- I-Disease 1 0.9999954700469971
T I-Disease 1 1.0
and O 0 1.0550287043997741e-07
increased O 0 8.813767493620617e-08
cellular O 0 7.255706009345886e-07
radioresistant O 0 5.084638814878417e-06
DNA O 0 1.909194907057099e-06
synthesis O 0 3.624923692768789e-06
. O 0 9.451487699152494e-07

Determination O 0 2.318842598469928e-05
of O 0 2.791280451219791e-08
the O 0 1.1579243341941492e-08
genomic O 0 1.783337495453452e-07
structure O 0 1.6366113797516846e-08
of O 0 7.868660167886787e-10
the O 0 5.794612345511041e-09
COL4A4 O 0 2.7559217414818704e-06
gene O 0 4.620821769663053e-08
and O 0 9.824402624758477e-09
of O 0 1.5092965099938738e-08
novel O 0 2.9375341910053976e-05
mutations O 0 0.01255120150744915
causing O 0 0.0004458065959624946
autosomal B-Disease 1 0.9999982118606567
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.9636170691228472e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.438720225152792e-06
a O 0 4.603159140970092e-06
progressive O 0 0.0008291434496641159
hematuric B-Disease 1 0.6047778725624084
glomerulonephritis I-Disease 1 0.9999998807907104
characterized O 0 7.701071444898844e-05
by O 0 1.3867838788428344e-07
glomerular B-Disease 0 0.03109818324446678
basement I-Disease 1 0.9312176704406738
membrane I-Disease 0 0.004629283212125301
abnormalities I-Disease 1 0.9983806610107422
and O 0 1.1904845820254195e-07
associated O 0 4.7853042417500546e-08
with O 0 2.580380176198105e-08
mutations O 0 9.56837197918503e-07
in O 0 6.849936173836113e-09
either O 0 1.6663905810787583e-08
the O 0 1.613978639625202e-08
COL4A3 O 0 1.0094241588376462e-05
or O 0 9.22234466571581e-09
the O 0 3.787189672976865e-09
COL4A4 O 0 2.1001255845476408e-06
gene O 0 2.858160641494578e-08
, O 0 3.127939018909842e-09
which O 0 1.5398626818097227e-09
encode O 0 6.080594694424235e-09
the O 0 1.5445433376726214e-08
alpha3 O 0 2.5755425667739473e-06
and O 0 5.261274793610937e-08
alpha4 O 0 3.0437145142059308e-06
type O 0 4.5058845898893196e-07
IV O 0 1.6331383449141867e-05
collagen O 0 4.525307758740382e-06
chains O 0 3.0375260394066572e-05
, O 0 1.1825591172964778e-07
respectively O 0 4.161376807587658e-07
. O 0 3.403975483706745e-07

To O 0 7.209189902823709e-07
date O 0 3.456785577782284e-07
, O 0 1.18454295261472e-08
mutation O 0 5.598761276814912e-08
screening O 0 1.5705220235417983e-08
in O 0 2.1740327316166486e-09
the O 0 1.4946140991511925e-09
two O 0 2.0375610532141764e-08
genes O 0 1.4605232934172818e-07
has O 0 5.338667392607022e-07
been O 0 3.4182306762886583e-07
hampered O 0 1.2877065273642074e-05
by O 0 1.0738667732823615e-08
the O 0 1.0803153926985942e-08
lack O 0 1.4580636253924695e-08
of O 0 2.9115141408908585e-09
genomic O 0 4.141403167068347e-07
structure O 0 2.8038419941367465e-07
information O 0 9.719916960193586e-08
. O 0 3.845217690923164e-07

We O 0 9.548861271468922e-06
report O 0 1.1718601200527701e-07
here O 0 6.569000010614445e-09
the O 0 2.7094904098134975e-09
complete O 0 9.753714280691383e-09
characterization O 0 6.312674827313458e-08
of O 0 2.2161508184126433e-09
the O 0 6.8534773411954575e-09
48 O 0 3.424955252739892e-08
exons O 0 6.643748662327198e-08
of O 0 1.7658888795679673e-09
the O 0 9.798615252520904e-09
COL4A4 O 0 2.1478201688296394e-06
gene O 0 3.291153660711643e-08
, O 0 7.664583967503802e-10
a O 0 1.7067889324096086e-09
comprehensive O 0 8.737337964248582e-09
gene O 0 5.78880445800678e-08
screen O 0 5.3860294428886846e-06
, O 0 1.1372446984125872e-08
and O 0 4.165233047359607e-09
the O 0 1.4123352487516172e-09
subsequent O 0 4.612586312902067e-09
detection O 0 8.393133299477995e-09
of O 0 8.042824739540322e-10
10 O 0 8.171853416172326e-09
novel O 0 8.495021575072315e-08
mutations O 0 1.7027910814704228e-07
in O 0 9.518360322147146e-09
eight O 0 2.6772008823172655e-06
patients O 0 2.3002206944511272e-05
diagnosed O 0 0.012275292538106441
with O 0 5.5979009630391374e-05
autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.5578785678371787e-05

Furthermore O 0 1.980709384952206e-05
, O 0 1.0500720293293853e-07
we O 0 7.311494520934048e-09
identified O 0 9.763019725994582e-09
a O 0 3.935102910190835e-09
glycine O 0 1.8957275926823058e-07
to O 0 5.843592276733034e-09
alanine O 0 1.45398175277478e-07
substitution O 0 1.8486399966377576e-08
in O 0 2.8525712902904843e-09
the O 0 5.001665304149583e-09
collagenous O 0 7.534601991210366e-07
domain O 0 1.9726055455748792e-08
that O 0 2.1868333810459717e-09
is O 0 1.0162532149138315e-08
apparently O 0 3.413588274270296e-07
silent O 0 1.2492505163663736e-07
in O 0 2.32774799435731e-09
the O 0 6.589642609355906e-09
heterozygous O 0 2.1715933939958632e-07
carriers O 0 3.036906903730596e-08
, O 0 4.958389698828114e-09
in O 0 1.0554610518909158e-08
11 O 0 3.1092577046365477e-07
. O 0 3.3573022051314183e-07

5 O 0 1.8303086108062416e-05
% O 0 1.8380156063813047e-07
of O 0 2.09460671030115e-09
all O 0 1.759866918860098e-09
control O 0 1.965817233440248e-07
individuals O 0 4.884721072073717e-09
, O 0 2.3491748546433655e-09
and O 0 5.111513878830465e-09
in O 0 2.4429371858758486e-09
one O 0 1.9086904501364188e-08
control O 0 2.0837516956362379e-07
individual O 0 5.2315520804313564e-09
homozygous O 0 1.0172018960474816e-07
for O 0 7.722297246104404e-10
this O 0 1.883827760451595e-09
glycine O 0 5.80053097110067e-07
substitution O 0 5.335455739441386e-07
. O 0 2.5953616500373755e-07

There O 0 4.246559456078103e-06
has O 0 3.6746757814398734e-07
been O 0 3.5600042025407674e-08
no O 0 7.020193315554479e-09
previous O 0 1.3677608379225603e-08
finding O 0 4.036782463856525e-09
of O 0 3.2221425527723113e-10
a O 0 3.90905530167629e-09
glycine O 0 4.744506654219549e-08
substitution O 0 7.278643465724599e-09
that O 0 2.2300798985241954e-09
is O 0 2.0803208045094834e-09
not O 0 1.3839989154718069e-09
associated O 0 3.20009507781549e-09
with O 0 1.4139013293501534e-09
any O 0 2.3198285958869747e-08
obvious O 0 1.0275422255290323e-06
phenotype O 0 2.120712088071741e-05
in O 0 5.157800941901769e-08
homozygous O 0 1.7231834135600366e-05
individuals O 0 7.800228729593073e-08
. O 0 3.062916107410274e-07

Founder O 0 0.0006998184835538268
BRCA1 O 0 0.0019433035049587488
and O 0 5.205311026657e-06
BRCA2 O 0 0.0005564457387663424
mutations O 0 8.903526577341836e-06
in O 0 8.794170724968353e-08
French O 0 2.2640633687842637e-05
Canadian O 0 8.721101039554924e-05
breast B-Disease 1 0.9999427795410156
and I-Disease 1 0.9982788562774658
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.308256848162273e-06
. O 0 2.1760515664936975e-06

We O 0 4.634610377252102e-06
have O 0 8.547127094971074e-08
identified O 0 8.408439100549003e-08
four O 0 2.5375952006356783e-08
mutations O 0 1.11692415316611e-07
in O 0 1.2429819395975983e-09
each O 0 2.7029041227422113e-09
of O 0 2.70945399449829e-09
the O 0 9.553027666697744e-07
breast B-Disease 1 0.9963310360908508
cancer I-Disease 0 0.00015852460637688637
- O 0 4.826424628845416e-05
susceptibility O 0 6.278131877479609e-06
genes O 0 3.2718699571887555e-07
, O 0 3.76599231799446e-08
BRCA1 O 0 9.934070476447232e-06
and O 0 7.253616445268563e-07
BRCA2 O 0 8.000136404007208e-06
, O 0 9.768570841117707e-09
in O 0 1.1751343009791526e-08
French O 0 8.241186151281e-06
Canadian O 0 1.2741812497552019e-05
breast B-Disease 1 0.9659972190856934
cancer I-Disease 0 0.0010561675298959017
and O 0 3.4630786103662103e-05
breast B-Disease 1 0.9999995231628418
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.3315897149368539e-06
from O 0 9.328815764320098e-08
Quebec O 0 1.267128754989244e-05
. O 0 1.3890237369196257e-06

To O 0 1.2664247606153367e-06
identify O 0 1.0343419489799999e-06
founder O 0 1.959531573447748e-06
effects O 0 1.0576978866083664e-06
, O 0 2.128205878193512e-08
we O 0 2.1096068891779396e-08
examined O 0 1.019070055008342e-07
independently O 0 1.033656147342299e-07
ascertained O 0 3.858004049561714e-07
French O 0 9.725274594529765e-07
Canadian O 0 2.2556901058123913e-06
cancer B-Disease 0 1.4018551155459136e-06
families O 0 7.507673593920572e-09
for O 0 3.296075079539662e-10
the O 0 1.1341053651747757e-09
distribution O 0 2.0991699489769644e-09
of O 0 8.476173651850161e-10
these O 0 4.216229143594319e-09
eight O 0 2.655627042713604e-07
mutations O 0 3.563344307622174e-06
. O 0 1.8273924240475026e-07

Mutations O 0 0.0011384777026250958
were O 0 3.9112356375881063e-07
found O 0 3.213957455727723e-08
in O 0 6.288852549829471e-09
41 O 0 1.49062685750323e-07
of O 0 4.495546157556873e-09
97 O 0 4.253313932167657e-07
families O 0 2.5267630121561524e-07
. O 0 2.9568192871920473e-07

Six O 0 2.8586023290699814e-06
of O 0 3.3699464552228164e-08
eight O 0 2.3194333209630713e-07
mutations O 0 1.504912006566883e-06
were O 0 8.966473075133763e-08
observed O 0 6.923021089733083e-08
at O 0 6.919245265635254e-08
least O 0 6.099717353436063e-08
twice O 0 1.0049386673927074e-06
. O 0 3.9965334508451633e-07

The O 0 5.6431472330586985e-06
BRCA1 O 0 0.00028205287526361644
C4446T O 0 4.364849883131683e-05
mutation O 0 1.6041924027376808e-05
was O 0 8.540866929251933e-07
the O 0 3.2264366733869565e-09
most O 0 3.503112244729323e-09
common O 0 1.5188264868015722e-08
mutation O 0 1.7110083661009412e-07
found O 0 1.6736114716309203e-08
, O 0 6.4021592471874555e-09
followed O 0 3.519596347700826e-08
by O 0 3.182941021862007e-09
the O 0 5.6471083809128686e-08
BRCA2 O 0 0.00014968289178796113
8765delAG O 0 1.8920167349278927e-05
mutation O 0 1.0047556315839756e-05
. O 0 6.59161912608397e-07

Together O 0 3.0180187877704157e-06
, O 0 4.8736861657516783e-08
these O 0 7.768481857794995e-09
mutations O 0 2.775929317522241e-07
were O 0 1.9296246378530668e-08
found O 0 5.211136411276129e-09
in O 0 5.572199146541834e-09
28 O 0 4.447557344633424e-08
of O 0 1.4025316463772697e-09
41 O 0 4.171055820734182e-07
families O 0 5.761626731271008e-09
identified O 0 1.6227449606276423e-08
to O 0 4.3834491592065206e-09
have O 0 1.6941989144925174e-08
a O 0 1.7188685319524666e-07
mutation O 0 4.684700343204895e-06
. O 0 4.0507762832930894e-07

The O 0 8.064043299782497e-07
odds O 0 1.5059442830533953e-06
of O 0 6.503896532450426e-09
detection O 0 3.065545683966775e-08
of O 0 7.541267055266587e-10
any O 0 1.3399422682525142e-09
of O 0 6.581625244805878e-10
the O 0 8.594924771898604e-09
four O 0 3.5655705232784385e-07
BRCA1 O 0 0.00012148175301263109
mutations O 0 6.358731297950726e-06
was O 0 4.093848019692814e-06
18 O 0 5.283419000079448e-07
. O 0 3.2106618164107203e-07

7x O 0 0.0009515922865830362
greater O 0 3.3779633668018505e-06
if O 0 8.769632131588878e-08
one O 0 8.600335554831418e-09
or O 0 2.866676007684532e-09
more O 0 1.801875870732772e-09
cases O 0 1.9235173454035248e-08
of O 0 2.2537506083608605e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.4447651665250305e-05
also O 0 3.3017676059898804e-07
present O 0 5.398299141035068e-09
in O 0 7.886002961754457e-09
the O 0 7.613638786096999e-08
family O 0 1.4363424725161167e-06
. O 0 7.29736314042384e-07

The O 0 2.238930164821795e-06
odds O 0 4.345045908848988e-06
of O 0 8.741455559402311e-09
detection O 0 6.066579771868419e-08
of O 0 1.6508849842722384e-09
any O 0 9.97355309451109e-10
of O 0 1.308742780814498e-09
the O 0 1.678374594860088e-08
four O 0 1.8191433355241315e-06
BRCA2 O 0 0.0009263993706554174
mutations O 0 9.978820344258565e-06
was O 0 5.07691993334447e-06
5 O 0 5.310100164024334e-07
. O 0 4.88253476760292e-07

3x O 0 0.00020560297707561404
greater O 0 2.396031732132542e-06
if O 0 5.999082475227624e-08
there O 0 8.133616447025815e-09
were O 0 1.4519526025935647e-08
at O 0 2.5661845981517217e-09
least O 0 1.3872603066289457e-09
five O 0 2.189320946754947e-09
cases O 0 3.076797039369694e-09
of O 0 2.317422875819375e-08
breast B-Disease 1 0.9485387206077576
cancer I-Disease 0 1.4133125660009682e-05
in O 0 2.4603568959946642e-08
the O 0 1.3527187547879294e-07
family O 0 2.9782841011183336e-06
. O 0 7.224840601338656e-07

Interestingly O 0 5.070502811577171e-05
, O 0 9.508547549330615e-08
the O 0 3.1863547356181243e-09
presence O 0 7.3513759524246325e-09
of O 0 1.865983145776795e-09
a O 0 1.951244712472544e-07
breast B-Disease 0 0.007890199311077595
cancer I-Disease 0 2.013924358834629e-06
case O 0 1.4512050228177031e-08
< O 0 5.7454656143818283e-08
36 O 0 2.7079417819209084e-08
years O 0 2.78751222104745e-09
of O 0 1.0667069449965538e-09
age O 0 3.083813737703167e-08
was O 0 1.1070765282283901e-07
strongly O 0 4.778087259182939e-09
predictive O 0 1.0915893966512158e-08
of O 0 5.843834860463915e-10
the O 0 1.3113364838446273e-09
presence O 0 4.004986120520471e-09
of O 0 4.447731072332317e-10
any O 0 7.369510557353465e-10
of O 0 4.438671652451376e-10
the O 0 1.1179765557756127e-08
eight O 0 3.5749849303101655e-07
mutations O 0 2.7159803721588105e-06
screened O 0 3.5840591863234295e-06
. O 0 5.034555101701699e-07

Carriers O 0 6.367409241647692e-06
of O 0 1.5740848624545833e-08
the O 0 9.863569516710413e-09
same O 0 1.9695454156476444e-08
mutation O 0 1.3599287740362342e-07
, O 0 2.2277373279422363e-09
from O 0 7.816827740647625e-10
different O 0 8.231921810875065e-10
families O 0 1.2635323010101729e-08
, O 0 6.488553028205502e-10
shared O 0 2.9739488649482837e-09
similar O 0 1.260232540545303e-08
haplotypes O 0 7.161148687373498e-07
, O 0 8.623266545271235e-09
indicating O 0 3.7191224322441485e-08
that O 0 7.558879078217728e-10
the O 0 1.2995020615136355e-09
mutant O 0 4.754961651087797e-07
alleles O 0 8.156316511076511e-08
were O 0 1.0888615520343592e-07
likely O 0 2.083176831035871e-08
to O 0 2.4780117957590164e-09
be O 0 2.7207693875652694e-09
identical O 0 1.5073229775453e-08
by O 0 1.9215875557421214e-09
descent O 0 1.254853003729295e-07
for O 0 7.97990007406213e-10
a O 0 6.416195219571819e-08
mutation O 0 2.5816115112320404e-07
in O 0 6.9219221465743885e-09
the O 0 3.0193717748261406e-08
founder O 0 1.8567959614301799e-06
population O 0 6.819616515940652e-08
. O 0 1.204799104925769e-07

The O 0 3.273752327004331e-07
identification O 0 1.258909350099202e-07
of O 0 1.4394092140435077e-08
common O 0 3.224375006993796e-07
BRCA1 O 0 0.00023051926109474152
and O 0 6.092222520237556e-06
BRCA2 O 0 0.00037180204526521266
mutations O 0 1.4723237882208196e-06
will O 0 4.1792871385837316e-09
facilitate O 0 1.516149161773228e-08
carrier O 0 1.1685455802989964e-07
detection O 0 1.0464890465300414e-07
in O 0 2.2758747775242227e-08
French O 0 9.311967914982233e-06
Canadian O 0 1.2344376045803074e-05
breast B-Disease 1 0.8978502750396729
cancer I-Disease 0 0.0006621317588724196
and O 0 3.8742371543776244e-05
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 7.577053111162968e-06
. O 0 2.0903646600345382e-06

Are O 0 5.824894287798088e-06
Dp71 O 0 0.0002430610911687836
and O 0 2.581889702923945e-06
Dp140 O 0 0.00018876955437008291
brain O 0 0.00019656162476167083
dystrophin O 0 4.3290296162012964e-05
isoforms O 0 2.3227169094752753e-06
related O 0 2.3894546075098333e-07
to O 0 1.373546751892718e-07
cognitive B-Disease 0 0.0003491686948109418
impairment I-Disease 0 0.0005224705091677606
in O 0 2.4664361262694e-05
Duchenne B-Disease 1 1.0
muscular I-Disease 1 0.9999986886978149
dystrophy I-Disease 1 0.9999953508377075
? O 0 0.00017185726028401405

Molecular O 0 1.842924757511355e-05
study O 0 4.795528525392001e-07
and O 0 7.273803248608601e-08
neuropsychological O 0 5.18985814323969e-07
analysis O 0 2.202305360299306e-08
were O 0 5.3065157601395185e-08
performed O 0 3.3423567913359875e-08
concurrently O 0 1.6751572573525664e-08
on O 0 2.0002146072783944e-07
49 O 0 1.5396864228023333e-06
patients O 0 2.1707215580590855e-07
with O 0 2.0192901502014138e-06
Duchenne B-Disease 1 0.9999998807907104
muscular I-Disease 1 0.9999980926513672
dystrophy I-Disease 1 0.9999967813491821
( O 0 7.62843001211877e-06
DMD B-Disease 1 1.0
) O 0 5.8930677226953776e-08
in O 0 8.133786977282398e-09
order O 0 7.331520279763026e-09
to O 0 1.7949469688360864e-09
find O 0 4.347768811641117e-09
a O 0 5.45776712712609e-09
molecular O 0 1.6723573637023037e-08
explanation O 0 5.783052259289434e-09
for O 0 1.071206789937662e-09
the O 0 2.5085098442900744e-08
cognitive B-Disease 0 2.112986976499087e-06
impairment I-Disease 0 1.0662151908036321e-06
observed O 0 1.4493218714051181e-07
in O 0 4.6308276324680264e-08
most O 0 2.204751126555493e-06
DMD B-Disease 1 1.0
patients O 0 4.977468415745534e-05
. O 0 1.3218524372859974e-06

Complete O 0 1.244218083229498e-06
analysis O 0 7.748833041887337e-08
of O 0 2.694205525344273e-09
the O 0 6.45729647530402e-09
dystrophin O 0 1.446429337192967e-06
gene O 0 6.360183419928944e-07
was O 0 2.4436583771603182e-05
performed O 0 7.872480978221574e-08
to O 0 1.9071209056420457e-09
define O 0 2.737187720924794e-08
the O 0 3.523826341833569e-09
localization O 0 2.7436483307496928e-08
of O 0 1.2012838501718193e-09
deletions O 0 4.3607687416624685e-07
and O 0 4.04220052985238e-08
duplications O 0 2.618347707539215e-07
in O 0 4.426600863638441e-09
relation O 0 1.3146277844100496e-08
to O 0 9.383848365018821e-09
the O 0 2.7639964983450227e-08
different O 0 6.533128384944575e-07
DMD B-Disease 1 0.9999997615814209
promoters O 0 6.163214857224375e-05
. O 0 1.0478007652636734e-06

Qualitative O 0 1.7673441107035615e-05
analysis O 0 3.1009423651084944e-07
of O 0 1.447754804928536e-08
the O 0 2.129553777763249e-08
Dp71 O 0 3.9706424104224425e-06
transcript O 0 2.263141141156666e-06
and O 0 4.213433513200471e-08
testing O 0 5.282469128786715e-09
for O 0 1.9810948714837906e-10
the O 0 4.5827333594594677e-10
specific O 0 4.396106534354516e-10
first O 0 3.816900129294254e-09
exon O 0 5.366917577021013e-08
of O 0 6.079666992064858e-09
Dp140 O 0 2.1545224626606796e-06
were O 0 2.3835939089167368e-07
also O 0 1.3452238079025847e-07
carried O 0 2.7216825060349947e-07
out O 0 2.865235444460268e-07
. O 0 4.2834034275074373e-07

Neuropsychological O 0 0.00031649842276237905
analysis O 0 3.4461386348993983e-06
assessed O 0 3.64269430974673e-06
verbal O 0 6.7034352468908764e-06
and O 0 3.0665287908959726e-07
visuospatial O 0 1.5758439985802397e-05
intelligence O 0 7.106687576197146e-07
, O 0 2.4217136740389833e-08
verbal O 0 3.9141534102782316e-07
memory O 0 6.189848591020564e-06
, O 0 6.497005244909815e-08
and O 0 1.3206562243794906e-07
reading O 0 6.967875378904864e-07
skills O 0 6.345872520796547e-07
. O 0 3.3535772558934696e-07

Comparison O 0 4.317576895118691e-06
of O 0 5.563950367104553e-08
molecular O 0 3.595321231841808e-07
and O 0 4.188881774780384e-08
psychometric O 0 1.014842951008177e-06
findings O 0 1.6734158236886287e-07
demonstrated O 0 7.13544210384498e-08
that O 0 2.5526620817117873e-09
deletions O 0 2.60391743722721e-07
and O 0 2.939078491692726e-08
duplications O 0 3.7605914826599474e-07
that O 0 2.461361425787345e-08
were O 0 6.33230712310251e-08
localized O 0 1.477298496865842e-07
in O 0 7.603607521389222e-09
the O 0 1.3086211225754596e-08
distal O 0 1.735952992021339e-06
part O 0 1.0599073618777766e-08
of O 0 1.0211704815077383e-09
the O 0 4.245749085640682e-09
gene O 0 6.804467034271511e-08
seemed O 0 1.4765012679163192e-07
to O 0 2.123979214729843e-09
be O 0 5.439227290793269e-09
preferentially O 0 8.280193952714399e-08
associated O 0 5.1377512022554583e-08
with O 0 6.775844241246887e-08
cognitive B-Disease 0 0.0001417288585798815
impairment I-Disease 0 4.747529965243302e-05
. O 0 7.758873152852175e-07

Two O 0 3.3888957204908365e-06
altered O 0 1.0087111149914563e-05
Dp71 O 0 2.4025663151405752e-05
transcripts O 0 1.3128232012604713e-06
and O 0 1.4557321570407566e-08
two O 0 1.0000779759877787e-08
deleted O 0 4.2339124206591805e-07
Dp140 O 0 2.909029888087389e-07
DNA O 0 6.793509044200619e-08
sequences O 0 6.369312188780896e-08
were O 0 1.7185628919946794e-08
found O 0 4.841376632924721e-09
in O 0 3.6786251822462646e-09
four O 0 3.158320964757877e-07
patients O 0 7.410478133351717e-07
with O 0 9.526515896141063e-07
severe O 1 0.850775420665741
cerebral B-Disease 1 0.9909219145774841
dysfunction I-Disease 0 0.13726377487182617
. O 0 3.0242304092098493e-06

These O 0 3.034840290183638e-07
findings O 0 8.912866178434342e-08
suggest O 0 1.4391429381532816e-08
that O 0 8.142506668917804e-10
some O 0 2.747709282324706e-10
sequences O 0 9.338461559593725e-09
located O 0 1.158078966057019e-08
in O 0 2.4492401440312506e-09
the O 0 5.9902989235638415e-09
distal O 0 6.19897662090807e-07
part O 0 8.112621685540944e-09
of O 0 9.698594150009399e-10
the O 0 3.492298006335659e-09
gene O 0 7.254323008965002e-08
and O 0 5.7916761164733543e-08
, O 0 1.3425850431403319e-09
in O 0 7.123319156754349e-10
particular O 0 3.362291778330473e-09
, O 0 3.3873508442638922e-09
some O 0 5.071000508394263e-09
DMD B-Disease 1 0.9936681389808655
isoforms O 0 1.4294317907115328e-07
expressed O 0 8.783186622451922e-09
in O 0 6.323710444178232e-09
the O 0 1.5713602863343112e-07
brain O 0 0.0004177509981673211
may O 0 3.921955453733972e-07
be O 0 2.388787390117386e-09
related O 0 3.5037737156073945e-09
to O 0 4.284038901403164e-09
the O 0 9.563530767309203e-08
cognitive B-Disease 0 1.6940466593950987e-05
impairment I-Disease 0 7.7119348134147e-06
associated O 0 1.9735922762720293e-07
with O 0 3.0616361073043663e-06
DMD B-Disease 1 1.0
. O 0 1.4651161563961068e-06
. O 0 1.0934752481261967e-06

I1307K O 0 0.0007499908097088337
APC O 0 9.510879317531362e-05
and O 0 7.878284122853074e-07
hMLH1 O 0 1.6898000467335805e-05
mutations O 0 1.412572487424768e-06
in O 0 4.251308194369585e-09
a O 0 2.1752864398649763e-08
non O 0 4.16323366891902e-08
- O 0 3.877271410601679e-06
Jewish O 0 4.84401198264095e-07
family O 0 1.1560270252175542e-07
with O 0 8.375210569511182e-08
hereditary B-Disease 0 0.3504500091075897
non I-Disease 0 0.00012882678129244596
- I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.47046009969199e-06

We O 0 3.100722778981435e-06
describe O 0 7.427727268805029e-07
a O 0 3.535354267114599e-07
French O 0 7.1029653554433025e-06
Canadian O 0 1.1755245395761449e-05
hereditary B-Disease 0 0.19936305284500122
non I-Disease 0 0.00023006912670098245
- I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.0874580513918772e-05
HNPCC B-Disease 0 0.0288506131619215
) O 0 2.45318801717076e-07
kindred O 0 6.567425771208946e-06
which O 0 6.686374121045446e-08
carries O 0 9.08927972886886e-08
a O 0 8.00533612732579e-08
novel O 0 1.204879936267389e-06
truncating O 0 1.3654191207024269e-05
mutation O 0 3.5069326713710325e-06
in O 0 1.0942079597953125e-07
hMLH1 O 0 3.2781514164526016e-05
. O 0 1.9635947410279186e-06

Interestingly O 0 9.965929348254576e-05
, O 0 2.747959229054686e-07
the O 0 3.837348572233168e-08
I1307K O 0 3.4772101571434177e-06
APC O 0 2.037955482592224e-06
polymorphism O 0 2.2877229639561847e-06
, O 0 4.858851543332321e-09
associated O 0 2.8768640802923073e-09
with O 0 3.7995093182807693e-10
an O 0 1.6939847302666067e-09
increased O 0 2.3731762155421166e-07
risk O 0 5.477437525769346e-07
of O 0 5.642765245283954e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 5.494902097780141e-07
is O 0 3.6539560710480146e-08
also O 0 4.7102432176870934e-08
present O 0 3.055462993728497e-09
in O 0 5.623566945445191e-09
this O 0 1.947780425837209e-08
family O 0 1.1994891337963054e-06
. O 0 5.540038614526566e-07

The O 0 2.006541535592987e-06
I1307K O 0 1.4929636563465465e-05
polymorphism O 0 1.8576851289253682e-05
has O 0 3.207766496871045e-07
previously O 0 7.739320295740981e-08
only O 0 4.843732082093766e-09
been O 0 2.727671244429075e-08
identified O 0 5.0823615538320155e-08
in O 0 3.0267508499548512e-09
individuals O 0 9.492936436927835e-10
of O 0 1.6345421682828487e-09
self O 0 1.6747710560593987e-06
- O 0 0.0004778827424161136
reported O 0 5.815148142573889e-06
Ashkenazi O 0 3.821837708528619e-06
Jewish O 0 3.9148889641182905e-07
origins O 0 1.3456296983349603e-06
. O 0 5.607090542980586e-07

In O 0 6.673288908132236e-07
addition O 0 4.6179142287883224e-08
, O 0 8.686838803839692e-09
in O 0 1.6616384934664552e-09
this O 0 2.205827076551259e-09
family O 0 3.5377279772319525e-08
, O 0 5.64533975122572e-09
there O 0 2.887160066578076e-09
appears O 0 1.314546835828878e-07
to O 0 3.445231433474305e-09
be O 0 6.867334700899619e-09
no O 0 4.4715076086276895e-09
relationship O 0 1.0403946149040166e-08
between O 0 1.1465403737531688e-08
the O 0 8.640619775235336e-09
I1307K O 0 6.621103807447071e-07
polymorphism O 0 4.2306106706746505e-07
and O 0 2.602016158093079e-09
the O 0 1.6280765624543392e-09
presence O 0 1.472998611973253e-08
or O 0 1.778650648986968e-08
absence O 0 3.3768440488302076e-08
of O 0 1.6684099435337885e-08
cancer B-Disease 0 6.870278866699664e-06
. O 0 5.612307774072178e-08
. O 0 3.673904984680121e-07

Identification O 0 1.8261465584146208e-06
of O 0 3.13885983871387e-08
a O 0 5.0929678252487065e-08
novel O 0 4.4414244371182576e-07
mutation O 0 3.086079516378959e-07
of O 0 2.522840825136541e-09
the O 0 1.494021972803239e-08
CPO O 0 3.934005235350924e-06
gene O 0 6.852213374486382e-08
in O 0 9.66851043671113e-09
a O 0 1.9186025213002722e-07
Japanese O 0 1.2557501349874656e-06
hereditary B-Disease 0 0.00023487389262299985
coproporphyria I-Disease 0 6.193225271999836e-05
family O 0 4.0628729038871825e-06
. O 0 1.1128089454359724e-06

Hereditary B-Disease 1 0.9997896552085876
coproporphyria I-Disease 0 0.01581026241183281
( O 0 5.648633759847144e-06
HCP B-Disease 0 0.00027016212698072195
) O 0 1.013715547060201e-07
is O 0 2.3713882413289866e-08
an O 0 6.366166616089686e-08
autosomal B-Disease 1 0.9806046485900879
dominant I-Disease 1 0.9649126529693604
disease I-Disease 0 0.048371803015470505
characterized O 0 3.5633647712529637e-06
by O 0 6.599330504286627e-08
a O 0 9.01115890883375e-06
deficiency B-Disease 0 0.0004916543839499354
of I-Disease 0 1.8027497716843754e-08
coproporphyrinogen I-Disease 0 7.636818918399513e-05
oxidase I-Disease 0 1.8297027963853907e-06
( O 0 5.7938084552233704e-08
CPO O 0 6.9371776589832734e-06
) O 0 1.3569770196397712e-08
caused O 0 2.4705471446395677e-08
by O 0 1.070834976246715e-09
a O 0 4.7117886481373716e-08
mutation O 0 5.693836442333122e-07
in O 0 1.1001654698361563e-08
the O 0 9.785712506982236e-08
CPO O 0 7.029005791991949e-05
gene O 0 2.583020204838249e-06
. O 0 7.651619284843036e-07

Only O 0 2.3676248019910417e-06
11 O 0 1.0392501508249552e-06
mutations O 0 2.3453287667507539e-07
of O 0 1.1902360208537743e-09
the O 0 3.3192810722226795e-09
gene O 0 1.2373791946629353e-07
have O 0 1.8176208982367825e-07
been O 0 3.626468867423682e-07
reported O 0 1.1380277555872453e-06
in O 0 1.7616383729546214e-07
HCP B-Disease 0 0.0027876319363713264
patients O 0 5.829896053910488e-06
. O 0 4.211842963286472e-07

We O 0 4.111595899303211e-06
report O 0 9.162420155917061e-08
another O 0 2.6103190720050407e-08
mutation O 0 3.3115745168288413e-07
in O 0 5.992561558088028e-09
a O 0 9.410361201389605e-08
Japanese O 0 7.772499657221488e-07
family O 0 8.588960440647497e-07
. O 0 3.9488651282226783e-07

Polymerase O 0 0.00024020115961320698
chain O 0 7.59112008381635e-05
reaction O 0 3.000976448674919e-06
- O 0 3.6249928143661236e-06
single O 0 4.5253105440679064e-07
strand O 0 2.6669565613701707e-06
conformational O 0 2.1329690014226799e-07
polymorphism O 0 4.860606281908986e-07
and O 0 5.529563917860969e-09
direct O 0 9.991036442613677e-09
sequence O 0 1.0065752320542742e-07
analyses O 0 1.2501872959091997e-07
demonstrated O 0 1.9865911582428453e-08
a O 0 1.3819975386297756e-08
C O 0 1.467924164444412e-07
to O 0 5.4578919161940576e-09
T O 0 2.4992147018565447e-07
substitution O 0 5.385978329996988e-09
in O 0 7.758556574977149e-10
exon O 0 5.061707142317573e-08
1 O 0 5.198449226639923e-09
of O 0 4.093216321443549e-10
the O 0 4.909688655629907e-09
CPO O 0 4.861273623646412e-07
gene O 0 2.235353058210876e-08
at O 0 5.7195164160361855e-09
nucleotide O 0 5.253734158827683e-08
position O 0 4.4436486490440075e-08
85 O 0 1.8527874345863893e-08
, O 0 3.98434529813585e-09
which O 0 1.2303467578078653e-08
lies O 0 2.714654279145634e-08
in O 0 1.8069764573525049e-09
the O 0 8.267707407583202e-09
putative O 0 4.246160472121119e-07
presequence O 0 2.2842688451873983e-07
for O 0 2.5384268020900436e-09
targeting O 0 5.0133778017880104e-08
to O 0 1.9102381898505882e-08
mitochondria O 0 1.4912936876498861e-06
. O 0 4.534676634193602e-07

This O 0 6.305610895651625e-07
mutation O 0 2.9134434953448363e-06
changes O 0 2.6135221986578472e-08
the O 0 4.077042703443112e-09
codon O 0 1.09589763042095e-07
for O 0 1.3028251810709435e-09
glutamine O 0 5.770736422050504e-08
to O 0 1.8612307250975846e-09
a O 0 1.5316967250100788e-08
termination O 0 2.2129738397325127e-07
codon O 0 3.691507401981653e-07
at O 0 2.1872603284123215e-08
amino O 0 1.0559527652276302e-07
acid O 0 1.8909587140569784e-07
position O 0 2.438530373183312e-07
29 O 0 1.161036948360561e-06
. O 0 2.5570986394996e-07

MaeI O 0 0.00018533968250267208
restriction O 0 4.4759694901586045e-06
analysis O 0 4.2814431822080223e-07
showed O 0 4.3704403651645407e-07
two O 0 3.6504501643719323e-09
other O 0 1.847740072058457e-09
carriers O 0 1.7784063999215505e-08
in O 0 2.8831923515326707e-09
the O 0 5.154968363285661e-08
family O 0 1.337177536697709e-06
. O 0 6.392808700184105e-07

The O 0 2.321853344255942e-06
C O 0 3.4325890737818554e-05
- O 0 0.005686333402991295
T O 0 0.0011892232578247786
mutation O 0 3.1081964380064164e-07
is O 0 2.61972421533585e-09
located O 0 6.406850161511102e-09
within O 0 2.6271098629848666e-09
a O 0 1.2296922591303883e-08
recently O 0 2.7800120960819186e-07
proposed O 0 2.6338595304764567e-08
putative O 0 1.5055738344926795e-07
alternative O 0 2.8492559422943486e-08
translation O 0 2.872895876748771e-08
initiation O 0 3.137435200528671e-08
codon O 0 3.172989977429097e-07
( O 0 1.1229068341833681e-08
TIC O 0 4.028846660730778e-07
- O 0 3.2004453487388673e-07
1 O 0 7.941519442056233e-09
) O 0 1.4162413464191559e-09
, O 0 5.273285141882411e-10
supporting O 0 3.008918669777927e-09
that O 0 3.451308794311103e-09
TIC O 0 5.863288947693945e-07
- O 0 7.481501143047353e-07
1 O 0 1.3080496685802245e-08
is O 0 1.5302037414954839e-09
the O 0 1.3281942212728381e-09
real O 0 5.653424040019672e-08
TIC O 0 5.176447643862048e-07
rather O 0 7.796284506866868e-09
than O 0 4.7138000169866245e-09
TIC O 0 7.761130405015138e-07
- O 0 6.435155341932841e-07
2 O 0 1.4953853622046154e-07
. O 0 5.092579158372246e-08
. O 0 2.1090964708037063e-07

Human B-Disease 0 1.5181222806859296e-05
complement I-Disease 0 2.528129334677942e-05
factor I-Disease 0 0.0003479192964732647
H I-Disease 1 1.0
deficiency I-Disease 1 0.9976218342781067
associated O 0 1.8048258425551467e-05
with O 0 0.0016865474171936512
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.499376751075033e-05

This O 0 2.2941257782349567e-07
study O 0 2.3772301460667222e-08
reports O 0 1.620042056060811e-08
on O 0 1.4201371634214865e-08
six O 0 3.570033868527389e-08
cases O 0 2.2053402659594212e-08
of O 0 1.301384742191658e-07
deficiency B-Disease 0 4.2443385609658435e-05
in I-Disease 0 2.507131169338095e-09
the I-Disease 0 2.7537547797606976e-09
human I-Disease 0 4.5277555038580886e-09
complement I-Disease 0 1.4126269931580282e-08
regulatory I-Disease 0 8.263927497864643e-08
protein I-Disease 0 1.0091011404256278e-07
Factor I-Disease 0 2.7972583893642877e-07
H I-Disease 1 0.9999991655349731
( O 0 5.35110480370804e-08
FH O 0 4.03709918828099e-06
) O 0 2.3083870370754767e-09
in O 0 9.764988817551057e-10
the O 0 1.8199333151613928e-09
context O 0 1.3580955027236996e-08
of O 0 8.106064264268298e-09
an O 0 3.186072945027263e-06
acute B-Disease 1 0.9999926090240479
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.627804173651384e-06

Five O 0 1.3229608839537832e-06
of O 0 1.1208825867470296e-08
the O 0 5.080449394512243e-09
cases O 0 1.1251794163058548e-08
were O 0 5.975351768938708e-08
observed O 0 4.027793565342108e-08
in O 0 5.5071236459980355e-09
children O 0 1.120979220559093e-07
presenting O 0 7.809986186657625e-07
with O 0 9.707504068501294e-05
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00012327708827797323
HUS B-Disease 1 0.9999728202819824
) O 0 4.010119482700247e-06
. O 0 5.137049356562784e-06

Two O 0 6.733405939485237e-07
of O 0 1.922838777090874e-08
the O 0 1.2879889155215096e-08
children O 0 1.780861254019328e-07
exhibited O 0 8.907756523512944e-07
a O 0 2.232516635558568e-06
homozygous O 1 0.9965672492980957
deficiency O 0 0.004126613028347492
characterized O 0 2.3108071900423965e-07
by O 0 4.365784622706315e-09
the O 0 4.768646366670737e-09
absence O 0 1.7081609016145194e-08
of O 0 3.910634316373063e-10
the O 0 2.1714798847938255e-09
150 O 0 3.961506234162471e-09
- O 0 8.311238275382493e-08
kD O 0 1.255574915148827e-07
form O 0 1.6023892213112845e-09
of O 0 1.0691125762463116e-09
Factor O 0 6.391253748461168e-08
H O 1 0.9999972581863403
and O 0 1.542897365425233e-08
the O 0 1.5455594581936793e-09
presence O 0 8.39705638355781e-09
, O 0 1.4382310897786965e-09
upon O 0 1.8219894482029986e-09
immunoblotting O 0 2.950022803815955e-07
, O 0 8.488064695555408e-10
of O 0 2.0891752217089277e-10
the O 0 2.1088333301833018e-09
42 O 0 4.733379910248914e-08
- O 0 1.615514548802821e-07
kD O 0 6.212683842932165e-07
Factor O 0 1.2209332567181264e-07
H O 1 0.6618607640266418
- O 0 2.39746640318117e-07
like O 0 1.311344632881628e-08
protein O 0 2.5659753433160404e-08
1 O 0 1.1421989576376745e-08
( O 0 4.575381407079249e-09
FHL O 0 3.6330735042611195e-07
- O 0 4.851204948863597e-07
1 O 0 2.163188383974557e-08
) O 0 1.8764332310183818e-09
and O 0 2.284807232300068e-09
other O 0 5.2452207022213315e-09
FH O 0 1.141000848292606e-05
- O 0 2.342805373700685e-06
related O 0 1.0898713753704214e-07
protein O 0 4.720635899957415e-07
( O 0 5.168199734839618e-08
FHR O 0 7.279469627974322e-06
) O 0 8.34771540780821e-08
bands O 0 1.2951053349752328e-06
. O 0 5.473208375406102e-07

Southern O 0 2.5539853595546447e-05
blot O 0 0.0001331554085481912
and O 0 1.5721876422958303e-07
PCR O 0 6.616546670557e-07
analysis O 0 5.279366721566703e-09
of O 0 6.112149675274736e-10
DNA O 0 2.6036458322664657e-08
of O 0 1.390412562862764e-09
one O 0 2.7068780994454755e-08
patient O 0 5.874304065400793e-07
with O 0 4.147161689616041e-07
homozygous O 1 0.9948694705963135
deficiency O 0 0.00016949395649135113
ruled O 0 1.392916857412274e-07
out O 0 5.674100478358923e-08
the O 0 2.142843680275064e-09
presence O 0 2.589652936535458e-09
of O 0 1.7557086340325156e-10
a O 0 2.409604071829108e-09
large O 0 2.4321322733555917e-09
deletion O 0 6.355138992830689e-08
of O 0 1.547033945392684e-09
the O 0 1.3910287144369704e-08
FH O 0 2.8124272830609698e-06
gene O 0 3.655196678664652e-08
as O 0 8.791700700783167e-09
the O 0 1.4995919173088623e-08
underlying O 0 2.8833424039476085e-06
defect O 0 2.150888576579746e-06
for O 0 2.095942441826537e-08
the O 0 2.109853994625155e-06
deficiency O 0 0.0013945994433015585
. O 0 3.246439064241713e-07

The O 0 1.8240685051296168e-07
other O 0 4.971287825838999e-09
four O 0 1.3948385557682741e-08
children O 0 3.974335882617197e-08
presented O 0 2.471310800444826e-08
with O 0 2.500637776847725e-07
heterozygous O 0 0.05394379422068596
deficiency O 0 6.33224262855947e-05
and O 0 2.9319174643660517e-08
exhibited O 0 1.1225046847584963e-07
a O 0 1.8224458386839615e-08
normal O 0 1.695272686674798e-07
immunoblotting O 0 3.8110788409539964e-06
pattern O 0 9.79160972747195e-07
of O 0 1.2292790119161623e-09
proteins O 0 5.751700893341649e-09
of O 0 2.5396713621006484e-09
the O 0 8.465550394021193e-08
FH O 0 0.00025085220113396645
family O 0 2.7229934858041815e-06
. O 0 8.7973643303485e-07

Factor B-Disease 0 0.34393110871315
H I-Disease 1 1.0
deficiency I-Disease 1 0.9824575781822205
is O 0 1.0733469935075846e-07
the O 0 5.0485073899153576e-08
only O 0 1.428572090844682e-06
complement B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
associated O 0 9.975956345442683e-07
with O 0 1.0829395478140214e-06
HUS B-Disease 1 0.9998749494552612
. O 0 5.094501830171794e-06

These O 0 7.125274805730442e-07
observations O 0 8.130344895107555e-07
suggest O 0 6.900977922441598e-08
a O 0 2.2854012016182423e-08
role O 0 4.058431812836716e-08
for O 0 1.0608781408905088e-08
FH O 0 1.8078333596349694e-05
and O 0 1.597133376662896e-07
/ O 0 3.6979840842832346e-06
or O 0 7.556507597428208e-08
FH O 0 1.547331703477539e-05
receptors O 0 3.3591916803743516e-07
in O 0 1.8387618538895367e-08
the O 0 6.053634393765606e-08
pathogenesis O 0 9.589095498085953e-06
of O 0 3.657387139810453e-07
idiopathic O 1 0.7688668370246887
HUS B-Disease 1 0.9999898672103882
. O 0 2.1122659745742567e-06
. O 0 1.8707362414716044e-06

Further O 0 1.2632789321287419e-06
evidence O 0 3.965287831420028e-08
for O 0 2.5078101817399556e-09
a O 0 1.3436283197165722e-08
major O 0 5.8649451517567286e-08
ancient O 0 4.3036476427005255e-07
mutation O 0 0.002038676291704178
underlying O 0 0.012126222252845764
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.1162442206114065e-06
linkage O 0 0.00010151737660635263
disequilibrium O 0 0.00015110184904187918
studies O 0 1.5912010553620348e-07
in O 0 2.3457687348127365e-08
the O 0 7.506459098749474e-08
Japanese O 0 4.4631343598666717e-07
population O 0 1.4461878095062275e-07
. O 0 2.601770177079743e-07

The O 0 0.0010061096400022507
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.02097228728234768
DM B-Disease 1 1.0
) O 0 2.762626763797016e-06
mutation O 0 2.1988612388668116e-06
is O 0 1.433176866072472e-08
an O 0 1.2970116536337173e-08
unstable O 0 3.465133340796456e-05
( O 0 8.843724685902998e-08
CTG O 0 1.5464232774320408e-06
) O 0 6.780237704617775e-09
n O 0 1.069447890245101e-07
repeat O 0 1.5263734098880377e-07
, O 0 4.076684767539973e-09
present O 0 1.3393981479481454e-09
at O 0 1.288091411311143e-09
a O 0 1.7814982822272896e-09
copy O 0 1.3185779579316659e-08
number O 0 1.094390578160187e-09
of O 0 5.75158864979386e-10
5 O 0 1.4356884570077e-08
- O 0 7.175484597610193e-07
37 O 0 1.1890242745948854e-07
repeats O 0 9.603672168623234e-08
on O 0 2.1699490204696303e-08
normal O 0 1.805688754075163e-08
chromosomes O 0 6.894872939255947e-08
but O 0 3.252250690977121e-09
amplified O 0 4.4502389329181824e-08
to O 0 3.7342604564116755e-09
50 O 0 6.9380079459335775e-09
- O 0 1.0804208727677178e-07
3000 O 0 9.065197303925743e-08
copies O 0 7.007580649087686e-08
on O 0 4.196953341306653e-06
DM B-Disease 1 0.9999994039535522
chromosomes O 0 4.892137803835794e-05
. O 0 1.3008366295252927e-06

Previous O 0 1.7437218048144132e-05
findings O 0 5.668004519066017e-07
in O 0 3.3810653832233584e-08
Caucasian O 0 3.085122216361924e-06
populations O 0 3.880612098328129e-08
of O 0 3.697970818450358e-09
a O 0 1.1662549468383077e-06
DM B-Disease 1 1.0
founder O 0 6.19311958871549e-06
chromosome O 0 6.422050319088157e-06
raise O 0 4.1376797099701434e-08
a O 0 7.314061356566981e-09
question O 0 8.201084256143076e-09
about O 0 1.5856067570041432e-09
the O 0 6.699376053909134e-10
molecular O 0 1.3806354282053235e-08
events O 0 1.1126371823877435e-08
involved O 0 5.819622561631377e-09
in O 0 4.072674641975027e-09
the O 0 1.9562991226962367e-08
expansion O 0 5.64485219456401e-07
mutation O 0 4.592136065184604e-06
. O 0 5.795239417238918e-07

To O 0 3.402868742341525e-07
investigate O 0 1.8612284691243985e-07
whether O 0 2.3656870240529315e-08
a O 0 3.866419717724057e-08
founder O 0 3.593603992158023e-07
chromosome O 0 1.5143665450523258e-06
for O 0 5.777561984388058e-09
the O 0 2.730201629219664e-07
DM B-Disease 1 1.0
mutation O 0 2.313410050192033e-06
exists O 0 9.673970957635447e-09
in O 0 1.022339879419576e-09
the O 0 2.933415066408429e-09
Japanese O 0 3.535002690568945e-08
population O 0 1.954500561396344e-09
, O 0 1.1040854897004238e-09
we O 0 2.957341260767521e-09
genotyped O 0 8.860507705321652e-08
families O 0 2.363728324183967e-09
using O 0 3.086507049943066e-09
polymorphic O 0 2.231311242439915e-07
markers O 0 1.3030169156991178e-06
near O 0 9.182362532555999e-07
the O 0 2.5659607771899573e-08
( O 0 2.3903975687744605e-08
CTG O 0 1.2097802937205415e-06
) O 0 7.539069812878552e-09
n O 0 1.8526397127516248e-07
repeat O 0 5.477646709550754e-07
region O 0 1.7656499551321758e-07
and O 0 7.885945763064228e-08
constructed O 0 1.0181439392908942e-05
haplotypes O 0 5.6604872952448204e-05
. O 0 1.6063014527389896e-06

Six O 0 4.129987246415112e-06
different O 0 1.8731806505911663e-07
haplotypes O 0 9.763824891706463e-06
were O 0 5.31562307060085e-07
found O 0 8.273153184745752e-08
and O 0 1.4539916719513712e-06
DM B-Disease 1 1.0
alleles O 0 1.084126142814057e-05
were O 0 9.853359870248823e-07
always O 0 4.184138617802091e-07
haplotype O 0 9.588061402610037e-06
A O 0 1.6143900438692071e-06
. O 0 1.284458335248928e-06

To O 0 4.532095658760227e-07
find O 0 1.1168985736276227e-07
an O 0 3.7026077759350073e-09
origin O 0 4.942668052621002e-09
of O 0 1.595119480946039e-09
the O 0 1.2121479819882097e-08
( O 0 1.4765091371771177e-08
CTG O 0 5.730088332711603e-07
) O 0 5.2176609699472465e-09
n O 0 1.1897309093455988e-07
repeat O 0 2.737342583714053e-07
mutation O 0 1.1106593689191868e-07
and O 0 3.247905056014133e-09
to O 0 8.351513924864662e-10
investigate O 0 4.851221202528677e-09
the O 0 1.012103401087927e-09
mechanism O 0 4.490276150903583e-09
of O 0 1.9913463933374231e-10
the O 0 4.1633727021483935e-10
expansion O 0 6.997520785034794e-09
mutation O 0 1.5994586988199444e-08
in O 0 5.348711473729395e-10
the O 0 1.4901706535397352e-09
Japanese O 0 1.86620834341511e-08
population O 0 1.0123737403944233e-09
we O 0 1.076733480154246e-09
have O 0 1.0218251800253597e-09
studied O 0 3.033628681592404e-09
90 O 0 9.652628030210053e-09
Japanese O 0 6.413417708017732e-08
DM B-Disease 1 0.9998847246170044
families O 0 1.9166908060697097e-08
comprising O 0 3.0315927546098465e-09
190 O 0 1.2381318192922208e-08
affected O 0 1.0186886889584912e-08
and O 0 1.4028159966983367e-08
130 O 0 1.6812604997085145e-07
unaffected O 0 1.0106938361786888e-06
members O 0 6.191674373212663e-08
. O 0 2.1811241879277077e-07

The O 0 1.115212057811732e-06
results O 0 3.2876155842131993e-07
suggest O 0 4.117454821539468e-08
that O 0 1.7239460969875608e-09
a O 0 8.242231785970944e-09
few O 0 7.854269234996991e-09
common O 0 5.944180703210122e-09
ancestral O 0 2.8633888859985746e-07
mutations O 0 9.886398402159102e-07
in O 0 7.045303895836241e-09
both O 0 1.6769186927945157e-08
Caucasian O 0 6.514012056868523e-06
and O 0 7.681084923660819e-08
Japanese O 0 2.070240157081571e-08
populations O 0 6.6233254436554034e-09
have O 0 2.747474914244208e-09
originated O 0 3.320598240819095e-09
by O 0 1.5305562373058024e-10
expansion O 0 2.345485805577141e-09
of O 0 3.8755859632644274e-10
an O 0 1.0119181048651171e-09
ancestral O 0 9.675562040456498e-08
n O 0 1.2283277328606346e-06
= O 0 3.5072699233751337e-07
5 O 0 2.4374323004394682e-08
repeat O 0 4.954809540436145e-08
to O 0 7.224742137879048e-09
n O 0 4.761273544318101e-07
= O 0 3.591068775676831e-07
19 O 0 7.058541484639136e-08
- O 0 4.6280678134280606e-07
37 O 0 1.1728283766387904e-07
copies O 0 1.303199184121695e-07
. O 0 2.0223012597853085e-07

These O 0 5.002526677344576e-07
data O 0 1.5766727301524952e-07
support O 0 2.0915695841949855e-08
multistep O 0 2.0920647614275367e-07
models O 0 7.239422217253377e-08
of O 0 2.4589201785829573e-09
triplet O 0 1.2839811461162753e-05
repeat O 0 5.060452963334683e-07
expansion O 0 6.641050021016781e-08
that O 0 6.063049617921479e-09
have O 0 5.339845898788553e-09
been O 0 3.97400823359817e-09
proposed O 0 4.0384846577978806e-09
for O 0 3.47853679194543e-09
both O 0 1.9439748655258882e-07
DM B-Disease 1 1.0
and O 0 5.992854767100653e-06
Friedreichs B-Disease 0 0.0003535334253683686
ataxia I-Disease 0 0.12211064994335175
. O 0 2.667236174147547e-07
. O 0 7.522870077991684e-07

The O 0 9.656753263698192e-07
molecular O 0 8.654558314447058e-07
basis O 0 3.118945244295901e-07
of O 0 1.605813486094121e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.016591669322224e-08
the O 0 2.0954349366775205e-08
western O 0 2.1090642121635028e-07
Cape O 0 8.571515195399115e-07
, O 0 9.484218743693873e-09
South O 0 4.20664818534533e-08
Africa O 0 1.419834347871074e-07
. O 0 2.4737067860769457e-07

Deficiency B-Disease 1 0.9785658717155457
of I-Disease 0 1.2660635206884763e-07
the I-Disease 0 6.882338965397139e-08
sixth I-Disease 0 1.878649186437542e-06
component I-Disease 0 8.150205133006239e-08
of I-Disease 0 1.9206605195165594e-09
human I-Disease 0 2.0148679169551542e-08
complement I-Disease 0 5.5960494904638836e-08
( O 0 2.216278538469396e-08
C6 O 0 3.6393676055013202e-06
) O 0 7.689260783649843e-09
has O 0 1.7340978430979703e-08
been O 0 4.121580232663291e-08
reported O 0 5.729815910626712e-08
in O 0 3.9827324771479766e-10
a O 0 5.034149097582485e-09
number O 0 1.6520315115897688e-09
of O 0 1.3710930168997493e-09
families O 0 6.772508331920335e-09
from O 0 4.572151546256009e-10
the O 0 1.9458115119164177e-09
western O 0 5.406648284633775e-08
Cape O 0 2.717206086799706e-07
, O 0 4.82129758339056e-09
South O 0 2.4198714143608413e-08
Africa O 0 1.2830830087295908e-07
. O 0 2.940341232715582e-07

Meningococcal B-Disease 1 0.9999799728393555
disease I-Disease 1 0.6777995228767395
is O 0 2.3431913120930403e-07
endemic O 0 1.2755602085690043e-07
in O 0 2.5318664498286125e-08
the O 0 5.0544429086585296e-08
Cape O 0 1.4130655472399667e-06
and O 0 2.977043500607124e-08
almost O 0 5.057323004820091e-09
all O 0 7.116067735069009e-10
pedigrees O 0 2.4339533410966396e-07
of O 0 3.680942839423551e-08
total O 0 0.003980063367635012
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 6.368060923023222e-08
C6Q0 O 0 9.286700333177578e-06
) O 0 9.790339206006138e-09
have O 0 1.8139042268217054e-08
been O 0 7.634608323314751e-08
ascertained O 0 2.5892182975439937e-07
because O 0 1.1009714917520341e-08
of O 0 3.290940142619547e-08
recurrent O 1 0.7691993117332458
disease O 0 0.002134986687451601
. O 0 1.735270984681847e-06

We O 0 4.029817318951245e-06
have O 0 8.001199347518195e-08
sequenced O 0 1.8019630942944787e-07
the O 0 1.3078925498177796e-08
expressed O 0 1.1737924410226697e-08
exons O 0 1.7081192993373406e-07
of O 0 4.966946853812715e-09
the O 0 2.724603476167431e-08
C6 O 0 1.228064047609223e-05
gene O 0 4.3400824267791904e-08
from O 0 2.557745348852336e-09
selected O 0 2.1699066987679316e-09
cases O 0 3.1236999653572184e-09
and O 0 1.207896804800157e-08
have O 0 1.1473190397737199e-08
found O 0 1.0125557281526198e-08
three O 0 6.9959060766677794e-09
molecular O 0 1.5428598771904944e-06
defects O 0 0.011989081278443336
leading O 0 1.533049100999051e-07
to O 0 3.0341162471358984e-08
total O 0 4.0622231267661846e-07
deficiency O 0 1.0170831956202164e-05
879delG O 0 7.101415917531995e-07
, O 0 7.751816077927742e-09
which O 0 6.632781435200741e-09
is O 0 9.3014818070003e-10
the O 0 1.6779384548470944e-09
common O 0 2.8185651146372948e-08
defect O 0 3.27109631825806e-07
in O 0 5.369259703513762e-09
the O 0 2.8645786187553313e-08
Cape O 0 6.104239673732081e-07
and O 0 1.680501604539586e-08
hitherto O 0 9.880217533009272e-08
unreported O 0 2.2272031330317077e-08
, O 0 3.2700648855410464e-09
and O 0 2.302033452750152e-09
1195delC O 0 1.7831742127327743e-07
and O 0 1.4920001234486335e-08
1936delG O 0 2.2781338770982984e-07
, O 0 4.061464942139992e-09
which O 0 1.7353111170237412e-09
have O 0 7.538581314747717e-09
been O 0 3.9533411211323255e-08
previously O 0 9.848496063113998e-08
reported O 0 8.41116616356885e-08
in O 0 4.789511010017122e-09
African O 0 3.029357031891777e-08
- O 0 1.0668564755178522e-05
Americans O 0 7.023369335001917e-07
. O 0 3.014791616351431e-07

We O 0 1.1080203876190353e-05
also O 0 2.462427914906584e-07
show O 0 1.5567680122785532e-07
that O 0 1.7367051130534605e-09
the O 0 6.643518180027286e-09
879delG O 0 1.7900164266393404e-06
and O 0 1.9121343086681009e-07
1195delC O 0 4.987404099665582e-05
defects O 0 0.002472905209288001
are O 0 2.2722173032008186e-09
associated O 0 1.789123338369336e-08
with O 0 3.1192541882774094e-08
characteristic O 0 4.575356069835834e-05
C6 O 0 0.13553276658058167
/ O 0 5.822060484206304e-05
C7 O 0 5.7488821767037734e-05
region O 0 3.152678402784659e-07
DNA O 0 5.576422381636803e-07
marker O 0 2.1601699700113386e-06
haplotypes O 0 5.435700586531311e-06
, O 0 1.828821538651937e-08
although O 0 6.070500990773553e-09
small O 0 1.5284951970784277e-08
variations O 0 1.3549463346862467e-06
were O 0 5.138153369443899e-07
observed O 0 1.4471468148258282e-06
. O 0 5.166761525288166e-07

The O 0 1.6178702253455413e-06
1936delG O 0 3.788209505728446e-05
defect O 0 3.163868677802384e-05
was O 0 1.6399818605350447e-06
observed O 0 4.1748354107085106e-08
only O 0 1.9774792914262207e-09
once O 0 2.3306368390763055e-08
in O 0 3.4513942814839993e-09
the O 0 1.3055347025670017e-08
Cape O 0 3.36536714939939e-07
, O 0 2.7152327053414638e-09
but O 0 1.1927175913584165e-09
its O 0 3.1879838768844593e-09
associated O 0 3.779398127790046e-08
haplotype O 0 4.184512363281101e-06
could O 0 5.486032250701101e-07
be O 0 3.750608712493886e-08
deduced O 0 1.3595453083325992e-06
. O 0 4.5033286255602434e-07

The O 0 4.859429054704378e-07
data O 0 8.173181953452513e-08
from O 0 6.136309238513604e-09
the O 0 4.990468038812423e-09
haplotypes O 0 1.5945081486279378e-06
indicate O 0 9.776795195648447e-08
that O 0 1.2759385770166887e-09
these O 0 6.809212083069838e-10
three O 0 9.214045526562131e-09
molecular O 0 1.0417130624773563e-06
defects O 0 0.0017978050746023655
account O 0 1.2967594109625225e-08
for O 0 1.898533996680385e-09
the O 0 1.484836786858068e-07
defects O 0 0.020228058099746704
in O 0 2.470069926374663e-09
all O 0 7.717217420655231e-10
the O 0 2.597508652613101e-09
38 O 0 3.815024385289689e-08
unrelated O 0 5.319416018778611e-08
C6Q0 O 0 4.526762040768517e-06
individuals O 0 4.642808804078413e-09
we O 0 6.012975450886415e-09
have O 0 2.426118417275802e-09
studied O 0 7.034535176586587e-09
from O 0 4.0001379986165375e-09
the O 0 2.557049150198054e-08
Cape O 0 2.4528610538254725e-06
. O 0 3.8690686210429703e-07

We O 0 6.438220680138329e-06
have O 0 9.295654734842174e-08
also O 0 3.693503813906318e-08
observed O 0 5.45814451413662e-08
the O 0 4.832382050068418e-09
879delG O 0 1.7535671759105753e-06
defect O 0 4.3251415604572685e-07
in O 0 8.621555913634893e-09
two O 0 3.324443866858928e-07
Dutch O 1 0.8271299600601196
C6 B-Disease 1 1.0
- I-Disease 1 0.9999797344207764
deficient I-Disease 1 0.9999990463256836
kindreds O 0 1.9085840904153883e-05
, O 0 1.1828790391632538e-08
but O 0 2.5455733076995557e-09
the O 0 6.447684608446025e-09
879delG O 0 9.66054813034134e-07
defect O 0 1.7040450472904922e-07
in O 0 2.8776214744397066e-09
the O 0 1.7805446006491366e-08
Cape O 0 6.643799110861437e-07
probably O 0 2.1407333861134248e-07
did O 0 3.019527383685272e-08
not O 0 2.474974447608247e-09
come O 0 3.184744690187813e-09
from O 0 5.296610927629786e-10
The O 0 2.280497124473868e-09
Netherlands O 0 8.110676219530433e-08
. O 0 2.2593960480321584e-08
. O 0 8.728064671004176e-08

Complement B-Disease 1 0.9996246099472046
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.1454756077000638e-06
seven O 0 1.2875975130555162e-07
further O 0 5.2724459465025575e-08
molecular O 0 8.320108463522047e-06
defects O 1 0.888428807258606
and O 0 1.5258393659678404e-07
their O 0 7.574573857027644e-08
associated O 0 8.598582326158066e-07
marker O 0 3.9296686736634e-05
haplotypes O 0 0.00010661139822332188
. O 0 2.020667579927249e-06

Seven O 0 4.032423930766527e-06
further O 0 2.327578840777278e-07
molecular O 0 6.087258270781604e-07
bases O 0 1.244813915945997e-06
of O 0 1.7087144442484714e-05
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.155840803652609e-07
described O 0 4.648810318030883e-06
. O 0 6.949612725293264e-07

All O 0 1.2226041690155398e-07
these O 0 5.082523735211453e-09
new O 0 1.2546945704627888e-08
molecular O 0 5.413457984104753e-07
defects O 0 5.9784473705803975e-05
involve O 0 8.657859318361716e-09
single O 0 6.688350850936331e-08
- O 0 1.660457996877085e-06
nucleotide O 0 9.282101842700285e-08
events O 0 9.148429569449945e-09
, O 0 4.487313631784673e-09
deletions O 0 1.4757890198779933e-07
and O 0 2.9451223682031014e-08
substitutions O 0 7.423493286751182e-08
, O 0 3.73646935614147e-09
some O 0 1.9888979352344904e-10
of O 0 6.859058321317946e-10
which O 0 1.297895213525635e-08
alter O 0 2.5927096203304245e-07
splice O 0 5.564497769228183e-06
sites O 0 1.473457302836323e-07
, O 0 2.4452271318864405e-08
and O 0 3.513291702006427e-08
others O 0 2.528643392452068e-07
codons O 0 4.997404630557867e-06
. O 0 5.714339295082027e-07

They O 0 9.019679509947309e-07
are O 0 4.022325583719066e-09
distributed O 0 4.73993644334314e-09
along O 0 1.1981402536775931e-08
the O 0 1.1347118800131284e-08
C7 O 0 7.311627086892258e-06
gene O 0 8.755493041689988e-08
, O 0 6.207031777449856e-09
but O 0 2.538218524250624e-09
predominantly O 0 3.861141184557937e-09
towards O 0 4.396645270077215e-09
the O 0 4.830796651589253e-09
3 O 0 1.3461554715377133e-07
end O 0 1.1359588825143874e-06
. O 0 5.104570277580933e-07

All O 0 9.223840606864542e-07
were O 0 1.1438802971497353e-07
found O 0 2.114166619548996e-08
in O 0 1.0437934072626831e-08
compound O 0 2.352019691898022e-06
heterozygous O 0 9.70558903645724e-06
individuals O 0 1.1275216138528776e-07
. O 0 2.4937554599091527e-07

The O 0 1.4932100384612568e-05
C6 O 0 0.027089817449450493
/ O 0 0.0006809309124946594
C7 O 0 0.00020603547454811633
marker O 0 2.4358661903534085e-05
haplotypes O 0 3.0221717679523863e-05
associated O 0 3.934163999019802e-07
with O 0 1.1699461310854531e-07
most O 0 1.3486732086676056e-06
C7 B-Disease 1 0.9993159770965576
defects I-Disease 1 0.9918909072875977
are O 0 4.420705224106314e-08
tabulated O 0 3.864311565848766e-06
. O 0 1.3097702833420044e-07
. O 0 6.282117510636454e-07

A O 0 7.141920832509641e-06
genome O 0 3.266412932134699e-06
- O 0 1.0815502946570632e-06
wide O 0 1.0092782787296528e-07
search O 0 1.0294593977278055e-07
for O 0 1.3815679267281666e-08
chromosomal O 0 0.00012548244558274746
loci O 0 3.887601906171767e-06
linked O 0 5.526157565327594e-06
to O 0 9.070800643939947e-08
mental O 0 2.6585039449855685e-05
health O 0 1.9015342900274845e-07
wellness O 0 8.41304085952288e-07
in O 0 1.0710683895354123e-08
relatives O 0 5.485091136847586e-08
at O 0 1.6972908412071774e-08
high O 0 1.7099073090776074e-07
risk O 0 3.3377770591869194e-07
for O 0 1.7158974685571593e-07
bipolar B-Disease 1 0.9999536275863647
affective I-Disease 1 0.9980467557907104
disorder I-Disease 0 0.042893100529909134
among O 0 1.6982363959527902e-08
the O 0 1.0401127958914458e-08
Old O 0 3.0004098334757145e-06
Order O 0 1.280497627931254e-07
Amish O 0 2.575783946667798e-05
. O 0 6.032691430846171e-07

Bipolar B-Disease 1 0.9999997615814209
affective I-Disease 1 0.9999983310699463
disorder I-Disease 1 0.9999982118606567
( O 0 0.00017517189553473145
BPAD B-Disease 1 0.9999998807907104
; O 0 0.00027024687733501196
manic B-Disease 1 0.999998927116394
- I-Disease 1 0.9999995231628418
depressive I-Disease 1 1.0
illness I-Disease 0 0.27291566133499146
) O 0 6.660776108446953e-08
is O 0 1.1658847220985535e-08
characterized O 0 9.676392664914601e-08
by O 0 4.806450348837643e-09
episodes O 0 1.093990476874751e-06
of O 0 2.4905792983531683e-08
mania B-Disease 0 0.0006246485863812268
and O 0 5.694048468285473e-07
/ O 0 1.4491669389826711e-05
or O 0 2.5045449092431227e-07
hypomania B-Disease 0 0.00019821879686787724
interspersed O 0 1.0812732398335356e-05
with O 0 5.1736243733557785e-08
periods O 0 4.633301102785481e-07
of O 0 6.607756830590006e-08
depression B-Disease 0 9.401042916579172e-05
. O 0 7.333886173910287e-07

Compelling O 0 1.1996208741038572e-05
evidence O 0 1.4779340062887059e-07
supports O 0 8.264889572728862e-08
a O 0 3.480622368101649e-08
significant O 0 1.5429797883825813e-08
genetic O 0 1.0802786931662922e-07
component O 0 3.772253975853346e-08
in O 0 5.701631611287894e-09
the O 0 1.992693476893237e-08
susceptibility O 0 3.095398824370932e-06
to O 0 1.851025643873072e-07
develop O 0 3.808546580330585e-06
BPAD B-Disease 1 0.9999997615814209
. O 0 2.50498464993143e-06

To O 0 3.7703696875723836e-07
date O 0 2.4727916070332867e-07
, O 0 1.429169582678469e-08
however O 0 3.364370337877176e-09
, O 0 9.438916315218648e-10
linkage O 0 1.3295121448209102e-07
studies O 0 6.745564551380312e-09
have O 0 7.560381654059256e-09
attempted O 0 1.4041697227185068e-07
only O 0 1.1086709328367306e-09
to O 0 1.0122540583523687e-09
identify O 0 3.547850369045591e-08
chromosomal O 0 1.3080470125714783e-05
loci O 0 5.519860906133545e-07
that O 0 2.6623004245607262e-08
cause O 0 6.531970342393834e-08
or O 0 1.7462323143035974e-08
increase O 0 2.0755223317792115e-08
the O 0 1.608250599360872e-08
risk O 0 1.6071963671038247e-07
of O 0 1.2236816004929096e-08
developing O 0 1.2176326436019735e-06
BPAD B-Disease 1 0.9999986886978149
. O 0 1.6095997352749691e-06

To O 0 7.06554544649407e-07
determine O 0 7.341991192788555e-08
whether O 0 1.583999598153696e-08
there O 0 1.1404595490205338e-08
could O 0 3.2000968985812506e-08
be O 0 3.359400757574349e-09
protective O 0 1.558887987584967e-07
alleles O 0 4.457765712118089e-08
that O 0 3.4818290473026536e-09
prevent O 0 1.6341003217235084e-08
or O 0 1.0071279810119904e-08
reduce O 0 1.9412084384384798e-08
the O 0 6.1131557593796515e-09
risk O 0 1.77834866832427e-08
of O 0 7.967991266788488e-10
developing O 0 3.252488056659786e-08
BPAD B-Disease 1 0.9999556541442871
, O 0 3.95137877973184e-09
similar O 0 7.951245772908067e-10
to O 0 1.2424296036428473e-09
what O 0 1.6561582105723005e-09
is O 0 1.990507980664802e-09
observed O 0 7.67973418192014e-09
in O 0 2.469495274937117e-09
other O 0 2.1105692837863899e-07
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 2.0166826431022855e-08
we O 0 6.02380056946572e-09
used O 0 1.1787668796614525e-07
mental O 0 1.2993489690416027e-05
health O 0 1.5260779662185087e-07
wellness O 0 2.6394905034976546e-06
( O 0 1.0490106561178436e-08
absence O 0 1.4023451733180536e-08
of O 0 4.428458932892454e-09
any O 0 1.6564155203013797e-07
psychiatric B-Disease 0 0.08575538545846939
disorder I-Disease 0 0.0038614554796367884
) O 0 6.352870229875407e-09
as O 0 5.411185277637287e-09
the O 0 3.2518673975800994e-08
phenotype O 0 3.7154893561819335e-06
in O 0 6.535855856526496e-09
our O 0 2.713587932134942e-08
genome O 0 7.733742535265264e-08
- O 0 7.414776064251782e-07
wide O 0 1.5631874816790514e-07
linkage O 0 1.0795419029818731e-06
scan O 0 1.0961230145767331e-06
of O 0 1.645164005026345e-09
several O 0 2.2360684415190235e-09
large O 0 4.856535174013743e-09
multigeneration O 0 7.61664409765217e-07
Old O 0 2.65179807001914e-07
Order O 0 1.3350703653713936e-08
Amish O 0 1.6788296761660604e-06
pedigrees O 0 1.0186341796725173e-06
exhibiting O 0 6.783371020446793e-08
an O 0 3.772546719460479e-09
extremely O 0 9.454961968913267e-08
high O 0 1.0827536698343465e-06
incidence O 0 0.00012352384510450065
of O 0 3.587892081213795e-07
BPAD B-Disease 1 1.0
. O 0 5.238502581050852e-06

We O 0 4.5652036533283535e-06
have O 0 5.971205041532812e-08
found O 0 2.0784538534712738e-08
strong O 0 1.0691865170997517e-08
evidence O 0 1.468041799235209e-09
for O 0 9.841201187299475e-10
a O 0 1.6907124589238265e-08
locus O 0 1.199118514705333e-06
on O 0 1.431560235687357e-06
chromosome O 0 0.0001374974672216922
4p O 0 8.453094778815284e-05
at O 0 1.6707225825030037e-07
D4S2949 O 0 7.769283456582343e-07
( O 0 1.463929422129695e-08
maximum O 0 2.3644600943839578e-08
GENEHUNTER O 0 1.2600831951203872e-06
- O 0 5.707531158805068e-07
PLUS O 0 3.425903116749396e-07
nonparametric O 0 1.0552978437772254e-06
linkage O 0 1.7201817854584078e-06
score O 0 3.878748202623683e-07
= O 0 2.8562703846546356e-07
4 O 0 3.7726426427298065e-08
. O 0 4.733260006162254e-09
05 O 0 1.3981326674183947e-07
, O 0 9.80706538200593e-09
P O 0 7.103150210241438e-07
= O 0 7.517046896055035e-08
5 O 0 6.330879376292842e-09
. O 0 1.0416449924832705e-09
22 O 0 5.114117573867816e-09
x O 0 1.622437650894426e-07
10 O 0 1.5275769982281417e-08
( O 0 3.105012469362123e-09
- O 0 1.9519652028066048e-07
4 O 0 2.0548819534838003e-08
) O 0 3.443063834041027e-09
; O 0 9.153822588814364e-09
SIBPAL O 0 4.2689430301834363e-07
Pempirical O 0 1.3387325736857747e-07
value O 0 2.8029947252150578e-09
< O 0 2.4129811038164917e-08
3 O 0 7.325831052895637e-09
x O 0 1.6386110246457974e-07
10 O 0 1.6490101728550144e-08
( O 0 2.941999310834831e-09
- O 0 5.473751230056223e-07
5 O 0 4.4742741067693714e-08
) O 0 1.5692367405506502e-09
) O 0 7.688816805462295e-10
and O 0 2.510231800201268e-09
suggestive O 0 3.495709393064317e-07
evidence O 0 1.5766410399464803e-09
for O 0 8.575303245272892e-10
a O 0 2.0363644992471563e-08
locus O 0 1.1852026773340185e-06
on O 0 3.1049305562191876e-06
chromosome O 0 0.008033215068280697
4q O 0 0.012949921190738678
at O 0 1.0674508388319737e-07
D4S397 O 0 1.5582874084429932e-06
( O 0 1.9241044313389466e-08
maximum O 0 4.335887382467263e-08
GENEHUNTER O 0 1.351864170828776e-06
- O 0 6.059323709450837e-07
PLUS O 0 2.0782940168828645e-07
nonparametric O 0 5.946882311036461e-07
linkage O 0 1.4683458857689402e-06
score O 0 2.2000745047989767e-07
= O 0 9.284119784069844e-08
3 O 0 1.548735362177922e-08
. O 0 3.5861180691654226e-09
29 O 0 4.7184350648876716e-08
, O 0 3.4611968846576247e-09
P O 0 3.6605138120648917e-07
= O 0 2.4897197192785825e-08
2 O 0 4.5511332480430156e-09
. O 0 1.1930497700873843e-09
57 O 0 1.7146208008966823e-08
x O 0 3.0342323498189216e-07
10 O 0 2.208231997258281e-08
( O 0 3.046175756082903e-09
- O 0 3.5619473237602506e-07
3 O 0 2.6380273965287415e-08
) O 0 2.4209365623306667e-09
; O 0 4.825345012449134e-09
SIBPAL O 0 3.69797334087707e-07
Pempirical O 0 1.5431425026690704e-07
value O 0 3.2565459218147907e-09
< O 0 1.648827741007608e-08
1 O 0 2.216996142223593e-09
x O 0 1.1733631311017234e-07
10 O 0 1.3859967396001593e-08
( O 0 2.3477235711055755e-09
- O 0 3.2762727641966194e-07
3 O 0 4.758726390718948e-08
) O 0 1.919843839459645e-09
) O 0 7.13524461737336e-10
that O 0 9.443238413453514e-10
are O 0 3.273872062337091e-09
linked O 0 1.0861717782972846e-06
to O 0 9.063934669484297e-08
mental O 0 4.6813205699436367e-05
health O 0 1.6697379123797873e-06
wellness O 0 2.5901248591253534e-05
. O 0 9.630505246605026e-07

These O 0 7.297537649719743e-07
findings O 0 2.543820869504998e-07
are O 0 6.14944317689492e-09
consistent O 0 2.8800114293403567e-08
with O 0 3.2442646347163873e-09
the O 0 7.857595463178768e-09
hypothesis O 0 3.4050820829634176e-08
that O 0 1.219261358542667e-09
certain O 0 2.466562509795267e-09
alleles O 0 7.96359245214262e-08
could O 0 5.8323266216575576e-08
prevent O 0 3.854947294712474e-08
or O 0 5.936295011110815e-09
modify O 0 7.215655983827673e-08
the O 0 1.6618578513316606e-08
clinical O 0 9.788605837002251e-08
manifestations O 0 8.084172975486581e-08
of O 0 2.78414482579592e-08
BPAD B-Disease 1 1.0
and O 0 1.1485828821378163e-07
perhaps O 0 2.477790950194958e-08
other O 0 8.722734534671872e-09
related O 0 1.925934839164256e-06
affective B-Disease 1 0.9989210367202759
disorders I-Disease 1 0.9671411514282227
. O 0 2.980395265694824e-06

Segregation O 0 0.004194387700408697
distortion O 1 0.5171686410903931
in O 0 0.0005384836695156991
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00015754016931168735

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9456406235694885
DM B-Disease 1 1.0
) O 0 2.0099719222343992e-06
is O 0 8.214629332314871e-08
an O 0 5.5142528765372845e-08
autosomal B-Disease 1 0.6580900549888611
dominant I-Disease 1 0.7212719917297363
disease I-Disease 0 0.04157484695315361
which O 0 2.941277728041314e-07
, O 0 5.86860116058574e-09
in O 0 3.551938076995498e-09
the O 0 6.257671270049059e-09
typical O 0 1.8057339445931575e-07
pedigree O 0 1.9125625385640888e-06
, O 0 7.16567560843373e-09
shows O 0 2.0795958732833242e-08
a O 0 9.587196814209165e-09
three O 0 2.6763627758441544e-08
generation O 0 2.345950491644544e-07
anticipation O 0 3.161620725222747e-07
cascade O 0 5.681340553564951e-06
. O 0 5.688891633326421e-07

This O 0 9.324970164925617e-07
results O 0 1.0878252396651078e-06
in O 0 5.458237524180731e-07
infertility B-Disease 1 0.9998549222946167
and O 1 0.9836175441741943
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.4028502593864687e-05
CDM B-Disease 0 4.1946765122702345e-05
) O 0 3.5463891379095e-08
with O 0 5.6818301175098895e-09
the O 0 1.914447445017231e-08
disappearance O 0 2.433538611512631e-06
of O 0 1.7002984975533764e-07
DM B-Disease 1 1.0
in O 0 1.083731945072941e-06
that O 0 2.215163448227031e-07
pedigree O 0 3.143792491755448e-05
. O 0 6.984734568504791e-07

The O 0 3.195199838046392e-07
concept O 0 2.1785380965866352e-07
of O 0 1.6554642101596073e-08
segregation O 0 5.447878379527538e-07
distortion O 0 1.8994833226315677e-05
, O 0 8.558444619666261e-09
where O 0 2.87072499105534e-09
there O 0 6.590619716639878e-10
is O 0 1.1291734214324833e-09
preferential O 0 1.3522462261050805e-08
transmission O 0 2.286627136527386e-07
of O 0 4.343465032086158e-10
the O 0 1.0615314183226587e-09
larger O 0 8.706594556429081e-09
allele O 0 7.61500444923513e-08
at O 0 1.3733000514548621e-08
the O 0 5.5418567512788286e-08
DM B-Disease 1 0.9999997615814209
locus O 0 7.625986199855106e-06
, O 0 6.543804431657918e-08
has O 0 5.142515746570098e-08
been O 0 1.3714597457692435e-08
put O 0 2.6327343860543806e-08
forward O 0 2.0534830724727726e-08
to O 0 3.761216671449574e-09
explain O 0 3.006510951308883e-08
partially O 0 2.579556621640222e-07
the O 0 4.640878348283195e-09
maintenance O 0 1.4813362270160724e-07
of O 0 2.3764776813095523e-08
DM B-Disease 1 1.0
in O 0 8.017561015094543e-08
the O 0 4.903729688976455e-08
population O 0 1.0320860610590898e-07
. O 0 2.0458585936466989e-07

In O 0 1.49518155012629e-06
a O 0 4.4585058844859304e-07
survey O 0 4.979831942364399e-07
of O 0 2.824603306805784e-08
DM B-Disease 1 1.0
in O 0 8.2793256694913e-08
Northern O 0 4.166753910794796e-07
Ireland O 0 3.7767253502352105e-07
, O 0 4.655615981619121e-08
59 O 0 3.0073286438891955e-07
pedigrees O 0 4.055447789141908e-06
were O 0 4.197751763967972e-07
ascertained O 0 5.172596502234228e-06
. O 0 4.2900919083876943e-07

Sibships O 0 0.000250044628046453
where O 0 3.6189231877870043e-07
the O 0 1.0286777651913326e-08
status O 0 7.708541360784693e-09
of O 0 1.0795631055771082e-09
all O 0 5.000060920856697e-10
the O 0 2.0397530331450753e-09
members O 0 5.9784279748953395e-09
had O 0 2.6418979359732475e-07
been O 0 2.3615573496726938e-08
identified O 0 1.980099462173257e-08
were O 0 1.439911745393374e-08
examined O 0 8.954097019397977e-09
to O 0 5.338885999961462e-10
determine O 0 4.339426595834084e-09
the O 0 2.3843174101756404e-09
transmission O 0 2.7665237212204374e-07
of O 0 9.759105745743568e-10
the O 0 2.468997450932875e-08
DM B-Disease 1 0.9999984502792358
expansion O 0 7.496043252785967e-08
from O 0 1.4952934890288816e-08
affected O 0 4.302851053239465e-08
parents O 0 1.1037196046004283e-08
to O 0 6.816077036120305e-09
their O 0 1.3111387886510784e-07
offspring O 0 5.624294772132998e-06
. O 0 3.228894911444513e-07

Where O 0 2.4825369564496214e-06
the O 0 2.688670974748675e-07
transmitting O 0 1.6197636796277948e-05
parent O 0 5.5136711125669535e-06
was O 0 2.4643500182719436e-06
male O 0 9.691054856375558e-07
, O 0 1.0904494018859623e-07
58 O 0 1.1897325293830363e-06
. O 0 3.0244561344261456e-07

3 O 0 6.388636393239722e-06
% O 0 1.8999084261395183e-07
of O 0 3.2588574061520603e-09
the O 0 1.1087285756161691e-08
offspring O 0 3.023728595508146e-06
were O 0 3.165878013078327e-07
affected O 0 1.769987001409845e-08
, O 0 4.736746550548787e-09
and O 0 8.02952460077222e-09
in O 0 1.1515036701936765e-09
the O 0 1.0847189813034674e-09
case O 0 6.857570067353436e-09
of O 0 6.71541933172648e-10
a O 0 5.193685481685861e-08
female O 0 1.609541413927218e-06
transmitting O 0 4.671031092584599e-06
parent O 0 3.775047048293345e-07
, O 0 1.7707771249320103e-08
68 O 0 6.184864105307497e-07
. O 0 2.5082354682126606e-07

7 O 0 0.00010514503810554743
% O 0 3.602598326324369e-06
were O 0 4.3549010797505616e-07
affected O 0 2.099250650644535e-06
. O 0 1.5443201846210286e-06

Studies O 0 2.7260853130428586e-06
on O 0 2.340169800163494e-07
meiotic O 0 5.729428266931791e-06
drive O 0 3.308908389954013e-06
in O 0 2.771427034531371e-07
DM B-Disease 1 1.0
have O 0 8.160998277162435e-07
shown O 0 2.5057170560671693e-08
increased O 0 1.1869380145412833e-08
transmission O 0 7.442206850782895e-08
of O 0 7.162993531650841e-10
the O 0 1.6847465644787007e-09
larger O 0 1.5001297981598327e-08
allele O 0 1.1066860139408163e-07
at O 0 2.4205224491424815e-08
the O 0 8.864429901223048e-08
DM B-Disease 1 0.9999997615814209
locus O 0 1.8891990976044326e-06
in O 0 6.837512245283506e-08
non O 0 5.664406330652128e-07
- O 0 0.04256902262568474
DM O 1 0.9999996423721313
heterozygotes O 0 8.242695912485942e-06
for O 0 6.111385886242715e-08
CTGn O 0 3.4853168472182006e-05
. O 0 7.077495638441178e-07

This O 0 2.9839736725989496e-07
study O 0 4.516011031796552e-08
provides O 0 1.2141054384073868e-08
further O 0 4.342655568478904e-09
evidence O 0 7.0507883975778896e-09
that O 0 3.5645482121537952e-09
the O 0 4.129732289470667e-08
DM B-Disease 1 0.9999994039535522
expansion O 0 2.427217395961634e-07
tends O 0 1.7450328471113608e-07
to O 0 5.647752043813625e-09
be O 0 2.825228229141885e-08
transmitted O 0 1.4711027915836894e-06
preferentially O 0 1.8357012550040963e-06
. O 0 5.602402666227135e-07

Diagnosis O 1 0.984129786491394
of O 0 6.847574695711955e-05
hemochromatosis B-Disease 1 1.0
. O 0 9.98914401861839e-05

If O 0 3.066538556595333e-05
untreated O 0 0.0003814891679212451
, O 0 2.1391383597801905e-06
hemochromatosis B-Disease 1 1.0
can O 0 1.1965976227656938e-05
cause O 0 2.8030235625919886e-05
serious O 0 1.696942672424484e-05
illness O 0 4.246739626978524e-05
and O 0 1.5074847681262327e-07
early B-Disease 0 7.167557214415865e-07
death I-Disease 0 6.115897576819407e-06
, O 0 2.1997950128138655e-08
but O 0 1.405537108922772e-08
the O 0 5.4023395534841256e-08
disease O 0 4.8611250349495094e-06
is O 0 1.9672814488558288e-08
still O 0 6.376313876899076e-08
substantially O 0 5.846376893714478e-07
under O 0 2.7661781132337637e-07
- O 1 0.941774308681488
diagnosed O 0 0.016217898577451706
. O 0 1.2349806866041035e-06

The O 0 3.6793889535147173e-07
cornerstone O 0 1.7124527857959038e-06
of O 0 1.4003886050772962e-08
screening O 0 4.5843204787843206e-08
and O 0 6.2419478474851076e-09
case O 0 7.362854326231627e-09
detection O 0 3.97768040727442e-08
is O 0 3.5893206185022564e-09
the O 0 2.989720027102294e-09
measurement O 0 1.9844519272282923e-07
of O 0 6.350325598702966e-09
serum O 0 6.021827516633493e-07
transferrin O 0 6.170424740048475e-07
saturation O 0 2.291329082027005e-07
and O 0 1.8866440854026223e-08
the O 0 2.2170185687286903e-08
serum O 0 2.193465888922219e-06
ferritin O 0 1.515058920631418e-05
level O 0 3.1421728863278986e-07
. O 0 3.90358508184363e-07

Once O 0 7.2023372013063636e-06
the O 0 1.735614034714672e-07
diagnosis O 0 1.325249013461871e-05
is O 0 2.4976628765216446e-08
suspected O 0 6.840198238933226e-07
, O 0 2.7908971134138483e-08
physicians O 0 3.314449514846274e-08
must O 0 3.2543849837196603e-09
use O 0 6.382845807451076e-09
serum O 0 6.798161393817281e-07
ferritin O 0 3.9268238651857246e-06
levels O 0 6.657550244426602e-08
and O 0 1.9524820871197335e-08
hepatic O 0 4.354329121269984e-06
iron O 0 9.027458872878924e-06
stores O 0 1.3915561112298747e-06
on O 0 5.356716883397894e-07
liver O 0 2.237752141809324e-06
biopsy O 0 2.849533075277577e-06
specimens O 0 6.0576512694865414e-09
to O 0 2.030731582891576e-09
assess O 0 5.514726097999301e-08
patients O 0 1.8855361716418884e-08
for O 0 7.827196668586112e-10
the O 0 5.596473506841448e-09
presence O 0 3.2614455136581455e-08
of O 0 2.286945033347365e-08
iron B-Disease 0 0.03813211992383003
overload I-Disease 0 0.00020390564168337733
. O 0 7.715633500993135e-07

Liver O 1 0.9295470118522644
biopsy O 0 0.12057017534971237
is O 0 1.4224529820694443e-07
also O 0 1.735967458671439e-08
used O 0 6.1976388465723176e-09
to O 0 2.2336004157352818e-09
establish O 0 7.89828646929891e-09
the O 0 2.1391397542203094e-09
presence O 0 1.4309724960526182e-08
or O 0 1.5456190993745622e-08
absence O 0 2.6001274022746657e-08
of O 0 1.0228863978056779e-08
cirrhosis B-Disease 0 1.1586108485062141e-05
, O 0 1.2957407591329684e-08
which O 0 4.4668215792853516e-08
can O 0 9.026824443481019e-08
affect O 0 1.001095142783015e-06
prognosis O 0 0.00021957202989142388
and O 0 4.3202030042266415e-07
management O 0 7.854584964661626e-07
. O 0 3.90125535432162e-07

A O 0 5.96403378949617e-06
DNA O 0 3.7762965803267434e-06
- O 0 3.909343831765e-06
based O 0 4.4794571607553735e-08
test O 0 6.144905917437882e-09
for O 0 1.5043410961368409e-09
the O 0 6.107619743289661e-09
HFE O 0 8.712920134712476e-06
gene O 0 9.421981417290226e-08
is O 0 4.2798000698951455e-09
commercially O 0 1.1781348341344255e-08
available O 0 2.3442825458630523e-09
, O 0 2.002010779378338e-09
but O 0 9.314761184597842e-10
its O 0 5.504684486012934e-10
place O 0 9.598944750166538e-09
in O 0 6.610502367720983e-09
the O 0 5.537429714763675e-08
diagnosis O 0 1.1148016710649244e-05
of O 0 2.4184831204365764e-07
hemochromatosis B-Disease 1 1.0
is O 0 1.1480040029709926e-06
still O 0 2.640942966536386e-07
being O 0 2.598808919174189e-07
evaluated O 0 1.0630636779751512e-06
. O 0 6.816078439442208e-07

Currently O 0 5.355778739613015e-06
, O 0 3.708100848598406e-08
the O 0 3.3637670426855948e-09
most O 0 1.0124625582363933e-09
useful O 0 9.015993507333064e-10
role O 0 5.7872893144406135e-09
for O 0 1.7590279233203887e-09
this O 0 2.565582413183165e-09
test O 0 6.64623023283184e-09
is O 0 1.2771486090912276e-09
in O 0 3.9594039158430405e-10
the O 0 1.281944439490701e-09
detection O 0 4.399566577717451e-08
of O 0 3.084460686864077e-08
hemochromatosis B-Disease 1 1.0
in O 0 9.642437248658098e-08
the O 0 1.3354396699583049e-08
family O 0 2.0777800813220892e-08
members O 0 1.394960147393931e-09
of O 0 1.2160238371805576e-09
patients O 0 1.3108195417999013e-08
with O 0 1.1446714687224357e-09
a O 0 1.8317510352972022e-07
proven O 0 3.7349647641349293e-07
case O 0 2.8266189389114516e-08
of O 0 6.789115047922678e-09
the O 0 4.983832013749634e-07
disease O 0 4.9495138227939606e-05
. O 0 6.48531738534075e-07

It O 0 1.911820390887442e-06
is O 0 9.579304105500341e-08
crucial O 0 2.4299711753883457e-07
to O 0 1.3981994015921373e-06
diagnose O 1 0.9999957084655762
hemochromatosis B-Disease 1 1.0
before O 0 0.001160204061307013
hepatic B-Disease 1 0.999098539352417
cirrhosis I-Disease 1 0.6612092852592468
develops O 0 2.441750439174939e-05
because O 0 2.0574042025600647e-07
phlebotomy O 0 5.262512058834545e-05
therapy O 0 1.4804712918703444e-05
can O 0 2.6327703039896733e-07
avert O 0 0.00022219910169951618
serious O 0 0.001094197854399681
chronic O 1 0.9986649751663208
disease O 0 0.002913959324359894
and O 0 1.74171916000887e-07
can O 0 4.032636269357681e-08
even O 0 4.8160426757704045e-08
lead O 0 2.126406712932294e-07
to O 0 1.8876232132924997e-08
normal O 0 2.3104479396351962e-07
life O 0 1.97714896899015e-07
expectancy O 0 1.3858719967174693e-06
. O 0 3.3828328582785616e-08
. O 0 1.7167879207136139e-07

Prevalence O 0 0.00018753689073491842
of O 0 9.171214543357564e-08
the O 0 4.205749704055961e-08
I1307K O 0 2.0181428226351272e-06
APC B-Disease 0 8.533555160283868e-07
gene O 0 1.2850337327563466e-07
variant O 0 2.595718058273633e-07
in O 0 1.235503965801854e-08
Israeli O 0 2.152528168153367e-06
Jews O 0 5.0964271025577546e-08
of O 0 1.4538418247056484e-09
differing O 0 1.9820266317083224e-08
ethnic O 0 4.920265794794432e-08
origin O 0 3.400532122554978e-08
and O 0 1.862173064637318e-07
risk O 0 1.3057858723186655e-06
for O 0 1.1170694961037952e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.059253337298287e-06

BACKGROUND O 0 0.00012623662769328803
& O 0 5.546231477637775e-05
AIMS O 0 1.729637006064877e-06
Israeli O 0 1.1682809599733446e-06
Jews O 0 5.584672280178893e-08
of O 0 3.983342100610798e-09
European O 0 3.7060221558249395e-08
birth O 0 1.6176172721316107e-06
, O 0 1.8024886472289836e-08
i O 0 2.7842775196518232e-08
. O 0 1.1154520640488386e-09
e O 0 8.039362953127238e-09
. O 0 9.418756885537505e-10
, O 0 1.5139406395192623e-09
Ashkenazim O 0 1.869973118573398e-07
, O 0 1.8767949416798047e-09
have O 0 5.304803263328495e-09
the O 0 1.136241323251852e-07
highest O 0 0.410380482673645
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 5.964530282653868e-05
of O 0 4.3006007643953126e-09
any O 0 1.1696578816611236e-08
Israeli O 0 3.296612021586043e-06
ethnic O 0 1.3792846402793657e-06
group O 0 4.364760570751969e-06
. O 0 7.852457883927855e-07

The O 0 4.157768671575468e-06
I1307K O 0 4.744596662931144e-05
APC B-Disease 0 1.0522576303628739e-05
gene O 0 2.7447586035123095e-06
variant O 0 2.349178248550743e-05
was O 0 1.777704164851457e-05
found O 0 8.029926590324976e-08
in O 0 4.684699206336518e-08
6 O 0 1.1701575886036153e-06
. O 0 4.981988013241789e-07

1 O 0 2.8480769742600387e-06
% O 0 6.064034607788926e-08
of O 0 1.5067128655843476e-09
American O 0 2.765900219969808e-08
Jews O 0 5.0149651542596985e-08
, O 0 6.325786117145071e-09
28 O 0 3.3907976870750645e-08
% O 0 1.6538507230379196e-09
of O 0 1.1111054298851286e-09
their O 0 8.537742360203993e-06
familial O 1 0.9999997615814209
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 4.606913535099011e-07
, O 0 2.4687382804700064e-08
but O 0 8.106899151982816e-09
not O 0 3.726334796283481e-09
in O 0 8.120919936516202e-09
non O 0 9.038315340603731e-08
- O 0 9.755774044606369e-06
Jews O 0 7.974192044457595e-07
. O 0 2.296198573503716e-07

We O 0 5.241271082923049e-06
assessed O 0 4.843748229177436e-07
the O 0 3.6516848211931574e-08
I1307K O 0 1.3469764326146105e-06
prevalence O 0 1.5316594499381608e-06
in O 0 1.0907984737684728e-08
Israeli O 0 1.302430405303312e-06
Jews O 0 2.4026386213904516e-08
of O 0 8.127238326771646e-10
differing O 0 1.1360002716287454e-08
ethnic O 0 2.5666068381724472e-08
origin O 0 2.6601991720553997e-08
and O 0 1.7306751942669507e-07
risk O 0 2.169650770156295e-06
for O 0 1.3342604688659776e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.9064930206222925e-06

METHODS O 0 6.2575109041063115e-06
DNA O 0 1.785906988516217e-06
samples O 0 1.52182408896806e-07
from O 0 5.080817544467209e-09
500 O 0 9.460730865384903e-09
unrelated O 0 1.5284864929299147e-08
Jews O 0 9.590306326856535e-09
of O 0 4.636222517007127e-10
European O 0 4.114626861451143e-09
or O 0 2.1286512552620707e-09
non O 0 2.2144943656599025e-09
- O 0 6.264851037940389e-08
European O 0 1.9511559035123582e-09
origin O 0 1.0648347759101284e-09
, O 0 3.1981287063054253e-10
with O 0 3.1086375140709777e-10
or O 0 5.95727867036544e-09
without O 0 7.377273791853156e-10
a O 0 2.4970945311508785e-09
personal O 0 3.294299943945589e-08
and O 0 6.215883985305481e-08
/ O 0 1.0301915835952968e-06
or O 0 1.1312176084743442e-08
family O 0 1.1872979932547878e-08
history O 0 2.828418832478974e-09
of O 0 2.6767594807353134e-09
neoplasia B-Disease 0 5.12487940795836e-06
, O 0 1.3752133654065801e-08
were O 0 9.92524284981755e-09
examined O 0 1.4529693004305955e-08
for O 0 4.3163106422383635e-10
the O 0 4.487347826653831e-09
I1307K O 0 2.1988410026096972e-07
variant O 0 9.534772260622049e-08
by O 0 1.2783624159240503e-09
the O 0 3.190270936315187e-09
allele O 0 9.811896717337731e-08
- O 0 3.361293750003824e-07
specific O 0 2.1763073121405796e-08
oligonucleotide O 0 4.752069344249321e-06
( O 0 1.157007432084356e-07
ASO O 0 4.729174634121591e-06
) O 0 2.515246144696448e-08
method O 0 1.8972647808368492e-07
. O 0 3.838970599190361e-07

RESULTS O 0 1.6890346159925684e-05
In O 0 6.847692191058741e-08
persons O 0 5.047063567076293e-08
at O 0 3.5838972678448044e-08
average O 0 9.216665262101742e-07
risk O 0 1.0067170705951867e-06
for O 0 1.4260662283049896e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.1343913065029483e-07
I1307K O 0 3.110205852863146e-06
was O 0 1.8293206949238083e-06
found O 0 3.248371172048792e-08
in O 0 2.7572564675892863e-08
5 O 0 4.740553833926242e-07
. O 0 4.3987196818306984e-07

0 O 0 9.129045793088153e-06
% O 0 2.4366335082959267e-07
of O 0 3.8665355361899856e-09
120 O 0 1.8120299927204542e-08
European O 0 2.074327021261979e-08
and O 0 8.131432593927457e-08
1 O 0 3.020394956365635e-07
. O 0 5.100628186482936e-07

6 O 0 4.4973945477977395e-05
% O 0 4.285953423277533e-07
of O 0 5.518532297799084e-09
188 O 0 6.128872342969771e-08
non O 0 2.5118326973938565e-08
- O 0 1.3266728728922317e-06
European O 0 3.78815201429461e-08
Jews O 0 7.600116447292748e-08
( O 0 1.5106213169246985e-08
P O 0 6.686705091851763e-07
= O 0 1.6667121371938265e-07
0 O 0 2.1388757431850536e-08
. O 0 5.42077183141032e-09
08 O 0 1.5740450010071072e-07
) O 0 4.978758028073571e-08
. O 0 1.801166007453503e-07

It O 0 3.1770671284903074e-06
occurred O 0 2.99502357847814e-06
in O 0 1.6354604781554372e-07
15 O 0 9.976698720493005e-07
. O 0 6.613354344153777e-07

4 O 0 1.4397325685422402e-05
% O 0 2.823564670961787e-07
of O 0 9.158468650127816e-09
52 O 0 5.076906859358132e-07
Ashkenazi O 0 4.355350483820075e-06
Israelis O 0 5.697824690287234e-06
with O 0 1.5336691205902753e-07
familial O 0 0.0018280961085110903
cancer B-Disease 0 0.00011817799531854689
( O 0 5.371136424514589e-08
P O 0 3.888981154887006e-06
= O 0 3.598432840590249e-07
0 O 0 3.3442315583442905e-08
. O 0 5.820854465099501e-09
02 O 0 8.190676226149662e-08
) O 0 2.8346405223089732e-09
and O 0 2.221518080602891e-08
was O 0 1.3338965345610632e-06
not O 0 3.585495456093213e-09
detected O 0 2.235246476800512e-08
in O 0 2.208184524121748e-09
51 O 0 6.281434394850294e-08
non O 0 1.1798528376516515e-08
- O 0 1.8058648265650845e-07
European O 0 1.7399354845792914e-08
Jews O 0 3.374094603714184e-08
at O 0 3.3964550283371864e-08
increased O 0 3.135987753921654e-07
cancer B-Disease 0 8.29837972560199e-06
risk O 0 9.714215138956206e-07
. O 0 3.4349096722507966e-07

Colorectal B-Disease 1 0.9996955394744873
neoplasia I-Disease 0 0.262647420167923
occurred O 0 0.00014037539949640632
personally O 0 2.6727466320153326e-06
or O 0 3.562055539418907e-08
in O 0 5.78934322703617e-09
the O 0 8.700867581978855e-09
families O 0 6.869299795653205e-09
of O 0 5.271866831968453e-10
13 O 0 8.8910603324166e-09
of O 0 7.962020487362054e-10
20 O 0 1.0679676698543972e-08
Ashkenazi O 0 1.1325003868023487e-07
I1307K O 0 8.62435598492084e-08
carriers O 0 4.9999102635922554e-09
, O 0 5.748342357669856e-10
8 O 0 2.7967519411475905e-09
of O 0 6.729574120178938e-10
whom O 0 2.9319630812096875e-07
also O 0 4.3200506638640945e-07
had O 0 6.478406362475653e-07
a O 0 1.3760635297899171e-08
personal O 0 3.152203476020077e-07
or O 0 1.3139565169240086e-07
family O 0 9.591919791773762e-08
history O 0 2.1699490204696303e-08
of O 0 4.3430052443227396e-08
noncolonic O 0 0.0002666311338543892
neoplasia B-Disease 0 0.0003775166114792228
. O 0 1.1821041425719159e-06

CONCLUSIONS O 0 1.658095425227657e-05
The O 0 4.4956345846003387e-07
I1307K O 0 7.891791028669104e-06
APC O 0 3.6748440379597014e-06
variant O 0 3.999791715614265e-06
may O 0 1.2225179091274185e-07
represent O 0 4.016008414708949e-09
a O 0 2.1784336112773417e-08
susceptibility O 0 2.194780108766281e-06
gene O 0 3.3833302381935937e-07
for O 0 4.1626628899393836e-07
colorectal B-Disease 1 1.0
, I-Disease 0 2.479805800703616e-07
or I-Disease 0 1.6159438231966305e-08
other I-Disease 0 6.5441261298815334e-09
, I-Disease 0 8.471413792676685e-08
cancers I-Disease 0 8.665495442983229e-06
in O 0 6.93956980768462e-09
Ashkenazi O 0 7.366927547991509e-06
Jews O 0 1.5616154769304558e-07
, O 0 7.598315754364648e-09
and O 0 2.9413159907676345e-08
partially O 0 5.108919367557974e-07
explains O 0 3.646596979933747e-08
the O 0 3.600709952422676e-09
higher O 0 9.041746551474716e-08
incidence O 0 0.0005218369187787175
of O 0 7.810448005329818e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.91965298768082e-07
European O 0 5.464977448355057e-07
Israelis O 0 5.328920087777078e-05
. O 0 1.2898963177576661e-06

Systematic O 0 1.3428923011815641e-05
analysis O 0 6.654261710536957e-07
of O 0 1.2391481618578837e-07
coproporphyrinogen O 0 3.022970304300543e-05
oxidase O 0 1.4395224752661306e-05
gene O 0 5.805837281513959e-05
defects O 1 0.8206012845039368
in O 0 5.673721261700848e-07
hereditary B-Disease 1 0.5547058582305908
coproporphyria I-Disease 0 0.0006243959069252014
and O 0 1.7200504771608394e-06
mutation O 0 1.0822233889484778e-05
update O 0 1.3168310033506714e-05
. O 0 2.4074290649878094e-06

Hereditary B-Disease 1 0.9998506307601929
coproporphyria I-Disease 0 0.03536294028162956
( O 0 6.925873549334938e-06
HC B-Disease 0 0.00018529374210629612
) O 0 1.96578170630346e-07
is O 0 6.74815368029158e-08
an O 0 3.222613145226205e-07
acute O 1 0.9788864850997925
hepatic B-Disease 1 0.999992847442627
porphyria I-Disease 1 0.9999972581863403
with O 0 3.603321601985954e-05
autosomal O 1 0.9997630715370178
dominant O 0 0.04155085235834122
inheritance O 0 0.021173395216464996
caused O 0 6.12473304499872e-05
by O 0 5.9023594900509124e-08
deficient B-Disease 0 8.420333870162722e-06
activity I-Disease 0 1.3369299267651513e-07
of I-Disease 0 1.5180791734792365e-08
coproporphyrinogen I-Disease 0 7.315410766750574e-05
III I-Disease 0 0.000259528897004202
oxidase I-Disease 0 7.680961971345823e-06
( O 0 2.0954232127223804e-07
CPO O 0 1.7853886674856767e-05
) O 0 1.323332838865099e-07
. O 0 2.9836436965524626e-07

Clinical O 0 0.00027829137980006635
manifestations O 0 1.7360194760840386e-05
of O 0 1.242712812654645e-07
the O 0 6.371645895342226e-07
disease O 0 3.514708441798575e-05
are O 0 1.0313338627554458e-08
characterized O 0 5.221755827733432e-07
by O 0 3.508309376343277e-08
acute O 0 3.466276757535525e-05
attacks O 0 4.183586861472577e-05
of O 0 2.500394884918933e-06
neurological B-Disease 1 0.9989215135574341
dysfunction I-Disease 0 0.08749296516180038
often O 0 1.4181972574078827e-06
precipitated O 0 1.8155643601858173e-06
by O 0 7.008794433716048e-09
drugs O 0 3.785219959695496e-08
, O 0 1.2395449111579637e-08
fasting O 0 1.5397407651107642e-06
, O 0 1.4142175430720272e-08
cyclical O 0 3.2669549909769557e-06
hormonal O 0 9.684821634436958e-06
changes O 0 1.1844688430073802e-07
, O 0 6.928754459067932e-08
or O 0 7.139464059946476e-07
infectious B-Disease 0 0.00014019884110894054
diseases I-Disease 0 0.00015102321049198508
. O 0 1.012519192045147e-06

Skin O 1 0.9999967813491821
photosensitivity O 1 0.9995071887969971
may O 0 0.001248399494215846
also O 0 5.548043304770545e-07
be O 0 3.5956944088866294e-08
present O 0 1.6808132841106271e-07
. O 0 6.459263204305898e-07

The O 0 1.7110618273363798e-06
seven O 0 3.039663170056883e-07
exons O 0 2.669595460247365e-06
, O 0 1.7431506904586058e-08
the O 0 5.952440318424124e-09
exon O 0 1.4807388879489736e-06
/ O 0 1.2675412790486007e-06
intron O 0 1.077307479135925e-05
boundaries O 0 1.7743255966706784e-06
and O 0 3.0005530504695344e-08
part O 0 5.7285562959918934e-09
of O 0 2.2058188609008766e-09
3 O 0 2.853481539943914e-08
noncoding O 0 1.583073014899128e-07
sequence O 0 1.3793036046649831e-08
of O 0 7.782745004014657e-10
the O 0 1.1899596863429451e-08
CPO O 0 2.6651005100575276e-06
gene O 0 5.743635611565878e-08
were O 0 3.0021613639519273e-08
systematically O 0 1.395855662167378e-07
analyzed O 0 1.0438093944742377e-08
by O 0 3.7980743550214413e-10
an O 0 8.390055872276037e-10
exon O 0 1.832593170547625e-07
- O 0 8.608099619777931e-07
by O 0 1.5416796728118243e-08
- O 0 2.423937985440716e-06
exon O 0 9.926163329510018e-06
denaturing O 0 0.00010959403880406171
gradient O 0 3.197156547685154e-05
gel O 0 5.043563942308538e-05
electrophoresis O 0 3.8540474633919075e-05
( O 0 6.120344409055178e-08
DGGE O 0 1.6091855741251493e-06
) O 0 9.999691741313654e-09
strategy O 0 2.6207253256416152e-08
followed O 0 6.709404587468271e-09
by O 0 4.920926999218977e-10
direct O 0 3.5701479550453996e-09
sequencing O 0 3.0444351040159745e-08
in O 0 8.903771053780929e-09
seven O 0 3.589137165249667e-08
unrelated O 0 2.868373769615573e-07
heterozygous O 0 2.2954091036808677e-06
HC B-Disease 0 2.098731965816114e-05
patients O 0 1.023298068503209e-06
from O 0 3.583200225421024e-08
France O 0 1.6259629092019168e-06
, O 0 2.895196082874918e-08
Holland O 0 6.484909249593329e-07
, O 0 1.0644474635057577e-08
and O 0 3.1098505104409924e-08
Czech O 0 1.866158925167838e-07
Republic O 0 2.800335892061412e-07
. O 0 3.394554823898943e-07

Seven O 0 1.2225369573570788e-05
novel O 0 5.66984408578719e-06
mutations O 0 5.07726326759439e-06
and O 0 1.8567993365081747e-08
two O 0 1.4633682710041285e-08
new O 0 1.2069448018792173e-07
polymorphisms O 0 0.00022313299996312708
were O 0 1.3544812418331276e-06
detected O 0 2.321352667422616e-06
. O 0 1.9734285672257101e-07

Among O 0 1.7139786905318033e-06
these O 0 5.452390539062435e-08
mutations O 0 8.876185688677651e-07
two O 0 2.4517047947369974e-08
are O 0 3.828341377243305e-08
missense O 0 1.6754685930209234e-05
( O 0 3.111986401904687e-08
G197W O 0 6.416917130991351e-07
, O 0 1.0201897993056264e-08
W427R O 0 2.5875496589833347e-07
) O 0 2.279818556161217e-09
, O 0 8.419874242271419e-10
two O 0 5.349489740069657e-09
are O 0 1.0508450110080503e-08
nonsense O 0 9.70248493104009e-07
( O 0 7.321039774410565e-09
Q306X O 0 1.1920114673102944e-07
, O 0 2.6741111547323726e-09
Q385X O 0 8.478024682290197e-08
) O 0 2.3673691895709226e-09
, O 0 5.322627893988852e-10
two O 0 6.740648039738062e-10
are O 0 3.420584093749568e-10
small O 0 5.258704138810799e-09
deletions O 0 8.784478495726944e-07
( O 0 1.4469209830281216e-08
662de14bp O 0 1.7564447318818566e-07
; O 0 4.629738814543316e-09
1168del3bp O 0 5.317499329748898e-08
removing O 0 8.170139231822304e-09
a O 0 6.647726369379825e-09
glycine O 0 1.6249198608875304e-07
at O 0 3.191027175830641e-08
position O 0 3.7002585884238215e-08
390 O 0 2.9715859994894345e-08
) O 0 2.6879229952925243e-09
, O 0 8.270842344337836e-10
and O 0 3.925103797541851e-09
one O 0 3.7714964484791835e-09
is O 0 2.2644985886444147e-09
a O 0 1.063913579457676e-08
splicing O 0 3.907521204382647e-06
mutation O 0 1.6564328007007134e-06
( O 0 1.3901215289990887e-08
IVS1 O 0 9.336022230854724e-07
- O 0 7.928065883788804e-07
15c O 0 9.182256803796918e-07
- O 0 4.905413675260206e-07
- O 0 2.81423558590177e-06
> O 0 3.9525195916212397e-07
g O 0 9.395758979735547e-07
) O 0 6.372092187234557e-09
which O 0 2.9654014799262995e-09
creates O 0 1.4041383167295862e-08
a O 0 4.847521495321416e-09
new O 0 2.2225563611755206e-08
acceptor O 0 1.564781939578097e-07
splice O 0 2.3007298295851797e-05
site O 0 6.333470082608983e-06
. O 0 1.058213456417434e-06

The O 0 1.5131020063563483e-06
pathological O 0 4.4320031520328484e-06
significance O 0 1.9683761820488144e-07
of O 0 8.218058233921965e-09
the O 0 1.6025062166136195e-08
point O 0 1.6565148825975484e-06
mutations O 0 7.078467660903698e-07
G197W O 0 2.785069739275059e-07
, O 0 7.059481887949914e-09
W427R O 0 8.666900441767211e-08
, O 0 1.9077321944394043e-09
and O 0 1.2460487086585204e-09
the O 0 6.926131890239162e-10
in O 0 2.7031823446321823e-09
- O 0 4.6368595008061675e-07
frame O 0 7.537824785686098e-06
deletion O 0 7.49025389268354e-07
390delGly O 0 5.969167204966652e-07
were O 0 6.088976789442313e-08
assessed O 0 1.4139451387507052e-08
by O 0 5.89935988948298e-10
their O 0 3.1252018750649313e-09
respective O 0 1.6496707999635873e-08
expression O 0 1.1110572906147809e-08
in O 0 1.2530939619281867e-09
a O 0 6.104277083807119e-09
prokaryotic O 0 1.7267243634933038e-08
system O 0 6.946098363158626e-09
using O 0 7.488137221400848e-09
site O 0 2.8808034358007717e-07
- O 0 2.783534682748723e-06
directed O 0 1.1788572464865865e-06
mutagenesis O 0 1.3713070075027645e-05
. O 0 5.700089786842e-07

These O 0 1.2025932392134564e-06
mutations O 0 6.25834627498989e-06
resulted O 0 1.157956788233605e-07
in O 0 7.376053545726791e-09
the O 0 1.4762050248862124e-08
absence O 0 9.061307792990192e-08
or O 0 2.3473353039094036e-08
a O 0 4.128606079234487e-08
dramatic O 0 1.8999097619598615e-06
decrease O 0 1.0204504405919579e-06
of O 0 1.201298083230995e-08
CPO O 0 6.473236862802878e-05
activity O 0 1.0100212648467277e-06
. O 0 4.350052620338829e-07

The O 0 1.2845158607888152e-06
two O 0 3.5662100117406226e-07
polymorphisms O 0 0.00021725463739130646
were O 0 2.001947336793819e-07
localized O 0 5.197203449824883e-07
in O 0 1.177070174662731e-08
noncoding O 0 1.0469177595950896e-06
part O 0 6.315586276173235e-09
of O 0 7.925596290370152e-10
the O 0 2.8279871777669996e-09
gene O 0 2.2782897346473874e-08
1 O 0 5.323635754450606e-09
) O 0 1.2255121362159116e-09
a O 0 1.1609828654002285e-08
C O 0 1.401651957166905e-06
/ O 0 2.8209478841745295e-06
G O 0 8.429131412412971e-06
polymorphism O 0 5.464779633257422e-07
in O 0 3.776499557517354e-09
the O 0 2.0104071296600523e-08
promotor O 0 2.4035200567595894e-06
region O 0 8.663826633892313e-08
, O 0 1.1049686499120526e-08
142 O 0 4.442750167754639e-08
bp O 0 7.449562531292031e-07
upstream O 0 3.153213157247592e-08
from O 0 9.265183620321693e-10
the O 0 1.0666438843287551e-09
transcriptional O 0 5.135047231874523e-08
initiation O 0 3.287458483214323e-08
site O 0 5.430585048316061e-08
( O 0 6.74965727753829e-09
- O 0 2.3763443834923237e-07
142C O 0 6.875515623505635e-07
/ O 0 4.012481724657846e-07
G O 0 2.489711505404557e-06
) O 0 6.698203769417432e-09
, O 0 2.003947674467099e-09
and O 0 4.2543577549736256e-09
2 O 0 1.2609057797874357e-08
) O 0 9.419529600762644e-10
a O 0 4.580847701163293e-09
6 O 0 5.2554479879063365e-08
bp O 0 7.592131510136824e-07
deletion O 0 2.466809121415281e-07
polymorphism O 0 2.607334010917839e-07
in O 0 2.284842315347646e-09
the O 0 4.263455810615824e-09
3 O 0 2.4607981430335713e-08
noncoding O 0 1.0129367211675344e-07
part O 0 6.9673151692484225e-09
of O 0 5.106424727507886e-10
the O 0 5.5510152030535664e-09
CPO O 0 1.5461106386283063e-06
gene O 0 4.2605154959574065e-08
, O 0 6.096713800474163e-09
574 O 0 5.210582898484972e-08
bp O 0 2.070542990395552e-07
downstream O 0 2.886126537759992e-08
of O 0 3.452537977732817e-10
the O 0 2.9857081251805084e-09
last O 0 2.3163137186088534e-08
base O 0 1.415826123007946e-08
of O 0 4.989638147101516e-10
the O 0 6.4330540894275146e-09
normal O 0 5.8472075181725813e-08
termination O 0 3.271448747454997e-07
codon O 0 8.097381396510173e-07
( O 0 2.7582876427345582e-08
+ O 0 3.473397782727261e-07
574 O 0 6.292250418482581e-07
delATTCTT O 0 1.8342802832194138e-06
) O 0 1.218632377231188e-07
. O 0 1.979416737185602e-07

Five O 0 4.6880431909812614e-06
intragenic O 0 1.9543396774679422e-05
dimorphisms O 0 1.36009075504262e-05
are O 0 2.3449278074849644e-08
now O 0 1.625861756338054e-08
well O 0 1.0709131359476487e-08
characterized O 0 1.5386237350867304e-07
and O 0 1.1982546510580505e-08
the O 0 4.431576439145601e-09
high O 0 4.735592540328071e-08
degree O 0 8.90699869415812e-09
of O 0 1.7164260013302624e-09
allelic O 0 4.897205485576706e-07
heterogeneity O 0 5.284623512125108e-07
in O 0 3.488092303882695e-08
HC B-Disease 0 3.94766429963056e-05
is O 0 1.488754435285955e-07
demonstrated O 0 6.483696779469028e-08
with O 0 1.5599618263806292e-09
seven O 0 4.3637116142747345e-09
new O 0 1.699953178224689e-09
different O 0 2.4077755345075502e-09
mutations O 0 3.124726433156866e-08
making O 0 1.509819824718761e-09
a O 0 5.626699550731473e-09
total O 0 4.5084354027835616e-09
of O 0 4.4586649927680355e-09
nineteen O 0 2.2652918687526835e-06
CPO O 0 7.803814514772967e-05
gene B-Disease 0 1.2273194442968816e-05
defects I-Disease 0 0.17039203643798828
reported O 0 2.097387778121629e-06
so O 0 3.598370312829502e-08
far O 0 5.1431829461989764e-08
. O 0 1.3753787442283283e-08
. O 0 1.3684410760106402e-07

Coincidence O 0 1.3940366443421226e-05
of O 0 5.2131674976862996e-08
two O 0 2.9035799542498353e-08
novel O 0 2.8128945928074245e-07
arylsulfatase O 0 2.4031578504946083e-06
A O 0 1.3205843174546317e-07
alleles O 0 4.627494263331755e-07
and O 0 8.764849468434477e-08
mutation O 0 1.424439233232988e-06
459 O 0 4.849031256526359e-07
+ O 0 4.460908940018271e-07
1G O 0 1.4846506019239314e-05
> O 0 1.3062724235624046e-07
A O 0 1.98931360273491e-08
within O 0 3.377550683580921e-09
a O 0 1.902928836727824e-08
family O 0 2.730758978941594e-07
with O 0 6.449839702327154e-07
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999929666519165
: O 0 1.731853416231388e-08
molecular O 0 4.5716856078570345e-08
basis O 0 2.4755566485623604e-08
of O 0 1.870591681552014e-08
phenotypic O 0 1.6077365216915496e-05
heterogeneity O 0 0.00020346966630313545
. O 0 2.1529428977373755e-06

In O 0 3.7985753920111165e-07
a O 0 1.7302065202784433e-07
family O 0 8.871685253097894e-08
with O 0 1.8570366577819186e-08
three O 0 3.6559052318807517e-07
siblings O 0 9.000003956316505e-06
, O 0 5.131539193570234e-09
one O 0 2.362655404652969e-09
developed O 0 5.0492008796254595e-08
classical O 0 1.0196610844559473e-07
late O 0 2.562169720476959e-05
infantile O 1 0.9997547268867493
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 4.126109615754103e-06
MLD B-Disease 1 0.9999748468399048
) O 0 4.329796610136327e-08
, O 0 7.889673803163078e-09
fatal O 0 6.648083399340976e-07
at O 0 9.075802154256962e-08
age O 0 5.558900895152874e-08
5 O 0 2.6219654003512005e-08
years O 0 8.889635694231401e-09
, O 0 2.9332360984568595e-09
with O 0 1.9823215069436628e-08
deficient O 0 2.5061888663913123e-05
arylsulfatase O 0 4.042041837237775e-06
A O 0 4.406965956604836e-07
( O 0 8.452868627273347e-08
ARSA O 0 1.0072231816593558e-05
) O 0 8.861635869550355e-09
activity O 0 2.1488366641619905e-08
and O 0 1.3523261621628535e-08
increased O 0 2.733640940277837e-07
galactosylsulfatide O 0 0.00015061449084896594
( O 0 6.959806455597572e-07
GS O 1 0.9999996423721313
) O 0 2.4519997054994747e-07
excretion O 0 2.116042196576018e-06
. O 0 4.4902611762154265e-07

The O 0 4.7629174559915555e-07
two O 0 4.805141884389741e-08
other O 0 7.93089327544294e-09
siblings O 0 2.200768221882754e-06
, O 0 2.279558941609139e-08
apparently O 0 2.8813613539568905e-07
healthy O 0 3.953831040348632e-08
at O 0 1.002363791968719e-08
12 O 0 9.712074700019002e-09
( O 0 1.585346742771776e-09
1 O 0 3.162426764902193e-09
/ O 0 3.606409393341892e-08
2 O 0 7.054582251697639e-09
) O 0 8.025676789813474e-10
and O 0 3.2740716804369185e-09
15 O 0 1.1039047898009358e-08
years O 0 4.226406336016453e-09
, O 0 1.792941795031311e-09
respectively O 0 5.061357111202369e-09
, O 0 1.0929429583583783e-09
and O 0 4.951641763284442e-09
their O 0 3.959753858140402e-09
father O 0 2.6549179210633156e-07
, O 0 9.76868186342017e-09
apparently O 0 1.0201065947512689e-07
healthy O 0 9.563053460226456e-09
as O 0 2.1075787781654753e-09
well O 0 3.699043071847541e-09
, O 0 5.178518058812642e-09
presented O 0 5.507315492536691e-08
ARSA O 0 0.00011763775546569377
and O 0 1.799584538275667e-06
GS O 1 0.9999960660934448
values O 0 5.268123359769561e-08
within O 0 4.563702749038612e-09
the O 0 3.80663456311936e-09
range O 0 9.592852734385815e-08
of O 0 1.2774178514973755e-07
MLD B-Disease 1 0.9999998807907104
patients O 0 1.692512523732148e-05
. O 0 4.732671357032814e-07

Mutation O 0 6.0218648286536336e-05
screening O 0 2.380943215030129e-06
and O 0 3.64626302484794e-08
sequence O 0 3.4019400629858865e-08
analysis O 0 1.5170950717902087e-08
disclosed O 0 4.941332321095615e-08
the O 0 1.376472269498663e-09
involvement O 0 8.082227331840386e-09
of O 0 1.6622343501637715e-09
three O 0 1.8242646504518234e-08
different O 0 5.919406120824533e-08
ARSA O 0 0.00737893208861351
mutations O 0 2.4443049824185437e-06
being O 0 1.3018397027053652e-08
the O 0 9.006471679562367e-10
molecular O 0 2.2810594302313802e-08
basis O 0 1.423559758961801e-08
of O 0 1.577427077847915e-08
intrafamilial O 0 2.3489497834816575e-05
phenotypic O 0 1.9982931917184032e-05
heterogeneity O 0 9.608536493033171e-05
. O 0 2.769509137579007e-06

The O 0 2.2129092940303963e-06
late O 0 9.29719226405723e-06
infantile O 0 0.11102643609046936
patient O 0 0.0001504626270616427
inherited O 0 7.077290501911193e-05
from O 0 1.2098962542950176e-07
his O 0 4.939485052091186e-07
mother O 0 2.9057102892693365e-06
the O 0 4.342473047813655e-09
frequent O 0 3.955754479534335e-08
0 O 0 3.486216826331656e-08
- O 0 9.027561986840738e-07
type O 0 5.053421432421601e-07
mutation O 0 9.684845281299204e-07
459 O 0 2.0985230264614074e-07
+ O 0 1.9371719872651738e-07
1G O 0 2.4373453015869018e-06
> O 0 9.671096989904981e-08
A O 0 4.095234729106778e-08
, O 0 3.7099385785666072e-09
and O 0 1.3371167284503827e-08
from O 0 6.443443556491957e-09
his O 0 2.1251275938993786e-07
father O 0 2.1790513926589483e-07
a O 0 1.072452349148989e-08
novel O 0 3.664243308776349e-08
, O 0 3.422387040430408e-09
single O 0 2.037949720090637e-08
basepair O 0 4.489841671784234e-07
microdeletion O 0 1.3736278958731418e-07
of O 0 1.2777261471086376e-09
guanine O 0 5.635638444800861e-08
at O 0 5.494177113263277e-09
nucleotide O 0 9.762744923591526e-08
7 O 0 1.911112867958309e-08
in O 0 7.525881251524424e-09
exon O 0 1.0311508731319918e-06
1 O 0 3.1486399620916927e-07
( O 0 1.0566377284249029e-07
7delG O 0 3.1475672130909516e-06
) O 0 1.072540669611044e-07
. O 0 2.8879114211122214e-07

The O 0 1.452774768040399e-06
two O 0 1.265335868083639e-06
clinically O 0 0.0007765944465063512
unaffected O 0 2.1912472220719792e-05
siblings O 0 1.6556619812035933e-05
carried O 0 4.811360554413113e-07
the O 0 3.0062928146890044e-08
maternal O 0 7.429551715176785e-06
mutation O 0 1.5797836567799095e-06
459 O 0 3.754553290491458e-07
+ O 0 3.5910446172238153e-07
1G O 0 3.142022023894242e-06
> O 0 9.575066428624268e-08
A O 0 7.74095951783238e-08
and O 0 6.080492909177337e-08
, O 0 2.0906751885263475e-09
on O 0 3.6138736447810516e-08
their O 0 2.1181707055006882e-08
paternal O 0 1.2746011179842753e-06
allele O 0 1.2177923736089724e-07
, O 0 2.1255921467400185e-09
a O 0 3.4895013545366282e-09
novel O 0 3.331257047989311e-08
cytosine O 0 7.819444647338969e-08
to O 0 2.1277337669545204e-09
thymidine O 0 2.566318642038823e-07
transition O 0 7.257228418211525e-08
at O 0 9.430733527437951e-09
nucleotide O 0 1.8053552253149974e-07
2435 O 0 7.659438665541529e-07
in O 0 8.427317510495413e-09
exon O 0 3.149865506202332e-07
8 O 0 1.6902133381790918e-07
, O 0 2.7963253934615295e-09
resulting O 0 2.391746356522617e-09
in O 0 1.0232098501816722e-09
substitution O 0 1.3713552071692447e-08
of O 0 4.6608557013883e-09
alanine O 0 4.304421054257546e-06
464 O 0 1.571597067595576e-06
by O 0 6.065156554768691e-08
valine O 0 0.0003412510850466788
( O 0 2.1224296631316975e-07
A464V O 0 4.119806362723466e-06
) O 0 1.9012134089280153e-07
. O 0 4.313040165015991e-07

The O 0 8.780761163507123e-06
fathers O 0 6.711541209369898e-05
genotype O 0 0.00016890298866201192
thus O 0 2.423355226710555e-06
was O 0 3.563371592463227e-06
7delG O 0 8.09298871899955e-05
/ O 0 3.8266603951342404e-05
A464V O 0 6.0764930822188035e-05
. O 0 1.5973664631019346e-06

Mutation O 0 0.0006806544843129814
A464V O 0 7.936271867947653e-05
was O 0 3.4912623050331604e-06
not O 0 7.665714285565173e-09
found O 0 9.565570557867886e-09
in O 0 9.393232858201372e-09
18 O 0 3.2703135843803466e-07
unrelated O 0 6.72332043905044e-06
MLD B-Disease 1 1.0
patients O 0 1.6193742339964956e-05
and O 0 1.5117389295937755e-07
50 O 0 1.2783878844402352e-07
controls O 0 3.0154640171531355e-06
. O 0 7.507317718591366e-07

A464V O 0 0.00028604624094441533
, O 0 8.261262109954259e-07
although O 0 1.4526014524562925e-07
clearly O 0 2.3555951145226572e-07
modifying O 0 1.6090519920908264e-06
ARSA O 0 0.0025152028538286686
and O 0 1.0510962056287099e-05
GS O 1 0.9999998807907104
levels O 0 1.2525065358204301e-06
, O 0 3.363884104601311e-08
apparently O 0 5.552584525503335e-07
bears O 0 1.3980032065319392e-07
little O 0 1.755074308107396e-08
significance O 0 8.836183340577008e-09
for O 0 4.166869960187114e-09
clinical O 0 1.4858551367069595e-07
manifestation O 0 8.780843359090795e-07
of O 0 1.1859155790716613e-07
MLD B-Disease 1 0.9999997615814209
, O 0 8.75853274351357e-08
mimicking O 0 1.2166761962362216e-06
the O 0 5.48360574725848e-08
frequent O 0 7.268037734320387e-06
ARSA O 0 0.002613167045637965
pseudodeficiency O 0 0.00014911321341060102
allele O 0 4.390595859149471e-05
. O 0 1.6288621509374934e-06

Our O 0 1.943602183018811e-05
results O 0 6.34802745480556e-07
demonstrate O 0 6.893518644801588e-08
that O 0 1.7537348240281858e-09
in O 0 2.6398432328988974e-09
certain O 0 5.719494655664903e-09
genetic O 0 2.7032563139073318e-06
conditions O 0 3.440116415731609e-05
MLD B-Disease 1 0.9999996423721313
- O 0 0.00010431791451992467
like O 0 5.971660925752076e-07
ARSA O 0 0.00037226450513117015
and O 0 7.785876050547813e-07
GS O 1 0.9999938011169434
values O 0 8.885893976184889e-08
need O 0 5.967286220709411e-09
not O 0 9.001009937392723e-10
be O 0 1.6224810384102284e-09
paralleled O 0 5.368099209590582e-07
by O 0 1.8179081351377135e-08
clinical O 0 9.334739843325224e-07
disease O 0 1.1017319820894045e-06
, O 0 1.753045930641406e-09
a O 0 6.075354441748004e-09
finding O 0 1.6102333688650106e-08
with O 0 3.332184661530846e-08
serious O 0 3.080416490774951e-07
diagnostic O 0 2.8474032660597004e-06
and O 0 3.8209378772080527e-07
prognostic O 0 0.0001283613091800362
implications O 0 2.761762516456656e-06
. O 0 1.1241818356211297e-06

Moreover O 0 2.8304115403443575e-05
, O 0 3.3907534202626266e-07
further O 0 3.8703532823092246e-07
ARSA O 0 0.00028887236840091646
alleles O 0 2.850560576916905e-06
functionally O 0 9.229208330907568e-07
similar O 0 3.228562306389904e-08
to O 0 2.296005163771042e-08
A464V O 0 3.778115342356614e-06
might O 0 1.2235769020207954e-07
exist O 0 5.0869850554136065e-09
which O 0 3.7369112249052705e-09
, O 0 1.511617941929444e-09
together O 0 3.716823071542308e-09
with O 0 2.558023570742307e-09
0 O 0 4.597954728069453e-08
- O 0 4.446083494258346e-06
type O 0 4.800177748620627e-07
mutations O 0 8.011534760044015e-07
, O 0 9.818820423390662e-09
may O 0 1.201043176024541e-07
cause O 0 1.1580618064499504e-07
pathological O 0 2.899813807744067e-06
ARSA O 0 0.01157019380480051
and O 0 1.3230329386715312e-05
GS O 1 0.9999998807907104
levels O 0 3.0529076866514515e-07
, O 0 3.109587698446603e-09
but O 0 1.0026098840043574e-09
not O 0 1.3009081589743232e-09
clinical O 0 3.451942376386796e-08
outbreak O 0 5.136898906243914e-08
of O 0 3.7239049621717868e-09
the O 0 3.6297279848440667e-07
disease O 0 2.472389860486146e-05
. O 0 3.5859759606182706e-08
. O 0 4.967006361766835e-07

Human O 0 0.0019400859018787742
MLH1 O 1 0.9997689127922058
deficiency O 1 0.9989168643951416
predisposes O 0 0.0011074128560721874
to O 0 4.907907623419305e-06
hematological B-Disease 1 0.8990397453308105
malignancy I-Disease 1 0.9865391850471497
and O 0 1.2569324098876677e-05
neurofibromatosis B-Disease 0 0.026182010769844055
type I-Disease 0 1.0641312655934598e-05
1 I-Disease 0 2.2607187020184938e-06
. O 0 2.8949646093678894e-06

Heterozygous O 0 0.00035071466118097305
germ O 0 0.0005332189612090588
- O 0 0.012449963018298149
line O 0 0.00023862179659772664
mutations O 0 1.3420502682492952e-06
in O 0 3.621765998218507e-09
the O 0 6.300667099168322e-09
DNA O 0 2.0162747205176856e-06
mismatch O 0 6.094425043556839e-05
repair O 0 2.9310529498616233e-05
genes O 0 1.2719017377094133e-06
lead O 0 3.947504865209339e-06
to O 0 6.1145851759647485e-06
hereditary B-Disease 1 0.9999991655349731
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.0371360986027867e-05

The O 0 5.9596391110972036e-06
disease O 0 6.375650991685688e-05
susceptibility O 0 3.7122308640391566e-06
of O 0 2.5784713031384854e-08
individuals O 0 7.817878611149354e-08
who O 0 3.7398408494482283e-06
constitutionally O 0 4.507106041273801e-06
lack O 0 3.4814323868204156e-08
both O 0 6.534085716936033e-09
wild O 0 3.005252722232399e-07
- O 0 4.463392906473018e-05
type O 0 6.005545287735004e-07
alleles O 0 4.33654918197135e-07
is O 0 1.0513224424357759e-07
unknown O 0 8.647331242173095e-07
. O 0 7.84772680617607e-07

We O 0 1.0762272722786292e-05
have O 0 8.994290112696035e-08
identified O 0 4.535987230269711e-08
three O 0 1.0731112887185645e-08
offspring O 0 2.4386909558415937e-07
in O 0 1.2023342321754171e-08
a O 0 4.308992174628656e-06
hereditary B-Disease 1 0.9999942779541016
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 3.326186060803593e-06
who O 0 1.3848599564880715e-06
developed O 0 7.49122591514606e-07
hematological B-Disease 0 5.9179812524234876e-05
malignancy I-Disease 0 2.5925912268576212e-05
at O 0 2.99493798650019e-08
a O 0 1.7418214426356826e-08
very O 0 8.279606333871925e-09
early O 0 6.850017797432884e-08
age O 0 2.3284862038508436e-08
, O 0 1.4465367792482198e-09
and O 0 5.436759042964923e-09
at O 0 3.3156617451624015e-09
least O 0 1.1369362118429649e-09
two O 0 1.0371210557025279e-09
of O 0 7.772242294201703e-10
them O 0 9.699505199023406e-09
displayed O 0 8.757962177696754e-07
signs O 0 2.9138971058273455e-07
of O 0 9.388360311390898e-09
neurofibromatosis B-Disease 0 0.00022778319544158876
type I-Disease 0 6.352242394314089e-07
1 I-Disease 0 3.9656890749029117e-07
( O 0 1.9084161806404154e-07
NF1 B-Disease 0 2.2480948246084154e-05
) O 0 1.6397710567161994e-07
. O 0 3.9537488305541046e-07

DNA O 0 1.045555472956039e-05
sequence O 0 1.0625801678543212e-06
analysis O 0 1.9613044344168884e-07
and O 0 3.2607676558882304e-08
allele O 0 2.250412052262618e-07
- O 0 1.9702449094438634e-07
specific O 0 9.65835500466028e-09
amplification O 0 3.6757236898665724e-07
in O 0 4.476491177740627e-09
two O 0 4.747059278997767e-08
siblings O 0 1.2839884220738895e-05
revealed O 0 1.8219890307591413e-06
a O 0 5.70322185922123e-07
homozygous O 0 0.00026645095204003155
MLH1 O 0 0.0006819021073170006
mutation O 0 1.7307293092017062e-06
( O 0 3.008266347137578e-08
C676T O 0 7.052915975691576e-07
- O 0 8.100091690721456e-06
- O 0 6.65984844090417e-05
> O 0 3.1479605695494683e-06
Arg226Stop O 0 1.0104344255523756e-05
) O 0 1.7126605200701306e-07
. O 0 3.4411129945510766e-07

Thus O 0 7.463980182365049e-06
, O 0 1.7025166698658722e-07
a O 0 8.114002980619262e-08
homozygous O 0 1.0385525456513278e-05
germ O 0 4.558828004519455e-05
- O 0 0.000983085366897285
line O 0 0.000640248297713697
MLH1 O 0 0.0004505629185587168
mutation O 0 4.3976051529170945e-06
and O 0 2.1637377756178466e-07
consequent O 0 6.374233635142446e-05
mismatch O 1 0.9963996410369873
repair O 1 0.9998255372047424
deficiency O 1 0.7393710613250732
results O 0 2.3509539914812194e-07
in O 0 3.4961320949378205e-08
a O 0 4.230540071148425e-06
mutator O 1 0.9688337445259094
phenotype O 0 0.002227314980700612
characterized O 0 4.617730155587196e-06
by O 0 2.4931085818025167e-07
leukemia B-Disease 0 0.04930010065436363
and O 0 7.633261702721938e-06
/ O 0 0.23724107444286346
or O 0 0.007506963796913624
lymphoma B-Disease 1 1.0
associated O 0 1.9001960254172445e-06
with O 0 5.355618100111315e-07
neurofibromatosis B-Disease 0 0.024079926311969757
type I-Disease 0 1.3728229077969445e-06
1 I-Disease 0 4.603026582117309e-07
. O 0 1.5421744592458708e-07
. O 0 6.304504154286406e-07

Missense O 1 0.9133024215698242
mutations O 0 0.0009603322250768542
in O 0 1.3174697244267009e-07
the O 0 1.0462131605493141e-08
most O 0 3.6341176734566716e-09
ancient O 0 7.697566140052459e-09
residues O 0 5.463915186965096e-08
of O 0 2.167598101010526e-09
the O 0 1.8578337090957575e-08
PAX6 O 0 8.147209882736206e-06
paired O 0 6.585687515325844e-07
domain O 0 8.903656834036155e-08
underlie O 0 4.443996317604615e-07
a O 0 6.524971496446597e-08
spectrum O 0 1.3824662801198428e-06
of O 0 1.2999680620850995e-07
human O 0 7.818264566594735e-05
congenital B-Disease 1 1.0
eye I-Disease 1 0.9999881982803345
malformations I-Disease 1 0.9997779726982117
. O 0 1.4235227354220115e-05

Mutations O 0 0.0003157160826958716
of O 0 1.5817720111499511e-07
the O 0 9.32933161834626e-08
human O 0 4.219727145482466e-07
PAX6 O 0 0.00019276622333563864
gene O 0 0.00017483982082922012
underlie O 0 0.37742486596107483
aniridia B-Disease 1 1.0
( O 0 0.000599473831243813
congenital B-Disease 1 0.9999908208847046
absence I-Disease 0 1.0695841865526745e-06
of I-Disease 0 1.5837580136235374e-08
the I-Disease 0 1.7997889756316e-07
iris I-Disease 0 0.0024691158905625343
) O 0 2.612340921359646e-08
, O 0 4.516611973315321e-09
a O 0 3.898841072214054e-08
rare O 0 1.3769267752650194e-06
dominant O 0 0.0009430503705516458
malformation B-Disease 1 0.5323634147644043
of I-Disease 0 5.3527585919255216e-08
the I-Disease 0 1.6526033732588985e-06
eye I-Disease 1 0.5423135757446289
. O 0 3.773884373003966e-06

The O 0 1.7529417846162687e-06
spectrum O 0 5.95957044424722e-06
of O 0 1.1491394502627372e-07
PAX6 O 0 0.00019141322991345078
mutations O 0 2.2274967705016024e-05
in O 0 4.1419997387492913e-07
aniridia B-Disease 1 1.0
patients O 0 3.7341458209994016e-06
is O 0 7.722447570301938e-09
highly O 0 1.315076669783366e-08
biased O 0 3.2600718213871005e-07
, O 0 5.607992292766539e-09
with O 0 2.875448767980515e-09
92 O 0 5.190615226524642e-08
% O 0 9.552985069660735e-10
of O 0 2.9850519278618037e-10
all O 0 4.994915592249072e-09
reported O 0 2.079847718050587e-06
mutations O 0 6.120263265074755e-07
leading O 0 6.622278903023471e-08
to O 0 5.8270752667510806e-09
premature O 0 2.0907324937979865e-07
truncation O 0 3.873192611081322e-07
of O 0 3.195679054712741e-09
the O 0 2.2094409857231767e-08
protein O 0 1.5289025157017022e-07
( O 0 6.6938996567955655e-09
nonsense O 0 1.1512433673033229e-07
, O 0 8.535633311268498e-10
splicing O 0 5.7382155915775e-08
, O 0 4.184200097512303e-09
insertions O 0 6.490453330343371e-08
and O 0 1.7479550251664477e-08
deletions O 0 1.454033053960302e-07
) O 0 2.4679178700637294e-09
and O 0 7.628592868513806e-09
just O 0 4.544335041600789e-08
2 O 0 2.7631847032694168e-08
% O 0 4.155789934401355e-09
leading O 0 1.7847121558389745e-09
to O 0 1.6378744194245343e-10
substitution O 0 1.3008237820244517e-09
of O 0 4.779215356798261e-10
one O 0 2.445805691309033e-08
amino O 0 2.3738682131124733e-08
acid O 0 1.7156446929789126e-08
by O 0 1.1241492181568447e-09
another O 0 2.3200543708412624e-08
( O 0 5.153287574444221e-08
missense O 0 7.104178166628117e-06
) O 0 9.040522286341002e-08
. O 0 2.3788841474470246e-07

The O 0 8.680902965352288e-07
extraordinary O 0 1.4950602178487316e-07
conservation O 0 2.751446004367608e-08
of O 0 1.7826302656231974e-09
the O 0 6.027569998678928e-09
PAX6 O 0 1.7489808215032099e-06
protein O 0 4.3915353131751544e-08
at O 0 9.597095562696722e-09
the O 0 3.0382032445430696e-09
amino O 0 7.100888410604966e-08
acid O 0 8.416975560976425e-08
level O 0 1.7395105800233068e-08
amongst O 0 8.70496741356419e-09
vertebrates O 0 1.3166025603084108e-08
predicts O 0 1.233590012361674e-07
that O 0 3.542486304297654e-09
pathological O 0 8.207156838579976e-07
missense O 0 0.0001170774339698255
mutations O 0 5.090994818601757e-06
should O 0 3.2961288809474354e-08
in O 0 4.524837837749374e-09
fact O 0 1.2819009853615171e-08
be O 0 7.01853286599885e-09
common O 0 8.933114692410982e-09
even O 0 3.0953874130545955e-08
though O 0 1.1733402693892003e-08
they O 0 4.4929659992476445e-09
are O 0 3.0371545278740086e-09
hardly O 0 1.177871240543027e-07
ever O 0 4.919711926731907e-08
seen O 0 2.3044580643727386e-07
in O 0 1.4669906533981703e-07
aniridia B-Disease 1 0.9999995231628418
patients O 0 8.746804269321728e-06
. O 0 6.714982418998261e-07

This O 0 3.5416715604696947e-07
indicates O 0 3.816312812432443e-07
that O 0 5.481658238437603e-09
there O 0 2.7910393995966842e-09
is O 0 1.4418677363181587e-09
a O 0 1.9788950922361437e-08
heavy O 0 1.0701355677156243e-05
ascertainment O 0 3.473517426755279e-05
bias O 0 1.4284303688327782e-05
in O 0 3.7025864596529345e-09
the O 0 1.891990786262454e-09
selection O 0 5.48483747309092e-09
of O 0 3.1464706395922803e-09
patients O 0 2.5275383563894138e-08
for O 0 3.3905698249014904e-09
PAX6 O 0 8.798582712188363e-06
mutation O 0 2.0702528047422675e-07
analysis O 0 5.493422605695741e-09
and O 0 9.232342002007954e-09
that O 0 2.0242272302795072e-09
the O 0 2.932336862215834e-08
missing O 0 6.094076070439769e-06
PAX6 O 0 0.0002171102969441563
missense O 0 0.0004160995886195451
mutations O 0 4.0742648707237095e-05
frequently O 0 1.041954237734899e-05
may O 0 1.630843826205819e-06
underlie O 0 1.947422424564138e-05
phenotypes O 0 2.069387301162351e-05
distinct O 0 6.603333986276994e-07
from O 0 3.1071886041900143e-07
textbook O 0 8.904796413844451e-05
aniridia B-Disease 1 0.9999988079071045
. O 0 5.537483957596123e-06

Here O 0 7.053601621009875e-06
we O 0 9.820583812825134e-08
present O 0 1.9818376273406102e-08
four O 0 2.6147237264240175e-08
novel O 0 1.0088160706800409e-06
PAX6 O 0 0.00029554430511780083
missense O 0 0.00038761741598136723
mutations O 0 7.440619810950011e-06
, O 0 5.285129667242927e-09
two O 0 1.2186016640214348e-08
in O 0 1.3347420058096304e-08
association O 0 7.720371009156679e-09
with O 0 2.034206048051601e-08
atypical O 0 2.0806626707781106e-05
phenotypes O 0 7.496908801840618e-05
ectopia B-Disease 0 5.7970519264927134e-05
pupillae I-Disease 0 4.24248501076363e-05
( O 0 6.949321829097244e-08
displaced B-Disease 0 4.580649601848563e-07
pupils I-Disease 0 6.319022531897645e-07
) O 0 9.37181425797462e-08
and O 0 1.568727384437807e-05
congenital B-Disease 1 0.9999983310699463
nystagmus I-Disease 0 0.0025969897396862507
( O 0 3.0794172545256515e-08
searching B-Disease 0 1.7832574883414054e-07
gaze I-Disease 0 1.9168488506693393e-05
) O 0 8.29161717064153e-09
, O 0 3.93627397343721e-09
and O 0 5.990641316344636e-09
two O 0 7.127237022785948e-09
in O 0 1.9964140562933608e-08
association O 0 6.682074449315678e-09
with O 0 3.4886895594610223e-09
more O 0 3.846765039838829e-08
recognizable O 0 5.172210148884915e-05
aniridia B-Disease 1 0.9999957084655762
phenotypes O 0 0.00043447455391287804
. O 0 1.6487670109199826e-06

Strikingly O 0 0.0002981135912705213
, O 0 1.72904705664223e-07
all O 0 3.5103160378469056e-09
four O 0 2.3098371215724e-08
mutations O 0 1.802055891175769e-07
are O 0 1.0143955675445682e-09
located O 0 1.8092533693447876e-08
within O 0 4.472889614248743e-09
the O 0 1.1294108759329902e-08
PAX6 O 0 2.7893142942048144e-06
paired O 0 3.544131175203802e-07
domain O 0 5.383125767366437e-08
and O 0 1.8274302959753186e-08
affect O 0 1.6357404319933266e-08
amino O 0 1.9003572049314243e-08
acids O 0 1.5923449225851982e-08
which O 0 2.025540180028429e-09
are O 0 4.0363415387822954e-10
highly O 0 1.1461745996754757e-09
conserved O 0 6.994491652534407e-09
in O 0 2.881740845950276e-09
all O 0 1.7364071291936511e-09
known O 0 3.5464836400933564e-08
paired O 0 2.664711473698844e-07
domain O 0 1.2415803496423905e-07
proteins O 0 2.370072991197958e-07
. O 0 2.9559285508184985e-07

Our O 0 6.061235581000801e-06
results O 0 3.213415595837432e-07
support O 0 2.1669215755082405e-08
the O 0 1.0376518311261407e-08
hypothesis O 0 4.6530946207212764e-08
that O 0 1.6757347731655159e-09
the O 0 1.225766932400063e-09
under O 0 1.6331834773453124e-09
- O 0 6.673708696780523e-08
representation O 0 7.778846011774476e-09
of O 0 5.85305182099205e-09
missense O 0 5.920944386161864e-05
mutations O 0 1.2964522966285585e-06
is O 0 6.859336210141009e-09
caused O 0 6.664562590685819e-08
by O 0 6.641718730548973e-09
ascertainment O 0 1.6519856217200868e-05
bias O 0 7.918545452412218e-05
and O 0 1.1040063441214443e-07
suggest O 0 1.7526589957128635e-08
that O 0 9.889108421035075e-10
a O 0 7.544075586451982e-09
substantial O 0 2.623856332206742e-08
burden O 0 4.443606016479862e-08
of O 0 2.646674657214021e-09
PAX6 B-Disease 0 2.2896892915014178e-05
- I-Disease 0 0.0006594703299924731
related I-Disease 0 2.8770305107173044e-06
disease I-Disease 0 1.4637510503234807e-05
remains O 0 1.834511351717083e-07
to O 0 9.790768196182853e-09
be O 0 2.230706286354689e-08
uncovered O 0 2.1966018266539322e-06
. O 0 1.5360960503585375e-07
. O 0 4.3396562432462815e-07

The O 0 9.69465986599971e-07
chromosomal O 0 4.377743607619777e-05
order O 0 8.140820995095055e-08
of O 0 7.078276631489189e-09
genes O 0 3.636615986124525e-07
controlling O 0 2.528508105115179e-07
the O 0 1.1178635794806269e-08
major O 0 4.6593648050929914e-08
histocompatibility O 0 8.708706218385487e-07
complex O 0 2.544497057499484e-08
, O 0 9.673417622479974e-09
properdin O 0 4.025981468203099e-07
factor O 0 3.2653733939014273e-08
B O 0 1.6091411225716001e-07
, O 0 1.4970714445894373e-08
and O 0 1.0158412351302104e-06
deficiency B-Disease 0 3.068783371418249e-06
of I-Disease 0 8.104638071770864e-10
the I-Disease 0 8.977730558967778e-09
second I-Disease 0 3.1338529993263364e-07
component I-Disease 0 7.045736793998003e-08
of I-Disease 0 7.318722072824357e-09
complement I-Disease 0 4.708402059350192e-07
. O 0 3.7512998574129597e-07

The O 0 2.9237594389996957e-07
relationship O 0 3.531293657488277e-07
of O 0 4.066589287532452e-09
the O 0 3.0138698203785452e-09
genes O 0 3.0574582865483535e-08
coding O 0 3.0008766316313995e-07
for O 0 9.6887431411119e-09
HLA O 0 1.1848727581309504e-06
to O 0 1.4963968952841356e-09
those O 0 5.396443292227104e-10
coding O 0 3.695314632068403e-08
for O 0 2.7597699681081167e-09
properdin O 0 5.849203716934426e-07
Factor O 0 3.817084248680658e-08
B O 0 5.643985545589203e-08
allotypes O 0 2.4251164632005384e-07
and O 0 3.809338267046769e-08
for O 0 2.685643707422969e-08
deficiency B-Disease 0 1.2792334018740803e-06
of I-Disease 0 3.2354321999328306e-10
the I-Disease 0 1.2420813266800224e-09
second I-Disease 0 3.081655464143296e-08
component I-Disease 0 1.3959883027325759e-08
of I-Disease 0 1.1499584617880032e-09
complement I-Disease 0 6.216453130036825e-08
( O 0 1.997571885681282e-08
C2 O 0 3.057871708733728e-06
) O 0 8.51393089362773e-09
was O 0 4.344869708461374e-08
studied O 0 5.7712834511391975e-09
in O 0 2.300883483741245e-09
families O 0 6.881968328542598e-09
of O 0 2.637291496299099e-09
patients O 0 2.2889224737809855e-07
with O 0 1.2556590718304506e-06
connective O 1 0.9999827146530151
tissue O 1 0.9997566342353821
disorders O 1 0.9314255714416504
. O 0 2.9222419470897876e-06

Patients O 0 0.0020213662646710873
were O 0 2.068582489300752e-06
selected O 0 5.251149204354988e-08
because O 0 1.249347736376194e-08
they O 0 2.4221803229806937e-08
were O 0 6.890955006610966e-08
heterozygous O 0 5.644523639602994e-07
or O 0 1.358590964173345e-07
homozygous O 0 9.993851563194767e-05
for O 0 1.641432572796475e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.3745247947081225e-06

12 O 0 1.738909304549452e-05
families O 0 3.8217362430259527e-07
with O 0 2.6727304813789488e-08
15 O 0 1.0908654246577498e-07
matings O 0 7.69515463616699e-06
informative O 0 9.056640010385308e-06
for O 0 8.738242468098179e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 9.047540174833557e-07
found O 0 3.318203880553483e-07
. O 0 4.3080822820229514e-07

Of O 0 6.250164688026416e-07
57 O 0 1.2163698102085618e-06
informative O 0 3.2370840585826954e-07
meioses O 0 2.8821605155826546e-06
, O 0 6.576496236476714e-09
two O 0 2.1519857007490373e-09
crossovers O 0 3.3917430641849933e-07
were O 0 1.194366774370792e-07
noted O 0 1.6471743080614942e-08
between O 0 1.106179468024493e-07
the O 0 0.0003145348164252937
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999892711639404
gene O 0 1.0514007442452566e-07
and O 0 1.1494766027908554e-08
the O 0 1.4313684459921205e-08
HLA O 0 3.739234443855821e-06
- O 0 3.878883944707923e-06
B O 0 1.1529947130384244e-07
gene O 0 2.4901849471348214e-08
, O 0 1.3015585276221486e-09
with O 0 5.963528559860265e-10
a O 0 7.124817624770685e-09
recombinant O 0 5.147206749711586e-08
fraction O 0 4.601306002882666e-08
of O 0 9.901683029056585e-09
0 O 0 3.4106273005818366e-07
. O 0 4.1691231444929144e-07

035 O 0 0.04218092933297157
. O 0 0.00022955397434998304

A O 0 1.882352080428973e-05
lod O 0 0.00038373694405891
score O 0 3.0495136797981104e-06
of O 0 1.4987799445975725e-08
13 O 0 1.661912421013767e-07
was O 0 1.10247867723956e-07
calculated O 0 5.772871958242831e-08
for O 0 4.9328452433883285e-09
linkage O 0 4.7737561544636264e-05
between O 0 0.002713325433433056
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
and O 0 6.926838125309587e-08
HLA O 0 5.251397396932589e-06
- O 0 2.861425173250609e-06
B O 0 9.221468388886933e-08
at O 0 3.934518044701463e-09
a O 0 3.76481290587094e-09
maximum O 0 1.5106271789022685e-08
likelihood O 0 5.7032085720720715e-09
value O 0 1.1738768845859227e-09
of O 0 3.200404663505907e-10
the O 0 1.5710905909571693e-09
recombinant O 0 1.7472251201411382e-08
fraction O 0 1.4534764503082442e-08
of O 0 4.000855646779655e-09
0 O 0 1.924971257949437e-07
. O 0 1.9845390397676965e-07

04 O 0 0.007991456426680088
. O 0 6.997586024226621e-05

18 O 0 5.07261574966833e-05
families O 0 3.238899921598204e-07
with O 0 1.6037599692708682e-08
21 O 0 9.798188926879448e-08
informative O 0 6.396400209496278e-08
matings O 0 7.884041224315297e-07
for O 0 9.531150979569247e-09
both O 0 1.7413098518659353e-08
properdin O 0 2.0633533495129086e-06
Factor O 0 8.586260946685798e-08
B O 0 1.4364367473262973e-07
allotype O 0 5.378998935157142e-07
and O 0 3.96891230991514e-08
HLA O 0 5.637934918922838e-06
- O 0 1.486238579673227e-05
B O 0 7.789455480633478e-07
were O 0 8.588013145072182e-08
found O 0 1.7683409225810465e-07
. O 0 4.1999621203103743e-07

Of O 0 9.380108849654789e-07
72 O 0 2.11181873055466e-06
informative O 0 9.971238341677235e-07
meioses O 0 1.0052482139144558e-05
, O 0 3.3294785595217036e-08
three O 0 1.7600791935024063e-08
recombinants O 0 6.869734988868004e-06
were O 0 1.8250638333938696e-07
found O 0 1.3489153793955211e-08
, O 0 1.9101606962834694e-09
giving O 0 1.1454992510095963e-09
a O 0 2.7799196278266436e-09
recombinant O 0 1.8394668899190947e-08
fraction O 0 1.818282768795143e-08
of O 0 5.298382177443273e-09
0 O 0 2.697997558698262e-07
. O 0 3.2380225434280874e-07

042 O 0 0.003884830977767706
. O 0 9.60130273597315e-05

A O 0 1.1387159247533418e-05
lod O 0 0.00018098752480000257
score O 0 8.707169740773679e-07
of O 0 4.433724054564436e-09
16 O 0 5.256811164144892e-08
between O 0 2.027412016047947e-08
HLA O 0 4.617166268872097e-06
- O 0 4.308096777094761e-06
B O 0 1.3543724719511374e-07
and O 0 4.779026507861772e-09
Factor O 0 2.3905526447265402e-08
B O 0 4.3669281524216785e-08
allotypes O 0 2.5801077185860777e-07
was O 0 8.43566709818333e-08
calculated O 0 2.074315297306839e-08
at O 0 2.505152085774398e-09
a O 0 4.481839344094851e-09
maximum O 0 8.43624281543498e-09
likelihood O 0 7.776383981195067e-09
value O 0 9.259105704373383e-10
of O 0 2.0477042284028357e-10
the O 0 8.800689621502045e-10
recombinant O 0 2.99852764840125e-08
fraction O 0 2.968889312171541e-08
of O 0 8.870192580445746e-09
0 O 0 4.1732195654731186e-07
. O 0 1.8794256106957619e-07

04 O 0 0.0066580199636518955
. O 0 0.0001853313879109919

A O 0 2.6148791221203282e-06
crossover O 0 3.3232406622119015e-06
was O 0 6.276037311181426e-06
shown O 0 4.432999034520435e-08
to O 0 1.5761629779120767e-09
have O 0 2.2759529372251563e-08
occurred O 0 2.091565498574255e-08
between O 0 2.185440939328487e-09
genes O 0 7.527690470965354e-09
for O 0 6.899708027141571e-10
Factor O 0 2.0457699534404128e-08
B O 0 1.1107737662996442e-07
and O 0 2.718893021835811e-08
HLA O 0 5.569371296587633e-06
- O 0 4.340862687968183e-06
D O 0 3.1180697988020256e-06
, O 0 1.8290368108964117e-09
in O 0 2.0991781646273466e-09
which O 0 3.017264660343244e-08
HLA O 0 2.26074234888074e-06
- O 0 1.5715446579633863e-06
D O 0 1.2667715054703876e-06
segregared O 0 1.6258685775483173e-07
with O 0 1.090946177839669e-08
HLA O 0 3.816014213953167e-06
- O 0 2.005036321861553e-06
A O 0 3.669888144486322e-07
and O 0 2.8050777700627805e-07
B O 0 1.0779544936667662e-06
. O 0 2.1858009802144807e-07

These O 0 3.1150898394116666e-07
studies O 0 3.7407140496270586e-08
suggest O 0 3.012940297253408e-08
that O 0 1.041899344578212e-09
the O 0 1.4627173916537117e-09
genes O 0 1.062429344500515e-08
for O 0 2.7277322622865086e-09
Factor O 0 1.2490765755046596e-07
B O 0 1.844315556809306e-05
and O 0 0.004110863897949457
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999992847442627
are O 0 1.4670845649433772e-09
located O 0 9.29212351508113e-09
outside O 0 6.061523283307224e-09
those O 0 6.830714327499265e-10
for O 0 1.5756400628674783e-09
HLA O 0 4.333343440521276e-06
, O 0 7.358446296734655e-09
that O 0 4.877214743181923e-10
the O 0 7.541338664651676e-10
order O 0 1.1669921695656171e-09
of O 0 9.842028303452821e-10
genese O 0 4.058556157815474e-07
is O 0 1.0023982532914033e-08
HLA O 0 3.0484244462058996e-07
- O 0 1.0025592445117582e-07
A O 0 5.4780237235263485e-08
, O 0 5.440680350687899e-09
- O 0 2.3129348392103566e-07
B O 0 5.8753350629103807e-08
, O 0 2.020924982915062e-09
- O 0 1.7354436465666367e-07
D O 0 2.9862795258850383e-07
, O 0 2.909415597329712e-09
Factor O 0 2.265255893973972e-08
B O 0 2.7118835532746743e-07
allotype O 0 3.256508716731332e-05
, O 0 2.0307526938267983e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999992847442627
, O 0 6.671962982096602e-09
that O 0 5.97995319928657e-10
the O 0 1.880005040533206e-09
genes O 0 9.980146131738366e-08
coding O 0 7.611948149133241e-06
for O 0 7.046542305033654e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
and O 0 3.28359774925957e-08
Factor O 0 5.155951754431953e-08
B O 0 1.033267835737206e-07
allotypes O 0 2.1421504925456247e-07
are O 0 8.625170577758468e-10
approximately O 0 2.4253825614550806e-09
3 O 0 6.765613846937413e-09
- O 0 2.2703171964622015e-07
- O 0 8.253088594756264e-07
5 O 0 1.5755986737531202e-08
centimorgans O 0 5.211040132735434e-08
from O 0 1.0132623629033333e-09
the O 0 1.4788222868489243e-09
HLA O 0 3.5905242157241446e-07
- O 0 9.095852959717377e-08
A O 0 2.4646688245866244e-08
and O 0 1.8424762160407226e-08
HLA O 0 1.4846868907625321e-06
- O 0 1.3626332702187938e-06
B O 0 7.090007869692272e-08
loci O 0 2.64226756030439e-08
, O 0 1.5984880086250541e-09
and O 0 2.689153566493019e-09
that O 0 1.5123100549629953e-09
the O 0 5.269990221989929e-09
apparent O 0 4.318110597978375e-07
lack O 0 5.8924132240179006e-09
of O 0 7.268276536187557e-10
recombinants O 0 4.6545861209779105e-07
between O 0 5.712430084514608e-09
the O 0 3.1088525087596963e-09
Factor O 0 2.4513353125144022e-08
B O 0 2.487786048277485e-07
gene O 0 1.8798697283273214e-06
and O 0 0.000802117632701993
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999955892562866
gene O 0 1.53095243149437e-07
suggests O 0 3.097909484495176e-08
that O 0 7.075721675242619e-10
these O 0 1.7685611308770888e-10
two O 0 4.237012074526092e-09
genes O 0 9.147019852662197e-08
lie O 0 5.53496874999837e-07
in O 0 4.154617094798141e-09
close O 0 7.751862796112619e-08
proximity O 0 5.525180668541907e-08
to O 0 1.7637960425531674e-08
one O 0 4.809625764323755e-08
another O 0 1.8118940658951033e-07
. O 0 3.9509254179392883e-07

Distribution O 0 5.312599114404293e-06
of O 0 1.3203968762809382e-07
emerin O 0 2.3162723664427176e-05
and O 0 4.994670916858013e-07
lamins O 0 1.1591082511586137e-05
in O 0 4.8638703731285204e-08
the O 0 5.208873687934101e-08
heart O 0 6.98647954777698e-06
and O 0 3.900284184510383e-08
implications O 0 7.397740375836293e-08
for O 0 2.6937955865946606e-08
Emery B-Disease 0 0.06855128705501556
- I-Disease 1 0.9983246922492981
Dreifuss I-Disease 1 0.9999562501907349
muscular I-Disease 1 0.9995952248573303
dystrophy I-Disease 1 0.996908962726593
. O 0 3.6705012007587356e-06

Emerin O 0 0.0004421680932864547
is O 0 4.809075448974909e-07
a O 0 6.420014386776529e-08
nuclear O 0 1.5464941327536508e-07
membrane O 0 1.6057286700288387e-07
protein O 0 2.0000277345388895e-07
which O 0 4.6892317584479315e-08
is O 0 8.713821664230181e-09
missing O 0 1.0532171756949538e-07
or O 0 3.1695901014927585e-08
defective O 0 2.527356173231965e-06
in O 0 2.7675949354488694e-07
Emery B-Disease 1 0.7680455446243286
- I-Disease 1 0.999967098236084
Dreifuss I-Disease 1 0.9999970197677612
muscular I-Disease 1 0.9999958276748657
dystrophy I-Disease 1 0.9999889135360718
( O 0 1.766602690622676e-05
EDMD B-Disease 1 0.9999992847442627
) O 0 1.932698523887666e-06
. O 0 2.064288310066331e-06

It O 0 3.7803824852744583e-06
is O 0 3.812667515035173e-08
one O 0 9.882551665896244e-09
member O 0 2.6008153408696444e-09
of O 0 3.974142681606452e-10
a O 0 3.1239043352115914e-08
family O 0 7.509481037004662e-08
of O 0 9.15427733616525e-09
lamina O 0 3.984271643275861e-06
- O 0 1.1270112736383453e-05
associated O 0 5.153218651798852e-08
proteins O 0 5.1970614478591415e-09
which O 0 6.04299543738307e-09
includes O 0 1.6545046221949633e-08
LAP1 O 0 5.042511020292295e-06
, O 0 2.7662007795470345e-08
LAP2 O 0 4.578008429234615e-06
and O 0 1.333969947836522e-07
lamin O 0 5.432183388620615e-05
B O 0 4.331756827014033e-06
receptor O 0 4.701501893578097e-06
( O 0 3.5058320690950495e-07
LBR O 0 0.00010428370296722278
) O 0 4.343652051375102e-07
. O 0 8.290796813525958e-07

A O 0 6.3383822634932585e-06
panel O 0 1.0772536143122124e-06
of O 0 1.6557104132175482e-08
16 O 0 1.7146690822755772e-07
monoclonal O 0 2.1087878394610016e-06
antibodies O 0 7.391590202132647e-07
( O 0 1.462004028951469e-08
mAbs O 0 4.054339513004379e-07
) O 0 6.550582298814334e-09
has O 0 2.3220954048497333e-08
been O 0 1.130415228089987e-08
mapped O 0 5.742451776313828e-07
to O 0 1.6839788452571725e-09
six O 0 2.1077315448536638e-09
specific O 0 6.177171552046445e-10
sites O 0 8.003866902583923e-09
throughout O 0 3.063253206647687e-09
the O 0 1.7312414835046752e-09
emerin O 0 1.4019258287589764e-07
molecule O 0 1.5701566269399336e-08
using O 0 1.1162656576857444e-08
phage O 0 2.00668409888749e-07
- O 0 1.0596772881399374e-07
displayed O 0 2.099503326746799e-08
peptide O 0 8.916619442800311e-09
libraries O 0 1.7356421855296844e-09
and O 0 5.0393555994787675e-09
has O 0 5.325067942152373e-09
been O 0 2.6712003720064104e-09
used O 0 2.2571893243394925e-09
to O 0 2.4505018014764346e-09
localize O 0 7.877089842622809e-07
emerin O 0 2.288682935613906e-06
in O 0 1.0600124333848271e-08
human O 0 3.1055233051802134e-08
and O 0 5.421084097179119e-07
rabbit O 0 0.0069358134642243385
heart O 0 0.00015261270164046437
. O 0 1.0312462563888403e-06

Several O 0 2.380752448516432e-06
mAbs O 0 2.2138585336506367e-05
against O 0 1.8500072940241807e-07
different O 0 4.084500915269018e-08
emerin O 0 9.081245480047073e-06
epitopes O 0 1.0549584658292588e-05
did O 0 2.7049691198044457e-07
not O 0 4.414189902490762e-09
recognize O 0 4.371025763560965e-09
intercalated O 0 1.3373183449516546e-08
discs O 0 4.70879285785486e-07
in O 0 8.675166363047992e-09
the O 0 6.128708918140546e-08
heart O 0 5.934015916864155e-06
, O 0 1.084436096476793e-08
though O 0 5.409142023182767e-09
they O 0 1.4636830636405307e-09
recognized O 0 4.876026693523272e-09
cardiomyocyte O 0 2.4046380531217437e-07
nuclei O 0 4.914497608865531e-08
strongly O 0 1.9236347625906092e-08
, O 0 1.560095719277399e-09
both O 0 1.3769896334281384e-09
at O 0 7.174373539697854e-09
the O 0 3.742731902178775e-09
rim O 0 2.8806221052946057e-07
and O 0 1.3567492018751182e-08
in O 0 6.516910122655872e-09
intranuclear O 0 1.3892861261410872e-06
spots O 0 2.6217260256089503e-06
or O 0 1.403092113605453e-07
channels O 0 1.4056437294129864e-06
. O 0 9.932316515914863e-07

A O 0 2.7554657208384015e-05
polyclonal O 0 0.00041758021689020097
rabbit O 0 0.00010478240437805653
antiserum O 0 6.265962292673066e-05
against O 0 1.6247105349975755e-06
emerin O 0 2.9720065867877565e-05
did O 0 4.557563784146623e-07
recognize O 0 4.23727257725659e-08
both O 0 6.4458522963661835e-09
nuclear O 0 5.728547947114748e-08
membrane O 0 3.799469538989797e-08
and O 0 1.4066366738063607e-08
intercalated O 0 6.817873554609832e-08
discs O 0 1.0115849136127508e-06
but O 0 9.831901515156005e-09
, O 0 1.2085321632326895e-09
after O 0 1.1475264072302593e-09
affinity O 0 4.299353761894054e-09
purification O 0 6.247224515476546e-09
against O 0 2.080035033102945e-09
a O 0 8.491194414261827e-09
pure O 0 2.983159674840863e-08
- O 0 5.144270744494861e-06
emerin O 0 2.6355087356932927e-06
band O 0 1.0067999056673216e-07
on O 0 6.9161290028318945e-09
a O 0 1.0293411456530066e-08
western O 0 6.023917364927911e-08
blot O 0 5.0926093535963446e-05
, O 0 1.0047261866930057e-07
it O 0 2.225585404858066e-08
stained O 0 3.393728911760263e-05
only O 0 7.569472160184887e-09
the O 0 1.0284227691670367e-08
nuclear O 0 3.707610289893637e-07
membrane O 0 1.0779863259813283e-06
. O 0 2.741467710620782e-07

These O 0 4.005290179520671e-07
results O 0 2.3762198964050185e-07
would O 0 2.3769128887352053e-08
not O 0 2.5468263054051477e-09
be O 0 1.7867627377654571e-09
expected O 0 7.644922028759993e-09
if O 0 2.805562226981806e-09
immunostaining O 0 1.82458180120193e-07
at O 0 3.971704742866677e-09
intercalated O 0 1.981606878587172e-08
discs O 0 1.3049642575424514e-06
were O 0 2.059064740933536e-07
due O 0 4.353918114929911e-09
to O 0 6.148138664840985e-10
a O 0 3.0447468990502102e-09
product O 0 4.588683211181888e-09
of O 0 2.1347734691090636e-10
the O 0 3.434248663225503e-09
emerin O 0 4.947717116010608e-07
gene O 0 5.2726267796288084e-08
and O 0 5.732843888495154e-08
, O 0 6.062448321131342e-09
therefore O 0 3.461104514101976e-09
, O 0 1.665785842597245e-09
cast O 0 1.6323060236800302e-08
some O 0 1.5057591840061946e-09
doubt O 0 4.073047232822091e-09
upon O 0 4.793923036316983e-10
the O 0 1.329182652831662e-09
hypothesis O 0 7.395172474389256e-08
that O 0 6.03500325269124e-08
cardiac B-Disease 0 0.002093283226713538
defects I-Disease 0 0.4479674994945526
in O 0 4.413258238855633e-07
EDMD B-Disease 1 1.0
are O 0 4.3791479242827336e-07
caused O 0 5.329018222255399e-07
by O 0 2.9976225945915758e-09
absence O 0 3.4279157290484363e-08
of O 0 8.362038173004294e-09
emerin O 0 1.0942275366687682e-05
from O 0 6.520816242527872e-08
intercalated O 0 1.9471881387289613e-06
discs O 0 3.6873549106530845e-05
. O 0 1.3242458862805506e-06

Although O 0 1.06305406006868e-05
emerin O 0 4.78688016301021e-05
was O 0 1.5034719353934634e-06
abundant O 0 1.6579036810071557e-08
in O 0 1.3315222258114545e-09
the O 0 1.5381425022553685e-09
membranes O 0 5.0958441022430634e-08
of O 0 2.6261379737491097e-09
cardiomyocyte O 0 6.808867283325526e-07
nuclei O 0 1.299814300637081e-07
, O 0 1.539734206801313e-08
it O 0 1.1439692748638208e-08
was O 0 6.579748514923267e-07
absent O 0 1.5999590985416035e-08
from O 0 9.013448876160624e-10
many O 0 7.604807339411934e-10
non O 0 1.3681233923534819e-08
- O 0 4.086912213097094e-06
myocyte O 0 2.156965092581231e-05
cells O 0 1.8852347238862421e-07
in O 0 1.2211285316254816e-08
the O 0 9.674509726664837e-08
heart O 0 1.963800605153665e-05
. O 0 9.55032191995997e-07

This O 0 2.1369638147916703e-07
distribution O 0 6.368230742737069e-08
of O 0 6.133383578799112e-09
emerin O 0 6.650215709669283e-06
was O 0 4.2697814706116333e-07
similar O 0 3.2342615252645146e-09
to O 0 5.6509414925187684e-09
that O 0 1.072625654963133e-09
of O 0 1.4108328949546944e-09
lamin O 0 1.4181065353113809e-06
A O 0 2.051043139772446e-07
, O 0 5.354461318773929e-09
a O 0 5.868444397094663e-09
candidate O 0 4.103272743805064e-08
gene O 0 5.4319730935503685e-08
for O 0 3.961022621012944e-09
an O 0 2.7860783902156072e-08
autosomal O 0 4.548071592580527e-05
form O 0 2.5933846359293966e-07
of O 0 1.926746790559264e-06
EDMD B-Disease 1 1.0
. O 0 1.0886496056627948e-05

In O 0 1.2899614603156806e-06
contrast O 0 2.2332237676891964e-06
, O 0 2.4525940034436644e-07
lamin O 0 0.000171019317349419
B1 O 0 0.0026434247847646475
was O 0 5.544226041820366e-06
absent O 0 1.7830008403052489e-07
from O 0 9.523662747312756e-09
cardiomyocyte O 0 6.970121830818243e-07
nuclei O 0 2.9529869038924517e-07
, O 0 9.904194797627497e-09
showing O 0 1.332265071596339e-07
that O 0 1.3618178584806628e-08
lamin O 0 6.154980655992404e-05
B1 O 0 0.00013007411325816065
is O 0 1.5146143894639863e-08
not O 0 1.2542895611034055e-09
essential O 0 1.0190555066458273e-09
for O 0 4.10243894410911e-10
localization O 0 3.8112059286277145e-08
of O 0 1.542272975996184e-09
emerin O 0 6.171590030135121e-07
to O 0 6.062552238006447e-09
the O 0 1.5187511692715816e-08
nuclear O 0 6.296674541772518e-07
lamina O 0 7.097359230101574e-06
. O 0 3.087969560056081e-07

Lamin O 0 0.023484190925955772
B1 O 0 0.3329460620880127
is O 0 3.253218892496079e-06
also O 0 6.045246436769958e-07
almost O 0 2.560141467711219e-07
completely O 0 2.7418755053076893e-06
absent O 0 1.7876690208140644e-06
from O 0 1.2041799379858276e-07
skeletal O 0 0.00041741086170077324
muscle O 0 6.3398911152035e-05
nuclei O 0 2.0525965737761e-05
. O 0 1.379668788104027e-06

In O 0 4.728020212496631e-05
EDMD B-Disease 1 0.9999984502792358
, O 0 8.269667262084113e-08
the O 0 3.451993357828087e-09
additional O 0 5.6581028751168105e-09
absence O 0 1.5430387634296494e-08
of O 0 9.467445494237836e-09
lamin O 0 0.0002798060013446957
B1 O 0 0.00047492372686974704
from O 0 6.268018637456407e-08
heart O 0 3.1847512218519114e-06
and O 0 9.870404937828425e-08
skeletal O 0 3.712512261699885e-05
muscle O 0 1.8223418010165915e-06
nuclei O 0 2.856193930256268e-07
which O 0 3.2032662744541085e-08
already O 0 7.981216754160414e-08
lack O 0 4.02370083918413e-08
emerin O 0 5.258267719909782e-06
may O 0 4.290967225983877e-08
offer O 0 1.1386288578663084e-09
an O 0 3.107558654846798e-10
alternative O 0 3.7962513133038556e-09
explanation O 0 2.425419642904103e-09
of O 0 1.0003043948714208e-09
why O 0 9.544521617499413e-09
these O 0 1.7181294165169447e-09
tissues O 0 2.983472313644597e-08
are O 0 1.368647417621105e-09
particularly O 0 1.079921929658667e-08
affected O 0 7.25947160162832e-08
. O 0 3.017258976001358e-08
. O 0 2.5969089278987667e-07

Genetic O 0 5.550443165702745e-05
mapping O 0 7.915337846498005e-06
of O 0 4.932434194415691e-08
the O 0 1.183457172260205e-07
copper B-Disease 0 5.070111001259647e-05
toxicosis I-Disease 0 0.00017043619300238788
locus O 0 2.2279907625488704e-06
in O 0 6.189490164842937e-08
Bedlington O 0 2.7268362828181125e-05
terriers O 0 3.309594467282295e-05
to O 0 6.643672634254472e-08
dog O 0 5.026968938182108e-05
chromosome O 0 2.2181402528076433e-05
10 O 0 6.234632365931247e-08
, O 0 1.4114789337327238e-09
in O 0 1.6864762919510667e-09
a O 0 3.279685856227843e-08
region O 0 3.009345448390377e-07
syntenic O 0 2.166743570342078e-06
to O 0 8.698262554673875e-09
human O 0 3.244185364792429e-08
chromosome O 0 1.0513659617572557e-05
region O 0 1.0456186601004447e-06
2p13 O 0 8.955549674283247e-06
- O 0 4.1554430936230347e-05
p16 O 0 3.8647576729999855e-05
. O 0 1.4342892882268643e-06

Abnormal O 1 0.9900649189949036
hepatic B-Disease 1 0.9807428121566772
copper I-Disease 0 0.0003201587242074311
accumulation I-Disease 0 3.4545553262432804e-06
is O 0 4.752005722252761e-08
recognized O 0 1.3389389152962394e-08
as O 0 2.449297653583926e-08
an O 0 1.6366757336072624e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 6.515880954793829e-07
man O 0 0.0013875087024644017
, O 0 4.932179820116289e-08
mouse O 0 3.173771619913168e-05
, O 0 1.3586064540049847e-07
rat O 0 5.521586717804894e-05
and O 0 4.4663534026767593e-07
dog O 0 7.675703818676993e-05
. O 0 7.582812031614594e-07

The O 0 7.605190148751717e-07
major O 0 6.240665015866398e-07
cause O 0 1.1726576758519514e-06
of O 0 9.131610312351768e-08
hepatic B-Disease 0 0.007013843860477209
copper I-Disease 0 0.0001019443225231953
accumulation I-Disease 0 1.085773078557395e-06
in O 0 4.557928789949983e-08
man O 0 3.082160674239276e-06
is O 0 7.702031012968291e-09
a O 0 6.001383212606015e-08
dysfunctional O 0 6.8477188506221864e-06
ATP7B O 0 1.4129729606793262e-05
gene O 0 1.1006429758708691e-06
, O 0 1.5240389927839715e-07
causing O 0 1.0276814464305062e-05
Wilson B-Disease 0 0.000333986448822543
disease I-Disease 0 0.0002711897832341492
( O 0 3.5851931556862837e-07
WD B-Disease 0 0.00045703042997047305
) O 0 6.665655973847606e-07
. O 0 7.520431495322555e-07

Mutations O 0 0.0003269643057137728
in O 0 9.420921287528472e-08
the O 0 3.1217005869166314e-08
ATP7B O 0 9.010565008793492e-06
genes O 0 2.6737561142908817e-07
have O 0 8.288078845453128e-08
also O 0 1.5686188703512016e-07
been O 0 1.0293160812580027e-07
demonstrated O 0 4.3964043072719505e-08
in O 0 8.973588094818297e-09
mouse O 0 2.832417521858588e-05
and O 0 1.4799002201471012e-06
rat O 0 0.00033238111063838005
. O 0 9.882251106319018e-07

The O 0 1.4216461750038434e-06
ATP7B O 0 3.68751680071e-05
gene O 0 3.0554640488844598e-06
has O 0 4.972931151314697e-07
been O 0 4.956936194844275e-08
excluded O 0 1.4546968962747542e-08
in O 0 1.9706114517958895e-09
the O 0 5.898935118153759e-09
much O 0 1.746325395401982e-08
rarer O 0 3.910206203272537e-07
human O 0 1.7094474458190234e-07
copper B-Disease 0 0.00010321799345547333
overload I-Disease 0 0.00020248185319360346
disease O 0 2.1767323232779745e-06
non B-Disease 0 4.490698302106466e-08
- I-Disease 0 4.32640990766231e-06
Indian I-Disease 0 1.5364008731921786e-07
childhood I-Disease 0 1.0605518582451623e-05
cirrhosis I-Disease 0 7.371418905677274e-05
, O 0 5.964386673440458e-08
indicating O 0 1.7722894654070842e-06
genetic O 0 5.978332865197444e-06
heterogeneity O 0 8.3881888713222e-05
. O 0 1.8467989093551296e-06

By O 0 4.297204441172653e-07
investigating O 0 4.833804041481926e-07
the O 0 5.576189110456653e-08
common O 0 2.296392040079809e-06
autosomal O 1 0.9064303040504456
recessive O 1 0.9992572665214539
copper B-Disease 1 0.9119600653648376
toxicosis I-Disease 1 0.6594329476356506
( O 0 3.0418348728744604e-07
CT B-Disease 0 4.106312553631142e-05
) O 0 2.4356522132507052e-08
in O 0 2.2974901980887807e-08
Bedlington O 0 7.486050890292972e-05
terriers O 0 8.967352187028155e-05
, O 0 4.286002663889121e-08
we O 0 1.0384576754063346e-08
have O 0 2.1814763329075504e-09
identified O 0 4.683383458825574e-09
a O 0 3.1801250521823476e-09
new O 0 1.5113590379201014e-08
locus O 0 6.740820595041441e-07
involved O 0 9.429154346207724e-08
in O 0 1.683145228525973e-06
progressive O 1 0.9825520515441895
liver B-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
. O 0 3.1464776384382276e-06

We O 0 2.469252876835526e-06
examined O 0 8.164361702256429e-07
whether O 0 3.3332465676494394e-08
the O 0 5.1953993107645147e-08
WD B-Disease 0 6.577601743629202e-05
gene O 0 2.945796040876303e-06
ATP7B O 0 8.999690908240154e-05
was O 0 1.6636329291941365e-06
also O 0 3.0601889022818796e-08
causative O 0 8.674276585907137e-08
for O 0 2.60036880916914e-09
CT B-Disease 0 5.540204256249126e-06
by O 0 2.3823674144551887e-09
investigating O 0 1.202953558987474e-08
the O 0 5.7175530976394384e-09
chromosomal O 0 2.2830237867310643e-05
co O 0 2.6742050067696255e-06
- O 0 2.8859396934421966e-06
localization O 0 3.125722400909581e-07
of O 0 6.275983288617226e-09
ATP7B O 0 1.0267967809340917e-05
and O 0 5.118511481327914e-08
C04107 O 0 2.038092361544841e-07
, O 0 1.3893866057657078e-09
using O 0 4.099327988171808e-09
fluorescence O 0 5.26820400637007e-08
in O 0 1.1849362380189632e-08
situ O 0 4.872371732744796e-07
hybridization O 0 2.924766420164815e-07
( O 0 2.8808301522076363e-08
FISH O 0 2.106443162119831e-07
) O 0 8.222922076583927e-08
. O 0 2.2684884015689022e-07

C04107 O 0 0.0001812090922612697
is O 0 3.763188942684792e-07
an O 0 3.148237226469064e-08
anonymous O 0 4.225836107707437e-07
microsatellite O 0 2.2505701053887606e-05
marker O 0 2.320366729691159e-05
closely O 0 1.135633965532179e-06
linked O 0 5.483487711899215e-06
to O 0 2.815143318457558e-07
CT B-Disease 0 0.0014593993546441197
. O 0 2.4075507099041715e-06

However O 0 6.260589998419164e-06
, O 0 2.7287725856695033e-07
BAC O 0 9.712051905808039e-06
clones O 0 1.6877615962584969e-06
containing O 0 7.110972433110874e-08
ATP7B O 0 9.23943935049465e-06
and O 0 2.69200839397854e-08
C04107 O 0 4.0769518250272085e-07
mapped O 0 5.284547910378024e-07
to O 0 1.048760545074856e-08
the O 0 1.0623522506136851e-08
canine O 0 1.0843639756785706e-05
chromosome O 0 1.0601786925690249e-05
regions O 0 7.628669607129268e-08
CFA22q11 O 0 1.9352437448105775e-06
and O 0 3.261209258198505e-08
CFA10q26 O 0 1.1820715144494898e-06
, O 0 6.740728419885045e-09
respectively O 0 2.1054866294889507e-08
, O 0 3.55618157144022e-09
demonstrating O 0 1.5082834536883638e-08
that O 0 9.006784651433009e-09
WD B-Disease 0 2.929611218860373e-05
cannot O 0 6.727090351432707e-08
be O 0 6.040425937214877e-09
homologous O 0 1.6472317554416804e-07
to O 0 1.0302509423354422e-07
CT B-Disease 0 0.0002981638826895505
. O 0 2.2258413991949055e-06

The O 0 3.424456963330158e-06
copper O 0 6.1911828197480645e-06
transport O 0 5.20068397236173e-07
genes O 0 5.076732918496418e-07
CTR1 O 0 7.79753736424027e-06
and O 0 1.7408257235729252e-07
CTR2 O 0 6.348349415929988e-05
were O 0 6.721018053212902e-07
also O 0 4.471049663834492e-08
excluded O 0 2.5092372624158088e-08
as O 0 2.9583173688507713e-09
candidate O 0 9.7636156937142e-09
genes O 0 4.786351315289039e-09
for O 0 2.028300638556857e-09
CT B-Disease 0 1.1158621418871917e-05
since O 0 7.497730791783397e-08
they O 0 3.0642697268490338e-09
both O 0 3.6178993134683424e-09
mapped O 0 2.5524407192278886e-06
to O 0 3.5841637213707145e-08
canine O 0 5.239762322162278e-05
chromosome O 0 0.00011943207209696993
region O 0 3.2919999739533523e-06
CFA11q22 O 0 6.946716166567057e-05
. O 0 1.297632366004109e-06

2 O 0 6.9992478529457e-05
- O 0 0.0003092250553891063
22 O 0 1.2590125152200926e-05
. O 0 1.4554622111973003e-06

5 O 0 0.00035060200025327504
. O 0 2.140375909220893e-05

A O 0 5.077665264252573e-06
transcribed O 0 5.562651040236233e-06
sequence O 0 5.507483251676604e-07
identified O 0 1.8438935001086065e-07
from O 0 2.03837635659454e-09
the O 0 1.3107038787651959e-09
C04107 O 0 1.3204936522015487e-07
- O 0 3.3579232194824726e-07
containing O 0 3.483631161316225e-08
BAC O 0 2.062670773739228e-06
was O 0 1.3991676439673029e-07
found O 0 3.0786286853157208e-09
to O 0 7.084053343930918e-10
be O 0 8.544738805404961e-10
homologous O 0 4.331454750428065e-09
to O 0 1.1405590916169217e-09
a O 0 7.897081211183377e-09
gene O 0 6.988026512999568e-08
expressed O 0 4.2643746311910036e-09
from O 0 2.0112038701114443e-09
human O 0 2.0231395225778215e-08
chromosome O 0 3.899677267327206e-06
2p13 O 0 8.2810845469794e-07
- O 0 3.716914079632261e-06
p16 O 0 4.2879401007667184e-07
, O 0 6.829141696584884e-09
a O 0 1.621996226219835e-08
region O 0 8.658804517835961e-08
devoid O 0 1.588897760029795e-07
of O 0 2.2670614274744594e-09
any O 0 1.3011149491148899e-08
positional O 0 1.0410236427560449e-05
candidate O 0 5.220314506004797e-06
genes O 0 4.684342457039747e-06
. O 0 9.933046385413036e-07

Molecular O 0 8.140126737998798e-06
analysis O 0 5.834406806570769e-07
of O 0 1.6049012785401828e-08
the O 0 1.498905710661802e-08
APC B-Disease 0 8.867943961377023e-07
gene O 0 1.0883508139158948e-07
in O 0 1.092355805809575e-08
205 O 0 8.976158483164909e-08
families O 0 3.201134646246828e-08
: O 0 5.823053594866678e-09
extended O 0 3.9623321868020867e-07
genotype O 0 1.3553750250139274e-05
- O 0 3.865908001898788e-05
phenotype O 0 5.762459750258131e-06
correlations O 0 4.797761334884854e-07
in O 0 1.3204780380249304e-08
FAP B-Disease 0 6.952051876396581e-07
and O 0 1.2576728103397272e-08
evidence O 0 1.8650936350894654e-09
for O 0 6.103144656322002e-10
the O 0 1.271189709051157e-09
role O 0 1.1863427573644003e-08
of O 0 3.1365958719220544e-09
APC B-Disease 0 4.4742273530573584e-07
amino O 0 4.6254601926420946e-08
acid O 0 1.0198166933150787e-07
changes O 0 9.423922620044323e-08
in O 0 2.4766653950791806e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.00908656045794487
. O 0 1.9920737486245343e-06

BACKGROUND O 0 4.549121513264254e-05
/ O 0 2.2949861886445433e-05
AIMS O 0 5.257473389974621e-07
The O 0 8.615178792581446e-09
development O 0 1.800955828912265e-08
of O 0 6.148711236164672e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.1454478254790956e-07
a O 0 2.3322510145362685e-08
variable O 0 7.87979672622896e-08
range O 0 3.8356141374151775e-08
of O 0 7.81002107430595e-09
extracolonic O 0 1.9917979443562217e-05
manifestations O 0 4.2745177779579535e-06
in O 0 4.840188466914697e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 1.0
( O 0 9.005118954519276e-06
FAP B-Disease 0 1.9780816728598438e-05
) O 0 8.129540418622128e-08
is O 0 7.633905951820452e-09
the O 0 5.293240512571629e-09
result O 0 6.48261933022809e-09
of O 0 1.338417487950494e-09
the O 0 4.673730558124589e-08
dominant O 0 1.176566456706496e-05
inheritance O 0 2.1893150915275328e-05
of O 0 6.322064109554049e-06
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999990463256836
coli I-Disease 1 0.9999998807907104
( O 0 2.9906937015766744e-06
APC B-Disease 0 1.08289650597726e-05
) O 0 2.6581000156511436e-07
gene O 0 8.136044925777242e-06
mutations O 0 2.480263174220454e-05
. O 0 1.5963581745381816e-06

In O 0 6.960642622289015e-07
this O 0 1.5353704085896425e-08
study O 0 5.748060249999298e-09
, O 0 1.6042486228329267e-09
direct O 0 5.976421579845237e-09
mutation O 0 3.266251624722827e-08
analysis O 0 1.2826145701083647e-09
of O 0 4.0758274533203576e-10
the O 0 5.931371394041207e-09
APC B-Disease 0 4.070875263550988e-07
gene O 0 1.0000344730087818e-07
was O 0 1.4568399819836486e-06
performed O 0 4.625062999252805e-08
to O 0 2.7771742683313505e-09
determine O 0 8.629407943772094e-08
genotype O 0 4.402002559800167e-06
- O 0 1.2290799531911034e-05
phenotype O 0 2.1718533389503136e-06
correlations O 0 2.53071306133279e-07
for O 0 3.201810816477746e-09
nine O 0 1.3716578450839734e-07
extracolonic O 0 4.8522047109145205e-06
manifestations O 0 1.468475829824456e-07
and O 0 6.6232366258134334e-09
to O 0 1.5337803249693138e-09
investigate O 0 1.2765794643598838e-08
the O 0 9.477382434397441e-09
incidence O 0 3.0958563002059236e-06
of O 0 6.644253147669588e-09
APC B-Disease 0 2.253181037303875e-06
mutations O 0 5.776054763373395e-07
in O 0 4.288725463652554e-08
non O 0 5.049103492638096e-06
- O 1 0.9997965693473816
FAP O 1 0.9997642636299133
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.414121228066506e-06

METHODS O 0 3.979467692261096e-06
The O 0 3.1085639307093516e-07
APC B-Disease 0 3.4808929285645718e-06
gene O 0 7.487496986868791e-07
was O 0 2.3810515870081872e-07
analysed O 0 9.065767159199822e-08
in O 0 9.724216099016303e-09
190 O 0 1.0557372576158741e-07
unrelated O 0 2.137852561645559e-07
FAP B-Disease 0 1.8701049384617363e-06
and O 0 7.139498592323434e-08
15 O 0 1.561794249482773e-07
non O 0 1.1103878705398529e-06
- O 1 0.9959101676940918
FAP O 1 0.9993948936462402
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 3.5085952276858734e-06
using O 0 1.56416106733559e-07
denaturing O 0 8.034839993342757e-05
gradient O 0 2.1947294953861274e-05
gel O 0 2.3121498088585213e-05
electrophoresis O 0 5.42281895832275e-06
, O 0 1.0534498606773468e-08
the O 0 2.4745876459064675e-09
protein O 0 2.41906388254165e-08
truncation O 0 5.198169787945517e-07
test O 0 3.009655102914621e-08
, O 0 3.1539573175365376e-09
and O 0 2.287345202134361e-09
direct O 0 2.1149613615989438e-08
sequencing O 0 6.113321546763473e-07
. O 0 3.893944153787743e-07

RESULTS O 0 1.8897266272688285e-05
Chain O 0 2.0042480173287913e-05
terminating O 0 2.166526655855705e-06
signals O 0 2.1891692085773684e-06
were O 0 4.126929198378093e-08
only O 0 2.2699431223571764e-09
identified O 0 3.1553852863908105e-08
in O 0 2.0827796376465813e-08
patients O 0 7.362086051898586e-08
belonging O 0 1.148378725446264e-08
to O 0 5.566112459831629e-09
the O 0 2.033453583294431e-08
FAP B-Disease 0 1.3129309763826313e-06
group O 0 8.386751915168134e-08
( O 0 1.4369760492627393e-08
105 O 0 2.9215772201496293e-07
patients O 0 3.968095541040384e-07
) O 0 7.464284124125697e-08
. O 0 2.1472966693636408e-07

Amino O 0 2.296232014487032e-05
acid O 0 2.1079874841234414e-06
changes O 0 4.127590358393718e-08
were O 0 8.664565953608871e-09
identified O 0 8.212573732180317e-09
in O 0 2.144896482647596e-09
four O 0 5.864363572527509e-08
patients O 0 4.7400565250654836e-08
, O 0 3.5652281127340757e-09
three O 0 4.674102438428918e-09
of O 0 6.41651087818218e-09
whom O 0 4.237354005454108e-07
belonged O 0 1.1300588198537298e-07
to O 0 2.9709723570192637e-09
the O 0 5.671024982945028e-09
non O 0 7.980882088531871e-08
- O 0 1.1297272976662498e-05
FAP O 0 2.792247414618032e-06
group O 0 9.675336514192168e-07
of O 0 3.423438101890497e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 4.429724140209146e-05
. O 0 1.213803102473321e-06

Genotype O 1 0.6546114087104797
- O 0 0.21271032094955444
phenotype O 0 0.0002594010147731751
correlations O 0 1.5209697266982403e-05
identified O 0 1.153372409135045e-06
significant O 0 3.608108656294462e-08
differences O 0 2.8330967438705557e-07
in O 0 3.364083056567324e-08
the O 0 1.5797093411151764e-08
nature O 0 1.2666161453012137e-08
of O 0 2.1139558992189222e-09
certain O 0 1.1127772481245302e-08
extracolonic O 0 4.300818090996472e-06
manifestations O 0 1.4843199380720762e-07
in O 0 3.117939684216253e-08
FAP B-Disease 0 5.3690032473241445e-06
patients O 0 1.0711116971151569e-07
belonging O 0 2.267533893984819e-08
to O 0 1.1484465822775292e-08
three O 0 1.2303449636874575e-07
mutation O 0 3.030255811609095e-06
subgroups O 0 5.865520961378934e-06
. O 0 8.586503668084333e-07

CONCLUSIONS O 0 6.893804675200954e-05
Extended O 0 1.489199621573789e-05
genotype O 0 0.0004829728859476745
- O 0 0.001547713647596538
phenotype O 0 2.4923196178860962e-05
correlations O 0 1.6149474504345562e-06
made O 0 7.60116023457158e-08
in O 0 5.8119464796391185e-09
this O 0 1.8842554183606808e-09
study O 0 4.812973131151921e-09
may O 0 1.6594069052189298e-07
have O 0 1.9976205134497604e-09
the O 0 8.186514244279408e-10
potential O 0 2.486273187329857e-09
to O 0 6.769921845339866e-10
determine O 0 1.5950951670617997e-09
the O 0 1.021026374559142e-09
most O 0 5.901993893608903e-10
appropriate O 0 1.374905966855522e-09
surveillance O 0 3.616721500065978e-08
and O 0 8.543782570313851e-09
prophylactic O 0 1.7732924106894643e-07
treatment O 0 3.701267914379969e-08
regimens O 0 8.691665698279394e-08
for O 0 2.191343106971999e-09
those O 0 4.553269317142394e-09
patients O 0 1.8280053026842324e-08
with O 0 5.98479443780775e-09
mutations O 0 1.4481297512247693e-06
associated O 0 3.1348569962119655e-08
with O 0 2.935157006334066e-08
life O 0 1.172935071735992e-06
threatening O 0 5.512611096492037e-05
conditions O 0 1.1385140169295482e-05
. O 0 5.315511657499883e-07

This O 0 1.834675913414685e-07
study O 0 4.410228626738899e-08
also O 0 1.5474538983539787e-08
provided O 0 5.568130401201188e-09
evidence O 0 2.849107394453654e-09
for O 0 7.836160054175423e-10
the O 0 5.340987208057868e-09
pathological O 0 3.256693901221297e-07
nature O 0 2.2850306535815434e-08
of O 0 2.490188721893105e-09
amino O 0 6.8941368169817e-08
acid O 0 6.710956057531803e-08
changes O 0 6.078646475060623e-09
in O 0 5.662475377476994e-09
APC O 0 1.4669515735477034e-07
associated O 0 6.9174084238454725e-09
with O 0 1.699784646369551e-09
both O 0 2.330507697934081e-08
FAP B-Disease 0 1.100711187973502e-06
and O 0 1.124892321513471e-07
non O 0 1.637921855035529e-06
- O 1 0.9997201561927795
FAP O 1 0.9997979998588562
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 5.212078394833952e-05
. O 0 2.8865895274066133e-07
. O 0 8.706729772711697e-07

Inherited B-Disease 1 0.9999895095825195
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999929666519165
and O 0 0.0018981355242431164
cancer B-Disease 0 0.017139356583356857
risk O 0 1.8284956695424626e-06
of O 0 2.388556374910422e-08
the O 0 1.5059730174016295e-07
APC O 0 2.0792149371118285e-05
I1307K O 0 2.5321949578938074e-05
polymorphism O 0 5.4287040256895125e-05
. O 0 1.6399380911025219e-06

Germ O 0 0.002349485643208027
- O 0 0.0007722916780039668
line O 0 2.4351602405658923e-05
and O 0 1.0440010100865038e-07
somatic O 0 1.8793659819493769e-06
truncating O 0 4.905618880002294e-06
mutations O 0 1.1053207344957627e-06
of O 0 4.2373837771947365e-09
the O 0 1.5285856136415532e-08
APC B-Disease 0 4.982097152606002e-07
gene O 0 7.253838418819214e-08
are O 0 3.957971728141274e-09
thought O 0 2.546040711592923e-08
to O 0 2.3921307601426633e-08
initiate O 0 1.4093126083025709e-05
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.0010696102399379015
formation O 0 4.175212779955473e-06
in O 0 1.5317005818360485e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.00010487567487871274
sporadic O 1 0.9983099699020386
colorectal O 1 1.0
carcinogenesis O 1 0.9854506254196167
, O 0 3.9378269320877735e-06
respectively O 0 8.552574399800505e-06
. O 0 2.1741182081314037e-06

Recently O 0 4.255012754583731e-05
, O 0 1.32640948891094e-07
an O 0 1.8481427943584094e-08
isoleucine O 0 7.204656139947474e-05
- O 0 1.754256481945049e-05
- O 0 3.258018477936275e-05
> O 0 1.1325710147502832e-06
lysine O 0 1.5014344398878166e-06
polymorphism O 0 1.0354335699958028e-06
at O 0 6.763461612990795e-08
codon O 0 1.3977407888887683e-06
1307 O 0 4.72062265544082e-06
( O 0 2.1882117451355043e-08
I1307K O 0 1.8686806413370505e-07
) O 0 1.975081875826845e-09
of O 0 3.715616148092238e-10
the O 0 3.4421443473320323e-09
APC B-Disease 0 1.744425475180833e-07
gene O 0 6.042951383733453e-08
has O 0 2.5392317581918178e-08
been O 0 7.023917003579072e-09
identified O 0 5.433482996863859e-09
in O 0 1.7831945919866143e-09
6 O 0 2.5528777314320905e-08
% O 0 4.2446965942133374e-09
- O 0 3.6980898698857345e-07
7 O 0 4.4264683651817904e-07
% O 0 2.6889330762003283e-09
of O 0 4.946202891709106e-10
the O 0 2.5949796977897677e-08
Ashkenazi O 0 1.1084906873293221e-05
Jewish O 0 5.190338470129063e-07
population O 0 7.285494518782798e-08
. O 0 1.7605501057005313e-07

To O 0 6.648184580626548e-07
assess O 0 2.9039406967967807e-07
the O 0 2.525023035104823e-08
risk O 0 3.916639812473477e-08
of O 0 1.251560410864272e-09
this O 0 3.441330553854982e-09
common O 0 8.012408869717547e-08
APC B-Disease 0 1.4430262353926082e-06
allelic O 0 2.911779802161618e-06
variant O 0 1.4235960406949744e-05
in O 0 1.97805911739124e-06
colorectal O 1 1.0
carcinogenesis O 0 0.014311533421278
, O 0 2.2164016399983666e-07
we O 0 1.583957320860918e-08
have O 0 3.978437135288004e-09
analyzed O 0 1.1456046777880147e-08
a O 0 4.7621018239851765e-09
large O 0 8.693352704369772e-09
cohort O 0 1.4835754313935468e-07
of O 0 2.1766839441994534e-09
unselected O 0 3.0962639812059933e-06
Ashkenazi O 0 4.394502866489347e-06
Jewish O 0 1.0097788560869958e-07
subjects O 0 5.9542031749515445e-08
with O 0 4.7004249381643604e-08
adenomatous B-Disease 0 7.918862684164196e-05
polyps I-Disease 0 0.00010064987145597115
and O 0 2.593780550341762e-07
. O 0 3.496566023386549e-07
or O 0 0.014600693248212337
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 4.0311903148904094e-08
for O 0 3.039084095490807e-09
the O 0 4.897112049206953e-08
APC O 0 6.81198571328423e-06
I1307K O 0 1.4764036677661352e-05
polymorphism O 0 2.5899817046592943e-05
. O 0 8.998852649710898e-07

The O 0 4.13459792980575e-06
APC O 0 1.646154123591259e-05
I1307K O 0 1.3530696378438734e-05
allele O 0 5.680928552465048e-06
was O 0 2.808461090353376e-07
identified O 0 3.701225637087191e-08
in O 0 4.7093249300189655e-09
48 O 0 7.675050994748744e-08
( O 0 3.004250626048588e-09
10 O 0 3.40663941500452e-09
. O 0 1.0186473886619751e-09
1 O 0 1.3488304695385978e-08
% O 0 3.918871893660025e-09
) O 0 9.735011685663153e-10
of O 0 3.070482978984046e-09
476 O 0 1.5878099475230556e-06
patients O 0 1.6057731500040973e-06
. O 0 3.7319276202651963e-07

Compared O 0 1.0780886441352777e-05
with O 0 3.565229533819547e-08
the O 0 4.614381321488281e-09
frequency O 0 8.401882212183409e-08
in O 0 1.7458118284352508e-09
two O 0 3.7082548143274607e-09
separate O 0 1.3875811610830624e-08
population O 0 3.3219791362171236e-09
control O 0 2.1198722777171497e-08
groups O 0 3.043527430079962e-09
, O 0 1.8212042984799837e-09
the O 0 4.6978949619358445e-09
APC O 0 3.3176405622725724e-07
I1307K O 0 4.361010326192627e-07
allele O 0 1.300923031521961e-07
is O 0 4.78468997755499e-09
associated O 0 4.559665534031865e-09
with O 0 1.0468953481890253e-09
an O 0 2.403875098977437e-09
estimated O 0 3.1279583367904706e-08
relative O 0 8.484204983005839e-08
risk O 0 6.58514736073812e-08
of O 0 4.324891555995691e-09
1 O 0 1.4579113383206277e-07
. O 0 3.9794491613065475e-07

5 O 0 8.361659274669364e-05
- O 0 8.921473636291921e-05
1 O 0 3.364556732776691e-06
. O 0 1.8577861737867352e-06

7 O 0 0.00017476615903433412
for O 0 3.90485001844354e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 0 0.10452064871788025
( O 0 4.838194058720546e-07
both O 0 1.9710944343387382e-07
P O 0 0.0002515144005883485
= O 0 8.063527275226079e-06
. O 0 1.0873589673110473e-07
01 O 0 3.301513743281248e-06
) O 0 1.1847897241068495e-07
. O 0 4.6309159529300814e-07

Furthermore O 0 1.5818362953723408e-05
, O 0 9.368758213668116e-08
compared O 0 9.046524951372703e-08
with O 0 1.2215664035863938e-08
noncarriers O 0 6.049864168744534e-06
, O 0 2.6665794905511575e-08
APC O 0 3.343256480548007e-07
I1307K O 0 5.068750397185795e-07
carriers O 0 7.541619595485827e-08
had O 0 3.859052455368328e-08
increased O 0 7.753619968298153e-09
numbers O 0 5.15429698921821e-09
of O 0 5.2255186844263335e-09
adenomas B-Disease 0 9.112698899116367e-05
and O 0 4.146121136727743e-05
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.8117952346801758
per O 0 7.735644658168894e-07
patient O 0 3.30629336531274e-06
( O 0 4.768275729816196e-08
P O 0 1.0920705790340435e-05
= O 0 4.5930332248644845e-07
. O 0 8.036234788733054e-09
03 O 0 1.137685572416558e-07
) O 0 3.761123412715506e-09
, O 0 1.5375587469890206e-09
as O 0 1.4519241364752133e-09
well O 0 3.287851546573961e-09
as O 0 1.6692495163894705e-09
a O 0 1.4925893410122626e-08
younger O 0 2.578117914708855e-07
age O 0 3.30756577682223e-08
at O 0 6.280057363028391e-08
diagnosis O 0 9.300385499955155e-06
. O 0 5.48238176634186e-07

We O 0 2.5245087726943893e-06
conclude O 0 4.3263298721285537e-07
that O 0 8.466903622661448e-09
the O 0 1.256624937440165e-08
APC O 0 9.525608106741856e-07
I1307K O 0 6.755898880328459e-07
variant O 0 8.800863611213572e-07
leads O 0 3.471328113846539e-07
to O 0 2.187368686179525e-08
increased O 0 1.2223201792949112e-06
adenoma B-Disease 1 0.9999977350234985
formation O 0 1.6102279687402188e-07
and O 0 7.829111581258985e-09
directly O 0 6.540170627289399e-09
contributes O 0 1.3991471092822394e-08
to O 0 1.3520005115452705e-09
3 O 0 1.45641534388119e-08
% O 0 3.439145412897915e-09
- O 0 1.6267804880953918e-07
4 O 0 4.571885980908519e-08
% O 0 1.5082080029316103e-09
of O 0 3.971202533481488e-10
all O 0 2.3935639248406915e-08
Ashkenazi O 0 0.004438756033778191
Jewish O 0 0.28911393880844116
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.6606055598676903e-06

The O 0 3.697941508562508e-07
estimated O 0 1.2373531887988065e-07
relative O 0 8.208505164475355e-08
risk O 0 3.7966369603736894e-08
for O 0 2.42705788799924e-09
carriers O 0 4.8490406356904714e-08
may O 0 1.652123771123115e-08
justify O 0 9.95204718634568e-09
specific O 0 1.9004759987950592e-09
clinical O 0 8.792287786718589e-09
screening O 0 7.805911472757998e-09
for O 0 3.427899075703067e-10
the O 0 6.813499209279428e-10
360 O 0 2.210225069632088e-08
, O 0 9.725323879550274e-10
000 O 0 1.7965670062736194e-09
Americans O 0 1.4049493790579959e-09
expected O 0 1.3363461448534508e-09
to O 0 1.093606094570987e-09
harbor O 0 4.249875473760767e-08
this O 0 5.333013475272708e-10
allele O 0 1.746805189384304e-08
, O 0 7.858700912244387e-10
and O 0 2.131316456654986e-09
genetic O 0 2.0600856132091394e-08
testing O 0 2.2425818979598944e-09
in O 0 4.90476326220346e-10
the O 0 1.1990723969290684e-09
setting O 0 1.7383763761813498e-08
of O 0 2.117466868511997e-09
long O 0 2.2459353488102352e-07
- O 0 1.9502472241583746e-06
term O 0 6.465703705771375e-08
- O 0 5.652204890793655e-07
outcome O 0 2.2980337632816372e-08
studies O 0 7.226726772557868e-09
may O 0 9.744881346307466e-09
impact O 0 1.8115876798674435e-08
significantly O 0 2.7262258299742825e-06
on O 1 0.9593945145606995
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 1.20413790227758e-06
in O 0 1.3390564213011658e-08
this O 0 1.5516507190227458e-08
population O 0 1.30582407109614e-07
. O 0 5.577911679210956e-07

Localization O 0 2.6119132598978467e-05
of O 0 1.2449476116671576e-07
human O 0 2.0432241853995947e-07
BRCA1 O 0 1.5001610336184967e-05
and O 0 2.2980300684594113e-07
its O 0 5.315166617947398e-08
loss O 0 2.5395036118425196e-07
in O 0 1.4575130435900974e-08
high O 0 6.249586590456602e-07
- O 0 0.00011354978050803766
grade O 0 6.728348580509191e-07
, O 0 1.795266157955666e-08
non B-Disease 0 2.582537490525283e-07
- I-Disease 0 0.16974060237407684
inherited I-Disease 1 0.7232149839401245
breast I-Disease 1 0.9998595714569092
carcinomas I-Disease 1 1.0
. O 0 1.0353000106988475e-05

Although O 0 8.624312499705411e-07
the O 0 2.5052392160773707e-08
link O 0 3.464125484242686e-07
between O 0 7.727195594497971e-08
the O 0 3.019470398157864e-07
BRCA1 O 0 0.016774429008364677
tumour B-Disease 1 0.9999997615814209
- O 0 3.204436507076025e-05
suppressor O 0 4.5317505282582715e-05
gene O 0 3.4369484183116583e-06
and O 0 3.5443240449239966e-06
hereditary B-Disease 1 0.9996767044067383
breast I-Disease 1 0.9999986886978149
and I-Disease 1 0.9999842643737793
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.0435132935526781e-07
established O 0 2.0274429246569525e-08
, O 0 2.610830218685578e-09
the O 0 8.409986596014107e-10
role O 0 1.1490798534907753e-08
, O 0 6.051738665746598e-09
if O 0 7.250235412037398e-10
any O 0 3.705085405147912e-10
, O 0 8.089486858153805e-10
of O 0 5.007295134085155e-10
BRCA1 O 0 8.93661024292669e-07
in O 0 2.480968852580645e-08
non B-Disease 0 7.445514143000764e-07
- I-Disease 0 0.4136224687099457
familial I-Disease 0 0.48845407366752625
cancers I-Disease 1 0.7534193396568298
is O 0 2.052970700106016e-07
unclear O 0 1.5083834341567126e-06
. O 0 4.576719732085621e-07

BRCA1 O 0 0.4145042300224304
mutations O 0 0.0006750376196578145
are O 0 7.747207320107918e-08
rare O 0 9.487551011488904e-08
in O 0 7.73384556396195e-08
sporadic B-Disease 0 0.08736316859722137
cancers I-Disease 1 0.9717941880226135
, O 0 1.3323972325451905e-07
but O 0 2.7445432593253827e-08
loss O 0 4.490689775593637e-08
of O 0 7.150234182518034e-09
BRCA1 O 0 1.6200739992200397e-05
resulting O 0 3.325747002236312e-07
from O 0 1.6359901877649463e-08
reduced O 0 1.815583487996264e-07
expression O 0 7.178646654892873e-08
or O 0 1.1362733864928032e-08
incorrect O 0 8.415194230337875e-08
subcellular O 0 1.9100543795502745e-06
localization O 0 6.340657705550257e-07
is O 0 6.809826480491665e-09
postulated O 0 9.20096496770384e-08
to O 0 5.84004888892764e-09
be O 0 2.060886128418815e-09
important O 0 1.5420347221350994e-09
in O 0 3.864751629834018e-09
non B-Disease 0 1.4223932964796404e-07
- I-Disease 0 0.00030444140429608524
familial I-Disease 0 0.48622381687164307
breast I-Disease 1 0.999988317489624
and I-Disease 1 0.9977383613586426
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 7.16347631168901e-06

Epigenetic O 0 0.0018443677108734846
loss O 0 0.0010484743397682905
, O 0 2.409509534118115e-07
however O 0 2.5128004565999618e-08
, O 0 8.372188275984627e-09
has O 0 3.5085772509546587e-08
not O 0 2.255605702217167e-09
received O 0 2.0906272268916837e-09
general O 0 1.1570208124922488e-09
acceptance O 0 1.6396231927728877e-08
due O 0 8.070951018623873e-09
to O 0 4.796989472310997e-09
controversy O 0 2.22991509701842e-08
regarding O 0 4.587405566525149e-09
the O 0 3.827967276492927e-09
subcellular O 0 4.1237393588744453e-07
localization O 0 1.1576951663982982e-07
of O 0 3.307210727498955e-09
BRCA1 O 0 7.336607836805342e-07
proteins O 0 1.2808207827674778e-08
, O 0 2.9152427138967596e-09
reports O 0 5.470429886855754e-09
of O 0 5.084508925001785e-10
which O 0 1.8396949741372737e-08
have O 0 1.5330002156588307e-08
ranged O 0 1.149667880895322e-07
from O 0 6.168905941628111e-10
exclusively O 0 2.6097897176668994e-09
nuclear O 0 8.993463751494346e-09
, O 0 9.76152603193725e-10
to O 0 7.138280522234197e-10
conditionally O 0 7.139675517464639e-08
nuclear O 0 1.8109037824842744e-08
, O 0 8.551913066590089e-10
to O 0 7.639874288756232e-10
the O 0 1.251589676343201e-08
ER O 0 1.4880794878990855e-05
/ O 0 1.1109470960946055e-06
golgi O 0 1.0403350643173326e-06
, O 0 1.0159101115903013e-08
to O 0 2.4811663834611863e-09
cytoplasmic O 0 2.0218210750044818e-07
invaginations O 0 7.332355380640365e-07
into O 0 3.595200581685276e-08
the O 0 5.4405273175461843e-08
nucleus O 0 1.4023632957105292e-06
. O 0 4.106682922611071e-07

In O 0 6.164183901091747e-07
an O 0 2.1613407952258967e-08
attempt O 0 8.533352229278535e-07
to O 0 5.1056410654837237e-08
resolve O 0 3.389624794181145e-07
this O 0 2.8174400590330606e-09
issue O 0 2.017875289084259e-08
, O 0 1.040914643368751e-08
we O 0 5.957847104554048e-09
have O 0 6.654221174073882e-09
comprehensively O 0 8.322309668074013e-07
characterized O 0 3.1596283633916755e-07
19 O 0 1.4557701888406882e-07
anti O 0 6.249347848097386e-07
- O 0 5.8301495300838724e-05
BRCA1 O 0 0.00010882818605750799
antibodies O 0 4.64986578663229e-06
. O 0 5.053170752944425e-07

These O 0 1.0248978696836275e-06
reagents O 0 2.3551035610580584e-06
detect O 0 8.158430659932492e-07
a O 0 4.741648140793586e-08
220 O 0 1.299582521596676e-07
- O 0 1.3459620049616206e-06
kD O 0 3.090345899181557e-06
protein O 0 1.9010809637620696e-07
localized O 0 1.7329263357623859e-07
in O 0 5.727310625758264e-09
discrete O 0 1.1711539826819717e-07
nuclear O 0 1.0911984560380006e-07
foci O 0 4.423775692430354e-07
in O 0 6.577273836683162e-09
all O 0 2.498404816364541e-09
epithelial O 0 2.333226092332552e-07
cell O 0 7.248690053529572e-06
lines O 0 1.1981779607594945e-05
, O 0 4.052481017424725e-09
including O 0 2.531589604615192e-09
those O 0 4.0629375419598546e-09
derived O 0 5.2784226767244036e-08
from O 0 1.1401500898955419e-07
breast B-Disease 0 0.0009386332822032273
malignancies I-Disease 0 0.00023930049792397767
. O 0 2.4711466721782926e-06

Immunohistochemical O 0 0.0009726096759550273
staining O 0 0.00014900774112902582
of O 0 2.975415043238172e-07
human O 0 5.447203079711471e-07
breast O 0 0.0015064447652548552
specimens O 0 2.440377500079194e-07
also O 0 3.0390773986255226e-07
revealed O 0 1.5367993455583928e-06
BRCA1 O 0 1.9584853362175636e-05
nuclear O 0 5.310901087796083e-07
foci O 0 1.1240210369578563e-05
in O 0 3.460054358583875e-07
benign O 0 0.007214093115180731
breast O 0 0.10383684933185577
, O 0 5.428807980933925e-07
invasive B-Disease 0 6.996444426476955e-05
lobular I-Disease 1 0.9890648126602173
cancers I-Disease 1 0.9736146330833435
and O 0 1.605573970664409e-06
low B-Disease 0 0.00015447469195351005
- I-Disease 0 0.4150964319705963
grade I-Disease 0 0.0003247335262130946
ductal I-Disease 1 0.9754181504249573
carcinomas I-Disease 1 1.0
. O 0 7.260355778271332e-05

Conversely O 0 4.9939808377530426e-05
, O 0 1.065086053131381e-06
BRCA1 O 0 4.147343133809045e-05
expression O 0 2.4192474938899977e-06
was O 0 1.9874778445228003e-06
reduced O 0 1.2446247410480282e-07
or O 0 2.409393751179323e-08
undetectable O 0 1.299676739563438e-07
in O 0 1.5975615275110044e-09
the O 0 2.4895236983013547e-09
majority O 0 2.559419343128866e-09
of O 0 8.104575899281485e-10
high O 0 1.7064097335151018e-07
- O 0 1.818389500840567e-05
grade O 0 2.9825994829479896e-07
, O 0 2.99802991321485e-08
ductal B-Disease 0 0.0001633318024687469
carcinomas I-Disease 1 1.0
, O 0 1.9206510160074686e-07
suggesting O 0 8.853496780147907e-08
that O 0 4.373218676079205e-09
absence O 0 1.979140407115665e-08
of O 0 5.862772489706458e-09
BRCA1 O 0 1.4867447134747636e-05
may O 0 1.7604259028303204e-07
contribute O 0 1.4139848181216053e-09
to O 0 6.211789416177282e-10
the O 0 2.346801197816717e-09
pathogenesis O 0 5.189754048728901e-08
of O 0 6.524193962853531e-10
a O 0 6.536379437704909e-09
significant O 0 8.195923051346199e-09
percentage O 0 9.668644196381138e-08
of O 0 1.2878857091891405e-08
sporadic B-Disease 0 0.40395742654800415
breast I-Disease 1 0.9999769926071167
cancers I-Disease 1 0.8726463317871094
. O 0 2.428602101645083e-07
. O 0 6.807451882195892e-07

